

**2023 ASCO<sup>®</sup>**  
ANNUAL MEETING

# PROGRAM

## Partnering With Patients: The Cornerstone of Cancer Care and Research

**June 2–6, 2023**

**McCormick Place | Chicago, IL & Online**

[meetings.asco.org](https://meetings.asco.org) | [#ASCO23](https://twitter.com/ASCO23)

Wi-Fi Network: ASCO23 | No Password Required

**ASCO<sup>®</sup>**  
AMERICAN SOCIETY OF CLINICAL ONCOLOGY  
KNOWLEDGE CONQUERS CANCER

# ANNUAL MEETING PROGRAM

## **59th Annual Meeting**

June 2–6, 2023

Chicago, Illinois

Copyright 2023 by the American Society of Clinical Oncology. All programs presented at the 2023 Annual Meeting constitute copyrighted presentations owned by the American Society of Clinical Oncology.

Copyright of the 2023 ASCO Annual Meeting Program is owned by the American Society of Clinical Oncology. ASCO reserves the rights to all recordings or reproductions or presentations at this Annual Meeting and all ASCO educational and scientific meetings.



## CONTENTS

<b>Scientific Sessions</b> .....	4
<b>Program Information</b> .....	6
<b>Online-Only Sessions</b> .....	7
<b>Continuing Education</b> .....	7
<b>Conflict of Interest Disclosure</b> .....	7
<b>Policies</b> .....	7
<b>Onsite Details</b> .....	8
<b>Planning Committees</b> .....	9
<b>Awards</b> .....	13
<b>Industry Expert Theater Schedule</b> .....	19
<b>Ancillary Events Directory</b> .....	21
<b>Program by Day</b> .....	25

## SCIENTIFIC SESSIONS

### Breast Cancer—Local/Regional/Adjuvant

Oral Abstract Session . . . . .	29
Rapid Abstract Session . . . . .	79
Poster Discussion Session . . . . .	120
Poster Session . . . . .	92

### Breast Cancer—Metastatic

Oral Abstract Session . . . . .	149
Clinical Science Symposium: The Dr. Bernard Fisher Memorial Annual Clinical Science Symposium Supported by the Breast Cancer Research Foundation: Harnessing the Breast Cancer Immune Response . . . . .	56
Poster Discussion Session . . . . .	117
Poster Session . . . . .	96

### Care Delivery and Regulatory Policy

Oral Abstract Session . . . . .	57
Poster Discussion Session . . . . .	175
Poster Session . . . . .	152

### Central Nervous System Tumors

Oral Abstract Session . . . . .	29
Clinical Science Symposium: Are Big Data Smart Enough to Answer Questions in Central Nervous System Tumors? . . . . .	113
Poster Discussion Session . . . . .	80
Poster Session . . . . .	58

### Developmental Therapeutics—Immunotherapy

Oral Abstract Session . . . . .	114
Clinical Science Symposium: Traversing Toxicities of Immuno-Oncology Agents: Molecular Predictors and Rational Outcomes . . . . .	173
Rapid Abstract Session . . . . .	31
Poster Discussion Session . . . . .	78
Poster Session . . . . .	34

### Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Oral Abstract Session . . . . .	122
Poster Discussion Session . . . . .	57
Poster Session . . . . .	40

### Gastrointestinal Cancer—Colorectal and Anal

Oral Abstract Session . . . . .	90
Clinical Science Symposium: Molecular Basis for Young-Onset Colorectal Cancer . . . . .	80
Poster Discussion Session . . . . .	152
Poster Session . . . . .	125

### Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Oral Abstract Session . . . . .	30
Clinical Science Symposium: Target or TIGIT in Hepatobiliary Cancer . . . . .	120
Poster Discussion Session . . . . .	149
Poster Session . . . . .	130

### Genitourinary Cancer—Kidney and Bladder

Oral Abstract Session . . . . .	150
Poster Discussion Session . . . . .	78
Poster Session . . . . .	46

### Genitourinary Cancer—Prostate, Testicular, and Penile

Oral Abstract Session . . . . .	91
Poster Discussion Session . . . . .	57
Poster Session . . . . .	50

### Gynecologic Cancer

Oral Abstract Session . . . . .	78
Clinical Science Symposium: Knives Out: Surgical Management of Gynecologic Cancers . . . . .	28
Poster Discussion Session . . . . .	175
Poster Session . . . . .	156

### Head and Neck Cancer

Oral Abstract Session . . . . .	123
Poster Discussion Session . . . . .	176
Poster Session . . . . .	161

### Health Services Research and Quality Improvement

Oral Abstract Session . . . . .	185
Poster Discussion Session . . . . .	81
Poster Session . . . . .	61

<b>Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant</b>	
Oral Abstract Session .....	27
Poster Discussion Session .....	149
Poster Session .....	137
<b>Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia</b>	
Oral Abstract Session .....	186
Poster Discussion Session .....	152
Poster Session .....	140
<b>Hematologic Malignancies—Plasma Cell Dyscrasia</b>	
Oral Abstract Session .....	58
Poster Discussion Session .....	173
Poster Session .....	143
<b>Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers</b>	
Oral Abstract Session .....	79
Poster Discussion Session .....	117
Poster Session .....	101
<b>Lung Cancer—Non–Small Cell Metastatic</b>	
Oral Abstract Session .....	186
Clinical Science Symposium: New Partners for EGFR-Mutant Lung Cancer .....	27
Rapid Abstract Session .....	148
Poster Discussion Session .....	120
Poster Session .....	105
<b>Melanoma/Skin Cancers</b>	
Oral Abstract Session .....	174
Poster Discussion Session .....	81
Poster Session .....	66
<b>Pediatric Oncology</b>	
Oral Abstract Session I .....	114
Oral Abstract Session II .....	123
Poster Discussion Session .....	176
Poster Session .....	165
<b>Prevention, Risk Reduction, and Hereditary Cancer</b>	
Oral Abstract Session .....	174
Clinical Science Symposium: Interplay Between Germline and Somatic Tumor Genomes .....	119
Poster Discussion Session .....	81
Poster Session .....	69
<b>Professional Development and Educational Advances</b>	
Clinical Science Symposium: No One Left Behind: Enhancing Equity in Oncology .....	80
Poster Discussion Session .....	117
Poster Session .....	110
<b>Sarcoma</b>	
Oral Abstract Session .....	150
Clinical Science Symposium: Biomarkers of the Future: New Strategies to Predict Sarcoma Outcomes .....	28
Poster Discussion Session .....	82
Poster Session .....	74
<b>Symptoms and Survivorship</b>	
Oral Abstract Session .....	124
Clinical Science Symposium: Geriatric Oncology Assessment to Implementation .....	113
Poster Discussion Session .....	176
Poster Session .....	167
<b>Cross-Cutting Theme Sessions</b>	
Special Clinical Science Symposium: The Promise of Neoadjuvant Immunotherapy Across Solid Tumors .....	34
Special Clinical Science Symposium: Role of the Microbiome in Immune Checkpoint Inhibitor Response and Resistance .....	113
Special Clinical Science Symposium: Moving Cellular Therapy Into Earlier Lines of Treatment in Hematologic Malignancies: Latest Efficacy Data and The Need to Improve Access .....	147
Highlights of the Day Session I .....	112
Highlights of the Day Session II .....	146
Highlights of the Day Session III .....	185
Plenary Session .....	117
ASCO Plenary Series: Rapid Abstract Updates .....	55

## PROGRAM INFORMATION

The Annual Meeting Program features the program organized by day. Dates and times are subject to change. For the most up-to-date version of the program, consult the Program Guide ([meetings.asco.org](https://meetings.asco.org)).

### Abstract Key

Abstract numbers may include the following prefixes:

**LBA:** Late-Breaking Abstract

**TPS:** Trials in Progress Abstract

### Cross-Cutting Tracks

The topics of clinical trials, disparities/health equity, ethics, immunotherapy, and value are important for all oncology professionals and cut across disease- and topic-based tracks. These cross-cutting themes have been incorporated into sessions of every track throughout the Meeting. For sessions that feature a cross-cutting track, search by track in the Program Guide.

### Online Resources

The Program Guide, located at [meetings.asco.org](https://meetings.asco.org), is the all-in-one location for important tools including:

- Livestream sessions
- Interactive session tools
- On-demand session videos and downloadable slide decks (available no later than 12 hours following the session)
- Abstracts, available for download

Attendees must use their ASCO.org username and password to log in. If you need help retrieving your username or password, visit the Technical Assistance or Member Services Desk in Concierge Services.

### Posters

On-demand access to posters, their videos, and corresponding slides (video and slide content is pending presenter submission) will be available to all attendees at the session start time at [meetings.asco.org](https://meetings.asco.org).

### Session Types

#### Scientific Program

##### Plenary Session

Abstract presentations in this session showcase scientific research deemed to have the highest merit and greatest impact on oncology research and practice. Experts in the field serve as discussants placing clinical research findings into perspective and sharing implications for future research.

##### Highlights of the Day Sessions

Expert discussants provide an overview of the most impactful and practice-changing abstracts presented within a specific disease track. Presentations focus on key findings and placing abstracts into clinical context.

##### Oral Abstract Sessions

Presenters summarize their novel research findings and provide background on their methodologies. Discussants analyze the significance of each abstract within the context of current knowledge, highlighting clinical application and implications for future research and practice. Abstract presenters and discussants answer questions during a moderated panel discussion.

##### Clinical Science Symposia

Presenters summarize research findings, while discussants place the abstracts in the appropriate context with a focus on how the findings apply to clinical practice. Abstracts in these sessions may span disease sites or disciplines, but they are unified by their focus on a key scientific topic.

##### Rapid Abstract Sessions

Presenters give an overview of their novel research and answer questions during a moderated panel discussion.

##### Poster and Poster Discussion Sessions

Presenters outline their research via posters displayed throughout their assigned session(s). Authors are available to answer questions from attendees regarding the data presented. Electronic posters and supplemental materials are available online beginning on the day of their assigned Poster Session(s). Following the display of poster presentations, invited discussants highlight and discuss selected abstracts, with a focus on how the findings apply to clinical practice and future research. Presenters and discussants answer questions during a moderated panel discussion.

#### Educational Program

##### Education Sessions

Education Sessions offer interdisciplinary or multidisciplinary explorations of focused areas of clinical oncology. ASCO's Annual Meeting Education Committee determines the topics and format for these sessions that will best serve the educational needs of Annual Meeting attendees. Particular care is taken to ensure that these sessions address multidisciplinary issues, symptom management, health services research, international perspectives, and pathology, as appropriate.

##### Case-Based Panels

The Case-Based Panels will center on a case-based discussion and utilize interactive technology to poll the audience throughout the duration of the session.

##### Award Lectures

Presented throughout the Annual Meeting, at the Mentorship and Career Development Roundtable, in-person, and on-demand, award lectures recognize distinguished award recipients.

##### Opening Session

The Opening Session includes the President's Address, a discussion with the U.S. Surgeon General on health worker well-being, the National Cancer Institute Director's remarks, David Karnofsky Award Lecture, and recognition of special award recipients and the Fellows of the American Society of Clinical Oncology (FASCO).

##### Ticketed Sessions

Ticketed sessions are limited-attendance sessions focusing on a specific topic between recognized experts and attendees. The format is informal with an emphasis on attendee interaction and discussion. These sessions require an additional registration fee.

##### Annual Business Meeting (ASCO Members Only)

The ASCO Annual Business Meeting is for ASCO Members to hear updates on the state of the Society. Members are encouraged to preregister online to attend this event.

## ONLINE-ONLY SESSIONS

Sessions will be available on-demand beginning Friday, June 2, at [meetings.asco.org](https://meetings.asco.org).

### ASCO-ACS Cancer Prevention Award Lecture

Deborah Schrag, MD, MPH, FASCO  
Memorial Sloan Kettering Cancer Center

### B.J. Kennedy Geriatric Oncology Award Lecture

Hans Wildiers, MD, PhD  
University Hospitals Leuven

### Gianni Bonadonna Breast Cancer Award Lecture

Angela DeMichele, MD, MSCE  
University of Pennsylvania

### Pediatric Oncology Award Lecture

Peter C. Adamson, MD, FASCO  
Sanofi

### Walther Cancer Foundation Endowed Supportive Oncology Award Lecture

Declan Walsh, MD, MSc, FACP, FRCP (Edin)  
Levine Cancer Institute

## CONTINUING EDUCATION

Sessions at the ASCO Annual Meeting will provide Continuing Medical Education (CME) credits and Maintenance of Certification (MOC) points from the ABIM and ABP for physicians. Participants should use the online Program Guide ([meetings.asco.org](https://meetings.asco.org)) to:

- Claim CME credit for sessions
- Request MOC points
- Provide feedback on sessions

Please visit [conferences.asco.org/am/continuing-education](https://conferences.asco.org/am/continuing-education) for more information about how to claim credit and request MOC points for ASCO Annual Meeting sessions.

Feedback, CME claims, and MOC requests are due by September 4, 2023.

For questions or assistance, contact [customerservice@asco.org](mailto:customerservice@asco.org).

## CONFLICT OF INTEREST DISCLOSURE

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I= Immediate family member;

Inst= My Institution). Disclosures are submitted per the ASCO Policy for Relationships with Companies.

Please email [coi@asco.org](mailto:coi@asco.org) with specific questions or concerns.

## POLICIES

Important policies for this Meeting, including the Attendee Code of Conduct, are available at [am.asco.org](https://am.asco.org).

The 2023 ASCO Annual Meeting is funded through Conquer Cancer<sup>®</sup>, the ASCO Foundation, by these sponsorship donors:

Meeting Sponsorship Platinum Level Donors: Daiichi Sankyo, Inc. and HELSINN

Meeting Sponsorship Gold Level Donor: Bristol Myers Squibb

ASCO and Conquer Cancer gratefully acknowledge the following major educational program donors of the 2023 ASCO Annual Meeting:

Education Program Donors (Visionary)

AbbVie, Inc.  
Astellas  
Bristol Myers Squibb  
Daiichi Sankyo, Inc.  
Lilly  
Merck & Co., Inc.



## ONSITE DETAILS

### ASCO Headquarters Office

Badge reprints and assistance are available in N427bc.

### Emergency Response for Visitors

If an alarm sounds in McCormick Place:

- Horns and strobes will turn on
- Visitors will be directed over the public announcement system to exit through the closest "Emergency Exit"
- Doors marked as "Stairs" also serve as emergency exits

In the event of a power failure, all emergency systems will run on emergency power. Temporary safe areas are available in open parking lots, roadways, and grass areas adjacent to McCormick Place.

### Faculty Registration and Speaker Ready Room

All faculty will check in at the Faculty Registration and Speaker Ready Room, located in the North Building, Room N426, to receive their badges and Meeting materials. Additionally, faculty and oral abstract presenters should report to N426 to review and submit their presentations at least 4 hours before their scheduled session.

### Exhibit Hall

Located in the South Building, Level 3, Hall A, the Exhibit Hall hosts exhibits, posters, the Industry Expert Theater, Innovation Hub, a Food Court, and ASCO Bistro. The exhibits highlight the most advanced treatments, products, and services in oncology and provide attendees the opportunity to meet representatives from pharmaceutical companies, scientific publishers, and advocacy groups. Posters are located on the far-right side of the Exhibit Hall and can be accessed from the Grand Concourse entrance or from the S101 lobby. The Poster pick up desk is in the S101 lobby.

A print copy of the Exhibitor Directory is available in Hall C (Registration), Gate 3 (Materials Pickup), and the Grand Concourse entrance to the Exhibit Hall.

Exhibits are open Saturday through Monday, 9:00 AM–5:00 PM. Posters are open Saturday to Monday, 8:00 AM–5:00 PM. Poster presenters can access their posters 1 hour prior to their Poster Session for morning sessions, and 30 minutes prior for afternoon sessions.

### Industry Expert Theater

The Industry Expert Theaters, located in the back of the Exhibit Hall, to the left of the Food Court, bring together industry leaders and attendees for hour-long, nonaccredited educational presentations on the latest in oncology practices, products, services, and technologies. Most sessions will be offered in person during the Meeting and will also be available on-demand after the Meeting at [am.asco.org](http://am.asco.org). Review the Theater schedule in this program or at [am.asco.org](http://am.asco.org).

### Career Connections

Located in Hall C (North Building, Level 2), this area features the ASCO Career Fair, allowing you to meet face-to-face with recruiters, take a professional headshot, and engage in additional learning opportunities.

### Communities of Practice

ASCO Communities of Practice provide an opportunity for individuals to come together and build community, fellowship, networking, and goals collaboration, both onsite at the Annual Meeting and virtually throughout the year. Interested attendees are welcome to join.

- **Adolescent and Young Adult (AYA) Oncology:** Friday, June 2, 1:00 PM–3:00 PM, N427a
- **International Medical Graduates (IMG):** Friday, June 2, 4:00 PM–6:00 PM, S103
- **Palliative Care:** Friday, June 2, 4:00 PM–6:00 PM, N427a
- **Ethics:** Saturday, June 3, 7:30 AM–9:30 AM, E256
- **Medical Educators:** Saturday, June 3, 7:30 AM–9:30 AM, S103
- **Geriatric Oncology:** Saturday, June 3, 8:00 AM–9:30 AM, N427a
- **Cancer Care for Veterans:** Saturday, June 3, 10:00 AM–12:00 PM, S103

### Services Available at McCormick Place

- **ASCO Store:** North Building, Level 3, ASCO Central
- **Charging for Electronic Devices:** Located on tables throughout McCormick Place
- **Chicago Concierge:** North Building, Level 3, ASCO Central
- **Childcare:** South Building, Level 1, S106
- **CE and Technical Assistance Help Desk:** North Building, Level 3, ASCO Central
- **First Aid Stations:** South Building, Level 2.5 near Business Center; East Building, Level 1 near Arie Crown Theater
- **Hotel Assistance Desk:** North Building, Level 3, ASCO Central
- **International Assistance Desk:** North Building, Level 3, ASCO Central
- **Internet Stations With Printers:** North Building, Level 2.5
- **Member Services Desk:** North Building, ASCO Central; ASCO Booth (#7004); Hall C
- **Nursing Lounge:** North Building, Room N227a
- **Poster Station:** Exhibit Hall
- **Prayer/Meditation Room:** North Building, ASCO Central
- **Registration:** North Building, Level 2, Hall C

### Shuttle Bus Service

Complimentary shuttle service is provided between McCormick Place and all official ASCO hotels, except those within walking distance. The complete shuttle schedule is available at [am.asco.org](http://am.asco.org). Please be sure to check the ASCO Shuttle sign in your hotel for any changes. Service will be approximately every 20 minutes. McCormick Place is the transfer point for all routes.

### Hours of Operation

Friday	8:00 AM–7:00 PM*
Saturday-Monday	6:45 AM–7:00 PM*
Tuesday	6:45 AM–1:30 PM*

\*Last shuttle departs McCormick Place at this time, and last shuttle departs hotels coming to McCormick Place approximately 90 minutes prior to this time.

If you have any questions regarding the shuttle or would like to make a reservation for a wheelchair accessible ASCO Shuttle, please see the ASCO Shuttle supervisor at McCormick Place during shuttle hours or call Kushner & Associates at 312-808-2000.

### #ASCO23 Social Media Featured Voices

Follow the official meeting hashtag #ASCO23 across social media channels and follow ASCO's Featured Voices for meeting takeaways and insights on Twitter and/or Instagram. We thank our members who have agreed to lead this social media conversation.

## PLANNING COMMITTEES

### 2022–2023 ASCO Board of Directors

#### Officers

*Chair of the Board*

**Everett E. Vokes, MD, FASCO**

*President*

**Eric P. Winer, MD, FASCO**

*President-Elect*

**Lynn M. Schuchter, MD, FASCO**

*Past President*

**Lori J. Pierce, MD, FASTRO, FASCO**

*Treasurer*

**Elizabeth A. Mittendorf, MD, PhD, MHCM, FASCO**

*Treasurer-Elect*

**Elizabeth R. Plimack, MD, MS**

#### Directors

Frederick Chite Asirwa, MD, MBChB

Ethan M. Basch, MD, MSc, FASCO

Lisa A. Carey, MD, FASCO

Mariana Chavez Mac Gregor, MD, MSc, FASCO

Tara O. Henderson, MD, MPH, FASCO

Carolyn B. Hendricks, MD, FASCO

Taofeek K. Owonikoko, MD, PhD

Ann H. Partridge, MD, MPH, FASCO

Enrique Soto Pérez de Celis, MD, MSc, PhD, FASCO

Gladys I. Rodriguez, MD

Michael A. Thompson, MD, PhD, FASCO

Karen M. Winkfield, MD, PhD, FASCO

#### Ex-Officio Members

Clifford A. Hudis, MD, FACP, FASCO, *ASCO Chief Executive Officer*

Howard A. Burris III MD, FACP, FASCO, *Chair of the Conquer Cancer Board*

### 2023 Conquer Cancer, the ASCO Foundation Board of Directors

*Chair*

Howard A. Burris III, MD, FACP, FASCO

*Treasurer*

Alexander Casdin, FASCO

*Secretary*

Amy C. Peterson, MD

*Chief Executive Officer*

Nancy R. Daly, MS, MPH, ex-officio

*Executive Vice Chair*

Clifford A. Hudis, MD, FACP, FASCO, ex-officio

*ASCO President*

Eric P. Winer, MD, FASCO, ex-officio

#### Directors

Kathryn Beal, MD

Riccardo Braglia

Lawrence H. Einhorn, MD, FASCO

Raj Mantena, RPh

Thomas A. Marsland, MD, FASCO

Robert J. Mayer, MD, FASCO

Gerald J. McDougall

Anne Moore, MD, FASCO

W. Charles Penley, MD, FASCO

Thomas G. Roberts, Jr., MD, FASCO

Steven T. Rosen, MD, FACP, FAIMBE, FASCO

Alexandra E.F. Shapiro

Sandra M. Swain, MD, FACP, FASCO

Margaret Tempero, MD, FASCO

Deanna B. van Gestel

### Cancer Communications Committee

Erica Mayer, MD MPH, FASCO—Chair

Charu Aggarwal, MD, MPH—Chair-Elect

Robert Dreicer, MD, MS, MACP, FASCO—Past Chair

Ann H. Partridge, MD, MPH, FASCO—Board Liaison

Jyoti D. Patel, MD, FASCO—Cancer.Net Liaison

Julie R. Gralow, MD, FACP, FASCO—ASCO Chief Medical Officer

Lauren Averett Byers, MD

Elizabeth Anne Comen, MD

Curtiland Deville, MD

Cathy Eng, MD, FACP, FASCO

Mark Fleming, MD

Glenn J. Hanna, MD

Melissa M. Hudson, MD, FASCO

Pamela L. Kunz, MD

Michael Lowe, MD

Bradley Alexander McGregor, MD

Kathleen N. Moore, MD, MS

Oreofe Olukemi Odejide, MD

Rita Nanda, MD

Olatoyosi Odenike, MD, FASCO

Corey Wayne Speers, MD, PhD

Heather J. Symons, MD

Jennifer Tseng, MD

## PLANNING COMMITTEES continued

### Annual Meeting Education Committee

Shom Goel, MBBS, PhD, FRACP—Chair  
Thomas LeBlanc, MD—Chair-Elect  
Jhanelle Gray, MD—Immediate Past Chair

### Breast Cancer

Rachel Freedman, MD, MPH—Track Leader  
Rachel Greenup, MD, MPH  
Hyo Han, MD  
Nadia Harbeck, MD  
Eleni Nackos, MD  
Daniel O'Neil, MD, MPH  
Jennifer Tseng, MD  
Julia White, MD

### Care Delivery and Regulatory Policy

Gabriel Brooks, MD, MPH—Track Leader  
Natalie Dickson, MD, MMHC, FACP  
Issam El Naqa, PhD  
Peter Marks, MD, PhD  
Travis Osterman, DO, MS

### Central Nervous System Tumors

Stephen Bagley, MD, MSCE—Track Leader  
Lizza Hendriks, MD, PhD  
Nancy Lin, MD  
Aaron Mammoser, MD, MS

### Developmental Therapeutics—Immunotherapy

Hussein Tawbi, MD, PhD—Track Leader  
Mario Bilusic, MD, PhD  
Saar Gill, MD, PhD  
Siwen Hu-Lieskovan, MD, PhD  
Randy Sweis, MD

### Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Peter O'Donnell, MD—Track Leader  
Jan Beumer, PhD, PharmD  
Manali Bhave, MD  
Ki Chung, MD  
Solmaz Sahebjam, MD

### Gastrointestinal Cancer—Colorectal and Anal

Olatunji Alese, MD, FWACS—Track Leader  
Jennifer Eads, MD  
Richard Kim, MD  
Kellie Mathis, MD  
Bruce Minsky, MD, FASCO

### Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Ryan Fields, MD, FACS—Track Leader  
Daniel Chang, MD  
Shadia Jalal, MD  
Mairead McNamara, PhD, BSc, MBCh  
Haeseong Park, MD, MPH  
Diane Simeone, MD

### Genitourinary Cancer—Kidney and Bladder

Simon Hughes, FRCR—Track Leader  
Leslie Ballas, MD  
Petros Grivas, MD, PhD  
Naomi Haas, MD  
Eric Singer, MD, MA, FASCO, MS, FACS

### Genitourinary Cancer—Prostate, Testicular, and Penile

David VanderWeele, MD, PhD—Track Leader  
Bradley Carthon, MD, PhD  
Heather Cheng, MD, PhD  
Howard Sandler, MD, FASCO, FASTRO

### Geriatric Oncology

Nikeshia Gilmore, PhD—Track Leader  
Mina Sedrak, MD, MS  
Tacara Soones, MD, MPH  
Melisa Wong, MD

### Global Health

Aparna Parikh, MD—Track Leader  
Anil D'Cruz, MBBS, DNB, FRCS  
Kunle Odunsi, MD, PhD  
Katherine Van Loon, MD, MPH

### Gynecologic Cancer

Rodney Rocconi, MD—Track Leader  
Lan Coffman, MD, PhD  
Katherine Kurnit, MD  
Linda Mileschkin, MD, MBBS, FRACP

### Head and Neck Cancer

Cesar Perez, MD—Track Leader  
Aditya Juloori, MD  
Brian O'Sullivan, MD  
Conor Steuer, MD

### Health Services Research and Quality Improvement

Eileen Shinn, PhD—Track Leader  
Kerin Adelson, MD  
Dawn Hershman, MD  
Viraj Master, MD  
Nadine McCleary, BSN, MD, MPH  
Kathryn Ruddy, MPH

### Hematologic Malignancies

Andrew Artz, MD, MS—Track Leader  
Kate Cwynarski, MD, PhD  
Eliza Hawkes, MD, MBBS, FRACP  
Sarah Larson, MD  
Lisa Law, MD  
Olatoyosi Odenike, MD

### Lung Cancer

Ibiayi Dagogo-Jack, MD—Track Leader  
Benjamin Besse, MD, PhD  
Pilar Garrido, MD, PhD  
Andreas Rimmner, MD  
Julia Rotow, MD  
Suresh Senan, MBBS, PhD

### Melanoma/Skin Cancers

Michael Sabel, MD, FACS—Track Leader  
Zeynep Eroglu, MD  
Anthony Joshua, MBBS, PhD, FRACP  
Georgina Long, MD, PhD, FRACP  
Suthee Rapisuwon, MD

### Pediatric Oncology

Jennifer McNeer, MD—Track Leader  
Prasanna Ananth, MD, MPH  
Kavita Dhodapkar, MD  
Sumit Gupta, MD, PhD

### Prevention, Risk Reduction and Hereditary Cancer

Erin Cobain, MD—Track Leader  
Suzette Delalogue, MD  
Bryson Katona, MD  
Bryan Schneider, MD  
Elena Stoffel, MD, MPH

### Professional Development and Educational Advances

Sam Brondfield, MD, MA—Track Leader  
Asrar Alahmadi, MBBS, MD  
Muhamad Alhaj Moustafa, MD  
Kathryn Bollin, MD  
Michelle Kim, MD  
Alfred Lee, MD, PhD

**Sarcoma**

Rashmi Chugh, MD—Track Leader  
Javier Martin Broto, MD, PhD  
Aimee Crago, MD, PhD, FACS  
Najat Daw, MD

**Symptoms and Survivorship**

Sarah Mougalian, MD—Track Leader  
Wendy Baer, MD  
Areej El-Jawahri, MD  
Kunal Kadakia, MD, FACP  
Sean Smith, MD  
Nicole Stout, DPT

**Liaisons**

Sana Al-Sukhun, MD, MSc—International Affairs Committee  
Sanford Jeames, PhD—Health Equity and Outcomes Committee  
Michael Jefford, PhD, MPH, MBBS—Health Equity and Outcomes Committee  
Kelsey Klute, MD—Evidence Based Medicine Committee  
Larissa Korde, MD, FASCO, MPH—Health Equity and Outcomes Committee  
Richard Lee, MD—Ethics Committee  
Therica Miller, CCRP, MBA—Research Committee  
Blase Polite, MD, MPP—Clinical Practice Committee

**Scientific Program Committee**

Kimmie Ng, MD, MPH—Chair  
Angela DeMichele, MD, MSCE—Chair-Elect  
Sonali Smith, MD, FASCO—Immediate Past Chair

**Biostatistics**

Jennifer Le-Rademacher, PhD—Track Leader  
Emily Dressler, PhD  
Megan Othus, PhD  
Fang-Shu Ou, PhD  
Byung Park, PhD  
Meredith Regan, ScD, FASCO  
Greg Yothers, PhD

**Breast Cancer—Metastatic**

Daniel Stover, MD—Track Leader  
Michael A. Danso, MD  
Gaorav Gupta, MD, PhD  
Ines Maria Luis, MD, PhD  
Maryam Lustberg, MD  
Rita Nanda, MD  
Anne Schott, MD

**Breast Cancer—Local/Regional/Adjuvant**

Erica Stringer-Reasor, MD—Track Leader  
Isabelle Bedrosian, MD  
Jennifer Bellon, MD  
Fatima Cardoso, MD  
Laura Dominici, MD  
Norah Lynn Henry, MD, PhD, FASCO, FACP  
Alastair Thompson, MD, MBChB, FRCS, FACS

**Care Delivery and Regulatory Policy**

Keerthi Gogineni, MD, MSPH—Track Leader  
Stacy Gray, MD  
Nathan Handley, MD, MBA  
Ray Page, DO, PhD, FACOI, FASCO  
Vonetta Williams, MD, PhD

**Central Nervous System Tumors**

Steven Chmura, MD, PhD—Track Leader  
Matthias Holdhoff, MD, PhD  
Jing Li, MD, PhD  
Rimas Lukas, MD  
Ian Parney, MD, PhD

**Developmental Therapeutics—Immunotherapy**

Lana Kandalaf, PhD, PharmD—Track Leader  
Benedito Carneiro, MD, MS  
Elena Elez, MD  
Edward Garon, MD, MS  
Dung Le, MD  
Jarushka Naidoo, MHS, MBCh  
Sarah Nikiforow, MD, PhD  
Amita Patnaik, MD

**Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology**

Komal Jhaveri, MD, FACP—Track Leader  
Jayesh Desai, MD, FRACP  
Ignacio Garrido-Laguna, MD, PhD  
Lisa Kachnic, MD, FASTRO  
Emil Lou, MD, PhD  
Jordi Rodon Ahnert, MD, PhD  
Manish Sharma, MD  
Ardaman Shergill, MD

**Gastrointestinal Cancer—Colorectal and Anal**

Tanios Bekaii-Saab, MD—Track Leader  
Michael Cecchini, MD  
Myriam Chalabi, MD, PhD  
Cathy Eng, MD, FACP, FASCO  
Christopher Hallemeier, MD  
Sorbarikor Piawah, MD, PhD  
Karyn Stitzenberg, MD  
Christine Walko, PharmD, FCCP, BCOP  
Y. Nancy You, MD, MHSc

**Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary**

David Cunningham, MD—Track Leader  
Massimo Falconi, MD  
Mary Feng, MD  
Jingquan Jia, MD, PhD  
Samuel Klempner, MD  
Eric Miller, MD, PhD  
Katrina Pedersen, MD, MS  
Harshabad Singh, MBBS  
Namrata Vijayvergia, MD  
Anna Wagner, MD

**Genitourinary Cancer—Kidney and Bladder**

Neha Vapiwala, MD, FASTRO, FACR—Track Leader  
Maria Bourlon, MD, MS  
David Braun, MD, PhD  
Manojkumar Bupathi, MD  
Anil Kapoor, MD  
Manuela Schmidinger, MD

**Genitourinary Cancer—Prostate, Testicular, and Penile**

Jorge Garcia, MD, FACP—Track Leader  
Mark Garzotto, MD  
Karen Hoffman, MD, MPH, MHSc  
Fatima Karzai, MD  
Shahneen Sandhu, MBBS, FRACP  
Russell Szmulewitz, MD

**Gynecologic Cancer**

Christina Annunziata, MD, PhD, FASCO—Track Leader  
Anuja Jhingran, MD  
Cornelia Kolberg-Liedtke, MD, PhD  
John Moroney, MD  
Tanja Pejovic, MD, PhD

**Head and Neck Cancer**

Glenn Hanna, MD—Track Leader  
Roselle de Guzman, MD, FASCO  
Luc Morris, MD  
Alexander Pearson, MD, PhD  
Nadeem Riaz, MD  
Sharon Spencer, MD

## PLANNING COMMITTEES continued

### Health Services Research and Quality Improvement

Victoria Blinder, MD—Track Leader  
Winson Cheung, MD, MPH  
Sheetal Kircher, MD  
Monika Krzyzanowska, MD, MPH, FRCPC, FASCO  
John Salsman, PhD  
Veena Shankaran, MD, MS  
Lova Sun, MD  
Alexi Wright, MD, MPH, FASCO

### Hematologic Malignancies—Leukemia, MDS, and Allotransplant

Lori Muffly, MD, MS—Track Leader  
Patrick Burke, MD  
Daniel Couriel, MD  
Michael Drazer, MD, PhD  
Jeremy Pantin, MBBS

### Hematologic Malignancies—Lymphoma and CLL

Ann LaCasce, MD—Track Leader  
Alexey Danilov, MD, PhD  
Justin Kline, MD  
Neha Mehta-Shah, MD  
Deborah Stephens, DO

### Hematologic Malignancies—Plasma Cell Dyscrasia

Asher Alban Chanan-Khan, MD—Track Leader  
Amandeep Godara, MD  
Andrzej Jakubowiak, MD, PhD  
Maria-Victoria Mateos, PhD  
Ajay Nooka, MBBS  
Ravi Vij, MD

### Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other

#### Thoracic Cancers

Vamsidhar Velcheti, MD, FCCP, FACP—Track Leader  
Nagla Abdel Karim, MD  
Chandra Belani, MD  
Alberto Chiappori, MD  
Jessica Donington, MD  
Clifford Robinson, MD  
Valerie Rusch, MD  
Shankar Siva, PhD

### Lung Cancer—Non–Small Cell Metastatic

Clarissa Mathias, MD, PhD—Track Leader  
Christine Bestvina, MD  
Apar Kishor Ganti, MD

Sarah Goldberg, MD  
Ticiana Leal, MD  
Raymond Osarogiagbon, MBBS, FACP  
Martin Reck, MD, PhD  
Marjorie Zauderer, MD, FACP, MS

### Melanoma/Skin Cancers

Harriet Kluger, MD—Track Leader  
Elizabeth Buchbinder, MD  
John Hyngstrom, MD, FACS  
Alexander Menzies, MBBS, PhD, FRACP

### Pediatric Oncology

Damon Reed, MD—Track Leader  
Mark Applebaum, MD  
Ami Desai, MD, MSCE  
Justine Kahn, MD, MS

### Prevention, Risk Reduction, and Hereditary Cancer

James Ford, MD, FASCO—Track Leader  
Abenaa Brewster, MD, MHS  
Heather Hampel, MS  
Joanne Jeter, MD, MS, FASCO  
Eduardo Vilar Sanchez, MD, PhD

### Professional Development and Educational Advances

Gregory Kalemkerian, MD—Track Leader  
Nishin Bhadkamkar, MD  
Julia Close, MD  
Annie Im, MD  
Niki Patel, MD

### Sarcoma

Herbert Loong, MBBS, FRCP—Track Leader  
Priscilla Merriam, MD  
R. Lor Randall, MD, FACS  
Breelyn Wilky, MD

### Symptoms and Survivorship

Amye Tevaarwerk, MD—Track Leader  
Efrat Dotan, MD  
Marilyn Hammer, PhD, RN, FAAN  
June McKoy, MD, MPH, JD, MBA  
Halle Moore, MD  
Debra A. Patt, MD, MBA, PhD, FASCO  
Tara Sanft, MD  
Ramy Sedhom, MD

## AWARDS

### ASCO 2023 SPECIAL AWARDS

#### Allen Lichter Visionary Leader Award

##### Monica M. Bertagnolli, MD, FACS, FASCO

Presented during the Opening Session, Saturday, June 3, 9:30 AM, Hall B1

#### ASCO-American Cancer Society Cancer Prevention Award

##### Deb Schrag, MD, MPH, FASCO

Presented during the Opening Session, Saturday, June 3, 9:30 AM, Hall B1

Lecture available on-demand at meetings.asco.org.

*This award is generously supported by the American Cancer Society.*

#### B.J. Kennedy Geriatric Oncology Award

##### Hans Wildiers, MD, PhD

Presented during the Opening Session, Saturday, June 3, 9:30 AM, Hall B1

Lecture available on-demand at meetings.asco.org.

#### David Karnofsky Memorial Award

##### Hagop M. Kantarjian, MD, FASCO

Presented during the Opening Session, Saturday, June 3, 9:30 AM, Hall B1

#### Excellence in Equity Award, Endowed by the American Cancer Society

##### Carmen E. Guerra, MD, MSCE, FACP

Presented during the Mentorship and Career Development Roundtable: A Discussion with ASCO's Special Award Recipients, Sunday, June 4, 10:00 AM, S103

*This award is generously supported by the American Cancer Society.*

#### Excellence in Teaching Award

##### David Gerson Poplack, MD

Presented during the Mentorship and Career Development Roundtable: A Discussion with ASCO's Special Award Recipients, Sunday, June 4, 10:00 AM, S103

#### Gianni Bonadonna Breast Cancer Award

##### Angela DeMichele, MD, MSCE

Presented during the Opening Session, Saturday, June 3, 9:30 AM, Hall B1

Lecture available on-demand at meetings.asco.org.

*This award is generously supported by GlaxoSmithKline Oncology.*

#### Humanitarian Award

##### Patrick J. Loehrer Sr., MD, FASCO

Presented during the Mentorship and Career Development Roundtable: A Discussion with ASCO's Special Award Recipients, Sunday, June 4, 10:00 AM, S103

#### Patient Advocate Award

##### Jane Perlmutter, PhD, MBA, FASCO

Presented during the Mentorship and Career Development Roundtable: A Discussion with ASCO's Special Award Recipients, Sunday, June 4, 10:00 AM, S103

#### COL (R) James E. Williams Jr., USA, MS, SPHR

Presented during the President's Dinner, Friday, June 3, 7:00 PM, Bridgeport Art Center

#### Pediatric Oncology Award

##### Peter C. Adamson, MD, FASCO

Presented during the Opening Session, Saturday, June 3, 9:30 AM, Hall B1

Lecture available on-demand at meetings.asco.org.

#### Science of Oncology Award

##### Alan Ashworth, PhD, FRS

Presented during the Science of Oncology Award Lecture, Monday, June 5, 9:45 AM, E451

#### Walther Cancer Foundation Supportive Oncology Award

##### Declan Walsh, MD, MSc, FACP, FRCP(Edin)

Presented during the Opening Session, Saturday, June 3, 9:30 AM, Hall B1

Lecture available on-demand at meetings.asco.org.

*This award is generously supported by Walther Cancer Foundation.*

#### Hologic, Inc. Endowed Women Who Conquer Cancer Mentorship Award

##### Carolyn D. Runowicz, MD, FASCO

Presented during the Mentorship and Career Development Roundtable: A Discussion with ASCO's Special Award Recipients, Sunday, June 4, 10:00 AM, S103

*This award is generously supported by Hologic, Inc.*

#### International Women Who Conquer Cancer Mentorship Award

##### Maria T. Bourlon, MD, MS

Presented during the Mentorship and Career Development Roundtable: A Discussion with ASCO's Special Award Recipients, Sunday, June 4, 10:00 AM, S103

*This award is generously supported by Eisai Inc. and Novartis Oncology.*

#### Fellows of the American Society of Clinical Oncology (FASCO)

Presented during the Opening Session, Saturday, June 3, 9:30 AM, Hall B1

Kerin Adelson, MD, FASCO

Neeraj Agarwal, MD, FASCO

Manmeet Ahluwalia, MD, MBA, FASCO

Sana A. Al Sukhun, MD, MSc, FASCO

Ajjai Alva, MD, FASCO

Carey K. Anders, MD, FASCO

Deborah K. Armstrong, MD, FASCO

Debra Barton, PhD, RN, FAAN, FASCO

Nancy Baxter, MD, MBA, PhD, FRCSC, FACS, FASCO

Emily K. Bergsland, MD, FASCO

Victoria Blinder, MD, MSc, FASCO

Abenaa M. Brewster, MD, MHS, FASCO

Eduardo Bruera, MD, FASCO

Elena Gabriela Chiorean, MD, FASCO

Suzanne Cole, MD, FACP, FASCO

Frances Collichio, MD, FASCO

Jeffery Crawford, MD, FASCO

Michael A. Danso, MD, FASCO

Apar Kishor Ganti, MD, FASCO

Roselle B. de Guzman, MD, FASCO

David W. Dougherty, MD, FASCO

Linda R. Duska, MD, MPH, FASCO

Frank D. Ferris, MD, FASCO

Geoffrey T. Gibney, MD, FASCO

Daniel A. Hamstra, MD, PhD, FASCO

R. Donald Harvey, PharmD, FASCO

Theodore S. Hong, MD, FASCO

Stephen P. Hunger, MD, FASCO

Joanne M. Jeter, MD, MS, FASCO

Gregory P. Kalemkerian, MD, FASCO

## AWARDS continued

Vicki L. Keedy, MD, MSCI, FASCO  
Elise C. Kohn, MD, FASCO  
Nicole M. Kuderer, MD, MS (Equiv.), FASCO  
Benjamin Levy, MD, FASCO  
Christopher H. Lieu, MD, FASCO  
Noelle LoConte, MD, FASCO  
Jennifer Mack, MD, MPH, FASCO  
Erica L. Mayer, MD, MPH, FASCO  
Larissa Nekhlyudov, MD, MPH, FASCO  
Grzegorz S. Nowakowski, MD, FASCO  
Olatoyosi Odenike, MD, FASCO  
Travis Osterman, DO, MS, FASCO  
Geoffrey R. Oxnard, MD, FASCO  
Nayan Parekh, PhD, FASCO  
Dinesh Pendharkar, MD, PhD, FASCO  
Jeffrey M. Peppercorn, MD, MPH, FASCO  
W. Kimryn Rathmell, MD, PhD, MMHC, FASCO  
Katherine E. Reeder-Hayes, MD, MBA, MSc, FASCO  
Gregory J. Riely, MD, PhD, FASCO  
Julia Howe Rowland, PhD, FASCO  
Jennifer E. Schwartz, MD, FRCPC, FASCO  
Rahul Seth, DO, FASCO  
Rachna T. Shroff, MD, FASCO  
Navneet Singh, MD, DM, FRCPC, FASCO  
Patricia A. Spears, FASCO  
Scott T. Tagawa, MD, MS, FACP, FASCO  
Antoinette R. Tan, MD, MHS, FASCO  
Tiffany A. Traina, MD, FASCO  
Apostolia M. Tsimberidou, MD, PhD, FASCO  
Nadine Tung, MD, FASCO  
Neha Vapiwala, MD, FACP, FASCO  
Matthew B. Yurgelun, MD, FASCO

### 2023 Conquer Cancer Foundation of ASCO Merit Awards

#### Special Merit Award Recipients

##### Bradley Stuart Beller Endowed Merit Award

This special recognition is given to the trainee or student who submitted the overall highest-ranking abstract as determined by the Scientific Program Committee.

William Chen, MD, University of California, San Francisco

##### Allen S. Lichter, MD, Endowed Merit Award

This special recognition is given to the trainee or student who submitted the second-highest ranking abstract as determined by the Scientific Program Committee.

Irene Reijers, MD, Netherlands Cancer Institute

##### Brigid Leventhal Special Merit Award

In honor of Brigid Leventhal, a physician-pioneer in pediatric research, the Brigid Leventhal Merit Award is presented to the trainee or student who submitted the highest-ranking abstract in pediatrics as determined by the Scientific Program Committee's Pediatrics Subcommittee.

Evan Neczypor, University of Chicago Pritzker School of Medicine

##### Pain and Symptom Management Special Merit Award

This special recognition is given to the trainee or student who submitted the highest-ranking abstract in pain and symptom management research as determined by the Scientific Program Committee.

Biplov Adhikari, MD, MedStar Union Memorial Hospital

##### James B. Nachman Endowed ASCO Junior Faculty Award in Pediatric Oncology

Established in memory of James B. Nachman, MD, professor of pediatrics at The University of Chicago and an internationally renowned pediatric cancer expert, this award is given to the junior faculty member who submitted the highest-ranking abstract in pediatric oncology as determined by the Scientific Program Committee.

Amy Armstrong, MD, Washington University in St. Louis

#### Merit Award Recipients

Merit Awards are given annually in recognition of outstanding abstracts submitted to the Annual Meeting. The Merit Award program was established to encourage more trainees and students to attend the Annual Meeting and to further promote clinical research in young scientists.

Umar Abdullahi, MBBS, MSc, The Christie NHS Foundation Trust  
Rachel Abelman, MD, Massachusetts General Hospital Cancer Center, Harvard Medical School

Elisa Agostinetto, MD, Institut Jules Bordet, Université Libre de Bruxelles

Luis Aguirre, MD, Moffitt Cancer Center

Muhammad Danyal Ahsan, Weill Cornell Medicine - Qatar

Rand Ajaj, The Hospital for Sick Children Research Institute

Amy An, MD, The University of Texas MD Anderson Cancer Center

Evelyn Arana-Chicas, DrPH, University of Rochester

Jacqueline Aredo, MD, MS, University of California, San Francisco

Prashanth Ashok Kumar, MBBS, Upstate University Hospital

Wint Yan Aung, MD, MS, Northwell Health

Yael Bar, MD, PhD, Massachusetts General Hospital

Syem Barakzai, MD, Massachusetts General Hospital

Justin Barnes, MD, MS, Washington University School of Medicine

Parva Bhatt, MD, Tufts Medical Center

Alexander Boardman, MD, Memorial Sloan Kettering Cancer Center

Sminu Bose, MD, Columbia University Medical Center

Geoffrey Bostany, University of Alabama at Birmingham School of Medicine

Lauren Boyle, DO, MS, The University of Texas Health Science Center - San Antonio

Emma Boys, FRACP, Children's Medical Research Institute, The University of Sydney

Kristen Brantley, PhD, Harvard School of Public Health

Lauren Brown, MBChB, Peter MacCallum Cancer Centre

Leticia Campoverde, MD, University of Miami Hospital, Jackson Memorial Hospital

David Cantor, MD, PhD, University of Pennsylvania

Anthony Carrozzi, HBSc, Princess Margaret Cancer Centre, University Health Network

Dan Ran Castillo, MD, Loma Linda University

Monica Chen, MD, Memorial Sloan Kettering Cancer Center\*

Eric Chen, MD, University Hospitals Seidman Cancer Center

Jane Chen, Warren Alpert Medical School of Brown University

Ronald Chow, MS, Princess Margaret Cancer Centre

Daniel Clausing, MD, University of Alabama at Birmingham

Jared Cohen, MD, Washington University

Veronica Conca, MD, Azienda Ospedaliera Universitaria Pisana, University of Pisa

Kevin Contrera, MD, MPH, The University of Texas MD Anderson Cancer Center

Valerie Crolley, MBBS, MRCP, University College London

Laynara Vitória Da Silva Vieira, Federal University of Piauí

Antonio DAlessio, MD, Imperial College London

Filippo Dall'Olio, MD, Institut Gustave Roussy\*

Edward Dee, MD, Memorial Sloan Kettering Cancer Center

Nicholas Demetriou, Feinberg School of Medicine, Northwestern University

Lisa Derosa, MD, PhD, Institut Gustave Roussy

Hedyeh Ebrahimi, MD, MPH, City of Hope Comprehensive Cancer Center

Minas Economides, MD, New York University

Maha Elsebaie, MBBS, John H. Stroger, Jr. Hospital of Cook County

Elizabeth Faour, MD, Princess Margaret Cancer Centre

Abdul Rehman Farooq, MBBS, Princess Margaret Cancer Centre

Mackenzie Fowler, PhD, University of Alabama at Birmingham

Gabriel Francisco Pereira Aleixo, MD, Cleveland Clinic Foundation\*

Annalice Gandini, MD, IRCCS Ospedale Policlinico San Martino

Diogo Garcia, MD, Mayo Clinic Florida

Georges Gebrael, MD, University of Utah

Arthur Geraud, MD, MSc, Institut Gustave Roussy

Tim Gregory, MD, The University of Texas MD Anderson Cancer Center

Piyush Grover, MBBS, PharmB, Melanoma Institute Australia\*

Alma Habib, MD, Ohio State University

Alec Hansen, MD, University of Utah

Emily Harrold, MBChB, Memorial Sloan Kettering Cancer Center\*

Merve Hasanov, MD, The University of Texas MD Anderson Cancer Center  
 Simon Heeke, PhD, The University of Texas MD Anderson Cancer Center  
 Alberto Hernando-Calvo, MD, Princess Margaret Cancer Centre  
 Florentine Hilbers, PhD, Netherlands Cancer Institute  
 Jeffrey How, MD, The University of Texas MD Anderson Cancer Center  
 S. M. Qasim Hussaini, MD, MS, Johns Hopkins University  
 Jenne Ingrassia, NYU Langone Health  
 Justin Jee, MD, PhD, Memorial Sloan Kettering Cancer Center  
 Jingran Ji, MD, City of Hope  
 Changchuan Jiang, MD, MPH, Roswell Park Comprehensive Cancer Center  
 Xianli Jiang, PhD, The University of Texas MD Anderson Cancer Center  
 Andrew Johns, MD, The University of Texas MD Anderson Cancer Center  
 Philipp Karschnia, MD, Ludwig Maximilian University  
 Fergus Keane, MBChB, MA, Memorial Sloan Kettering Cancer Center\*  
 Hiba Khan, MD, MPH, University of Washington, Fred Hutchinson Cancer Center  
 Julie Koenig, MD, Harvard Radiation Oncology Program  
 Noam Kopmar, MD, University of Washington, Fred Hutchinson Cancer Center  
 Chipso Kwendakwema, MD, Fred Hutchinson Cancer Center  
 Chris Labaki, MD, Dana-Farber Cancer Institute, Brigham and Women's Hospital  
 Kristine Lacuna, MD, CCRP, Columbia University Medical Center  
 Nayan Lamba, MD, Brigham and Women's Hospital  
 Howard Lee, MD, University of California, San Francisco  
 Emily Liang, MD, Fred Hutchinson Cancer Center  
 Sifan Lu, SUNY Downstate Health Sciences University  
 Minke Lucas, MD, Netherlands Cancer Institute\*  
 J. Alberto Maldonado, National Cancer Institute, National Institutes of Health  
 Anna Maloney, MPH, Frank H. Netter MD School of Medicine at Quinnipiac University  
 Naveen Manisundaram, MD, The University of Texas MD Anderson Cancer Center  
 Jennifer Marks, MD, Georgetown University\*  
 Arielle Medford, MD, Massachusetts General Hospital, Harvard Medical School  
 Thais Megid, MD, Princess Margaret Cancer Centre, University Health Network  
 Gordon Moffat, MD, FRCPC, Princess Margaret Cancer Centre, University Health Network, University of Toronto  
 Masood Moghul, MBBS, FRCS (Urol), Royal Marsden Hospital NHS Trust  
 Golnaz Morad, DDS, PhD, The University of Texas MD Anderson Cancer Center  
 Samyukta Mullangi, MD, MBA, Memorial Sloan Kettering Cancer Center  
 Khalis Mustafayev, MD, PhD, The University of Texas MD Anderson Cancer Center  
 Vidhya Nair, DO, Ascension Providence Hospital, Michigan State University  
 Blessie Nelson, MBBS, DMRT, The University of Texas MD Anderson Cancer Center  
 Martina Pagliuca, MD, Institut Gustave Roussy  
 Ishan Paranjpe, MD, Stanford University  
 Rima Patel, MD, Icahn School of Medicine at Mount Sinai  
 Kateryna Petrykey, PhD, St. Jude Children's Research Hospital  
 Kayla Polcari, MD, MPH, University of Chicago  
 Lakshmi Bhavani Potluri, MD, Wayne State University, DMC Sinai-Grace Hospital  
 Naveen Premnath, MD, University of Texas Southwestern Medical Center  
 John Rhee, MD, MPH, Massachusetts General Hospital  
 Irbaz Riaz, MBBS, MS, Dana-Farber Cancer Institute  
 Damian Rieke, MD, Charité Universitätsmedizin Berlin, Freie Universität Berlin and  
 Humboldt- Universität Zu Berlin, Charité Comprehensive Cancer Center, German Cancer Consortium (DKTK)  
 Elizabeth Rodriguez, McGovern Medical School at The University of Texas Health Science Center at Houston  
 Gregory Roloff, MD, University of Chicago  
 Samuel Rosner, MD, Johns Hopkins University

Karina Ruiz-Esteves, MD, Massachusetts General Hospital  
 Nicholas Rydzewski, MD, MPH, National Institutes of Health, National Cancer Institute  
 Kirin Saint, Memorial Sloan Kettering Cancer Center  
 Akhil Santhosh, MD, All India Institute of Medical Sciences, New Delhi  
 Patricia Mae Santos, MD, Memorial Sloan Kettering Cancer Center  
 Jayastu Senapati, MD, DM, The University of Texas MD Anderson Cancer Center  
 Kanan Shah, MD, NYU Grossman School of Medicine  
 Jeffrey Shevach, MD, University of Pennsylvania  
 Belen Sierra-Rodero, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana,  
 Hospital Universitario Puerta de Hierro-Majadahonda  
 Jason Silberman, MD, Massachusetts General Hospital  
 Surbhi Singhal, MD, Stanford University  
 James Smithy, MD, MHS, Memorial Sloan Kettering Cancer Center  
 Joao Paulo Solar Vasconcelos, MD, BC Cancer, Vancouver Cancer Centre  
 Davide Soldato, MD, IRCCS Ospedale Policlinico San Martino, Università degli Studi di Genova  
 Ji Son, MD, MS, The University of Texas MD Anderson Cancer Center  
 Pavlina Spiliopoulou, MD, PhD, Princess Margaret Cancer Centre, University Health Network,  
 University of Toronto\*  
 Alexandra Stanciu, Institut Jules Bordet  
 Ziyin Tang, PhD, Emory University  
 Kekoa Tapparra, MD, PhD, Stanford University  
 Paolo Tarantino, MD, Dana-Farber Cancer Institute\*  
 Akiko Tateishi, MD, PhD, National Cancer Center Hospital  
 Megan Tesch, MD, Dana-Farber Cancer Institute  
 Andrew Tiu, MD, Georgetown University  
 Chinwe Udemgba, University of Chicago  
 Isabella van Duin, MD, University Medical Center Utrecht  
 Floris Verheij, Memorial Sloan Kettering Cancer Center  
 Zachary Walsh, Columbia University Medical Center  
 Xiancheng Wu, MD, University of Pittsburgh  
 Nikhil Yegya-Raman, MD, University of Pennsylvania  
 James Yu, MD, Moffitt Cancer Center  
 \*Supported by a newly endowed Merit Award in 2023.

*These awards are generously supported by Terri Armstrong, Chris Armstrong, and Mark Gilbert, ASCO Employees, the Association of Northern California Oncologists, AstraZeneca, BeiGene, Friends and Family of Dr. and Mrs. Ronald Beller, Dr. and Mrs. Douglas W. Blayney, Breast Cancer Research Foundation®, Bristol Myers Squibb, Stephen A. Cannistra, MD, Jonathan K. and Cora Y. Cho Charitable Fund, Friends, Family, and Colleagues of Dr. Cecil "Pete" Coggins, Michael Craig Cox, PharmD, MHS, BCOP, Trailblazing patient Mark A. Crafts and Generous Supporters of Team Crafty, Bill and Karen Dahut, Steve and Audra Edward, Eisai Inc., Estate of Darla C. Ellis, Epiphany Partners Inc., Flatiron Health, Inc., GlaxoSmithKline Oncology, Harborside, Friends, Colleagues, and Family of Joe Hogan, Melissa M. Hudson, MD, FASCO and Albert E. Weeks, MD, Kimberly Irvine, Nicole M. Kuderer, MD, and Gary H. Lyman, MD, MPH, FASCO, Natasha B. Leighl, MD, FASCO, William T. Leslie, MD, Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company, Maryland/District of Columbia Society of Clinical Oncology, Friends and Colleagues of Theresa Mays, Melanoma Research Foundation, Therese Marie Mulvey, MD, FASCO, Friends and Family of Dr. James B. Nachman, New Rhein Healthcare, LLC, Friends and Colleagues of Dr. Larry Norton, Dr. Kathleen Pritchard Medicine Professional Corporation, The QuadW Foundation, Gabrielle Betty Rocque, MD, MSPH, Sarah Cannon Research Institute, Frances A. Shepherd, MD, FASCO, Stephen A. Sherwin, MD, Drs. Rachna and Puneet Shroff, The Sontag Foundation, Supporters of Innovations and Research in Medical Education, Syndax Pharmaceuticals, Inc., Nizar M. Tannir, MD, Anthony and Marilyn Tolcher, Dr. Michael and Deborah Troner, and William S. Yaus, Jeffrey W. Yaus, and Kathleen Y. Wolin, ScD.*

#### **2023 Annual Meeting Research Awards**

Jacqueline Aredo, MD, MS, University of California, San Francisco  
 Susan Cabello Porrata, University of Puerto Rico, Mayaguez Campus  
 Onyema Chido-Amajuoyi, MD, MPH, Texas A&M School of Medicine/Christus Health



## AWARDS continued

Maha Elsebaie, MD, John H. Stroger, Jr. Hospital of Cook County  
Diana Jaber, George Washington University School of Medicine and Health Sciences  
J. Maldonado, University of Texas Medical Branch, National Institutes of Health  
Nia Mitchell, Duke University School of Medicine  
Jillian Moran, Rutgers University  
Kikelola Oyeleye, MBBS, MPH, Meharry Medical College  
José Valentín López, University of Minnesota

*These awards are generously provided by Association of Northern California Oncologists, Eisai Inc., and Massachusetts Society of Clinical Oncologists.*

### 2023 Career Development Awards

Nour Abuhadra, MD, Memorial Sloan Kettering Cancer Center  
Clark DuMontier, MPH, MD, Brigham and Women's Hospital  
Narjust Florez, MD, Dana-Farber Cancer Institute  
Riaz Gillani, MD, Dana-Farber Cancer Institute  
Lily Gutnik, MD, MPH, University of Alabama at Birmingham  
Gina Keiffer, MD, Thomas Jefferson University Hospital  
Ivan Kotchetkov, MD, Memorial Sloan Kettering Cancer Center  
Shria Kumar, MD, MSCE, University of Miami Miller School of Medicine  
Sally Lau, MD, MPH, New York University School of Medicine  
Paul Lin, PhD, MD, The University of Texas MD Anderson Cancer Center  
Julia McGuinness, MD, Columbia University  
Afaf Osman, MD, University of Utah  
Krishnan Patel, MD, National Cancer Institute\*  
Yoanna Pumpalova, MD, Columbia University  
Irbaz Riaz, MBBS, MS, Mayo Clinic - Arizona  
Kamya Sankar, MD, Cedars-Sinai Medical Center  
Bilal Siddiqui, MD, The University of Texas MD Anderson Cancer Center  
Stephanie M. Smith, MD, MPH, Stanford University  
Puja Umaretiya, MD, Dana-Farber Cancer Institute  
Winston Wong, MD, Memorial Sloan Kettering Cancer Center  
Siddhartha Yadav, MD, Mayo Clinic - Minnesota  
Chen Zhao, MD, National Cancer Institute\*  
*\*Peer-reviewed and determined as fundable but not funded by Conquer Cancer®, the ASCO Foundation.*

*These awards are generously supported by AbbVie, Inc., AstraZeneca, Breast Cancer Research Foundation®, Bristol Myers Squibb, DMV Conquerors, Brandon C. Gromada Head & Neck Cancer Foundation, Janssen Research & Development, LLC., Lilly, Walther Cancer Foundation, and Generous Supporters of the Women Who Conquer Cancer.*

### 2023 Long-term International Fellowship

Musliu Adetola Tolani, MBBS, ChM, FWACS, FMCS  
Home Institution: Ahmadu Bello University (Nigeria)  
Host Institution: Northwestern University

*This award is generously funded through Conquer Cancer®, the ASCO Foundation.*

### 2023 Global Oncology Young Investigator Awards

Sarah Nyagabona, MD, MMed, Muhimbili University of Health and Allied Sciences (Tanzania)  
Michael McNeil, MD, MPH, St. Jude Children's Research Hospital  
Rizine Mzikamanda, MBBS, MMed, Baylor College of Medicine  
Children's Foundation Malawi (Malawi)  
Asteria Kimambo, MD, MMed, Muhimbili University of Health and Allied Sciences (Tanzania)  
Soniya Dulal, MD, DM, B.P.Koirala Institute of Health Sciences (Nepal)

*These awards are generously funded through Conquer Cancer®, the ASCO Foundation.*

### 2023 International Development and Education Awards

Omar Abdihamid, MBBS, Garissa County Hospital, Garissa Cancer Center (Kenya)  
Anita Eseenam Agbeko, MBChB, PhD, FGCS, FWACS, Komfo Anokye Teaching Hospital (Ghana)  
Eduard-Alexandru Bonci, MD, PhD, Prof. Dr. Ion Chiricutu Institute of Oncology (Romania)

Rosa Elena Caballero, MD, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (Mexico/Colombia)  
Sergio Contreras Garduño, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (Mexico)  
Paula Isabel Gimena Franco, MD, St. Luke's Medical Center (Philippines)  
Josh Thomas Georgy, MD, MBBS, DM, Christian Medical College, Vellore (India)  
Alamdar Jafarov, MD, Azerbaijan Medical University (Azerbaijan)  
Adeline Koh Mei Lau, MD, Hospital Umum Sarawak (Malaysia)  
Garima Nirmal, MD, MBBS, DM, Sarvodaya Hospital Faridabad (India)  
Chukwuma Eze Okereke, MBBS, FWACS, Federal Medical Center, Owo (Nigeria)  
Ishtiaq Ur Rahim, MD, MBBS, Square Hospitals Ltd., Dhaka, Bangladesh (Bangladesh)  
Asmita Rayamajhi, MD, MBBS, Birat Medical College and Teaching Hospital (Nepal)  
Panot Sainamthip, MD, Chulalongkorn University (Thailand)  
Daniela Shveid Gerson, MD, MSc, ABC Hospital, Mexico City (Mexico)  
Rogelio N. Velasco, Jr., MD, Lung Center of the Philippines (Philippines)

*These awards are generously supported by AbbVie, Inc.*

### 2023 International Development and Education Awards in Palliative Care

Oumou Kimso, MD, Treichville University Hospital (Côte d'Ivoire)  
Krithika S. Rao, MD, MBBS, Kasturba Medical College, Manipal, Manipal Academy of Higher Education (India)  
Fahmi Usman Seid, MD, Hawassa University College of Medicine and Health Sciences (Ethiopia)  
Sudip Thapa, MD, MBBS, PhD, Bhaktapur Cancer Hospital (Nepal)  
Ulku Miray Yildirim, MD, Istanbul University, Oncology Institute, Pediatric Hematology-Oncology (Turkey)

*These awards are generously funded through Conquer Cancer®, the ASCO Foundation.*

### 2023 International Innovation Grants

Aparna Sharma, MD, All India Institute of Medical Sciences (Mexico)  
Rubina Suwal, MDS, Binaytara Foundation Cancer Center (Nepal)  
Pamela Bakkabulindi, MBChB, Health Support Initiatives (Uganda)  
Haydee Verduzco-Aguirre, MD, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (Mexico)  
Shakilu Jumanne, MD, The University of Dodoma (Tanzania)

*These awards are generously funded through Conquer Cancer®, the ASCO Foundation.*

### 2023 Oncology Summer Internships

Promise Ufomadu, Baylor College of Medicine  
Sofia Pedroza, Baylor College of Medicine  
Destiny Iwuh, Baylor College of Medicine  
Nicole Nyamongo, Baylor College of Medicine  
Michael Allison, Baylor College of Medicine  
Ludvinna BazileRutgers, New Jersey Medical School  
Yaxel Levin-Carrion, Rutgers New Jersey Medical School  
Kimberly Cartagena, Rutgers New Jersey Medical School  
Oladotun Ebunlomo, Rutgers New Jersey Medical School  
Simona Alomary, Rutgers New Jersey Medical School  
Frida Calderon Gutierrez, Ohio State University  
Ellen Essien, Ohio State University  
August Gonzalez, Ohio State University  
Chiamaka Enemu, Ohio State University  
Taylor Weatherly, Ohio State University  
Chizitaram Vanessa Ogbuji, University of Arizona  
Christian Henry, University of Arizona  
Gustavo Miranda, University of Arizona  
Damaris Zapien, University of Arizona  
Esther Melton, University of California, San Francisco  
Marc Anthony Pastor, University of California, San Francisco  
Nawal Hassan, University of California, San Francisco  
Mezvah Nobi, University of Kansas  
Samira Shorey, University of Kansas  
Shefaa Allan, University of Kansas

Alice Azzun, University of Kansas  
 Michael Allevalo, University of Michigan  
 Amanda Rivas, University of Michigan  
 Mana Yacim, University of Michigan  
 Shannon Ballard, University of Mississippi  
 Kaylee Zettler, University of Mississippi  
 Kamryn Davis, University of Mississippi  
 Dustin Bishop, University of Mississippi  
 Hannah Craft, University of Mississippi  
 Awa Jobe, University of Pittsburgh  
 Faith Kehinde, University of Pittsburgh  
 Felix Aggor, University of Pittsburgh  
 Rochelle Fletcher, University of Pittsburgh  
 Tonge Enoch, University of Pittsburgh  
 Carlos Chavez Perez, University of Pennsylvania  
 Jessica Ferber, University of Pennsylvania  
 Evan Rosario, University of Pennsylvania  
 Joshua Pesantes, University of Pennsylvania  
 Royce Hooks, University of Pennsylvania  
 Dominic Chung, University of Pennsylvania  
 Camila Lage, University of Rochester  
 Kalese Goodwin, University of Rochester  
 Oumou Toure, University of Rochester  
 London Smith, University of Rochester  
 Mohammed Almelehi, University of Rochester  
 Diego Villamarin, University of Rochester

*These awards are generously supported by the McKesson Foundation and the R & D Impact Foundation.*

### **2023 Young Investigator Awards**

Fawzi Abu Rous, MD, Henry Ford Health System  
 Duaa Al-Rawi, MD, PhD, Memorial Sloan Kettering Cancer Center  
 Himachandana Atluri, MD, The University of Texas MD Anderson Cancer Center  
 Casey Bermack, PhD, The University of Texas MD Anderson Cancer Center  
 Vincent Bernard Pagan, MD, PhD, The University of Texas MD Anderson Cancer Center  
 Deepak Bhamidipati, MD, The University of Texas MD Anderson Cancer Center  
 Manisha Bhattacharya, MD, MBA, University of Pittsburgh  
 Elizabeth Carstens, MD, Dana-Farber Cancer Institute  
 Tafadzwa L. Chaunzwa, MD, Brigham and Women's Hospital  
 Leena Chehab, MD, Children's Hospital of Philadelphia  
 Lanyi Chen, MD, Columbia University Medical Center  
 Monica Chen, MD, Memorial Sloan Kettering Cancer Center  
 Brian Chernak, MD, Columbia University Medical Center  
 Philip Choi, MD, PhD, Memorial Sloan Kettering Cancer Center  
 Kyle Concannon, MD, The University of Texas MD Anderson Cancer Center  
 Samuel Cytryn, MD, Memorial Sloan Kettering Cancer Center  
 Minas Economides, MD, New York University  
 Roy Elias, MD, Johns Hopkins University  
 Arielle Elkrief, MD, Memorial Sloan Kettering Cancer Center  
 Madhulika Eluri, MD, The University of Texas MD Anderson Cancer Center  
 Kirkpatrick Fergus, MD, University of California, San Francisco  
 Jesús Fuentes Antrás, MSc, MD, University Health Network  
 Kathryn Gessner, MD, PhD, University of North Carolina, Chapel Hill  
 Caitlin Gribbin, MD, MS, Weill Medical College of Cornell University  
 Saurav Halder, MD, Johns Hopkins University  
 Alexandra Haugh, MD, MPH, University of California, San Francisco  
 Emily Harrold, MBBCh, Memorial Sloan Kettering Cancer Center  
 S. M. Qasim Hussaini, MD, MS, Johns Hopkins University  
 Jeremy B. Jacox, MD, PhD, Yale University  
 Justin Jee, MD, PhD, Memorial Sloan Kettering Cancer Center  
 Jingran Ji, MD, City of Hope  
 Kristine Karvonen, MD, Seattle Children's Research Institute  
 Monica Kasbekar, MD, PhD, Columbia University Medical Center  
 Andrew Katims, MD, MPH, Memorial Sloan Kettering Cancer Center  
 Fergus Keane, MBChB, MA, Memorial Sloan Kettering Cancer Center  
 Hiba Khan, MD, MPH, Fred Hutchinson Cancer Center  
 Danielle Kirkey, MD, Fred Hutchinson Cancer Center

Kristine Lacuna, CCRP, MD, Columbia University Medical Center  
 Arjun Lakshman, MD, MBBS, MRCP, Mayo Clinic - Minnesota  
 Pietro Lapidari, MD, Gustave Roussy  
 Hugo Lara-Martinez, MD, University of Southern California  
 Yonit Lavin, MD, PhD, Memorial Sloan Kettering Cancer Center  
 Marla Lipsyc-Sharf, MD, Dana-Farber Cancer Institute  
 Justin Lo, MD, PhD, Vanderbilt University Medical Center  
 Jaclyn LoPiccolo, MD, PhD, Dana-Farber Cancer Institute  
 Gohar Manzar, MD, PhD, The University of Texas MD Anderson Cancer Center  
 Meredith McAdams, MD, National Cancer Institute\*  
 Arielle Medford, MD, Massachusetts General Hospital  
 Jeremy Meier, MD, PhD, University of North Carolina, Chapel Hill  
 Xiaoli Mi, MD, Memorial Sloan Kettering Cancer Center  
 Guilherme Nader Marta, MD, Institut Jules Bordet  
 Haley Newman, MD, Children's Hospital of Philadelphia  
 Anthony T. Nguyen, MD, PhD, Cedars-Sinai Medical Center  
 Timothy Ohlsen, MD, Seattle Children's Research Institute  
 Andrew Pellatt, MD, The University of Texas MD Anderson Cancer Center  
 Curtis Perry, MD, PhD, Yale University  
 Meera Ragavan, MD, MPH, University of California, San Francisco  
 Yun Ryu, MD, PhD, Columbia University Medical Center  
 Elizabeth Sakach, MD, Emory University  
 Khaled Sanber, MD, PhD, Johns Hopkins University  
 Patricia Mae Garcia Santos, MD, MS, Memorial Sloan Kettering Cancer Center  
 Enrique Sanz Garcia, MD, PhD, University Health Network  
 Kara Schenk, MD, Johns Hopkins University  
 Brett Schroeder, MD, National Cancer Institute\*  
 Anthony Serritella, MD, Northwestern University  
 Irtiza Sheikh, DO, The University of Texas MD Anderson Cancer Center  
 Alexander Sherry, MD, The University of Texas MD Anderson Cancer Center  
 Brian Shinder, MD, Memorial Sloan Kettering Cancer Center  
 Anupriya Singhal, MD, PhD, Memorial Sloan Kettering Cancer Center  
 Sarah Skuli, MD, PhD, University of Pennsylvania  
 Anna Jo Smith, MD, University of Pennsylvania  
 Pavlina Spiliopoulou, PhD, MD, University Health Network  
 Andrew Srisuwananukorn, MD, Icahn School of Medicine at Mount Sinai  
 Robert Stanley, MD, PhD, Memorial Sloan Kettering Cancer Center  
 Andrew Stiff, MD, PhD, Ohio State University  
 Jane Sze Yin Sui, MBBCh BAO, MRCP, Memorial Sloan Kettering Cancer Center  
 Michael Sun, MD, Weill Medical College of Cornell University  
 Lynn Symonds, MD, University of Washington  
 Kekoa Tapparra, MD, PhD, Stanford University  
 Rohit Thummalapalli, MD, Memorial Sloan Kettering Cancer Center  
 Joshua Tobin, MD, PhD, The University of Queensland  
 Seda Tolu, MD, Columbia University Medical Center  
 Jennifer Tsai, MD, PhD, Memorial Sloan Kettering Cancer Center  
 Samuel Urrutia, MD, The University of Texas MD Anderson Cancer Center  
 Johannes van der Mijn, PhD, MD, The Netherlands Cancer Institute  
 Yuxuan Wang, MD, PhD, Johns Hopkins University  
 H. Catherine Wilbur, MD, Johns Hopkins University  
 Nina Theresa Yoh, MD, Columbia University Medical Center  
 Jacob Zaemes, MD, Georgetown University Medical Center  
 Yumeng Zhang, MD, Moffitt Cancer Center, University of South Florida  
 \*Peer-reviewed and determined as fundable but not funded by Conquer Cancer®, the ASCO Foundation.

*These awards are generously provided by Anonymous, AbbVie, Inc., AbbVie Oncology, American Association for Cancer Research, American Society of Clinical Oncology, Association for Value-Based Cancer Care, Association of Northern California Oncologists, AstraZeneca, Dr. Charles M. Baum and Carol A. Baum, Franci Blassberg and Joe Rice, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals, Inc., Nina Lesavoy Brady, Breast Cancer Research Foundation®, Bristol Myers Squibb, Howard A. Burris, III, MD, and Karen Y. Burris, Stephen A. Cannistra, MD, Casdin Family Foundation, Mr. and Mrs. Charles and Trisha Elcan, Epiphany Partners, Inc., F Cancer, Florida Society of Clinical Oncology, Dr. and Mrs. Thomas F. Frist, Jr., Gateway for Cancer Research, GlaxoSmithKline Oncology, HELSINN, Friends and Family of Dr. Arti*

## **AWARDS** *continued*

Hurria, Illumina, Janssen Oncology, Journal of Clinical Oncology, Dr. Judith and Alan Kaur, LA Kunkel Foundation, The John and Elizabeth Leonard Family Foundation, Lilly, Lobular Breast Cancer Alliance, Massachusetts Society of Clinical Oncologists, Georgia and Michael Michelson, Victoria H. Montgomery, Dr. Anne Moore, New Rhein Foundation, Novartis Oncology, Pediatric Oncologists and Friends of Conquer Cancer, Pfizer Oncology, The QuadW Foundation Inc, The Norman & Ruth Rales Foundation, Thomas G. Roberts, Jr., MD, FASCO, and Susan M. DaSilva, DNP, Colleagues, Friends, and Family of Dr. Gladys Rodriguez and Dr. Narjust Florez, Sapiente Family Foundation, Sarah Cannon Research Institute, Aaron and Barbro Sasson, Friends and Family of Hattie Sherman, The Sontag Foundation, Strike 3 Foundation, Swim Across America, Texas Society of Clinical Oncology, Tomasello Family, Vaniam Group LLC., Wawa Foundation, Generous Supporters of the Women Who Conquer Cancer, and Women Leaders in Oncology LLC.

### **Conquer Cancer Funded Research**

Conquer Cancer®, the ASCO Foundation, congratulates the following award recipients whose abstracts were selected for the 2023 Annual Meeting. Their abstracts include the results of the research funded by Conquer Cancer®, the ASCO Foundation. Visit [CONQUER.ORG](http://CONQUER.ORG) for more information about the impact of the Conquer Cancer Grants and Awards Program.

Aaron Mitchell, MD, MPH, 2017 Young Investigator Award, Abstract 6599  
Abdulazeez Salawu, PhD, MBBS, MSc, MRCP, 2022 Young Investigator Award, Abstract 11509  
Alexander Boardman, MD, 2022 Young Investigator Award, Abstract 2513  
Allison Betof Warner, MD, PhD, 2022 Career Development Award, Abstract TPS9606  
Andrew Hantel, MD, 2022 Career Development Award, Abstract 6525  
Andrew Hantel, MD, 2022 Career Development Award, Abstract 6540  
Anurekha Hall, MD, MS, 2021 Young Investigator Award, Abstract 10026  
Christopher Jensen, MD, MS, 2021 Young Investigator Award, Abstract 12065  
Daniel Lage, MD, 2020 Career Pathway Grants in Symptom Management, Abstract 1544  
Deborah Forst, MD, 2019 Career Development Award, Abstract 12008  
Erin Bange, MD, 2021 Young Investigator Award, Abstract 1537  
Gladys Rodriguez, MD, 2022 Young Investigator Award, Abstract 6558  
Gulam Manji, MD, 2015 Young Investigator Award, Abstract TPS4200  
Harshraj Leuva, MBBS, 2021 Young Investigator Award, Abstract 5076

Heather McArthur, MD, MPH, 2019 Advanced Clinical Research Award, Abstract TPS635  
Joannie Ivory, MD, MSPH, 2022 Young Investigator Award, Abstract 1055  
Lilit Karapetyan, MD, MSc, 2022 Young Investigator Award, Abstract 9565  
Manoj Menon, MD, 2018 Young Investigator Award, Abstract 582  
Maria Alice Franzoi, MD, 2022 Career Development Award, Abstract 12081  
Mariya Rozenblit, MD, 2020 Young Investigator Award, Abstract 576  
Mateo Mejia Saldarriaga, MD, 2022 Young Investigator Award, Abstract 8058  
Mengxi Zhou, MSc, 2021 Young Investigator Award, Abstract 5085  
Merve Hasanov, MD, 2022 Young Investigator Award, Abstract 2012  
Nayan Lamba, MD, BA, 2022 Young Investigator Award, Abstract 2011  
Neelima Vidula, MD, 2020 Career Development Award, Abstract TPS1134  
Omolola Salako, MBBS, 2021 International Innovation Grant, Abstract 6628  
Shahla Bari, MD, 2021 Young Investigator Award, Abstract 4564  
Stephen Bagley, MD, MSCE, 2020 Career Development Award, Abstract 2004  
Sushma Agrawal, MD, 2020 International Innovation Grant, Abstract 4016  
William Chen, MD, 2022 Young Investigator Award, Abstract 2009  
Alyssa Pereslete, 2022 Medical Student Rotation for Underrepresented Populations, Abstract e21216  
Atul Batra, MD, DM, 2021 International Innovation Grant, Abstract e13528  
David Yang, MD, 2022 Young Investigator Award, Abstract e17002  
Jessica Hawley, MD, MS, 2019 Young Investigator Award, Abstract e17089  
Kah Poh Loh, MBCh, MS, 2022 Career Development Award, Abstract e13678  
Laura Petrillo, MD, 2020 Career Development Award, Abstract e24210  
Risa Wong, MD, 2020 Career Pathway Grants in Symptom Management, Abstract e17019  
Sridevi Rajeeve, MD, 2022 Young Investigator Award, Abstract e13626  
Wenxin Xu, MD, 2020 Young Investigator Award, Abstract e16518  
Yanin Chavarri Guerra, MD, MSc, 2021 International Innovation Grant, Abstract e18592

*All listings are as of April 20, 2023, and reflect institutions at the time of award. See [ASCO.org/grants-awards](http://ASCO.org/grants-awards) for an up-to-date list of grant and award recipients.*

## INDUSTRY EXPERT THEATER SCHEDULE

The Industry Expert Theaters, located in the back of the Exhibit Hall, to the left of the Food Court, bring together industry leaders and attendees for hour-long, nonaccredited educational presentations on the latest in oncology practices, products, services, and technologies.

Most sessions will be offered in person during the Meeting and will also be available on-demand after the Meeting at [am.asco.org](http://am.asco.org).

Industry Expert Theater sessions are not official presentations of the 2023 ASCO Annual Meeting and are not sponsored, endorsed, or accredited by ASCO, Association for Clinical Oncology, CancerLinQ, or Conquer Cancer<sup>®</sup>, the ASCO Foundation. These sessions are not CME-accredited.

*This schedule is subject to change. Information listed is current as of March 24, 2023. For the most up-to-date information, please visit [am.asco.org](http://am.asco.org).*

### Saturday, June 3

**Time:** 9:30 AM–10:30 AM

**Title:** A Treatment Option for Patients With Myelodysplastic Syndromes

**Description:** Educational presentation on the first and only erythroid maturation agent.

**Company:** Bristol Myers Squibb

**Presenter:** Christina Hughes, PhD, Senior Director, U.S. Medical Myeloid, Reblozyl Lead, Bristol Myers Squibb

**Location:** Theater 1

**Time:** 9:30 AM–10:30 AM

**Title:** Future Developments in Tumor Treating Fields in Oncology

**Description:** Tumor Treating Fields (TTFields) are electric fields that exert physical forces to disrupt cellular processes critical for cancer cell viability and tumor progression. Please join our Industry Expert Theater as we discuss some of the future directions for TTFields.

**Company:** Novocure

**Presenter:** Moshe Giladi, PhD, Chief Scientific Officer, Novocure GmbH

**Location:** Theater 2

**Time:** 12:30 PM–1:30 PM

**Title:** LUNSUMIO (mosunetuzumab-axgb): A Novel, First-in-class, T cell Engaging Bispecific Antibody in 3L+ Follicular Lymphoma

**Description:** Join us for a clinical presentation that introduces the first bispecific antibody targeting both CD20 on B cells and CD3 on T cells. Learn about the proposed mechanism of action and its potential impact on patients with FL who have received  $\geq 2$  lines of systemic therapy.

**Company:** Genentech

**Presenter:** Ginna Laport, VP Global Head of Hematology NHL CLL, MDZX, Genentech

**Location:** Theater 1

**Time:** 12:30 PM–1:30 PM

**Title:** The POSEIDON Regimen: IMFINZI<sup>®</sup> (durvalumab) + IMJUDO<sup>®</sup> (tremelimumab-actl) and Platinum-Based Chemotherapy. The First and Only Finite-Course<sup>a</sup> Anti-CTLA-4 in a Dual Immunotherapy + Platinum-Based Chemotherapy<sup>b</sup> Regimen for mNSCLC

**Description:** Presentation of the first dual IO regimen approved for mNSCLC.

**Company:** AstraZeneca

**Presenters:**

Lee Krug, MD, Global Clinical Head, Late Development Oncology, AstraZeneca  
Xiaojin Shi, MD, Global Clinical Program Lead, Late Development Oncology, AstraZeneca

**Location:** Theater 2

**Time:** 3:00 PM–4:00 PM

**Title:** AI-Enabled Precision Medicine is Here: Leveraging Insights Derived From Data to Advance Cancer Care

**Description:** Join us as we explore the intersection of real-world data, machine learning, and genomic sequencing. We will dive into Tempus' suite of technologies and NGS platform which work together to rapidly deliver insights that are transforming precision oncology and revolutionizing patient care.

**Company:** Tempus Labs, Inc.

**Presenters:**

Kate Sasser, Chief Scientific Officer, Tempus Labs, Inc.  
Calvin Chao, MD, SVP of Medical Affairs, Tempus Labs, Inc.

**Location:** Theater 2

**Time:** 3:00 PM–4:00 PM

**Title:** Personalized Immune Therapies for Solid Tumors

**Description:** Immune cell therapies could become the next generation of interventions for solid tumors. Northwest Biotherapeutics is developing cell therapies for solid tumors. The presentation focuses on action mechanisms, immune responses, combination therapies, imaging analyses, and manufacturing considerations.

**Company:** Northwest Biotherapeutics

**Presenter:** Marnix Bosch, MD, PhD, MBA, Chief Technical Officer, Northwest Biotherapeutics

**Location:** Theater 1

### Sunday, June 4

**Time:** 9:45 AM–10:45 AM

**Title:** Sanofi Oncology Pipeline With Focus on Tusamitamab Ravtansine: A Novel CEACAM5-Directed Antibody Drug Conjugate for Patients With Advanced NSCLC

**Description:** Join us for an overview of Sanofi's oncology pipeline with a focus on tusamitamab ravtansine (SAR408701), an ADC selectively targeting CEACAM5-expression tumors with promising antitumor activity and a favorable safety profile in heavily pretreated patients with CEACAM5 positive advanced NSQ NSCLC.

**Company:** Sanofi

**Presenters:**

Phillip Dennis, MD, PhD, Vice President, Lung Cancer Strategy Global Project Head, CEACAM-5, Sanofi Oncology Development  
Giovanni Abbadessa, MD, PhD, Vice President, Head, Oncology Early Development, Sanofi Oncology Development

**Location:** Theater 2

**Time:** 9:45 AM–10:45 AM

**Title:** Shifting the Paradigm for Early Cancer Detection: A Multi-Biomarker Class Approach to Multi-Cancer Early Detection Testing

**Description:** An innovative multi-biomarker class approach to MCED test design is showing great potential in early cancer detection. With cancer estimated to be the number 1 cause of death in the U.S. by 2030, MCED testing combined with standard of care screening may be the paradigm shift needed to help reduce its burden.

**Company:** Exact Sciences

**Presenter:** Tomasz Beer, MD, FACP, Chief Medical Officer and VP Multi-Cancer Early Detection, Exact Sciences

**Location:** Theater 1

**Time:** 11:30 AM–12:30 PM

**Title:** An Overview of Clinical Data for ENHERTU (fam-trastuzumab deruxtecan-nxki) in HER2-Expressing Metastatic Breast Cancer

**Description:** Please join us for an informative program that will cover and explore updated data on the efficacy and safety of ENHERTU.

**Company:** Daiichi Sankyo

**Presenter:** Mary Pinder-Schenck, MD, VP and Head of Global Medical Affairs, Daiichi Sankyo

**Location:** Theater 2

---

**Time:** 11:30 AM–12:30 PM

**Title:** Gilead Sciences' Commitment to Oncology through Scientific Innovation

**Description:** With pioneering science that is driven by our internal discovery efforts & external collaborations, learn more about Gilead's mission to deliver 10+ transformative medicines by 2030.

**Company:** Gilead Sciences, Inc.

**Presenter:** Bill Grossman, MD, PhD, Senior Vice President, Oncology Clinical Development, Gilead Sciences, Inc.

**Location:** Theater 1

---

**Time:** 4:15 PM–5:15 PM

**Title:** Learn about a different approach to BTK inhibition: PP-PT-US-0216@Lilly USA, LLC 2022. All rights reserved.

**Description:** Join this peer-led program to learn more about a different approach to BTK inhibition.

**Company:** Eli Lilly and Company

**Presenter:** John Pagel, MD, PhD, Eli Lilly and Company

**Location:** Theater 1

---

**Time:** 4:15 PM–5:15 PM

**Title:** Treatment Options for Certain Patients With Select Advanced Upper Gastrointestinal Cancers

**Description:** This presentation will: provide an overview of esophageal and gastric cancers; review the clinical data for a treatment option for certain patients with advanced esophageal or GEJ cancer; and review the clinical data for a treatment option for certain patients with advanced gastric or GEJ cancer.

**Company:** Merck & Co., Inc.

**Presenter:** Bryan O'Neill, MD, Medical Consult and Review Physician, Merck & Co., Inc.

**Location:** Theater 2

---

## Monday, June 5

**Time:** 9:30 AM–10:30 AM

**Title:** A Treatment Option for Certain Patients With Locally Advanced or Metastatic Urothelial Carcinoma

**Description:** This presentation will: review data for a treatment option for certain patients with locally advanced or mUC who are cisplatin-ineligible; review a case of a hypothetical patient with mUC; and understand how to monitor and manage potential select adverse reactions associated with this treatment option.

**Company:** Merck & Co., Inc.

**Presenter:** Ved Desai, DO, Medical Consult and Review Physician, Merck & Co., Inc.

**Location:** Theater 2

---

**Time:** 9:30 AM–10:30 AM

**Title:** Advancements in Hematologic Therapies

**Company:** Genentech

**Presenter:** Ginna Laport, VP Global Head of Hematology NHL CLL, MDZX, Genentech

**Location:** Theater 1

---

**Time:** 11:30 AM–12:30 PM

**Title:** Janssen Oncology Invites You to Learn More About a Treatment Option for Patients Diagnosed With Multiple Myeloma who are Relapsed/Refractory and Have Received ≥4 Prior Lines of Therapy

**Company:** Janssen Biotech, Inc.

**Presenter:** Tim J. Peterson, PharmD, BCOP, Medical Science Liaison, Multiple Myeloma, Janssen Biotech, Inc.

**Location:** Theater 1

---

**Time:** 11:30 AM–12:30 PM

**Title:** Treatment Options for Patients With NSCLC (Non–Small Cell Lung Cancer)

**Description:** TAGRISSO in the treatment of NSCLC with certain *EGFR*-mutated genes in both early and late stage lung cancer focuses on both resectable and unresectable tumor growth and the advancement of pertinent survival rates including overall survival and will point on key indications based on clinical trials.

**Company:** AstraZeneca

**Presenter:** Ilker Arslan, MD, Medical Lead Lung Cancer, AstraZeneca Pharmaceuticals-Oncology

**Location:** Theater 2

---

**Time:** 3:00 PM–4:00 PM

**Title:** Explore Data for an FDA-Approved Treatment Option in HR+, HER2- Breast Cancer in Certain Adjuvant or Metastatic Settings. PP-AL-US-2989<sup>®</sup> Lilly USA, LLC 2021. All rights reserved.

**Description:** Join this peer-led program to explore data for an FDA-approved treatment option in HR+, HER2-breast cancer in certain adjuvant or metastatic settings.

**Company:** Eli Lilly and Company

**Presenter:** Stacy Moulder, MD, Associate VP-Global Development Lead, Eli Lilly and Company

**Location:** Theater 1

## ANCILLARY EVENTS DIRECTORY

Below is a list of educational events hosted by other CME-accredited providers taking place in Chicago during the 2023 ASCO Annual Meeting. For more information regarding these events, consult the contact information in the listings below.

*The events listed in this directory are not official events of the 2023 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.*

---

**Title:** Video Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of NonSmall Cell Lung Cancer

**Date and Time:** Friday, June 2, 2023; 6:30 PM-9:00 PM CT (Dinner and Registration 6:00 PM CT)

**Location:** Hilton Chicago, Grand Ballroom—Level 2

**CME Provider and Supporter(s):** This event is organized and accredited by Research to Practice and supported through educational grants provided by AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc., Janssen Biotech Inc., administered by Janssen Scientific Affairs LLC, Lilly, Novocure Inc., Regeneron Pharmaceuticals Inc., and Takeda Pharmaceuticals USA Inc.

**Registration and Contact Information:** To register for this complimentary event, visit <http://www.researchtopractice.com/Meetings/chicago2023>. For additional information, email [meetings@researchtopractice.com](mailto:meetings@researchtopractice.com) or call +1(305)-377-2828/ Toll Free (800)-233-6153.

**Event Summary:** This hybrid CME-accredited event will focus on the latest data and treatment recommendations for the management of lung cancer. Six expert investigators will serve as the faculty, and president of Research To Practice (RTP), Dr. Neil Love, will serve as program moderator.

To support the Consensus or Controversy? (CoC) theme, 6 faculty members will be asked to respond to survey questions related to the management of non-small cell lung cancer (NSCLC). Additionally, 3 junior lung cancer clinical investigators will also complete the survey and provide an explanation or justification for their survey responses and share the scientific rationale guiding their thinking. Then each junior investigator will participate in a video-recorded interview with Dr. Love. After the video interviews, the survey responses from all 9 investigators will be summarized and developed into Treatment Preference Matrices (TPMs) to graphically depict the collective perspectives of the group.

Dr. Love will present summarized survey results and share the TPMs. Video excerpts from the junior investigators interviews will be broadcast, and the faculty will be asked to discuss if they agree or disagree with the junior investigators answers and provide their own perspectives. Each faculty member will present recently published research data and ongoing clinical trials related to the topics and questions addressed via the survey.

Attendees will be able to participate in interactive polling, and results will be juxtaposed with the findings from the investigator survey to observe educational gaps to prompt further discussion.

### Faculty

Neil Love, MD—Moderator  
*Research To Practice*

*\*Additional faculty to be announced.*

---

**Title:** Mastering *MET* and *cMET* and Recognizing Their Role in Advanced NSCLC

**Date and Time:** Friday, June 2, 2023; 7:00 PM-8:00 PM CT (Dinner and Registration at 6:30 PM CT)

**Location:** Hilton Chicago, Continental A

**CME Provider and Supporter(s):** This activity is jointly provided by Oakstone Publishing and PeerVoice, accredited by Oakstone Publishing, and supported by an educational grant from AbbVie.

**Registration and Contact Information:** To register for this event, visit [www.peervoice.com/NSCLC-Chicago23](http://www.peervoice.com/NSCLC-Chicago23). For additional information, email [virginie.colombani@peervoice.com](mailto:virginie.colombani@peervoice.com) or call +33-745-1345-82.

**Event Summary:** This live CME-accredited symposium will provide oncology clinicians who are involved in the care of patients with NSCLC with updates and improved clarity on c-MET protein overexpression and *MET* gene amplification or mutations in NSCLC. The expert panel of three faculty will explore c-MET and *MET* pathways, their influence on prognosis and outcomes in NSCLC, their impact on acquired resistance to targeted therapies, and the practical challenges associated with detecting and targeting these alterations in patients with NSCLC. Through participation in the symposium, clinicians will have improved knowledge on the rationale for targeting c-MET and *MET* pathways in NSCLC, improved knowledge of clinical evidence for the association of c-MET-directed signaling pathways with acquired resistance to targeted therapies, and improved competence in the use of and response to results of recommended testing strategies for evaluation of c-MET overexpression and *MET* amplification or mutations in patients with NSCLC.

### Faculty

D. Ross Camidge, MD, PhD—Course Director  
*University of Colorado Anschutz, University of Colorado Cancer Center*

Jonathan W. Goldman, MD  
*UCLA, Providence St. John's Health Center and UCLA Santa Monica Medical Center*

Edgardo Santos, MD, FACP  
*Genesis Care US, Florida Atlantic University, FLASCO, and The FLASCO Foundation*

---

**Title:** Changing Practice in HR-Positive/*HER2*-Negative Metastatic Breast Cancer: The ADC Edition

**Date and Time:** Saturday, June 3, 2023; 7:00 PM-8:30 PM CT (Registration 6:30 PM-7:00 PM CT)

**Location:** Hilton Chicago, Continental C

**CME Provider and Supporter(s):** This event is organized and accredited by Medscape Oncology and supported by an educational grant provided by Gilead Sciences, Inc.

**Registration and Contact Information:** To register for this event, visit <https://www.medscape.org/symposium/HRposHERnegbreastcancer>. For additional information, email [hwashington@medscapelive.com](mailto:hwashington@medscapelive.com) or call 678-953-0304.

**Event Summary:** Antibody-drug conjugates (ADCs) are a newer therapeutic entity that consists of the monoclonal antibody (mAb) against a tumor-specific (or tumor-overexpressed) antigen, the potent cytotoxic agent, and the linker that joins them. Advances with ADCs in the treatment of hormone receptor (HR)-positive metastatic breast cancer offer opportunities for improved outcomes for many patients. In this symposium, an expert panel will delve into a practical discussion using case studies to highlight important clinical decisions for patients with HR-positive/human epidermal growth factor receptor 2 (*HER2*)-negative metastatic breast cancer.

### Faculty

Aditya Bardia, MD, MPH, FASCO  
*Mass General Hospital Cancer Center, Harvard Medical School*

Komal Jhaveri, MD, FACP  
*Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College*

Paolo Tarantino, MD  
*Dana-Farber Cancer Institute, Harvard Medical School*

---

**Title:** B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence

**Date and Time:** Saturday, June 3, 2023; 6:30 PM-8:30 PM CT (Dinner and Registration at 6:00 PM CT)

**Location:** Hilton Chicago, International South

**CME Provider and Supporter(s):** This event is organized and accredited by Physicians' Education Resource, LLC and supported through educational grants provided by BeiGene USA, Inc. and Lilly.

**Registration and Contact Information:** To register for this event, visit <https://www.gotoper.com/asco23btki>. For additional information, email [info@gotoper.com](mailto:info@gotoper.com) or call (609)-378-3701.

## ANCILLARY EVENTS DIRECTORY continued

**Event Summary:** Inhibition of Bruton's tyrosine kinase (BTK) forms an integral part of the treatment continuum for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL). Applications for BTK inhibitors have advanced both in terms of being applied to earlier lines of therapy, as well as the establishment of next-generation BTK inhibitors. Several BTK inhibitors have been approved in CLL/SLL and MCL; however, the benefit from first-generation agents can be truncated by intolerance of therapy and/or the development of resistance. To address this unmet need, next-generation BTK inhibitors with increased specificity and novel mechanisms of action, including noncovalent, reversible binding, have been developed.

This cutting-edge program will describe the state of the art in therapy for patients with CLL/SLL and MCL and will illustrate innovations incorporated into next-generation BTK inhibitors. Case-based panel discussions will help illustrate how current and emerging approaches can be applied to address unmet medical needs in patients with CLL/SLL and MCL. Throughout the program, attendees will have the opportunity to ask the expert faculty questions to incorporate expert perspectives into clinical practice.

### Faculty

William G. Wierda, MD, PhD—Chair  
*The University of Texas MD Anderson Cancer Center*

Andre H. Goy, MD  
*Hackensack Meridian Health Oncology Care Transformation Service, John Theurer Cancer Center*

Nicole Lamanna, MD  
*Columbia University Irving Medical Center*

Susan M. OBrien, MD  
*University of California, Irvine*

---

**Title:** After More Than a Decade: Can We Now Enhance Treatment of Patients With LA SCCHN?

**Date and Time:** Saturday, June 3, 2023; 7:00 PM-8:00 PM CT (Dinner and Registration at 6:30 PM CT)

**Location:** Hilton Chicago, Continental A

**CME Provider and Supporter(s):** This activity is jointly provided by Oakstone Publishing and PeerVoice, accredited by Oakstone Publishing, and supported by an educational grant from Merck KGaA, Darmstadt, Germany.

**Registration and Contact Information:** To register for this event, visit [www.peervoice.com/SCCHNChicago23](http://www.peervoice.com/SCCHNChicago23). For additional information, email [ayse.potter@peervoice.com](mailto:ayse.potter@peervoice.com) or call +44-754-0688-037.

**Event Summary:** This live program will cover emerging targeted therapies for management of locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). The overall medical education goal of the activity is to help clinicians understand the rationale and clinical data for emerging targeted therapies for patients with LA SCCHN who are chemoradiotherapy (CRT)-eligible and how they may impact future treatment of these patients.

Upon completion of this activity, participants should be able to:

- summarize the strengths and limitations of current standards of care for CRT-eligible locally LA SCCHN,
- evaluate the role of emerging therapeutic options as part of the treatment paradigm for patients with LA SCCHN who are CRT-eligible based on current clinical evidence, and
- identify patient and disease characteristics that may inform eligibility and suitability for novel targeted therapies in patients with LA SCCHN who are CRT-eligible.

### Faculty

Kevin Harrington, PhD, FRCR, FRCP—Course Director  
*The Institute of Cancer Research, The Royal Marsden Hospital*

Barbara Burtness, MD  
*Yale University, School of Medicine, Smilow Cancer Hospital*

Ezra Cohen, MD, FRCPSC, FASCO  
*University of California San Diego, UC San Diego Moores Cancer Center*







**American Society of Clinical Oncology  
2023 ASCO Annual Meeting (June 2 - June 6, 2023)**

*Meeting Program*

**Abstract Key**

**LBA:** Late-Breaking Abstract

**TPS:** Trials in Progress Abstract

Friday, June 2, 2023

**1:00 PM - 2:15 PM Education Session**

**How to Approach Advanced Thyroid Cancer in 2023**

Location: S100a

**Zoukaa Sargi, MD, MPH**

Sylvester Comprehensive Cancer Center, University of Miami  
*Controversies in Surgical Management of Locally Advanced Thyroid Cancer*

**Maria Papaleontiou, MD - Chair**

University of Michigan  
*Recurrent and Metastatic Thyroid Cancer: When and Where Do We Start?*

**Christine H. Chung, MD**

Moffitt Cancer Center  
*Molecular Targeted Therapy for Differentiated and Anaplastic Thyroid Carcinomas*

*Panel Question and Answer*

---

**1:00 PM - 2:15 PM Education Session**

**Local Therapies for Metastatic Sarcoma: Why, When, How?**

Location: S404

**Nadia N. Laack, MD**

Mayo Clinic  
*Radiation Therapy in Metastatic Sarcoma: Modalities, Innovation, and Considerations Across the Ages*

**Kelvin Hong, MD**

Johns Hopkins University  
*New Frontiers in Interventional Oncology for the Treatment of Sarcoma*

**Peter Hohenberger, MD, PhD**

Mannheim University Medical Center, University of Heidelberg  
*The Role of Surgical Therapy for Sarcoma Metastases*

**Nadia Hindi, MD - Chair**

Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Universidad Autónoma de Madrid  
*Incorporating Systemic Therapies With Local Modalities in Metastatic Sarcoma*

*Panel Question and Answer*

---

**1:00 PM - 2:15 PM Education Session**

**Management of Multiple Myeloma in Special Patient Populations: No Patient Left Behind**

Location: E450

**Shakira Jeanene Grant, MBBS**

The University of North Carolina at Chapel Hill  
*Merging Molecular and Aging Assessments to Guide Therapy in Older Patients With Myeloma*

**Sikander Ailawadhi, MD - Chair**

Mayo Clinic  
*The Real-World Impact of Racial and Ethnic Disparity Issues in Multiple Myeloma*

**Claudio Cerchione, MD, PhD**

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS  
*Treatment Options for Patients With Myeloma and Renal Failure*

*Panel Question and Answer*

**1:00 PM - 2:15 PM Education Session**

**Managing a Long and Winding Road: ER-Positive Breast Cancer**

Location: Hall D1

**Michael Gnant, MD, FACS**

Medical University of Vienna  
*Late Recurrences in ER-Positive Breast Cancer: What Else Can We Do?*

**Nicholas C. Turner, MD, PhD—Chair**

The Royal Marsden NHS Foundation Trust  
*Using CDK4/6 Inhibitor in Early-Stage and Advanced HR+ Breast Cancer*

**Cristina Hernando, MD**

Hospital Clinico Universitario  
*Selective Estrogen Receptor Downregulators in Breast Cancer: Where Do We Stand?*

*Panel Question and Answer*

---

**1:00 PM - 2:15 PM Education Session**

**Molecular Profiling in Neuro-oncology: Where Are We, Where Are We Headed, and How Do We Ensure Everyone Can Come Along?**

Location: S102

**Patrick Y. Wen, MD - Chair**

Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School  
*DNA, RNA, and the Methylome: The Role of Next-Generation Sequencing in Brain Tumor Management*

**Mei-Yin Polley, PhD**

University of Chicago Medical Center  
*Precision Oncology Trials for Primary Brain Tumors: One Size Does Not Fit All*

**Alyx B. Porter, MD**

Mayo Clinic  
*Leveling the Playing Field: Addressing Racial, Geographic, and Socio-economic Disparities in Implementation of Brain Tumor Diagnostics*

*Panel Question and Answer*

---

**1:00 PM - 2:15 PM Education Session**

**Next-Generation Approaches to Immuno-oncology in Gastrointestinal Cancers: Beyond Checkpoint Inhibitors**

Location: Arie Crown Theater

**Maria Pia Morelli, MD, PhD**

The University of Texas MD Anderson Cancer Center  
*Current Immuno-oncology Approaches and the Future for New Combinations in Gastrointestinal Cancers*

**J. Randolph Hecht, MD - Chair**

David Geffen School of Medicine at the University of California  
*Vaccines, Oncolytic Viruses, CAR T and Beyond*

**James C. Yang, MD**

National Cancer Institute, National Institutes of Health  
*Neoantigen TCR Cell Therapy in Gastrointestinal Malignancies*

*Panel Question and Answer*

**1:00 PM - 2:30 PM Clinical Science Symposium**

**New Partners for EGFR-Mutant Lung Cancer**

Location: S406

**Sarah B. Goldberg, MD - Chair**  
Yale Cancer Center

**Salman Rafi Punekar, MD - Chair**  
Laura and Isaac Perlmutter Cancer Center, NYU Langone

- 1:00 PM Pasi A. Janne, MD, PhD**  
Dana-Farber Cancer Institute  
*Two Decades of Progress in EGFR-Mutated Non-Small Cell Lung Cancer*
- 1:12 PM Abstract 8508:** Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR-mutated non-small cell lung cancer.  
First Author: Jacqueline V. Aredo, MD, MS
- 1:24 PM Misako Nagasaka, MD, PhD (Discussion of Abstract(s) 8508)**  
Chao Family Comprehensive Cancer Center, University of California Irvine Healthcare  
*Targeting Lung Cancer Where It Starts*
- 1:36 PM Abstract LBA9009:** A phase III study comparing EGFR tyrosine kinase inhibitor (EGFR-TKI) monotherapy and EGFR-TKI with inserted cisplatin (CDDP) plus pemetrexed (PEM) as a first-line treatment in patients (pts) with advanced non-squamous non-small-cell lung cancer (NSqNSCLC) harboring EGFR activating mutation (EGFR-NSqNSCLC): JCOG1404/WJOG8214L, AGAIN study.  
First Author: Shintaro Kanda, MD, PhD
- 1:48 PM Abstract 9013:** Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: Analysis of tissue IHC and ctDNA NGS.  
First Author: Benjamin Besse, MD, PhD
- 2:00 PM Carlos G.M. Ferreira, MD, PhD (Discussion of Abstract(s) LBA9009-9013)**  
Oncoclincas Institute  
*New Friends, Old Friends in EGFR-Mutated Non-Small Cell Lung Cancer*
- 2:12 PM** Panel Question and Answer

---

**1:00 PM - 3:15 PM Workshop**

**In-Person Workshop: Building Partnership During Challenging Conversations With Patients**

*Limited attendance*

Location: S405

**Timothy D. Gilligan, MD, MS, FASCO - Chair**  
Cleveland Clinic

**Tara B. Sanft, MD - Chair**  
Yale University

**Calvin Chou, MD, PhD**  
University of California, San Francisco  
Faculty

**Sonia Malhotra, MD, MS, FAAP, FAAHPM**  
Tulane Medical University  
Faculty

**1:00 PM - 4:00 PM Oral Abstract Session**

**Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft**

Location: S100bc

**Andrew S. Artz, MD, MS - Chair**  
City of Hope National Medical Center

**Vanessa Elaine Kennedy, MD - Chair**  
University of California, San Francisco

- 1:00 PM Abstract 7000:** Safety and efficacy of obecabtagene autoleucl (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed/refractory adult B-cell acute lymphoblastic leukemia (r/r B-ALL): Top line results of the pivotal FELIX study.  
First Author: Claire Roddie, PhD, FRCPATH, MBChB, MRCP
- 1:12 PM Abstract 7001:** Outcomes following brexucabtagene autoleucl administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.  
First Author: Gregory Roloff, MD
- 1:24 PM Abstract 7002:** Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed/refractory T-ALL.  
First Author: LaQuisa C. Hill, MD
- 1:36 PM Rawan Faramand, MD (Discussion of Abstract(s) 7000-7002)**  
H. Lee Moffitt Cancer Center and Research Institute  
*Much Ado About ALL CAR T*
- 1:48 PM** Panel Question and Answer
- 2:00 PM Abstract 7003:** Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspaterecept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)-naive transfusion-dependent (TD) patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS).  
First Author: Guillermo Garcia-Manero, MD
- 2:12 PM Abstract 7004:** IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA).  
First Author: Amer Methqal Zeidan, MBBS
- 2:24 PM Abstract 7005:** A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia.  
First Author: Anthony Selwyn Stein, MD
- 2:36 PM Anand Ashwin Patel, MD (Discussion of Abstract(s) 7003-7005)**  
University of Chicago Medical Center  
*Myeloid for Measure: New Therapeutics in Myelodysplastic Syndromes and Acute Myeloid Leukemia*
- 2:48 PM** Panel Question and Answer
- 3:00 PM Abstract 7006:** Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703.  
First Author: Matthew Joseph Wieduwilt, MD, PhD
- 3:12 PM Abstract 7007:** A phase I trial of dose-adjusted EPOCH plus inotuzumab ozogamicin (InO) in adults with relapsed/refractory (R/R) B lymphoblastic leukemia/lymphoma (B-ALL).  
First Author: Noam Edward Kopmar, MD

## Friday, June 2, 2023

**3:24 PM Abstract 7008:** Specialty cancer care and survival in AYA ALL: A U.S. multi-state analysis.  
First Author: Lori S. Muffly, MD, MS

**3:36 PM George Yaghmour, MD (Discussion of Abstract(s) 7006-7008)**  
USC Norris Cancer Center  
*ALL's Well That Ends Well in ALL*

**3:48 PM** Panel Question and Answer

---

### 1:00 PM - 5:00 PM Workshop

#### In-Person Workshop: Genomics 101 for Oncologists

*Limited attendance. It is recommended to bring a laptop or tablet to this session, though not required.*

Location: S105ab

**Ramaswamy Govindan, MD - Chair**  
Washington University School of Medicine

**Phillip Michaels, MD - Chair**  
Beth Israel Deaconess Medical Center

**Kate P. Shane-Carson, MS, LGC**  
The Ohio State University Medical Center  
*Genetic Counselor Perspective*

**Siddhartha Devarakonda, MD**  
Washington University School of Medicine  
*Medical Oncologist Perspective*

**Michael E. Hurwitz, MD, PhD**  
Yale School of Medicine  
*Medical Oncologist Perspective*

---

### 2:45 PM - 4:00 PM Education Session

#### Personalizing Surveillance in Head and Neck Cancer

Location: S102

**Nishant Agrawal, MD - Chair**  
University of Chicago  
*Monitoring and Surveillance in Head and Neck Cancer*

**Kristen L. Baugnon, MD**  
Emory University School of Medicine  
*Imaging Guidelines and Novel Modalities for Surveillance*

**Glenn J. Hanna, MD**  
Dana-Farber Cancer Institute  
*Genomic and Molecular Modalities for Head and Neck Cancer Surveillance*

*Panel Question and Answer*

---

### 2:45 PM - 4:15 PM Clinical Science Symposium

#### Biomarkers of the Future: New Strategies to Predict Sarcoma Outcomes

Location: S404

**Rashmi Chugh, MD - Chair**  
Michigan Medicine

**Breelyn A. Wilky, MD - Chair**  
University of Colorado Anschutz Medical Campus

**2:45 PM Abstract 11509:** Molecular residual disease (MRD) detection using bespoke circulating tumor DNA (ctDNA) assays in localized soft tissue sarcoma (STS).  
First Author: Abdulazeez Salawu, MBBS, PhD, MSc, MRCP

**2:57 PM Abstract 11510:** The clinical value of tumor-informed minimal residual disease detection in sarcoma.  
First Author: Yiwei Fu

**3:09 PM Brian D. Crompton, MD (Discussion of Abstract(s) 11509-11510)**  
Dana-Farber Cancer Institute  
*Individualized MRD Detection in Sarcomas: How Far Have We Come?*

**3:21 PM Abstract 11511:** Histopathological response (HR) after neoadjuvant chemotherapy (ChT) for high-risk soft tissue sarcomas (STS): A planned analysis of the ISG-STS-1001 trial.  
First Author: Sandro Pasquali, MD, PhD

**3:33 PM Abstract 11512:** Deep learning with whole slides images to predict histological response to neoadjuvant chemotherapy in patients with resectable high grade soft-tissue sarcomas: A multicenter study.  
First Author: Benjamin Adjaj

**3:45 PM To be determined (Discussion of Abstract(s) 11511-11512)**  
*New Perspectives in Pathologic Response to Neoadjuvant Chemotherapy in Sarcomas*

**3:57 PM** Panel Question and Answer

---

### 2:45 PM - 4:15 PM Clinical Science Symposium

#### Knives Out: Surgical Management of Gynecologic Cancers

Location: E451

**John William Moroney, MD - Chair**  
University of Chicago

**David M. O'Malley, MD - Chair**  
James Gynecologic Oncology Mill Run, Ohio State University

**2:45 PM Michael T. McHale, MD**  
University of California, San Diego  
*Knives Out: Surgical Management of Gynecologic Cancers*

**2:57 PM Abstract 5509:** Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up.  
First Author: Lot Aronson, MD

**3:09 PM Abstract 5510:** Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: The CHIPOR randomized phase III trial.  
First Author: Jean-Marc Classe, MD, PhD

**3:21 PM Robert P. Edwards, MD (Discussion of Abstract(s) 5509-5510)**  
UPMC Magee-Womens Hospital  
*The Heat Is On: What Is the Role of HIPEC in Ovarian Cancer Management?*

**3:33 PM Abstract LBA5511:** An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC). A Gynecologic Cancer Inter-group study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE).  
First Author: Marie Plante

**3:45 PM** **Jose Alejandro Rauh-Hain, MD, MPH (Discussion of Abstract(s) LBA5511)**  
The University of Texas MD Anderson Cancer Center  
*Cut Less? Decreasing Morbidity in Early Cervical Cancer*

**3:57 PM** Panel Question and Answer

---

## 2:45 PM - 4:15 PM Education Session

### New Drugs in Oncology: Incorporation Into Practice

Location: E450

**Meredith McKean, MD - Chair**  
Sarah Cannon Research Institute, Tennessee Oncology

**Jayesh Desai, MBBS, FRACP - Chair**  
Peter MacCallum Cancer Centre

**Kathleen N. Moore, MD, MS**  
College of Medicine, University of Oklahoma  
*New Frontiers in Drug Development: Targeting Folate Receptor Alpha*

**Rachna T. Shroff, MD, FASCO**  
University of Arizona Cancer Center  
*FGFR Inhibition: Crossing the Heme/Solid Tumor Divide*

Panel Question and Answer

**Vivek Subbiah, MD**  
The University of Texas MD Anderson Cancer Center  
*Expanding the Benefit: Dabrafenib/Trametinib for BRAF V600E Solid Tumors*

**Karim Fizazi, MD**  
Institut Gustave Roussy, University of Paris-Saclay  
*Taking Radioligands to the Next Level: Targeting PSMA with Lutetium 177*  
Panel Question and Answer

---

## 2:45 PM - 5:45 PM Oral Abstract Session

### Breast Cancer—Local/Regional/Adjuvant

Location: Hall D1

**Kevin Kalinsky, MD, MS - Chair**  
Emory University Hospital

**Katia Khoury, MD - Chair**  
University of Alabama at Birmingham

**2:45 PM** **Abstract LBA500:** Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients with HR+/HER2 early breast cancer.  
First Author: Dennis J. Slamon, MD, PhD

**2:57 PM** **Abstract 501:** Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).  
First Author: Erika P. Hamilton, MD

**3:09 PM** **Abstract 502:** Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial.  
First Author: Nicholas C. Turner, MD, PhD

**3:21 PM** **Nadia Harbeck, MD, PhD (Discussion of Abstract(s) LBA500-502)**  
Ludwig Maximilians University of Munich  
*Cyclin' Through the Inhibitors*

**3:33 PM** Panel Question and Answer

**3:45 PM** **Abstract 503:** Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials.  
First Author: Richard G. Gray

**3:57 PM** **Abstract 504:** Evaluation of PAM50 intrinsic subtypes and risk of recurrence (ROR) scores in premenopausal women with early-stage HR+ breast cancer: A secondary analysis of the SOFT trial.  
First Author: Lauren Claire Brown, MBChB

**4:09 PM** **Abstract 505:** Association of tumor-infiltrating lymphocytes (TILs) with clinicopathologic characteristics and prognosis in young women with HR+/HER2- breast cancer (BC).  
First Author: Megan E. Tesch, MD

**4:21 PM** **Ines Maria Vaz Duarte Luis, MD, PhD (Discussion of Abstract(s) 503-505)**  
Gustave Roussy  
*Thinking Differently About Breast Cancer in Young Women*

**4:33 PM** Panel Question and Answer

**4:45 PM** **Abstract LBA506:** 3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC).  
First Author: Javier Cortes, MD, PhD

**4:57 PM** **Abstract 507:** Differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in sTIL-high and sTIL-low triple-negative breast cancer (TNBC): Biomarker analysis of the NeOPACT trial.  
First Author: Shane R. Stecklein, MD

**5:09 PM** **Abstract 508:** Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials.  
First Author: Robert Kerrin Hills, DPhil, MA, MSc

**5:21 PM** **Justin M. Balko, PhD, PharmD (Discussion of Abstract(s) LBA506-508)**  
Vanderbilt University Medical Center  
*Should Biomarkers Guide Therapy for Early-Stage Breast Cancer?*

**5:33 PM** Panel Question and Answer

---

## 2:45 PM - 5:45 PM Oral Abstract Session

### Central Nervous System Tumors

Location: S100a

**Steven J. Chmura, MD, PhD - Chair**  
University of Chicago Bucksbaum Institute for Clinical Excellence

**Matthias Holdhoff, MD, PhD - Chair**  
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

**2:45 PM** **Abstract 2000:** A phase 0/1b study of AZD1390 plus radiotherapy in patients with recurrent glioblastoma.  
First Author: Nader Sanai, MD

**2:57 PM** **Abstract 2001:** Evaluating the diagnostic performance of <sup>18</sup>F-fluciclovine for detection of recurrent brain metastases after radiation therapy: Results from a prospective phase 2 trial.  
First Author: Rupesh Kotecha, MD

Friday, June 2, 2023

- 3:09 PM Abstract 2002:** Phase II study of short course hypofractionated proton beam therapy incorporating 18F-DOPA-PET/MRI for elderly patients with newly diagnosed glioblastoma. First Author: Sujay A. Vora, MD
- 3:21 PM Abstract 2003:** A phase II study analyzing pre-operative stereotactic radiosurgery followed by resection for patients with 1-4 brain metastases. First Author: Namita Agrawal, MD
- 3:33 PM Arnab Chakravarti, MD (Discussion of Abstract(s) 2000-2003)**  
The Ohio State University  
*Radiation-Based Innovation in Central Nervous System Tumors*
- 3:45 PM** Panel Question and Answer
- 3:57 PM Abstract 2004:** PD1 inhibition and G1TR agonism in combination with fractionated stereotactic radiotherapy for the treatment of recurrent glioblastoma: A phase 2, multi-arm study. First Author: Stephen Joseph Bagley, MD, MSCE
- 4:09 PM Abstract 2005:** Anti-telomerase vaccine in patients with newly diagnosed, unmethylated MGMT glioblastoma: A phase II study. First Author: Antoine F. Carpentier
- 4:21 PM Abstract 2006:** Phase II trial of pembrolizumab in patients with brain metastases. First Author: Priscilla Kaliopi Brastianos, MD
- 4:33 PM Abstract 2007:** INB-200 phase I study of gene modified autologous gamma-delta ( $\gamma\delta$ ) T cells in patients with newly diagnosed glioblastoma multiforme (GBM) receiving maintenance temozolomide (TMZ). First Author: Mina Lobbous, MD, MSPH
- 4:45 PM Betty Kim, MD, PhD (Discussion of Abstract(s) 2004-2007)**  
The University of Texas MD Anderson Cancer Center  
*Still Trying: Novel Immunotherapy Approaches in Central Nervous System Tumors*
- 4:57 PM** Panel Question and Answer
- 5:09 PM Abstract 2008:** Belzutifan treatment for von Hippel-Lindau (VHL) disease-associated central nervous system (CNS) hemangioblastomas (HBs) in the phase 2 LITESPARK-004 study. First Author: Othon Iliopoulos, MD
- 5:21 PM Ian F. Parney, MD, PhD (Discussion of Abstract(s) 2008)**  
Mayo Clinic  
*Discussion*
- 5:33 PM** Panel Question and Answer

---

**2:45 PM - 5:45 PM Oral Abstract Session**

**Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary**

Location: Arie Crown Theater

**Samuel J. Klempner, MD - Chair**  
Mass General Cancer Center

**Mary Uan-Sian Feng, MD - Chair**  
University of California, San Francisco

- 2:45 PM Abstract 4000:** ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer. First Author: Masanori Terashima, MD, PhD, FACS

- 2:57 PM Abstract 4001:** Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial. First Author: Shuqiang Yuan, MD
- 3:09 PM David H. Ilson, MD, PhD (Discussion of Abstract(s) 4000-4001)**  
Memorial Sloan Kettering Cancer Center  
*Is Timing Everything? Immunotherapy in Localized Gastroesophageal Junction and Gastric Cancer*
- 3:21 PM** Panel Question and Answer
- 3:33 PM Abstract 4002:** Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation. First Author: Masatoshi Kudo, MD, PhD
- 3:45 PM Abstract 4003:** Health-related quality of life (HRQoL) in the phase 3 KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) versus placebo plus gem/cis for advanced biliary tract cancer (BTC). First Author: Changhoon Yoo, MD, PhD
- 3:57 PM Abstract 4004:** Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC). First Author: George Lau, MD
- 4:09 PM Namrata Vijayvergia, MD (Discussion of Abstract(s) 4002-4004)**  
Fox Chase Cancer Center  
*Putting the Patient First: PROs and Immune-Related Uh-Ohs*
- 4:21 PM** Panel Question and Answer
- 4:33 PM Abstract LBA4005:** Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: A multicenter randomized phase-II trial (NORPACT-1). First Author: Knut Jørgen Labori, MD, PhD
- 4:45 PM Abstract 4006:** Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial. First Author: Eileen Mary O'Reilly, MD
- 4:57 PM Abstract 4007:** Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study. First Author: Yoshiaki Nakamura, MD, PhD
- 5:09 PM Abstract 4008:** Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC). First Author: Shubham Pant, MD
- 5:21 PM Andrew H. Ko, MD, FASCO (Discussion of Abstract(s) LBA4005-4008)**  
University of California, San Francisco  
*Targets and Triplets in Pancreaticobiliary Tumors*
- 5:33 PM** Panel Question and Answer

**3:00 PM - 4:00 PM Case-Based Panel**

**A Patient's Journey From Early-Stage to Metastatic Lung Cancer**

Location: S406

**Deepa Rangachari, MD - Chair**  
Beth Israel Deaconess Medical Center  
*Moderator*

**Giulia Veronesi, MD**  
European Institute of Oncology  
*Surgeon's Perspective: Selecting the Best Surgical Technique*

**Delvys Rodriguez-Abreu, MD, PhD**  
Hospital Universitario Insular De Gran Canaria  
*Medical Oncology Perspective: Neoadjuvant Versus Adjuvant Therapy—What Guides Us for Every Patient*

**Julia K. Rotow, MD**  
Dana-Farber Cancer Institute  
*Medical Oncology Perspective: Personalized Approaches to Treating Metastatic Disease*

**Jill E. Feldman, MA**  
EGFR Resisters  
*Patient Perspective: A Patient's Perspective in a Personalized Era*  
  
*Panel Question and Answer*

**3:45 PM - 5:00 PM Education Session**

**Creating a Memorable Presentation Through the Integration of Learning Science**

Location: S504

**Jennifer E. Schwartz, MD, FRCPC, FASCO - Chair**  
Indiana University School of Medicine  
*How to Make It Stick: Why Learning Science Is Transformative for Teaching*

**Sam Brondfield, MD, MA**  
University of California, San Francisco  
*Approaching Full Capacity: Cognitive Load Theory and Its Application to Teaching*

**Rami Manochakian, MD**  
Mayo Clinic  
*Acing Teaching: Analogy, Contrasting Cases, and Elaboration*

**Katherine Jean Walsh, MD, FACP**  
Vanderbilt University Medical Center  
*Just in Time! Meeting Your Learners Where They Are*  
  
*Panel Question and Answer*

**4:30 PM - 5:45 PM Education Session**

**Antibody-Drug Conjugates: New Opportunities in Gynecologic Cancer**

Location: S100bc

**Bhavana Pothuri, MD, MS - Chair**  
New York University School of Medicine  
*What's Here and What's on the Horizon*

**Stella K. Kim, MD**  
University of Texas Medical School at Houston  
*Management of Unique Ocular Toxicities*

**Sachia Stonefeld Powell**  
Patient Advocate  
*What Makes Treatment Worth It*  
  
*Panel Question and Answer*

**4:45 PM - 5:45 PM Rapid Abstract Session**

**Developmental Therapeutics—Immunotherapy**  
Location: E450

**Benedito A. Carneiro, MD, MS - Chair**  
Legoretta Cancer Center, Brown University

**Sarah Marie Larson, MD - Chair**  
UCLA Medical Center

**4:45 PM Abstract 2512:** Baseline autoantibody profiling in patients with NSCLC with pre-existing autoimmune diseases or who had received prior anti-PD-1 therapy before enrolling in the TAIL study.  
First Author: Delvys Rodriguez-Abreu, MD, PhD

**4:51 PM Abstract 2513:** Targeting CD47 in lymphoid malignancies with CAR T cells.  
First Author: Alexander Paul Boardman

**4:57 PM Abstract 2514:** Association of common inherited NOD2 mutations with exceptional response to immune checkpoint inhibitors.  
First Author: Megan Babette Barnet, MBBS, PhD, FRACP

**5:03 PM Abstract 2515:** Intestinal microbiome characterization in immune checkpoint inhibition (ICI) resistant disease.  
First Author: Pavlina Spiliopoulou, MD, PhD

**5:09 PM Abstract 2516:** Association of ctDNA tumor fraction with survival in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIRO2-Lung/IFCT1301 trial.  
First Author: Filippo Gustavo Dall'Olio, MD

**5:15 PM** Panel Question and Answer

**4:45 PM - 5:45 PM Case-Based Panel**

**Navigating Retroperitoneal Sarcoma: Twists, Turns, and Challenges Ahead**

Location: S404

**Julia Lee Close, MD - Chair**  
University of Florida  
*Moderator*

**Christina Vadala Angeles, MD**  
University of Michigan, Rogel Cancer Center  
*Surgical Oncology Perspective*

**Elizabeth H. Baldini, MD, MPH**  
Brigham and Women's Hospital  
*Radiation Oncology Perspective*

**Mark Andrew Dickson, MD**  
Memorial Sloan Kettering Cancer Center  
*Medical Oncologist Perspective*

*Panel Question and Answer*



**Friday, June 2, 2023**

**4:45 PM - 5:45 PM Case-Based Panel**

**Primary CNS Lymphoma: A Patient-Centered Approach to Treatment Selection**

Location: E451

**Carole Soussain, MD, PhD - Chair**

Institut Curie

*Moderator*

**Gerald Illerhaus, MD**

Klinikum Stuttgart, Klinik für Hämatologie, Onkologie und Palliativmedizin  
*Hematology/Oncology Perspective*

**Andrea K. Ng, MD, MPH**

Brigham and Women's Hospital

*Radiation Oncology Perspective*

**Christopher Fox, MD**

Nottingham University Hospitals NHS Trust UK

*Hematology/Oncology Perspective*

*Panel Question and Answer*

**8:00 AM - 8:45 AM Education Session**

**How to Navigate the Annual Meeting (Students, Trainees, and Junior Faculty Only)**

Location: S501

**Aakash Desai, MD, MPH - Chair**  
Mayo Clinic  
*Harnessing the Power of Social Media*

**Andrea Anampa-Guzmán**  
Universidad Nacional Mayor de San Marcos  
*Networking During the Meeting*

**Maria Cecilia Mathias, MD**  
Oncoclínicas  
*Must-See Sessions*  
*Panel Question and Answer*

---

**8:00 AM - 9:00 AM Case-Based Panel**

**Gliomas in Adolescents and Young Adults: Which Paradigm Works Best?**

Location: S504

**Nicholas G. Gottardo, MBChB, PhD, FRACP - Chair**  
Princess Margaret Hospital for Children  
*Moderator*

**Julie Bennett, MD**  
The Hospital for Sick Children  
*Pediatric Oncology Perspective*

**Derek S. Tsang, MD, MSc**  
University of Toronto  
*Radiation Oncologist Perspective*

**Mary Jane Lim-Fat, MD**  
Sunnybrook Health Sciences Center  
*Medical Oncology Perspective*  
*Panel Question and Answer*

---

**8:00 AM - 9:00 AM Case-Based Panel**

**Optimizing Brain Metastases Treatments to Minimize and Manage Neurologic Toxicities**

Location: S100bc

**Lizza Hendriks, MD, PhD - Chair**  
Maastricht University Medical Centre, GROW School for Oncology and Reproduction  
*Moderator*

**Dieta Brandsma, MD, PhD**  
Netherlands Cancer Institute  
*The Medical Oncologist Perspective*

**Vinai Gondi, MD**  
Northwestern Medicine Cancer Center  
*The Radiation Oncologist Perspective*

**Veronica Chiang, MD**  
Yale University  
*The Neurosurgeon's Perspective*  
*Panel Question and Answer*

**8:00 AM - 9:15 AM Education Session**

**Current Therapeutic Targets in Cancer Cachexia: A Pathophysiologic Approach**

Location: E451

**Kunal C. Kadakia, MD - Chair**  
Levine Cancer Institute  
*The Central Nervous System and Cancer Cachexia*

**Jill Hamilton-Reeves, PhD, RD**  
University of Kansas Medical Center  
*Nutrient Signaling and Multimodality Approaches for Cancer Cachexia*

**Vickie Baracos, PhD**  
University of Alberta (Canada)  
*Skeletal Muscle and Cancer Cachexia*  
*Panel Question and Answer*

---

**8:00 AM - 9:15 AM Education Session**

**Emerging Therapies for Colorectal Cancer**

Location: Arie Crown Theater

**Christina Wu, MD**  
Mayo Clinic  
*Molecular Targets in Colorectal Cancer: Moving Beyond EGFR, BRAF, and dMMR*

**Olatunji B. Alese, MD, FWACS - Chair**  
Emory University Winship Cancer Institute  
*Targeting DNA Repair Abnormalities in Microsatellite Stable Colorectal Cancer: An Effective Strategy?*

**Jennifer Rachel Eads, MD**  
University of Pennsylvania  
*Antibody Drug Conjugates in Colorectal Cancer: We Need to Do Better*  
*Panel Question and Answer*

---

**8:00 AM - 9:15 AM Education Session**

**Implementing Innovation: Informatics-Based Technologies to Improve Care Delivery and Clinical Research**

Location: S404

**James C. Yao, MD**  
The University of Texas MD Anderson Cancer Center  
*Sharing Protocols: The Current State of Chemotherapy Protocol Interoperability*

**Travis Osterman, DO, MS, FASCO - Chair**  
Vanderbilt University Medical Center  
*Interoperability in Action: Progress in Implementing the mCODE Oncology Data Standard*

**Monika K. Krzyzanowska, MD, MPH, FRCPC**  
Princess Margaret Cancer Centre  
*Implementing ePROs in Real-World Oncology Practice*  
*Panel Question and Answer*

Saturday, June 3, 2023

**8:00 AM - 9:15 AM Education Session**

**Management of Aggressive Lymphoma**

Location: S100a

**Kerry J. Savage, MD - Chair**

BC Cancer

*Frontline Management of Patients With Peripheral T-Cell Lymphoma*

**Manali K. Kamdar, MD**

University of Colorado Hospital

*Therapeutic Options for Patients With Primary Refractory/Early Relapse of Diffuse Large B-Cell Lymphoma*

**Matthew Steven Davids, MD**

Dana-Farber Cancer Institute

*Advances in the Management of Richter Syndrome*

*Panel Question and Answer*

---

**8:00 AM - 9:15 AM Education Session**

**The Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything In Between**

Location: Hall D2

**Erica Michelle Stringer-Reasor, MD - Chair**

University of Alabama at Birmingham

*Neoadjuvant Therapy in Triple-Negative Breast Cancer: Where We Are and What's Next?*

**Hyo S. Han, MD**

H. Lee Moffitt Cancer Center and Research Institute

*Tailoring Post-Neoadjuvant Therapy in Triple-Negative Breast Cancer*

**Praveen Vikas, MD**

University of Iowa

*Management of Immunotoxicities in the Short and Long Term*

*Panel Question and Answer*

---

**8:00 AM - 9:15 AM Ticketed Session**

**Clinical Controversies: Second-Line Transplant for Nonseminomatous Germ Cell Tumor**

Location: E253d

**Daniel W. Lin, MD - Chair**

University of Washington Medical Center

*Debate Moderator*

**Edmund K. Waller, MD, PhD, FACP**

Emory University

*Pro: Second-Line, High-Dose Chemotherapy in Patients With Refractory/Recurrent NSGCT Saves Lives*

**Christian K. Kollmannsberger, MD, FRCPC**

University of British Columbia

*Con: Standard-Dosing Combination Chemotherapy Is Sufficient for Second-Line Therapy in Most Patients With Recurrent/Refractory NSGCT*

*Panel Question and Answer*

**8:00 AM - 9:30 AM Special Clinical Science Symposium**

**The Promise of Neoadjuvant Immunotherapy Across Solid Tumors**

Location: Hall D1

**Harriet M. Kluger, MD - Chair**

Yale Cancer Center

**8:00 AM Myriam Chalabi, MD, PhD**

Netherlands Cancer Institute

*Harnessing the Power of the Immune System: Will Solid Tumors Respond Better to Immunotherapy in the Neoadjuvant Setting?*

**8:10 AM**

**Abstract LBA100:** KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC. First Author: Heather A. Wakelee, MD, FASCO

**8:20 AM**

**Mark M. Awad, MD, PhD (Discussion of Abstract(s) LBA100)**

Dana-Farber Cancer Institute

*Pre-op, Post-op, or Both? Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer*

**8:30 AM**

**Abstract 101:** The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo. First Author: Irene L.M. Reijers, MD

**8:40 AM**

**Jedd D. Wolchok, MD, PhD, FASCO (Discussion of Abstract(s) 101)**

Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College

*Are We Ready for a Paradigm Shift to Neoadjuvant Immunotherapy in Melanoma?*

**8:50 AM**

**Abstract 102:** Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): Evaluation of immune subtyping in the response predictive subtypes (RPS). First Author: Denise M. Wolf, PhD

**9:00 AM**

**Elizabeth A. Mittendorf, MD, PhD, MHCM, FASCO (Discussion of Abstract(s) 102)**

Dana-Farber Brigham Cancer Center

*I-SPY Biomarkers of Immunotherapy Response: Neoadjuvant Immunotherapy Trials as a Platform for Biomarker Discovery*

**9:10 AM**

Panel Question and Answer

---

**8:00 AM - 11:00 AM Poster Session**

**Developmental Therapeutics—Immunotherapy**

Location: Hall A

Abstracts on Boards 359-370 will be discussed during the Developmental Therapeutics—Immunotherapy Poster Discussion Session. See the online program guide ([meetings.asco.org](http://meetings.asco.org)) for session details.

**Posters by Topic**

**Antibodies:** Boards 367, 371- 379, 505a-505b

**Cellular Immunotherapy:** Boards 359-361, 380-398, 506a-506b

**Circulating Biomarkers:** Boards 399- 403

**Immunobiology:** Boards 364, 404- 410

**New Targets and New Technologies (IO):** Boards 362, 366, 411-430, 507a-509b

**PD1/PD-L1 Inhibitor Monotherapy:** Boards 431- 438, 510a

**PD1/PD-L1 Inhibitor Combinations:** Boards 365, 368, 439-451, 453, 510b, 511a

**Tissue-Based Biomarkers:** Boards 454- 469

**Vaccines:** Boards 370, 470-473, 511b-512a

**Other Checkpoint Inhibitors (Monotherapy or Combination):** Boards 369, 474- 476

**Other IO-Related Topics:** Boards 363, 477-504, 512b- 513b

Board 359 **ABSTRACT 2517:** Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL).  
First Author: Frederick L. Locke, MD

Board 360 **ABSTRACT 2518:** CLDN6 CAR-T cell therapy of relapsed/refractory solid tumors ± a CLDN6-encoding mRNA vaccine: Dose escalation data from the BNT211-01 phase 1 trial using an automated product.  
First Author: Andreas Mackensen, MD

Board 361 **ABSTRACT 2519:** A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors.  
First Author: Benjamin L. Schlechter, MD

Board 362 **ABSTRACT 2520:** A phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors.  
First Author: Dongmei Ji, MD

Board 363 **ABSTRACT 2521:** Safety and early biologic effects of phase 1 PERIO-01 trial of pressure-enabled drug delivery (PEDD) of TLR9 agonist SD-101 and immune checkpoint inhibition (ICI) in uveal melanoma metastatic to the liver (MUM).  
First Author: Kamaneh Montazeri, MD

Board 364 **ABSTRACT 2522:** The immune microenvironment in hormone positive, HER2 negative breast cancer: A focus on tumour infiltrating lymphocytes, spatial phenotypes and tertiary lymphoid structures.  
First Author: Mairi Lucas, MBChB

Board 365 **ABSTRACT 2523:** A phase 1a dose-escalation study of PY159, a monoclonal antibody targeting TREM1 (triggering receptor expressed on myeloid cells 1).  
First Author: Ira Seth Winer, MD, PhD

Board 366 **ABSTRACT 2524:** A phase 1 study of AGEN2373, a novel CD137 agonist antibody designed to avoid hepatotoxicity, in patients with advanced solid tumors.  
First Author: Minal A. Barve, MD

Board 367 **ABSTRACT 2525:** First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors.  
First Author: Adil Daud, MD

Board 368 **ABSTRACT 2526:** A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors.  
First Author: Pei Shu, PhD

Board 369 **ABSTRACT 2527:** A phase 1 dose-escalation study of RiMO-301 with palliative radiation in advanced tumors.  
First Author: Matthew Koshy, MD

Board 370 **ABSTRACT 2528:** AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk with KRAS G12D- or G12R-mutated pancreatic and colorectal cancer.  
First Author: Eileen Mary O'Reilly, MD

Board 371 **ABSTRACT 2529:** Phase 1 first-in-human study of PF-07257876, a novel CD47/PD-L1 bispecific checkpoint inhibitor, in patients with PD-1/PD-L1-refractory and -naive advanced solid tumors.  
First Author: Benedito A. Carneiro, MD, MS

Board 372 **ABSTRACT 2530:** A phase Ib trial of the VEGF fusion protein HB002.1T plus chemotherapy in patients with advanced solid tumors.  
First Author: Junli Xue, PhD

Board 373 **ABSTRACT 2531:** A phase 1, first-in-human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors.  
First Author: Anthony W. Tolcher, MD, FASCO

Board 374 **ABSTRACT 2532:** A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cIn-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.  
First Author: Judy S. Wang, MD

Board 375 **ABSTRACT 2533:** Leveraging innate immunity with AFM24, a novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager: Interim results for the non-small cell lung cancer (NSCLC) cohort.  
First Author: Anthony B. El-Khoueiry, MD

Board 376 **ABSTRACT 2534:** Clinical development of the bispecific PSMαxCD3 antibody CC-1.  
First Author: Christopher Hackenbruch

Board 377 **ABSTRACT 2535:** Preliminary results of a phase I dose escalation study of IMM2510, a PD-L1 and VEGF bispecific fusion protein, in patients with advanced tumors.  
First Author: Xiangdong Cheng, MD

Board 378 **ABSTRACT 2536:** Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors.  
First Author: Ye Guo, MD

Board 379 **ABSTRACT 2537:** Preliminary results of a phase 1/2, first-in-human, open-label, dose escalation study of ZL-1211 (anti-Claudin 18.2 mAb) in patients with unresectable or metastatic solid tumors.  
First Author: Sunil Sharma

Board 380 **ABSTRACT 2538:** A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors.  
First Author: Bob T. Li, MD, PhD, MPH

Board 381 **ABSTRACT 2539:** Peri Cruiser CAR-T: An innovative platform to reduce on-target off-tumor toxicity of CAR-T therapy.  
First Author: Shuangshuang Zhang, PhD

Board 382 **ABSTRACT 2540:** Selective recognition of over-expressed self-antigens in solid tumors using calibrated CAR-T therapy.  
First Author: Farzad Haerizadeh, PhD

Board 383 **ABSTRACT 2541:** A phase 1/2 study of the safety, tolerability, and preliminary efficacy of the anti-GITR monoclonal antibody, INCAGN01876, combined with immunotherapies (IO) in patients (Pts) with advanced cancers.  
First Author: Martin Gutierrez, MD

Board 384 **ABSTRACT 2542:** Effect of a novel expansion process on tumor-infiltrating lymphocyte (TIL) polyfunctionality, cytotoxicity, and expansion, while preserving cells in a less differentiated and more stem-like phenotype.  
First Author: Andrew Yuhas

Board 385 **ABSTRACT 2543:** AFNT-211: An FAS-41BB-enhanced TCR-T cell therapy with stem-like properties targeting KRAS G12V-expressing solid tumors.  
First Author: Michele Hoffmann

- Board 387 **ABSTRACT 2545:** A pilot study of lymphodepletion intensity for PBMC-derived, neoantigen-specific CD8+ T cells (Neo-Ts) therapy in patients with advanced solid tumors.  
First Author: Dandan Li, MD
- Board 388 **ABSTRACT 2546:** A phase 1 dose escalation trial of ex-vivo expanded allogeneic cord blood-derived natural killer cell immunotherapy for pediatric solid tumor malignancies.  
First Author: Sajad Khazal
- Board 389 **ABSTRACT 2547:** Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared *KRAS* and *TP53* mutations expressed by solid tumors in first-in-human phase 1 study.  
First Author: Maria Pia Morelli, MD, PhD
- Board 390 **ABSTRACT 2548:** Effect of the killing style of individual CAR T cells on the clinicopathological behavior of therapeutic products in the clinic.  
First Author: Ahmed Z Gad
- Board 391 **ABSTRACT 2549:** Phase I results of human endogenous retrovirus type-E (HERV-E) TCR transduced T-cells in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC).  
First Author: Rosa Nadal, MD, PhD
- Board 392 **ABSTRACT 2550:** Initial results from a first in human dose escalation trial of a novel immune stimulating oncolytic adenovirus, AdAPT-001<sup>TGF-β Trap</sup>.  
First Author: Anthony Paul Conley, MD
- Board 393 **ABSTRACT 2551:** Harnessing the power of tumor-infiltrating lymphocytes: A first-in-human study of GT201 as monotherapy in advanced solid tumors.  
First Author: Yarong Liu
- Board 394 **ABSTRACT 2552:** MT-6402, an engineered toxin body (ETB) targeting PD-L1: Interim efficacy and safety data.  
First Author: Minal A. Barve, MD
- Board 395 **ABSTRACT 2553:** Preclinical evaluation of targeting PRAME with TCR mimic CAR T cells in AML.  
First Author: Danielle Kirkey, MD
- Board 396 **ABSTRACT 2554:** Product characteristics and clinical trial design for T-Plex: Multiplexed, enhanced T cell receptor engineered T cell therapy for solid tumors.  
First Author: Shrikanta Chattopadhyay, MD
- Board 397 **ABSTRACT 2555:** Preclinical testing of FOLR1-CAR T cells against osteosarcoma (OS).  
First Author: Michelle Choe
- Board 398 **ABSTRACT 2556:** A novel platform to enrich for tumor-specific T cells in non-small-cell lung cancer.  
First Author: Stephanie J Hachey, PhD
- Board 399 **ABSTRACT 2557:** A subset of neutrophils as a predictive biomarker for immunotherapy response in patients with non-small-cell lung cancer and melanoma.  
First Author: Yuval Shaked, PhD, BSc
- Board 400 **ABSTRACT 2558:** The exploratory case-control study on prediction of immune checkpoint inhibitor-induced thyroiditis by human leukocyte antigen types.  
First Author: Yutaka Natori, PhD
- Board 401 **ABSTRACT 2559:** C-reactive protein as a response biomarker to immune checkpoint blockade: A meta-analysis.  
First Author: Alexander B Karol, MD
- Board 402 **ABSTRACT 2560:** Blood-based assessment of patients with mismatch repair-deficient tumors enrolled in NCI-MATCH Arm Z1D (nivolumab).  
First Author: Chris Alan Karlovich, PhD
- Board 403 **ABSTRACT 2561:** Clinical outcomes of immune checkpoint inhibitor treatment in patients with classic cold tumors identified to have a high tumor mutational burden via ctDNA.  
First Author: Reagan Barnett, PhD
- Board 404 **ABSTRACT 2562:** Time-dependent efficacy of immune checkpoint inhibitors in the treatment of metastatic cancers: A meta-analysis.  
First Author: Thierry Landre, PharmD
- Board 405 **ABSTRACT 2563:** Pan-cancer analysis of natural killer (NK) cell infiltration in human malignancies: Molecular features and clinical implications.  
First Author: Nick Zorko, MD, PhD
- Board 406 **ABSTRACT 2564:** Leflitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial.  
First Author: Mirella Nardo, MD
- Board 407 **ABSTRACT 2565:** The prognostic ability of immune scoring system Immunoscore in patients with localized colon cancer: A systematic review and meta-analysis.  
First Author: John Lois Padayao, MD
- Board 408 **ABSTRACT 2566:** Modi-1, anti-citrullinated neoepitope vaccine, alone and combined with checkpoint inhibitors in patients with head and neck, breast, renal, and ovarian cancers: ModifiY phase I/II basket clinical trial—Report after completion of monotherapy dose-finding.  
First Author: Christian H.H Ottensmeier, MD, PhD, FRCP
- Board 409 **ABSTRACT 2567:** Investigation of synthetic lethality gene pairs in the DNA damage response pathway in response to immunotherapy in pan-cancer.  
First Author: Hongyan Huang
- Board 410 **ABSTRACT 2568:** VirMAP for cancer: Characterization of the intratumoral virome in virally associated cancers and a resource for investigators.  
First Author: Yongwoo David Seo, MD
- Board 411 **ABSTRACT 2569:** A phase 1 first-in-human study of interferon beta (IFNβ) and membrane-stable CD40L expressing oncolytic virus (MEM-288) in solid tumors including non-small-cell lung cancer (NSCLC).  
First Author: Andreas Nicholas Saltos, MD
- Board 412 **ABSTRACT 2570:** Uliledimab and toripalimab combination therapy in treatment naive advanced NSCLC: Phase 1b/2 clinical trial results using CD73 as a potential predictive biomarker.  
First Author: Qing Zhou, MD, PhD
- Board 413 **ABSTRACT 2571:** Enhancing STING activation by cyclic dinucleotide-manganese particles for systemic cancer immunotherapy.  
First Author: Xingwu Zhou
- Board 414 **ABSTRACT 2572:** Phase 1 clinical trial results for NG-350A, a novel transgene-armed and tumor-selective vector: Differential effects of intravenous (IV) versus intratumoral (IT) dosing on immune pharmacodynamics (PD).  
First Author: Minesh Patel, BSc
- Board 415 **ABSTRACT 2573:** T cell engager (TCE) score in patients treated with bispecific CD3 TCE in phase I clinical trials.  
First Author: Noé Herbel
- Board 416 **ABSTRACT 2574:** A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors.  
First Author: Jayesh Desai, MBBS, FRACP

- Board 417 **ABSTRACT 2575:** IMPORT-201 (IMP-MEL): A phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist IMM60 and pembrolizumab for advanced melanoma and metastatic non-small cell lung cancer (NSCLC).  
First Author: Nicholas Coupe, MBBS
- Board 418 **ABSTRACT 2576:** Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Updated results from a phase Ib study.  
First Author: Chenyu Mao, MD
- Board 419 **ABSTRACT 2577:** Efficacy and safety of IBI110 in combination with sintilimab and lenvatinib in first-line of advanced hepatocellular carcinoma: Preliminary results from a phase Ib study.  
First Author: Ming Liu, MD
- Board 420 **ABSTRACT 2578:** Dynamic change of immune phenotype assessed by artificial intelligence (AI)-powered analysis of tumor-infiltrating lymphocytes (TILs) during neoadjuvant durvalumab with or without tremelimumab (D+/-T) in head and neck squamous cell carcinoma (HNSCC).  
First Author: Hyunwook Kim, MD
- Board 421 **ABSTRACT 2579:** Multiplexed trackable intratumor microdosing of the investigational STING agonist TAK-676 alone and in combination in the native tumor microenvironment of patients with head and neck cancer: A phase 0 trial.  
First Author: Karthik Rajasekaran, MD
- Board 422 **ABSTRACT 2580:** The initial report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors.  
First Author: Siqing Fu, PhD
- Board 423 **ABSTRACT 2581:** SpliceO: A robust platform for the discovery and validation of splicing-derived neoantigens.  
First Author: Gayatri Arun, PhD
- Board 424 **ABSTRACT 2582:** Patient perspectives on BCMA-targeted therapies for multiple myeloma: A survey conducted in a patient advocacy group.  
First Author: Jennifer M. Ahlstrom, BA
- Board 425 **ABSTRACT 2583:** Use of proteomimetic polymers for delivery of tumor antigens and adjuvants through formation of stable electrostatic complexes with small molecule STING agonists.  
First Author: Max Mu Wang, MPH
- Board 426 **ABSTRACT 2584:** Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.  
First Author: Carlos A. Gomez-Roca, MD
- Board 427 **ABSTRACT 2585:** Relationship between tumor microenvironment (TME)-based histomic TGF $\beta$  signature (TGFBs), stromal fibroblast recruitment, and exclusion of immune cells as immunotherapy resistance mechanisms.  
First Author: Gahee Park, PhD
- Board 428 **ABSTRACT 2586:** Clinical outcomes in phase 1 clinical trials (Ph1-CT) when treating patients (pts) with novel immunotherapy (IT) agents at early lines for advanced disease.  
First Author: Juan José Soto, MD
- Board 430 **ABSTRACT 2588:** Patient-derived skin MicroOrganoSpheres and clinical response to immunotherapy.  
First Author: Rikhia Chakraborty
- Board 431 **ABSTRACT 2589:** Safety and efficacy of HB0025, an anti-PD-1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: Preliminary results from an FIH trial.  
First Author: Yiqun Du, MD
- Board 432 **ABSTRACT 2590:** Efficacy and predictors of response of nivolumab in treatment-refractory MSI solid tumors: Results of a tumor-agnostic DRUP cohort.  
First Author: Birgit S. Geurts, MD
- Board 433 **ABSTRACT 2591:** Immunotherapy for localized dMMR/MSI tumors: First interim analysis of the IMHOTEP trial.  
First Author: Christelle De La Fouchardiere, MD
- Board 434 **ABSTRACT 2592:** Differences in real-world pembrolizumab dosing patterns (every 3 weeks versus every 6 weeks) across a large cancer center network.  
First Author: Divya Natesan
- Board 435 **ABSTRACT 2593:** Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases.  
First Author: Mark Charles Korpics, MD, MS
- Board 436 **ABSTRACT 2594:** Genomic alterations associated with response to immune checkpoint inhibitors in rare cancers: A biomarker exploration study from the Australian Molecular Screening and Therapeutics (MoST) Program.  
First Author: Maya Kansara, BSc Hons, PhD
- Board 437 **ABSTRACT 2595:** Immune checkpoint inhibitor in high-risk oral potentially malignant disorders (IMPEDE study): An interim analysis on safety.  
First Author: Andrea Alberti
- Board 438 **ABSTRACT 2596:** Retrospective analysis on association of ABO blood type and immune checkpoint inhibitor response.  
First Author: Akshee Batra
- Board 439 **ABSTRACT 2597:** Phase II basket trial evaluating the efficacy of pembrolizumab (PE) combined with vorinostat (VO) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma (SCC).  
First Author: Christophe Le Tourneau, MD, PhD
- Board 440 **ABSTRACT 2598:** Phase 1B study of avelumab and whole brain radiotherapy (WBRT) in patients with leptomeningeal disease (LMD) from epithelial carcinomas: Final results and molecular analyses with single cell RNA sequencing.  
First Author: Yolanda Pina, MD
- Board 441 **ABSTRACT 2599:** A phase 1/2 study of retifanlimab (INCMGA00012, Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) combination therapy in patients (Pts) with advanced solid tumors.  
First Author: Omid Hamid, MD
- Board 442 **ABSTRACT 2600:** IMM01 plus tislelizumab in patients with advanced solid tumors and lymphoma: An open-label, multicenter, phase 1b/2 dose escalation and expansion study (IMM01-04).  
First Author: Zhengbo Song, MD, PhD
- Board 443 **ABSTRACT 2601:** A phase 1B dose escalation study of ETC-159 in combination with pembrolizumab in advanced or metastatic solid tumours.  
First Author: David Shao Peng Tan, PhD, FRCP, MBBS
- Board 444 **ABSTRACT 2602:** Deciphering primary and acquired immunotherapy resistance with whole genome and transcriptome analysis (WGTA).  
First Author: Sofia Genta, MD

- Board 445 **ABSTRACT 2603:** PD-1 inhibitors combined with radiotherapy and GM-CSF, sequentially followed by IL-2 (PRaG 2.0) regimen in advanced refractory solid tumors: A prospective, multicenter, single-arm clinical trial.  
First Author: Pengfei Xing
- Board 446 **ABSTRACT 2604:** Durvalumab + tremelimumab in biologically selected advanced/metastatic solid tumors.  
First Author: Christelle De La Fouchardiere, MD
- Board 447 **ABSTRACT 2605:** The impact of renin-angiotensin-aldosterone system inhibitors on immune checkpoint inhibitor-associated adverse cardiovascular events.  
First Author: Cho Hung Chiang, MD
- Board 448 **ABSTRACT 2606:** Updated results and biomarker analyses from the phase 2 trial (BBCAPX study) of sintilimab plus bevacizumab and CapeOx as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer.  
First Author: Ying Yuan
- Board 449 **ABSTRACT 2607:** Prospective cardiovascular surveillance of immune checkpoint inhibitor-based combination therapy in patients with early-stage, triple-negative breast cancer.  
First Author: Vishnu Venkatesh, MD
- Board 450 **ABSTRACT 2608:** The controversial abscopal effect: A single-center experience about the combination of stereotactic radiotherapy with pembrolizumab in patients with metastatic dMMR/MSI-H colorectal cancer.  
First Author: Annalice Gandini, MD
- Board 451 **ABSTRACT 2609:** A novel method that leverages existing data to conduct comparative analyses of competing assets: Sugemalimab and agents targeting the PD-L1/PD-1 axis as an example.  
First Author: Antonio Tito Fojo, MD, PhD
- Board 453 **ABSTRACT 2611:** DURTRERAD: A phase II open-label study evaluating feasibility and efficacy of durvalumab (D) and durvalumab plus tremelimumab (DT) in combination with radiotherapy (RT) in non-resectable locally advanced HPV-negative head and neck squamous cell carcinoma (LA-HNSCC).  
First Author: Ulrich Keilholz, MD
- Board 454 **ABSTRACT 2612:** MyTACTIC: Efficacy and safety of atezolizumab (atezo) + chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR).  
First Author: David R. Spigel, MD, FASCO
- Board 455 **ABSTRACT 2613:** High transferrin receptor expression marks tumors with increased immune-effector infiltration and expression of targetable checkpoint molecules: Results of a multi-cancer analysis in solid tumors.  
First Author: Asaad Trabolsi, MD
- Board 456 **ABSTRACT 2614:** Pan-cancer analysis of IDO1 transcriptome expression and its impact on outcome in patients treated with immune checkpoint inhibitors.  
First Author: Yu Fujiwara, MD
- Board 457 **ABSTRACT 2615:** Distributional range of tumor mutational burden (TMB) across multiple cancer types emphasizing the importance of different cutoff values in different tumor types for clinical interpretation: A consensus statement from the SEQUOIA consortium.  
First Author: Wojciech Swat, PhD
- Board 458 **ABSTRACT 2616:** Quantitative 3D assessment of the lung cancer microenvironment using multi-resolution open-top light-sheet microscopy.  
First Author: Caleb R Stoltzfus, PhD
- Board 459 **ABSTRACT 2617:** Incorporating long non-coding RNA (lncRNA) into genome-wide biomarker screening for prognostic gene signatures of immunotherapy outcomes.  
First Author: Xuefeng Wang, PhD
- Board 460 **ABSTRACT 2618:** Genomic landscapes to characterize mismatch-repair deficiency (dMMR)/microsatellite instability-high (MSI-H) gastrointestinal (GI) cancers stratified by tumor mutation burden (TMB).  
First Author: Jingyuan Wang, PhD
- Board 461 **ABSTRACT 2619:** STK11 alterations as predictive biomarkers of resistance to immune checkpoint inhibitors in multiple cancers with mismatch repair gene alterations.  
First Author: Michael Iglesia, MD, PhD
- Board 462 **ABSTRACT 2620:** The differential response to immune checkpoint inhibitors (ICIs) according to mismatch repair alterations in gastrointestinal (GI) non-colorectal cancers (non-CRCs) and the impact of dual vs. monotherapy ICIs on survival in GI (CRC and non-CRC) cancers.  
First Author: Moh'd M. Khushman, MD
- Board 463 **ABSTRACT 2621:** Artificial intelligence (AI)-powered spatial analysis of macrophages in tumor microenvironment and its association with interferon-gamma (IFNG) signature and immune phenotype (IP) in pan-cancer dataset.  
First Author: Chiyoon Oum, MS
- Board 464 **ABSTRACT 2622:** Spatial distribution of B cells and lymphocyte clusters for the treatment of non-small cell lung cancer.  
First Author: Corinne Ramos, PhD
- Board 465 **ABSTRACT 2623:** Role of HLA class-I antigen peptide loading complex components in immune evasion and treatment sensitivity in human lung cancer.  
First Author: Adrien Costantini, MD
- Board 466 **ABSTRACT 2624:** Pan-cancer associations of B7-H3 (CD276) transcriptional expression across human malignancies.  
First Author: Justin Hwang, PhD
- Board 467 **ABSTRACT 2625:** Clinical and biological activity of FLX475, an oral CCR4 antagonist, in advanced cancer.  
First Author: Dirk G. Brockstedt, PhD
- Board 468 **ABSTRACT 2626:** Novel STK11 differentiation phenotype classifier STK11-DPC: Immunosuppressive tumor microenvironment (TME) and response to immune checkpoint blockade (ICB) in STK11-deficient NSCLC.  
First Author: Jacob Kaufman, MD, PhD
- Board 469 **ABSTRACT 2627:** Tracking plasticity along with proliferation and immune evasion using FOXC1, MKI67 and PDL1 for prediction of therapeutic response and risk for hyperprogressive disease with PD1/PDL1 inhibitors in advanced/metastatic cancers: Pan-tumor validation in clinical trial and real-world cohorts.  
First Author: Partha S Ray, MD
- Board 470 **ABSTRACT 2628:** Phase I evaluation of PRGN-2009 alone and in combination with bintrafusp alfa in patients (pts) with recurrent/metastatic (R/M) HPV-associated cancers (HPV-C).  
First Author: Charalampos S. Floudas, MD, MS, DMSc
- Board 471 **ABSTRACT 2629:** Effect of personalized immunization with GNOS-PV02 of patients with hepatocellular carcinoma on TCR clonal expansion, tumor infiltration, and vaccine-specific reactivity.  
First Author: Renzo Perales, PhD

- Board 472 **ABSTRACT 2630:** Immunogenicity and clinical activity of tipapkinogen sovavivec (TG4001), an HPV-16 cancer vaccine: A randomized phase 2 study in advanced anogenital cancers.  
First Author: Christophe Le Tourneau, MD, PhD
- Board 474 **ABSTRACT 2632:** Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting fusion protein, in combination with atezolizumab in patients with advanced solid tumors.  
First Author: Anwaar Saeed, MD
- Board 475 **ABSTRACT 2633:** A phase I study of nelmastobart (hSTC810), an anti-BTN1A1 antibody, in patients with advanced solid tumors.  
First Author: Soohyeon Lee, MD, PhD
- Board 476 **ABSTRACT 2634:** Using machine learning to characterize lung cancer microenvironment and the development of a model to predict the presence of similar microenvironment in other cancers.  
First Author: Ahmad Charifa, MD
- Board 477 **ABSTRACT 2635:** Multisystem immune-related adverse events from dual agent immunotherapy use.  
First Author: Yuchen Li
- Board 478 **ABSTRACT 2636:** Cardiotoxicity surveillance among patients with cancer treated with immunotherapy.  
First Author: Juliana Goes Martins Fagundes, MD
- Board 479 **ABSTRACT 2637:** Comparing the impact of steroid sparing immunosuppression vs. steroid monotherapy for immune-related adverse events in non-small cell lung cancer and melanoma.  
First Author: Sharjeel Syed, MD
- Board 480 **ABSTRACT 2638:** Immune-related pneumonitis with nivolumab (NIVO)-based treatments for solid tumors: A pooled analysis of 25 phase 3 CheckMate trials.  
First Author: Jarushka Naidoo, MHS, MBBCh
- Board 481 **ABSTRACT 2639:** A phase II randomized trial of talimogene laherparepvec (T-VEC) oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors.  
First Author: Christopher A. Barker, MD
- Board 482 **ABSTRACT 2640:** A phase I/IIa study to assess the safety, tolerability, PK, and PD of T3011, a genetically modified oncolytic virus (OVs) administered intravenously (IV) in patients with advanced solid tumors.  
First Author: Ziming Li, MD
- Board 483 **ABSTRACT 2641:** The incidence of thyroid-related adverse events in solid tumors receiving immune checkpoint blockade with curative intent: A meta-analysis.  
First Author: Susu Zhou, MD
- Board 484 **ABSTRACT 2642:** The study of immune-related adverse events in a community-based centre.  
First Author: Sandhya Cautha
- Board 485 **ABSTRACT 2643:** Association between physical activity, immune-related adverse events, and mortality in patients undergoing immune checkpoint inhibition.  
First Author: Rik Jasper Verheijden, MSc
- Board 486 **ABSTRACT 2644:** Development of a novel immune-related toxicity grading system for predicting outcomes in patients with solid tumours treated with immune checkpoint inhibitors (ICI).  
First Author: Matthaïos Kapiris, MD
- Board 487 **ABSTRACT 2645:** Effect of fecal transplantation on patients' reported outcome after immune checkpoint inhibitor colitis.  
First Author: Yinghong Wang, MD, PhD, MS
- Board 488 **ABSTRACT 2646:** Sex differences in burden of adverse events in patients receiving immunotherapy.  
First Author: Rosalba Miceli, PhD
- Board 489 **ABSTRACT 2647:** Timing of immunotherapy-induced pneumonitis in patients with primary lung malignancy.  
First Author: Megan Winter, DO
- Board 490 **ABSTRACT 2648:** Risk of immune-related adverse events (irAE) with immune checkpoint inhibitors (ICI) in patients (pts) with family history (FH) of autoimmune disease (AID).  
First Author: Piyush Grover, MBBS, BPharm
- Board 491 **ABSTRACT 2649:** Edema and serositis as an adverse event in patients with cancer receiving immune checkpoint blockade: Systematic review to evaluate this immune-related adverse event and associated treatment strategies.  
First Author: Evelyn Elias, MBBCh, MSc
- Board 492 **ABSTRACT 2650:** Immune related adverse events (irAEs) in patients with solid tumors and advanced chronic kidney disease (CKD) receiving checkpoint inhibitors (CPIs).  
First Author: Dalia Kaakour, MD, MS, MPH
- Board 493 **ABSTRACT 2651:** Real-world data: Clinical characteristics and outcomes of patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab in Veteran Health Administration.  
First Author: Munaf Alkadimi, MD
- Board 494 **ABSTRACT 2652:** Frequency of delayed immune-related adverse events (irAEs) in hospitalized patients treated with immune checkpoint inhibitors (ICIs).  
First Author: Sienna Durbin, MD
- Board 495 **ABSTRACT 2653:** Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients (pts) with cardiac metastases (mets) from solid tumors.  
First Author: Amin Nassar, MD
- Board 496 **ABSTRACT 2654:** Pan tumor outcomes to immune checkpoint inhibitors in patients of Native American origin in the United States: The multicenter POINT-US study.  
First Author: Minh Duc Phan, MD
- Board 497 **ABSTRACT 2655:** Incidence and characterization of neurological adverse events among a retrospective cohort of patients receiving immune checkpoint inhibitors.  
First Author: John C. Hunting, MD, MPH
- Board 498 **ABSTRACT 2656:** A comprehensive pan-cancer analysis of PD-L1 expression using clone E1L3N in Chinese patients with cancer.  
First Author: Huangbin Lu
- Board 499 **ABSTRACT 2657:** Fecal microbiota transplantation for refractory immune-checkpoint-inhibitor colitis.  
First Author: Arielle Elkrief, MD
- Board 500 **ABSTRACT 2658:** Factors associated with severe immune checkpoint inhibitor-induced pneumonitis.  
First Author: Hamzah Abu-Sbeih, MD, MSc
- Board 501 **ABSTRACT 2659:** Immune-related adrenal insufficiency: A single center retrospective analysis.  
First Author: Natalya Polshina
- Board 502 **ABSTRACT 2660:** Impact of obesity on the risk of immune-related adverse events (irAEs) among patients receiving immune-checkpoint inhibitors (ICI) treatment: A retrospective cohort study.  
First Author: Mohamed I. Elsaid, PhD, MPH, ALM



- Board 503 **ABSTRACT 2661:** Discontinuation of immunotherapy over 2 years for patients with non-small cell lung cancer (NSCLC): A search for predictors.  
First Author: Priscilla Cascetta, MD
- Board 504 **ABSTRACT 2662:** Incidence, risk factors, and outcomes of immune-related adverse events (irAEs) in a prospective, pan-tumor population.  
First Author: Aanika Balaji, MD, MPH
- Board 505a **ABSTRACT TPS2663:** Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma.  
First Author: Jiajian Liu, PhD
- Board 505b **ABSTRACT TPS2664:** A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors.  
First Author: Jordi Rodon Ahnert, MD, PhD
- Board 506a **ABSTRACT TPS2665:** A phase 1 trial of umbilical cord blood-derived tumor-reactive PD-L1+ natural killer cells engineered to express soluble IL-15 (TRACK-NK) in patients with non-small-cell lung cancer (NSCLC) refractory to PD-1/PD-L1 inhibitors.  
First Author: Miguel Angel Villalona-Calero, MD
- Board 506b **ABSTRACT TPS2666:** A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors.  
First Author: Yara Abdou, MD
- Board 507a **ABSTRACT TPS2667:** Phase I study of NEROFE and doxorubicin in KRAS-mutated ST2-positive solid tumors.  
First Author: Benjamin Adam Weinberg, MD
- Board 507b **ABSTRACT TPS2668:** GNC-038, a tetra-specific antibody, in patients with R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia: A phase 1 study design and rationale.  
First Author: Jianxiang Wang, MD
- Board 508a **ABSTRACT TPS2669:** A phase I/II dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with prospectively confirmed claudin 6-positive solid tumors.  
First Author: Timothy A. Yap, MD, PhD
- Board 508b **ABSTRACT TPS2670:** A phase I/II dose escalation and expansion trial to evaluate safety and preliminary efficacy of BNT141 in patients with claudin-18.2-positive solid tumors.  
First Author: Kyriakos P. Papadopoulos, MD
- Board 509a **ABSTRACT TPS2671:** Trial START-001: A phase 1/2 study of STAR0602, a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors post checkpoint inhibitor (CPI) treatment.  
First Author: Ryan J. Sullivan, MD
- Board 509b **ABSTRACT TPS2672:** A first-in-human study of XTX301, a masked, tumor-activated interleukin-12 (IL-12), in patients with advanced solid tumors.  
First Author: John George Knecht, MD
- Board 510a **ABSTRACT TPS2673:** A phase II study of durvalumab re-treatment +/- prednisone in patients who discontinued prior checkpoint therapy due to immune related toxicity (CCTG IND.238A).  
First Author: Peter Michael Ellis, MD, PhD
- Board 511a **ABSTRACT TPS2675:** High-dose vitamin C to enhance neoadjuvant immune checkpoint therapy in mismatch repair proficient colon cancer: The ALFEO pilot study.  
First Author: Andrea Sartore-Bianchi, MD

- Board 511b **ABSTRACT TPS2676:** Phase 1/2 study of mRNA-4359 administered alone and in combination with immune checkpoint blockade in adult participants with advanced solid tumors.  
First Author: John D. Powderly, MD
- Board 512a **ABSTRACT TPS2677:** Phase 2 trial of epidermal growth factor (EGF) vaccine CIMAvax in combination with pembrolizumab in first line and maintenance setting in advanced non-small cell lung cancer patients.  
First Author: Prantesh Jain, MD, FACP
- Board 512b **ABSTRACT TPS2678:** A phase I trial of diphencyprone for cutaneous neurofibromas in adult patients with neurofibromatosis type 1.  
First Author: Dina Poplasky, BA
- Board 513a **ABSTRACT TPS2679:** A prospective observational study investigating the impact of immune checkpoint inhibitors for cancer on fertility in males and females of child-bearing age (immuno-fertility).  
First Author: Rachel J Keogh

---

**8:00 AM - 11:00 AM Poster Session**

**Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology**

Location: Hall A

Abstracts on Boards 207-218 will be discussed during the Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Poster Discussion Session. See the online program guide ([meetings.asco.org](https://meetings.asco.org)) for session details.

**Posters by Topic**

**Chemotherapy and Antibody-Drug Conjugates:** Boards 212- 214, 219- 227, 351a- 354a

**Circulating Biomarkers:** Boards 228-242, 244- 260

**Molecular Diagnostics and Imaging:** Boards 261- 277

**New Targets and New Technologies (Non-IO):** Boards 215, 278- 288

**Pharmacology:** Boards 289-291

**Radiopharmaceuticals:** Boards 354b- 355b

**Small Molecules:** Boards 207-208, 210, 216-218, 292-308, 356a- 358a

**Tissue-Based Biomarkers:** Boards 209, 309-337

**Other Developmental Therapeutics:** Boards 338-344, 346-350, 358b

- Board 207 **ABSTRACT 3009:** First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy.  
First Author: Timothy A. Yap, MD, PhD
- Board 208 **ABSTRACT 3010:** First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer.  
First Author: Timothy A. Yap, MD, PhD
- Board 209 **ABSTRACT 3011:** FUTURE-SUPER: A randomized, subtyping-based umbrella phase II trial for first-line treatment of metastatic triple-negative breast cancer.  
First Author: Shao Zhimin, MD
- Board 210 **ABSTRACT 3012:** Debio 0123-101: A phase 1 trial of Debio 0123 in combination with carboplatin in advanced solid tumors—Safety, pharmacokinetic, and preliminary antitumor activity data.  
First Author: Hans Gelderblom, MD

- Board 212 **ABSTRACT 3014:** Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: Results from a phase 2 basket trial (HERALD/EPOC1806).  
First Author: Hiroya Taniguchi, MD, PhD
- Board 213 **ABSTRACT 3015:** Dose escalation results from a first-in-human study of ABBV-400, a novel c-Met-targeting antibody-drug conjugate, in advanced solid tumors.  
First Author: Manish Sharma, MD
- Board 214 **ABSTRACT 3016:** First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors.  
First Author: Yakun Wang, PhD
- Board 215 **ABSTRACT 3017:** ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3-targeting antibody-drug conjugate, in patients with advanced solid tumor.  
First Author: Jie Wang, MD
- Board 216 **ABSTRACT 3018:** Phase 1 trial evaluating TTI-101, a first-in-class, orally bioavailable, small molecule, inhibitor of STAT3, in patients with advanced solid tumors.  
First Author: Apostolia Maria Tsimberidou, MD, PhD, FASCO
- Board 217 **ABSTRACT 3019:** Preliminary safety and efficacy of tinengotinib tablets as monotherapy and combination therapy in advanced solid tumors: A phase Ib/II clinical trial.  
First Author: Sarina A. Piha-Paul, MD
- Board 218 **ABSTRACT 3020:** A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors.  
First Author: Alexander E. Drilon, MD
- Board 219 **ABSTRACT 3021:** A phase II study of tinostamustine in patients (pts) with advanced solid tumours.  
First Author: Anna Tinker, MD
- Board 220 **ABSTRACT 3022:** Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.  
First Author: Brian Ko, MD
- Board 221 **ABSTRACT 3023:** Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study.  
First Author: Kathleen N. Moore, MD, MS
- Board 222 **ABSTRACT 3024:** SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001).  
First Author: Antoine Hollebecque, MD
- Board 223 **ABSTRACT 3025:** Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers.  
First Author: Dazhi Liu, PharmD
- Board 224 **ABSTRACT 3026:** A phase 1 dose escalation/expansion study of FID-007, a novel nanoparticle paclitaxel formulation, in patients with solid tumors.  
First Author: Jacob Stephen Thomas, MD
- Board 225 **ABSTRACT 3027:** Mirzotamab clezutoclast as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose expansion results.  
First Author: Benedito A. Carneiro, MD, MS
- Board 226 **ABSTRACT 3028:** A novel genetic marker of fluoropyrimidine-induced cardiovascular toxicity.  
First Author: Claire Palles
- Board 227 **ABSTRACT 3029:** A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors.  
First Author: Fei Ma, MD
- Board 228 **ABSTRACT 3030:** Changes in ctDNA levels as an early indicator of outcomes in advanced NSCLC treated with TKI: Initial findings from a retrospective aggregate analysis of 8 clinical trials.  
First Author: Hillary Stires, PhD
- Board 229 **ABSTRACT 3031:** Plasma lipidomic profiling of chemotherapy-induced peripheral neuropathy.  
First Author: Nicole Yeung, BSc (Hons I)
- Board 230 **ABSTRACT 3032:** First report of ELUCIDATOR study: A prospective observational multicenter study on resistance mechanisms in patients with early disease progression during osimertinib.  
First Author: Yasuyuki Mizumori, MD, PhD
- Board 231 **ABSTRACT 3033:** Diagnostic value of hPG<sub>80</sub>, as a new multi-cancer blood biomarker, in 16 different cancers: Results of the ONCOPRO prospective study.  
First Author: Benoit You, MD, PhD
- Board 232 **ABSTRACT 3034:** First report of tumor-informed circulating tumor DNA in fibrolamellar carcinoma in adolescents and young adults: 51 patients.  
First Author: Elise McKenna
- Board 233 **ABSTRACT 3035:** Early detection of lung cancer using small RNAs.  
First Author: Amita Sharma
- Board 234 **ABSTRACT 3036:** Longitudinal mutational analysis of TP53 in plasma circulating tumor DNA (ctDNA) in patients (pts) with solid tumors in a phase I study of BI 907828, an MDM2-p53 antagonist.  
First Author: Alexander Peltzer
- Board 235 **ABSTRACT 3037:** Long-term clinical outcomes of cancers diagnosed following detection by a blood-based multi-cancer early detection (MCED) test.  
First Author: Adam H Buchanan, MS, MPH
- Board 236 **ABSTRACT 3038:** A novel three-biomarker signature (CA-62, CEA, CYFRA 21-1) and early-stage NSC lung cancer detection.  
First Author: Janneta Tcherkassova, PhD
- Board 237 **ABSTRACT 3039:** Outcomes in participants with a false positive multi-cancer early detection (MCED) test: Results from 4 years follow-up from DETECT-A, the first large, prospective, interventional MCED study.  
First Author: Anne Marie Lennon, MD, PhD
- Board 238 **ABSTRACT 3040:** The detection of multiple cancer types with an extended set of methylation and protein markers.  
First Author: Viatcheslav E Katerov, PhD, MS
- Board 239 **ABSTRACT 3041:** Longitudinal circulating tumor DNA monitoring in patients with esophageal squamous cell carcinoma.  
First Author: Shogo Takei, MD
- Board 240 **ABSTRACT 3042:** A 5-hydroxymethylcytosine-based noninvasive model for ultrasensitive early detection of colorectal advanced adenoma and adenocarcinoma: The METHOD-2 study.  
First Author: Jianmin Xu, PhD

Saturday, June 3, 2023

- Board 241 **ABSTRACT 3043:** Distinguishing between cancer-related mutations and clonal hematopoiesis using cell-free RNA (cfRNA) expression levels in a machine learning model.  
First Author: Maher Albitar, MD
- Board 242 **ABSTRACT 3044:** FS-1502 in HER2-positive advanced breast cancer: Results from an open-label, phase 1 study.  
First Author: Qiao Li, MD
- Board 244 **ABSTRACT 3046:** RAS testing of circulating cell-free DNA (cfDNA) from tissue RAS/BRAF wild-type metastatic colorectal carcinoma (mCRC) patients: Preliminary data from the Liquid Biopsy Monoclonal Antibodies in mCRC (LIBImAb) study.  
First Author: Anna Maria Rachiglio
- Board 245 **ABSTRACT 3047:** Molecular profiling of ctDNA from NCI-MATCH patients enrolled for treatment with mTOR1/2 inhibitor sapanisertib (arm M) and the Hedgehog pathway inhibitor vismodegib (arm T).  
First Author: Jennifer S. LoCoco, PhD
- Board 246 **ABSTRACT 3048:** Construction of DNA methylation-based biomarkers for diagnosis of hepatocellular carcinoma.  
First Author: Ximing Xu
- Board 247 **ABSTRACT 3049:** ctDNA-based genomic landscape analysis to evaluate molecular brake and gatekeeper mutations in FGFR2 alterations.  
First Author: Paul Severson, PhD
- Board 248 **ABSTRACT 3050:** Association of tumor-informed minimal residual disease (MRD) with clinical outcomes for muscle invasive bladder cancer (MIBC): A multicenter retrospective real-world analysis.  
First Author: Ajitha Kommalapati, MD
- Board 249 **ABSTRACT 3051:** Detection of early-stage cancers using circulating orphan non-coding RNAs in blood.  
First Author: Mehran Karimzadeh, PhD
- Board 250 **ABSTRACT 3052:** Development and evaluation of a multi-cancer screening (MCS) test for cancers common in Asia.  
First Author: Michelle Pek, PhD
- Board 251 **ABSTRACT 3053:** CfDNA NGS detection of fusions acquired as mechanisms of resistance in the post-EGFR setting across multiple solid tumors.  
First Author: Arielle Yablonovitch, PhD
- Board 252 **ABSTRACT 3054:** Sequential monitoring of tumor macrophage fusion cells in the circulation of metastatic breast cancer and their prognostic value.  
First Author: Kirby P. Gardner
- Board 253 **ABSTRACT 3055:** Pan-cancer detection and tissue-of-origin identification by whole-genome sequencing of plasma cell-free DNA.  
First Author: Wei Guo, PhD
- Board 254 **ABSTRACT 3056:** Clonal hematopoiesis (CH) associated mutations in patients with advanced solid tumors enrolled in phase I clinical trials.  
First Author: Julieta Rodriguez, MD
- Board 255 **ABSTRACT 3057:** NMR metabolomics in bladder cancer: Identification and monitoring of serum biomarkers during Pt-based treatment.  
First Author: Roberta Giorgione, MD
- Board 256 **ABSTRACT 3058:** Diagnostic application of circulating CDH17 biomarker for screening GI malignancies.  
First Author: Lui Ng, Mphil, PhD
- Board 257 **ABSTRACT 3059:** Concordance of circulating and solid tumor DNA through comprehensive genomic profiling in a large integrated cancer network.  
First Author: William LaFramboise, PhD
- Board 258 **ABSTRACT 3060:** Preclinical circulating tumor DNA (ctDNA) shedding duration and prognostic implications of modeling 3669 participants from American Cancer Society Cancer Prevention Study-3 (CPS-3) and Circulating Cell-free Genome Atlas substudy 3 (CCGA3).  
First Author: Alpa Patel, PhD
- Board 259 **ABSTRACT 3061:** Liquid biopsy identification of ERBB2 amplified and HER2 expressing metastatic breast cancer: Comparison and combination of cell and cell-free platforms.  
First Author: Giuseppe Di Caro, PhD
- Board 260 **ABSTRACT 3062:** ctDNA analysis of NTRK fusion and mechanisms of acquired resistance to TRK inhibitors.  
First Author: Karthigayini Sivaprakasam, PhD
- Board 261 **ABSTRACT 3063:** Potential improvement in the diagnostic accuracy in detecting the estrogen receptor status in metastatic and recurrent breast cancer using 18F-FES PET/CT in the US.  
First Author: Adolfo Fuentes-Alburo, MD
- Board 262 **ABSTRACT 3064:** <sup>68</sup>Ga-FAPI-46 PET for cancer imaging: A prospective single-arm clinical trial.  
First Author: Wolfgang P. Fendler, MD
- Board 263 **ABSTRACT 3065:** Utility of artificial intelligence-based genomic classification of occult malignancies in clinical practice.  
First Author: Sourat Darabi, PhD, MS
- Board 264 **ABSTRACT 3066:** Tumor mutational burden as a predictive biomarker for molecularly matched therapy in two independent pan-cancer cohorts.  
First Author: Damian Tobias Rieke, MD
- Board 265 **ABSTRACT 3067:** A panel of seven protein tumor markers for multi-cancer early detection by artificial intelligence.  
First Author: Shichun Tu
- Board 266 **ABSTRACT 3068:** Deep neural networks to predict pathological invasiveness through surgical resection images: A computer vision based prospective clinical trial in pulmonary nodules.  
First Author: Henian Yao, MS
- Board 267 **ABSTRACT 3069:** Systematic review and meta-analysis of the accuracy and applicability of blood-based multi-cancer early detection (MCED) in the general population.  
First Author: Joo Hee Park, MD
- Board 268 **ABSTRACT 3070:** A machine learning-based multi-dimensional model integrating clinical, radiomics, and cell-free DNA methylation biomarkers for the classification of pulmonary nodules.  
First Author: Wenhua Liang, MD
- Board 269 **ABSTRACT 3071:** Large retrospective validation study of metabolomic biomarkers for resectable lung cancer detection and risk assessment.  
First Author: Philippe Joubert, MD, PhD, FRCP
- Board 270 **ABSTRACT 3072:** Liquid biopsy in combination with PET/CT versus PET/CT alone in diagnosis of lung cancer in small nodules.  
First Author: Rajesh Shah
- Board 271 **ABSTRACT 3073:** MYC amplification segment-size mutual exclusivity analysis with other oncogenic events in a pan-cancer sequencing cohort.  
First Author: Matteo Repetto, MD

- Board 272 **ABSTRACT 3074:** Genomic characterization of FGFR-altered solid tumors using a clinically annotated pan-cancer repository.  
First Author: Noura J. Choudhury, MD
- Board 273 **ABSTRACT 3075:** Detecting early stage breast cancer using low-depth cell-free DNA fragmentomics: A multi-center cohort study.  
First Author: Jiaqi Liu, MD
- Board 274 **ABSTRACT 3076:** Aggregated analysis of 1,000 patients with cancer to assess the benefits of integrated whole exome and whole transcriptome sequencing.  
First Author: Konstantin Chernyshov
- Board 275 **ABSTRACT 3077:** Alternative allele frequency recalibration after NGS data analysis.  
First Author: Maxim Ivanov
- Board 276 **ABSTRACT 3078:** Multimodal machine learning analysis of more than 220,000 tumor profiles to diagnose molecular and morphological subtypes of cancer.  
First Author: Jim Abraham, PhD
- Board 277 **ABSTRACT 3079:** In silico approaches to patient selection: Credentialing elraglusib as a novel treatment in metastatic melanoma resistant to checkpoint inhibitors.  
First Author: Joseph McDermott
- Board 278 **ABSTRACT 3080:** Phase 1/1b study of SY-5609, a selective and potent CDK7 inhibitor, in advanced solid tumors and in 2L/3L pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine +/- nab-paclitaxel.  
First Author: Babar Bashir, MD, MS, FACP
- Board 279 **ABSTRACT 3081:** Tolerability and preliminary activity of the potent, selective, oral CDK7 inhibitor SY-5609 in combination with fulvestrant in patients with advanced hormone receptor-positive (HR+), HER2- breast cancer (BC).  
First Author: Dejan Juric, MD
- Board 280 **ABSTRACT 3082:** Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors.  
First Author: Gottfried E. Konecny, MD
- Board 281 **ABSTRACT 3083:** A phase 1/2, first-in-human trial of ZB131, a novel antibody targeting cancer-specific plectin (CSP) in advanced solid tumors.  
First Author: David Sommerhalder, MD
- Board 282 **ABSTRACT 3084:** First-in-human dose-escalation study of NBF-006, a novel investigational siRNA targeting GSTP, in patients with non-small cell lung, pancreatic, or colorectal cancer.  
First Author: Anthony W. Tolcher, MD, FASCO
- Board 283 **ABSTRACT 3085:** Characterization of MCL-1 in patients with colorectal cancer (CRC): Expression, molecular profiles, and outcomes.  
First Author: Pooja Mittal, MS
- Board 284 **ABSTRACT 3086:** Inpatient comparative efficacy of selective RET inhibitors using growth modulation index in patients with RET aberrant cancers.  
First Author: Mohamed Alaa Gouda, MD, MSc
- Board 285 **ABSTRACT 3087:** CBX-12-101: A first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients (pts) with advanced or metastatic solid tumors.  
First Author: Ildefonso I Rodriguez Rivera, MD
- Board 286 **ABSTRACT 3088:** Comprehensive CRISPR-enabled functional genomics profiling to identify targetable cancer genes in primary acute myeloid leukemia (AML).  
First Author: Stephane Corbel, PhD
- Board 287 **ABSTRACT 3089:** Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study.  
First Author: Funda Meric-Bernstam, MD
- Board 288 **ABSTRACT 3090:** Pan-cancer landscape of FOXA1 alterations: Insights and clinical implications.  
First Author: Edward Christopher Dee, MD
- Board 289 **ABSTRACT 3091:** Proposition of a drug score to predict the clinical usefulness of therapeutic dose monitoring of oral molecularly targeted therapies.  
First Author: Arthur Geraud, MD, MSc
- Board 290 **ABSTRACT 3092:** Hypersensitivity reaction to taxanes following COVID-19 vaccination.  
First Author: Bennett Osantowski, MD
- Board 291 **ABSTRACT 3093:** Bevacizumab exposure and tumor response in patients with platinum resistant epithelial ovarian cancer.  
First Author: Judith Michels, MD, PhD
- Board 292 **ABSTRACT 3094:** EZH2/EZH1 inhibitor tilmimetostat (CPI-0209) in patients with advanced solid tumors or hematologic malignancies: Preliminary phase II results.  
First Author: Charles Drescher, MD
- Board 293 **ABSTRACT 3095:** BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation.  
First Author: Manish R. Patel, MD
- Board 294 **ABSTRACT 3096:** Phase II trial of dabrafenib and trametinib in patients with BRAFV600E/R or non-BRAFV600 mutated advanced solid tumors: Results from the BELIEVE trial (NCCH1901).  
First Author: Makoto Tahara, MD, PhD
- Board 295 **ABSTRACT 3097:** Safety, pharmacokinetics and anti-tumor activity of RP12146, a PARP1/2 inhibitor, in patients with locally advanced or metastatic solid tumors.  
First Author: Piotr Jan Wysocki, MD, PhD
- Board 296 **ABSTRACT 3098:** A phase 1, multicenter, open-label study of a new BRAF inhibitor ABM-1310 in adult patients (pts) with BRAFV600-mutated solid tumors.  
First Author: Sarina A. Piha-Paul, MD
- Board 297 **ABSTRACT 3099:** Phase 1 results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) or gemcitabine (gem) in advanced solid tumors.  
First Author: Ryan C. Lynch, MD
- Board 298 **ABSTRACT 3100:** First-in-human phase 1 study of pimicotinib (ABSK021), a CSF-1R inhibitor, in patients with advanced solid tumors.  
First Author: Gerald Steven Falchook, MD
- Board 299 **ABSTRACT 3101:** Clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.  
First Author: Laurien J. Zeveerijn, MD
- Board 300 **ABSTRACT 3102:** Efficacy and safety of futibatinib for refractory advanced solid malignancies with FGFR alterations identified in circulating tumor DNA: TIFFANY, A GOZILA-affiliated Trial.  
First Author: Tomoko Jogo, MD, PhD

- Board 301 **ABSTRACT 3103:** A multicenter, open-label, single-arm, phase 1 dose-escalation and phase 2 dose-expansion study to evaluate the safety, tolerability, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1.  
First Author: Xiaojie Hu, MD
- Board 302 **ABSTRACT 3104:** A phase 2 study of the WEE1 inhibitor AZD1775 in SETD2-deficient advanced solid tumor malignancies.  
First Author: Edward Maldonado, MD
- Board 303 **ABSTRACT 3105:** RAF-inhibitor rechallenge therapy in BRAF aberrated pan-cancers: RE-RAFFLE study.  
First Author: Blessie Elizabeth Nelson, MBBS, DMRT
- Board 304 **ABSTRACT 3106:** Dose optimization of novel BRAF inhibitor FORE8394 based on PK and efficacy results.  
First Author: Eric Jeffrey Sherman, MD
- Board 305 **ABSTRACT 3107:** A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.  
First Author: Susanna Varkey Ulahannan, MD
- Board 306 **ABSTRACT 3108:** Phase II study of crizotinib in patients with MET amplification and MET exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2.  
First Author: Niamh Coleman, PhD, MBBS, MRCP
- Board 307 **ABSTRACT 3109:** First-in-human phase 1 trial of the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of WSD0922-Fu: Initial report from dose escalation cohort.  
First Author: Sani Haider Kizilbash, MBBS, MPH
- Board 308 **ABSTRACT 3110:** First-in-human (FIH) phase I dose escalation study (part A) of the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K $\delta$ ) rognolisib in patients with advanced cancer and dose confirmation in uveal melanoma (part B).  
First Author: Anna Maria Di Giacomo, MD
- Board 309 **ABSTRACT 3111:** Comprehensive genomic profiling before the first-line setting versus after the completion of standard of care in patients with previously untreated advanced solid tumors: The prospective FIRST-Dx study.  
First Author: Junichi Matsubara, MD, PhD
- Board 310 **ABSTRACT 3112:** Discovery of gene fusions in driver-negative NCI-MATCH screening samples.  
First Author: Stefan T Kaluziak, PhD
- Board 311 **ABSTRACT 3113:** Impact of patient travel time on disparities in precision oncology clinical trials.  
First Author: Yuji Uehara, MD
- Board 312 **ABSTRACT 3114:** The relationship between the change with neoadjuvant chemotherapy in the tumor-infiltrating lymphocyte (TIL) expressions and pathological response in breast cancer patients.  
First Author: Ahmet Bilici
- Board 313 **ABSTRACT 3115:** Talazoparib (Tala) in patients (pts) with solid tumors with *BRCA1/2* mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.  
First Author: Gordan Srkalovic, MD, PhD
- Board 314 **ABSTRACT 3116:** Molecular classification of cancer site of origin and lineage.  
First Author: Nicholas Robert Ryzewski, MD, MPH
- Board 315 **ABSTRACT 3117:** Temsirolimus (T) in patients (pts) with solid tumors with PIK3CA mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.  
First Author: Carmen Julia Calfa, MD
- Board 316 **ABSTRACT 3118:** The genomic, transcriptomic, and immunological landscape of TROP2 in solid tumors.  
First Author: Asaad Trabolsi, MD
- Board 317 **ABSTRACT 3119:** Novel deep learning-based prognostic prediction model for colorectal cancer using hematoxylin and eosin-stained whole slide images.  
First Author: Teppei Konishi
- Board 318 **ABSTRACT 3120:** Pan-cancer diagnostic proteomic signature of tissue-of-origin (TOO) using data-independent acquisition mass spectrometry (DIA-MS) from 1289 human tissue samples.  
First Author: Emma Boys, FRACP
- Board 319 **ABSTRACT 3121:** Tumor agnostic efficacy and safety of erdafitinib (erda) in patients (pts) with advanced solid tumors with prespecified FGFR alterations (FGFRalt): RAGNAR primary analysis.  
First Author: Shubham Pant, MD
- Board 320 **ABSTRACT 3122:** Characterizing telomerase reverse transcriptase (TERT) promoter mutations (mut) across sex, race, and cancer types.  
First Author: Talal El Zarif, MD
- Board 321 **ABSTRACT 3123:** Homologous recombination deficiency (HRD) in non-small cell lung cancer: Genomic analysis using an RNA-based HRD algorithm.  
First Author: Stephanie Thiede, PhD
- Board 322 **ABSTRACT 3124:** Caveat emptor: A descriptive analysis of guideline-recommended biomarker inclusion in targeted NGS panels for metastatic non-small cell lung cancer (mNSCLC).  
First Author: John Leonard Fox, MD
- Board 323 **ABSTRACT 3125:** Clinical activity of mitogen-activated protein kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancers: A systematic review and meta-analysis.  
First Author: Matthew Dankner, MD, PhD
- Board 324 **ABSTRACT 3126:** Genetic heterogeneity between paired primary and metastatic solid tumors and implications for neoantigen-based personalized cancer vaccines.  
First Author: Timothy I Shaw, PhD
- Board 325 **ABSTRACT 3127:** Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.  
First Author: Subotheni Thavaneswaran, PhD, FRACP, MMed
- Board 326 **ABSTRACT 3128:** Multi-omic characterization of RCC1 expression and its association with molecular alterations, immune phenotypes, and cancer outcomes.  
First Author: Brian Warnecke, DO
- Board 327 **ABSTRACT 3129:** A 19-protein signature to predict outcomes in a cohort of stage II and III CRC.  
First Author: Rosemary Habib, BSc, MBBS
- Board 328 **ABSTRACT 3130:** Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer.  
First Author: Dorte Nielsen
- Board 329 **ABSTRACT 3131:** Patient access to precision medicine: Identifying barriers to biomarker testing in non-small cell lung cancer.  
First Author: Ayse Levent, MSc
- Board 330 **ABSTRACT 3132:** NRG1 fusions in solid tumors.  
First Author: Brinda Gupta, MD

- Board 331 **ABSTRACT 3133:** The genomic, transcriptomic, and immunologic landscape in solid tumors expressing leukocyte immunoglobulin-like receptor B2 (LILRB2).  
First Author: Sandra Jones, MD
- Board 332 **ABSTRACT 3134:** Characterizing the landscape of RING-type E3 ubiquitin transferase-altered (RNF43 alt) colorectal cancer (CRC) and defining unique subsets with potential therapeutic vulnerabilities in microsatellite instability-high (MSI-H) CRC.  
First Author: Abdul Rafah Naqash, MD
- Board 333 **ABSTRACT 3135:** Exploring expression levels of HER2, HER3, MET, Claudin18.2, and MUC16 across 16 cancer types using an artificial intelligence-powered immunohistochemistry analyzer.  
First Author: Seunghwan Shin, MD
- Board 334 **ABSTRACT 3136:** Use of a systems-biology informed machine learning model to predict drug response using clinically available NGS data.  
First Author: Maayan Baron, PhD
- Board 335 **ABSTRACT 3137:** Impact of HER2 assay sensitivity on the ability to detect tumors with low to ultra-low HER2 expression: A TMA study on more than 10,000 tumors from more than 100 tumor entities.  
First Author: Maximilian Lennartz, MD
- Board 336 **ABSTRACT 3138:** Pathway enrichment analysis in tumors with high mutation burdens and interferon- $\gamma$  signature expression: A pancancer analysis.  
First Author: Xuanyi Li, MD
- Board 337 **ABSTRACT 3139:** Evolution of HER2 scores after neoadjuvant systemic therapy in breast cancer.  
First Author: Esther G Chong
- Board 338 **ABSTRACT 3140:** A four-tier classification system for studying homologous recombination repair gene reversion mutations as a mechanism of resistance to PARP inhibitors and platinum chemotherapy.  
First Author: Qiuxiang Ou
- Board 339 **ABSTRACT 3141:** Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer.  
First Author: David S. Hong, MD
- Board 340 **ABSTRACT 3142:** Treatment of chronic hepatitis C virus infection to increase access to cancer clinical trials in patients with hematologic malignancies: A prospective observational study.  
First Author: Khalis Mustafayev, MD, PhD
- Board 341 **ABSTRACT 3143:** Dupilumab for the treatment of dermatologic adverse events associated with MEK and EGFR inhibitors.  
First Author: Stephanie Gu
- Board 342 **ABSTRACT 3144:** Novel LTK fusions based on NGS sequencing data in Chinese patients with solid tumors.  
First Author: Hui Chen
- Board 343 **ABSTRACT 3145:** Immune modulation and the oral live biotherapeutic product, MRx0518, in treatment-naive patients with cancer: Updated safety data.  
First Author: Mark Lythgoe, MBBS
- Board 344 **ABSTRACT 3146:** Tumor-agnostic genomic and clinical analysis of solid tumors with *BRAF* fusions.  
First Author: Monica F Chen
- Board 346 **ABSTRACT 3148:** Phase 1 studies of D07001-F4 and D07001-softgel capsule: Oral metronomic gemcitabine in subjects with advanced solid tumors.  
First Author: Chia-Chi Lin, MD, PhD
- Board 347 **ABSTRACT 3149:** Reporting and impact of subsequent cycle toxicities in oncology phase I clinical trials.  
First Author: Avina Rami
- Board 348 **ABSTRACT 3150:** The characteristics of metabolic related pathways under different anoikis activities revealed by pan-cancer analyses.  
First Author: Shanshan Xiao
- Board 349 **ABSTRACT 3151:** Development of bifunctional CRBN-SOS1 degraders for treatment of mutant KRAS cancers.  
First Author: Kyle Begovich, PhD
- Board 350 **ABSTRACT 3152:** A powerful drug combination strategy targeting BRAF-mutant melanoma.  
First Author: Luke Daniel Rothermel, MD
- Board 351a **ABSTRACT TPS3153:** TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors.  
First Author: Yelena Y. Janjigian, MD
- Board 351b **ABSTRACT TPS3154:** XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers.  
First Author: Erika P. Hamilton, MD
- Board 352b **ABSTRACT TPS3156:** EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors.  
First Author: Charu Aggarwal, MD
- Board 353a **ABSTRACT TPS3157:** Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors.  
First Author: Justin A Call, MD
- Board 353b **ABSTRACT TPS3158:** TROPION-Lung04: Phase 1b, multicenter study of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy  $\pm$  carboplatin in advanced/metastatic non-small cell lung cancer (mNSCLC).  
First Author: Hossein Borghaei, DO, MS
- Board 354a **ABSTRACT TPS3159:** Phase 1 trial of a novel C'Dot drug conjugate (CDC), ELU001, in patients with solid tumors known to overexpress folate receptor alpha (FR $\alpha$ ).  
First Author: Wen Wee Ma, MBBS
- Board 354b **ABSTRACT TPS3160:** First-in-human clinical trial design of a first-in-class theranostic approach with a peptide-based radioligand targeting CA IX-expressing tumors.  
First Author: Darren R. Feldman, MD
- Board 355a **ABSTRACT TPS3161:** FRONTIER: FAPi radioligand open-label, phase 1 study to evaluate safety, tolerability and dosimetry of [Lu-177]-PNT6555—A dose escalation study for treatment of patients with select solid tumors.  
First Author: Lisa Bodei, MD, PhD
- Board 355b **ABSTRACT TPS3162:** Phase 1 trial of GD2-SA-DA:<sup>177</sup>Lu-DOTA drug complex in patients with recurrent or refractory metastatic solid tumors known to express GD2 including small cell lung cancer (SCLC), sarcoma, and malignant melanoma.  
First Author: Taofeek K. Owonikoko, MD, PhD
- Board 356a **ABSTRACT TPS3163:** A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination with trametinib, in mutant BRAF V600 solid tumors.  
First Author: Meredith McKean, MD

- Board 356b **ABSTRACT TPS3164:** A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations. First Author: J. Thaddeus Beck, MD, FACP
- Board 357a **ABSTRACT TPS3165:** A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors. First Author: Jordi Rodon Ahnert, MD, PhD
- Board 357b **ABSTRACT TPS3166:** SPARK, studying pathways of resistance in KRAS-driven cancers: A remote plasma ctDNA participation study to identify mechanisms of resistance to KRAS inhibitors. First Author: Biagio Ricciuti, MD
- Board 358a **ABSTRACT TPS3167:** BrUOG 387: Phase Ib investigator-initiated trial of a heat shock protein 90 inhibitor (HSP90i) combined with a CDK4/6i in advanced breast cancer progressing on CDK4/6i and in solid tumors with retinoblastoma (Rb)-deficiency (IND163592). First Author: Wafik S. El-Deiry, MD, PhD, FACP
- Board 358b **ABSTRACT TPS3168:** Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I). First Author: Gopa Iyer, MD

**8:00 AM - 11:00 AM Poster Session**

**Genitourinary Cancer—Kidney and Bladder**

Location: Hall A

Abstracts on Boards 1-12 will be discussed during the Genitourinary Cancer—Kidney and Bladder Poster Discussion Session. See the online program guide ([meetings.asco.org](http://meetings.asco.org)) for session details.

**Posters by Topic**

**Biologic Correlates:** Boards 13-17, 93a

**Kidney Cancer:** Boards 9-12, 18-57, 93b-95a

**Urothelial Cancer—Advanced/Metastatic Disease:** Boards 4-8, 58, 76, 95b-98a

**Urothelial Cancer—Local-Regional Disease:** Boards 13, 77-86, 98b-100b

**Other GU Kidney and Bladder Cancer:** Boards 87-92, 101a-101b

- Board 1 **ABSTRACT 4509:** Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): A multicenter phase 2 trial. First Author: Minas P. Economides, MD
- Board 2 **ABSTRACT 4510:** Tumour factors and the variation in non-muscle invasive bladder cancer recurrence after transurethral resection surgery between sites: Results from the RESECT study. First Author: Fortis Gaba
- Board 3 **ABSTRACT 4511:** Fibroblast growth factor receptor 3 (FGFR3) alterations in PROOF 302: A phase III trial of infgratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC). First Author: Petros Grivas, MD, PhD
- Board 4 **ABSTRACT 4512:** Impact of histology on the efficacy and safety of pembrolizumab (pembro) monotherapy for advanced urothelial carcinoma (UC) in the phase 3 KEYNOTE-045 and KEYNOTE-361 trials. First Author: Patrizia Giannatempo, MD

- Board 5 **ABSTRACT 4513:** Outcomes by complete response to first-line pembrolizumab or platinum-based chemotherapy in advanced urothelial carcinoma (UC) in KEYNOTE-361. First Author: Ozgur Ozyilkan, MD
- Board 6 **ABSTRACT 4514:** Safety analysis by UGT1A1 status of TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI). First Author: Yohann Loriot, MD, PhD
- Board 7 **ABSTRACT 4515:** Estimated net benefit of avelumab (AVE) + best supportive care (BSC) vs BSC alone for patients (pts) with advanced urothelial carcinoma (aUC) using a quality-adjusted time without cancer symptoms or toxicity (Q-TWiST) analysis. First Author: Thomas Powles, MD
- Board 8 **ABSTRACT 4516:** Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial. First Author: Joaquim Bellmunt, MD, PhD
- Board 9 **ABSTRACT 4517:** The impact of surgery on patients with VHL-associated tumors: An international patient survey. First Author: Murali Sundaram, MBA, MS, PhD
- Board 10 **ABSTRACT 4518:** First-line lenvatinib + pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study. First Author: Chung-Han Lee, MD, PhD
- Board 11 **ABSTRACT 4519:** Efficacy of first-line (1L) immunotherapy (IO)-based regimens in patients with sarcomatoid and/or rhabdoid (S/R) metastatic non-clear cell renal cell carcinoma (nccRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). First Author: Chris Labaki, MD
- Board 12 **ABSTRACT 4520:** Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh). First Author: Bradley Alexander McGregor, MD
- Board 13 **ABSTRACT 4521:** Effect of KDR mutations on efficacy of immune checkpoint inhibitors in patients with bladder cancer. First Author: Honghai Dai
- Board 14 **ABSTRACT 4522:** Age-, sex-, and race-related differences in outcomes of patients with muscle-invasive bladder cancer treated with radical cystectomy: The role of biology versus access to standard medical care. First Author: Akshay Sood, MD
- Board 15 **ABSTRACT 4523:** Prognostic significance of pretreatment immune cell infiltration in muscle invasive bladder cancer treated with definitive chemoradiation: Analysis of NRG RTOG 0524 and 0712. First Author: Matthew Pierre Deek, MD
- Board 16 **ABSTRACT 4524:** Determinants of resistance to nivolumab (nivo) monotherapy investigated through genomic and transcriptomic analysis of renal cell carcinoma (RCC) tumors from the HCRN GU16-260 study. First Author: David A. Braun, MD, PhD
- Board 17 **ABSTRACT 4525:** Biomarker-driven prospective clinical trial in renal cell carcinoma: Developing machine learning models to allocate patients to treatment arms using RNA sequencing. First Author: Anupama Reddy, PhD

- Board 18 **ABSTRACT 4526:** A phase I/II study to evaluate the safety, pharmacodynamics, and efficacy of entinostat in combination with atezolizumab and bevacizumab in patients with renal cell carcinoma.  
First Author: Roberto Pili, MD
- Board 19 **ABSTRACT 4527:** Health-related quality of life (HRQoL) of risk-based patient subgroups with advanced renal cell cancer (aRCC) treated with nivolumab plus cabozantinib (NIVO+CABO) vs sunitinib (SUN) in the CheckMate 9ER trial.  
First Author: David Cella, PhD
- Board 20 **ABSTRACT 4528:** Effect on outcomes of toxicity-related dose reduction in TKI monotherapy or TKI-IO combination therapy for advanced renal cell carcinoma.  
First Author: Giacomo Nuvola
- Board 21 **ABSTRACT 4529:** CASSIOPE: A prospective non-interventional study of cabozantinib treatment following prior vascular endothelial growth factor (VEGF) -targeted therapy in patients with advanced renal cell carcinoma (aRCC).  
First Author: Michael D. Staehler, MD, PhD
- Board 22 **ABSTRACT 4530:** Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with cabozantinib or other tyrosine kinase inhibitors (TKIs) after checkpoint inhibitor (CPI) therapy.  
First Author: Daniel Yick Chin Heng, MD, MPH
- Board 23 **ABSTRACT 4531:** Use of real-world evidence to benchmark clinical trial results: A case study in von Hippel-Lindau (VHL) disease.  
First Author: W. Marston Linehan, MD
- Board 24 **ABSTRACT 4532:** Head-to-head effectiveness and safety of pembrolizumab plus axitinib vs. nivolumab plus ipilimumab in metastatic renal cell carcinoma in the United States.  
First Author: Dvir Aran, PhD
- Board 25 **ABSTRACT 4533:** Preliminary results from a phase II study comparing sunitinib alone or with stereotactic body radiotherapy (SBRT) for newly diagnosed oligo-metastatic renal cell carcinoma.  
First Author: Yang Liu
- Board 26 **ABSTRACT 4534:** Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC).  
First Author: Katy Beckermann, MD, PhD
- Board 27 **ABSTRACT 4535:** Immune landscape of patients with metastatic non-clear cell renal cell carcinoma (nccRCC) treated with atezolizumab plus bevacizumab.  
First Author: Renee Maria Saliby, MD, MSc
- Board 28 **ABSTRACT 4536:** Unique molecular underpinnings by genetic ancestry in localized clear cell renal cell carcinoma.  
First Author: Roy Elias, MD
- Board 29 **ABSTRACT 4537:** Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial.  
First Author: Chung-Han Lee, MD, PhD
- Board 30 **ABSTRACT 4538:** Characterizing progression to subsequent lines of therapy in metastatic renal cell carcinoma (mRCC) after nivolumab plus ipilimumab (Nivo+Ipi): Results from the International mRCC Database Consortium (IMDC).  
First Author: Audreylie Lemelin, MD
- Board 31 **ABSTRACT 4539:** Disease-free survival in operated patients with nmRCC using machine learning.  
First Author: Gaëlle Margue
- Board 32 **ABSTRACT 4540:** Health-related quality of life (HR-QOL) measures in renal cell carcinoma (RCC): Patient-reported relevance of items of the FKSI-19, EORTC QLQ-C30, and EQ-5D.  
First Author: Cristiane Decat Bergerot, PhD
- Board 33 **ABSTRACT 4541:** Core biopsy (bx) accuracy and safety of biopsy and preoperative immunotherapy in predicting histological subtype and nuclear grade in ECOG-ACRIN EA8143 perioperative nivolumab (nivo) versus observation in patients (pts) with renal cell carcinoma (RCC) undergoing nephrectomy.  
First Author: Naomi B. Haas, MD
- Board 34 **ABSTRACT 4542:** T cell receptor-engineered T cells targeting a human endogenous retrovirus in kidney cancer.  
First Author: Stefan Barisic, MD
- Board 35 **ABSTRACT 4543:** Immunoglobulin as a predictive biomarker for the efficacy of immune checkpoint inhibitor combined with VEGF-TKI in metastatic renal cell carcinoma.  
First Author: Honglei Cui
- Board 36 **ABSTRACT 4544:** Global circulating free DNA methylation and fragmentome deconvolution in patients with metastatic renal cell carcinoma treated with immunotherapy (GOLDEN).  
First Author: Pavlina Spiliopoulou, MD, PhD
- Board 37 **ABSTRACT 4545:** Genomic determinants of progression-free survival after second line of therapy (PFS-2) for patients on immunotherapy-based combination therapies for advanced clear cell renal cell carcinoma.  
First Author: Kelly N. Fitzgerald, MD
- Board 38 **ABSTRACT 4546:** Adjuvant everolimus in patients (Pts) with localized non-clear cell renal cell carcinoma (RCC): Subgroup analysis from the Everest trial (SWOG S0931).  
First Author: Shuchi Gulati, MD, MS
- Board 39 **ABSTRACT 4547:** Response to immune checkpoint inhibitor (ICI) rechallenge in patients with metastatic renal cell carcinoma who progressed on prior ICI: A systematic review and meta-analysis.  
First Author: Garima Gupta, MD
- Board 40 **ABSTRACT 4548:** Serum soluble MAdCAM - 1: A new biomarker for cancer immunotherapy.  
First Author: Carolina Alves Costa Silva, MD
- Board 41 **ABSTRACT 4549:** Biomarkers of response to first-line nivolumab therapy in patients with advanced renal cell carcinoma (RCC) enrolled in the HCRN GU16-260 trial.  
First Author: Nourhan El Ahmar, DM
- Board 42 **ABSTRACT 4550:** Association of host immune signatures with response to immunotherapy-based regimens in patients with metastatic renal cell carcinoma (mRCC).  
First Author: Eddy Saad, MD, MS
- Board 43 **ABSTRACT 4551:** CD8 cell PET imaging with 89-Zr-crfmirlimab berdoxam (crfmirlimab) in patients with metastatic renal cell carcinoma (mRCC) receiving checkpoint inhibitors (CPIs): Association with response and tissue CD8 expression.  
First Author: Sumanta Kumar Pal, MD, FASCO
- Board 44 **ABSTRACT 4552:** Role of cytoreductive nephrectomy (CN) in metastatic clear cell renal cell carcinoma (mccRCC) in the era of immunotherapy (IO): An analysis of the National Cancer Database (NCDB).  
First Author: Maroun Bou Zerdan, MD



- Board 45 **ABSTRACT 4553:** Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study.  
First Author: Laurence Albiges, MD, PhD
- Board 46 **ABSTRACT 4554:** <sup>89</sup>Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma: Results from phase 3 ZIRCON study.  
First Author: Brian M. Shuch, MD
- Board 47 **ABSTRACT 4555:** Impact of smoking status (SS) on the clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first line (1L) immuno-oncology (IO)-combination regimens: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).  
First Author: Georges Gebrael, MD
- Board 48 **ABSTRACT 4556:** Assessment of short-chain fatty acid (SCFA) and circulating cytokine trends in a clinical trial of nivolumab/ipilimumab and CBM588 in metastatic renal cell carcinoma (mRCC).  
First Author: Nazli Dizman, MD
- Board 49 **ABSTRACT 4557:** Association of neutrophil to eosinophil ratio (NER) with clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with first-line (1L) immune checkpoint inhibitors (ICI) –based regimens.  
First Author: Marc Eid
- Board 50 **ABSTRACT 4558:** Characterization of the immuno-phenotype and tumor specificity of CD8+ T-cells in chromophobe renal cell carcinoma (ChRCC) and renal oncocytic neoplasms.  
First Author: Chris Labaki, MD
- Board 51 **ABSTRACT 4559:** Germline mutations in hereditary renal cell carcinoma (RCC) genes among 32,240 patients with all cancer types.  
First Author: Maria Isabel Carlo, MD
- Board 52 **ABSTRACT 4560:** Patient priorities and expectations of systemic therapy in metastatic renal cell carcinoma.  
First Author: Dena Battle, BS
- Board 53 **ABSTRACT 4561:** Association between intra-tumoral microbiome and clinical benefit (CB) from immunotherapy (IO) in patients with metastatic renal cell carcinoma (mRCC).  
First Author: Luis A Meza, MD
- Board 54 **ABSTRACT 4562:** Pathologic concordance rate and outcomes by histologic subtype in advanced papillary renal cell (pRCC) carcinoma: An analysis from the SWOG S1500 (PAPMET) trial.  
First Author: Abhishek Tripathi, MD
- Board 55 **ABSTRACT 4563:** Kidney cancer mortality in the United States between 1999 and 2020: An observational analysis of outcomes by gender, race, and ethnicity.  
First Author: Nour Abdallah, MD
- Board 56 **ABSTRACT 4564:** Microbial metabolism of tryptophan is associated with resistance to immune checkpoint (ICB) therapy in renal cell cancer (RCC).  
First Author: Shahla Bari, MD
- Board 57 **ABSTRACT 4565:** Gender disparities in metastatic RCC therapies and outcomes.  
First Author: Olivia French Gordon
- Board 58 **ABSTRACT 4566:** Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC), combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma: An open-label phase 1b/2 study.  
First Author: Xinan Sheng, MD
- Board 59 **ABSTRACT 4567:** Real-world response rates and clinical outcomes of patients treated with first-line (1L) platinum-based chemotherapy (PBC) in advanced urothelial cancer (aUC).  
First Author: Helen H Moon
- Board 60 **ABSTRACT 4568:** Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data.  
First Author: Terence W. Friedlander, MD
- Board 61 **ABSTRACT 4569:** Final results from SAUL, a single-arm international real-world study of atezolizumab (atezo) in 1004 patients (pts) with pretreated locally advanced/metastatic urinary tract carcinoma (UTC).  
First Author: Cora N. Sternberg, MD, FACP
- Board 62 **ABSTRACT 4570:** Mismatch repair deficiency and microsatellite instability-high in urothelial carcinoma: A systematic review and meta-analysis.  
First Author: Elias Chandran, FRACP, MBBS
- Board 63 **ABSTRACT 4571:** A phase I study of bintrafusp alfa and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic genitourinary (GU) malignancies.  
First Author: Nicholas I. Simon, MD, MSc
- Board 64 **ABSTRACT 4572:** Biomarkers of response to sacituzumab govitecan (SG) and efficacy after treatment with enfortumab vedotin (EV) in advanced urothelial carcinoma (aUC): Analysis of the UNITE study.  
First Author: Tanya Jindal, BS, BA
- Board 65 **ABSTRACT 4573:** Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.  
First Author: Tanya Jindal, BS, BA
- Board 66 **ABSTRACT 4574:** Outcomes with immune checkpoint inhibitors (ICI) in patients (pts) with MTAP alterations (alt) in advanced urothelial carcinoma (aUC).  
First Author: Rafee Talukder, MD
- Board 67 **ABSTRACT 4575:** EphrinB2 (B2) expression predicts poor response to PD1/L1 antibodies (Ab) in metastatic urothelial carcinoma (mUC).  
First Author: Sarmad Sadeghi, MD, PhD
- Board 68 **ABSTRACT 4576:** Clinical utility of plasma ctDNA sequencing in metastatic urothelial carcinoma.  
First Author: Clara Helal
- Board 69 **ABSTRACT 4577:** Evaluating the use of circulating tumor DNA (ctDNA) in patients with urothelial cancer in the context of FGFR-targeted therapy.  
First Author: Elena Schönlau, MSc
- Board 70 **ABSTRACT 4578:** Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy: Interim results from the phase 2 ARCADIA trial.  
First Author: Patrizia Giannatempo, MD
- Board 71 **ABSTRACT 4579:** Efficacy of sacituzumab govitecan (SG) in locally advanced (LA) or metastatic urothelial cancer (mUC) by trophoblast cell surface antigen 2 (Trop-2) expression.  
First Author: Yohann Lorient, MD, PhD
- Board 72 **ABSTRACT 4580:** The effect of antibiotic (Abx) use on immune checkpoint inhibitor (ICI) efficacy in patients (pts) with metastatic urothelial carcinoma (mUC) in a real-world setting.  
First Author: Ubenthira Patgunarajah, MD

- Board 74 **ABSTRACT 4582:** Presence of CD8<sup>+</sup> cytotoxic T-cells in proximity to tumor cells, TIM3, CTLA-4 and prognostic implications for muscle-invasive urothelial cancer.  
First Author: Nicolaus F. Debatin
- Board 75 **ABSTRACT 4583:** Assessing tumor-infiltrating immune cells and outcomes with cisplatin- versus carboplatin-based treatment in advanced urothelial cancer (UC): Survival analysis of three platinum-treated UC cohorts.  
First Author: Konrad Stawiski, MD, PhD
- Board 76 **ABSTRACT 4584:** Genome-wide aneuploidy detected in circulating cell-free DNA of patients with metastatic urothelial cancer as a predictive biomarker of response to pembrolizumab.  
First Author: Youssra Salhi
- Board 77 **ABSTRACT 4585:** Final analysis results from a multi-center clinical study of tislelizumab combined with gemcitabine and cisplatin as neoadjuvant therapy in patients with cT2-T4aN0M0 MIBC.  
First Author: Tianxin Lin
- Board 78 **ABSTRACT 4586:** Survival outcomes in patients with muscle-invasive bladder cancer receiving neoadjuvant chemotherapy stratified by number of cycles.  
First Author: Anumita Chakraborty, MD
- Board 79 **ABSTRACT 4587:** CDH1-mutated clinically advanced urothelial bladder cancer (UBC): A genomic landscape and real-world clinical outcome study (RWCOS).  
First Author: Kyle M Rose, MD, MS
- Board 80 **ABSTRACT 4588:** Survival outcomes of sarcomatoid versus classic urothelial carcinoma of bladder.  
First Author: Rohan Garje, MD
- Board 81 **ABSTRACT 4589:** Accuracy of genome-wide mutational analysis for tumor-informed ctDNA-guided MRD monitoring in bladder cancer.  
First Author: Iver Nordentoft, PhD, MS
- Board 82 **ABSTRACT 4590:** Phase I/II randomized clinical trial of in-clinic acupuncture prior to BCG in patients with high-risk non-muscle invasive bladder cancer.  
First Author: Sarah P. Psutka, MD, MS
- Board 83 **ABSTRACT 4591:** Biology and performance of pre- and post-pembrolizumab (Pembro) vesical imaging-reporting and data system (VI-RADS) to predict the pathological response in muscle-invasive urothelial bladder cancer (MIBC): Full data analysis from a clinical trials pipeline.  
First Author: Andrea Necchi, MD
- Board 84 **ABSTRACT 4592:** Survival outcomes of micropapillary versus classic variant, loco-regional bladder cancer: A 2004-2019 National Cancer Database analysis.  
First Author: Rohan Garje, MD
- Board 85 **ABSTRACT 4593:** Open versus robotic-assisted radical cystectomies: A risk analysis.  
First Author: Rishabh Simhal, BS
- Board 86 **ABSTRACT 4594:** The impact of neoadjuvant chemotherapy on 30-day radical cystectomy outcomes.  
First Author: Kerith Ruoyao Wang, BA
- Board 87 **ABSTRACT 4595:** Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H.  
First Author: Thomas W. Flaig, MD
- Board 88 **ABSTRACT 4596:** A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104).  
First Author: Ashish M. Kamat, MD
- Board 89 **ABSTRACT 4597:** CABOSUN II: Results from a phase 2, open-label, multi-center randomized study of cabozantinib (CABO) vs. sunitinib (SUN) for non-clear cell renal cell carcinoma (NCCRC).  
First Author: Andrew Johns, MD
- Board 90 **ABSTRACT 4598:** Associations of diet with survival of patients (pts) with metastatic cancer of the urothelium (mUC) and renal cell carcinoma (mRCC) on immune checkpoint blockade (ICB).  
First Author: Brendan John Guercio, MD
- Board 91 **ABSTRACT 4599:** Gender and postoperative surgical margin status in MIBC: An analysis of the National Cancer Database.  
First Author: Olivia French Gordon
- Board 92 **ABSTRACT 4600:** Association of <sup>18</sup>F-FDG PET characteristics and survival outcomes using whole body tumor analysis in patients (pts) with metastatic genitourinary (GU) malignancies.  
First Author: Nicholas I. Simon, MD, MSc
- Board 93a **ABSTRACT TPS4601:** KEYNOTE-905/EV-303: A phase 3 study to evaluate the efficacy and safety of perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC).  
First Author: Andrea Necchi, MD
- Board 93b **ABSTRACT TPS4602:** ARC-20: A phase 1 dose-escalation and dose-expansion study to investigate the safety, tolerability, and pharmacology of HIF-2 $\alpha$  inhibitor AB521 monotherapy in patients with clear cell renal cell carcinoma and other solid tumors.  
First Author: Toni K. Choueiri, MD
- Board 94a **ABSTRACT TPS4603:** LITESPARK-024: Randomized phase 1/2 study of belzutifan with or without palbociclib for treatment of advanced renal cell carcinoma (RCC).  
First Author: David F. McDermott, MD
- Board 94b **ABSTRACT TPS4604:** NRG-GU012: Randomized phase II stereotactic ablative radiation therapy (SABR) for patients with metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI).  
First Author: William A. Hall, MD
- Board 95a **ABSTRACT TPS4605:** Phase 1b/2 study of combination <sup>177</sup>Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC.  
First Author: Elshad Hasanov, MD, PhD
- Board 95b **ABSTRACT TPS4606:** SOGUG-vexillum: Phase II non-randomized clinical trial of nivolumab/ipilimumab maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer.  
First Author: Guillermo de Velasco, MD, PhD
- Board 96a **ABSTRACT TPS4607:** A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects.  
First Author: Elias Chandran, FRACP, MBBS
- Board 96b **ABSTRACT TPS4608:** A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.  
First Author: Sarmad Sadeghi, MD, PhD
- Board 97a **ABSTRACT TPS4609:** MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).  
First Author: Shilpa Gupta, MD

Saturday, June 3, 2023

- Board 97b **ABSTRACT TPS4610:** A phase II trial with copanlisib plus avelumab as maintenance therapy for metastatic bladder cancer after platinum-based chemotherapy. First Author: Hizra Farrukh
- Board 98a **ABSTRACT TPS4611:** TROPHY-U-01 Cohort 4 (C4): Sacituzumab govitecan (SG) in combination with cisplatin (cis) as first-line (1L) therapy, followed by maintenance avelumab plus (+) SG or zimberelimab (zim) + SG in patients (pts) with treatment (Tx)-naive metastatic urothelial cancer (mUC). First Author: Chethan Ramamurthy, MD
- Board 98b **ABSTRACT TPS4612:** ALTER-UC-007: A prospective phase 2 study of anlotinib with gemcitabine and cisplatin or anlotinib with penpulimab as perioperative treatment for patients with muscle-invasive urothelial carcinoma (MIUC). First Author: Hailiang Zhang, MD
- Board 99a **ABSTRACT TPS4613:** A phase 3 multicenter study to evaluate the safety and efficacy of padeliporfin vascular targeted photodynamic therapy (VTP) in treatment of low-grade (LG) upper tract urothelial cancer (UTUC). First Author: Jonathan Coleman, MD
- Board 99b **ABSTRACT TPS4614:** An in-progress phase 2 window of opportunity (WOO) trial of targeted therapy with erdafitinib for patients with recurrent FGFR3-altered non-muscle-invasive bladder cancer (NMIBC). First Author: Neeta DSouza
- Board 100a **ABSTRACT TPS4615:** A phase I dose-escalation clinical trial with PLZ4-coated paclitaxel-loaded micelles (PPM) in patients with recurrent or refractory non-myo-invasive bladder cancer. First Author: Hizra Farrukh
- Board 100b **ABSTRACT TPS4616:** Phase 2 trial of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) for the treatment of non-muscle invasive BCG unresponsive urothelial carcinoma of the bladder. First Author: Guarionex Joel DeCastro, MD, MPH
- Board 101a **ABSTRACT TPS4617:** Adding mitomycin (MM) to bacillus Calmette-Guérin (BCG) as adjuvant intravesical therapy for high-risk, non-muscle-invasive urothelial bladder cancer (NMIBC): BCGMM; ANZUP 1301. First Author: Dickon Hayne, MD, FRCS, MBBS
- Board 101b **ABSTRACT TPS4618:** Phase 1b/2 dose expansion, open-label study to evaluate safety and anti-tumor activity of intravesical instillation of TARA-002 in adults with high-grade non-muscle invasive bladder cancer. First Author: Wei Sun, MD, PhD

---

## 8:00 AM - 11:00 AM Poster Session

### Genitourinary Cancer—Prostate, Testicular, and Penile

Location: Hall A

Abstracts on Boards 103-113 will be discussed during the Genitourinary Cancer—Prostate, Testicular, and Penile Poster Discussion Session. See the online program guide ([meetings.asco.org](https://meetings.asco.org)) for session details.

#### Posters by Topic

**Biologic Correlates:** Boards 115-117, 192a

**Biomarkers/Imaging/Epidemiology/Outcomes:** Boards 105, 118-133, 192b-193b

**Germ Cell/Testicular Cancer:** Boards 134-136, 194a-195a

**Penile Cancer:** Boards 137-138

**Prostate Cancer—Advanced/Castrate-Resistant:** Boards 104-109, 112-113, 139-162, 195b-198a

**Prostate Cancer—Advanced/Hormone-Sensitive:** Boards 103, 108, 163-182, 198b-201b

**Prostate Cancer—Local-Regional Disease:** Boards 110, 183-190, 202a-203a

**Other Prostate, Testicular, or Penile Cancer:** Boards 191, 203b

- Board 103 **ABSTRACT 5009:** PSMA PET guided salvage radiotherapy among patients with prostate cancer in the post-prostatectomy setting: A single center post-hoc analysis. First Author: Clayton P Smith, MD
- Board 104 **ABSTRACT 5010:** Prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) disease extent and overall survival (OS) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC): An international multicenter retrospective study. First Author: Boris A. Hadaschik, MD
- Board 105 **ABSTRACT 5011:** Do bone scans over-stage disease compared to PSMA PET? An international multicenter retrospective study with blinded independent readers. First Author: Wolfgang P. Fendler, MD
- Board 106 **ABSTRACT 5012:** Health-related quality of life (HRQoL) and pain outcomes for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone (abi) and olaparib (ola) versus (vs) abi and placebo (pbo) in the phase III PROpel trial. First Author: Antoine Thiery-Vuillemin, MD, PhD
- Board 107 **ABSTRACT 5013:** Patient-reported outcomes (PROs) among men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase 3 study (TALAPRO-2). First Author: Neeraj Agarwal, MD, FASCO
- Board 108 **ABSTRACT 5014:** Patient reported quality of life (QOL) and survival outcomes: Analysis of ECOG-ACRIN E3805 chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PCa). First Author: Daniel Sentana Lledo, MD
- Board 109 **ABSTRACT 5015:** A prospective trial of apalutamide and abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. First Author: Daniel J. George, MD, FASCO
- Board 110 **ABSTRACT 5016:** Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP). First Author: Tian Zhang, MD, MHS
- Board 112 **ABSTRACT 5018:** Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody <sup>225</sup>Ac-J591 and beta-radioligand <sup>177</sup>Lu-PSMA I&T. First Author: Scott T. Tagawa, MD, FASCO, FACP, MS
- Board 113 **ABSTRACT 5019:** Final results from phase I study of PSCA-targeted chimeric antigen receptor (CAR) T cells in patients with metastatic castration resistant prostate cancer (mCRPC). First Author: Tanya B. Dorff, MD
- Board 115 **ABSTRACT 5021:** Clonal hematopoiesis in the phase 3 Alliance A031201 trial of metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor (AR)-targeted therapies. First Author: Jeffrey Lee Jensen, MD, PhD

- Board 116 **ABSTRACT 5022:** Association of adaptive immunity/inflammatory genes with survival in prostate cancer.  
First Author: Austin Hopper, MD
- Board 117 **ABSTRACT 5023:** Clinical analysis of optimized neural network risk models to predict clinically significant prostate cancer and avoid unnecessary prostate biopsies.  
First Author: Christopher J.D. Wallis, MD
- Board 118 **ABSTRACT 5024:** Clinical implications of molecular alterations in intraductal carcinoma of the prostate.  
First Author: Benjamin Miron, MD
- Board 119 **ABSTRACT 5025:** Prostate cancer public health system database from Brazil: Racial disparities and heterogeneity of treatment interventions to understand evidence-based practice patterns in a large real-world database.  
First Author: Daniel Herchenhorn, MD, PhD
- Board 120 **ABSTRACT 5026:** Longitudinal transcriptome profiling of localized hormone-sensitive tumors in treatment-naive ENACT patients with prostate cancer with and without enzalutamide (ENZA).  
First Author: Ashley Ross, MD, PhD
- Board 121 **ABSTRACT 5027:** AI-enabled analysis of H&E-stained prostate cancer tissue images: Assessing risk for metastasis prior to apalutamide (APA) treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).  
First Author: Pooya Mobadersany, PhD
- Board 122 **ABSTRACT 5028:** Building a predictive model for outcomes with [<sup>177</sup>Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: Preliminary results.  
First Author: Ken Herrmann, MD
- Board 123 **ABSTRACT 5029:** The performance of prostate specific antigen (PSA) testing in the population based NPCC cohort.  
First Author: Jan Oldenburg, MD
- Board 124 **ABSTRACT 5030:** Predicting absolute benefit in risk of metastasis of androgen deprivation therapy added to radiation therapy in patients with newly diagnosed prostate cancer using Prolaris.  
First Author: Jonathan David Tward, MD, PhD
- Board 125 **ABSTRACT 5031:** Prevalence of mismatch repair deficiency in a large prospective prostate cancer cohort.  
First Author: Ciara S. McNevin, MD
- Board 126 **ABSTRACT 5032:** Sequential metastasis-directed therapy (MDT) for oligometastatic prostate cancer (Oligo PCa) assessed by PET-based imaging.  
First Author: Alberto Carretero-González, MD, PhD
- Board 127 **ABSTRACT 5033:** Prevalence of intra-patient inter-metastatic heterogeneity in mCRPC patients based on triple-tracer PET imaging: The 3TMPO study.  
First Author: Frederic Pouliot, MD, PhD
- Board 128 **ABSTRACT 5034:** Genetic ancestry associations with somatic mutations in a real-world cohort of over 3,000 patients with prostate cancer.  
First Author: Francisco M De La Vega, DSc
- Board 129 **ABSTRACT 5035:** Digital histopathology-based multi-modal artificial intelligence scores predict risk of progression in a randomized phase III trial in patients with nonmetastatic castration-resistant prostate cancer.  
First Author: Felix Y Feng, MD
- Board 130 **ABSTRACT 5036:** HERCULES: A prostate cancer (PC) sequencing panel for parallel analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs).  
First Author: Daniel Bsteh
- Board 131 **ABSTRACT 5037:** Association of plant-based diet index with quality of life in patients with prostate cancer.  
First Author: Stacy Loeb, MD, PhD, MS
- Board 132 **ABSTRACT 5038:** The impact of household income on prostate cancer diagnosis, treatment, and outcomes.  
First Author: John Panzone, BS
- Board 133 **ABSTRACT 5039:** <sup>64</sup>Cu-SAR-bisPSMA (PROPELLER) positron emission tomography (PET) imaging in patients with confirmed prostate cancer.  
First Author: Eva Lengyelova
- Board 134 **ABSTRACT 5040:** A single-arm, phase II study of durvalumab (D) and tremelimumab (T) for relapsed/refractory germ cell tumors (GCT).  
First Author: Samuel A Funt, MD
- Board 135 **ABSTRACT 5041:** Prognostic factors for relapse in patients with clinical stage I testicular seminoma: A nationwide, population-based cohort study.  
First Author: Thomas Wagner, MD
- Board 136 **ABSTRACT 5042:** Hospital Anxiety and Depression Scale (HADS) score trends among testicular cancer survivors: A longitudinal study.  
First Author: Khalid Y. Alkhatib, MD
- Board 137 **ABSTRACT 5043:** Phase II study of the efficacy of retifanlimab (Rf) (INCMGA00012) in penile squamous cell carcinoma (PSqCC): ORPHEUS final analysis.  
First Author: Xavier Garcia del Muro, MD
- Board 138 **ABSTRACT 5044:** Penile squamous cell carcinoma (PSCC) with elevated tumor mutational burden (TMB): A genomic landscape study.  
First Author: Rebecca A Sager, MD, PhD
- Board 139 **ABSTRACT 5045:** Effects of [<sup>177</sup>Lu] Lu-PSMA-617 on overall survival in TheraP versus VISION randomized trials: An exploratory analysis.  
First Author: Yu Yang Soon, MSc, MBBS
- Board 140 **ABSTRACT 5046:** Tumor dosimetry of [<sup>177</sup>Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: Results from the VISION trial sub-study.  
First Author: Bernd J. Krause, MD
- Board 141 **ABSTRACT 5047:** Concurrent chemo-hormonal therapy of enzalutamide (ENZ) and cabazitaxel (CAB) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final analysis of objective response rate (ORR), radiographic progression-free survival (rPFS), and overall survival (OS).  
First Author: Alexandra Sokolova, MD
- Board 142 **ABSTRACT 5048:** Bone biomarkers and subsequent survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): Results from the phase III SWOG S1216 trial of androgen deprivation +/- orteronel.  
First Author: Primo N Lara Jr., MD
- Board 143 **ABSTRACT 5049:** Impact of synchronous (sync) vs metachronous (meta) metastasis at the presentation on survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with androgen receptor signaling inhibitors (ARSIs).  
First Author: Georges Gebrael, MD
- Board 144 **ABSTRACT 5050:** Real-world safety and effectiveness of radium-223 (<sup>223</sup>Ra) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated in the US: The non-interventional REASSURE study.  
First Author: Daniel Y. Song, MD
- Board 145 **ABSTRACT 5051:** The effect of a reduced dose of enzalutamide on fatigue and cognition.  
First Author: Joanneke Overbeek

- Board 146 **ABSTRACT 5052:** A novel abiraterone acetate oral suspension for patients with metastatic prostate cancer: An open-label, phase 3, randomized trial.  
First Author: Imanol Martinez, MD
- Board 147 **ABSTRACT 5053:** Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study.  
First Author: Arun Azad, PhD, MBBS, FRACP
- Board 148 **ABSTRACT 5054:** Final results of a pilot study of docetaxel and carboplatin for treatment of patients with mCRPC containing biallelic inactivation of genes in the homologous recombination DNA repair pathway.  
First Author: Ruben Raychaudhuri
- Board 149 **ABSTRACT 5055:** PSMA expression and response to <sup>177</sup>Lu-PSMA-617 (LuPSMA) in men with vs. without DNA damage repair (DDR) mutations.  
First Author: Ruben Raychaudhuri
- Board 150 **ABSTRACT 5056:** Use of circulating tumor DNA (ctDNA) to complement tumor tissue homologous recombination repair (HRR) gene alteration testing in TALAPRO-2, a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).  
First Author: Arun Azad, PhD, MBBS, FRACP
- Board 151 **ABSTRACT 5057:** Tumor heterogeneity and treatment response assessment using next generation imaging and liquid biopsy in patients with metastatic castration resistant prostate cancer receiving abiraterone (ANGELA): A single-center prospective observational trial.  
First Author: Yao Zhu, MD, PhD
- Board 152 **ABSTRACT 5058:** mFAST-SeqS based aneuploidy score in circulating cell-free DNA and role as early response marker in patients with metastatic prostate cancer treated with androgen receptor signaling inhibitor.  
First Author: Khrystany T. Isebia
- Board 153 **ABSTRACT 5059:** Characterizing the molecular landscape of early onset and average onset prostate cancer.  
First Author: Ifeanyichukwu Ogbuuro, MD
- Board 154 **ABSTRACT 5060:** The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide.  
First Author: Siyuan S Guo, PhD
- Board 155 **ABSTRACT 5061:** Associations between androgen-directed treatments and AR mutational landscapes in the circulating tumor DNA of a real-world metastatic prostate cancer cohort.  
First Author: Elisa M. Ledet, PhD
- Board 156 **ABSTRACT 5062:** Phase I trial of enzalutamide (Enz) plus the glucocorticoid receptor antagonist relacorilant (Rela) for patients with metastatic castration resistant prostate cancer.  
First Author: Kunal Desai, MD, MS, MBA
- Board 157 **ABSTRACT 5063:** Early changes of PSMA PET signal after initiation of androgen receptor signaling inhibitors in mCRPC: An international multicenter retrospective study.  
First Author: Lena Unterrainer, MD
- Board 158 **ABSTRACT 5064:** Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus <sup>177</sup>lutetium-prostate specific membrane antigen-617 (<sup>177</sup>Lu-PSMA-617) in the LuPARP trial.  
First Author: Anis Hamid, MBBS
- Board 159 **ABSTRACT 5065:** Deutenzalutamide, an oral deuterated androgen receptor inhibitor, vs placebo for patients with mCRPC who have experienced treatment failure with abiraterone and docetaxel: Results of the HC-1119-04 phase 3 trial.  
First Author: Ding-Wei Ye, MD, PhD
- Board 160 **ABSTRACT 5066:** Enzalutamide vs abiraterone in patients with prostate cancer with and without type 2 diabetes mellitus.  
First Author: Amy L Shaver, PhD, PharmD, MPH
- Board 161 **ABSTRACT 5067:** Determinants of widespread metastases and of metastatic tropism in patients with prostate cancer: A genomic analysis of primary and metastatic tumors.  
First Author: Edward Christopher Dee, MD
- Board 162 **ABSTRACT 5068:** Genomic alterations and self-reported Agent Orange exposure in United States veterans with metastatic prostate cancer.  
First Author: JJ Haijing Zhang, MD
- Board 163 **ABSTRACT 5069:** Association of dynamic changes in serological markers with survival in de novo metastatic hormone-sensitive prostate cancer.  
First Author: Soumyajit Roy, MBBS
- Board 164 **ABSTRACT 5070:** Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).  
First Author: Susan Halabi, PhD, FASCO
- Board 165 **ABSTRACT 5071:** Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC).  
First Author: Charles J. Ryan, MD
- Board 166 **ABSTRACT 5072:** Enzalutamide, docetaxel and androgen deprivation (ENZADA trial) for metastatic castrate sensitive prostate cancer (mCSPC).  
First Author: Earle F Burgess, MD
- Board 167 **ABSTRACT 5073:** The relationship between a priori defined prognostic risk groups and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC).  
First Author: Susan Halabi, PhD, FASCO
- Board 168 **ABSTRACT 5074:** Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216).  
First Author: Mamta Parikh, MD, MS
- Board 169 **ABSTRACT 5075:** Differential tumor gene expression profiling of obese and non-obese patients (pts) with prostatic adenocarcinoma (PC).  
First Author: Vinay Mathew Thomas, MBBS
- Board 170 **ABSTRACT 5076:** Comparing the efficacy of abiraterone and enzalutamide in United States veterans with metastatic castration-sensitive prostate cancer (mCSPC) by estimating rates of tumor growth (g-rate).  
First Author: Harshraj Leuva, MBBS
- Board 171 **ABSTRACT 5077:** Depth of PSA nadir and subsequent PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19).  
First Author: Rahul Raj Aggarwal, MD
- Board 172 **ABSTRACT 5078:** Assessing racial differences in time to treatment escalation following androgen-deprivation therapy among veterans with prostate cancer.  
First Author: Nadine Adriana Friedrich, MD

- Board 173 **ABSTRACT 5079:** Treatment and survival of de novo metastatic hormone sensitive prostate cancer among African American US Veterans.  
First Author: Rigoberto De Jesus Pizarro
- Board 174 **ABSTRACT 5080:** Baseline circulating tumor cell (CTC) count as a prognostic marker of overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.  
First Author: Amir Goldkorn, MD
- Board 175 **ABSTRACT 5081:** Cost-effectiveness analysis (CEA) of seven treatment regimens in metastatic hormone-sensitive prostate cancer (mHSPC): A public payer perspective using network meta-analysis.  
First Author: Manish Kohli, MD
- Board 176 **ABSTRACT 5082:** Landscape and impact of germline pathogenic variants (PVs) in metastatic hormone sensitive prostate cancer (mHSPC): Ancillary study of E3805 CHAARTED.  
First Author: Anis Hamid, MBBS
- Board 177 **ABSTRACT 5083:** Development and independent validation of a predictive gene expression signature based on RB1, PTEN, and TP53 in patients with metastatic hormone-sensitive metastatic prostate cancer (mHSPC).  
First Author: Oscar Reig Torras, MD PhD
- Board 178 **ABSTRACT 5084:** CABIOS trial: A phase Ib study of cabozantinib and nivolumab in combination with abiraterone in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC).  
First Author: Jesse Meir Zaretsky, MD, PhD
- Board 179 **ABSTRACT 5085:** An analysis to inform the timing of docetaxel use leveraging data from the United States Veterans Administration on patients with metastatic castration-sensitive prostate cancer (mCSPC).  
First Author: Mengxi Zhou, MSc
- Board 180 **ABSTRACT 5086:** Androgen-deprivation therapy and risk of dementia in patients with prostate cancer: Clinical outcomes from real-world data.  
First Author: Dina Elantably, MD
- Board 181 **ABSTRACT 5087:** Phase 2 study of olaparib (without ADT) in men with biochemically recurrent prostate cancer (BCR) after prostatectomy.  
First Author: Catherine Handy Marshall, MD, MPH
- Board 182 **ABSTRACT 5088:** The role of volume of disease for treatment selection in patients with metastatic castration sensitive prostate cancer (mCSPC): A living meta-analysis.  
First Author: Syed Arsalan Ahmed Naqvi, MBBS
- Board 183 **ABSTRACT 5089:** Early findings from the GARUDA trial: The impact of a genetic signature of late radiation toxicity on prostate cancer treatment decision making.  
First Author: Joanne B. Weidhaas, MD, PhD
- Board 184 **ABSTRACT 5090:** Pre-surgical <sup>68</sup>Ga-PSMA-11 PET for biochemical recurrence risk assessment: A surrogate of pelvic lymph node dissection? Follow-up analysis of a multicenter prospective phase 3 imaging trial.  
First Author: Loic Djaileb
- Board 185 **ABSTRACT 5091:** PSMA PET findings in an “EMBARK-like” cohort of patients with high-risk non-metastatic hormone-sensitive prostate cancer: A single center post-hoc retrospective analysis.  
First Author: Wesley Robert Armstrong, BS
- Board 186 **ABSTRACT 5092:** Socio-demographic, clinical, and genetic predictors of low versus high Gleason score among men with prostate cancer in the Detroit Research on Cancer Survivorship (ROCS) cohort.  
First Author: Samantha Goodenow
- Board 187 **ABSTRACT 5093:** Racial differences in the utilization of MRI-guided biopsy before prostate cancer diagnosis.  
First Author: Grace L. Lu-Yao, PhD, MPH
- Board 188 **ABSTRACT 5094:** Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology/RTOG 0521 phase III trial.  
First Author: Ryan Phillips
- Board 189 **ABSTRACT 5095:** Post radical prostatectomy (RP) PSA outcomes following 6 vs 18 months of perioperative androgen deprivation therapy (ADT) in men with localized high risk prostate cancer (LHRPC): Results of Part 2 of a randomized phase 2 trial.  
First Author: Rana R. McKay, MD
- Board 190 **ABSTRACT 5096:** Testosterone recovery following androgen suppression and prostate radiotherapy (TRANSPORT): Updated individual patient data meta-analyses from the MARCAP consortium.  
First Author: Wee Loon Ong, MBBS
- Board 191 **ABSTRACT 5097:** Comparative real-world (RW) evidence on darolutamide (Daro), enzalutamide (Enza), and apalutamide (Apa) for patients (Pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the United States: DEAR.  
First Author: Alicia K. Morgans, MD, MPH
- Board 192a **ABSTRACT TPS5098:** Whole-food plant-based diet (WFPBD) to control weight and metabo-inflammation in overweight/obese men with prostate cancer (PC) receiving androgen deprivation therapy (ADT): A multi-center randomized control trial.  
First Author: Nicole Jacobs
- Board 192b **ABSTRACT TPS5099:** GUIDE: A randomized non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (ANZUP 1903).  
First Author: Ciara Conduit, MBBS
- Board 193a **ABSTRACT TPS5100:** CLIMATE: Assessing the clinical utility of miR-371a-3p as a marker of residual disease in stage 1 testicular germ cell tumour (TGCT) following orchiectomy: ANZUP 1906.  
First Author: Ciara Conduit, MBBS
- Board 193b **ABSTRACT TPS5101:** A study of prospective monitoring of patients with recurrent prostate cancer using serial PSMA imaging (18F-DCFPyL).  
First Author: Mohammad O. Atiq, MD
- Board 194a **ABSTRACT TPS5102:** P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs).  
First Author: Danka Sinikovic Zebic, FRACP, MBBS, BSc
- Board 194b **ABSTRACT TPS5103:** SWOG S1823/CCTG GCC1: Translational observational investigational study of the liquid biomarker microRNA 371a-3p in newly diagnosed germ cell tumours—Real-world trial design, rapid accrual, and robust secondary use of data opportunities.  
First Author: Antoine Morin Coulombe, MD, FRCPC

## Saturday, June 3, 2023

- Board 195a **ABSTRACT TPS5104:** AGCT1531: Evaluating the utility of circulating microRNA in the management of children, adolescents, and adults with malignant germ cell tumors.  
First Author: Furqan Shaikh, MD
- Board 195b **ABSTRACT TPS5105:** A phase (Ph) I/II trial of abiraterone acetate in combination with tildrakizumab (anti-IL23 monoclonal antibody) in patients with metastatic castration-resistant prostate cancer (mCRPC).  
First Author: Christina Guo, MBBS
- Board 196a **ABSTRACT TPS5106:** The Maverick trial: A phase 2 study of abivertinib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).  
First Author: Rana R. McKay, MD
- Board 196b **ABSTRACT TPS5107:** A randomized phase II study of apalutamide with or without carotuximab (ant-CD105) in metastatic, castration-resistant prostate cancer.  
First Author: Edwin Melencio Posadas, MD, FACP
- Board 197a **ABSTRACT TPS5108:** HB-300, a novel arenavirus-based cancer immunotherapy in patients with metastatic castration-resistant prostate cancer.  
First Author: David D. Chism, MD, MS
- Board 197b **ABSTRACT TPS5109:** First-in-class oral innate immune activator BXCL701 combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) variant: Randomized phase 2b trial.  
First Author: Rahul Raj Aggarwal, MD
- Board 198a **ABSTRACT TPS5110:** A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.  
First Author: Chinmay Jani, MBBS
- Board 198b **ABSTRACT TPS5111:** A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naïve prostate cancer: ARAMON study.  
First Author: Xin Gao, MD
- Board 199a **ABSTRACT TPS5112:** Open-label study of darolutamide plus androgen-deprivation therapy (ADT) vs ADT in metastatic hormone-sensitive prostate cancer using an external control arm (ARASEC).  
First Author: Neal D. Shore, MD, FACS
- Board 199b **ABSTRACT TPS5113:** A feasibility study of <sup>177</sup>Lu-PSMA radioligand therapy alternated with radium-223 in patients with bone-metastatic, oligo-metastatic, hormone-sensitive prostate cancer after curative therapy: The DUET study.  
First Author: André Vis, MD, PhD
- Board 200a **ABSTRACT TPS5114:** ProSperA: Phase I study to evaluate safety, tolerability and preliminary efficacy of a bispecific PSMAxCD3 antibody in men with biochemical recurrence of prostate cancer.  
First Author: Christopher Hackenbruch
- Board 200b **ABSTRACT TPS5115:** APPROACH trial: Multimodal approach in patients with mHSPC: A pragmatic, randomized, phase 3 trial of androgen-deprivation therapy (ADT) plus apalutamide (APA) versus ADT plus apalutamide (APA) and local treatment—Meet-URO 29 study.  
First Author: Valentina Guadalupi, MD
- Board 201a **ABSTRACT TPS5116:** PSMAddition: A phase 3 trial to compare treatment with <sup>177</sup>Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer.  
First Author: Scott T. Tagawa, MD, FASCO, FACP, MS
- Board 201b **ABSTRACT TPS5117:** Phase 1/2a study of PRL-02, a long-acting intramuscular (IM) depot injection of abiraterone decanoate, in patients (pts) with advanced prostate cancer.  
First Author: Neal D. Shore, MD, FACS
- Board 202a **ABSTRACT TPS5118:** Phase III study of local or systemic therapy intensification directed by PET in prostate cancer patients with post-prostatectomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.  
First Author: Neha Vapiwala, MD, FACR, FASTRO, FASCO
- Board 202b **ABSTRACT TPS5119:** Prime-boost immunotherapeutic trial in men with biochemical recurrence after definitive local therapy for prostate cancer.  
First Author: Mark N. Stein, MD
- Board 203a **ABSTRACT TPS5120:** Exercise to enhance cardiovascular health among Black patients with prostate cancer with androgen deprivation therapy: The POWER trial.  
First Author: Dong-Woo Kang
- Board 203b **ABSTRACT TPS5121:** A multi-center natural history study of precision-based genomics in prostate cancer (PC).  
First Author: Himisha Beltran, MD

---

### 9:30 AM - 12:00 PM Opening Session

#### **ASCO Opening Session Featuring the President's Address, a Discussion with the U.S. Surgeon General, NCI Director's Remarks, Presentation of the Fellows of the American Society of Clinical Oncology, and David A. Karnofsky Award and Lecture**

Location: Hall B1

#### **Clifford A. Hudis, MD, FASCO, FACP**

American Society of Clinical Oncology  
*Welcome and Introduction of Eric P. Winer, MD, FASCO*

#### **Eric P. Winer, MD, FASCO**

ASCO President, 2022-2023  
*President's Address*

#### **Vice Admiral Vivek H. Murthy, MD, MBA**

U.S. Public Health Service  
*A Discussion With the U.S. Surgeon General on Health Worker Well-Being*

#### **Marcella Nunez Smith, MD, MHS**

Yale School of Medicine  
*A Discussion With the U.S. Surgeon General on Health Worker Well-Being*

#### **Monica M. Bertagnolli, MD, FACS, FASCO**

National Cancer Institute  
*NCI Director's Remarks*

#### **Howard A. Burris III, MD, FACP, FASCO**

Tennessee Oncology/Sarah Cannon Research Institute  
*Conquer Cancer Top Donor Recognition Awards*

#### **Lori J. Pierce, MD, FASTRO, FASCO**

University of Michigan  
*Presentation of Awards and the Fellows of the American Society of Clinical Oncology (FASCO)*

#### **Hagop M. Kantarjian, MD, FASCO**

The University of Texas MD Anderson Cancer Center  
*David Karnofsky Award Lecture*

**12:30 PM - 1:45 PM Education Session**

**ASCO Plenary Series: Rapid Abstract Updates**

Location: Arie Crown Theater

**Mohamed E. Salem, MD - Chair**

Levine Cancer Institute

**Toni K. Choueiri, MD - Chair**

Dana-Farber Cancer Institute, Harvard Medical School

**Renato G. Martins, MD, MPH**

Virginia Commonwealth University  
*Updates on Abstract 388570: Landscape of Pathogenic Germline Variants in Patients With Lung Cancer*

**Angela DeMichele, MD, MSCE**

University of Pennsylvania  
*Updates on Abstract 390216: Adjuvant Palbociclib for ER+ Breast Cancer (PALLAS Trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): A Preplanned Analysis of the Stage IIA Cohort*

**Edward Chow, MBBS**

Odetta Cancer Centre, Sunnybrook Health Sciences Centre  
*Updates on Abstract 390226: Mepitel Film for the Prevention of Acute Radiation Dermatitis in Breast Cancer: A Randomized Multi-centre Open-Label Phase 3 Trial*

**Melissa L. Johnson, MD**

Sarah Cannon Research Institute  
*Updates on Abstract 397600: ARC-7: Randomized Phase 2 Study of Domvanalimab + Zimberelimab ± Etrumadenant Versus Zimberelimab in First-Line, Metastatic, PD-L1-High Non-Small Cell Lung Cancer (NSCLC)*

**Michael Heinrich, MD, FACP**

Portland VA Health Care System and OHSU Knight Cancer Institute  
*Updates on Abstract 397784: Mutational Heterogeneity of Imatinib Resistance and Efficacy of Ripretinib vs Sunitinib in Patients With Gastrointestinal Stromal Tumor: ctDNA Analysis From INTRIGUE*

**Elias Jabbour, MD**

The University of Texas MD Anderson Cancer Center  
*Updates on Abstract 398868: First Report of PhALLCON: A phase 3 Study Comparing Ponatinib vs Imatinib in Newly Diagnosed Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL)*

**Rui-hua Xu, MD, PhD**

Sun Yat-sen University Cancer Center  
*Updates on Abstract 405736: Zolbetuximab + Capox in 1L Claudin-18.2+ (CLDN18.2+)/HER2 Locally Advanced (LA) or Metastatic Gastric or Gastroesophageal Junction (mG/GEJ) Adenocarcinoma: Primary Phase 3 Results From Glow*

**Shubham Pant, MD**

The University of Texas MD Anderson Cancer Center  
*Updates on Abstract 425082: Krystal-1: Activity and Safety of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Harboring a KRASG12C Mutation*

*Panel Question and Answer*

---

**1:15 PM - 2:15 PM Case-Based Panel**

**Rare Gynecologic Cancers: A Case of Gestational Trophoblastic Neoplasia**

Location: S102

**Martina Cathryn Murphy, MD - Chair**

University of Florida Health Shands Hospital  
*Moderator*

**Kevin Meyer Elias, MD**

Brigham and Women's Hospital  
*Gynecologic Oncology Perspective*

**Benoit You, MD, PhD**

Lyon Sud Hospital  
*Medical Oncology Perspective*

**John T. Soper, MD**

University of North Carolina at Chapel Hill  
*Surgical Perspective*

*Panel Question and Answer*

---

**1:15 PM - 2:30 PM Education Session**

**Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress**

Location: Hall B1

**Benjamin Philip Levy, MD, FASCO**

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins  
Medicine  
*The ABCs of ADCs*

**Enriqueta Felip, MD, PhD**

Vall d'Hebron University Hospital  
*Antibodies for Everybody: Targets and Toxicity of ADCs in Lung Cancer*

**Benjamin J. Solomon, MBBS, PhD - Chair**

Peter MacCallum Cancer Centre  
*HER2 Homecoming: The Journey to Trastuzumab Deruxtecan*

*Panel Question and Answer*

---

**1:15 PM - 2:30 PM Education Session**

**Early-Onset Cancers: Rising Trends and Novel Strategies**

Location: E451

**Christopher Hanyoung Lieu, MD, FASCO - Chair**

University of Colorado Cancer Center  
*Early-Onset Colorectal Cancer: Rising Incidence and Opportunities for Prevention and Treatment*

**Naveen Pemmaraju, MD**

The University of Texas MD Anderson Cancer Center  
*Adolescents and Young Adults With Hematologic Malignancies: Patient Characteristics and Special Considerations*

**Alicia Latham, MD, MS**

Memorial Sloan Kettering Cancer Center  
*Early-Onset Cancer and Genetic Predisposition: Knowns and Unknowns*

---

**1:15 PM - 2:30 PM Education Session**

**How to Make Evidence-Based Integrative Medicine a Part of Everyday Oncology Practice**

Location: S404

**Ting Bao, MD - Chair**

Memorial Sloan Kettering Cancer Center  
*How to Incorporate Integrative Oncology Into Patient Care*

**Heather Greenlee, PhD, ND, MPH**

Fred Hutchinson Cancer Center  
*Appropriate Use of Dietary Supplements During and After Cancer Treatment*



Saturday, June 3, 2023

**Linda E. Carlson, PhD**

University of Calgary Cumming School of Medicine  
*Mind-Body Approaches to Help Cancer Survivors*

*Panel Question and Answer*

---

**1:15 PM - 2:30 PM Education Session**

**Patient and Caregiver Advocate Engagement in Geriatric Oncology Research: Embracing Diversity**

Location: E350

**Allison Magnuson, DO, MS**

University of Rochester Medical Center  
*How to Effectively Engage With Patient and Caregiver Advocates With Diverse Perspectives in Geriatric Oncology Research*

**Lisa M. Lowenstein, PhD - Chair**

The University of Texas MD Anderson Cancer Center  
*The Role of Patient and Caregiver Advocates in Implementation Science in Geriatric Oncology Research*

**Chuck O'Shea**

City of Hope  
*A Patient's Perspective to Engaging in Geriatric Oncology Research*

*Panel Question and Answer*

---

**1:15 PM - 2:30 PM Education Session**

**State-of-the-Art Care in Pancreatic Cancer**

Location: Hall D1

**Syed A. Ahmad, MD, FACS - Chair**

University of Cincinnati Medical Center  
*State of the Art and New Developments in Surgery for Pancreatic Cancer*

**Mark H. O'Hara, MD**

Hospital of the University of Pennsylvania  
*State of the Art and New Developments in Systemic Therapy for Pancreatic Cancer*

**Lauren E. Henke, MD**

Washington University School of Medicine  
*State of the Art and New Developments in Radiation Oncology for Pancreatic Cancer*

---

**1:15 PM - 2:30 PM Education Session**

**The Launch of the Access to Oncology Medicines (ATOM) Coalition**

Location: S504

**Danny Milner, MD - Chair**

American Society for Clinical Pathology  
*The Power of Coalition Building*

**Miriam Claire Mutebi, MMed, MSc**

Aga Khan University Hospital  
*Understanding What Is Needed to Successfully Bridge Access Gaps*

**Gilberto Lopes, MD, FASCO**

Sylvester Comprehensive Cancer Center, University of Miami  
*The Potential for Using the ATOM Model to Impact Cancer Mortality in LMICs*

*Panel Question and Answer*

**1:15 PM - 2:30 PM Ticketed Session**

**Meet the Professors: Horses, Zebras, and Unicorns—Variant Histologies in Urothelial Cancer**

Location: E253d

**Evita Sadimin, MD - Chair**

City of Hope  
*The Pathologist*

**Piyush K. Agarwal, MD**

University of Chicago Medical Center  
*The Urologist*

**Ali Raza Khaki, MD, MS**

Stanford University  
*The Oncologist*

*Panel Question and Answer*

---

**1:15 PM - 2:45 PM Clinical Science Symposium**

**The Dr. Bernard Fisher Memorial Annual Clinical Science Symposium Supported by the Breast Cancer Research Foundation: Harnessing the Breast Cancer Immune Response**

Location: S406

**Ana Christina Garrido-Castro, MD - Chair**

Dana-Farber Cancer Institute

**Jeremy Meyer Force, DO, MA - Chair**

Duke University

- 1:15 PM Abstract 1009:** Characterization of the immune micro-environment in matched primary and metastatic breast cancer lesions from the AURORA study: BIG 14-01. First Author: Florentine Hilbers, PhD
- 1:27 PM Abstract 1010:** Association of tumor infiltrating lymphocyte quantity with survival in patients (pts) with metastatic breast cancer (MBC) receiving microtubule-targeting agents: Post hoc analysis CALGB 40502 (Alliance). First Author: Daniel G. Stover, MD
- 1:39 PM Kim Blenman, PhD, MS (Discussion of Abstract(s) 1009-1010)**  
Yale University  
*Tumor-Infiltrating Lymphocytes: Important unTIL They're Not*
- 1:51 PM Abstract 1011:** RNA expression levels from peripheral immune cells, a minimally invasive liquid biopsy source to predict response to therapy, survival and immune-related adverse events in patients with triple negative breast cancer enrolled in the GeparNuevo trial. First Author: Hanna Hübner, PhD
- 2:03 PM Abstract 1012:** BRACELET-1 (PrE0113): Inducing an inflammatory phenotype in metastatic HR+/HER2- breast cancer with the oncolytic reovirus pelareorep in combination with paclitaxel and avelumab. First Author: Amy Sanders Clark, MD, MSCE
- 2:15 PM Sherene Loi, MD (Discussion of Abstract(s) 1011-1012)**  
Peter MacCallum Cancer Centre  
*Immune Awakening: Dynamic Immune Cell Monitoring and Immunotherapy*
- 2:27 PM** Panel Question and Answer

**1:15 PM - 2:45 PM Poster Discussion Session**

**Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology**

Location: S100bc

**Aparna Kalyan, MD - Chair**  
Northwestern University

**Jordi Rodon Ahnert, MD, PhD - Chair**  
The University of Texas MD Anderson Cancer Center

- 1:15 PM Komal L. Jhaveri, MD, FACP (Discussion of Abstract(s) 3009-3011)**  
Memorial Sloan Kettering Cancer Center  
*"Cycling" Toward the FUTURE in Breast Cancer and Beyond*
- 1:27 PM** Panel Question and Answer
- 1:37 PM Stephanie Lheureux, MD, PhD (Discussion of Abstract(s) 3012-3014)**  
Princess Margaret Cancer Center, University Health Network  
*Damage Control: Emerging Therapies for the DDR Pathway*
- 1:49 PM** Panel Question and Answer
- 1:59 PM Valentina Boni, MD, PhD (Discussion of Abstract(s) 3015-3017)**  
NEXT Madrid- University Hospital Quironsalud Madrid  
*Ticket to Ride the ADC Train: Calling for Newer Targets*
- 2:11 PM** Panel Question and Answer
- 2:21 PM Wells A. Messersmith, MD, FACP, FASCO (Discussion of Abstract(s) 3018-3020)**  
University of Colorado Cancer Center  
*Small Molecules: Ready for the Big Game?*
- 2:33 PM** Panel Question and Answer

Posters discussed in this session are on display in the Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Poster Session. To view abstract titles and presentations, see the online program guide ([meetings.asco.org](http://meetings.asco.org)).

**1:15 PM - 2:45 PM Poster Discussion Session**

**Genitourinary Cancer—Prostate, Testicular, and Penile**

Location: E450

**Mark Garzotto, MD - Chair**  
Portland Veterans Affairs Medical Center

**Christina Guo, MBBS - Chair**  
Institute of Cancer Research

- 1:15 PM Louise Emmett, MD, MBChB, FRACP (Discussion of Abstract(s) 5009-5011)**  
St Vincent's Hospital  
*Looking for Prostate Cancer: Will Novel Imaging Light the Way?*
- 1:27 PM** Panel Question and Answer
- 1:37 PM Ravi Amrit Madan, MD (Discussion of Abstract(s) 5012-5014)**  
National Cancer Institute  
*Quality in the Context of Quantity: Evaluating Treatment Intensification*
- 1:49 PM** Panel Question and Answer

- 1:59 PM Joaquin Mateo, MD, PhD (Discussion of Abstract(s) 5015-LBA5017)**  
Vall d'Hebron Institute of Oncology (VHIO)  
*Right Treatment, Right Setting for Systemic Therapy*
- 2:11 PM** Panel Question and Answer
- 2:21 PM Pedro C. Barata, MD, MSc (Discussion of Abstract(s) 5018-5020)**  
University Hospitals Seidman Cancer Center  
*Looking Ahead: Novel Agents in Castration-Resistant Prostate Cancer*
- 2:33 PM** Panel Question and Answer

Posters discussed in this session are on display in the Genitourinary Cancer—Prostate, Testicular, and Penile Poster Session. To view abstract titles and presentations, see the online program guide ([meetings.asco.org](http://meetings.asco.org)).

**1:15 PM - 4:15 PM Oral Abstract Session**

**Care Delivery and Regulatory Policy**

Location: S100a

**Keerthi Gogineni, MD, MSPH - Chair**  
Winship Cancer Institute of Emory University School of Medicine

**Raymond Mailhot Vega, MD, MPH - Chair**  
University of Florida Proton Institute

- 1:15 PM Abstract 1500:** AI blood signature in common blood tests for detection of gastric cancer in a cohort of 190,000 individuals  
First Author: Tsz Chun Bryan Wong, MPhil
- 1:27 PM Abstract 1501:** Large-scale observational prospective cohort study of a multi-cancer early detection (MCED) test in symptomatic patients referred for cancer investigation.  
First Author: Brian D Nicholson
- 1:39 PM Abstract 1502:** Childhood leukemia survival in the US-Mexico border: Building sustainable leukemia care using health systems strengthening models.  
First Author: Paula Aristizabal, MD, MS
- 1:51 PM Peter Paul Yu, MD (Discussion of Abstract(s) 1500-1502)**  
Hartford HealthCare  
*Reimagining and Rebuilding Cancer Diagnosis and Treatment*
- 2:03 PM** Panel Question and Answer
- 2:15 PM Abstract 1503:** Analysis of patient-physician portal secure message content and the associated cost savings in oncology practice.  
First Author: Brandon Anderson, MD
- 2:27 PM Abstract 1504:** Prior authorizations for oral anticancer drugs and delayed prescription fills.  
First Author: Michael Anne Kyle
- 2:39 PM Abstract 1505:** SCORE: A multisite randomised controlled trial evaluating shared care for colorectal cancer survivors.  
First Author: Michael Jefford, PhD, MBBS, MPH
- 2:51 PM Fumiko Chino, MD (Discussion of Abstract(s) 1503-1505)**  
Memorial Sloan Kettering Cancer Center  
*Threading the Needle of Patient Access and Provider Well-Being*
- 3:03 PM** Panel Question and Answer

## Saturday, June 3, 2023

- 3:15 PM Abstract 1506:** Observational prospective study of physical activity in patients with cancer to define an objective performance status (OPS).  
First Author: Eva Ruiz-Hispán, MD
- 3:27 PM Abstract 1507:** A cognitive behavioral digital therapeutic for anxiety and depression in patients with cancer: A decentralized randomized controlled trial.  
First Author: Sean R. Zion, PhD
- 3:39 PM Abstract 1508:** Remote symptom-monitoring of patients with advanced lung cancer: A Danish national randomized controlled trial—The ProWide study.  
First Author: Rasmus Blechingberg Friis, MD, PhD
- 3:51 PM Raymond U. Osarogiagbon, FACP, MBBS (Discussion of Abstract(s) 1506-1508)**  
Baptist Cancer Center  
*Partnering With the Patient: Digital Diagnostics and Therapeutics*
- 4:03 PM** Panel Question and Answer

---

### 1:15 PM - 4:15 PM Oral Abstract Session

#### Hematologic Malignancies—Plasma Cell Dyscrasia

Location: Hall D2

##### Amandeep Godara, MD - Chair

Huntsman Cancer Institute

##### Luciano J. Costa, MD, PhD - Chair

University of Alabama at Birmingham

- 1:15 PM Abstract 8000:** Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study.  
First Author: Stefan Knop, MD
- 1:27 PM Abstract 8001:** Maintenance therapy with carfilzomib, pomalidomide, and dexamethasone (KPd) in high-risk myeloma patients (pts): A phase 2 study with a safety run-in.  
First Author: Ajay K. Nooka, MBBS
- 1:39 PM Abstract 8002:** First results from the RedirectT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).  
First Author: Yael C. Cohen, MD
- 1:51 PM Andrzej J. Jakubowiak, MD, PhD (Discussion of Abstract(s) 8000-8002)**  
University of Chicago  
*Combinations Still in the Spotlight!*
- 2:03 PM** Panel Question and Answer
- 2:15 PM Abstract 8003:** Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.  
First Author: Bhagirathbhai R. Dholaria, MBBS
- 2:27 PM Abstract 8004:** Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM).  
First Author: Adam Samuel Sperling, MD, PhD
- 2:39 PM Abstract 8005:** Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM).  
First Author: Juan Du, MD, PhD

- 2:51 PM Francesca Gay, MD, PhD (Discussion of Abstract(s) 8003-8005)**  
University of Torino  
*Fast-Tracking Immunotherapy*
- 3:03 PM** Panel Question and Answer
- 3:15 PM Abstract 8006:** LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.  
First Author: Hans C. Lee, MD
- 3:27 PM Abstract 8007:** A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): DREAMM-3.  
First Author: Katja Weisel, MD
- 3:39 PM Abstract 8008:** Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.  
First Author: Ajay K. Nooka, MBBS
- 3:51 PM Ravi Vij, MD (Discussion of Abstract(s) 8006-8008)**  
Washington University School of Medicine  
*Betting on BCMA*
- 4:03 PM** Panel Question and Answer

---

### 1:15 PM - 4:15 PM Poster Session

#### Central Nervous System Tumors

Location: Hall A

Abstracts on Boards 370-381 will be discussed during the Central Nervous System Tumors Poster Discussion Session. See the online program guide ([meetings.asco.org](https://meetings.asco.org)) for session details.

##### Posters by Topic

**Biologic Correlates:** Boards 378, 382-383

**Brain Metastases:** Boards 370-372, 384-397, 437a

**Primary CNS Tumors—Glioma:** Boards 373-381, 398-429, 437b-440b

**Primary CNS Tumors—Non-Glioma:** Boards 430-436

- Board 370 **ABSTRACT 2013:** Pretreatment clinical parameters associated with intracranial progression burden following an initial stereotactic radiosurgery course in a multi-institutional brain metastases cohort.  
First Author: Christina C Huang, MD, MS
- Board 371 **ABSTRACT 2014:** A radiomic-based predictive model of lung adenocarcinoma brain metastases and molecular subtypes.  
First Author: Xiancheng Wu, MD
- Board 372 **ABSTRACT 2015:** Longitudinal single-cell (sc) immune profiling of cerebrospinal fluid (CSF) from melanoma patients (pts) with leptomeningeal disease (LMD) treated with intrathecal (IT) and intravenous (IV) nivolumab (N).  
First Author: Golnaz Morad, DDS, PhD
- Board 373 **ABSTRACT 2016:** Long-term survival with IDH wildtype glioblastoma: First results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419).  
First Author: Michael Weller, MD
- Board 374 **ABSTRACT 2017:** RANO 2.0: Proposal for an update to the Response Assessment in Neuro-Oncology (RANO) Criteria for high- and low-grade gliomas in adults.  
First Author: Patrick Y. Wen, MD

- Board 376 **ABSTRACT 2019:** BORTEM-17: A phase IB/II single arm, multicentre study investigating the efficacy of sequential bortezomib and temozolomide in recurrent GBM with unmethylated MGMT promoter—The results of an interim analysis.  
First Author: Dorota Goplen, MD, PhD
- Board 377 **ABSTRACT 2020:** EO2401 (E) peptide immunotherapy + nivolumab (N) +/- bevacizumab (B) in recurrent glioblastoma (GB): EOGBM1-18/ROSALIE.  
First Author: Wolfgang Wick, MD
- Board 378 **ABSTRACT 2021:** Immune profiling in patients with glioblastoma treated with VT1021 in a phase I/II expansion study.  
First Author: Jian Jennifer Chen, PhD
- Board 379 **ABSTRACT 2022:** Ombipepimut dosing emulsion (ODE) + bevacizumab (bev) vs bev alone in patients (pts) with recurrent or progressive glioblastoma (rGBM).  
First Author: Samuel A. Goldlust, MD
- Board 380 **ABSTRACT LBA2023:** A randomised phase II multicentre study of ipilimumab with temozolomide vs temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: Ipi-Glio.  
First Author: Paul James Mulholland, PhD, MBBS
- Board 381 **ABSTRACT 2024:** Final analysis of 2-THE-TOP: A phase 2 study of TTFIELDS (Optune) plus pembrolizumab plus maintenance temozolomide (TMZ) in patients with newly diagnosed glioblastoma.  
First Author: David D. Tran, MD, PhD
- Board 382 **ABSTRACT 2025:** Short-length DNA fragments in plasma to predict clinical outcome in unresected glioblastoma patients.  
First Author: Maxime Fontanilles, MD PhD
- Board 383 **ABSTRACT 2026:** Association of CDK4 amplification with duration of response to bevacizumab in glioblastoma.  
First Author: John L. Villano, MD, PhD
- Board 384 **ABSTRACT 2027:** ctDNA detection in patients with brain metastases arising from solid tumors.  
First Author: Laura Alder, MD
- Board 385 **ABSTRACT 2028:** Evaluating the diagnostic performance of leptomeningeal diagnosis with CNSide compared to standard cytology.  
First Author: Haley Appel, PA-C
- Board 386 **ABSTRACT 2029:** Leptomeningeal carcinomatosis and brain metastases in gastroesophageal carcinoma: A real-world analysis of outcomes, clinical and pathologic characteristics.  
First Author: Thais Baccili Cury Megid, MD
- Board 387 **ABSTRACT 2030:** A radiomics model developed from pre-metastatic brain magnetic resonance imaging to predict brain metastasis in non-small-cell lung cancer: Evidence to the seed-and-soil theory.  
First Author: Xiao Chu, PhD, MMed
- Board 388 **ABSTRACT 2031:** INTRAMET: Results of a prospective, single-arm, open-label phase II trial of intraoperative radiotherapy after resection of brain metastases.  
First Author: Stefanie Brehmer, MD
- Board 389 **ABSTRACT 2032:** Risk of brain metastases in metastatic non-small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from three randomized clinical trials involving first-line atezolizumab treatment.  
First Author: Yue Zhou
- Board 390 **ABSTRACT 2033:** The prognostic role of ventricular size and its dynamics in patients with leptomeningeal metastases from solid tumors.  
First Author: Emilie Le Rhun, MD, PhD
- Board 391 **ABSTRACT 2034:** A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.  
First Author: Anna-Maria Lazaratos, BSc
- Board 392 **ABSTRACT 2035:** HER2-low breast cancer brain metastases: Incidence and treatment implications.  
First Author: Rania Chehade, MSc, MD
- Board 393 **ABSTRACT 2036:** Assessment of electronic health record (EHR)-based machine learning (ML) in predicting risk of brain metastasis among patients with early-stage non-small-cell lung cancer (eNSCLC).  
First Author: Hossein Honarvar, PhD
- Board 394 **ABSTRACT 2037:** Large-scale clinicogenomic models of solid tumor CNS metastasis.  
First Author: Justin Jee
- Board 395 **ABSTRACT 2038:** Surgically targeted radiation therapy (STaRT) for recurrent glioblastoma: Initial outcomes from a prospective multicenter registry.  
First Author: Ahmad Ozair, MD
- Board 396 **ABSTRACT 2039:** Multi-cancer brain metastasis risk score development and validation using 220,246 whole transcriptomes and machine learning.  
First Author: Jim Abraham, PhD
- Board 397 **ABSTRACT 2040:** Cerebrospinal fluid immunological cytokines to predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases: GASTO 1060.  
First Author: Likun Chen
- Board 398 **ABSTRACT 2041:** Analysis of tumor progression among patients with glioma after COVID-19 infection.  
First Author: Tim A Gregory, MD
- Board 399 **ABSTRACT 2042:** Safety, efficacy, and biomarker analysis of response to engineered tumor-infiltrating lymphocytes secreting anti-PD-1 antibody in recurrent glioblastoma: An open-label, two-arms, phase 1 study.  
First Author: Yu Yao, MD
- Board 400 **ABSTRACT 2043:** An exploratory clinical trial on intralumbar injection of B7H3-specific allogeneic universal CAR-T cells in patients with recurrent high-grade gliomas.  
First Author: Xiaoyun Shang
- Board 401 **ABSTRACT 2044:** Lisavanbulin in patients with recurrent glioblastoma: Phase 2a results and a consolidated analysis of response-predictive biomarkers.  
First Author: Juanita Suzanne Lopez, PhD, MRCP
- Board 402 **ABSTRACT 2045:** A single-arm, phase 2 clinical trial of abemaciclib in adult patients with recurrent grade 3 oligodendroglioma.  
First Author: Stephen Joseph Bagley, MD, MSCE
- Board 403 **ABSTRACT 2046:** Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade glioma patients: OLA-TMZ-RTE-01.  
First Author: Dinu Stefan, MD, PhD student
- Board 404 **ABSTRACT 2047:** Final results of phase 2 trial of personal dendritic cell (DC) vaccines loaded with autologous tumor antigens (ATA) in newly diagnosed glioblastoma (GBM).  
First Author: Daniela Annenelie Bota, MD, PhD

**Saturday, June 3, 2023**

- Board 405 **ABSTRACT 2048:** Potential predictive biomarker for response to radiotherapy and CXCL12 inhibition in glioblastoma in the phase I/II GLORIA trial.  
First Author: Frank Anton Giordano, MD
- Board 406 **ABSTRACT 2049:** Post-marketing surveillance safety analysis of patients with CNS malignancies treated with tumor treating fields (TTFields) therapy between 2011–2022.  
First Author: Maciej M. Mrugala, MD, PhD
- Board 407 **ABSTRACT 2050:** Safety and efficacy of tumor treating fields (TTFields) prior and concomitant to radiotherapy in patients with newly diagnosed glioblastoma: Results from PriCoTTF.  
First Author: Seid Kebir, MD
- Board 408 **ABSTRACT 2051:** A phase 0 pharmacokinetic trigger trial of infigratinib in patients with recurrent high-grade glioma.  
First Author: Nader Sanai, MD
- Board 409 **ABSTRACT 2052:** H3.3-K27M neoantigen vaccine elicits anti-tumor T cell immunity against diffuse intrinsic pontine glioma: The phase I ENACTING trial.  
First Author: Yang Zhang, MD, PhD
- Board 410 **ABSTRACT 2053:** Phase 1 study of primumab in brain cancer.  
First Author: Jose Arganda Carrillo, MD
- Board 411 **ABSTRACT 2054:** Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial.  
First Author: Emilie Le Rhun, MD, PhD
- Board 412 **ABSTRACT 2055:** New ESMO scale for clinical actionability of molecular targets (ESCAT) for gliomas based on a multicentric real world data cohort using next-generation sequencing (NGS).  
First Author: Oriol Mirallas
- Board 413 **ABSTRACT 2056:** Distinct molecular features and potential therapeutic strategies for spinal cord gliomas.  
First Author: Frances Elaine Chow, MD
- Board 414 **ABSTRACT 2057:** Prospective phase I study of checkpoint blockade for the treatment of patients with newly diagnosed high-grade glioma prior to radio-chemotherapy: Results of nivolumab plus ipilimumab treatment arm.  
First Author: Santosh Kesari, MD, PhD
- Board 415 **ABSTRACT 2058:** Lisavanbulin (BAL101553), a novel, oral microtubule destabilizer plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma: A phase 1 Adult Brain Tumor Consortium study (ABTC1601).  
First Author: Matthias Holdhoff, MD, PhD
- Board 416 **ABSTRACT 2059:** Real-world experience with tumor treating fields (TTFields) in newly diagnosed glioblastoma: A survival meta-analysis with systematic review.  
First Author: Matthew T. Ballo, MD
- Board 417 **ABSTRACT 2060:** Safety and feasibility of JAK inhibitor ruxolitinib in newly-diagnosed high-grade gliomas (CRUX): Final toxicity report.  
First Author: Manmeet Singh Ahluwalia, MD, MBA, FASCO
- Board 418 **ABSTRACT 2061:** Phase I and pharmacodynamic study of arsenic trioxide plus radiotherapy for newly diagnosed glioblastoma.  
First Author: Samuel Ryu, MD
- Board 419 **ABSTRACT 2062:** Efficacy of function-enhanced, re-activatable, dual-specific CAR T cells pre-loaded with oncolytic virus for immunotherapy of high-grade glioma.  
First Author: Mason Webb, MD, PhD
- Board 420 **ABSTRACT 2063:** Depth of radiographic response (DpR) and time to tumor regrowth (TTG) to predict overall survival following anti-VEGF therapy in recurrent glioblastoma.  
First Author: Benjamin M. Ellingson, PhD
- Board 421 **ABSTRACT 2064:** Ultrasensitive detection and monitoring of central nervous system tumors from plasma using personalized whole-genome ctDNA profiling.  
First Author: Ivy Tran
- Board 422 **ABSTRACT 2065:** Immune checkpoint inhibitor (ICI) therapy in glioblastoma: Institutional experience at the Massachusetts General Hospital (MGH).  
First Author: John Yohan Rhee, MD
- Board 423 **ABSTRACT 2066:** Vulnerability to immune therapy in BRAF- and MYB-altered pediatric gliomas.  
First Author: Michael DeCuyper, MD, PhD
- Board 424 **ABSTRACT 2067:** Phase I study of BTK inhibitor ibrutinib with temozolomide and radiation in newly-diagnosed glioblastoma (EQUILIBRIUM): Final trial report.  
First Author: Manmeet Singh Ahluwalia, MD, MBA, FASCO
- Board 425 **ABSTRACT 2068:** Interrogating drug action and immune response in organotypic glioma microenvironment.  
First Author: Jiyong Liang, MD, PhD
- Board 426 **ABSTRACT 2069:** A phase 0/2 trigger trial of niraparib in patients with newly diagnosed glioblastoma.  
First Author: Shwetal Mehta, PhD
- Board 427 **ABSTRACT 2070:** Investigation of leptomeningeal disease in high grade glioma and characterization of molecular alterations.  
First Author: Madison L. Shoaf, MD, MS
- Board 428 **ABSTRACT 2071:** Intra-operative desorption-electrospray ionization mass-spectrometry for real-time diagnosis, margin assessment, and maximization of brain cancer resection.  
First Author: Diogo Garcia
- Board 429 **ABSTRACT 2072:** Intraoperative glioma characterization using time-resolved fluorescence spectroscopy.  
First Author: Simon Menaker, MD
- Board 430 **ABSTRACT 2073:** Detection of methylation-based prognostic signatures in liquid biopsy specimens from patients with meningiomas.  
First Author: Grayson Herrgott, MPH
- Board 431 **ABSTRACT 2074:** FOXC1 expression in meningiomas.  
First Author: Michelle Wedemeyer, MD, PhD
- Board 432 **ABSTRACT 2075:** 3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas.  
First Author: Emeline Tabouret, MD
- Board 433 **ABSTRACT 2076:** The ketogenic diet plus standard of care for adults with recently diagnosed glioblastoma: Results from a phase 1 trial.  
First Author: Lj Amaral, MS, RD
- Board 434 **ABSTRACT 2077:** Osmotic blood-brain barrier disruption with mannitol followed by methotrexate, rituximab, and carboplatin in treating patients with newly diagnosed primary central nervous system lymphoma.  
First Author: Prakash Ambady, MD, MBBS

- Board 435 **ABSTRACT 2078:** Belzutifan treatment of Von Hippel-Lindau (VHL) related central nervous system (CNS) hemangioblastomas (HBs): A single institution experience.  
First Author: Othon Iliopoulos, MD
- Board 436 **ABSTRACT 2079:** MTHFR polymorphisms and neurotoxicity and overall survival after methotrexate-based therapy in primary CNS lymphoma.  
First Author: Philipp Karschnia, MD
- Board 437a **ABSTRACT TPS2080:** The clinical relevance of margins in frameless stereotactic radiosurgery for intact brain metastases: A randomized trial of 0 vs 2 mm margins.  
First Author: Aditya Juloori, MD
- Board 437b **ABSTRACT TPS2081:** A phase 0/1a study of BI 907828 concentrations in brain tissue and a nonrandomized, open-label, dose escalation study of BI 907828 in combination with radiotherapy in patients with newly diagnosed glioblastoma (GBM).  
First Author: Jann Nagina Sarkaria, MD
- Board 438a **ABSTRACT TPS2082:** A first-in-human pharmacodynamic evaluation of dual polyamine depletion for patients with high-grade gliomas.  
First Author: Cecile Riviere-Cazaux
- Board 438b **ABSTRACT TPS2083:** Phase 3 TRIDENT study (EF-32): Tumor treating fields (TTFields; 200 kHz) concomitant with chemoradiation, and maintenance TTFields therapy/temozolomide in newly diagnosed glioblastoma.  
First Author: Wenyin Shi, PhD
- Board 439a **ABSTRACT TPS2084:** Low-intensity focused ultrasound with systemic microbubble oscillators for blood-brain barrier disruption for liquid biopsy in glioblastoma (LIBERATE).  
First Author: Manmeet Singh Ahluwalia, MD, MBA, FASCO
- Board 439b **ABSTRACT TPS2085:** Efficacy and safety study of neoadjuvant efineptakin alfa (NT-17) and pembrolizumab in recurrent glioblastoma.  
First Author: Mason Webb, MD, PhD
- Board 440a **ABSTRACT TPS2086:** Phase 1b multicenter study to evaluate CHM 1101 in patients with recurrent or progressive glioblastoma.  
First Author: Jason Blair Litten, MD
- Board 440b **ABSTRACT TPS2087:** Phase II trial of combination pembrolizumab, olaparib, and temozolomide for patients with recurrent glioma.  
First Author: Lauren Schaff, MD

---

**1:15 PM - 4:15 PM Poster Session**

**Health Services Research and Quality Improvement**

Location: Hall A

Abstracts on Boards 1-12 will be discussed during the Health Services Research and Quality Improvement Poster Discussion Session. See the online program guide ([meetings.asco.org](https://meetings.asco.org)) for session details.

**Posters by Topic**

**Healthcare Equity/Access to Care:** Boards 1-3, 13-51, 145a-145b

**Quality of Care/Quality Improvement:** Boards 10-12, 52-74

**Real-World Data/Outcomes:** Boards 4-6, 8, 75-129

**Value/Cost of Care:** Boards 7, 9, 130-144

- Board 1 **ABSTRACT 6509:** Strategies to increase accrual of underrepresented populations in Alliance NCTN trials.  
First Author: Electra D. Paskett, PhD

- Board 2 **ABSTRACT 6510:** How patient-clinician education can strengthen partnerships and promote tangible actions to improve clinical trial diversity in breast and lung cancer trials.  
First Author: Tariqa Ackbarali, PhD, MS
- Board 3 **ABSTRACT 6511:** Mediators of racial/ethnic inequities in clinical trial participation among US patients with cancer, 2011-2022.  
First Author: Jenny Guadamuz, PhD, MSPH
- Board 4 **ABSTRACT 6512:** Comparison of incident breast cancer cases in the largest national US tumor registries.  
First Author: Jennifer Kay Plichta, MD
- Board 5 **ABSTRACT 6513:** Big data in oncology: Challenges and solutions.  
First Author: Neil J. Shah, MD
- Board 6 **ABSTRACT 6514:** Enhancement in line of therapy (LoT) derivation from real-world data (RWD) from electronic health records (EHR) via integration of medical claims data.  
First Author: Smita Agrawal, PhD
- Board 7 **ABSTRACT 6515:** End-of-life spending analysis of randomized trial of machine learning nudges to prompt serious illness communication among patients with cancer.  
First Author: Ravi Bharat Parikh, MD
- Board 8 **ABSTRACT 6516:** Biosimilar uptake and cost savings analysis before and after implementation of a pharmacist-driven substitution program within a National Community Oncology Network: One-year follow-up.  
First Author: Melody Chang, RPh, BPharm, MBA
- Board 9 **ABSTRACT 6517:** The impact of adverse financial events on healthcare utilization and treatment costs at the end of life.  
First Author: Chipso Natasha Kwendakwema
- Board 10 **ABSTRACT 6518:** A multi-level system quality improvement project to reduce disparities in lung cancer screening: The Sylvester Lung Screening Project.  
First Author: Nicole Ann Gay, APRN-C
- Board 11 **ABSTRACT 6519:** Guideline-concordant use of olanzapine as part of a 4-drug antiemetic regimen for high emetic risk chemotherapy across the state of Michigan.  
First Author: Ashley Bowen, MS, RD
- Board 12 **ABSTRACT 6520:** Impact of a web-based decision aid on socioeconomically disadvantaged patients' engagement in decision making (Alliance A231701CD).  
First Author: Jessica R. Schumacher, PhD
- Board 13 **ABSTRACT 6521:** Curating clinical trials: Helping patients find hope by exploring clinical trial opportunities.  
First Author: Rhonda Abdel-Nabi, BSc. Biology and Biochemistry (Health and Biomedical Stream), MSc. Translational Health Science
- Board 14 **ABSTRACT 6522:** The Man Van: Mobile targeted case finding for prostate cancer.  
First Author: Masood Moghul, MBBS, FRCS (Urol)
- Board 15 **ABSTRACT 6523:** Association of social vulnerability with delays in starting guideline-adherent adjuvant therapy among patients with head and neck cancer.  
First Author: Joshua Lee Cagle, BS
- Board 16 **ABSTRACT 6524:** Analysis and optimization of equitable US cancer clinical trial center access by travel time.  
First Author: Hassal Lee, MD PhD

Saturday, June 3, 2023

- Board 17 **ABSTRACT 6525:** Are enrollment criteria for phase II and III clinical trials in acute myeloid leukemia arbitrarily restrictive?  
First Author: Andrew Hantel, MD
- Board 18 **ABSTRACT 6526:** Evaluating social vulnerability impact on care and prognosis of head & neck-nervous system cancers in the US.  
First Author: Salim Lutfallah, BS
- Board 19 **ABSTRACT 6527:** Association of measures of socio-economic deprivation with healthcare utilization in elderly patients enrolled in SWOG cancer clinical trials.  
First Author: Dawn L. Hershman, MD, MS, FASCO
- Board 20 **ABSTRACT 6528:** Racial disparities in utilization of first line targeted therapies for metastatic breast cancer.  
First Author: Yehoda M. Martei, MD, MSCE
- Board 21 **ABSTRACT 6529:** Healthcare coverage, access, and affordability among adult immigrant cancer survivors in the United States.  
First Author: Patricia Mae Garcia Santos, MD
- Board 22 **ABSTRACT 6530:** Impact of free hospital-provided rideshare service on radiation therapy completion rates: A matched cohort analysis.  
First Author: Eric Chen, MD
- Board 23 **ABSTRACT 6531:** Associations of loneliness and mortality risk among cancer survivors in the United States.  
First Author: Jingxuan Zhao, MPH
- Board 24 **ABSTRACT 6532:** Outcomes of Black (B) versus White (W) patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without orteronel (Ort): Analysis of pt-level data from SWOG-1216 phase 3 trial.  
First Author: Nicolas Sayegh, MD
- Board 25 **ABSTRACT 6533:** Selection biases in the systematic collection of breast biobank specimens.  
First Author: Yael Bar, MD, PhD
- Board 26 **ABSTRACT 6534:** Beyond transportation: Financial hardship, food insecurity, and care access barriers among US cancer survivors with transportation barriers to care.  
First Author: Changchuan Jiang, MD, MPH
- Board 27 **ABSTRACT 6535:** County-level jail incarceration and cancer mortality in the US.  
First Author: Jingxuan Zhao, MPH
- Board 28 **ABSTRACT 6536:** An intersectional approach to cervical cancer screening disparities by race/ethnicity and immigrant status.  
First Author: Jane J. Chen, BS
- Board 29 **ABSTRACT 6537:** Associations of cancer history, food insecurity, and nonmedical financial worry and mortality risk in the US.  
First Author: Zhiyuan Zheng, PhD
- Board 30 **ABSTRACT 6538:** The association between continuity of Medicaid enrollment and cancer survival in young adults diagnosed with cancer.  
First Author: Kimberly J. Johnson, PhD
- Board 31 **ABSTRACT 6539:** Association of Medicaid expansion with timely receipt of treatment and survival among patients with HER2-enriched breast cancer.  
First Author: Kewei Sylvia Shi, MPH
- Board 32 **ABSTRACT 6540:** Disparities in uptake of novel therapies for acute myeloid leukemia.  
First Author: Andrew Hantel, MD
- Board 33 **ABSTRACT 6541:** Talk, test, and take one click to curb prostate cancer mortality.  
First Author: Sandhya Cautha
- Board 35 **ABSTRACT 6543:** Racial and ethnic disparities in employment of patients and caregivers following breast cancer diagnosis.  
First Author: Marisa C. Weiss, MD
- Board 36 **ABSTRACT 6544:** Depression, systemic inflammation, and exposure to discrimination among sexual and gender minority (SGM) cancer survivors.  
First Author: Charles Stewart Kamen, PhD, MPH
- Board 37 **ABSTRACT 6545:** Association of major adverse financial events and later stage cancer diagnosis in the US.  
First Author: Robin Yabroff, PhD
- Board 38 **ABSTRACT 6546:** Racial disparities in cancer mortality in patients with gastrointestinal malignancies following Medicaid expansion.  
First Author: Naveen Manisundaram, MD
- Board 39 **ABSTRACT 6547:** What is your preferred language? Evaluating equal access to oncology clinical studies for non-English-speaking participants.  
First Author: Dame Idossa, MD
- Board 40 **ABSTRACT 6548:** Sexual orientation and gender identity data collection among NCI community oncology research program (NCORP) practices: A 5-year landscape update.  
First Author: Elizabeth Jane Cathcart-Rake, MD
- Board 41 **ABSTRACT 6549:** Patient-level interventions to increase guideline concordant treatment among Black breast cancer patients: Can they close the racial gap in survival after diagnosis?  
First Author: Juan Yanguela, MSc
- Board 42 **ABSTRACT 6550:** Disparities in clinical trial enrolment at a Canadian comprehensive cancer centre: A 15-year retrospective study.  
First Author: Gilla Shapiro
- Board 43 **ABSTRACT 6551:** The intersection of neighborhood-level disadvantage and overall lung cancer survival.  
First Author: Kathleen Kennedy, MD
- Board 44 **ABSTRACT 6552:** Impact of the COVID-19 pandemic on insurance transitions among commercially insured cancer patients in Washington state.  
First Author: Scott David Ramsey, PhD
- Board 45 **ABSTRACT 6553:** Translated consent documents (CDs) and use in non-industry sponsored studies (NISS).  
First Author: Maria A Velez, MD
- Board 46 **ABSTRACT 6554:** Examining clinical trial eligibility for oncology patients with human immunodeficiency virus (HIV): A global cross-sectional analysis.  
First Author: Umar Abdullahi, MBBS MSc
- Board 47 **ABSTRACT 6555:** Disparities in lung cancer screening in a diverse urban population and the impact of a community-based navigational program.  
First Author: Hina Khan, MD
- Board 48 **ABSTRACT 6556:** Racial disparity in dose intensity of early-stage breast cancer chemotherapy.  
First Author: Margaret Q. Rosenzweig, PhD, AOCNP, FAAN
- Board 49 **ABSTRACT 6557:** A quantitative synthesis of disparities in the inclusion of racial/ethnic minorities and older women in breast cancer trials.  
First Author: Mahnoor Islam, M.B.B.S

- Board 50 **ABSTRACT 6558:** Disparities in intensity of care at the end-of-life for patients with gastrointestinal cancer.  
First Author: Gladys M. Rodriguez, MD
- Board 51 **ABSTRACT 6559:** Source of funding and enrollment disparity in cancer clinical trials.  
First Author: Irbaz Bin Riaz, MBBS, MS
- Board 52 **ABSTRACT 6560:** CONSENT: Randomized controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials.  
First Author: Abhijit Pal, BSc, FRACP, MBBS
- Board 53 **ABSTRACT 6561:** The patient experience of prior authorization for cancer care: Anxiety, delays, and the erosion of trust.  
First Author: Fumiko Chino, MD
- Board 54 **ABSTRACT 6562:** Survival analysis of patients treated at oncology practices with more aggressive end-of-life practice patterns.  
First Author: Maureen Canavan, PhD, MPH
- Board 56 **ABSTRACT 6564:** Use of direct oral anticoagulants (DOACs) in oncology: A phase IV study on impact of edoxaban treatment in Italian patients with cancer with venous thromboembolism during antineoplastic therapy (EDO1 trial, GOIRC 05-2018).  
First Author: Filippo Giovanardi, MD, PhD
- Board 57 **ABSTRACT 6565:** The IMPACT of an interdisciplinary goals-of-care program on readmission rates at a comprehensive care center.  
First Author: Cerena Leung, MD
- Board 58 **ABSTRACT 6566:** Trends of using immune checkpoint inhibitors near end of life in limited resources setting: Experience of single cancer center in the MENA region.  
First Author: Kamal Hosni Al-Rabi, MD
- Board 59 **ABSTRACT 6567:** Reducing infusion center wait times in a resource-limited setting.  
First Author: Amy Little Jones, MD
- Board 60 **ABSTRACT 6568:** The effects of social determinants of health on colorectal cancer screening.  
First Author: Isabelle Franklin
- Board 61 **ABSTRACT 6569:** Profile of toxicities and quality of life in long-term survivors treated with immunotherapy: A prospective cross sectional trial.  
First Author: Paolo Bossi
- Board 62 **ABSTRACT 6570:** Multimodal interventions targeting identified barriers to improve lung cancer screening in northeast Georgia.  
First Author: Swathi Kanakamedala, DO
- Board 63 **ABSTRACT 6571:** Just ASK: A quality improvement project to enhance smoking assessment and treatment.  
First Author: Graham W. Warren, MD, PhD, FASCO
- Board 64 **ABSTRACT 6572:** Use of germline testing in patients with prostate, pancreatic, or ovarian cancer in Washington (WA) state.  
First Author: Qin Sun
- Board 65 **ABSTRACT 6573:** Reporting of patient reported outcomes in randomized clinical trials (RCTs) in non-small cell lung cancer (NSCLC) patients (pts).  
First Author: Laura Palmeri, MD, PhD
- Board 66 **ABSTRACT 6574:** Incidence of infusion related reactions of daratumumab-hyaluronidase-fihj: Pre-post intervention study of premedication omission.  
First Author: Kashyap Padmaraju, PharmD
- Board 67 **ABSTRACT 6575:** Machine learning and postoperative complications: Determining risk before surgery in patients with cancer.  
First Author: Matthew C Hernandez
- Board 68 **ABSTRACT 6576:** Data driven insights from multiple OCM practices to optimize care for managing high-risk cancer patients across multiple cancer types.  
First Author: Srisairam Achuthan, PhD
- Board 69 **ABSTRACT 6577:** Palliative care consultation and end-of-life outcomes in a retrospective cohort of patients treated with immune checkpoint inhibitors.  
First Author: Chance H. Bloomer, MD
- Board 70 **ABSTRACT 6578:** Mortality among oncology patients with multiple unplanned hospital admissions.  
First Author: Thomas J Roberts, MD, MBA
- Board 71 **ABSTRACT 6579:** Use of statistical process control charts to identify impactful implementation strategies for an ePRO-based symptom management program across the SIMPRO Consortium.  
First Author: Jim W Doolin, MD
- Board 72 **ABSTRACT 6580:** The association between systemic anticancer therapy (SACT) at the end of life (EOL) and acute care use among patients treated at oncology practices participating in the Oncology Care Model (OCM).  
First Author: Maureen Canavan, PhD, MPH
- Board 73 **ABSTRACT 6581:** Real-world program-based lung cancer care.  
First Author: Wei Liao, PhD, MS
- Board 74 **ABSTRACT 6582:** Proportion of patients in phase I solid tumor oncology trials receiving treatments that are clinically efficacious.  
First Author: Carlos Umberto Muzlera
- Board 75 **ABSTRACT 6583:** The association of HIV and other risk factors with triple-negative breast cancer in South African women.  
First Author: Jacob Dubner, BA
- Board 76 **ABSTRACT 6584:** Breast cancer staging for patients with "low risk" disease: Are they all the same?  
First Author: Jennifer Kay Plichta, MD
- Board 77 **ABSTRACT 6585:** Trends in the use of maintenance therapy in ovarian cancer.  
First Author: Naomi N. Adjei, MD, MS, MPH
- Board 78 **ABSTRACT 6586:** Survival of patients with solid tumors and sepsis admitted to intensive care in a tertiary oncology center: A retrospective analysis.  
First Author: Sam Smith, MB BChir, MA
- Board 79 **ABSTRACT 6587:** Real-world analysis of cardiac, gastrointestinal, and hematologic toxicities between commonly used antiemetics in everyday oncology clinical practice.  
First Author: Kavitha Beedupalli, MBBS
- Board 80 **ABSTRACT 6588:** Multicenter, retrospective population-based study on the incidence of medication-related osteonecrosis of the jaw in patients with breast cancer with bone metastases.  
First Author: Christine Brunner, MD
- Board 81 **ABSTRACT 6589:** Real-world evidence to inform clinical insights on tissue-agnostic approvals of therapies.  
First Author: George W. Sledge Jr., MD, FASCO
- Board 82 **ABSTRACT 6590:** Site of metastasis (SoM) and its impact on clinical outcomes in 8 cancer cohorts.  
First Author: Rohini George, PhD



Saturday, June 3, 2023

- Board 83 **ABSTRACT 6591:** Malnutrition risk at diagnosis and influence on survival in patients with solid tumors at a large academic cancer center.  
First Author: Kunal C. Kadakia, MD
- Board 84 **ABSTRACT 6592:** Real-world behavioral restriction practices of cancer patients (pts).  
First Author: Eliya Shachar, MD
- Board 85 **ABSTRACT 6593:** Measuring variation in the quality of systemic anti-cancer therapy delivery across hospitals: A national population-based evaluation.  
First Author: Jemma Megan Boyle, PhD
- Board 86 **ABSTRACT 6594:** Tumor lysis syndrome in solid tumors: A retrospective cohort study of the National Inpatient Sample from 2016 to 2019.  
First Author: Akshit Chitkara, MD
- Board 87 **ABSTRACT 6595:** Real-world response endpoints in patients with mNSCLC treated with chemotherapy across real-world datasets.  
First Author: Brittany Avin McKelvey, PhD
- Board 88 **ABSTRACT 6596:** Molecular testing utilization in patients with advanced non-small cell lung cancer (NSCLC) in Washington (WA) state.  
First Author: Lauren Shih, MD
- Board 89 **ABSTRACT 6597:** Disparities in PI3K/mTOR inhibitor use, toxicities, and outcomes among patients with metastatic breast cancer.  
First Author: Claire Sathe, MD, JD
- Board 90 **ABSTRACT 6598:** Decomposing racial differences in financial hardship among older cancer survivors.  
First Author: Elizabeth Davis, MPH
- Board 91 **ABSTRACT 6599:** Commercial vs. Medicaid insurance and use of high-priced anticancer treatments.  
First Author: Aaron Philip Mitchell, MD, MPH
- Board 92 **ABSTRACT 6600:** The evolving landscape of chemotherapy for the treatment of early-stage breast cancer from 2006-2019: Results of a retrospective cohort study.  
First Author: Jenna Bhimani, MBBS MPH
- Board 93 **ABSTRACT 6601:** Integrating the 31-gene expression profile test into clinical decision-making to guide risk-aligned care decisions for patients with stage I-III cutaneous melanoma: NCI-SEER Analysis.  
First Author: David Hyams, MD
- Board 94 **ABSTRACT 6602:** Evaluating depth of disparities in relation to relative survival rates: Analysis of SEER data.  
First Author: Alma Habib
- Board 95 **ABSTRACT 6603:** Demographic disparities in lung cancer mortality and trends in the United States between 1999 and 2020: A population-based CDC database analysis.  
First Author: Alexander Didier
- Board 96 **ABSTRACT 6604:** Association between severe adverse event management and overall survival in patients treated with immune checkpoint inhibitor with advanced non-small-cell lung cancer.  
First Author: Jarushka Naidoo, MHS, MBCh
- Board 97 **ABSTRACT 6605:** Intrathecal drug delivery systems for cancer pain control: Insights on current contemporary practices in the US.  
First Author: Vasudha Goel, MD
- Board 98 **ABSTRACT 6606:** The safety of seasonal influenza vaccination among patients prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data.  
First Author: Alicia Ann Grima, BSc, MPH
- Board 99 **ABSTRACT 6607:** Development of natural language processing (NLP) models for extracting key features from unstructured notes to create real-world data (RWD) assets for clinical research at scale.  
First Author: Smita Agrawal, PhD
- Board 100 **ABSTRACT 6608:** A pragmatic, single-arm clinical trial of a dose-adjustment algorithm for preventing cytopenia-related delays during FOLFOX chemotherapy.  
First Author: Gabriel A. Brooks, MD, MPH
- Board 101 **ABSTRACT 6609:** Assessment of patient reported outcomes (PROs) completion patterns in patients with cancer: Examining real-world data.  
First Author: Nada Al-Antary, MD
- Board 102 **ABSTRACT 6610:** Molecular diagnostic classification for cancers of unknown primary (CUP): Post-testing diagnosis and treatment impact analysis from real-world claims data.  
First Author: Zachary Rivers, PhD, PharmD
- Board 103 **ABSTRACT 6611:** Using real-world evidence (RWE) in regulatory decision making: A study of 6 oncology approvals with RWE included in the product label.  
First Author: Jihong Zong, MD, PhD
- Board 104 **ABSTRACT 6612:** Patient reported outcomes (PROs) collection modalities among patients diagnosed with cancer: Online vs in-person.  
First Author: Eric Adjei Boakye, PhD
- Board 105 **ABSTRACT 6613:** An assessment of the provider financial risk impacts of adoption of biosimilars in the Medicare Oncology Care Model.  
First Author: Joshua A. Roth, PhD, MHA
- Board 106 **ABSTRACT 6614:** An application of extrapolating clinical data from single-arm trials to assess comparative effectiveness.  
First Author: Kangho Suh, PharmD, PhD
- Board 107 **ABSTRACT 6615:** Racial disparities in survival and stage at diagnosis among adolescent and young adult patients with cancer.  
First Author: Kekoa A. Taparra, MD, PhD
- Board 108 **ABSTRACT 6616:** Real world utilization and disparities in outcome in the use of novel anti-androgen agents for metastatic prostate cancer.  
First Author: Samina Hirani, MD
- Board 109 **ABSTRACT 6617:** Effects of concomitant gut-microbiome altering medications on immune checkpoint inhibitors therapy: A retrospective study.  
First Author: Rohit Singh, MD
- Board 110 **ABSTRACT 6618:** An indirect comparison of elranatamab's (ELRA) objective response rate (ORR) from MagnetisMM-3 (MM-3) vs real-world external control arms in triple-class refractory (TCR) multiple myeloma (MM).  
First Author: Luciano J. Costa, MD, PhD
- Board 111 **ABSTRACT 6619:** Real-world outcomes of patients (pts) with malignant solid tumors treated with immune checkpoint inhibitors (ICI) in relation to smoking status: The SAKK 80/19 SMOKER study.  
First Author: Tamer El Saadany, MD
- Board 112 **ABSTRACT 6620:** The impact of using Elsevier ClinicalPath oncology treatment pathways on survival and cost of care.  
First Author: Monica Schmidt, PhD, MPH
- Board 113 **ABSTRACT 6621:** Rates of emergency department visits and acute-care hospital admissions after starting chemotherapy or having surgery across six community-based cancer centers.  
First Author: Michael J. Hassett, MD, MPH, FASCO

- Board 114 **ABSTRACT 6622:** Improved outcomes from reflex comprehensive genomic profiling-guided precision therapeutic selection across a major US healthcare system.  
First Author: Brian Piening, PhD
- Board 115 **ABSTRACT 6623:** Financial toxicity, quality of life, symptom burden, and access to resources in early-phase clinical trial (EP-CT) participants.  
First Author: Sienna Durbin, MD
- Board 116 **ABSTRACT 6624:** Evaluation of cachexia and outcomes in patients with aggressive B-cell non-Hodgkin lymphoma.  
First Author: Nicholas Demetriou
- Board 117 **ABSTRACT 6625:** Efficacy-effectiveness gap with immune checkpoint inhibitors in solid cancers: A population based cohort study.  
First Author: Saroj Niraula, MD, FRCPC, MSc
- Board 118 **ABSTRACT 6626:** Electronic health record (EHR)-based machine learning (ML) to predict disease recurrence after surgical resection of early-stage non-small cell lung cancer (eNSCLC).  
First Author: Steven Pisano, MS
- Board 119 **ABSTRACT 6627:** Endoscopist volume and the quality of colonoscopy of the Korean National Cancer Screening Program.  
First Author: Dong Jun Kim, MPH
- Board 120 **ABSTRACT 6628:** An ehealth intervention during radical radiotherapy: Patient-Reported Outcome Side effects (PROSE) study—An emerging approach from sub-Saharan Africa.  
First Author: Omolola Salako, MBBS
- Board 121 **ABSTRACT 6629:** Real-world study of treatment patterns and clinical outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) post-approval of immunotherapy in the community oncology setting.  
First Author: Alexander I. Spira, MD, PhD, FACP
- Board 122 **ABSTRACT 6630:** Evaluation of studies with commonly used real world data sources submitted to ASCO journals: Initial steps toward furthering transparent reporting.  
First Author: Benjamin Bates, MD
- Board 123 **ABSTRACT 6631:** Racial disparities in hospitalization outcomes among patients with cholangiocarcinoma.  
First Author: Inimfon Jackson, MD, PhD, MPH
- Board 124 **ABSTRACT 6632:** Cancer survival (SURVCANCER BRAZIL): Analysis of 132,621 cases from 19 hospital-based registries in southernmost Brazilian state comparing public and private insurance.  
First Author: Juliana Giacomazzi, PhD
- Board 125 **ABSTRACT 6633:** Real-world analysis of commercially insured and Medicare Advantage patients with advanced cancer and rates of molecular testing.  
First Author: Stacey DaCosta Byfield, PhD, MPH
- Board 126 **ABSTRACT 6634:** Prognosis and risk of suicide after cancer diagnosis.  
First Author: Connor J Kinslow, MD, BS
- Board 127 **ABSTRACT 6635:** A comparison of the Optum Clinigenomics Solid Tumor Database and the SEER Population-Based Cancer Registry.  
First Author: Alexa Woodward, PhD, MS
- Board 128 **ABSTRACT 6636:** Disparity in regional recruitment across global cancer trials: A meta-analysis.  
First Author: Noureen Asghar, MD
- Board 129 **ABSTRACT 6637:** Real world data for venous thromboembolisms (VTEs) in patients with active cancer: Thromboprophylaxis pooled analysis from GMaT and ACT4CAT studies.  
First Author: Nikolaos Tsoukalas, MD, PhD, MS
- Board 130 **ABSTRACT 6638:** Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction (PCR) versus next-generation sequencing (NGS) testing strategies in metastatic non-small cell lung cancer (mNSCLC).  
First Author: Christine M. Bestvina, MD
- Board 131 **ABSTRACT 6639:** Oncologists' receipt of pharmaceutical industry payments and use of non-recommended and low-value cancer care services.  
First Author: Aaron Philip Mitchell, MD, MPH
- Board 132 **ABSTRACT 6640:** Palliative care as a component of high-value and cost-saving care during hospitalization for metastatic cancer.  
First Author: Sifan Lu
- Board 133 **ABSTRACT 6641:** The role of private insurance characteristics in the out-of-pocket costs of patients with multiple myeloma.  
First Author: Hamlet Gasoyan, PhD
- Board 134 **ABSTRACT 6642:** Estimated life-years gained and resultant cost savings from follow-up colonoscopy after a positive multi-target stool DNA (mt-sDNA) test for colorectal cancer screening in commercially insured and Medicare populations.  
First Author: A. Mark Fendrick, MD
- Board 135 **ABSTRACT 6643:** Unnecessary thrombophilia testing reduction: Quality improvement project.  
First Author: Konstantin Golubykh
- Board 136 **ABSTRACT 6644:** Association between targeted cancer drug net health benefit and uptake, patient out-of-pocket spending, and total spending.  
First Author: Kelsey S. Lau-Min, MD, MS
- Board 137 **ABSTRACT 6645:** Association of early completion of portable medical orders with inpatient costs at end-of-life for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).  
First Author: Marissa LoCastro, BS
- Board 138 **ABSTRACT 6646:** Maxed out: Reaching the annual maximum out-of-pocket limit among insured patients diagnosed with cancer.  
First Author: Matthew P. Banegas, PhD, MPH
- Board 139 **ABSTRACT 6647:** National survey of financial burdens and experience among patients with cancer receiving charitable co-pay assistance.  
First Author: Jeffrey M. Peppercom, MD, MPH
- Board 140 **ABSTRACT 6648:** A health economic model to assess the impact of prehabilitation on hospital cost savings in gastrointestinal cancer, modelled on English National Health Service tariff.  
First Author: Bernarda Zamora Zamora Talaya
- Board 141 **ABSTRACT 6649:** Value-driven colorectal cancer survivorship through partnership with primary care.  
First Author: Gloria Hui Jia Chan, MBBS MRCP MCI
- Board 142 **ABSTRACT 6650:** Impact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: A cost consequence analysis using linked administrative data.  
First Author: Alberto Hernando-Calvo, MD

## Saturday, June 3, 2023

- Board 143 **ABSTRACT 6651:** The impact of a cancer-specific novel therapy adjustment (NTA) in Medicare value-based care programs: A simulation exercise.  
First Author: Erica Feinberg, PharmD
- Board 144 **ABSTRACT 6652:** Assessment of price variation in colorectal cancer screening procedures at US hospitals.  
First Author: Ishan Paranjpe
- Board 145a **ABSTRACT TPS6653:** The FOR ME (Fostering Opportunities in Research through Messaging and Education) study: Developing a culturally sensitive narrative intervention to promote equity in clinical trials.  
First Author: Neha Hippalgaonkar, MD
- Board 145b **ABSTRACT TPS6654:** Understanding patient acceptance and compliance of a blood-based colorectal cancer screening test.  
First Author: Karen Kim, MD

---

### 1:15 PM - 4:15 PM Poster Session

#### Melanoma/Skin Cancers

Location: Hall A

Abstracts on Boards 272-283 will be discussed during the Melanoma/Skin Cancers Poster Discussion Session. See the online program guide ([meetings.asco.org](https://meetings.asco.org)) for session details.

#### Posters by Topic

**Advanced/Metastatic Disease:** Boards 272-273, 275-276, 278, 280, 282-317, 320-327, 355a-363b

**Biologic Correlates:** Boards 328-330, 332

**Local-Regional Disease:** Boards 277, 279, 281, 333-348, 364a-364b

**Other Melanoma/Skin Cancers:** Boards 349-354, 365a-366a

- Board 272 **ABSTRACT 9509:** Initial efficacy and safety of RP1 + nivolumab in patients with anti-PD-1–failed melanoma from the ongoing phase 1/2 IGRYTE study.  
First Author: Bartosz Chmielowski, MD, PhD
- Board 273 **ABSTRACT 9510:** Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.  
First Author: Lu Si, MD
- Board 275 **ABSTRACT LBA9512:** Survival after Isolated Hepatic Perfusion as a Treatment for Uveal Melanoma Liver Metastases - Results from a Randomized Controlled Trial (the SCANDIUM trial).  
First Author: Roger Olofsson Bagge, MD, PhD
- Board 276 **ABSTRACT 9513:** Tumor infiltrating lymphocyte (TIL) harvest and ex vivo expansion from primary and metastatic (met) uveal melanoma (UM) tumors.  
First Author: Sapna Pradyuman Patel, MD
- Board 277 **ABSTRACT 9514:** NeoPlus: A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma.  
First Author: Lili Mao, MD
- Board 278 **ABSTRACT LBA9515:** Minimal residual disease by circulating tumor DNA as a biomarker of recurrence free survival in resected high-risk melanoma patients treated with mRNA-4157/V940, a personalized cancer vaccine, and pembrolizumab.  
First Author: Matteo S. Carlino, PhD, FRACP, MBBS
- Board 279 **ABSTRACT 9516:** Revisiting the optimal neoadjuvant immunotherapy regimen in resectable stage III melanoma based on the interferon gamma signature: A pooled analysis.  
First Author: Minke W. Lucas, MD

- Board 280 **ABSTRACT 9517:** Final clinical results and first translational correlates of a phase 2 trial of adaptively dosed nivolumab and ipilimumab based on early radiographic assessment in advanced melanoma (ADAPT-IT).  
First Author: James William Smithy, MD, MHS
- Board 281 **ABSTRACT 9518:** Efficacy of adjuvant therapy in patients (pts) with AJCC v8 stage IIIA cutaneous melanoma.  
First Author: Piyush Grover, MBBS, BPharm
- Board 282 **ABSTRACT 9519:** Cemiplimab for kidney organ transplant recipients with advanced cutaneous squamous cell carcinoma: CONTRAC-1.  
First Author: Glenn J. Hanna, MD
- Board 283 **ABSTRACT 9520:** Role of nivolumab maintenance therapy in advanced melanoma patients following severe immune-related adverse events from combination nivolumab and ipilimumab.  
First Author: Anna Maloney, MPH
- Board 284 **ABSTRACT 9521:** Real-world treatment patterns and clinical outcomes among subgroups of BRAF-positive metastatic melanoma patients treated with dabrafenib + trametinib.  
First Author: Zeynep Eroglu, MD
- Board 285 **ABSTRACT 9522:** Subsets of interferon signaling and response to immune checkpoint blockade.  
First Author: Daniel Lee, MD
- Board 286 **ABSTRACT 9523:** The validity of a machine learning algorithm in predicting response to immune checkpoint inhibitors in melanoma.  
First Author: Faisal Fa'ak, MBBS
- Board 287 **ABSTRACT 9524:** Identification of RPTOR mutation as a novel predictor of efficacious immunotherapy in melanoma.  
First Author: Yongzhao Li
- Board 288 **ABSTRACT 9525:** CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma.  
First Author: Peter Kar Han Lau, PhD, FRACP, BSc, MBBS
- Board 289 **ABSTRACT 9526:** Leveraging longitudinal clinical annotations and panel sequencing to characterize dynamics of organotropism in metastatic melanoma.  
First Author: Tyler J Aprati, BS
- Board 290 **ABSTRACT 9527:** Preliminary safety and efficacy results from an open-label, multicenter, phase 1 study of RP2 as a single agent and in combination with nivolumab in a cohort of patients with uveal melanoma.  
First Author: Joseph J. Sacco, MD
- Board 291 **ABSTRACT 9528:** Anti-PD1 plus BRAF/MEK inhibitors (triplet therapy) after failure of standard therapy in patients (pts) with advanced melanoma.  
First Author: Lisa Zimmer, MD
- Board 292 **ABSTRACT 9529:** Risk of further progression or death among durable progression-free survivors with melanoma in PD-1 blockade trials: Implications for imaging surveillance.  
First Author: Lei Deng, MD
- Board 293 **ABSTRACT 9530:** Early safety and efficacy from a phase I clinical study of TWP-101, a novel CD137 agonist antibody, in patients with advanced melanoma and urothelial carcinoma.  
First Author: Jun Guo, MD

- Board 294 **ABSTRACT 9531:** Encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for unresectable locally advanced or metastatic BRAF V600-mutant melanoma: Results from STARBOARD safety lead-in (SLI).  
First Author: Dirk Schadendorf, MD
- Board 295 **ABSTRACT 9532:** A prediction model for response to immune checkpoint inhibition in advanced melanoma.  
First Author: Isabella A.J. van Duin, MD
- Board 296 **ABSTRACT 9533:** A phase I, randomized, controlled, multicentre trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab in patients with uveal melanoma metastases (the SCANDIUM 2 trial).  
First Author: Roger Olofsson Bagge, MD, PhD
- Board 297 **ABSTRACT 9534:** Phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant Merkel cell carcinoma and cutaneous squamous cell carcinoma.  
First Author: Andrew Scott Brohl, MD
- Board 298 **ABSTRACT 9535:** Updated results from an ongoing phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via IT injection as monotherapy or combined with pembrolizumab in advanced solid tumors.  
First Author: Jiaxin Niu, MD, PhD
- Board 299 **ABSTRACT 9536:** Targeting AMP kinase in melanoma: A phase I trial of phenformin with dabrafenib/trametinib.  
First Author: Paul B. Chapman, MD
- Board 300 **ABSTRACT 9537:** Avelumab as second-line or later (2L+) treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Analysis of real-world outcomes in France using the CARADERM registry and the French national healthcare database.  
First Author: Astrid Blom Fily
- Board 301 **ABSTRACT 9538:** Immune infiltrates in metastatic uveal melanoma liver metastases and associations with clinical outcomes.  
First Author: Katherine Emilie Rhoades Smith, MD
- Board 302 **ABSTRACT 9539:** Economic evaluation for the US of relatlimab and nivolumab (RELA+NIVO) versus nivolumab (NIVO) monotherapy in untreated advanced melanoma.  
First Author: Osama Aqel, BPharm
- Board 303 **ABSTRACT 9540:** Interim results from a phase I/II study of duvelisib PI3K $\delta$  $\gamma$  inhibitor and nivolumab in patients with advanced unresectable melanoma who have progressed on anti-PD1 therapy.  
First Author: Jingxiao Jin, MD
- Board 304 **ABSTRACT 9541:** Updated safety and efficacy results from the phase I study of either LBL-007 (an anti-LAG-3 antibody) in combination with toripalimab (an anti-PD-1 antibody) or LBL-007 in combination with toripalimab and axitinib in patients with advanced melanoma.  
First Author: Xue Bai, MD
- Board 305 **ABSTRACT 9542:** Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS)  $\geq$ 3y on nivolumab (NIVO)  $\pm$  ipilimumab (IPI) or IPI in CheckMate 067.  
First Author: F. Stephen Hodi, MD
- Board 306 **ABSTRACT 9543:** The effect of LNS8801 alone and in combination with pembrolizumab in patients with metastatic uveal melanoma.  
First Author: Alexander Noor Shoushtari, MD
- Board 307 **ABSTRACT 9544:** Breaking primary checkpoint inhibitor resistance: Interim analysis of a multicenter phase II study by intermittent application of an alkylating agent among patients with metastatic melanoma.  
First Author: Lucie Heinzerling, MD, PhD, MPH
- Board 308 **ABSTRACT 9545:** Real-world comparison between 6 weeks versus 3 weeks adjuvant pembrolizumab in high-risk stage IIB-IIID cutaneous malignant melanoma: Experience from an academic cancer center.  
First Author: Manan Shah, MD
- Board 309 **ABSTRACT 9546:** Neoadjuvant T-VEC + nivolumab combination therapy for resectable early metastatic (stage IIB/C/D-IV M1a) melanoma with injectable disease: NIVEC trial.  
First Author: Lisanne P. Zijlker
- Board 310 **ABSTRACT 9547:** Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: Results from the observational study GEM1801.  
First Author: Pablo Ayala de Miguel
- Board 311 **ABSTRACT 9548:** A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced melanoma: Poor-prognosis subgroup analysis.  
First Author: Inderjit Mehmi, MD
- Board 312 **ABSTRACT 9549:** Determinants of racial disparities in immune-related adverse events (irAE) with checkpoint inhibition (ICI) in melanoma.  
First Author: Milad Ibrahim, PhD
- Board 313 **ABSTRACT 9550:** Phase II clinical trial of camrelizumab combined with famitinib for advanced acral and mucosal melanoma.  
First Author: Lili Mao, MD
- Board 314 **ABSTRACT 9551:** Final results: Dose escalation study of a personalized peptide-based neoantigen vaccine in patients with metastatic melanoma.  
First Author: Sofie Kirial Mørk, MD, PhD
- Board 315 **ABSTRACT 9552:** Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).  
First Author: Dirk Schadendorf, MD
- Board 316 **ABSTRACT 9553:** Melanomas lacking HLA class I expression and response to checkpoint inhibitor.  
First Author: Paul B. Chapman, MD
- Board 317 **ABSTRACT 9554:** Safety and preliminary efficacy of intrathecal (IT) and intravenous (IV) nivolumab (N) for patients (pts) with leptomeningeal disease (LMD).  
First Author: Isabella Claudia Glitza, MD, PhD, MSc
- Board 320 **ABSTRACT 9557:** High dose ipilimumab (Ipi) plus temozolomide (TMZ) after progression on standard or low dose Ipi in advanced melanoma.  
First Author: Julie Williamson, MD
- Board 321 **ABSTRACT 9558:** The impact of emotional distress on pathologic response and survival after neoadjuvant combination immune checkpoint blockade (ICB) in high-risk stage III melanoma.  
First Author: Irene L.M. Reijers, MD
- Board 322 **ABSTRACT 9559:** A phase 2 study of alrizomadlin (APG-115) in combination with pembrolizumab in patients with unresectable or metastatic cutaneous melanoma that has failed immuno-oncologic (IO) drugs.  
First Author: Montaser F. Shaheen, MD
- Board 323 **ABSTRACT 9560:** Machine learning (ML)-based quantification of tumor-infiltrating lymphocytes (TIL) and clinical outcomes of patients with melanoma treated with immune-checkpoint inhibitors (ICI).  
First Author: Elio Adib, MD

- Board 324 **ABSTRACT 9561:** Correlation of DNA methylation signatures with response to immune checkpoint inhibitors in metastatic melanoma.  
First Author: Julia Maria Ressler
- Board 325 **ABSTRACT 9562:** Association of ultra-sensitive ctDNA assay to identify actionable variants and response to immune checkpoint inhibitor (ICI) therapy in metastatic melanoma.  
First Author: Christoffer Gebhardt, MD
- Board 326 **ABSTRACT 9563:** Interim analysis of a phase II study of nivolumab/ipilimumab plus cabozantinib in patients with unresectable advanced melanoma.  
First Author: Geoffrey Thomas Gibney, MD, FASCO
- Board 327 **ABSTRACT 9564:** Analysis of overall survival (OS) and progression-free survival (PFS) in the phase 1b clinical trial of anti-PD-1 ab (toripalimab) plus intrahepatic injection of OrienX010 in stage IV melanoma with liver metastases.  
First Author: Chuanliang Cui, MD
- Board 328 **ABSTRACT 9565:** Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum: Outcomes for patients with melanoma.  
First Author: Lilit Karapetyan, MD, MSc
- Board 329 **ABSTRACT 9566:** Exploring the clinical significance of specific immune-related adverse events (irAE) in patients with melanoma undergoing immune checkpoint inhibitor (ICI) therapy.  
First Author: Nethanel Asher, MD
- Board 330 **ABSTRACT 9567:** Transforming growth factor-b1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in advanced basal cell carcinoma.  
First Author: Bernardo Leon Rapoport, MD
- Board 332 **ABSTRACT 9569:** De-correlating immune checkpoint inhibitor toxicity and response in melanoma via the microbiome.  
First Author: Nyelia F Williams, BS
- Board 333 **ABSTRACT 9570:** Overall survival after the introduction of adjuvant treatment in stage III melanoma: A nationwide registry based study.  
First Author: Hildur Helgadóttir, MD, PhD
- Board 334 **ABSTRACT 9571:** Population-based validation of the Melanoma Institute Australia (MIA) and the Memorial Sloan-Kettering Cancer Center (MSKCC) predictive tool for sentinel node status in patients with melanoma.  
First Author: Rasmus Mikiver
- Board 335 **ABSTRACT 9572:** Tumor-informed circulating tumor DNA (TI-ctDNA) based molecular residual disease (MRD) detection and relapse risk for patients with stage II-IV melanoma in surgical remission: A single center experience.  
First Author: Logan Rhea, DO
- Board 336 **ABSTRACT 9573:** Discovery and validation of AMLor as a prognostic biomarker for non-ulcerated cutaneous AJCC stage I/II melanoma.  
First Author: Penny Lovat, PhD
- Board 337 **ABSTRACT 9574:** Intralesional therapy, limb infusion/perfusion, and immune checkpoint inhibitors as first-line therapy in surgically unresectable melanoma in-transit metastases.  
First Author: Danielle K DePalo, MD
- Board 338 **ABSTRACT 9575:** Nature and management of melanoma recurrences following adjuvant anti-PD-1 (PD1) therapy.  
First Author: Rachel Woodford
- Board 339 **ABSTRACT 9576:** NEO-CESQ study: Neoadjuvant plus adjuvant treatment with cemiplimab in surgically resectable, high risk stage III/IV (M0) cutaneous squamous cell carcinoma.  
First Author: Paolo Antonio Ascierto, MD
- Board 340 **ABSTRACT 9577:** Association of circulating tumor DNA kinetics with disease recurrence in patients with stage IIIB/C/IV melanoma treated with adjuvant immunotherapy in CheckMate 238.  
First Author: Mahrukh M Syeda, MS
- Board 341 **ABSTRACT 9578:** Melanoma disparities in urban vs rural communities in the era of immunotherapy: An NCDB analysis.  
First Author: Rachel Akers, BS, MS
- Board 342 **ABSTRACT 9579:** A pilot study of the neoadjuvant use of vemurafenib plus cobimetinib in patients with BRAF-mutant melanoma with palpable lymph node metastases: Survival results.  
First Author: Teresa M. Petrella, MD, FRCPC
- Board 343 **ABSTRACT 9580:** Prognostic significance of immune-related adverse events and immunosuppression in patients with melanoma receiving adjuvant anti-PD-1 therapy.  
First Author: Andrew David Knight, MD
- Board 344 **ABSTRACT 9581:** Intralesional oncolytic virotherapy with talimogene laherparepvec in patients with cutaneous lymphomas and non-melanoma skin cancers.  
First Author: Egle Ramelyte, MD, PhD
- Board 345 **ABSTRACT 9582:** Longitudinal circulating tumor DNA monitoring for detection of molecular residual disease in patients with surgically resected stage II/III melanoma.  
First Author: Revathi Kollipara, MD
- Board 346 **ABSTRACT 9583:** Expanded cohort and extended follow-up of neoadjuvant plus adjuvant (neo + adj) dabrafenib (D) and trametinib (T) in patients (pts) with surgically resectable stage (stg) III/IV melanoma.  
First Author: Tarin Hennegan, MPAS
- Board 347 **ABSTRACT 9584:** [<sup>18</sup>F]FDG-PET to identify pathological responses upon neoadjuvant immune checkpoint blockade in cutaneous squamous cell carcinoma.  
First Author: Sabine E. Breukers, MD
- Board 348 **ABSTRACT 9585:** FDG-PET/CT response and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma.  
First Author: Milton Jos De Barros E Silva, MD, Msc
- Board 349 **ABSTRACT 9586:** Successful management of Australian patients with locally advanced keratinocyte cancer (KC) and/or extensive skin field cancerization (ESFC), using widefield volumetric arc radiation therapy (VMAT): Report with 24-month follow-up.  
First Author: Andrew Potter, MBBS, FRANZCR
- Board 350 **ABSTRACT 9587:** Comprehensive genomic profiling (CGP) of clinically advanced and metastatic cutaneous adnexal carcinomas (CAs; MCADCA): A genomic landscape study.  
First Author: Maroun Bou Zerdan, MD
- Board 351 **ABSTRACT 9588:** A phase Ib study of endogenous T cell therapy using SLC45A2-specific CD8 T cells for patients with metastatic uveal melanoma.  
First Author: Suzanne Phillips, CCRP, BSc, BSN, OCN
- Board 352 **ABSTRACT 9589:** Early ctDNA reduction may identify patients with stable disease and long OS on tebentafusp.  
First Author: Dan Feng

- Board 353 **ABSTRACT 9590:** Survival outcomes associated with liver-directed therapies in patients with metastatic uveal melanoma.  
First Author: Michael M Caplan, MD
- Board 354 **ABSTRACT 9591:** Long-term outcomes of chronic immune-related adverse events from adjuvant anti-PD-1 therapy for high-risk resected melanoma.  
First Author: Rachel S Goodman, MBA
- Board 355a **ABSTRACT TPS9592:** ARTISTRY-6: Nemvaleukin alfa monotherapy in patients with advanced mucosal and cutaneous melanoma.  
First Author: Jeffrey S. Weber, MD, PhD
- Board 355b **ABSTRACT TPS9593:** Camrelizumab combined with anlotinib and nab-paclitaxel in patients with untreated advanced mucosal melanoma: A single-arm, multi-center, exploratory study.  
First Author: Di Wu, MD
- Board 356a **ABSTRACT TPS9594:** A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A\*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM).  
First Author: Diwakar Davar, MBBS
- Board 356b **ABSTRACT TPS9595:** Phase Ib/II study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combination in metastatic melanoma refractory to prior immune checkpoint inhibitor therapy with and without CNS disease.  
First Author: Saya Jacob, MD
- Board 357a **ABSTRACT TPS9596:** Phase II study of niraparib in patients with advanced melanoma with genetic homologous recombination (HR) mutation/alteration.  
First Author: Kevin B. Kim, MD
- Board 357b **ABSTRACT TPS9597:** Phase 1 study of SGN-BB228, an investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific, in patients with advanced melanoma and other solid tumors (SGNBB228-001).  
First Author: Jason Timothy Henry, MD
- Board 358a **ABSTRACT TPS9598:** A phase 3 trial comparing fianlimab (anti-LAG-3) plus cemiplimab (anti-PD-1) to pembrolizumab in patients with completely resected high-risk melanoma.  
First Author: Timothy J. Panella, MD
- Board 358b **ABSTRACT TPS9599:** OMNIA-1: A phase I/II study, an IL-2R- $\beta\gamma$  targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti-PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma.  
First Author: Paolo Antonio Ascierto, MD
- Board 359a **ABSTRACT TPS9600:** NOTOS: A pivotal study of navtemadlin, a first-in-class mouse double minute 2 inhibitor (MDM2i), in patients (pts) with TP53 wild-type (TP53<sup>WT</sup>) Merkel cell carcinoma (MCC) for whom anti PD-1/L1 therapy has failed.  
First Author: Michael K.K. Wong, MD, PhD
- Board 359b **ABSTRACT TPS9601:** Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design.  
First Author: Alexander Christopher Jonathan Van Akkooi, PhD
- Board 360a **ABSTRACT TPS9602:** A phase 3 trial of fianlimab (anti-LAG-3) plus cemiplimab (anti-PD-1) versus pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma.  
First Author: Ana Baramidze
- Board 360b **ABSTRACT TPS9603:** A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.  
First Author: Zeynep Eroglu, MD
- Board 361a **ABSTRACT TPS9604:** A pilot, open study to assess efficacy and safety of ON-01910 (rigosertib) in patients with recessive dystrophic epidermolysis bullosa associated locally advanced/metastatic squamous cell carcinoma.  
First Author: Lauren Banner, BS
- Board 361b **ABSTRACT TPS9605:** Phase II study of nivolumab (nivo) in combination with relatlimab (rela) in patients (pts) with active melanoma brain metastases (MBM).  
First Author: Suzanne Phillips, CCRP, BSc, BSN, OCN
- Board 362a **ABSTRACT TPS9606:** A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel, LN-144) for patients with asymptomatic melanoma brain metastases.  
First Author: Allison Betof Warner, MD, PhD
- Board 362b **ABSTRACT TPS9607:** A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.  
First Author: Daniel Olson, MD
- Board 363b **ABSTRACT TPS9609:** The DIET study: A randomized controlled trial of a high fiber diet in cancer patients (pts) receiving immune checkpoint blockade (ICB).  
First Author: Rachel Farias, MPH
- Board 364a **ABSTRACT TPS9610:** A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in high-risk stage II cutaneous melanoma: NeoReNi II.  
First Author: Maria Gonzalez, BN, BA
- Board 364b **ABSTRACT TPS9611:** KEYVIBE-010: Adjuvant coformulated vibostolimab with pembrolizumab versus adjuvant pembrolizumab in patients with high-risk stage II-IV melanoma.  
First Author: Georgina V. Long, MD, PhD, FRACP
- Board 365a **ABSTRACT TPS9612:** NADOM trial: Neoadjuvant/adjuvant trial of darovasertib in ocular melanoma (OM).  
First Author: Roderick O'day, FRANZCO MBBS LLB BSc
- Board 365b **ABSTRACT TPS9613:** PLUME: A single-arm phase II trial evaluating the combination of pembrolizumab and lenvatinib in metastatic uveal melanoma (mUM) patients (pts) previously treated or not with tebentafusp.  
First Author: Manuel Rodrigues, MD
- Board 366a **ABSTRACT TPS9614:** CemiplimAb-rwlc survivorship and epidemiology (CASE): A prospective study of safety and efficacy of cemiplimab in patients with advanced basal cell carcinoma in a real-world setting.  
First Author: Soo J Park, MD

---

**1:15 PM - 4:15 PM Poster Session**

**Prevention, Risk Reduction, and Hereditary Cancer**

Location: Hall A

Abstracts on Boards 146-157 will be discussed during the Prevention, Risk Reduction, and Hereditary Cancer Poster Discussion Session. See the online program guide ([meetings.asco.org](https://meetings.asco.org)) for session details.

**Posters by Topic**

**Cancer Prevention:** Boards 152-153, 161-162, 164, 167, 170-172, 175-179, 190-192, 194, 196, 199-200, 202-203, 206, 208, 210, 212-215, 225, 229, 232, 255, 257, 260, 267-268, 269a

**Epidemiology:** Boards 154, 158-160, 163, 165-166, 168-169, 174, 180, 188-189, 193, 198, 204, 207, 209, 252, 258, 259, 262, 266

**Germline Genetic Testing:** Boards 151, 155-156, 181-185, 195, 216, 218-219, 223-224, 228, 230-231, 233, 235-238, 240, 242, 244, 246-248, 250-251, 253, 261, 263-265

**Hereditary Cancer Syndromes:** Boards 146-150, 157, 186-187, 211, 217, 220-222, 226-227, 234, 239, 241, 243, 245, 249, 254, 256, 269b-270a

**Prevention of Primary and Secondary Malignancies:** Board 201

Board 146 **ABSTRACT 10513:** Famitinib for familial adenomatous polyposis-associated aggressive desmoid tumors: A single-center exploratory study.  
First Author: Sai Ge, PhD

Board 147 **ABSTRACT 10514:** Lorpucitinib (JNJ-64251330) in patients with familial adenomatous polyposis (FAP): Results from a phase 1b study.  
First Author: Robert Hüneburg, MD

Board 148 **ABSTRACT 10515:** Real-world outcomes and safety in patients with VHL associated tumors receiving belzutifan.  
First Author: Anusha Chidharla, MD

Board 149 **ABSTRACT 10516:** Neoplasia detection via colonoscopic surveillance among young patients with MSH6 and PMS2-associated Lynch syndrome.  
First Author: Alicia Latham, MD, MS

Board 150 **ABSTRACT 10517:** Clinical and molecular characterization of microsatellite stable (MSS) tumors in patients with Lynch syndrome (LS).  
First Author: Emily Harrold, MBBCh

Board 151 **ABSTRACT 10518:** High-risk constitutional MLH1 methylation as a cause of early-onset colorectal and endometrial cancers displaying mismatch repair deficiency and MLH1 methylation.  
First Author: Megan Philippa Hitchins

Board 152 **ABSTRACT 10519:** Early real-world (RW) experience with a multi-cancer early detection (MCED) test.  
First Author: Candace Westgate, DO

Board 153 **ABSTRACT 10520:** Clinical evaluation of cancer signal origin prediction and diagnostic resolution following multi-cancer early detection testing.  
First Author: Eric A. Klein, MD

Board 154 **ABSTRACT 10521:** Real-world performance of a multi-cancer early detection test based on integrative analysis of cell-free DNA whole-methylome sequencing.  
First Author: Yulong LI, PhD

Board 155 **ABSTRACT 10522:** Germline mutations and the presence of clonal hematopoiesis of indeterminate potential (CHIP) in 20,963 patients with BRCA-associated cancers.  
First Author: Catherine Handy Marshall, MD, MPH

Board 156 **ABSTRACT 10523:** Prevalence of unexpected actionable germline pathogenic variants identified on broad-based multi-gene panel testing in a cohort of cancer patients.  
First Author: Kara K. Landry, MD

Board 157 **ABSTRACT 10524:** CDH1 incidental findings in patients with personal or family history of breast cancer.  
First Author: Hiam Abdel-Salam, MS

Board 158 **ABSTRACT 10525:** The impact of climate change on cancer incidence in U.S. women: Who is most affected?  
First Author: Caitlin Ruth Johnson, MPH

Board 159 **ABSTRACT 10526:** Twenty-year patterns in area deprivation index and risk of metastatic prostate cancer at initial diagnosis among men in Ohio.  
First Author: Jennifer Cullen, PhD, MPH

Board 160 **ABSTRACT 10527:** Trends in diagnosis of de novo metastatic hormone sensitive prostate cancer in US Veterans, 2002-2021.  
First Author: Nada Al masalmeh, MD

Board 161 **ABSTRACT 10528:** Breast cancer: Global patterns of incidence, mortality, and trends.  
First Author: Ephrem Tadele Sedeta, MD, MS

Board 162 **ABSTRACT 10529:** Comparison of 5- and 10-year breast cancer risk predictions.  
First Author: John L. Hopper, PhD

Board 163 **ABSTRACT 10530:** Epidemiologic effectors on the breast tumor microenvironment: Results from the Cancer Prevention Study-II and -3 cohorts.  
First Author: Maha AT Elsebaie

Board 164 **ABSTRACT 10531:** Clinical characteristics of interval breast cancer within 12 months and 13-24 months in Utah.  
First Author: Mei Wei, MD

Board 165 **ABSTRACT 10532:** Trends in mortality caused by neoplasms of the heart in the United States between 2000 and 2019: An observational analysis of disparities by gender and race.  
First Author: Abhishek Shahapurkar

Board 166 **ABSTRACT 10533:** Epidemiological and clinicopathological features of patients (pts) with early- (EOPC) and late-onset pancreatic cancer (LOPC): A mono-institutional retrospective analysis.  
First Author: Maria Bensi, MD

Board 167 **ABSTRACT 10534:** Cardiorespiratory fitness and BMI in youth and site-specific cancer mortality in men: A population-based cohort study with register linkage.  
First Author: Aron Onerup, MD, PhD

Board 168 **ABSTRACT 10535:** Examining the potential for lead-time bias by estimating stage-specific proportions of deaths due to diagnosed cancer.  
First Author: Ellen T. Chang, ScD

Board 169 **ABSTRACT 10536:** Obesity and breast cancer in women under age 40.  
First Author: Rabia Cattie, MD

Board 170 **ABSTRACT 10537:** The impact of high body mass index on hepatocellular carcinoma in viral hepatitis and cirrhosis.  
First Author: Moonho Kim, PhD

Board 171 **ABSTRACT 10538:** Association between excess body mass index trajectory and change in monoclonal protein level in patients diagnosed with monoclonal gammopathy of undetermined significance.  
First Author: Lawrence Liu, MD

Board 172 **ABSTRACT 10539:** County-level food insecurity to predict cancer incidence and mortality in the United States, 2015-2020.  
First Author: Krista Y. Chen, BS, MS

Board 174 **ABSTRACT 10541:** The role of metabolic perturbations in mediating the effects of ambient air pollution on lung cancer in the cancer prevention studies.  
First Author: Donghai Liang, PhD

Board 175 **ABSTRACT 10542:** Global burden and economic impact of vaccine-preventable cancer mortality.  
First Author: Goran Bencina, PhD, MPharm

- Board 176 **ABSTRACT 10543:** Impact of social media messages on perceived risk and severity of adverse effects and regret of HPV vaccination: The moderating role of decision-making preference.  
First Author: Jorge Villegas, PhD.
- Board 177 **ABSTRACT 10544:** The impact of HPV vaccination in Florida compared to New York.  
First Author: Thanuja Neerukonda, MD
- Board 178 **ABSTRACT 10545:** Barriers to cervical cancer screening in a developing Middle Eastern country: A nationwide survey.  
First Author: Ahmed A Abdulelah, MD
- Board 179 **ABSTRACT 10546:** Incomplete HPV vaccination among individuals aged 27-45 years in the United States: A mixed effect analysis of individual and contextual factors.  
First Author: Victor Adekanmbi, MD, PhD
- Board 180 **ABSTRACT 10547:** Sex differences in cancer incidence rates by race and ethnicity: Results from the Surveillance, Epidemiology, and End Results (SEER) Registry (2000-2019).  
First Author: Sararat Tosakoon
- Board 181 **ABSTRACT 10548:** Polygenic risk scores in assessing lung cancer susceptibility in non-Hispanic White and Black populations.  
First Author: Matthew R Trendowski, PhD
- Board 182 **ABSTRACT 10549:** Racial disparities in germline testing among men with pancreas, breast and metastatic prostate cancers in two health systems.  
First Author: Jeffrey Shevach
- Board 183 **ABSTRACT 10550:** Disparities in germline genetic testing results from a cohort of 493,515 Black and White patients.  
First Author: Rachel Wyatt, MS, CGC
- Board 184 **ABSTRACT 10551:** Characterizing medical mistrust (MM) in a socio-demographically diverse sample of patients with cancer.  
First Author: Cindy Park, MD
- Board 185 **ABSTRACT 10552:** Training oncologists (Oncs) to conduct better informed discussions with African American (AA) cancer (CA) patients (pts) about tumor genomic profiling (TGP): Results of a randomized pilot trial of Gene Pilot Pro (GPP).  
First Author: Michael J. Hall, MD, MSc
- Board 186 **ABSTRACT 10553:** Integrated clinical, pathologic, and genetic data in a racially diverse hereditary breast cancer cohort.  
First Author: Kenna Koehler, MD
- Board 187 **ABSTRACT 10554:** African American women who carry the BRCA1/2 mutation: Clinical characteristics and prevention strategies.  
First Author: Ujjwal Karki
- Board 188 **ABSTRACT 10555:** Racial disparities in aging-related comorbidity among breast cancer survivors.  
First Author: Kirsten Nguyen
- Board 189 **ABSTRACT 10556:** Sleep health and quality of life in African American cancer survivors: The Detroit ROCS Cohort.  
First Author: Jennifer Lynn Beebe-Dimmer, PhD, MPH
- Board 190 **ABSTRACT 10557:** Prevalence of and racial/ethnic distribution of full-body skin examination among sexual and gender minority patients.  
First Author: Jincong Q. Freeman, MS, MPH
- Board 191 **ABSTRACT 10558:** Melanoma literacy and predictors for skin self-examination in three western U.S. states: A population-based survey.  
First Author: Jacob Nelson, DO
- Board 192 **ABSTRACT 10559:** Vitamin D deficiency as a risk factor for breast cancer development.  
First Author: James David Mackey, MD
- Board 193 **ABSTRACT 10560:** A nationwide population based primary CNS lymphoma (PCNSL) analysis: Do Hispanics have better outcomes?  
First Author: Ysaith Orellana
- Board 194 **ABSTRACT 10561:** Elevated cancer risk among individuals with combinations of cancer-related risk factors: A large claims database analysis.  
First Author: Ze Cong, PhD
- Board 195 **ABSTRACT 10562:** Modeling genetic testing (GT) attitudes in a socio-demographically diverse cohort of patients (pts) with cancer: The importance of race/ethnicity and medical mistrust (MM).  
First Author: Michael J. Hall, MD, MSc
- Board 196 **ABSTRACT 10563:** Assessing disparities in lung cancer screening eligibility among high-risk individuals.  
First Author: Abdi Gudina, PhD
- Board 198 **ABSTRACT 10565:** Patient-level factors associated with the use of active surveillance: The Talking About Prostate Cancer Cohort.  
First Author: Nita Mukand, MPH, PharmD, MBA
- Board 199 **ABSTRACT 10566:** Colorectal cancer and digital/live screening navigation: Promoting prevention through personalized recommendations and access.  
First Author: Kim Newcomer, RDA
- Board 200 **ABSTRACT 10567:** The impact of extending CRC screening to the older population: Results from CRC-AIM microsimulation model.  
First Author: Derek W. Ebner, MD
- Board 201 **ABSTRACT 10568:** Navigation program for LDCT lung cancer screening implementation: A quality initiative.  
First Author: Jasmine Shrestha
- Board 202 **ABSTRACT 10569:** The probability of lung cancer in patients with incidentally detected pulmonary nodules detected via low-dose computed tomography screening in China.  
First Author: Guo Lan-Wei
- Board 203 **ABSTRACT 10570:** LungFlag, a machine-learning (ML) personalized tool for assessing lung cancer risk in a community setting, to evaluate performance in flagging non-small cell lung cancer (NSCLC) regardless of sex or race.  
First Author: David Morgenstern, PhD
- Board 204 **ABSTRACT 10571:** Assessing the risk of gastrointestinal cancers among cannabis users compared to nicotine users.  
First Author: Shanawar Ali Waris, BS
- Board 206 **ABSTRACT 10573:** Rates of routine cancer screening compared with pre-pandemic levels.  
First Author: Allison H Oakes, PhD
- Board 207 **ABSTRACT 10574:** Incidence, landscape and survival outcome of de novo malignancy after double lung transplantation.  
First Author: Liam Il-Young Chung, MD, MPH
- Board 208 **ABSTRACT 10575:** Enhancing lung cancer screening through 'Saved by the Scan': Lessons from a multi-pronged public service advertising program.  
First Author: Shreyas S Bellur, MBBS



Saturday, June 3, 2023

- Board 209 **ABSTRACT 10576:** A multivariate analysis of low-dose CT lung cancer screening in a Michigan community hospital network.  
First Author: Jason Law, BS, MS
- Board 210 **ABSTRACT 10577:** Patient navigation for lung cancer screening in an urban safety-net system: A pragmatic randomized clinical trial.  
First Author: Sheena Bhalla, MD
- Board 211 **ABSTRACT 10578:** Long-term clinical and psychosocial outcomes of surveillance in Li Fraumeni syndrome.  
First Author: Milita Zaheed, FRACP, MBBS, MMed
- Board 212 **ABSTRACT 10579:** Effect of colorectal cancer screening on 1-year mortality and medical costs: Real-world evidence from the largest commercial medical claims database in the US.  
First Author: Chi Mai Nguyen, PhD
- Board 213 **ABSTRACT 10580:** Colorectal cancer screening with blood-based tests: Estimated impact of a 1-, 2-, or 3-year screening interval compared with annual FIT and triennial mt-sDNA strategies.  
First Author: A. Mark Fendrick, MD
- Board 214 **ABSTRACT 10581:** The role of molecular biomarker CDKN-2A in early diagnosis of colorectal cancer.  
First Author: Yakov Ten, MD
- Board 215 **ABSTRACT 10582:** Does adherence to cancer prevention guidelines before diagnosis associate with improved cancer survival?  
First Author: Evan W. Davis, MPH
- Board 216 **ABSTRACT 10583:** Genetic testing into survivorship after diagnosis of breast cancer.  
First Author: Steven Katz, MPH
- Board 217 **ABSTRACT 10584:** Women with pathogenic variants in moderate penetrance breast cancer genes: How frequently do they meet high penetrance genetic testing criteria?  
First Author: Nicole Casasanta, MD, BS
- Board 218 **ABSTRACT 10585:** Twenty-one gene recurrence scores in individuals with breast cancer associated with CHEK2 and ATM germline pathogenic variants.  
First Author: Payal Deepak Shah, MD
- Board 219 **ABSTRACT 10586:** Analysis of ATM germline mutations in solid tumors from Chinese patients.  
First Author: Tao Fu
- Board 220 **ABSTRACT 10587:** Characteristics and clinical outcome of BRCA germline mutation carriers with advanced breast cancer treated with PARP (poly ADP-ribose polymerase) inhibitors: A single institution experience.  
First Author: Fatma Nihan Akkoc Mustafayev
- Board 221 **ABSTRACT 10588:** Comprehensive analysis of patients with cancer with a positive CHEK2 test: Are we getting closer to a genotype/phenotype correlation?  
First Author: Ana Fragoso
- Board 222 **ABSTRACT 10589:** Investigation of cancer predisposition in Fanconi anemia heterozygotes: A DiscovEHR cohort population study.  
First Author: Joseph Deng
- Board 223 **ABSTRACT 10590:** Rates of potentially actionable germline variants in homologous recombination repair genes in a large international cohort outside of the United States.  
First Author: Sarah M. Nielsen, MS, CGC
- Board 224 **ABSTRACT 10591:** Implementation of universal pan-cancer germline genetic testing in an Arab population: The Jordanian Exploratory Cancer Genetics (Jo-ECAG) study.  
First Author: Hikmat Abdel-Razeq, MD
- Board 225 **ABSTRACT 10592:** Real life use of biomarkers of homologous recombination deficiency (HRD) status beyond BRCA to predict the effectiveness of PARP inhibitors in ovarian cancer patients.  
First Author: Lorena Incorvaia, MD, PhD
- Board 226 **ABSTRACT 10593:** A pan-cancer statistical study of microsatellite instability and Lynch syndrome-associated mismatch repair genes germline mutations.  
First Author: Huiya Cao
- Board 227 **ABSTRACT 10594:** Hereditary breast and ovarian cancer syndrome: A misnomer?  
First Author: Jessica M. Weiss, BA
- Board 228 **ABSTRACT 10595:** Effect of somatic-germline genomic integration on the contribution of pathogenic germline genetic variants (gPV) to colorectal cancer (CRC) carcinogenesis.  
First Author: Emily Harrold, MBBSCh
- Board 229 **ABSTRACT 10596:** Cost-effectiveness analyses of population-based multi-gene testing for the prevention of breast and ovarian cancer in the United States.  
First Author: Fangjian Guo, MD, PhD
- Board 230 **ABSTRACT 10597:** A randomized controlled trial evaluating pretest cancer genetics educational video or in-person genetic counseling.  
First Author: Yanin Chavarri Guerra, MD, MSc
- Board 231 **ABSTRACT 10598:** Technology-enhanced acceleration of germline evaluation for therapy (TARGET): Results of a randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing.  
First Author: Veda N. Giri, MD
- Board 232 **ABSTRACT 10599:** Evaluating interventions to increase the uptake of NCCN genetic counseling recommendations.  
First Author: Sophie Stempel, BS
- Board 233 **ABSTRACT 10600:** Scalable new model of genomic care delivery: Assessing psychological outcomes.  
First Author: Stacy W. Gray, MD
- Board 234 **ABSTRACT 10601:** Genetic testing outcomes and pathogenic germline mutation prevalence in renal cell carcinoma.  
First Author: Charles B Nguyen, MD
- Board 235 **ABSTRACT 10602:** Clinical utility of reporting research genetic predisposition testing results to Total Cancer Care participants.  
First Author: Megan Leigh Hutchcraft, MD
- Board 236 **ABSTRACT 10603:** Healthcare utilization among individuals diagnosed with Lynch syndrome through a universal germline genetic testing program.  
First Author: Heather Hampel, MS
- Board 237 **ABSTRACT 10604:** Healthcare utilization among individuals diagnosed with hereditary breast-ovarian cancer syndrome through a universal germline genetic testing program.  
First Author: Stacy W. Gray, MD
- Board 238 **ABSTRACT 10605:** Validation of a guidelines-based brief patient-administered digital tool to assess the need for germline genetic testing.  
First Author: Callan Russell, MS

- Board 239 **ABSTRACT 10606:** A comprehensive analysis of clinical characterization in 149 Chinese patients with Lynch syndrome.  
First Author: Junqiong Lin
- Board 240 **ABSTRACT 10607:** Using patient-reported outcomes to assess the impact of germline genetic testing on prostate cancer patients.  
First Author: Sarah M. Nielsen, MS, CGC
- Board 241 **ABSTRACT 10608:** Somatic profiling guides germline genetic testing in patients with mutations in cancer predisposition genes.  
First Author: Sourat Darabi, PhD, MS
- Board 242 **ABSTRACT 10609:** Prospective prevalence estimation of BRCA1, BRCA2, and other germline mutations associated with hereditary pancreatic cancer (HPC) using a comprehensive gene panel in an unselected cohort of Mexican patients with pancreatic ductal adenocarcinoma (PDAC).  
First Author: Vanessa Rosas Camargo, MD
- Board 243 **ABSTRACT 10610:** Cancer risk and characteristics in older female BRCA1/2 mutation carriers.  
First Author: Bipin Ghimire
- Board 244 **ABSTRACT 10611:** Beyond the standards: The impact of provider collaboration on referrals to genetic counseling.  
First Author: Eric S Fowler, MS
- Board 245 **ABSTRACT 10612:** Digital cancer genetic risk assessment in a gynecologic oncology clinic.  
First Author: Emily Webster, MD
- Board 246 **ABSTRACT 10613:** Impact of early testing and analysis of germline genetic mutation patterns in patients with breast cancer: A single institution experience.  
First Author: Aswanth Reddy, MD
- Board 247 **ABSTRACT 10614:** Therapeutic applications of germline testing for cancer predisposition genes in Asia in the real world.  
First Author: Seng Wee Cheo
- Board 248 **ABSTRACT 10615:** Utility of multi-gene panel-based germline analysis following genomic profiling and cascade testing in advanced solid tumors: An initial report of the BRANCH study.  
First Author: Takeshi Kuwata, MD, PhD
- Board 249 **ABSTRACT 10616:** A population-based study of BRCA breast cancer incidence and prognosis in the Italian Emilia Romagna region: The MUTina study.  
First Author: Laura Cortesi, MD
- Board 250 **ABSTRACT 10617:** Eliminating barriers to uptake of germline genetic testing for patients with advanced cancer: The GTAC study.  
First Author: Kara K. Landry, MD
- Board 251 **ABSTRACT 10618:** Geographical impact on prostate cancer genetic testing eligibility: A preliminary study from an academic cancer center.  
First Author: Samantha Beck, MSc - Genetic Counseling
- Board 252 **ABSTRACT 10619:** Perceived mental and physical health in patients with common cancers: A study using the PROMIS framework in All of Us database.  
First Author: Rajaa Abdelnasir Elyas Mohamed Salih, MD
- Board 253 **ABSTRACT 10620:** Spectrum of germline pathogenic variants among patients with cancer in Mexico.  
First Author: Jose Luis Rodriguez Olivares, MD
- Board 254 **ABSTRACT 10621:** Clinical and social importance of follow-up assessment of family members of patients with BRCA mutations.  
First Author: Ivana Lucia de Oliveira Nascimento, MD PhD
- Board 255 **ABSTRACT 10622:** A scalable approach to democratizing cancer risk stratification: One healthcare system's approach using a patient-facing digital platform.  
First Author: Heather Fecteau, MS, CGC
- Board 256 **ABSTRACT 10623:** Impact of risk-reducing mastectomy on quality of life of women with Li-Fraumeni syndrome.  
First Author: Natalia Polidorio, MD
- Board 257 **ABSTRACT 10624:** Newly diagnosed lung cancer in hospitalized patients during the COVID-19 pandemic: How well are LDCTs utilized?  
First Author: Jonathan Assis, DO
- Board 258 **ABSTRACT 10625:** Risk of death among lung cancer patients before and during the COVID-19 pandemic.  
First Author: Teddy Tai Loy Lee
- Board 259 **ABSTRACT 10626:** Immunogenicity after COVID-19 vaccination in patients with solid tumor and hospital staff: A prospective single-center observational study.  
First Author: Yuki Katsuya, MD, PhD
- Board 260 **ABSTRACT 10627:** AI to characterize patients with lung or ovarian cancer and those with cachexia for discovery of undiagnosed, misdiagnosed, and miscoded patients at scale in a privacy-preserving manner.  
First Author: Yike Guo, PhD
- Board 261 **ABSTRACT 10628:** Learned lessons from a US-wide outreach program to broaden enrollment to the PRO-MISE Registry, a prostate cancer genetic registry.  
First Author: Channing Judith Paller, MD
- Board 262 **ABSTRACT 10629:** Inverse association of post-transplant malignancy and graft failure on survival outcome following double lung transplantation.  
First Author: Jeeyeon Lee, PhD
- Board 263 **ABSTRACT 10630:** Prevalence of pathogenic germline variants in a cohort of patients with early onset non-small cell lung cancer (EOLUNG).  
First Author: Maria Jove, MD
- Board 264 **ABSTRACT 10631:** Validation of a breast cancer polygenic risk score in 15,490 Brazilians using exome sequencing.  
First Author: Flavia Eichenberger Rius, PhD
- Board 265 **ABSTRACT 10632:** Implementing a germline testing program using fingernail specimens for patients with hematologic malignancies and initial clinical findings.  
First Author: Michael Francis Walsh, MD
- Board 266 **ABSTRACT 10633:** Overall and non-lung cancer incidence in the National Lung Screening Trial (NLST) as indicators of potential for multi-cancer screening.  
First Author: Ellen T. Chang, ScD
- Board 267 **ABSTRACT 10634:** Correlation of unobserved incidence of cancer in earlier stages with the observed incidence.  
First Author: Jagpreet Chhatwal, PhD
- Board 268 **ABSTRACT 10635:** Pre-diagnosis dietary patterns and risk of multiple myeloma in the NIH-AARP cohort.  
First Author: Richa Parikh, MD
- Board 269a **ABSTRACT TPS10636:** Metformin for chemoprevention of lung cancer in high-risk overweight or obese individuals.  
First Author: Isra Nour, MBBS

## Saturday, June 3, 2023

- Board 269b **ABSTRACT TPS10637:** Characterization of pre-malignant lesions in patients with pediatric neurofibromatosis type 1 using a novel whole-body magnetic resonance imaging technique.  
First Author: Nicole M. Baca, MD
- Board 270a **ABSTRACT TPS10638:** Connecting Black families in Houston, Texas, to hereditary cancer genetic counseling, genetic testing, and cascade testing by using a simple cancer genetic risk assessment and telegenetics.  
First Author: Darya Aleksandrovna Kizub, MD, BA

### 1:15 PM - 4:15 PM Poster Session

#### Sarcoma

Location: Hall A

Abstracts on Boards 447-458 will be discussed during the Sarcoma Poster Discussion Session. See the online program guide (meetings.asco.org) for session details.

#### Posters by Topic

**Bone Tumors:** Boards 453, 459-469, 513a-514a

**Gastrointestinal Stromal Tumors (GIST):** Boards 456-458, 470-477, 514b

**Molecular Targets/Biomarkers/Tumor Biology:** Boards 478-482

**Soft Tissue Tumors:** Boards 447-452, 454-455, 483, 485-509, 511-512, 515a-518b

- Board 447 **ABSTRACT 11513:** Impact of pregnancy in women with desmoid fibromatosis: An international retrospective observational study.  
First Author: Marco Fiore, MD, FACS
- Board 448 **ABSTRACT 11514:** Tumor volume and T2 hyperintensity changes from DeFi: A phase 3, randomized, controlled trial of nirogacestat in patients with desmoid tumors.  
First Author: Thierry Alcindor, MD, MSc
- Board 449 **ABSTRACT 11515:** RINGSIDE phase 2/3 trial of AL102 for treatment of desmoid tumors (DT): Phase 2 results.  
First Author: Mrinal M. Gounder, MD
- Board 450 **ABSTRACT 11516:** A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27).  
First Author: Young Kwang Chae, MD, MBA
- Board 451 **ABSTRACT 11517:** A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma.  
First Author: Sujana Movva, MD
- Board 452 **ABSTRACT 11518:** Interim results of a phase II trial of first line retifanlimab (R) plus gemcitabine and docetaxel (GD) in patients (pts) with advanced soft tissue sarcoma (STS).  
First Author: Evan Rosenbaum, MD
- Board 453 **ABSTRACT 11519:** SARC037: Results of phase I study of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in relapsed/refractory Ewing sarcoma (ES).  
First Author: Patrick Grohar
- Board 454 **ABSTRACT 11520:** SELISARC: A Spanish Sarcoma Group (GEIS) phase I/II trial of selinexor plus gemcitabine in selected sarcoma subtypes—Results of the phase I part.  
First Author: Javier Martin Broto, MD, PhD

- Board 455 **ABSTRACT 11521:** A phase I study of nanoparticle albumin-bound sirolimus (NAB-S) combined with pazopanib (PAZO) in patients with advanced soft tissue sarcoma (STS).  
First Author: Lee D. Cranmer, MD, PhD
- Board 456 **ABSTRACT 11522:** Multi-omic characterization of gastrointestinal stromal tumor (GIST) in a large real-world patient cohort.  
First Author: Jonathan C. Trent, MD, PhD
- Board 457 **ABSTRACT 11523:** Clinical efficacy of avapritinib in gastrointestinal stromal tumors (GIST) with different KIT genotypes: Post hoc analysis of the phase 1 NAVIGATOR and phase 1/2 CS3007-101 trials.  
First Author: Michael C. Heinrich, MD, FACP
- Board 458 **ABSTRACT 11524:** Overall survival and long-term safety in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Updated analyses from INTRIGUE.  
First Author: Robin Lewis Jones, MD, MBBS, MRCP, BSc
- Board 459 **ABSTRACT 11525:** Two schedules of vincristine, irinotecan and temozolomide (VIT) for patients with relapsed or refractory Ewing sarcoma: A randomized controlled phase 2 trial.  
First Author: Jie Xu, MD
- Board 460 **ABSTRACT 11526:** Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate as neoadjuvant therapy for osteosarcoma: A single-arm, exploratory phase II trial.  
First Author: Qinglian Tang
- Board 461 **ABSTRACT 11527:** PEPN1924, a phase 2 study of trastuzumab deruxtecan (DS-8201a, T-DXd) in adolescents and young adults with recurrent HER2+ osteosarcoma: A Children's Oncology Group Pediatric Early-Phase Clinical Trial Network study.  
First Author: Damon R. Reed, MD
- Board 462 **ABSTRACT 11528:** Variations in the approach to lung metastases in osteosarcoma among pediatric and adult patients.  
First Author: Victoria A Wytiaz, MD, MA
- Board 463 **ABSTRACT 11529:** Evaluation of local control strategies on patterns of treatment failure in patients with localized Ewing sarcoma treated on AEWS1031: A report from the Children's Oncology Group.  
First Author: Safia K. Ahmed, MD
- Board 464 **ABSTRACT 11530:** ALMB-0168, a novel Cx43 hemichannel agonist monoclonal antibody, for metastatic or unresectable osteosarcoma after standard chemotherapy: A multicenter, open-label, single-arm, phase 1 study.  
First Author: Jingnan Shen, MD
- Board 465 **ABSTRACT 11531:** ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma.  
First Author: Kristine Peregrino Lacuna, MD, CCRP
- Board 466 **ABSTRACT 11532:** Phase I study of the mutant IDH1 inhibitor ivosidenib: Long-term safety and clinical activity in patients with conventional chondrosarcoma.  
First Author: William D. Tap, MD
- Board 467 **ABSTRACT 11533:** A phase 2 study of an anti-PD-L1 antibody (atezolizumab) in dedifferentiated chondrosarcoma.  
First Author: Mohamad Adham Salkeni, MD

- Board 468 **ABSTRACT 11534:** Prolonged 14-day continuous infusion of high-dose ifosfamide (14IFO) for relapsed/refractory high-grade osteosarcoma (R/R HOS): A retrospective multicenter cohort study.  
First Author: Elisa Tirtei, MD
- Board 469 **ABSTRACT 11535:** Survival outcomes in pediatric patients with metastatic Ewing sarcoma who achieve a rapid complete response of pulmonary metastases.  
First Author: Audra J Reiter, MD, MPH
- Board 470 **ABSTRACT 11536:** Outcomes in patients with advanced gastrointestinal stromal tumor who did not have baseline ctDNA detected in the INTRIGUE study.  
First Author: Jonathan C. Trent, MD, PhD
- Board 471 **ABSTRACT 11537:** Safety, pharmacokinetics (PK), and clinical activity of bezucastinib + sunitinib in previously-treated gastrointestinal stromal tumor (GIST): Results from part 1 of the phase 3 Peak study.  
First Author: William D. Tap, MD
- Board 472 **ABSTRACT 11538:** Combination targeted therapy with avapritinib and sunitinib in patients with refractory gastrointestinal stromal tumors after failure of standard treatments: A small prospective pilot study.  
First Author: Yanzhe Xia
- Board 473 **ABSTRACT 11539:** Fluorine-18 fluorodeoxyglucose (<sup>18</sup>FDG)-uptake assessment of PDGFRA mutant gastrointestinal stromal tumors (GIST): A retrospective multicenter Italian study.  
First Author: Maria Concetta Nigro, MD
- Board 474 **ABSTRACT 11540:** Antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST).  
First Author: Haibo Qiu, MD, PhD
- Board 475 **ABSTRACT 11541:** Clinical utility of liquid-based comprehensive genomic profiling (CGP) in gastrointestinal stromal tumors (GIST).  
First Author: Lindsey Hildebrand, MD
- Board 476 **ABSTRACT 11542:** Longitudinal follow-up and outcomes of pediatric and adult patients with SDH-deficient GIST.  
First Author: Urania Dagalakis, MD
- Board 477 **ABSTRACT 11543:** Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors (GIST) as ≥4th line therapy: Long-term update from a single-arm, phase 2 trial.  
First Author: Jian Li, D.Phil
- Board 478 **ABSTRACT 11544:** Exploratory novel biomarker and resistance mechanism of milademetan, an MDM2 inhibitor, in amplified MDM2 intimal sarcoma from an open-label phase 1b/2 trial (NCCH1806/MK004).  
First Author: Takafumi Koyama, MD, PhD
- Board 479 **ABSTRACT 11545:** Large versus limited molecular profiling panel screening program in patients with metastatic sarcoma: An exploratory subgroup analysis from the ProfiLER 02 trial.  
First Author: Mehdi Brahmi, MD, PhD
- Board 480 **ABSTRACT 11546:** Alternative splicing (AS) regulation as a novel therapeutic target in soft-tissue sarcoma (STS).  
First Author: David Silva Moura, PhD, MSc
- Board 481 **ABSTRACT 11547:** Novel genomic alterations and transcriptomic-based tumor microenvironment classification of sarcoma and their impact on treatment decision making.  
First Author: Irina Zhuk, MD
- Board 482 **ABSTRACT 11548:** Next generation sequencing reveals targetable mutations in multiple sarcoma histologies.  
First Author: Rodney Dixon Dorand Jr., MD, PhD
- Board 483 **ABSTRACT 11549:** Loss of the DNA repair gene RNase H2 and a unique subset of DDR-deficient leiomyosarcomas.  
First Author: Michael Nakazawa, MD, PhD
- Board 485 **ABSTRACT 11551:** Aristolochic acid (AA) exposure and telomere maintenance mechanism in liver angiosarcoma (AS).  
First Author: Tom Wei-Wu Chen, MD, PhD
- Board 486 **ABSTRACT 11552:** Phase 1 trial of avelumab with hypofractionated thoracic radiation therapy (HT-RT) in patients with metastatic soft-tissue sarcomas (mSTS).  
First Author: Shane H Zaidi, PhD, MBBCh, FRCR
- Board 487 **ABSTRACT 11553:** Efficacy and safety of anlotinib combined with anthracycline and ifosfamide followed by anlotinib maintenance in advanced soft tissue sarcoma: A single-arm, phase 2 trial.  
First Author: Zengjun Liu
- Board 488 **ABSTRACT 11554:** A phase Ia/Ib, dose-escalation/expansion study of the MDM2-p53 antagonist BI 907828 in patients (pts) with solid tumors: Safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS).  
First Author: Patricia LoRusso, DO, PhD, FASCO
- Board 489 **ABSTRACT 11555:** Results of SOC-2082 phase 2 study using metronomic gemcitabine, doxorubicin and docetaxel plus nivolumab as second/third-line therapy for advanced sarcoma.  
First Author: Nadezhda Omelchenko, MD
- Board 490 **ABSTRACT 11556:** Interim results of a phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin for advanced leiomyosarcoma.  
First Author: Neal Shiv Chawla, MD
- Board 491 **ABSTRACT 11557:** Metronomic dosing of selinexor in select soft tissue sarcomas (STS).  
First Author: Aisha Alshibany, MBBS
- Board 492 **ABSTRACT 11558:** Results from phase I/II study of NY-ESO-1-specific TCR gene-transduced T cell therapy (TBI-1301, mipetresgene autoleucl) in patients with advanced synovial sarcoma.  
First Author: Akira Kawai, MD
- Board 493 **ABSTRACT 11559:** Efficacy and safety profile of pimicotinib (ABSK021) in tenosynovial giant cell tumor (TGCT): Phase 1b update.  
First Author: Lu Yao, MD
- Board 494 **ABSTRACT 11560:** Evaluation of hyperprogression in patients with sarcoma treated with targeted therapy and/or immunotherapy in early-phase clinical trials.  
First Author: Aisha Alshibany, MBBS
- Board 495 **ABSTRACT 11561:** Novel MRI scoring system to assess osseous malignancy in patients with soft tissue sarcoma following radiotherapy.  
First Author: Gayathri Vijayakumar, BS
- Board 496 **ABSTRACT 11562:** HH2853, an EZH1/2 inhibitor, in patients with epithelioid sarcoma: Preliminary results from the phase 1 part of a first-in-human phase I/II study.  
First Author: Zhengfu Fan
- Board 497 **ABSTRACT 11563:** The SPEARHEAD-1 trial of afamitresgene autoleucl (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma.  
First Author: Brian Andrew Van Tine, MD

**Saturday, June 3, 2023**

- Board 498 **ABSTRACT 11564:** Impact of nirogacestat on pain, a key symptom in patients with desmoid tumors (DT): Results from the phase 3 DeFi study.  
First Author: Winette T.A. Van Der Graaf, PhD
- Board 499 **ABSTRACT 11565:** A phase II trial with safety lead-in to evaluate the addition of sotigalimab, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advanced sarcoma.  
First Author: Sminu (Sam) Bose, MD
- Board 500 **ABSTRACT 11566:** A phase II clinical trial of chidamide in combination with toripalimab in patients with advanced soft tissue sarcoma.  
First Author: Xing Zhang, PhD
- Board 501 **ABSTRACT 11567:** Immune correlates of outcome in patients with leiomyosarcoma (LMS) treated with durvalumab plus olaparib or cediranib: Transcriptome analysis from the DAPPER study.  
First Author: Abdulazeez Salawu, PhD, MBBS, MSc, MRCP
- Board 502 **ABSTRACT 11568:** Intratumoral INT230-6 (cisplatin, vinblastine, shao) alone or with ipilimumab prolonged survival with favorable safety in adults with refractory sarcomas.  
First Author: Christian Frederick Meyer, MD, PhD
- Board 503 **ABSTRACT 11569:** Phase I/II study to evaluate penpulimab combined with anlotinib and epirubicin in the first-line treatment of soft tissue sarcoma: Updated.  
First Author: Yuhong Zhou, MD
- Board 504 **ABSTRACT 11570:** A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with advanced sarcoma: Results of expansion cohorts.  
First Author: Ciara Marie Kelly, MD, MBBCh
- Board 505 **ABSTRACT 11571:** Trabectedin (T) versus adriamycin plus dacarbazine (A-DA) in advanced solitary fibrous tumor (SFT): Results from a phase II randomised clinical study (STRADA).  
First Author: Silvia Stacchiotti, MD
- Board 506 **ABSTRACT 11572:** Efficacy of eribulin administered in combination with an immune checkpoint inhibitor (ICI) and anlotinib as salvage treatment for patients (pts) with advanced adult soft tissue sarcoma (STS).  
First Author: Xi Guo, MD
- Board 507 **ABSTRACT 11573:** Trabectedin failure-free survival (TFFS) after resuming trabectedin (T) in advanced myxoid liposarcoma (MLPS) patients.  
First Author: Chiara Fabbri, MD
- Board 508 **ABSTRACT 11574:** Outcome of patients (PTS) with advanced epithelioid hemangioendothelioma (EHE) after failure on sirolimus (S).  
First Author: Claudia Giani
- Board 509 **ABSTRACT 11575:** Risk stratification tools to help decide on adjuvant chemotherapy usage in resected soft tissue sarcomas: A 10 year review of an Irish sarcoma centre experience.  
First Author: Catherine Weadick
- Board 511 **ABSTRACT 11577:** Clinical implications of recurring mutations in myxoid liposarcoma (MLS).  
First Author: Prapassorn Thirasastr, MD, MSc
- Board 512 **ABSTRACT 11578:** DCK expression by RNAseq as a potential biomarker of gemcitabine response in sarcoma.  
First Author: David A. Liebner, MD
- Board 513a **ABSTRACT TPS11579:** AOST2031: An in-progress COG phase 3 randomized controlled trial comparing open vs thoracoscopic management of pulmonary metastases in patients with osteosarcoma.  
First Author: John J Doski, MD
- Board 513b **ABSTRACT TPS11580:** A randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in participants with relapsed or refractory Ewing sarcoma.  
First Author: Gertjan Van Hal
- Board 514a **ABSTRACT TPS11581:** ENLIGHTen-01: A phase 1 study of fluorescein-specific (FITC-E2)-CAR T cells in combination with folate-fluorescein (UB-TT170) for osteosarcoma.  
First Author: Catherine Michelle Albert, MD
- Board 514b **ABSTRACT TPS11582:** INSIGHT: A phase 3, randomized, multicenter, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib harboring KIT exon 11 + 17 and/or 18 mutations.  
First Author: Suzanne George, MD
- Board 515a **ABSTRACT TPS11583:** ENVASARC: A pivotal trial of envafolelimab and envafolelimab in combination with ipilimumab in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.  
First Author: Richard F. Riedel, MD
- Board 515b **ABSTRACT TPS11584:** Alliance A092104: A randomized phase 2/3 study of olaparib plus temozolomide versus investigator's choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy.  
First Author: Kristine Peregrino Lacuna, MD, CCRP
- Board 516a **ABSTRACT TPS11585:** A phase 2, open-label, adaptive, dose-ranging study with long-term extension to evaluate the safety, tolerability, efficacy, and pharmacokinetics of intra-articular AMB-05X injections in patients with tenosynovial giant cell tumor.  
First Author: Hans Gelderblom, MD
- Board 516b **ABSTRACT TPS11586:** PEMBROCABOSARC: Combination of pembrolizumab and cabozantinib in patients with advanced sarcomas.  
First Author: Sabrina Sellan-Albert, MSc
- Board 517a **ABSTRACT TPS11587:** SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.  
First Author: Mark Andrew Dickson, MD
- Board 517b **ABSTRACT TPS11588:** Engagement of patient participation in genomics research by the Osteosarcoma and Leiomyosarcoma Count Me In Projects of the Cancer Moonshot funded PE-CGS Network.  
First Author: Suzanne George, MD
- Board 518a **ABSTRACT TPS11589:** Phase 1 dose-expansion study of oral TP-1287, a cyclin-dependent kinase 9 (CDK9) inhibitor, in patients with Ewing sarcoma (EWS).  
First Author: Gregory Michael Cote, MD
- Board 518b **ABSTRACT TPS11590:** A phase II study of palbociclib combined with retifanlimab in patients with advanced dedifferentiated liposarcoma.  
First Author: Sandra P. D'Angelo, MD

**2:15 PM - 3:00 PM Education Session**

**ASCO Voices**

Location: Arie Crown Theater

**Shom Goel, MBBS, PhD, FRACP - Chair**

The Sir Peter MacCallum Department of Oncology, University of Melbourne  
*Welcome and Introduction*

**Rajasree Pia Chowdry, MD**

Louisiana State University Health Sciences Center  
*The Long Road to Equity: Life in Cancer Alley*

**Shaan Beg, MD, MS**

Science 37  
*Partnering With Patients for Modern Clinical Trials*

**Anthony Victor D'Amico, MD, PhD**

Brigham and Women's Hospital  
*Everything Happens for a Reason*

**Samantha Siegel, MD**

The Permanente Medical Group  
*There Is No Cancer Lottery*

**Michael Thomas Serzan, MD**

Dana-Farber Cancer Institute  
*If You Want to Go Fast, Go Alone; If You Want to Go Far, Go Together*

---

**3:00 PM - 4:00 PM Case-Based Panel**

**Oligometastatic Breast Cancer: Bridging the Science With Patient Preferences**

Location: E451

**Mariana Chavez Mac Gregor, MD, MSc, FASCO - Chair**

The University of Texas MD Anderson Cancer Center  
*Moderator*

**Mehra Golshan, MD**

Yale School of Medicine  
*The Surgeon's Perspective*

**Alice Y. Ho, MD, MBA**

Duke University Medical Center  
*The Radiation Oncologist's Perspective*

**Heather Anne Parsons, MD, MPH**

Dana-Farber Cancer Institute  
*The Medical Oncologist's Perspective*

*Panel Question and Answer*

---

**3:00 PM - 4:00 PM Case-Based Panel**

**Shared Decision-Making for Older Adults With Cancer Using Available Treatment Tools**

Location: S102

**Daniel R. Richardson, MD, MSc, MA - Chair**

UNC Lineberger Comprehensive Cancer Center  
*Moderator*

**Clark DuMontier, MD, MPH**

Brigham and Women's Hospital  
*A Geriatrician's Perspective*

**Kah Poh Loh, MBBCh, MS**

James P Wilmot Cancer Institute  
*A Geriatric Oncologist's Perspective*

**Melisa L. Wong, MD**

University of California, San Francisco  
*A Medical Oncologist's Perspective*

*Panel Question and Answer*

---

**3:00 PM - 4:15 PM Education Session**

**How to Utilize Patient-Reported Outcomes in Children With Cancer**

Location: S504

**Bryce Reeve, PhD**

Duke University School of Medicine  
*Listen to the Children: Giving Pediatric Patients a Voice in PRO Reporting*

**Lillian Sung, MD, PhD - Chair**

The Hospital for Sick Children  
*Screen Time: Development of an Electronic Platform for PRO Reporting in Children*

**Katie Ash Greenzang, MD**

Dana-Farber Cancer Institute  
*Game Changers: How PRO Measures Can Guide Treatment Choices in Pediatric Oncology*

*Panel Question and Answer*

---

**3:00 PM - 4:15 PM Education Session**

**Practicing in a Polarized Society: Ethics and Social Justice in Oncology**

Location: S404

**Avram Denburg, MD, PhD, MSc, FRCPC - Chair**

Hospital for Sick Children  
*Understanding the History of Physician Participation in Social Justice Movements*

**Karen Marie Winkfield, MD, PhD, FASCO**

Vanderbilt University Medical Center  
*A Seat at the Table: Partnerships to Achieve Racial Justice for Black Americans With Cancer*

**Ana I. Velazquez Manana, MD, MSc**

University of California San Francisco  
*Ending Systemic Racism in Oncology: The Role and Responsibility of the Clinician*

**Felipe Santa Rosa Roitberg, MD**

Instituto do Câncer do Estado de São Paulo  
*Global Access to Vaccines That Prevent Cancer: Who Gets Left Behind?*

*Panel Question and Answer*

---

**3:00 PM - 4:15 PM Ticketed Session**

**Clinical Controversies for Colorectal Peritoneal Metastases: Is Cytoreductive Surgery and Intraperitoneal Chemotherapy the Best Approach?**

Location: E253d

## Saturday, June 3, 2023

**Maria C. Russell, MD, FACS - Chair**  
Emory University Hospital Midtown  
*Moderator*

**Travis Edward Grotz, MD**  
Mayo Clinic  
*CRS/HIPEC Should be the Standard of Care for Peritoneal-only Colorectal Metastases: Agree*

**Colette Pameijer, MD**  
Penn State Cancer Institute  
*CRS/HIPEC Should be the Standard of Care for Peritoneal Only Colorectal Metastases: Disagree*  
  
*Panel Question and Answer*

---

### 3:00 PM - 4:30 PM Poster Discussion Session

**Developmental Therapeutics—Immunotherapy**  
Location: S100bc

**Geraldine Helen O'Sullivan Coyne, MD, PhD - Chair**  
National Cancer Institute

**To be determined - Chair**

- 3:00 PM To be determined (Discussion of Abstract(s) 2517-2519)**  
*Exits Off the Auto Heme Malignancy Track for CAR T*
- 3:12 PM** Panel Question and Answer
- 3:22 PM Aaron Elliott Lisberg, MD (Discussion of Abstract(s) 2520-2522)**  
University of California, Los Angeles  
*Meeting the Tumor in Its Environment*
- 3:34 PM** Panel Question and Answer
- 3:44 PM Elena Garralda, MD, MSc (Discussion of Abstract(s) 2523-2525)**  
Vall d'Hebron University Hospital  
*Novel Targets and Novel Approaches to Challenging Targets*
- 3:56 PM** Panel Question and Answer
- 4:06 PM Megan Eileen Daly, MD (Discussion of Abstract(s) 2526-2528)**  
University of California, Davis  
*Biology, Chemistry, and Physics*
- 4:18 PM** Panel Question and Answer

Posters discussed in this session are on display in the Developmental Therapeutics—Immunotherapy Poster Session. To view abstract titles and presentations, see the online program guide ([meetings.asco.org](https://meetings.asco.org)).

---

### 3:00 PM - 4:30 PM Poster Discussion Session

**Genitourinary Cancer—Kidney and Bladder**  
Location: E450

**Andrea B. Apolo, MD - Chair**  
National Cancer Institute

**Thomas W. Flaig, MD - Chair**  
University of Colorado Cancer Center Anschutz Medical Campus

- 3:00 PM Maria De Santis, MD (Discussion of Abstract(s) 4509-4511)**  
Charité Universitätsmedizin Berlin  
*Optimizing Outcomes in Upfront Management of Localized Bladder Cancer*
- 3:12 PM** Panel Question and Answer
- 3:22 PM Andrea Necchi, MD (Discussion of Abstract(s) 4512-4514)**  
Vita-Salute San Raffaele University  
*Advanced Urothelial Carcinoma: Striking a Balance of Efficacy and Safety*
- 3:34 PM** Panel Question and Answer
- 3:44 PM Benjamin Garmez, MD (Discussion of Abstract(s) 4515-4517)**  
Sarah Cannon Research Institute at Tennessee Oncology  
*The Power of Patients' Experiences to Inform Therapeutic Decisions*
- 3:56 PM** Panel Question and Answer
- 4:06 PM Manuela Schmidinger, MD (Discussion of Abstract(s) 4518-4520)**  
Medical University of Vienna  
*Adding Clarity to Non-Clear Cell Carcinoma*
- 4:18 PM** Panel Question and Answer

Posters discussed in this session are on display in the Genitourinary Cancer—Kidney and Bladder Poster Session. To view abstract titles and presentations, see the online program guide ([meetings.asco.org](https://meetings.asco.org)).

---

### 3:00 PM - 6:00 PM Oral Abstract Session

**Gynecologic Cancer**

Location: Hall D1

**Christina M. Annunziata, MD, PhD, FASCO - Chair**  
National Cancer Institute/National Institutes of Health

**Tanja Pejovic, MD, PhD - Chair**  
Oregon Health & Science University

- 3:00 PM Abstract 5500: KEYNOTE-826:** Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.  
First Author: Bradley J. Monk, MD
- 3:12 PM Abstract 5501:** In situ immune impact of nivolumab + ipilimumab combination before standard chemoradiation therapy (RTCT) for FIGO IB3-IVA in patients (pts) with cervical squamous carcinoma: COLIBRI trial, a GINECO study.  
First Author: Isabelle Laure Ray-Coquard, MD, PhD
- 3:24 PM Abstract 5502:** Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.  
First Author: Charles A. Leath III, MD, MSPH
- 3:36 PM Catheryn M. Yashar, MD (Discussion of Abstract(s) 5500-5502)**  
UC San Diego Moores Cancer Center  
*Cervical Cancer: Not Immune to Benefit?*
- 3:48 PM** Panel Question and Answer

- 4:00 PM Abstract 5503:** Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).  
First Author: Matthew A. Powell, MD
- 4:12 PM Abstract 5504:** Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial.  
First Author: Mansoor Raza Mirza, MD
- 4:24 PM Abstract 5516:** Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial.  
First Author: Huaying Wang, MD, PhD
- 4:36 PM Gini F. Fleming, MD (Discussion of Abstract(s) 5503-5516)**  
University of Chicago Medicine  
*Mining the Landscape of Immunotherapy in Uterine Cancer*
- 4:48 PM** Panel Question and Answer
- 5:00 PM Abstract 5505:** Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018).  
First Author: Rebecca Christian Arend, MD
- 5:12 PM Abstract LBA5506:** Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.  
First Author: Philipp Harter, MD, PhD
- 5:24 PM Abstract 5508:** Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolR $\alpha$ ) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolR $\alpha$  expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort.  
First Author: Ana Oaknin, MD, PhD
- 5:36 PM Christina Fotopoulou, MD, PhD (Discussion of Abstract(s) 5505-5508)**  
Imperial College London  
*New Kids on the Block for Ovarian Cancer*
- 5:48 PM** Panel Question and Answer

---

**3:00 PM - 6:00 PM Oral Abstract Session**

**Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers**

Location: Hall B1

**Mauricio Burotto, MD - Chair**  
Bradford Hill

**Vamsidhar Velcheti, MD, FCCP, FACP - Chair**  
NYU Laura and Isaac Perlmutter Cancer Center

- 3:00 PM Abstract 8500:** Surgical outcomes of patients with resectable non-small-cell lung cancer receiving neoadjuvant immunotherapy with nivolumab plus relatlimab or nivolumab: Findings from the prospective, randomized, multicentric phase II study NEOpredict-Lung.  
First Author: Clemens Aigner, MD, MBA

- 3:12 PM Abstract 8501:** Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study.  
First Author: Shun Lu, PhD
- 3:24 PM Kurt A. Schalper, MD, PhD (Discussion of Abstract(s) 8500-8501)**  
Yale University  
*Arming the Immune Legion: Neo-Adventures in Lung Cancer*
- 3:36 PM** Panel Question and Answer
- 3:48 PM Abstract 8502:** First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC).  
First Author: Martin Wermke, MD
- 4:00 PM Abstract 8503:** Exploratory biomarker analysis of the phase 3 KEYNOTE-604 study of pembrolizumab plus etoposide for extensive-stage SCLC.  
First Author: Charles M. Rudin, MD, PhD
- 4:12 PM Abstract 8504:** SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC).  
First Author: Nagla Fawzy Abdel Karim, MD
- 4:24 PM Alberto Chiappori, MD (Discussion of Abstract(s) 8502-8504)**  
H. Lee Moffitt Cancer Center and Research Institute  
*Small Cell, Mighty Hopes*
- 4:36 PM** Panel Question and Answer
- 4:48 PM Abstract LBA8505:** IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (Pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.  
First Author: Quincy S. Chu, MD
- 5:00 PM Abstract 8506:** Efficacy, cellular and molecular determinants of PD-1 checkpoint inhibition in relapsed mesothelioma.  
First Author: Dean Anthony Fennell, PhD, FRCP
- 5:12 PM Abstract 8507:** Association of somatic mutations and histologic subtype/grade on prognosis and PD-L1 expression in mesothelioma.  
First Author: Allen Chengzhi Zhu, PhD
- 5:24 PM Marjorie Glass Zauderer, MD, MS, FACP (Discussion of Abstract(s) LBA8505-8507)**  
Memorial Sloan Kettering Cancer Center  
*Mesothelioma: Shifting the Odds*
- 5:36 PM** Panel Question and Answer

---

**4:30 PM - 5:30 PM Rapid Abstract Session**

**Breast Cancer**  
Location: E451

**Rachel A. Freedman, MD, MPH - Chair**  
Dana-Farber Cancer Institute

**Marie Wood, MD, FASCO - Chair**  
University of Colorado



Saturday, June 3, 2023

- 4:30 PM **Abstract 509:** Assessment of risk of overall and late distant recurrence by Breast Cancer Index in postmenopausal women with early-stage, HR+ breast cancer in the TEAM trial.  
First Author: John MS Bartlett
- 4:36 PM **Abstract 510:** Prognosis and trends in chemotherapy use for patients with stage IA triple-negative breast cancer (TNBC): A population-based study.  
First Author: Paolo Tarantino, MD
- 4:42 PM **Abstract 511:** Racial/ethnic differences in 21-gene recurrence score and survival among estrogen receptor-positive breast cancer patients.  
First Author: Jasmin Gill
- 4:48 PM **Abstract 512:** A randomized controlled trial of a mobile app and tailored messages to improve outcomes among women with breast cancer receiving adjuvant endocrine therapy.  
First Author: Ilana Graetz, PhD
- 4:54 PM **Abstract LBA1013:** TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC).  
First Author: Zefei Jiang, MD
- 5:00 PM **Abstract LBA637:** Nine-weeks versus one-year trastuzumab for early-stage HER2+ breast cancer: 10-year update of the Short-HER phase III randomized trial.  
First Author: Pier Franco Conte, MD
- 5:06 PM Panel Question and Answer

---

#### 4:30 PM - 6:00 PM Clinical Science Symposium

##### Molecular Basis for Young-Onset Colorectal Cancer

Location: Hall D2

**Christine Marie Walko, PharmD, FCCP, BCOP - Chair**  
H. Lee Moffitt Cancer Center and Research Institute

**Fang-Shu Ou, PhD - Chair**  
Mayo Clinic

- 4:30 PM **Abstract 3509:** Transcriptional metabolic profiling in young onset colorectal cancer (CRC) patients.  
First Author: Deepak Vadehra, DO
- 4:42 PM **Oliver Peacock, PhD (Discussion of Abstract(s) 3509)**  
MD Anderson Cancer Center  
*Divergent Pathways May Underpin Early-Onset Colorectal Cancer*
- 4:54 PM **Abstract 3510:** Metabolomic differences in young-onset versus average-onset colorectal adenocarcinoma.  
First Author: Thejus Jayakrishnan, MD
- 5:06 PM **Christian Jobin, MD (Discussion of Abstract(s) 3510)**  
University of Florida  
*Carcinogenic Origins of Early Onset of Colorectal Cancer*
- 5:18 PM **Abstract 3511:** Evaluation of genomic alterations in early-onset versus late-onset colorectal cancer.  
First Author: Eric Michael Lander, MD
- 5:30 PM **Aaron James Scott, MD (Discussion of Abstract(s) 3511)**  
University of Arizona Cancer Center  
*The Molecular Landscape in Early-Onset Colorectal Cancer*
- 5:42 PM Panel Question and Answer

#### 4:30 PM - 6:00 PM Clinical Science Symposium

##### No One Left Behind: Enhancing Equity in Oncology

Location: S100a

**Annie P. Im, MD - Chair**  
University of Pittsburgh Medical Center

**Nishin Bhadkamkar, MD - Chair**  
The University of Texas MD Anderson Cancer Center

- 4:30 PM **Abstract 11000:** Differential burnout by race, sex, and sexual orientation in academic oncology.  
First Author: Bismarck Odei, MD
- 4:42 PM **Curtiland Deville, MD (Discussion of Abstract(s) 11000)**  
Johns Hopkins University  
*Burnout in Oncology: One Size Does Not Fit All*
- 4:54 PM **Abstract 11001:** The ticking "biological clock": Reproductive assistance, costs, and elective fertility preservation in female oncologists and trainees.  
First Author: Emily MacDuffie, MD
- 5:06 PM **Ariela Lucy Marshall, MD (Discussion of Abstract(s) 11001)**  
University of Pennsylvania  
*Uncovering the Reproductive Costs for Women in Oncology: The Time Is Now*
- 5:18 PM **Abstract 11002:** Diversity, equity, & inclusion (DEI) and health equity (HE) education in hematology/oncology (HO) fellowship: A longitudinal curriculum.  
First Author: Norin Ansari, MD, MPH
- 5:30 PM **Gerald Hsu, MD, PhD (Discussion of Abstract(s) 11002)**  
San Francisco VA Medical Center  
*Integrating DEI Into the Fellowship Curriculum*
- 5:42 PM Panel Question and Answer

---

#### 4:30 PM - 6:00 PM Poster Discussion Session

##### Central Nervous System Tumors

Location: S504

**Jing Li, MD, PhD - Chair**  
The University of Texas MD Anderson Cancer Center

**Kelli Pointer, MD, PhD - Chair**  
Dartmouth

- 4:30 PM **David Kamson, MD, PhD (Discussion of Abstract(s) 2013-2015)**  
Johns Hopkins Brain Tumor Group  
*Omics and Ostics in Central Nervous System Metastases*
- 4:42 PM Panel Question and Answer
- 4:52 PM **Jennie Webster Taylor, MD, MPH (Discussion of Abstract(s) 2016-2017)**  
University of California, San Francisco  
*Early Endpoints and Late Survival in Central Nervous System Tumors*
- 5:04 PM Panel Question and Answer
- 5:14 PM **Patrick Roth, MD (Discussion of Abstract(s) 2018-2019)**  
University Hospital Zurich and University of Zurich  
*Bullseye? Target Selection and Trial Design*
- 5:26 PM Panel Question and Answer

**5:36 PM Mahua Dey, MD (Discussion of Abstract(s) 2020-2024)**  
UW-Madison  
*Vaccines, Checkpoints, and Electrical Fields: Immunotherapy and Glioblastoma Multiforme*

**5:48 PM** Panel Question and Answer

Posters discussed in this session are on display in the Central Nervous System Tumors Poster Session. To view abstract titles and presentations, see the online program guide (meetings.asco.org).

---

**4:30 PM - 6:00 PM Poster Discussion Session**

**Health Services Research and Quality Improvement**

Location: E350

**Anne C. Chiang, MD, PhD, FASCO - Chair**  
Yale University School of Medicine

**Victoria Susana Blinder, MD, MSc, FASCO - Chair**  
Memorial Sloan Kettering Cancer Center

**4:30 PM Carmen Guerra, MD, MSCE, FACP (Discussion of Abstract(s) 6509-6511)**  
University of Pennsylvania School of Medicine  
*Representing the Underrepresented: Improving Clinical Trial Enrollment*

**4:42 PM** Panel Question and Answer

**4:52 PM Eileen H. Shinn, PhD (Discussion of Abstract(s) 6512-6514)**  
The University of Texas MD Anderson Cancer Center  
*Making Big Data Work for Us*

**5:04 PM** Panel Question and Answer

**5:14 PM Sheetal Mehta Kircher, MD (Discussion of Abstract(s) 6515-6517)**  
Robert H. Lurie Comprehensive Cancer Center of Northwestern University  
*Is It Worth It: Strategic Spending to Improve Care*

**5:26 PM** Panel Question and Answer

**5:36 PM Amy Iarrobino Laughlin, MD (Discussion of Abstract(s) 6518-6520)**  
Orlando Health  
*Quality Improvement: Examples From Screening, Symptom Management, and Decision-Making*

**5:48 PM** Panel Question and Answer

Posters discussed in this session are on display in the Health Services Research and Quality Improvement Poster Session. To view abstract titles and presentations, see the online program guide (meetings.asco.org).

---

**4:30 PM - 6:00 PM Poster Discussion Session**

**Melanoma/Skin Cancers**

Location: S406

**John Robert Hyingstrom, MD, FACS - Chair**  
Huntsman Cancer Institute at the University of Utah

**Sarah A. Weiss, MD - Chair**  
Rutgers Cancer Institute of NJ

**4:30 PM Mario Sznol, MD (Discussion of Abstract(s) 9509-9510)**  
Yale University  
*What Was Old May Be New Again in Advanced Melanoma*

**4:42 PM** Panel Question and Answer

**4:52 PM Richard D. Carvajal, MD (Discussion of Abstract(s) LBA9512-9514)**  
Northwell Health Cancer Institute  
*Where to Next for Rare Melanoma Subtypes?*

**5:04 PM** Panel Question and Answer

**5:14 PM Caroline Robert, MD (Discussion of Abstract(s) LBA9515-9517)**  
Gustave Roussy  
*Measure Twice, Treat Once: Investigating Biomarkers to Improve Treatments*

**5:26 PM** Panel Question and Answer

**5:36 PM Kim Allyson Margolin, MD, FASCO (Discussion of Abstract(s) 9518-9520)**  
St. John's Cancer Institute  
*To Treat or Not to Treat? Challenging Scenarios in Skin Cancer*

**5:48 PM** Panel Question and Answer

Posters discussed in this session are on display in the Melanoma/Skin Cancers Poster Session. To view abstract titles and presentations, see the online program guide (meetings.asco.org).

---

**4:30 PM - 6:00 PM Poster Discussion Session**

**Prevention, Risk Reduction, and Hereditary Cancer**

Location: S102

**Phuong L. Mai, MD, MS - Chair**  
University of Pittsburgh Medical Center

**Joanne M. Jeter, MD, FASCO - Chair**  
Huntsman Cancer Institute at the University of Utah

**4:30 PM Peter Stanich, MD (Discussion of Abstract(s) 10513-10515)**  
The Ohio State University Wexner Medical Center  
*Targeted Therapeutics for Hereditary Cancer Syndromes*

**4:42 PM** Panel Question and Answer

**4:52 PM Michael J. Hall, MD, MSc (Discussion of Abstract(s) 10516-10518)**  
Fox Chase Cancer Center  
*New Insights in Lynch Syndrome*

**5:04 PM** Panel Question and Answer

**5:14 PM Eliezer Mendel Van Allen, MD (Discussion of Abstract(s) 10519-10521)**  
Dana-Farber Cancer Institute  
*Multicancer Early Detection: Ready for Clinical Implementation?*

**5:26 PM** Panel Question and Answer

**5:36 PM Heather Hampel, MS (Discussion of Abstract(s) 10522-10524)**  
City of Hope National Medical Center  
*Management of Incidental Germline Findings*

**5:48 PM** Panel Question and Answer

Posters discussed in this session are on display in the Prevention, Risk Reduction, and Hereditary Cancer Poster Session. To view abstract titles and presentations, see the online program guide (meetings.asco.org).

Saturday, June 3, 2023

**4:30 PM - 6:00 PM Poster Discussion Session**

**Sarcoma**

Location: S404

**Varun Monga, MBBS - Chair**

University of Iowa

**Angela C. Hirbe, MD, PhD - Chair**

Washington University in Saint Louis

- 4:30 PM Elizabeth J. Davis, MD (Discussion of Abstract(s) 11513-11516)**  
Vanderbilt University Medical Center  
*Latest Perspectives on Desmoid Fibromatosis*
- 4:42 PM** Panel Question and Answer
- 4:52 PM Tom Wei-Wu Chen, MD (Discussion of Abstract(s) 11517-11518)**  
National Taiwan University Hospital  
*Choosing Your "Plus One": Immunotherapy Combinations in Sarcomas*
- 5:04 PM** Panel Question and Answer
- 5:14 PM Priscilla Merriam, MD (Discussion of Abstract(s) 11519-11521)**  
Dana-Farber Cancer Institute  
*In Pursuit of Synergy: Combinations in Sarcomas*
- 5:26 PM** Panel Question and Answer
- 5:36 PM Margaret von Mehren, MD (Discussion of Abstract(s) 11522-11524)**  
Fox Chase Cancer Center, Temple University Health System  
*Exploring the Genomic Landscape in GIST: Implications for Treatment*
- 5:48 PM** Panel Question and Answer

Posters discussed in this session are on display in the Sarcoma Poster Session. To view abstract titles and presentations, see the online program guide ([meetings.asco.org](http://meetings.asco.org)).

**4:45 PM - 5:45 PM Case-Based Panel**

**A Multidisciplinary Case-Based Discussion of PSMA PET-Positive Prostate Cancer**

Location: E450

**Howard M. Sandler, MD, FASCO, FASTRO - Chair**

Cedars-Sinai Medical Center

*Moderator*

**Baris Turkbey, MD**

National Cancer Institute/National Institutes of Health

*PSMA-PET Imaging: Radiology Perspective*

**Phuoc T. Tran, MD, PhD**

University of Maryland

*PSMA-PET Imaging: Radiation Oncology Perspective*

**Dana E. Rathkopf, MD**

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center

*PSMA-PET Imaging: Medical Oncology Perspective*

*Panel Question and Answer*

---

**4:45 PM - 6:00 PM Ticketed Session**

**Fireside Chat: International Collaborations to Take Us ALL Into the Future—What Might Childhood ALL Therapy Look Like in 25 Years?**

Location: E253d

**Martin Schrappe, MD, PhD**

University Hospital Schleswig-Holstein

*Collaboration in Acute Lymphoblastic Leukemia Trials: Lessons Learned*

**Mignon L. Loh, MD**

Seattle Children's Hospital

*Can the Past Inform the Future in Childhood Acute Lymphoblastic Leukemia?*

*Panel Question and Answer*















**7:30 AM - 9:30 AM Education Session**

**Training Program Directors' Breakfast**

Location: S103

**7:00 AM** Breakfast and Networking

**7:30 AM** **Deepa Rangachari, MD - Chair**  
Beth Israel Deaconess Medical Center  
*Structures and Processes to Promote Deliberate Professional Development*

**7:50 AM** Small Group Discussion: Professional Development in Your Program

**8:15 AM** **Elizabeth Henry, MD**  
Loyola University  
*Goal-Concordant Professional Development for Diverse Careers in Hematology/Oncology*

**Nazik Hammad, MD**  
Cancer Center of Southeastern Ontario  
*Goal-Concordant Professional Development for Diverse Careers in Hematology/Oncology*

**8:45 PM** Large Group Discussion

**9:10 AM** Large Group Discussion: Future Directions

**9:25 AM** Wrap-up and Adjourn With Dr. Deepa Rangachari

**8:00 AM - 9:00 AM Case-Based Panel**

**Payment Reform: Lessons Learned From the Oncology Care Model and Implications for the Enhancing Oncology Model**

Location: S404

**Gabrielle Betty Rocque, MD, MSPH, FASCO - Chair**  
University of Alabama at Birmingham  
*Moderator*

**Aaron J. Lyss, MBA**  
OneOncology  
*Perspective on Strategies to Success in the Oncology Care Model*

**Theresa Dreyer, MPH**  
Association of American Medical Colleges  
*Perspective on Lessons Learned from Academic Practices Participating in the Oncology Care Model*

**Lalan S. Wilfong, MD**  
US Oncology Network  
*Perspective on the Enhancing Oncology Model*

*Panel Question and Answer*

**8:00 AM - 9:15 AM Education Session**

**Artificial Intelligence for Drug Development: Fad or Future?**

Location: S100bc

**Arsela Prelaj, MD**  
Fondazione IRCCS Istituto Nazionale Tumori  
*A Machine Learning Framework to Improve Treatment Selection*

**Dean Ho, PhD, BS, MS**  
UCLA Medical Center  
*Using AI to Optimize Drug Combinations and Dosing*

**Alexander T. Pearson, MD, PhD - Chair**

University of Chicago  
*Pathology Image-Based Detection of Clinically Actionable Genetic Alterations*

*Panel Question and Answer*

**8:00 AM - 9:15 AM Education Session**

**ASCO/AACR Joint Session: Targeting the Cell Cycle in Cancer**

Location: S100a

**Eric P. Winer, MD, FASCO - Chair**  
Yale Cancer Center  
*Chair and Moderator*

**Robert H. Vonderheide, MD, DPhil - Chair**  
Abramson Cancer Center at the University of Pennsylvania  
*Chair and Moderator*

**Peter Sicinski, MD, PhD**  
Dana-Farber Cancer Institute  
*Cell Cycle Dysregulation in Cancer: Mechanisms and Therapeutic Implications*

**Angela DeMichele, MD, MSCE**  
University of Pennsylvania  
*Cell Cycle Inhibition in the Clinic: State of the Art*

**Shom Goel, MBBS, PhD, FRACP**  
The Sir Peter MacCallum Department of Oncology, University of Melbourne  
*The Future of CDK Inhibitors: Beyond 4 and 6*

*Panel Question and Answer*

**8:00 AM - 9:15 AM Education Session**

**COVID and Other Viral Infections in Patients With Hematologic Malignancies**

Location: S102

**Lindsey Baden, MD - Chair**  
Brigham and Women's Hospital  
*COVID Vaccination and Prophylactic Strategies With Hematologic Malignancies*

**Lisa K. Hicks, MD**  
St. Michael's Hospital and University of Toronto  
*Management of COVID in Patients With Hematologic Malignancies*

**John H. Baird, MD**  
City of Hope  
*Viral Infection After CAR-T Therapy: Risk Factors, Monitoring, and Management*

*Panel Question and Answer*

**8:00 AM - 9:15 AM Education Session**

**Improving Cancer Outcomes by Addressing Social Determinants of Health**

Location: E350

**Reginald Tucker-Seeley, ScD**  
Zero - The End of Prostate Cancer  
*Social Determinants of Health: Why Do They Matter and What Can Be Done?*

Sunday, June 4, 2023

**Chanita Hughes Halbert, PhD**  
University of Southern California  
*Using Digital Tools to Address the Social Determinants of Health*

**Ruth C. Carlos, MD, MS - Chair**  
University of Michigan  
*Measuring and Acting Upon Financial Toxicity Through Cancer Care Delivery Research*

*Panel Question and Answer*

---

### 8:00 AM - 9:15 AM Education Session

#### Knowing the Unknown: The Future of Prognostic Tools in Melanoma

Location: E451

**Michael S. Sabel, MD, FACS - Chair**  
University of Michigan  
*Gene Expression Profiles in Melanoma: Ready for Prime Time?*

**Helen Rizos, PhD**  
Macquarie University  
*Beyond Tissue Biopsies: Liquid Biomarkers in Melanoma*

**Sandra L. Wong, MD, MS, FACS, FASCO**  
Dartmouth-Hitchcock Medical Center  
*Shifting Landscapes: The Evolving Role of Sentinel Lymph Node Biopsy in Melanoma*

*Panel Question and Answer*

---

### 8:00 AM - 9:15 AM Education Session

#### PARP Inhibitors: Optimal Selection and Toxicity Management

Location: E450

**Susan Feinberg**  
Facing Our Risk of Cancer Empowered  
*Living on a PARPi*

**Michael Friedlander, MD, PhD**  
Prince of Wales Hospital  
*Real-World Experience in Managing PARP Inhibitor Toxicities*

**William P. Tew, MD - Chair**  
Memorial Sloan Kettering Cancer Center  
*Updates on the Status on PARP Inhibitors in Ovarian Cancer*

*Panel Question and Answer*

---

### 8:00 AM - 9:15 AM Education Session

#### Putting It Together: Big Data in Pediatric Oncology

Location: S406

**Norman E. Sharpless, MD**  
Independent Contractor  
*The Childhood Cancer Data Initiative: Why a Big Data Effort in Pediatric Oncology Has Been Prioritized by the NCI*

**Samuel Louis Volchenboum, MD, PhD - Chair**  
University of Chicago Medical Center  
*The Importance of Data Harmonization Within the Childhood Cancer Data Initiative Efforts*

**Lindsay Frazier, MD**  
Dana-Farber Cancer Institute  
*Practical MAGIC: Using Data Commons to Impact Care of Patients With Germ Cell Tumors*

*Panel Question and Answer*

---

### 8:00 AM - 9:15 AM Education Session

#### Rational Combinations: The Road to Personalized Immunotherapy

Location: Arie Crown Theater

**Harriet M. Kluger, MD**  
Yale Cancer Center  
*Resistance to Immunotherapy Combinations: Phenotypes and Mechanisms*

**Eytan Ruppin, MD, PhD**  
National Cancer Institute  
*Applying Big Data to Precision Immunotherapy*

**Siwen Hu-Lieskovan, MD, PhD - Chair**  
Huntsman Cancer Institute, University of Utah  
*Biomarker Driven Combination Strategies: NCI i-Match and Beyond*

*Panel Question and Answer*

---

### 8:00 AM - 9:15 AM Ticketed Session

#### Meet the Professors: Innovations for Hereditary Cancer Syndromes—Cancer Screening and Cascade Testing

Location: E253d

**Susan M. Domchek, MD, FASCO**  
Abramson Cancer Center, University of Pennsylvania  
*New Approaches to Screening and Surveillance for Hereditary Cancer Syndromes*

**Matthew B. Yurgelun, MD, FASCO**  
Dana-Farber Cancer Institute  
*Navigating Cascade Testing for Families*

*Panel Question and Answer*

---

### 8:00 AM - 11:00 AM Oral Abstract Session

#### Gastrointestinal Cancer—Colorectal and Anal

Location: Hall D2

**Karyn Beth Stitzenberg, MD, MPH - Chair**  
The University of North Carolina at Chapel Hill

**Andrea Cercek, MD - Chair**  
Memorial Sloan Kettering Cancer Center

**8:00 AM Abstract 3500:** FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study.  
First Author: Carlotta Antoniotti, MD, PhD

- 8:12 AM Abstract 3501:** Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.  
First Author: Kanwal Pratap Singh Raghav, MBBS
- 8:24 AM Tanios S. Bekaii-Saab, MD (Discussion of Abstract(s) 3500-3501)**  
Mayo Clinic  
*TRIBE Meets DESTINY: A LEAP Forward in the Treatment of Advanced Colorectal Cancer*
- 8:36 AM** Panel Question and Answer
- 8:48 AM Abstract LBA3503:** Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial.  
First Author: Lars Henrik Jensen, MD, PhD
- 9:00 AM Abstract LBA3504:** Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial.  
First Author: Thierry Conroy, MD
- 9:12 AM Abstract 3505:** Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial.  
First Author: Jianwei Zhang, MD
- 9:24 AM Y. Nancy You, MD (Discussion of Abstract(s) LBA3503-3505)**  
The University of Texas MD Anderson Cancer Center  
*Neoadjuvant Treatment Strategies in Colon and Rectal Cancers: What Is the Worth?*
- 9:36 AM** Panel Question and Answer
- 9:48 AM Abstract 3506:** NeoRAS wild-type metastatic colorectal cancer in the SCRUM-Japan GOZILA study.  
First Author: Hiroki Osumi, MD, PhD
- 10:00 AM Abstract 3507:** Phase III FIRE-4 study (AIO KRK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC.  
First Author: Sebastian Stintzing, MD
- 10:12 AM Abstract 3508:** Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L, and RAS/BRAF WT: A biomarker study of the phase III PARADIGM trial.  
First Author: Kentaro Yamazaki, MD, PhD
- 10:24 AM John H. Strickler, MD (Discussion of Abstract(s) 3506-3508)**  
Duke University Medical Center  
*Clonal RAS Wars in Advanced Colorectal Cancer and EGFR Inhibitors: The Battle of Liquid and Tissue Biopsy*
- 10:36 AM** Panel Question and Answer

---

**8:00 AM - 11:00 AM Oral Abstract Session**

**Genitourinary Cancer—Prostate, Testicular, and Penile**

Location: Hall B1

**Fatima Karzai, MD - Chair**

Genitourinary Malignancies Branch, CCR, NCI, NIH

**Sophia C. Kamran, MD - Chair**

Massachusetts General Hospital and Harvard Medical School

- 8:00 AM Abstract LBA5000:** Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.  
First Author: Alberto Bossi, MD
- 8:12 AM Abstract 5001:** Development and validation of an AI-derived digital pathology-based biomarker to predict benefit of long-term androgen deprivation therapy with radiotherapy in men with localized high-risk prostate cancer across multiple phase III NRG/RTOG trials.  
First Author: Andrew J. Armstrong, MD
- 8:24 AM Abstract 5002:** Prognostic impact of PSA nadir (n)  $\geq 0.1$  ng/mL within 6 months (m) after completion of radiotherapy (RT) for localized prostate cancer (PCa): An individual patient-data (IPD) analysis of randomized trials from the ICECAP collaborative.  
First Author: Praful Ravi, MRCP, MBBS
- 8:36 AM Karen E. Hoffman, MD, MHSc, MPH (Discussion of Abstract(s) LBA5000-5002)**  
MD Anderson Cancer Center  
*Hitting the Sweet Spot With Radiation and Androgen Deprivation*
- 8:48 AM** Panel Question and Answer
- 9:00 AM Abstract 5003:** Presence of somatic/germline homologous recombination repair (HRR) mutations and outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving first-line (1L) treatment stratified by BRCA status.  
First Author: David Olmos, MD, PhD
- 9:12 AM Abstract 5004:** TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.  
First Author: Karim Fizazi, MD
- 9:24 AM Abstract 5005:** LuPARP: Phase 1 trial of <sup>177</sup>Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).  
First Author: Shahneen Sandhu, MBBS, FRACP
- 9:36 AM David James VanderWeele, MD, PhD (Discussion of Abstract(s) 5003-5005)**  
Northwestern University  
*DDR and PARP Inhibition: What's the Damage?*
- 9:48 AM** Panel Question and Answer
- 10:00 AM Abstract 5006:** Long term follow-up analysis of plasma miR371 expression to detect early relapse in patients with clinical stage I testicular germ cell tumors on surveillance.  
First Author: Lucia Nappi, MD, PhD, FRCPC
- 10:12 AM Abstract 5007:** The genomic and transcriptomic landscapes of chemotherapy naive vs post-chemotherapy germ cell tumors.  
First Author: Aditya Bagrodia, MD
- 10:24 AM Abstract 5008:** Primary retroperitoneal lymph node dissection (RPLND) in seminoma stage IIA-IIC  $\leq 3$ cm: Combined results of the SWENOTECA (Swedish Norwegian Testicular Cancer Group) and Cologne.  
First Author: Torgrim Tandstad, MD, PhD
- 10:36 AM Ben Tran, MBBS, FRACP (Discussion of Abstract(s) 5006-5008)**  
Peter MacCallum Cancer Centre  
*Germinating Data for Germ Cell Tumors*
- 10:48 AM** Panel Question and Answer

Sunday, June 4, 2023

8:00 AM - 11:00 AM Poster Session

Breast Cancer—Local/Regional/Adjuvant

Location: Hall A

Abstracts on Boards 344-355 will be discussed during the Breast Cancer—Local/Regional/Adjuvant Poster Discussion Session. See the online program guide ([meetings.asco.org](https://meetings.asco.org)) for session details.

Posters by Topic

**Adjuvant Therapy:** Boards 347, 356-390, 445a-447b

**Biologic Correlates:** Boards 345-346, 391-412, 448a-448b

**Local-Regional Therapy:** Boards 353-355, 413-418, 449a-451b

**Neoadjuvant Therapy:** Boards 344, 349-352, 419-442, 444, 452a-455b

- Board 344 **ABSTRACT 514:** Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival.  
First Author: Hope S. Rugo, MD, FASCO
- Board 345 **ABSTRACT 515:** ECOG-ACRIN E2197: Comparison of HER2 gene expression by RT-PCR across all HER2 immunohistochemistry groups with recurrence analysis.  
First Author: Nhu Thuy Can, MD
- Board 346 **ABSTRACT 516:** AI-based HER2-low IHC scoring in breast cancer across multiple sites, clones, and scanners.  
First Author: Patrick Frey, PhD
- Board 347 **ABSTRACT 517:** Outcomes according to treatment received for small node-negative HER2+ breast tumors in the Surveillance, Epidemiology, and End Results (SEER) database, 2010-2019.  
First Author: Adrienne Gropper Waks, MD
- Board 349 **ABSTRACT 519:** Gene expression signatures, stromal tumor infiltrating lymphocytes (sTILs), and change in tumor cellularity to predict pathological complete response (pCR) after 12 week de-escalated neoadjuvant endocrine therapy (ET) vs paclitaxel + dual HER2 blockade in the WSG-TP-II trial.  
First Author: Monika Karla Graeser, MD
- Board 350 **ABSTRACT LBA520:** Oral paclitaxel, Carboplatin, and Dostarlimab (OPE/Cb/D) without and with Trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.  
First Author: Kay T Yeung, MD, PhD
- Board 351 **ABSTRACT 521:** MammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2- breast cancer in NBRST.  
First Author: Peter D. Beitsch, MD
- Board 352 **ABSTRACT 522:** Primary efficacy analyses of NeoR-HEA, neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer.  
First Author: Elisa Agostinnetto, MD
- Board 353 **ABSTRACT 523:** A randomized controlled trial comparing primary tumor resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group study JCOG1017.  
First Author: Tadahiko Shien, MD, PhD
- Board 354 **ABSTRACT 524:** Axillary surgery efficacy for patients with breast cancer receiving neoadjuvant chemotherapy on NSABP B40 and B41.  
First Author: Raymond Mailhot Vega, MD, MPH
- Board 355 **ABSTRACT 525:** Long-term oncologic outcomes after omitting axillary surgery in older women with early stage, node-negative breast cancer: A systematic review and meta-analysis.  
First Author: Mariam Rana, BSc, MBBS

- Board 356 **ABSTRACT 526:** Differences of prediction performances by multigene assays in patients with breast cancer with distinct genetic backgrounds.  
First Author: Fei Xing
- Board 357 **ABSTRACT 527:** Efficacy of ovarian function suppression of 3-monthly versus monthly GnRH agonist as endocrine therapy for premenopausal breast cancer patients.  
First Author: Daniella Audi Blotta, MD
- Board 358 **ABSTRACT 528:** Differential benefit of capecitabine-based chemotherapy among TNBC subtypes in the context of the CBCSG010 study.  
First Author: Junjie Li
- Board 359 **ABSTRACT 529:** Assessing the marginal costs of radiation therapy and antiestrogen therapy for post-lumpectomy, early-stage breast cancer across Medicaid and Medicare plans.  
First Author: Victoria Wu, BA
- Board 360 **ABSTRACT 530:** Association between patient-reported outcomes and therapeutic outcomes in patients with breast cancer: A pooled individual-participant data analysis.  
First Author: Natansh Modi
- Board 361 **ABSTRACT 531:** The impact of the 4R Oncology model on OncotypeDx turnaround time.  
First Author: Jenny Wei, MD
- Board 362 **ABSTRACT 532:** A multicenter phase II study of vaccines to prevent recurrence in patients with HER2-positive breast cancer.  
First Author: Hyo S. Han, MD
- Board 363 **ABSTRACT 533:** Does RSCLin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, Influence, CTS-5)? A TEAM Pathology substudy.  
First Author: Ana-Alicia Beltran-Bless, MD
- Board 364 **ABSTRACT 534:** Real-world impact of TAILORx on chemotherapy use and SOFT/TEXT on ovarian function suppression uptake in a population based-cohort of women 40 years and under with HR-positive, HER2-negative, axillary lymph node negative breast cancer.  
First Author: Malek B. Hannouf Jr., MD, PhD
- Board 365 **ABSTRACT 535:** Disease-free survival (DFS) as a surrogate for overall survival (OS) in patients (pts) with HR+/HER2 early breast cancer (EBC): A correlation analysis.  
First Author: Michael Untch, MD, PhD
- Board 366 **ABSTRACT 536:** Image-only deep learning risk model performance in patients with known germline mutations.  
First Author: Faezeh Sodagari, MD
- Board 367 **ABSTRACT 537:** Effect of astragalus polysaccharides (PG2) treatment of adjuvant chemotherapy-induced fatigue in premenopausal patients with breast cancer.  
First Author: Kun Ming Rau, MD
- Board 368 **ABSTRACT 538:** Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bNOM0 breast cancer.  
First Author: Yuko Takahashi, MD, PhD
- Board 369 **ABSTRACT 539:** HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).  
First Author: June Evelyn Jeon
- Board 370 **ABSTRACT 540:** Pulsed electrical fields in combination with anti-PD1 and survival of mice with TNBC (EMT6) murine breast tumor.  
First Author: Ebtesam Nafie, PhD

- Board 371 **ABSTRACT 541:** Impact of endocrine therapy adherence on racial disparities in breast cancer survival. First Author: Kimberley T Lee, MD, MHS
- Board 372 **ABSTRACT 542:** Real-world outcomes with adjuvant nonsteroidal aromatase inhibitors (NSAIs) vs tamoxifen (TAM) in patients with hormone receptorpositive/human epidermal growth factor receptor 2negative (HR+/HER2) early breast cancer (EBC): A US database analysis. First Author: Stephanie L. Graff, MD
- Board 373 **ABSTRACT 543:** The worldwide impact of HER2-targeted treatments in women with breast cancer: An epidemiological modeling study. First Author: David J. Press, PhD, MPhil
- Board 374 **ABSTRACT 544:** Pathologic complete response after neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers. First Author: Sara P. Myers, MD, PhD
- Board 375 **ABSTRACT 545:** Validation of a novel and rapid reagent free assay to predict outcomes for adjuvant therapy decision making in hormone receptor-positive breast cancer. First Author: Charles Coombes
- Board 376 **ABSTRACT 546:** Influence of hormone therapy timing intake on disease free survival (DFS) for patients with high-risk early breast cancer: Results of the UCBG-UNIRAD phase III randomized trial. First Author: Sylvie Giacchetti, MD, MSc
- Board 377 **ABSTRACT 547:** Prognostic role of HER2 expression in patients with ER-positive/HER2-negative breast cancer: Results from a population-based cancer registry study. First Author: Antonino Musolino, MD, PhD, MSc
- Board 378 **ABSTRACT 548:** Additional prognostic value of the BCT score in patients with ER+HER2- breast cancer receiving 21-gene assay-guided adjuvant treatments. First Author: Sung Gwe Ahn, MD, PhD
- Board 379 **ABSTRACT 549:** An analysis of breast cancer index scores predicting benefit of extended endocrine therapy by race. First Author: Nicholas Siu-Li, BS
- Board 380 **ABSTRACT 550:** Cardiac safety and efficacy for patients with early-stage breast cancer treated with pegylated liposomal doxorubicin (PLD) or doxorubicin. First Author: Lichen Tang, MD
- Board 381 **ABSTRACT 551:** Influence of adherence to adjuvant endocrine therapy in early breast cancer: Results from a large German real-world claims data analysis. First Author: Dominik Dannehl, MD
- Board 382 **ABSTRACT 552:** Beneficial effect of repeated participation in breast cancer screening upon survival. First Author: Robert A. Smith, PhD
- Board 383 **ABSTRACT 553:** State-of-the-art management of HER2-negative early breast cancer: Treatment patterns among healthcare professionals and concordance with expert recommendations. First Author: Marie N. Becker, PhD
- Board 384 **ABSTRACT 554:** SEER analysis of 9-year breast cancer specific mortality (BCSM) in patients (pts) with invasive lobular breast cancer (ILC) assessed by the 21-gene Breast Recurrence Score assay. First Author: Charles E. Geyer Jr., MD
- Board 385 **ABSTRACT 555:** Impact of neoadjuvant chemo-immunotherapy on surgical outcomes and time to radiation in triple negative breast cancer. First Author: Sara P. Myers, MD, PhD
- Board 386 **ABSTRACT 556:** Detection of homologous recombination deficiency (HRD) using a novel genomic and epigenomic liquid biopsy assay in patients with breast cancer. First Author: Catalin Barbacioru, PhD
- Board 387 **ABSTRACT 557:** Trends and outcomes of systemic therapy in hormone receptor-positive early-stage male breast cancer: A propensity score analysis. First Author: Liuwen Yu, MM
- Board 388 **ABSTRACT 558:** Decision value of the circulating tumor DNA on the adjuvant anti-Her2 regimens in patients with Her2-positive breast cancer treated with neoadjuvant therapy. First Author: Po-Han Lin, MD
- Board 389 **ABSTRACT 559:** Utility of Ki67 in guiding adjuvant abemaciclib therapy for patients with hormone receptor (HR)-positive, early breast cancer (EBC). First Author: Rima Patel, MD
- Board 390 **ABSTRACT 560:** Influence of ovarian function suppression on quality of life in breast cancer survivors during adjuvant endocrine therapy. First Author: Natalija Dedic Plavetic, MD, PhD (c)
- Board 391 **ABSTRACT 561:** Prognosis of squamous cell carcinoma of the breast by biological subtypes and the efficacy of radiotherapy: The Japanese Breast Cancer Registry analysis. First Author: Mami Ogita
- Board 392 **ABSTRACT 562:** Survival outcomes of young patients under 40 with breast cancer in Asian countries according to subtype: An international multicenter cohort study. First Author: Jinyong Kim
- Board 393 **ABSTRACT 563:** Association of human epidermal growth factor receptor 2 expression with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer. First Author: Sung Jun Ma, MD
- Board 394 **ABSTRACT 564:** Impact of race on Blueprint genomic subtyping in HER2+ breast cancer. First Author: Sonya A. Reid, MD, MPH
- Board 395 **ABSTRACT 565:** Lipidomic signature from plasma to detect localised breast cancer. First Author: Gillian Lamoury, MD
- Board 396 **ABSTRACT 566:** Correlation of gene signatures of Kaiso and LC3A/B protein expression with distinct tumor ecosystems and to predict response to breast cancer therapy. First Author: Sandeep K. Singhal, PhD
- Board 397 **ABSTRACT 567:** Association of anthracyclines induced cardiotoxicity (AIC) in patients with early breast cancer (eBC) with germline BRCA1/2 (gBRCA1/2) mutation: BRCAN study. First Author: Juan José Serrano Domingo, MD
- Board 398 **ABSTRACT 568:** Comprehensive profiling of mutational signatures and machine learning and subtypes of homologous recombination deficiency. First Author: Joonoh Lim, MD, PhD
- Board 399 **ABSTRACT 569:** ERBB2 mRNA expression to distinguish HER2-low/neg breast cancer prognosis. First Author: Yueping Liu, MD

- Board 400 **ABSTRACT 570:** Do HER2 low tumors have a distinct clinicopathologic phenotype?  
First Author: Natália Polidorio, MD
- Board 401 **ABSTRACT 571:** Outcomes in premenopausal patients with HR+/HER2- breast cancer and lymph node micro-metastasis based on the 21-gene recurrence score.  
First Author: Nadeem Bilani, MD
- Board 402 **ABSTRACT 572:** Clinical meaning of stromal tumor infiltrating lymphocytes (sTIL) in luminal early breast cancer.  
First Author: Esmeralda García-Torralba, MD, PhD
- Board 403 **ABSTRACT 573:** Phase II randomized window of opportunity trial evaluating cytotoxic and immunomodulatory effects of intratumoral INT230-6 in early stage breast cancer: The INVINCIBLE trial.  
First Author: Melanie Spears
- Board 404 **ABSTRACT 574:** Treatment outcomes in patients with discordant recurrence score and RSclin risk predictions.  
First Author: Augustin Vannier
- Board 405 **ABSTRACT 575:** Impact of HER2 low expression in the Oncotype DX RS in patients with operable hormone receptor positive early stage breast cancer.  
First Author: Laura Sofia Munoz-Arcos, MD
- Board 406 **ABSTRACT 576:** Somatic mutations in tumor-adjacent normal breast tissue in young women with high risk family history.  
First Author: Mariya Rozenblit
- Board 407 **ABSTRACT 577:** Exploring HER2-low disease: Does it impact breast cancer survival?  
First Author: Assumpció López-Paradís
- Board 408 **ABSTRACT 578:** Extracellular vesicle-derived non-coding RNAs to predict outcome in patients with triple-negative breast cancer (TNBC) with residual disease (RD).  
First Author: Shane R Stecklein, MD
- Board 409 **ABSTRACT 579:** Differential genomic and transcriptomic analysis of invasive lobular and ductal carcinomas.  
First Author: Jason A Mouabbi, MD
- Board 410 **ABSTRACT 580:** Assessment of the differential profile of breast intratumoral bacteria in treatment responders and nonresponders.  
First Author: Amedra Basgaran
- Board 411 **ABSTRACT 581:** Characteristics associated with spatially resolved immune landscapes in triple-negative breast cancer in the FinXX trial and Mayo Clinic cohort.  
First Author: Saranya Chumsri, MD
- Board 412 **ABSTRACT 582:** The somatic mutation profile of breast cancer in Uganda.  
First Author: Manoj Menon, MD
- Board 413 **ABSTRACT 583:** Phase II study on feasibility of sentinel lymph node biopsy for ycN0 patients treated with primary chemotherapy in cT1-3N1M0 breast cancer (SHARE study).  
First Author: Rikiya Nakamura, BA
- Board 414 **ABSTRACT 584:** 10-year mastectomy trends among breast cancer phenotypes: A national cohort study.  
First Author: Matthew Lewis Pierotti, MD
- Board 415 **ABSTRACT 585:** Racial/ethnic and socioeconomic differences in breast cancer surgery performed and delayed surgical treatment: Mediating impact on mortality.  
First Author: Ayrton Bangolo
- Board 416 **ABSTRACT 586:** Disease outcomes by race in patients with high-risk triple negative breast cancer with residual disease after neoadjuvant chemotherapy: A post-hoc analysis of the EA1131 randomized clinical trial.  
First Author: Olga Kantor, MD
- Board 417 **ABSTRACT 587:** Association of minimizing the false negative rate of axillary staging surgery in patients with cN1 breast cancer after neoadjuvant chemotherapy with surgical overtreatment.  
First Author: Alison Laws, MD
- Board 418 **ABSTRACT 588:** A phase II randomized clinical trial to assess toxicity and quality of life of patients with breast cancer with hypofractionated versus conventional fractionation radiotherapy with regional nodal irradiation.  
First Author: Gabriel Oliveira Bernardes Gil
- Board 419 **ABSTRACT 589:** Invasive disease free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab.  
First Author: Sonya Chew, MBBS, MRCP
- Board 420 **ABSTRACT 590:** Effect of tumor microenvironment on chemotherapy response of patients with triple-negative breast cancer receiving neoadjuvant chemotherapy.  
First Author: Jae-Joon Kim, MD
- Board 421 **ABSTRACT 591:** Neoadjuvant giredestrant + palbociclib (P) vs. anastrozole (A) + P in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+, HER2- eBC): Patient (pt)-reported outcomes (PROs) in the randomized, open-label, international phase II coopERA BC study.  
First Author: Yeon Hee Park, MD, PhD
- Board 422 **ABSTRACT 592:** Use of machine learning to predict pathological complete response using multi-modal data from I-SPY2 clinical trials.  
First Author: Fahad Shabbir Ahmed, MBBS
- Board 423 **ABSTRACT 593:** Taxane combined with lobaplatin or anthracycline for neoadjuvant treatment of triple-negative breast cancer: A single-center, randomized, controlled, phase-II clinical study.  
First Author: Cheng Wang
- Board 424 **ABSTRACT 594:** Use of PLR and NLR to evaluate the efficacy and prognosis of neoadjuvant chemotherapy with lobaplatin in triple-negative breast cancer.  
First Author: Cheng Wang
- Board 425 **ABSTRACT 595:** Association between pCR, TILs, and Ki-67 at baseline and after 2 weeks in patients with triple-negative breast cancer (TNBC) treated with atezolizumab and chemotherapy +/- a preceding atezolizumab monotherapy window: A translational analysis of the neoMono trial.  
First Author: Ramona Erber, MD
- Board 426 **ABSTRACT 596:** Neoadjuvant therapy of HER2 directed conventional dendritic cell (DC1) intratumoral (IT) therapy plus weekly paclitaxel, trastuzumab, and pertuzumab in patients with HER-2 positive breast cancer: NATASHA trial.  
First Author: Hyo S. Han, MD
- Board 427 **ABSTRACT 597:** Artificial intelligence (AI) -based machine learning models (ML) for predicting pathological complete response (pCR) in patients with hormone receptor (HoR) -positive/HER2-negative early breast cancer (EBC) undergoing neoadjuvant chemotherapy (NCT): A retrospective cohort study.  
First Author: Luca Mastrantoni, MD

- Board 428 **ABSTRACT 598:** Association between genomic alterations and response of triple-negative breast cancers (TNBC) to talimogene laherparepvec (TVEC) in combination with neoadjuvant chemotherapy (NACT).  
First Author: Hatem Hussein Soliman, MD
- Board 429 **ABSTRACT 599:** Longitudinal MRI-based fusion novel model to predict pathological complete response in breast cancer treated with neoadjuvant chemotherapy: A multicenter, retrospective study.  
First Author: Kun Wang, MD
- Board 430 **ABSTRACT 600:** Association of HER2/CEP17 ratio with pCR after HER2-directed neoadjuvant treatments in the phase III NeoALTTO trial.  
First Author: Christian F. Singer, MD, MPH
- Board 431 **ABSTRACT 601:** Circulating tumor DNA (ctDNA) monitoring in patients with breast cancer receiving neoadjuvant palbociclib and endocrine therapy: A secondary analysis of the NeoRHEA phase 2 study.  
First Author: Alexandra Stanciu
- Board 432 **ABSTRACT 602:** Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin followed by adjuvant tislelizumab in patients with early triple-negative breast cancer.  
First Author: Zefei Jiang, MD
- Board 433 **ABSTRACT 603:** Neoadjuvant single-dose trilaciclib prior to combination chemotherapy in patients with early triple-negative breast cancer: Safety, efficacy, and immune correlate data from a phase 2 study.  
First Author: Jeremy Meyer Force, DO, MA
- Board 434 **ABSTRACT 604:** NeolRX trial: Immunologic induction with peri-lymphatic cytokines to enhance pembrolizumab (pembro) response in stage II/III triple-negative breast cancer (TNBC).  
First Author: David B. Page, MD
- Board 435 **ABSTRACT 605:** Moderate physical exercise and immune system modulation in patients with breast cancer treated with neoadjuvant chemotherapy.  
First Author: Ornella Garrone, MD
- Board 436 **ABSTRACT 606:** Prospective evaluation of pathologic response with neoadjuvant chemo-immunotherapy in metaplastic breast cancer.  
First Author: Nour Abuhadra, MD
- Board 437 **ABSTRACT 607:** A prospective, phase II, neoadjuvant clinical study based on chemotherapy sensitivity in hormone receptor-positive, HER2-negative breast cancer: FINEST study.  
First Author: Li Chen
- Board 438 **ABSTRACT 608:** Association of biophysics-based biomarker with tumor volumetric response in breast cancer treated with immunotherapy.  
First Author: Daniel Cook, PhD
- Board 439 **ABSTRACT 609:** Whole-genome sequencing based assessment of HER2 focal amplification for precision oncology of breast cancers.  
First Author: Ryul Kim, MD, PhD
- Board 440 **ABSTRACT 610:** Social determinants of health and utilization of neoadjuvant chemotherapy in patients with triple negative breast cancer (TNBC) in the community oncology setting.  
First Author: Michael A. Danso, MD, FASCO
- Board 441 **ABSTRACT 611:** Use of PROMIS to capture patient reported outcomes over time for patients on I-SPY2.  
First Author: Saya Jacob, MD
- Board 442 **ABSTRACT LBA612:** Oral Paclitaxel and Dostarlimab with or without Trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.  
First Author: Rebecca Arielle Shatsky, MD
- Board 444 **ABSTRACT 614:** The proliferation biomarker SPAG5 expression in HER2 low and HER2 overexpression early breast cancer (BC) predicting tumour response to neoadjuvant chemotherapy (NACT) with and without trastuzumab.  
First Author: Tarek Mohamed Ahmed Abdel-Fatah, PhD
- Board 445a **ABSTRACT TPS615:** LESS: Single-arm study to de-escalate adjuvant endocrine therapy duration in postmenopausal women with HR+ HER2- early-stage breast cancer at very low risk of metastasis.  
First Author: Elise Deluche, MD, PhD
- Board 445b **ABSTRACT TPS616:** lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician's choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2- eBC).  
First Author: Charles Geyer
- Board 446a **ABSTRACT TPS617:** Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neoadjuvant and postoperative adjuvant anti-HER2 therapy: Flamingo-01.  
First Author: Snehal Patel, BS, MBA, MS
- Board 446b **ABSTRACT TPS618:** Prospective single-arm study of endocrine therapies with ovarian function suppression in premenopausal patients with node-positive early breast cancer with low genomic risk (INTERSTELLAR trial, KBCSG-25).  
First Author: Sung Gwe Ahn, MD, PhD
- Board 447a **ABSTRACT TPS619:** ASCENT-05/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple-negative breast cancer (TNBC) and residual disease after neoadjuvant therapy (NAT) and surgery.  
First Author: Sara M. Tolaney, MD, MPH
- Board 447b **ABSTRACT TPS620:** A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2-positive breast cancer with molecular residual disease (KAN-HER2 MRD).  
First Author: Mitchell Elliott, MD, FRCPC
- Board 448a **ABSTRACT TPS621:** FLEX, a real-world evidence full transcriptome study of 30,000 patients with early-stage breast cancer.  
First Author: Eric Allen Brown, MD
- Board 448b **ABSTRACT TPS622:** MRD assay to evaluate recurrence and response via a tumor-informed assessment: MARIA-Breast observational trial.  
First Author: Edward D. Esplin, MD, PhD, FACP, FACMG
- Board 449a **ABSTRACT TPS623:** NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer.  
First Author: Julia R. White, MD
- Board 449b **ABSTRACT TPS624:** Selective avoidance of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with HER-2 positive/triple negative breast cancer: Prospective, multi-center, single-arm study (ASLAN)  
First Author: Jai Min Ryu, MD, PhD (c)



- Board 450a **ABSTRACT TPS625:** SMALL: Open surgery versus minimally invasive vacuum-assisted excision for small screen-detected breast cancer—A UK phase III randomised multi-centre trial.  
First Author: Stuart McIntosh, PhD, MBChB, FRCS
- Board 450b **ABSTRACT TPS626:** MELODY (Methods for Localization of Different Types of Breast Lesions): A prospective non-interventional multicenter cohort study to evaluate different imaging-guided methods for localization of malignant breast lesions (EUBREAST-4/iBRA-NET).  
First Author: Maggie Banys-Paluchowski
- Board 451a **ABSTRACT TPS627:** Omission of breast surgery for predicted pCR patients with MRI and vacuum-assisted biopsy in breast cancer after neoadjuvant chemotherapy: A multicenter, single-arm, non-inferiority trial (OPTIMIST trial).  
First Author: Ji-Jung Jung, MD
- Board 451b **ABSTRACT TPS628:** Tailored axillary surgery (TAS) in patients with clinically node-positive breast cancer in the upfront surgery setting: A prospective, single-arm, multicenter trial.  
First Author: Kaori Terata, MD, PhD
- Board 452a **ABSTRACT TPS629:** Phase 1 dose-escalation, dose-expansion trial of intratumoral HER2- and HER3-primed dendritic cells injections for the treatment of early-stage TNBC and HR low positive breast cancer: DecipHER trial.  
First Author: Ricardo L Costa, MD, MS
- Board 452b **ABSTRACT TPS630:** DIRECT2: A randomized phase III trial with a fasting mimicking diet program to improve chemotherapy in patients with hormone receptor positive, HER2-negative breast cancer—A Dutch Breast Cancer Research Group study (BOOG).  
First Author: Nadia de Gruil, MD, Msc
- Board 453a **ABSTRACT TPS631:** Metformin with neoadjuvant chemotherapy in localized triple negative and HER2neu-positive breast cancer: A prospective phase 2 open label randomised controlled trial (McBETH).  
First Author: Mouna Bidaraguppe B M, MBBS, MD
- Board 453b **ABSTRACT TPS632:** ORACLE-RIPA study: A phase II, randomized, open-label, parallel-group study comparing the immune modulation effect of neoadjuvant ribociclib, palbociclib, and abemaciclib in early ER+/HER2- breast cancer.  
First Author: I-Chun Chen, MD, PhD
- Board 454a **ABSTRACT TPS633:** A randomized phase 2 non-inferiority trial of (Z)-endoxifen and exemestane + goserelin as neoadjuvant treatment for premenopausal women with ER+/HER2- breast cancer (EVANGELINE).  
First Author: Matthew P. Goetz, MD
- Board 454b **ABSTRACT TPS634:** Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neo-HIP): An open label randomized phase II trial.  
First Author: Heather L. McArthur, MD, MPH
- Board 455a **ABSTRACT TPS635:** A single-arm phase 2 study of peri-operative immune checkpoint inhibition and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer.  
First Author: Heather L. McArthur, MD, MPH
- Board 455b **ABSTRACT TPS636:** A phase II study of concurrent WOKVAC vaccination with neoadjuvant chemotherapy and HER2-targeted monoclonal antibody therapy.  
First Author: William R Gwin III, MD

**8:00 AM - 11:00 AM Poster Session**

**Breast Cancer—Metastatic**

Location: Hall A

Abstracts on Boards 235-246 will be discussed during the Breast Cancer—Metastatic Poster Discussion Session. See the online program guide ([meetings.asco.org](http://meetings.asco.org)) for session details.

**Posters by Topic**

**Biologic Correlates:** Boards 248-260, 332a

**HER2-Positive:** Boards 235-237, 261-274, 332b-334b

**Hormone Receptor-Positive:** Boards 238-240, 245, 275-304, 335a-341a

**Triple-Negative:** Boards 244, 246, 305-316, 341b-343a

**Other/Nonsubtype Specific Breast Cancer:** Boards 241-243, 317-331, 343b

- Board 235 **ABSTRACT 1014:** Efficacy of tucatinib+trastuzumab+capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: A French multicenter retrospective study.  
First Author: Jean-Sebastien Frenel, MD, PhD
- Board 236 **ABSTRACT 1015:** Pertuzumab retreatment in patients with HER2-positive locally advanced/metastatic breast cancer: Overall survival results of a phase III randomized trial (JBCRG-M05: PRECIOUS).  
First Author: Yutaka Yamamoto, MD, PhD
- Board 237 **ABSTRACT 1016:** The association of centromere amplification and response to trastuzumab in HER2+ metastatic breast cancer.  
First Author: Charlotte Andrieu
- Board 238 **ABSTRACT 1017:** LEONARDA-1: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+, HER2- locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy.  
First Author: Binghe Xu, MD, PhD
- Board 239 **ABSTRACT 1018:** First-line systemic treatment with palbociclib in women aged  $\geq 70$  years presenting with hormone receptor-positive advanced breast cancer: Results from the PALOMAGE program.  
First Author: Elisabeth Carola, MD
- Board 240 **ABSTRACT 1019:** Clinico-molecular characteristics associated with outcomes in breast cancer patients treated with CDK4/6 inhibitors: Results from the AURORA Molecular Screening Initiative.  
First Author: Elisa Agostinetto, MD
- Board 241 **ABSTRACT 1020:** Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04.  
First Author: Shanu Modi, MD
- Board 242 **ABSTRACT 1021:** HER2-low status discordance between primary and recurrent/metastatic breast cancer in a large-scale cohort.  
First Author: Mingxi Lin
- Board 243 **ABSTRACT 1022:** Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study.  
First Author: Rachel Occhiogrosso Abelman, MD
- Board 244 **ABSTRACT 1023:** Cyclin E cytoplasmic isoform to predict outcome and benefit to capecitabine treatment in patients with HR+/HER2- metastatic breast cancer from the GEICAM/2013-02 PEARL study.  
First Author: Angel Guerrero, MD

- Board 245 **ABSTRACT 1024:** Early prediction of endocrine responsiveness in ER+/HER2 negative MBC: Pilot study with 18F-fluoroestradiol (18F-FES) CT/PET. First Author: Alessandra Gennari, MD, PhD
- Board 246 **ABSTRACT 1025:** Prostate-specific membrane antigen (PSMA) expression in patients with metastatic triple negative breast cancer: Initial results of the PRISMA study. First Author: Guilherme Nader Marta, MD
- Board 248 **ABSTRACT 1027:** Clinical features, genomic landscapes, and survival outcomes of HER2-low breast cancer. First Author: Jin Juan
- Board 249 **ABSTRACT 1028:** Concordance between liquid and tissue biopsy in participants with newly diagnosed recurrent breast cancer. First Author: Ana Elisa Lohmann, MD, PhD
- Board 250 **ABSTRACT 1029:** Effect of homologous recombination deficient (HRD) breast cancers on a distinct immune marker phenotype by comprehensive genomic and immune profiling (CGIP). First Author: Heidi Chwan Ko, DO
- Board 251 **ABSTRACT 1030:** Comparison of immune microenvironment between primary and metastatic breast tumors. First Author: Heidi Chwan Ko, DO
- Board 252 **ABSTRACT 1031:** Metastatic patterns and outcomes by HER2 and hormone receptor (HR) status in patients (pts) with metastatic breast cancer (mBC). First Author: Qianyu Yuan, PhD
- Board 253 **ABSTRACT 1032:** Gene expression profiling of paired primary breast cancers and brain metastases to identify brain metastases-specific biological changes. First Author: Gaia Griguolo, MD
- Board 254 **ABSTRACT 1033:** UGT1A1 \*28/\*28 genotype and risk of toxicity and disease progression in breast cancer patients treated with sacituzumab govitecan-hziy. First Author: Megan Wong, BS
- Board 255 **ABSTRACT 1034:** Negative estrogen receptor expression assessed by 18F-FES PET in metastatic breast cancer with ER-positive primary tumor. First Author: Biyun Wang
- Board 256 **ABSTRACT 1035:** Comprehensive characterization of androgen receptor expression in breast cancer. First Author: Priya Jayachandran, MD
- Board 257 **ABSTRACT 1036:** Metastatic breast cancer (MBC) with ultra-high tumor mutational burden (UHTMB): A comprehensive genomic profiling (CGP) study. First Author: Kristina Fanucci, MD
- Board 258 **ABSTRACT 1037:** Association of C-MYC, MYC target gene, and unfolded protein response (UPR) expression with clinical benefit from the oral aurora kinase A (AURKA) inhibitor, alisertib (A), in combination with paclitaxel (P) compared with P alone in patients (Pts) with HER2-negative metastatic breast cancer (MBC). First Author: Sara A. Byron, PhD
- Board 259 **ABSTRACT 1038:** Multi-factor dynamic analysis of ctDNA and CTC to aid the diagnostic prognosis of patients with metastatic breast cancer (MBC). First Author: Qiang Zhang, PhD
- Board 260 **ABSTRACT 1039:** Genomic characterization of the GATA3 mutational landscape in breast cancer. First Author: Jason A Mouabbi, MD
- Board 261 **ABSTRACT 1040:** Preclinical and early clinical data of ZN-1041, a best-in-class BBB penetrable HER2 inhibitor to treat breast cancer with CNS metastases. First Author: Fei Ma
- Board 262 **ABSTRACT 1041:** Preclinical and early clinical data of ZN-1041 in combination with trastuzumab deruxtecan to treat breast cancer with or without CNS metastases. First Author: Carey K. Anders, MD, FASCO
- Board 263 **ABSTRACT 1042:** Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive metastatic breast cancer: Final results from the phase 2 ICU trial. First Author: Huimin Lv
- Board 264 **ABSTRACT 1043:** Cardiac function of long-responders to dual anti-HER2 antibodies amongst patients with HER2 positive advanced breast cancer. First Author: Kelvin K H Bao, FRCR, MBBChir, MA
- Board 265 **ABSTRACT 1044:** Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): Updated results from a phase 1b/2 study. First Author: Xiaojia Wang, MD, PhD
- Board 266 **ABSTRACT 1045:** Updated results from a phase 2 study on dalcipiclib and pyrotinib, a dual-oral chemotherapy-free regimen in HER2-positive advanced breast cancer (DAP-HER-01). First Author: Min Yan, MD
- Board 267 **ABSTRACT 1046:** PLEASURABLE: Results and biomarkers analysis from the phase II study of dalcipiclib combined with pyrotinib and endocrine therapy (ET) in women with dual-receptor positive (ER+/HER2+) metastatic breast cancer (MBC). First Author: Jian Zhang, MD
- Board 268 **ABSTRACT 1047:** Real-world treatment patterns in patients with HER2+ unresectable or metastatic breast cancer: Interim results from HER2 REAL Asia cohort. First Author: Soo-Chin Lee, MD
- Board 269 **ABSTRACT 1048:** Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases: 3-year follow-up results from the phase 2 PERMEATE trial. First Author: Min Yan, MD
- Board 270 **ABSTRACT 1049:** Artificial intelligence-powered tumor-infiltrating lymphocytes analyzer to reveal distinct immune landscapes in breast cancer by molecular subtype and HER2 score. First Author: Seunghwan Shin, MD
- Board 271 **ABSTRACT 1050:** Secondary primary malignancy risk by ER, PR, and HER-2 status in post-menopausal women with breast cancer: A population-based analysis. First Author: Muhammad Hammad Khan
- Board 272 **ABSTRACT 1051:** Real-world patient characteristics and treatment patterns associated with tucatinib therapy in patients with HER2+ metastatic breast cancer. First Author: Carey K. Anders, MD, FASCO
- Board 273 **ABSTRACT 1052:** HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers. First Author: Joshua Z. Drago, MD
- Board 274 **ABSTRACT 1053:** Validation of a single-cell sequencing assay for the detection of circulating tumor cells in metastatic breast cancer. First Author: David Bourdon, PhD

- Board 275 **ABSTRACT 1054:** First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors. First Author: David Sommerhalder, MD
- Board 276 **ABSTRACT 1055:** Impact of race and age on intrinsic subtype distribution and treatment decisions in metastatic breast cancer: Preliminary analysis of HARMONY (LCCC1829). First Author: Joannie M. Ivory, MD, MSPH
- Board 277 **ABSTRACT 1056:** Comparative overall survival of patients in trials of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer. First Author: Coralea Kappel, MD
- Board 278 **ABSTRACT 1057:** Lasofoxifene (LAS) plus abemaciclib (Abema) for treating ESR1-mutated ER+/HER2- metastatic breast cancer (mBC) after progression on prior therapies: ELAINE 2 study update. First Author: Senthil Damodaran, MD, PhD
- Board 279 **ABSTRACT 1058:** Prognostic factors in hormone receptor positive oligometastatic breast cancer. First Author: Lacaze Jean Louis, MD
- Board 280 **ABSTRACT 1059:** Circulating tumor cells (CTCs) dynamics after CDK4/6i for hormone-receptor positive (HR+) metastatic breast cancer (MBC): A biomarker analysis of the PACE randomized phase II study. First Author: Lorenzo Gerratana, MD
- Board 281 **ABSTRACT 1060:** ctDNA mutational profiles in luminal breast cancer with early vs late distant relapse: Geicam/2014-03. First Author: Angel Guerrero, MD
- Board 282 **ABSTRACT 1061:** Interim analyses (IA) of the giredestrant (G), G + abemaciclib (A), and G + ribociclib (R) arms in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced/metastatic BC (ER+, HER2- LA/ mBC). First Author: Mafalda Oliveira, MD, PhD
- Board 283 **ABSTRACT 1062:** Endocrine therapy resistance (ETR) in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+, HER2- mBC): Prevalence, biomarker characteristics, and outcomes. First Author: Rinath Jeselsohn, MD
- Board 284 **ABSTRACT 1063:** Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician's choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2 advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial. First Author: Nagi S. El Saghir, MD, FASCO, FACP
- Board 285 **ABSTRACT 1064:** Efficacy and safety of tenalisib, a PI3K  $\delta/\gamma$  and SIK3 inhibitor, in patients with locally advanced or metastatic breast cancer: Updated results from an on-going phase II study. First Author: Tamta Makharadze, MD
- Board 286 **ABSTRACT 1065:** Efficacy analysis of CDK4/6 inhibitors (CDKi) + endocrine therapy (ET) treatment in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (aBC): Biomarker analysis including chemoendocrine score (CES) by CDKi type in SOLTI-1801\_CDK-PREDICT study. First Author: Pablo Tolosa Ortega, MD
- Board 287 **ABSTRACT 1066:** Clinical activity of camizestrant, a next-generation SERD, versus fulvestrant in patients with a detectable ESR1 mutation: Exploratory analysis of the SERENA-2 phase 2 trial. First Author: Mafalda Oliveira, MD, PhD
- Board 288 **ABSTRACT 1067:** Capivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2- advanced breast cancer (ABC): Characterization and management of common adverse events (AEs) from the phase 3 CAPitello-291 trial. First Author: Hope S. Rugo, FASCO
- Board 289 **ABSTRACT LBA1068:** Palbociclib (P) plus Tamoxifen (TAM)  $\pm$  goserelin in women with hormone receptor-positive (HR+)/HER2-negative (HER2) advanced breast cancer (ABC): Primary results of NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial. First Author: Takahiro Kogawa, MD, PhD
- Board 290 **ABSTRACT 1069:** Exploratory biomarker analysis of aceLERA breast cancer (BC): Phase II study of giredestrant vs. physician's choice of endocrine therapy (PCET) for previously treated, estrogen receptor-positive, HER2-negative advanced BC (ER+, HER2- aBC). First Author: Ann Collier, PhD
- Board 291 **ABSTRACT 1070:** Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis by prior duration of CDK4/6i plus endocrine therapy (ET). First Author: Virginia G. Kaklamani, MD
- Board 292 **ABSTRACT 1071:** Indirect treatment comparison of first-line CDK4/6-inhibitors in post-menopausal patients with HR+/HER2- metastatic breast cancer. First Author: Joseph J Zhao, MBBS
- Board 293 **ABSTRACT 1072:** A multicenter, single-arm, open-label trial of biroiciclib, a CDK4/6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer. First Author: Jiayu Wang, MD
- Board 294 **ABSTRACT 1073:** Clinical outcomes and correlation with longitudinal circulating tumor (ct)DNA dynamics of a phase I/II study of GSK525762 combined with fulvestrant in patients with hormone receptor-positive/HER2-negative (HR+/HER2) advanced or metastatic breast cancer. First Author: David W. Cescon, MD, PhD
- Board 295 **ABSTRACT 1074:** ESR1 mutational landscape and impact of co-existing resistance variants on clinical outcomes in patients with metastatic breast cancer. First Author: Arielle J Medford, MD
- Board 296 **ABSTRACT 1075:** Impact of pathogenic germline BRCA1/2 and PALB2 mutations and tumor aneuploidy in patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors. First Author: Jesús Fuentes Antrás, MD, MSc
- Board 297 **ABSTRACT 1076:** Comparing the prognostic and predictive utility of serum thymidine kinase 1 and CA 15-3 in patients with hormone receptor positive metastatic breast cancer starting first-line endocrine therapy in SWOG S0226. First Author: Erin Frances Cobain, MD
- Board 298 **ABSTRACT 1077:** Relation between circulating biomarkers at diagnosis of early luminal-like breast cancer and subsequent risk of distant metastases. First Author: Yentl Lambrechts
- Board 299 **ABSTRACT 1078:** Alpelisib + endocrine therapy in patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study. First Author: Stephen Chia, MD, FRCPC

- Board 300 **ABSTRACT 1079:** A phase I trial of palbociclib (palbo) and bosutinib (bos) with fulvestrant (fulv) in patients (pts) with hormone receptor–positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) refractory to an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i).  
First Author: Candace Bavette Mainor, MD
- Board 301 **ABSTRACT 1080:** Phase 1/2 dose expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with ER+ metastatic breast cancer.  
First Author: Ezra Rosen, MD
- Board 302 **ABSTRACT 1081:** Real-world (RW) outcomes of patients (pts) with advanced breast cancer (aBC) with and without resistance alterations (alts) detected in cell-free circulating tumor DNA (ctDNA) prior to CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) treatment.  
First Author: Seth Andrew Wander, MD, PhD
- Board 303 **ABSTRACT 1082:** Trop-2 mRNA expression and association with clinical outcomes with sacituzumab govitecan (SG) in patients with HR+/HER2- metastatic breast cancer (mBC): Biomarker results from the phase 3 TROPiCS-02 study.  
First Author: Aditya Bardia, MD, MPH, FASCO
- Board 304 **ABSTRACT 1083:** Discovery of CDK4/6 bifunctional degraders for ER+/HER2- breast cancer.  
First Author: Hannah Majeski, PhD
- Board 305 **ABSTRACT 1084:** Targeting squalene epoxidase in breast-to-brain metastasis: A new therapeutic target for brain extravasation and colonization using animal models.  
First Author: Pony Yu-Ling Lee, PhD
- Board 306 **ABSTRACT 1085:** Influence of chromatin remodeling molecule ARID1A on metastatic heterogeneity in triple negative breast cancer: Binding of YAP.  
First Author: Ye Wang
- Board 307 **ABSTRACT 1086:** The overall survival analysis of FUTURE-C-PLUS: Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for advanced, immunomodulatory triple-negative breast cancer—An open-label, single-arm, phase 2 trial.  
First Author: Li Chen, PhD
- Board 308 **ABSTRACT 1087:** Olaparib (O) + ceralasertib (C) in patients (pts) with metastatic triple-negative breast cancer (mTNBC): Translational analysis of the VIOL-ETTE trial.  
First Author: Natalia Lukashchuk, PhD
- Board 309 **ABSTRACT 1088:** ARID1A deficiency in triple-negative breast cancer induces adaptive immune resistance and sensitivity to immune checkpoint inhibitors.  
First Author: Margaret Chen
- Board 310 **ABSTRACT 1089:** The case for acceleration of prospective multi- stakeholder led community-based research in young Black women with triple negative breast cancer (TNBC).  
First Author: Jeanne Regnante, BS
- Board 311 **ABSTRACT 1090:** Sociodemographic and clinico-pathologic factors of triple negative breast cancer at an academic urban safety-net hospital.  
First Author: Judy Wang
- Board 312 **ABSTRACT 1091:** Phase Ib study of talimogene laherparepvec (T-VEC) in combination with chemotherapy (CT) or endocrine therapy (ET) in patients with metastatic, unresectable, or locoregionally recurrent HER2-negative breast cancer (BC).  
First Author: Laura Ann Huppert, MD
- Board 313 **ABSTRACT 1092:** Early efficacy evaluation of ORIN1001, a first in class IRE1 alpha inhibitor, in advanced solid tumors.  
First Author: Mothaffar F. Rimawi, MD
- Board 314 **ABSTRACT 1093:** Olaparib (O) in advanced triple negative breast cancer (aTNBC) patients (pts) with BRCA1/2 promoter methylation: GEICAM/2015-06 study (COMETA-Breast).  
First Author: Juan De La Haba, MD
- Board 315 **ABSTRACT 1094:** The impact of social determinants of health (SDOH) on use of germline genetic testing for triple-negative breast cancer (TNBC) in the community oncology setting.  
First Author: Robert Lawrence Reid, MD
- Board 316 **ABSTRACT 1095:** Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer.  
First Author: Nan Chen, MD, MS
- Board 317 **ABSTRACT 1096:** Efficacy of oral selective estrogen receptor degraders (SERD)s in the treatment of estrogen receptor positive (ER+), HER2-negative metastatic breast cancer (MBC): A stratified analysis of the ESR1 wild type (wt) and mutant (mt) subgroups.  
First Author: Joseph J Zhao, MBBS
- Board 318 **ABSTRACT 1097:** High dose alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Results from the randomized phase 3 OLIGO study.  
First Author: Annemiek Van Ommen-Nijhof, MD
- Board 319 **ABSTRACT 1098:** Prognostic value of tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer (BC): A focus on inflammatory BC.  
First Author: Eleonora Nicolò, MD
- Board 320 **ABSTRACT 1099:** Phase II study of trifluridine/tipiracil (FTD/TPI) in HER2-negative metastatic breast cancers with or without prior exposure to fluoropyrimidines.  
First Author: Joline Si Jing Lim, MBBS, MRCP
- Board 321 **ABSTRACT 1100:** Preliminary results from a first-in-human study of ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients with locally advanced/metastatic solid tumors.  
First Author: Fei Ma
- Board 322 **ABSTRACT 1101:** Actionability of comprehensive genomic profiling compared to the tissue-based and plasma-based assay in patients with metastatic breast cancer: A real-world study.  
First Author: Hiroshi Tada, MD, PhD
- Board 323 **ABSTRACT 1102:** Social determinants of health factors and palliative care services use among patients with metastatic breast cancer in Florida.  
First Author: Fantine Giap, MD
- Board 324 **ABSTRACT 1103:** Association between baseline radiological tumor burden and outcomes in patients with metastatic breast cancer treated with an immune checkpoint inhibitor.  
First Author: Lauren Claire Brown, MBChB
- Board 325 **ABSTRACT 1104:** Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis.  
First Author: Chiara Molinelli, MD

- Board 326 **ABSTRACT 1105:** Biomarker analysis of phase II pembrolizumab maintenance treatment after chemotherapy response in patients with HER2-negative inflammatory breast cancer and triple-negative breast cancer.  
First Author: Toshiaki Iwase, MD, PhD
- Board 327 **ABSTRACT 1106:** Association of pretreatment chest CT abnormalities with trastuzumab deruxtecan-associated pneumonitis.  
First Author: Rachel Occhiogrosso Abelman, MD
- Board 328 **ABSTRACT 1107:** Pilot study of a micro-organosphere drug screen platform to lead care in advanced breast cancer (MODEL-ABC).  
First Author: David Graham, PhD
- Board 329 **ABSTRACT 1108:** Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: A single center retrospective cohort study.  
First Author: Laura Ann Huppert, MD
- Board 330 **ABSTRACT 1109:** Distribution and outcomes of HER2-low and HER2-zero metastatic breast cancer in Black and younger women.  
First Author: Paola Zagami, MD
- Board 331 **ABSTRACT 1110:** Imbalance in treatment discontinuation without progression between experimental and control arms among randomized trials in advanced breast cancer.  
First Author: Faris Tamimi, MD
- Board 332a **ABSTRACT TPS1111:** Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/6 inhibition with addition of ipatasertib in metastatic ER+/HER2- breast cancer patients without circulating tumour (ct) DNA suppression (FAIM).  
First Author: Alicia Frances Clare Okines, MD, BSc, FRCP, MBChB
- Board 332b **ABSTRACT TPS1112:** Phase IIa study of  $\alpha$ DC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2<sup>+</sup> breast cancer.  
First Author: Shipra Gandhi, MD
- Board 333a **ABSTRACT TPS1113:** Phase I study of adoptive T cell therapy following HER2-pulsed dendritic cell vaccine and pepinemab/trastuzumab in patients with metastatic HER2-positive breast cancer (MBC).  
First Author: Hyo S. Han, MD
- Board 333b **ABSTRACT TPS1114:** A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors.  
First Author: Sara A. Hurvitz, MD, FACP
- Board 334a **ABSTRACT TPS1115:** HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer.  
First Author: Erika P. Hamilton, MD
- Board 334b **ABSTRACT TPS1116:** UCLA B-13: A phase 1b trial evaluating the safety of ribociclib, tucatinib, and trastuzumab in patients with metastatic, HER2+ breast cancer and a multicenter, randomized, open-label, phase 2 study of preoperative treatment with ribociclib, trastuzumab, tucatinib, with or without fulvestrant versus docetaxel, carboplatin, trastuzumab, and pertuzumab in HR+/HR-, HER2+ breast cancer.  
First Author: Nicholas Patrick McAndrew, MD, MSCE
- Board 335a **ABSTRACT TPS1117:** EPIK-B6: A phase 2, open-label, 2-part, multicenter study of alpelisib in combination with fulvestrant for men and postmenopausal women with PIK3CA mutation HR-positive, HER2-negative, advanced breast cancer, which progressed on/after aromatase inhibitor treatment in Japan.  
First Author: Hiroji Iwata, MD
- Board 335b **ABSTRACT TPS1118:** A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1).  
First Author: Sara A. Hurvitz, MD, FACP
- Board 336a **ABSTRACT TPS1119:** eVERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2- LA/mBC).  
First Author: Erica L. Mayer, MD, MPH, FASCO
- Board 336b **ABSTRACT TPS1120:** AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization.  
First Author: Nuhad K. Ibrahim, MD
- Board 337a **ABSTRACT TPS1121:** TACTIVE-U: Phase 1b/2 umbrella study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER+ advanced or metastatic breast cancer.  
First Author: Rachel M. Layman, MD
- Board 337b **ABSTRACT TPS1122:** VERITAC-2: A global, randomized phase 3 study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer.  
First Author: Mario Campone, MD, PhD
- Board 338a **ABSTRACT TPS1123:** INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2-) PIK3CA-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC).  
First Author: Dejan Juric, MD
- Board 338b **ABSTRACT TPS1124:** CAPTOR-BC: Comprehensive analysis of spatial, temporal and molecular biomarkers predicting response and resistance to first-line treatment with ribociclib + ET in HR+, HER2- advanced breast cancer.  
First Author: Peter A. Fasching, MD
- Board 339a **ABSTRACT TPS1125:** Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58.  
First Author: Tomás Pascual, MD
- Board 339b **ABSTRACT TPS1126:** Harnessing olaparib, palbociclib, and endocrine therapy: A phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA mutation-associated, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (HOPE).  
First Author: Alexandra Torres, BA

- Board 340a **ABSTRACT TPS1127:** A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor–positive (ER+)/HER2-negative (HER2-) breast cancer.  
First Author: Virginia F. Borges, MD, MMedSc
- Board 341a **ABSTRACT TPS1129:** The Amelia-1 study: A phase 1b/2 trial of evexomostat (SDX-7320) plus fulvestrant and alpelisib in patients with advanced breast cancer at risk for alpelisib-induced hyperglycemia.  
First Author: Peter Cornelius, PhD
- Board 341b **ABSTRACT TPS1130:** A phase 2 randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): ELEVATE-TNBC.  
First Author: Natalie Rainey, MD
- Board 342a **ABSTRACT TPS1131:** The ARETHA study: A phase 2 randomized control trial of eribulin with evexomostat (SDX-7320) or placebo for patients with metastatic triple-negative breast cancer (TNBC) and metabolic dysfunction.  
First Author: Sherry Shen, MD
- Board 342b **ABSTRACT TPS1132:** A randomized phase II clinical trial of talazoparib maintenance therapy in patients with triple-negative breast cancer who showed platinum-sensitivity on first- or second-line platinum-based chemotherapy: KCSG BR21-10.  
First Author: Joohyuk Sohn, MD, PhD
- Board 343a **ABSTRACT TPS1133:** Phase I/II study of stereotactic radiosurgery with concurrent olaparib followed by adjuvant durvalumab and physician’s choice systemic therapy in patients with breast cancer brain metastases.  
First Author: Colette Shen, MD, PhD
- Board 343b **ABSTRACT TPS1134:** Phase II study of a PARP inhibitor in somatic BRCA1/2 mutant metastatic breast cancer (MBC).  
First Author: Neelima Vidula, MD

---

**8:00 AM - 11:00 AM Poster Session**

**Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers**

Location: Hall A

Abstracts on Boards 139-150 will be discussed during the Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Poster Discussion Session. See the online program guide ([meetings.asco.org](https://meetings.asco.org)) for session details.

**Posters by Topic**

**Adjuvant Therapy:** Boards 149, 151-156

**Biologic Correlates:** Boards 157-162

**Mesothelioma:** Boards 163-164, 226a-228a

**Non-Small Cell Lung Cancer—Local-Regional Disease:** Boards 141, 147-148, 150, 165-201, 228b-231b

**Small Cell Lung Cancer:** Boards 139, 143, 145-146, 202-224, 232a-234a

**Thymic Malignancies:** Boards 225, 234b

- Board 139 **ABSTRACT 8512:** Final survival data from a randomized phase II trial comparing high-dose with standard-dose twice-daily (BID) thoracic radiotherapy (TRT) in limited stage small-cell lung cancer (LS SCLC).  
First Author: Bjørn Henning Grønberg, MD, PhD

- Board 141 **ABSTRACT 8514:** CRES<sup>3</sup>T: A single-arm confirmatory trial of S-1 plus cisplatin with concurrent radical-dose radiotherapy followed by surgery for superior sulcus tumor.  
First Author: Kazuya Takamochi, MD, PhD
- Board 143 **ABSTRACT 8516:** The prognostic value of patient reported outcomes (PROs) and clinical/demographic variables in the CASPIAN study.  
First Author: Apar Kishor Ganti, MD, FASCO
- Board 145 **ABSTRACT 8518:** Phase II study of durvalumab plus olaparib as maintenance therapy in extensive-stage small-cell lung cancer (TRIDENT): Preliminary efficacy and safety results.  
First Author: Yan Huang, MD
- Board 146 **ABSTRACT 8519:** Associations between patient-reported nutritional status, survival, and toxicity among patients with limited stage small-cell lung cancer (LS SCLC) in a randomized trial of high-dose, twice-daily (BID) thoracic radiotherapy (TRT).  
First Author: Evgenia Taranova, PhD
- Board 147 **ABSTRACT 8520:** Pembrolizumab vs placebo for early-stage non-small-cell lung cancer after resection and adjuvant therapy: Subgroup analysis of patients who received adjuvant chemotherapy in the phase 3 PEARLS/KEYNOTE-091 study.  
First Author: Kersti Oselin, MD, PhD
- Board 148 **ABSTRACT 8521:** Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial.  
First Author: Jonathan Spicer, MD, PhD, FRCPC
- Board 149 **ABSTRACT 8522:** IMPower010: Exploratory analysis of disease-free survival by KRAS status in patients with stage II-IIIa NSCLC treated with adjuvant atezolizumab vs best supportive care.  
First Author: Martin Reck, MD, PhD
- Board 150 **ABSTRACT 8523:** Response to neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in oncogene-driven resectable non-small cell lung cancer (NSCLC).  
First Author: Samuel Rosner, MD
- Board 151 **ABSTRACT 8524:** Predictive value of co-existing genetic alterations and tumor mutation burden for patients with completely resected non-small cell lung cancer harboring EGFR mutation: Biomarker analysis of phase III IMPACT study.  
First Author: Satoshi Ikeda, MD, PhD
- Board 152 **ABSTRACT 8525:** Safety and efficacy of QL1706 plus carboplatin/etoposide (EC) as first-line (1L) treatment for extensive-stage small-cell lung cancer (ES-SCLC): The results from a phase II single-arm study.  
First Author: Yun Fan, PhD
- Board 153 **ABSTRACT 8526:** Clinical and financial implications of ADUARA trial on a real-world population.  
First Author: Bharathi Muthusamy, MD
- Board 154 **ABSTRACT 8527:** A study of tumor neoantigen burden and HLA-LOH by whole-exome sequencing to characterize immune biomarkers of lung cancer.  
First Author: Wei Wang, PhD
- Board 155 **ABSTRACT 8528:** Dynamic ctDNA to inform the precise management of resected NSCLC: LUNGCA-2 study.  
First Author: Liang Xia
- Board 156 **ABSTRACT 8529:** Differential expression analysis of circRUNX1 in patients with early resected EGFR-mutant NSCLC.  
First Author: Carlos Pedraz, PhD

- Board 157 **ABSTRACT 8530:** Elucidating the genomic and transcriptomic landscape of L858R vs ex19del EGFR-mutated NSCLC.  
First Author: Stephanie Pei Li Saw, MRCP, MBBS
- Board 158 **ABSTRACT 8531:** Prevalence of EGFR mutations in patients with resected stage I-III non-squamous NSCLC: Results from the EARLY-EGFR study.  
First Author: Ross A. Soo, MD
- Board 159 **ABSTRACT 8532:** Examining ultrafine particle pollution and lung cancer risk in a large, diverse cohort.  
First Author: Arthur Bookstein, MPH
- Board 160 **ABSTRACT 8533:** Clinical validation of an activity-based enzyme assay for early stage lung cancer.  
First Author: Paul W. Dempsey, PhD
- Board 161 **ABSTRACT 8534:** Multi-genomic analysis of compound and uncommon EGFR mutations in patients with non-small cell lung cancer.  
First Author: Jayoung Park
- Board 162 **ABSTRACT 8535:** Validation of recurrence prediction using circulating tumor DNA in patients with curatively treated early stage non-small cell lung cancer.  
First Author: Milou Schuurbijs, MD
- Board 163 **ABSTRACT 8536:** Real-life efficacy of nivolumab plus ipilimumab combination in untreated, unresectable malignant pleural mesotheliomas: Result of French early access program—MESOIMMUNE – GFPC 04-2021.  
First Author: Olivier Bylicki, MD, MSc
- Board 164 **ABSTRACT 8537:** Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors.  
First Author: Raffit Hassan, MD
- Board 165 **ABSTRACT 8538:** Long-term outcomes of single and five fraction schedules of stereotactic body radiation therapy for early-stage central or peripheral NSCLC: Neither fractionation nor location matter?  
First Author: Karen Huang
- Board 166 **ABSTRACT 8539:** EGFR assessment using next generation sequencing as a reflex testing on surgically resected non-squamous non-small cell lung carcinoma.  
First Author: Samantha Goffinet, MD
- Board 167 **ABSTRACT 8540:** Stereotactic body radiation therapy with sequential immunotherapy as neoadjuvant therapy in resectable non-small cell lung cancer (SACTION-01 study).  
First Author: Zerui Zhao, MD, PhD
- Board 168 **ABSTRACT 8541:** The RESECT study: Factors associated with overall survival (OS) and relapse-free survival (RFS) among patients with stages I-III resected NSCLC without known EGFR mutations.  
First Author: Jhanelle Elaine Gray, MD
- Board 169 **ABSTRACT 8542:** Two-year lung cancer survival between 2000 to 2020: Results from 3 French nationwide cohorts.  
First Author: Didier Debieuvre, MD
- Board 170 **ABSTRACT 8543:** Association of nuclear shape in the tumor epithelium with response to atezolizumab in NSCLC.  
First Author: Patrick Leo, PhD
- Board 171 **ABSTRACT 8544:** Radiation therapy (RT)-free pembrolizumab plus chemotherapy (P+C) for PD-L1 TPS  $\geq 50\%$  locally advanced non-small cell lung cancer (LA-NSCLC): An early report analyzing depth of response from multicenter single arm phase II study (Evolution trial: WJOG11819L).  
First Author: Akito Hata, MD
- Board 172 **ABSTRACT 8545:** Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data.  
First Author: John Heymach, MD, PhD
- Board 173 **ABSTRACT 8546:** A systematic comparison of whole genome sequencing and targeted panel sequencing for precision oncology.  
First Author: Ji-Hyung Park, MD
- Board 174 **ABSTRACT 8547:** SAKK 16/18: Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC)—A multicenter phase II trial.  
First Author: Laetitia A Mauti, MD, PhD
- Board 175 **ABSTRACT 8548:** Sequential intravenous chemotherapy with drug-eluting bead bronchial arterial chemoembolization for the treatment of stages III and IV lung squamous cell carcinoma: A retrospective controlled clinical study.  
First Author: Jianfei Tu
- Board 176 **ABSTRACT 8549:** Prospective dynamic sampling and molecular residual disease monitoring to predict clinical outcomes for patients with unresectable, locally advanced non-small cell lung cancer undergoing radical radiotherapy.  
First Author: Jia-Tao Zhang
- Board 177 **ABSTRACT 8550:** Association of circulating CD103<sup>+</sup> T cells with major pathological response in a randomized phase 2 trial of neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small cell lung cancer.  
First Author: Zachary Walsh, BA
- Board 178 **ABSTRACT 8551:** Association of peripheral memory B cell population maintenance and long term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial).  
First Author: Belen Sierra-Rodero
- Board 179 **ABSTRACT 8552:** Phase II trial of consolidation pembrolizumab (pembro) after proton reirradiation (re-RT) for thoracic recurrences of non-small cell lung cancer (NSCLC).  
First Author: Nikhil Yegya-Raman, MD
- Board 180 **ABSTRACT 8553:** Genomic comparison of MET exon 14 skipping and MET amplified non-small cell lung cancer.  
First Author: Rachel Minne, BS
- Board 181 **ABSTRACT 8554:** Stereotactic ablative radiotherapy with nivolumab for early-stage operable non-small cell lung cancer: A phase 2 study.  
First Author: Gustavo Schwartzman, MD
- Board 182 **ABSTRACT 8555:** Assessing the efficacy and safety of DEB-BACE combined with intravenous chemotherapy for the treatment of intermediate to advanced lung adenocarcinoma after progression of targeted drug resistance.  
First Author: Lingqiang Lai

- Board 183 **ABSTRACT 8556:** Phase Ib study of neoadjuvant concurrent chemoradiation plus durvalumab followed by surgery and adjuvant durvalumab for resectable stage III NSCLC.  
First Author: Jiyun Lee, MD
- Board 184 **ABSTRACT 8557:** Development of a novel blood-based RNA gene expression platform for early-stage lung cancer diagnosis.  
First Author: Martin J Keiser III, BS
- Board 185 **ABSTRACT 8558:** Benefit of post-operative radiation therapy for incompletely resected stage I-IIIa non-small cell lung cancer: An analysis of the National Cancer Database.  
First Author: Sindu Iska, MD
- Board 186 **ABSTRACT 8559:** Large scale evaluation of pulmonary nodule workup: A real-world study of over 150,000 patients in New York State.  
First Author: Vamsidhar Velcheti, MD, FCCP, FACP
- Board 187 **ABSTRACT 8560:** Mortality benefit of a blood-based biomarker panel for lung cancer and the PLCO cohort.  
First Author: Johannes Fahrman, PhD
- Board 188 **ABSTRACT 8561:** Incidence, outcomes, and risk factors of acute immune checkpoint inhibitor (ICI) pneumonitis post-chemoradiation with durvalumab for patients with locally advanced non-small cell lung cancer (LA-NSCLC): A population-based multicenter study.  
First Author: Chloe Lim, MD
- Board 189 **ABSTRACT 8562:** Impact of SARS-COV2 infection on the clinical outcomes in patients with lung cancer compared to all other cancers.  
First Author: Vaishali Deenadayalan, MD
- Board 190 **ABSTRACT 8563:** Development and validation of a prediction model for the recurrence of stage 1 EGFR mutation positive NSCLC in patients using machine learning with WES-based gene sets.  
First Author: Akiko Tateishi, MD, PhD
- Board 191 **ABSTRACT 8564:** Phase II trial of safety and efficacy of tislelizumab plus chemotherapy in stage II-IV non small cell lung cancer (LungMark).  
First Author: Yaobin Lin
- Board 192 **ABSTRACT 8565:** Association of immune-related adverse events and efficacy outcomes in phase II trial of consolidation nivolumab plus ipilimumab or nivolumab alone after chemoradiation in patients with unresectable stage III non-small-cell lung cancer (NSCLC).  
First Author: Cynthia Wei, MD
- Board 194 **ABSTRACT 8567:** EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC).  
First Author: Amin Nassar, MD
- Board 195 **ABSTRACT 8568:** A combinatorial model of plasma proteins and LDCT imaging and the diagnosis of pulmonary nodules.  
First Author: Meng Yang
- Board 196 **ABSTRACT 8569:** Cancer risk assessment in patients with persistent pulmonary nodules and its correlation with cancer-free survival.  
First Author: Hui Li, MD, PhD
- Board 198 **ABSTRACT 8571:** Optimal number of lymph node stations associated with improved survival among non-small cell lung cancer (NSCLC) patients.  
First Author: Meredith Ray, PhD, MPH
- Board 199 **ABSTRACT 8572:** Reevaluating the role of adjuvant chemotherapy in early-stage, resectable NSCLC with high-risk clinical and pathologic features.  
First Author: Brendan Heiden, MD
- Board 200 **ABSTRACT 8573:** Acute hospitalizations after proton beam therapy (PBT) versus intensity-modulated radiotherapy (IMRT) for locally advanced non-small-cell lung cancer (LA-NSCLC) in the era of immune checkpoint inhibitor (ICI) consolidation: A retrospective propensity score weighted study.  
First Author: Michelle Iocolano, MD
- Board 201 **ABSTRACT 8574:** Association of single-click radiomic classifier with response and prognosis in non-small cell lung cancers (NSCLC) treated with immune checkpoint inhibitors.  
First Author: Amogh Hiremath
- Board 202 **ABSTRACT 8575:** A theranostic approach: Imaging and therapy of delta-like ligand 3-expressing small cell lung cancers.  
First Author: Salomon Tendler, MD
- Board 203 **ABSTRACT 8576:** Reconsidering the cutoff between sensitive and refractory relapses in extensive-stage small cell lung cancer in the era of immunotherapy.  
First Author: Masahiro Torasawa
- Board 204 **ABSTRACT 8577:** Analysis of tumor- and circulating-free DNA methylation to identify clinically relevant small cell lung cancer subtypes.  
First Author: Simon Heeke, PhD
- Board 205 **ABSTRACT 8578:** Pathological images machine learning and prediction of long-term efficacy for immunotherapy in small cell lung cancer.  
First Author: Yuki Sato
- Board 206 **ABSTRACT 8579:** Phase I/II combination study of tificemalimab with toripalimab in patients with refractory extensive stage small cell lung cancer (ES-SCLC).  
First Author: Ying Cheng, MD
- Board 207 **ABSTRACT 8580:** Updated safety and efficacy results of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) from a phase II trial.  
First Author: Dawei Chen, MD
- Board 208 **ABSTRACT 8581:** Characteristics and outcomes of patients with small cell lung cancer (SCLC) detected with CT screening at a single health system.  
First Author: Manasi Manoj Godbole, MD
- Board 209 **ABSTRACT 8582:** Tarlatamab in small cell lung cancer (SCLC): Safety and efficacy analyzed by baseline brain metastasis.  
First Author: Stephane Champiat, MD, PhD
- Board 210 **ABSTRACT 8583:** Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.  
First Author: Lionel Falchero, MD
- Board 211 **ABSTRACT 8584:** IFCT-2105 lurbinclin real-world effectiveness and treatment sequences in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) who received lurbinectedin as part of the French Early Access Program (EAP-ATU).  
First Author: Nicolas Girard, MD, PhD
- Board 212 **ABSTRACT 8585:** Phase Ib/IIa study assessing the safety and efficacy of AL8326 monotherapy in patients with ≥3rd line small cell lung cancer (SCLC) treatment.  
First Author: Xiaochun Zhang, MD, PhD



Sunday, June 4, 2023

- Board 213 **ABSTRACT 8586:** Tumor microenvironment-mediated immune profiles and efficacy of platinum doublet chemotherapy plus ICIs stratified by DLL3 expression in small cell lung cancer.  
First Author: Masayuki Shirasawa
- Board 214 **ABSTRACT 8587:** Efficacy and safety of high dose twice-daily thoracic radiotherapy versus standard dose for limited stage small-cell lung cancer: A multicentre, open-label randomised, phase 3 trial.  
First Author: Jiayi Yu, MD
- Board 215 **ABSTRACT 8588:** The effect of various social determinants of health on overall survival in the SCLC population.  
First Author: Matthew M Mirsky, MD
- Board 216 **ABSTRACT 8589:** Assessing inpatient outcomes for patients with small cell lung cancer presenting with superior vena cava thrombosis.  
First Author: Jay Vakil, DO
- Board 217 **ABSTRACT 8590:** A multicenter phase I/II trial of induction chemotherapy followed by camrelizumab, apatinib, plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer.  
First Author: Chengzhi Zhou
- Board 218 **ABSTRACT 8591:** Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC.  
First Author: Sophie Cousin, MD
- Board 219 **ABSTRACT 8592:** Dissecting small cell lung cancer subtypes with cell-free DNA fragmentomes.  
First Author: Lorenzo Rinaldi, PhD
- Board 220 **ABSTRACT 8593:** Phase 2 small cell lung cancer (SCLC) cohort of a phase 1b/2 trial of a liposomal formulation of eribulin in combination with nivolumab.  
First Author: Koichi Azuma, MD, PhD
- Board 221 **ABSTRACT 8594:** Spatially resolved multi-region transcriptomic subtyping and assessment of gene expression profiles associated with long-term benefit from chemo-immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).  
First Author: Melina Peressini
- Board 222 **ABSTRACT 8595:** Role of consolidative thoracic and prophylactic cranial radiation in extensive stage small cell lung cancer in chemo-immunotherapy era.  
First Author: Jai Kumar Khatri
- Board 223 **ABSTRACT 8596:** Brain metastasis burden and management in small cell lung cancer: An analysis of 8705 patients.  
First Author: Karolina Gaebe, BMath
- Board 224 **ABSTRACT 8597:** Molecular predictors and immunomodulatory role of dual checkpoint inhibitor blockade using ipilimumab/nivolumab in patients with extensive stage small cell lung cancer.  
First Author: Anne C. Chiang, MD, PhD, FASCO
- Board 225 **ABSTRACT 8598:** Utilization of circulating tumor DNA (ctDNA) analysis to detect minimal residual disease post-surgery and disease progression in metastatic thymic tumors.  
First Author: Fatemeh Ardeshir-Larijani, MD
- Board 226a **ABSTRACT TPS8599:** Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: A phase 3, randomised trial (DREAM3R).  
First Author: Patrick M. Forde, MD
- Board 226b **ABSTRACT TPS8600:** A randomised phase II trial of niraparib versus active symptom control in patients with previously treated mesothelioma: NERO.  
First Author: Gareth Owen Griffiths, PhD, BS
- Board 227a **ABSTRACT TPS8601:** Nivolumab with chemotherapy in pleural mesothelioma after surgery: The NICITA trial.  
First Author: Rajiv Shah, MD
- Board 227b **ABSTRACT TPS8602:** Neoadjuvant immunotherapy in sarcomatoid mesothelioma (Alliance A082101).  
First Author: Aaron Scott Mansfield, MD
- Board 228a **ABSTRACT TPS8603:** Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).  
First Author: Aaron Scott Mansfield, MD
- Board 228b **ABSTRACT TPS8604:** NeoCOAST-2: A phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC).  
First Author: Florian Guisier
- Board 229a **ABSTRACT TPS8605:** A phase I-III platform study evaluating the safety and efficacy of multiple therapies in patients with biomarker-defined locally advanced, unresectable stage III non-small-cell lung cancer (NSCLC).  
First Author: Luis G. Paz-Ares, PhD
- Board 229b **ABSTRACT TPS8606:** A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC.  
First Author: Yuming Zhu
- Board 230a **ABSTRACT TPS8607:** Phase 3 study of durvalumab with SBRT for unresected stage I/II, lymph-node negative NSCLC (PACIFIC-4/RTOG3515).  
First Author: Clifford Grant Robinson, MD
- Board 230b **ABSTRACT TPS8608:** A master screening study to determine biomarker status and trial eligibility for patients with malignant tumors.  
First Author: Benjamin J. Solomon, MBBS, PhD
- Board 231a **ABSTRACT TPS8609:** Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).  
First Author: Mustafa Özgüröğlu, MD
- Board 231b **ABSTRACT TPS8610:** Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage III NSCLC (PACIFIC-9).  
First Author: Fabrice Barlesi, MD, PhD
- Board 232a **ABSTRACT TPS8611:** Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304).  
First Author: Luis G. Paz-Ares, PhD
- Board 232b **ABSTRACT TPS8612:** A phase II study to evaluate the efficacy and safety of combination therapy of durvalumab (MEDI4736) and amrubicin in patients with recurrent small cell lung cancer (SCLC): Aphrodite trial, in progress.  
First Author: Yuka Kato, MD, PhD
- Board 233a **ABSTRACT TPS8613:** A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial).  
First Author: Benjamin Besse, MD, PhD

- Board 233b **ABSTRACT TPS8614:** Prophylactic cerebral irradiation or active brain magnetic resonance imaging surveillance in small-cell lung cancer patients (EORTC-1901: PRIMALung).  
First Author: Antonin Levy, MD, PhD
- Board 234a **ABSTRACT TPS8615:** Dares: A phase II trial of durvalumab and ablative radiation in extensive stage small cell lung cancer.  
First Author: Aditya Juloori, MD
- Board 234b **ABSTRACT TPS8616:** Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) for patients with pleural metastases from thymic malignancies.  
First Author: Andreas Rimner, MD

---

**8:00 AM - 11:00 AM Poster Session**

**Lung Cancer—Non-Small Cell Metastatic**

Location: Hall A

Abstracts on Boards 1-12 will be discussed during the Lung Cancer—Non-Small Cell Metastatic Poster Discussion Session. See the online program guide ([meetings.asco.org](https://meetings.asco.org)) for session details.

**Posters by Topic**

**Biologic Correlates:** Boards 1-2, 8, 10, 14-29, 127a

**Non-Small Cell Lung Cancer—Advanced/Metastatic Disease:**

Boards 3-7, 9, 11-12, 30-125, 127b-138b

- Board 1 **ABSTRACT 9025:** SI-B001 plus chemotherapy in patients with locally advanced or metastatic EGFR/ALK wild-type non-small cell lung cancer: A phase II, multicenter, open-label study.  
First Author: Yuangyuan Zhao, MD
- Board 2 **ABSTRACT 9014:** Safety and preliminary efficacy of YK-029A, a novel EGFR TKI, in patients with advanced NSCLC harboring ex20ins, T790M or rare mutations.  
First Author: Jianchun Duan, MD
- Board 3 **ABSTRACT 9015:** FAK inhibition with novel FAK/ALK inhibitor APG-2449 could overcome resistance in NSCLC patients who are resistant to second-generation ALK inhibitors.  
First Author: Yuxiang Ma, MD
- Board 4 **ABSTRACT LBA9016:** Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT).  
First Author: Anne-Marie C. Dingemans, MD, PhD
- Board 5 **ABSTRACT 9017:** Intracranial and systemic efficacy of repotrectinib in advanced ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1.  
First Author: Jessica Jiyeong Lin, MD
- Board 6 **ABSTRACT 9018:** Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAF<sup>V600E</sup>) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.  
First Author: Gregory J. Riely, MD, PhD, FASCO
- Board 7 **ABSTRACT 9019:** LIBELULE: A randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer.  
First Author: Aurélie Swalduz, MD

- Board 8 **ABSTRACT 9020:** Large-scale transcriptomic profiling of the tumor immune microenvironment in ALK+ lung cancer.  
First Author: Vincent K. Lam, MD
- Board 9 **ABSTRACT 9021:** Tepotinib + osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (ME-Tamp) after first-line (1L) osimertinib.  
First Author: Daniel Shao-Weng Tan, PhD, MBBS, BSc
- Board 10 **ABSTRACT 9022:** Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo).  
First Author: Natalie I Vokes, MD, MPhil
- Board 11 **ABSTRACT LBA9023:** First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS).  
First Author: David Paul Carbone, MD, PhD, FASCO
- Board 12 **ABSTRACT 9024:** Safety and clinical activity of target-preserving anti-CTLA-4 antibody ONC-392 as monotherapy in NSCLC patients who progressed on PD(L)1-targeted immunotherapy.  
First Author: Kai He, MD, PhD
- Board 14 **ABSTRACT 9026:** Large-scale comparative analysis of clinico-genomic characteristics, treatment outcomes and resistant mechanisms of ALK/ROS1/RET-rearranged non-small cell lung cancer (NSCLC) in a nationwide genomic screening project (LC-SCRUM-Asia/TRY).  
First Author: Yosuke Kagawa
- Board 15 **ABSTRACT 9027:** The genomic, transcriptomic, and immunological landscape of SGLT2 in lung cancer.  
First Author: Heng Tan, MD, PhD
- Board 16 **ABSTRACT 9028:** Peripheral myeloid cells as prognostic markers in patients (pts) with non-small cell lung cancer (NSCLC) treated with cemiplimab: Pooled analysis of EMPOWER-Lung 1 and EMPOWER-Lung 3 phase 3 trials.  
First Author: Joseph Christopher Murray, MD, PhD
- Board 17 **ABSTRACT 9029:** Impact of EML4-ALK fusion variant and co-occurring TP53 mutation on treatment duration of first-line next-generation ALK TKIs in ALK fusion+ NSCLC.  
First Author: Kaushal Parikh, MD
- Board 18 **ABSTRACT 9030:** Real-world testing and treatment patterns among patients with stage IV non-small cell lung cancer: A retrospective observational study.  
First Author: Jeffrey A. Scott, MD
- Board 19 **ABSTRACT 9031:** MSH3 and MSH6 gene polymorphisms: Association with lung cancer susceptibility and prognostic value in patients with NSCLC undergoing platinum-based chemotherapy.  
First Author: Navneet Singh, MD, FRCP, DM, FASCO
- Board 20 **ABSTRACT 9032:** Impact of genomic alterations measured in circulating tumor DNA (ctDNA) on clinical response to telisotuzumab vedotin treatment in patients with non-small cell lung cancer (NSCLC).  
First Author: D. Ross Camidge, MD, PhD

- Board 21 **ABSTRACT 9033:** Analytical and clinical validation of Oncomine Dx Target (ODxT) test and local testing for identifying patients with HER2 (ERBB2)-mutant (HER2m) non-small-cell lung cancer (NSCLC) for treatment with trastuzumab deruxtecan (T-DXd) in DESTINY-Lung01/02 (DL-01/02).  
First Author: Bob T. Li, MD, PhD, MPH
- Board 22 **ABSTRACT 9034:** Molecular characterization of resistance to immune checkpoint inhibitor and chemotherapy treatment in advanced non-small cell lung cancer.  
First Author: Jordan Kardos, PhD
- Board 23 **ABSTRACT 9035:** The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP.  
First Author: Philip C. Mack, PhD
- Board 24 **ABSTRACT 9036:** Efficacy and safety of polymeric micelle paclitaxel (PM - Pac) plus tislelizumab and carboplatin for first-line treatment of patients with advanced squamous non-small-cell lung cancer.  
First Author: Meiqi Shi
- Board 25 **ABSTRACT 9037:** Exploring the potential of combination immune checkpoint strategies in non-small cell lung cancer (NSCLC).  
First Author: Aakash Desai, MD, MPH
- Board 26 **ABSTRACT 9038:** Co-mutational status and PD-L1 expression in KRAS mutant non-small cell lung cancer (NSCLC): Role in treatment selection and association with clinical outcomes.  
First Author: Hina Khan, MD
- Board 27 **ABSTRACT 9039:** Effects of mutations in SWI/SNF subunits on context-specific prognosis in driver positive and driver negative NSCLC.  
First Author: Benjamin Herzberg, MD
- Board 28 **ABSTRACT 9040:** TROP2 expression and response to immune checkpoint inhibition in patients with advanced non-small cell lung cancer.  
First Author: Antoine Italiano, MD
- Board 29 **ABSTRACT 9041:** Pre-treatment plasma-informed circulating tumor DNA detection as an early identification of therapeutic benefit for patients with untreated advanced lung squamous cell carcinoma.  
First Author: Tao Jiang, MD, PhD
- Board 30 **ABSTRACT 9042:** Treatment at twilight: Is less more in the management of octogenarians with non-small cell lung cancer (NSCLC)?  
First Author: Ethan Burns, MD
- Board 31 **ABSTRACT 9043:** Factors impacting outcomes in individuals  $\geq 80$  years with non-small cell lung cancer (NSCLC): A National Cancer Database (NCDB) analysis.  
First Author: Ethan Burns, MD
- Board 32 **ABSTRACT 9044:** A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation positive non-squamous, advanced non-small-cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B.  
First Author: Tatsuro Fukuhara, MD, PhD
- Board 33 **ABSTRACT 9045:** Uncommon *EGFR* mutations conducted with osimertinib in patients with NSCLC (UNICORN): A phase 2 study.  
First Author: Yusuke Okuma, MD, PhD
- Board 34 **ABSTRACT 9046:** Role of immunotherapy in stage IV non-small cell lung cancer with liver metastasis: A NCDB analysis.  
First Author: Takefumi Komiya, MD, PhD
- Board 35 **ABSTRACT 9047:** Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) non-small cell lung cancer (NSCLC).  
First Author: Byoung Chul Cho, MD, PhD
- Board 36 **ABSTRACT 9048:** Initial chemotherapy for locally advanced and metastatic NUT carcinoma: A report from the NUT Carcinoma Registry.  
First Author: Jia Luo, MD
- Board 37 **ABSTRACT 9049:** Thoracic SMARCA4-deficient cancer descriptors and clinicopathologic determinants of survival: Analysis of a pooled database.  
First Author: Frankie Lee Powell
- Board 38 **ABSTRACT 9050:** Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced/metastatic non-small-cell lung cancer (NSCLC): First report of ARTEMIDE-01.  
First Author: Kristoffer Staal Rohrberg, MD, PhD
- Board 39 **ABSTRACT 9051:** Clinical outcomes among patients with advanced non-small cell lung cancer who received targeted therapy in a real-world setting.  
First Author: Mo Yang, PhD
- Board 40 **ABSTRACT 9052:** Prognostic and predictive implications of plasma ctDNA in guiding first-line targeted therapy for metastatic HER2-mutant non-small cell lung cancer (NSCLC).  
First Author: Si-Yang Liu, MD
- Board 41 **ABSTRACT 9053:** Safety and efficacy of immune checkpoint inhibitors in cancer patients and pre-existing autoimmune disease: A systematic review and meta-analysis in non-small cell lung cancer.  
First Author: Wint Yan Aung, MD, MS
- Board 42 **ABSTRACT 9054:** Phase II trial of lazertinib in epidermal growth factor receptor (EGFR) mutation-positive (M+), metastatic non-small cell lung cancer (NSCLC) patients with asymptomatic or mild symptomatic brain metastases after failure of EGFR tyrosine kinase inhibitor (TKI) (KCSG LU20-15).  
First Author: Min Hee Hong, MD
- Board 43 **ABSTRACT 9055:** Assessment of sociodemographic disparities in outcomes among pts with metastatic NSCLC (mNSCLC) receiving select immuno-oncology (IO) regimens: CORRELATE.  
First Author: Stephen V. Liu, MD
- Board 44 **ABSTRACT 9056:** Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer.  
First Author: Jessica Jiyeong Lin, MD
- Board 45 **ABSTRACT 9057:** The safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: Preclinical mouse model and phase I/IIa clinical study.  
First Author: Myeong Geun Choi
- Board 46 **ABSTRACT 9058:** Impact of first-line immunotherapy on survival and intracranial outcomes from a real-world cohort of non-small cell lung cancer patients with brain metastases at diagnosis.  
First Author: Benoît Nigen, MD
- Board 47 **ABSTRACT 9059:** Phase 2 clinical trial of the proautophagic drug ABTL0812 combined with paclitaxel and carboplatin in first-line patients with advanced squamous non-small cell lung carcinoma.  
First Author: Joaquim Bosch-Barrera, MD, PhD

- Board 48 **ABSTRACT 9060:** Long-term outcomes of tepotinib in patients with MET exon 14 skipping NSCLC from the VISION study.  
First Author: Paul K. Paik, MD
- Board 49 **ABSTRACT 9061:** Long-term follow-up of “adjuvant” pembrolizumab following locally ablative therapy for oligometastatic non-small cell lung cancer.  
First Author: David John Cantor, MD, PhD
- Board 50 **ABSTRACT 9062:** Mechanisms of resistance to tyrosine kinase inhibitor treatments in patients with ROS1 fusion-positive non-small cell lung cancer.  
First Author: Jialei Wang
- Board 51 **ABSTRACT 9063:** Management of patients with ALK-positive advanced non-small cell lung cancer who received brain radiotherapy on study in the phase 3 CROWN trial.  
First Author: Todd Michael Bauer, MD
- Board 52 **ABSTRACT 9064:** Emerging phase 1 data of BLU-451 in advanced NSCLC with EGFR exon 20 insertions.  
First Author: Danny Nguyen, MD
- Board 53 **ABSTRACT 9065:** First results from the RETgistry: A global consortium for the study of resistance to RET inhibition in RET-altered solid tumors.  
First Author: Alissa Jamie Cooper, MD
- Board 54 **ABSTRACT 9066:** Efficacy and safety of PD-1/PD-L1 inhibitor plus platinum-based chemotherapy vs. platinum-based chemotherapy alone in patients with previously untreated advanced large-cell neuroendocrine cancer of the lung.  
First Author: Fengchun Mu
- Board 55 **ABSTRACT 9067:** Sex differences in prognostic utility of peripheral eosinophil count in first-line immune checkpoint therapy against metastatic NSCLC.  
First Author: Hyunwoo Kwon, MD, PhD
- Board 56 **ABSTRACT 9068:** Nivolumab (Nivo) plus ipilimumab (Ipi) 6-month treatment versus continuation in patients with advanced non-small-cell-lung cancer (aNSCLC): 3-year results of the IFCT-1701 DICIPLE phase 3 trial.  
First Author: Gerard Zalcman, MD, PhD
- Board 57 **ABSTRACT 9069:** Spectrum of acquired KRAS mutations in driver mutation-positive non-small cell lung cancer.  
First Author: Joshua E. Reuss, MD
- Board 58 **ABSTRACT 9070:** Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series.  
First Author: Xiuning Le, MD, PhD
- Board 59 **ABSTRACT 9071:** Sexual dysfunction in women with lung cancer: Updates from the SHAWL study.  
First Author: Narjust Florez, MD
- Board 60 **ABSTRACT 9072:** Outcomes of patients with advanced EGFR mutant lung cancer treated with first line (1L) osimertinib (osi) who would not have met eligibility criteria for the FLAURA trial.  
First Author: Connor Wells, MD
- Board 61 **ABSTRACT 9073:** Efficacy and safety of sunvozertinib in treatment naive NSCLC patients with EGFR exon20 insertion mutations.  
First Author: Yan Xu, MD, PhD
- Board 62 **ABSTRACT 9074:** Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib.  
First Author: Helena Alexandra Yu, MD
- Board 63 **ABSTRACT 9075:** Circulating tumor DNA (ctDNA) monitoring to inform maintenance outcomes in patients (pts) with advanced NSCLC treated with induction atezolizumab+carboplatin+nab-paclitaxel (A+CnP).  
First Author: Bruna Pellini, MD
- Board 64 **ABSTRACT 9076:** Utility of ctDNA tumor fraction to inform negative liquid biopsy (LBx) results and need for tissue reflex in advanced non-small cell lung cancer (aNSCLC).  
First Author: Christian Diego Rolfo, MD, PhD, MBA
- Board 65 **ABSTRACT 9077:** Treatment patterns and unmet need for patients with advanced non-small cell lung cancer and poor performance status: A real-world evidence study.  
First Author: Stephen V. Liu, MD
- Board 66 **ABSTRACT 9078:** Integrated efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC in the ALTA-1L and J-ALTA studies.  
First Author: D. Ross Camidge, MD, PhD
- Board 67 **ABSTRACT 9079:** A biomarker study of atezolizumab (atezo) + bevacizumab (bev) + carboplatin (carbo) + paclitaxel (pac) (ABCP) for patients with NSCLC harboring EGFR mutations (EGFRm) after failure of TKI therapy: NEJ043.  
First Author: Satoshi Watanabe, MD, PhD
- Board 68 **ABSTRACT 9080:** Tislelizumab plus chemotherapy in patients with advanced brain metastases of non-squamous non-small cell lung cancer: A multicenter, prospective, open-label phase 2 study.  
First Author: Yan Huang, MD
- Board 69 **ABSTRACT 9081:** Patient-reported outcomes of furonertinib versus gefitinib in patients with locally advanced or metastatic, EGFR mutation-positive non-small cell lung cancer (FURLONG): A multicenter, double-blind, randomized phase 3 study.  
First Author: Yuankai Shi, MD
- Board 70 **ABSTRACT 9082:** Mobocertinib efficacy in patients with NSCLC and EGFR exon 20 insertion mutations (ex20ins) identified by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA).  
First Author: Joel W. Neal, MD, PhD
- Board 71 **ABSTRACT 9083:** Clinical and genomic predictors of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer.  
First Author: Kathryn C. Arbour, MD
- Board 72 **ABSTRACT 9084:** Survival associations and driver oncogene overlap for copy-number amplifications of ERBB2, KRAS and MET in non-small cell lung cancer.  
First Author: Alexander Watson, MD, DPhil
- Board 73 **ABSTRACT 9085:** Impact on turnaround times (TAT) among non-squamous non-small cell lung cancer (NSCLC) patients across three time periods with varying biomarker testing techniques.  
First Author: Zhen (Jason) Fan, MD
- Board 74 **ABSTRACT 9086:** Immune checkpoint inhibitors use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B.  
First Author: Joohyun Hong
- Board 75 **ABSTRACT 9087:** Phase II results of ivonescimab (AK112/ SMT112), a novel PD-1/VEGF bispecific, in combination with chemotherapy for first line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) in EGFR/ALK.  
First Author: Li Zhang, MD

- Board 76 **ABSTRACT 9088:** First line (1L) durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2): Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.  
First Author: Michael Thomas Mark, MD
- Board 77 **ABSTRACT 9089:** Safety, efficacy and biomarker data in non-small cell lung cancer patients treated with the anti-IL1RAP antibody nadunolimab in combination with platinum doublet.  
First Author: Luis G. Paz-Ares, PhD
- Board 78 **ABSTRACT 9090:** The impact of PD-L1 expression and co-mutations on outcome of KRAS-driven non-small-cell lung cancer.  
First Author: Petros Christopoulos, MD, PhD
- Board 79 **ABSTRACT 9091:** RET testing and treatment patterns among aNSCLC patients in US clinical practice.  
First Author: Eunice Kim, RPh, MS
- Board 80 **ABSTRACT 9092:** Explore ALK: Alectinib activity in patients with ALK+ metastatic non-small cell lung cancer—A national real world analysis (GFPC 03-2019).  
First Author: Aurélie Swalduz, MD
- Board 81 **ABSTRACT 9093:** A phase I trial of sequential dosing of sonidegib and pembrolizumab in advanced solid tumors (aST) and non-small-cell lung cancer (NSCLC).  
First Author: Mohamed Shanshal, MD
- Board 82 **ABSTRACT 9094:** Characterization of diverse targetable alterations in ERBB2 and ERBB3 in 93,465 non-small cell lung cancers (NSCLC).  
First Author: Dazhi Liu, PharmD
- Board 83 **ABSTRACT 9095:** Updated molecular analysis of MET exon 14 skipping mutations (METex14) in non-small cell lung cancer (NSCLC).  
First Author: Jennifer Aline Marks, MD
- Board 84 **ABSTRACT 9096:** Long-term outcome for patients with advanced non-small-cell lung cancer treated by autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy: NSCLC-CCICC-002.  
First Author: Liang Liu
- Board 85 **ABSTRACT 9097:** A nation-wide genomic screening project for further development of targeted therapies in treatment-refractory non-small-cell lung cancer (LC-SCRUM-TRY).  
First Author: Hiroki Izumi, MD, PhD
- Board 86 **ABSTRACT 9098:** Retrospective clinical analysis of circulating tumor DNA (ctDNA)-based molecular response (MR) and baseline blood-based tumor mutational burden (bTMB) for monitoring response in phase 3 trial of bintrafusp alfa vs. pembrolizumab treatment of non-small cell lung cancer (NSCLC).  
First Author: Zheng Feng, DrPH, PhD
- Board 87 **ABSTRACT 9099:** Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.  
First Author: Martin Reck, MD, PhD
- Board 88 **ABSTRACT 9100:** RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non-small cell lung cancer (NSCLC).  
First Author: Joshua E. Reuss, MD
- Board 89 **ABSTRACT 9101:** Association between duration of immunotherapy and overall survival in advanced non-small-cell lung cancer.  
First Author: Lova Sun, MD
- Board 90 **ABSTRACT 9102:** The final analysis of a phase I/II study of nivolumab, ipilimumab combined with nintedanib in advanced non-small cell lung cancer.  
First Author: Sonam Puri, MD
- Board 91 **ABSTRACT 9103:** Anti-tumor activity of sunvozertinib in NSCLC with EGFR sensitizing mutations after failure of EGFR TKI treatment.  
First Author: James Chih-Hsin Yang, MD, PhD
- Board 92 **ABSTRACT 9104:** Association of alterations in multiple tumor suppressor genes with poor outcomes in patients with EGFR-mutant lung cancer.  
First Author: Paul Stockhammer, MD, PhD
- Board 93 **ABSTRACT 9105:** Safety and efficacy of inetetamab in combination with pyrotinib in HER2 mutant patients with non-small cell lung cancer (NSCLC): An open-label, phase Ib trial.  
First Author: Wenfeng Fang, MD, PhD
- Board 94 **ABSTRACT 9106:** Dacomitinib for patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations: Do mutation patterns matter?  
First Author: Hong-Shuai Li
- Board 95 **ABSTRACT 9107:** Clinical and molecular features of long-term response to anti-PD-(L)1 therapy in patients with advanced non-small cell lung cancer.  
First Author: Rohit Thummalapalli, MD
- Board 96 **ABSTRACT 9108:** Tissue and plasma-based mechanisms of resistance to first-line osimertinib in EGFR-mutant NSCLC: A multi-institutional cohort.  
First Author: Zofia Piotrowska, MD
- Board 97 **ABSTRACT 9109:** Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study.  
First Author: Makenzi Colleen Evangelist, MD
- Board 98 **ABSTRACT 9110:** Efficacy and safety of SY-3505, a third-generation ALK TKI, in ALK-positive advanced non-small cell lung cancer: Results from a phase I/II, multi-center study.  
First Author: Yuankai Shi, MD
- Board 99 **ABSTRACT 9111:** A first-in-human phase I, dose-escalation and dose-expansion study of SY-5007, a highly potent and selective RET inhibitor, in Chinese patients with advanced RET positive solid tumors.  
First Author: Caicun Zhou, PhD, ABFT
- Board 100 **ABSTRACT 9112:** Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of GEC255, a novel KRAS<sup>G12C</sup> inhibitor, in advanced solid tumors.  
First Author: Yan Zhang, MD
- Board 101 **ABSTRACT 9113:** First-in-human, multicenter phase I study of TGRX-326 in patients with advanced ALK-positive non-small cell lung cancer.  
First Author: Hongyun Zhao, PhD
- Board 102 **ABSTRACT 9114:** SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: Efficacy and safety data from a phase 2 study.  
First Author: Wenfeng Fang, MD, PhD
- Board 103 **ABSTRACT 9115:** Implementation strategies for monitoring adherence in real time (iSMART): A pilot randomized trial.  
First Author: Katharine A. Rendle, PhD, MSW, MPH
- Board 104 **ABSTRACT 9116:** Characteristics of long-term survivors with EGFR mutant (EGFRm) metastatic non-small cell lung cancer (mNSCLC).  
First Author: Melina Elpi Marmarelis, MD

- Board 105 **ABSTRACT 9117:** Association between real-world, upfront, next-generation sequencing and overall survival (OS) in advanced non-small-cell lung cancer (aNSCLC) in the United States.  
First Author: Benjamin Philip Levy, FASCO
- Board 106 **ABSTRACT 9118:** Clinical, pathologic, and genomic hallmarks of KRAS-amplified non-small cell lung cancer.  
First Author: Biagio Ricciuti, MD
- Board 107 **ABSTRACT 9119:** FDA analysis of toxicity profiles of oral TKIs recently approved for non-small cell lung cancer based on receipt of prior immune checkpoint inhibitor therapy.  
First Author: Yufan Liu, PharmD
- Board 108 **ABSTRACT 9120:** Stimulator of interferon gene (STING) expression as a biomarker for overall survival in PDL1-negative, TMB-low non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs).  
First Author: Matthew James Hadfield
- Board 109 **ABSTRACT 9121:** Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition.  
First Author: Scott N. Gettinger, MD
- Board 110 **ABSTRACT 9122:** A decision-making tool for first-line treatment in advanced non-small-cell lung cancer based on plasma proteome biomarkers.  
First Author: Itamar Sela, PhD
- Board 111 **ABSTRACT 9123:** Amplification of wild-type RET and clinical response to selpercatinib for non-small-cell lung cancer (NSCLC).  
First Author: Malini Marion Gandhi, BS
- Board 112 **ABSTRACT 9124:** Multi-center real-world data curation and assessment of tumor growth rate and overall survival in advanced NSCLC treated with PD-(L)1 immune checkpoint inhibitor therapy.  
First Author: Chiharu Sako, PhD
- Board 113 **ABSTRACT 9125:** Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results.  
First Author: Andreas Nicholas Saltos, MD
- Board 114 **ABSTRACT 9126:** Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study—Updated safety and identification of the recommended phase 2 dose.  
First Author: Anna Rachel Minchom, MD, BCh, MB, MRCP
- Board 115 **ABSTRACT 9127:** Changes in PD-L1 and tumor mutational burden between paired samples and relationship to immune checkpoint inhibitor outcomes in non-small cell lung cancer.  
First Author: Alessandro Di Federico
- Board 116 **ABSTRACT 9128:** Results from a first-in-human phase 1B study of a complement factor H inhibitor (GT103) in patients with non-small cell lung cancer (NSCLC).  
First Author: Jeffrey Melson Clarke, MD
- Board 117 **ABSTRACT 9129:** Clinical and genomic landscape of EGFR-mutant lung cancers (LCs) with squamous and adenosquamous differentiation.  
First Author: Arielle Elkrief, MD
- Board 118 **ABSTRACT 9130:** Evaluating generalizability of practice-changing randomized clinical trials in non-small cell lung cancer using machine learning-based in-silico trials.  
First Author: Xavier Orcutt, MD
- Board 119 **ABSTRACT 9131:** A phase 2a study evaluating the efficacy and safety of sutedinib in patients with advanced non-small-cell lung cancer (NSCLC) harboring uncommon EGFR mutations.  
First Author: Fengying Wu, MD
- Board 120 **ABSTRACT 9132:** Artificial intelligence algorithm developed to predict immune checkpoint inhibitors efficacy in non-small-cell lung cancer.  
First Author: Mehrdad Rakaee, PhD
- Board 121 **ABSTRACT 9133:** Investigating racial inequities of circulating tumor DNA (ctDNA) use in patients with non-small cell lung cancer: A real world analysis.  
First Author: Angelica D'Aiello, MD
- Board 122 **ABSTRACT 9134:** Amivantamab and lazertinib in treatment-naive EGFR-mutated advanced non-small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS.  
First Author: Se-Hoon Lee, PhD
- Board 123 **ABSTRACT 9135:** Final results from a phase II trial of CIMAvax-EGF and nivolumab as second-line (2L) therapy after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).  
First Author: Rachel Frascati, PhD
- Board 124 **ABSTRACT 9136:** Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status.  
First Author: Charu Aggarwal, MD
- Board 125 **ABSTRACT 9137:** Risk factors for venous thromboembolism (VTE) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib versus either agent alone.  
First Author: Nicolas Girard, MD, PhD
- Board 127a **ABSTRACT TPS9139:** A phase III, multicenter, double-blinded, randomized, active-controlled study on the efficacy and safety of QL1706 with chemotherapy (CT) as first-line therapy for PD-L1-negative advanced or metastatic non-small-cell lung cancer (NSCLC).  
First Author: Li Zhang, MD
- Board 127b **ABSTRACT TPS9140:** A phase 1a/1b study of aurora kinase A inhibitor VIC-1911 as monotherapy and in combination with sotorasib for the treatment of KRAS G12C-mutant non-small-cell lung cancer.  
First Author: Sarah B. Goldberg, MD
- Board 128a **ABSTRACT TPS9141:** STAR-121: A phase 3, randomized study of domvanalimab (DOM) and zimberelimab (ZIM) in combination with chemotherapy vs pembrolizumab (pembro) and chemotherapy in patients with untreated metastatic non-small cell lung cancer (mNSCLC) with no actionable gene alterations.  
First Author: Delvys Rodriguez-Abreu, MD, PhD
- Board 128b **ABSTRACT TPS9142:** A phase 2 multi-arm study of magrolimab in combination with docetaxel in patients with locally advanced or metastatic solid tumors: ELEVATE Lung and UC.  
First Author: Vivek Subbiah, MD
- Board 129a **ABSTRACT TPS9143:** ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC).  
First Author: Sukhmani Kaur Padma, MD

- Board 129b **ABSTRACT TPS9144:** KontRAsT-02: A phase III trial investigating the efficacy and safety of the KRAS<sup>G12C</sup> inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C-mutated NSCLC.  
First Author: Federico Cappuzzo, MD
- Board 130a **ABSTRACT TPS9145:** REFINE-Lung: A multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design.  
First Author: Michael Seckl, MD, PhD, FCRP, FMedSci
- Board 130b **ABSTRACT TPS9146:** PRESERVE-003: Phase 3, two-stage, randomized study of ONC-392 versus docetaxel in metastatic non-small cell lung cancers that progressed on PD-1/PD-L1 inhibitors.  
First Author: Mark A. Socinski, MD
- Board 131a **ABSTRACT TPS9147:** Phase 1 multicenter dose escalation and dose expansion study of antibody-drug conjugate (ADC) MYTX-011 in subjects with non-small cell lung cancer.  
First Author: Alexander I. Spira, MD, PhD, FACP
- Board 131b **ABSTRACT TPS9148:** ARC-10: A phase 3 study to evaluate zimberelimab + domvanalimab versus pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic non-small-cell lung cancer.  
First Author: Christos Chouaid, MD, PhD
- Board 132a **ABSTRACT TPS9149:** Phase 2 study of telisotuzumab vedotin (Teliso-V) monotherapy in patients with previously untreated MET-amplified locally advanced/metastatic non-squamous non-small cell lung cancer (NSQ NSCLC).  
First Author: Hidehito Horinouchi, MD, PhD
- Board 132b **ABSTRACT TPS9150:** Circulating tumor DNA to guide furmonertinib monotherapy or combination therapy in advanced EGFR mutant non-small cell lung cancer (NSCLC): A randomized, open-label, multicenter study (FOCUS-C).  
First Author: Wenfeng Fang, MD, PhD
- Board 133a **ABSTRACT TPS9151:** LUNG-IST-127: A pilot phase II study of maintenance cabozantinib plus pembrolizumab for patients with metastatic squamous non-small cell lung cancer (sqNSCLC) with disease control following induction therapy.  
First Author: Ryan Huu-Tuan Nguyen, DO
- Board 133b **ABSTRACT TPS9152:** A phase II multi-cohort single-arm study of tiragolumab with atezolizumab plus bevacizumab in previously treated advanced non-squamous non-small-cell lung cancer.  
First Author: Joshua E. Reuss, MD
- Board 134a **ABSTRACT TPS9153:** Aumolertinib with chemotherapy or alone compared with osimertinib in patients with EGFR-mutant non-small-cell lung cancer (TREBLE).  
First Author: Melissa Lynne Johnson, MD
- Board 134b **ABSTRACT TPS9154:** Phase 1b/2a safety and tolerability study of bemcentinib (BEM) with pembrolizumab/carboplatin/pemetrexed in first line (1L) advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation.  
First Author: Rajwanth Veluswamy, MD
- Board 135a **ABSTRACT TPS9155:** VELOCITY-Lung: A phase (Ph) 2 study evaluating safety and efficacy of domvanalimab (dom) + zimberelimab (zim) + sacituzumab govitecan (SG), or etrumadenant (etruma) + dom + zim, or etruma + zim in patients (pts) with treatment-naive metastatic non-small cell lung cancer (mNSCLC).  
First Author: Alexander I. Spira, MD, PhD, FACP

- Board 135b **ABSTRACT TPS9156:** A phase 1 study to assess BDTX-1535, an oral EGFR inhibitor, in patients with glioblastoma or non-small-cell lung cancer.  
First Author: Melissa Lynne Johnson, MD
- Board 136b **ABSTRACT TPS9158:** A phase II trial of JDQ443 in KRAS G12C-mutated NSCLC with PD-L1 expression 1% or PD-L1 expression  $\geq 1\%$  and an STK11 co-mutation.  
First Author: Colin R Lindsay, MBChB, PhD
- Board 137a **ABSTRACT TPS9159:** A first-in-human, open-label, dose escalation and expansion study of orally administered NX-019 in patients with advanced EGFR mutant cancer.  
First Author: Alexander I. Spira, MD, PhD, FACP
- Board 137b **ABSTRACT TPS9160:** Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT).  
First Author: Daniel Adam Breadner, MD
- Board 138a **ABSTRACT TPS9161:** LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.  
First Author: Benjamin Besse, MD, PhD
- Board 138b **ABSTRACT TPS9162:** CAN-2409 plus prodrug with standard of care immune checkpoint inhibitor for patients with stage III/IV NSCLC.  
First Author: Charu Aggarwal, MD

---

## 8:00 AM - 11:00 AM Poster Session

### Professional Development and Educational Advances

Location: Hall A

Abstracts on Boards 456-467 will be discussed during the Professional Development and Educational Advances Poster Discussion Session. See the online program guide ([meetings.asco.org](https://meetings.asco.org)) for session details.

### Posters by Topic

**Clinician Burnout and Resiliency:** Boards 459-460, 468-470

**Education Research:** Boards 461, 464-467, 478-495

**Social Media Research:** Boards 462-463, 471-474

**Workplace Disparities/Issues:** Boards 456-458, 475-476

- Board 456 **ABSTRACT 11003:** Workplace sexual harassment in academic oncology.  
First Author: Divya Yerramilli, MD, MBBS
- Board 457 **ABSTRACT 11004:** Should I stay, or should I go? Factors associated with intent to leave academic oncology.  
First Author: Ana I. Velazquez Manana, MD, MSc
- Board 458 **ABSTRACT 11005:** Hematology/oncology program director perspectives on recruitment and inclusion of a diverse workforce.  
First Author: Ana I. Velazquez Manana, MD, MSc
- Board 459 **ABSTRACT 11006:** A multifaceted approach to wellness in a hematology/oncology fellowship program.  
First Author: Thejal Srikumar, MD
- Board 460 **ABSTRACT 11007:** Remote delivery of a mindfulness-based intervention to decrease stress levels and promote coping among health-care workers during the COVID-19 pandemic.  
First Author: Joelle Antoine Helou

- Board 461 **ABSTRACT 11008:** Tumor Board Tuesday and awareness of novel therapies and toxicities in solid tumor oncology.  
First Author: Johnathan Ebben, MD, PhD
- Board 462 **ABSTRACT 11009:** Assessment of YouTube as an information source for immune checkpoint inhibitors (ICIs).  
First Author: Tulika Garg, MBBS
- Board 463 **ABSTRACT 11010:** Quality and accessibility of liquid biopsy information: An analysis of online content.  
First Author: Henry Kazunaru Litt, MD
- Board 464 **ABSTRACT 11011:** Defining the educational needs for a community-based hematology/oncology career: A national needs assessment.  
First Author: Shubham Agrawal, MBBS
- Board 465 **ABSTRACT 11012:** Integration of clinical trial development in hematology and oncology fellowship training: Washington University School of Medicine experience.  
First Author: Christine Auberle, MD
- Board 466 **ABSTRACT 11013:** Novel curriculum for training in medical cannabis in oncologic populations for oncology trainees.  
First Author: Rushad Patell, MBBS
- Board 467 **ABSTRACT 11014:** Innovating the hematology/oncology (H/O) curriculum for internal medicine (IM) residents: A modified flipped classroom (FC) approach.  
First Author: Parva Kiran Bhatt, MD
- Board 468 **ABSTRACT 11015:** Creating an infrastructure to address physician and advanced practice provider burnout at a complex community cancer care delivery system.  
First Author: Alison Tray, AOCNP, MSN, APRN
- Board 469 **ABSTRACT 11016:** Addressing resiliency and burnout: A quantitative needs assessment of oncology physician assistants (PAs).  
First Author: Eric Daniel Tetzlaff, MHS
- Board 470 **ABSTRACT 11017:** The implementation of a self-care tool for patients that may reduce clinician burden.  
First Author: Jenny Wei, MD
- Board 471 **ABSTRACT 11018:** Characterizing imposter syndrome among oncologists on social media.  
First Author: Eleonora Teplinsky, MD
- Board 472 **ABSTRACT 11019:** Impact and engagement of a virtual platform to provide equitable oncology education globally.  
First Author: Yan Leyfman, MD
- Board 473 **ABSTRACT 11020:** Reliability of audiovisual information on lung cancer from cancer organizations.  
First Author: Hardik Dand
- Board 474 **ABSTRACT 11021:** How reliable are post-mastectomy breast reconstruction videos on YouTube?  
First Author: Nina Morena, MA
- Board 475 **ABSTRACT 11022:** The impact of physician gender on patient satisfaction in an academic hematology/oncology practice.  
First Author: Alaina Marie Turchi, MD
- Board 476 **ABSTRACT 11023:** A review of diversity, equity, and inclusion (DEI) efforts by medical oncology journals.  
First Author: Inas Abuali, MD, FACP
- Board 478 **ABSTRACT 11025:** Bringing the teaching close to home: Implementation of a near-peer model for an introductory hematology-oncology fellowship lecture series.  
First Author: Jonathan L Berry, MD
- Board 479 **ABSTRACT 11026:** Fellow-led didactics in a hematology/oncology fellowship program.  
First Author: Rajat Thawani, MD
- Board 480 **ABSTRACT 11027:** Utility of a novel trainee-level hematology/oncology podcast in graduate medical education.  
First Author: Ronak Mistry, DO, BA
- Board 481 **ABSTRACT 11028:** Teaching how to navigate difficult conversations: A combined palliative care–oncology didactic simulation intervention for hematology/oncology fellows.  
First Author: Megan Dupuis, MD, PhD
- Board 482 **ABSTRACT 11029:** Hematology and oncology fellow education about sexual and reproductive health: A survey of program directors in the United States.  
First Author: Jennifer B. Reese, PhD
- Board 483 **ABSTRACT 11030:** Recommendations for medical cannabis use in cancer patients by US oncology fellows and the impact of receiving prior training.  
First Author: Kian Tehranchi, MD
- Board 484 **ABSTRACT 11031:** The Brown University cancer prevention & survivorship curriculum: A case study on program development in an internal medicine residency.  
First Author: Elizabeth R Francis, MD MPH
- Board 485 **ABSTRACT 11032:** Mapping objectives of a new interprofessional morbidity and mortality conference to ACGME core competencies in hematology/oncology.  
First Author: Aditya Sharma, MD
- Board 486 **ABSTRACT 11033:** The cognitive load of inpatient consults involving immune-related adverse events.  
First Author: Sam Brondfield, MD, MA
- Board 487 **ABSTRACT 11034:** The impact of oncology hospitalist utilization on resident education.  
First Author: Sunil Mahesh Bhatt, MD
- Board 488 **ABSTRACT 11035:** Multimodality, online oncology learning resources: Meeting residents where they are—A pilot to create a new oncology curriculum.  
First Author: Jennifer King, MD
- Board 489 **ABSTRACT 11036:** Efficacy of a hematology/oncology podcast curriculum at a community-based internal medicine program.  
First Author: Madeline Campbell Fitzpatrick, MD
- Board 490 **ABSTRACT 11037:** Effects of a focused one-day interactive session on oncology research on medical students' interest in and understanding of oncology research.  
First Author: Jawad Alrawabdeh
- Board 491 **ABSTRACT 11038:** Early introduction to clinical radiation oncology through a self-directed competency-based medical student curriculum.  
First Author: Cheryl Claunch
- Board 492 **ABSTRACT 11039:** A pilot curriculum to transition from 2D to 3D image-guided brachytherapy: A preliminary needs assessment.  
First Author: Joy Ogunmuyiwa, MD, MPH
- Board 493 **ABSTRACT 11040:** Web-based patient educational material on chimeric antigen receptor T-cell therapy: Quantitative assessment of readability.  
First Author: Rahul Kumar Thakur
- Board 494 **ABSTRACT 11041:** Empowering self-advocacy for breast health: A successful educational campaign on breast cancer risk and screening recommendations.  
First Author: Matthew Culbert, MD



Sunday, June 4, 2023

Board 495 **ABSTRACT 11042:** Clinicians' experiences with patients with cancer or their families who endorse medical misinformation.  
First Author: Amitabha Palmer, PhD

---

**8:15 AM - 9:30 AM Highlights of the Day Session**

**Highlights of the Day Session #1**

Location: Hall D1

**Erika P. Hamilton, MD - Chair**

Sarah Cannon Research Institute, Tennessee Oncology

**8:15 AM N. Lynn Henry, MD, PhD, FACP, FASCO**  
University of Michigan Rogel Cancer Center  
*Highlights of Breast Cancer: Local/Regional/Adjuvant*

**8:30 AM Chandrikha Chandrasekharan, MD**  
University of Iowa  
*Highlights of Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary*

**8:45 AM Anjali S. Advani, MD**  
Cleveland Clinic  
*Highlights of Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft*

**9:00 AM Rodney Paul Rocconi, MD**  
University of Alabama at Birmingham  
*Highlights of Gynecologic Cancer*

**9:15 AM Aneel Paulus, MD, MS**  
Mayo Clinic  
*Highlights of Hematologic Malignancies—Plasma Cell Dyscrasia*

---

**9:45 AM - 10:45 AM Case-Based Panel**

**Multidisciplinary Management of Salivary Gland Cancers**

Location: S404

**Alan Loh Ho, MD, PhD - Chair**

Memorial Sloan Kettering Cancer Center  
*Moderator*

**Nicole Grace Chau, MD**

BC Cancer Agency  
*Medical Oncology Perspective*

**Jonathan Daniel Schoenfeld, MD**

Brigham and Women's Hospital  
*Radiation Oncology Perspective*

**Ellie Maghami, MD**

City of Hope  
*Head and Neck Surgeon's Perspective*

*Panel Question and Answer*

---

**9:45 AM - 11:00 AM Education Session**

**Cancer During Pregnancy: Medical, Psychosocial, Ethical, and Legal Considerations**

Location: E451

**Ann H. Partridge, MD, MPH, FASCO - Chair**

Dana-Farber Cancer Institute  
*A Framework for Patient-centered Care in the Management of Cancer During Pregnancy*

**Alison W. Loren, MD, MSCE**

University of Pennsylvania  
*Treatment Options and Timing in the Management of Cancer during Pregnancy*

**Frederic Amant, MD**

UZ Gasthuisberg - Katholieke University Leuven  
*Obstetric and Neonatal Issues in the Multidisciplinary Management of Cancer during Pregnancy*

*Panel Question and Answer*

---

**9:45 AM - 11:00 AM Education Session**

**Embracing Myeloma CAR T: From Scientific Design to Clinical Impact**

Location: S406

**Ivan Borrello, MD**

Tampa General Hospital  
*The Design and Biologic Principles of CAR-T Therapy for Multiple Myeloma*

**Paula Rodríguez-Otero, MD, PhD**

Clínica Universidad de Navarra  
*Clinical Impact and Sequencing of CAR-T Therapy for Multiple Myeloma*

**Surbhi Sidana, MD - Chair**

Stanford University  
*Broadening Access to Novel Multiple Myeloma Therapeutics: We Must Do Better*

*Panel Question and Answer*

---

**9:45 AM - 11:00 AM Education Session**

**Partnering With Patients—Making It Real**

Location: E350

**Eric P. Winer, MD, FASCO - Chair**

Yale Cancer Center  
*Moderator*

**Michael Milken, MBA**

Chair of Milken Institute  
*Panelist*

**Lynn Chehab, MD**

NorthShore University Health System  
*Panelist*

---

**9:45 AM - 11:00 AM Education Session**

**Shared Decision-Making in the Care of Patients With Cancer**

Location: S102

**Victor Montori, MD - Chair**

Mayo Clinic  
*Shared Decision-Making as a Method of Cancer Care*

**Yvonne Bombard, PhD**

University of Toronto; Li Ka Shing Knowledge Institute of St Michael's Hospital  
*Shared Decision-Making for Cancer Genetic Testing*

**Mark Andrew Lewis, MD**  
Intermountain Healthcare  
*Shared Decision-Making: The Patient Perspective*  
Panel Question and Answer

---

**9:45 AM - 11:00 AM Education Session**

**The Future of Equitable Access to Clinical Trials**  
Location: S100bc

**Steven Gore, MD - Chair**  
National Cancer Institute  
*The NCI CATCHUP Program*

**Lola A. Fashoyin-Aje, MD, MPH**  
U.S. Food and Drug Administration  
*The FDA Project Equity and Guidance to Improve Under-represented Enrollment to Trials*

**Ana Acuna-Villaorduna, MD**  
Montefiore Medical Center/Albert Einstein College of Medicine  
*Under-represented and Underserved in Early Clinical Trials*  
Panel Question and Answer

---

**9:45 AM - 11:00 AM Ticketed Session**

**Meet the Professors: Nuts and Bolts—Building a Needs Assessment Toolkit for Survivorship**  
Location: E253d

**Nicole Lynn Stout, DPT**  
West Virginia University Cancer Institute  
*Workflows to Facilitate Implementation of a Comprehensive Needs Assessment*

**Michael Jefford, PhD, MBBS, MPH**  
Peter MacCallum Cancer Centre  
*Closing the Loop: Identifying, Assessing, and Meeting the Needs of Survivors and Providers*  
Panel Question and Answer

---

**9:45 AM - 11:15 AM Clinical Science Symposium**

**Are Big Data Smart Enough to Answer Questions in Central Nervous System Tumors?**  
Location: E450

**Nancy U. Lin, MD - Chair**  
Dana-Farber Cancer Institute

**Rupesh Kotecha, MD - Chair**  
Miami Cancer Institute

**9:45 AM Jeanette Eckel-Passow, PhD**  
Mayo Clinic  
*Bringing Clarity to Big Brain Data*

**9:57 AM Abstract 2009:** Clinical and analytical validation of a targeted gene expression biomarker predicting meningioma outcomes and radiotherapy responses.  
First Author: William Cheng Chen, MD

**10:09 AM Abstract 2010:** Prognostic evaluation of surgical re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group.  
First Author: Philipp Karschnia, MD

**10:21 AM Abstract 2011:** A genomic score to predict local control among patients with brain metastases managed with radiation.  
First Author: Nayan Lamba, MD, BA

**10:33 AM Abstract 2012:** External validation and nomogram for risk factors of CNS metastasis in patients with clinically localized melanoma.  
First Author: Merve Hasanov, MD

**10:45 AM To be determined (Discussion of Abstract(s) 2009-2012)**  
*Clinical Applications of Large Data Sets to Small Neurons*

**10:57 AM** Panel Question and Answer

---

**9:45 AM - 11:15 AM Special Clinical Science Symposium**

**Geriatric Oncology Assessment to Implementation**  
Location: S504

**Efrat Dotan, MD - Chair**  
Fox Chase Cancer Center

**Tanya Marya Wildes, MD, MSCI - Chair**  
University of Nebraska Medical Center

**9:45 AM Abstract 12009:** Electronic frailty index predicts 30-day mortality from chemotherapy in breast, colorectal and lung cancer.  
First Author: Agnieszka Michael, MD, PhD

**9:57 AM Abstract 12010:** Frailty status determined by an electronic health record embedded frailty index and hospitalization risk among older adults following the initiation of cancer chemotherapy.  
First Author: Heidi D. Klepin, MD, MS, FASCO

**10:09 AM Carolyn J. Presley, MD (Discussion of Abstract(s) 12009-12010)**  
Ohio State University Wexner Medical Center  
*Distinguishing Old Versus Frail*

**10:21 AM Abstract 12011:** Web-based patient-reported outcome measures (PROMs) in elderly cancer patients: A French multicentric prospective feasibility trial (the FASTOCH study).  
First Author: Mathilde Cancel, MD

**10:33 AM Abstract 12012:** Cost-utility of geriatric assessment in older adults with cancer: Results from the 5C trial.  
First Author: Yeva Sahakyan, MD, MSc

**10:45 AM Aminah Jatoi, MD (Discussion of Abstract(s) 12011-12012)**  
Mayo Clinic  
*Practical Considerations in Geriatric Assessments*

**10:57 AM** Panel Question and Answer

---

**9:45 AM - 11:15 AM Special Clinical Science Symposium**

**Role of the Microbiome in Immune Checkpoint Inhibitor Response and Resistance**  
Location: Hall D1

Sunday, June 4, 2023

**Kimie Ng, MD, MPH - Chair**  
Dana-Farber Cancer Institute

**Sorbarikor Piawah, MD, MPH - Chair**  
UCSF

- 9:45 AM Laurence Zitvogel, MD, PhD**  
Gustave Roussy  
*Setting the Stage: What We Know About the Microbiome and Cancer*
- 9:57 AM Abstract 103:** Friendly-user score assessing gut dysbiosis and resistance to immune checkpoint inhibitors (ICI).  
First Author: Lisa Derosa, MD, PhD
- 10:09 AM To be determined (Discussion of Abstract(s) 103)**  
*Trusting Your Gut: Using the Microbiome to Predict Immunotherapy Response*
- 10:21 AM Abstract LBA104:** Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial.  
First Author: Hedyeh Ebrahimi, MD, MPH
- 10:33 AM Abstract 105:** Fecal microbiota transplantation combined with anti-PD-1 inhibitor for unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor.  
First Author: Sook Ryun Park, MD, PhD
- 10:45 AM Thomas Gajewski, MD, PhD (Discussion of Abstract(s) LBA104-105)**  
University of Chicago Medical Center  
*Can Bugs Help Drugs? Microbiome Modifiers of Immunotherapy Response*
- 10:57 AM** Panel Question and Answer

---

### 9:45 AM - 12:45 PM Oral Abstract Session

**Developmental Therapeutics—Immunotherapy**  
Location: Arie Crown Theater

**Elena Elez, MD - Chair**  
Vall d'Hebron University Hospital

**Anna Spreafico, MD, PhD - Chair**  
Princess Margaret Cancer Centre

- 9:45 AM Abstract 2501:** Initial results from the phase 2A trial of visugromab (CTL-002) + nivolumab in advanced/metastatic anti-PD1/-L1 relapsed/refractory solid tumors (The GDFATHER-TRIAL).  
First Author: Ignacio Melero Bermejo, MD, PhD
- 9:57 AM Abstract 2502:** Initial results from a first-in-human, phase I study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 in patients with advanced solid tumors.  
First Author: Ecaterina Elena Dumbrava, MD
- 10:09 AM Sandip Pravin Patel, MD (Discussion of Abstract(s) 2501-2502)**  
UC San Diego Moores Cancer Center  
*Immune Modulators Beyond PD-(L)1*
- 10:21 AM** Panel Question and Answer
- 10:37 AM Abstract 2503:** Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types.  
First Author: David R. Gandara, MD, FASCO

- 10:49 AM Abstract 2504:** Evaluation of change in RECIST tumor size and survival in patients with rare cancers treated with checkpoint inhibitor therapy (SWOG S1609).  
First Author: Megan Othus, PhD
- 11:01 AM Suzanne Eleanor Dahlberg, PhD (Discussion of Abstract(s) 2503-2504)**  
Boston Children's Hospital  
*Pan-Tumor Prediction and Assessment of Response to Immunotherapy*
- 11:13 AM** Panel Question and Answer
- 11:29 AM Abstract 2505:** Interim update of the ATRC-101 phase 1b trial in advanced solid tumors.  
First Author: Bartosz Chmielowski, MD, PhD
- 11:41 AM Abstract 2507:** Phase I study of the bifunctional anti-PD-L1/TGF- $\beta$ R1I agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors.  
First Author: Kaichao Feng, MD
- 11:53 PM Abstract 2508:** Phase 1/2 Study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors: Phase 1 DF1001 monotherapy dose-escalation results.  
First Author: Howard Safran, MD
- 12:05 PM Emiliano Calvo, MD, PhD (Discussion of Abstract(s) 2505, 2507-2508)**  
START Madrid-CIOCC, Centro Integral Oncológico Clara Campal  
*Next-Generation Immunotherapy*
- 12:17 PM** Panel Question and Answer

---

### 9:45 AM - 12:45 PM Oral Abstract Session

**Pediatric Oncology I**  
Location: S100a

**Ami Vijay Desai, MD, MSCE - Chair**  
University of Chicago Medical Center

**Michael Vincent Ortiz, MD - Chair**  
Memorial Sloan Kettering Cancer Center

- 9:45 AM Abstract 10000:** High risk neuroblastoma (HR-NB) with MNA and age 18 months: Results from the HR-NBL1/SIOPEX trial.  
First Author: Ruth Lydia Ladenstein, MD, MBA
- 9:57 AM Abstract 10001:** Irinotecan and temozolomide combined with dasatinib and rapamycin for patients with relapsed or refractory neuroblastoma: Results of the prospective randomized RIST trial.  
First Author: Selim Corbacioglu, MD, PhD
- 10:09 AM Abstract 10002:** A multicenter cooperative group study of late effects after high-risk neuroblastoma: COG AL-TE15N2—LEAHRN study.  
First Author: Tara O. Henderson, MD, MPH, FASCO
- 10:21 AM Sara Michele Federico, MD (Discussion of Abstract(s) 10000-10002)**  
St. Jude Children's Research Hospital  
*Advances and Opportunities in Neuroblastoma Treatment*
- 10:33 AM** Panel Question and Answer

- 10:45 AM Abstract 10003:** Biological Medicines for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication (BIOMEDE): Final results of an international randomized phase II platform trial comparing 3 targeted therapies in combination with radiotherapy from ITCC, SIOPE-Brain and ANZCHOG. First Author: Jacques Grill, MD, PhD
- 10:57 AM Abstract 10004:** Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study. First Author: Lindsay Baker Kilburn, MD
- 11:09 AM Abstract 10005:** Treatment of focal anaplastic Wilms tumor (FAWT): A report from the Children's Oncology Group (COG) AREN0321 and AREN03B2 studies. First Author: Amy E. Armstrong, MD
- 11:21 AM Sabine Mueller, MD, PhD (Discussion of Abstract(s) 10003-10005)**  
University of California-San Francisco  
*Microscopes to Molecular: Informing Treatment Approaches in Pediatric Rare Tumors*
- 11:33 AM** Panel Question and Answer
- 11:45 AM Abstract 10006:** Palbociclib in solid tumor patients with genomic alterations in the cyclin D-CDK4/6-INK4a-Rb pathway: Results from NCI-COG Pediatric MATCH trial Arm I (APEC1621I). First Author: Margaret E Macy, MD
- 11:57 AM Abstract 10007:** Erdafitinib in patients with FGFR-altered tumors: Results from the NCI-COG Pediatric MATCH trial arm B (APEC1621B). First Author: Alice Lee, MD
- 12:09 PM Abstract 10008:** Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children's Oncology Group (COG) ADVL1823 cohort A. First Author: Theodore Willis Laetsch, MD
- 12:21 PM Sarah Cohen-Gogo, MD, PhD (Discussion of Abstract(s) 10006-10008)**  
Sickkids Hospital  
*Getting Personal: Matched Targeted Therapy in Pediatric Solid Tumors*
- 12:33 PM** Panel Question and Answer

---

**10:00 AM - 11:00 AM Award Roundtable**

**Mentorship and Career Development Roundtable: A Discussion With ASCO's Special Award Recipients**  
Location: S103

**Lori J. Pierce, MD, FASTRO, FASCO**  
University of Michigan  
*Moderator*

**Carmen E. Guerra, MD, MSCE, FACP**  
University of Pennsylvania  
*Excellence in Equity Award Recipient, Endowed by the American Cancer Society*

**David Gerson Poplack, MD**  
Baylor College of Medicine  
*Excellence in Teaching Award Recipient*

**Carolyn D. Runowicz, MD, FASCO**  
Florida International University Herbert Wertheim College of Medicine  
*Hologic, Inc. Endowed Women Who Conquer Cancer Mentorship Award Recipient*

**Patrick J. Loehrer Sr., MD, FASCO**  
Indiana University Melvin and Bren Simon Comprehensive Cancer Center  
*Humanitarian Award Recipient*

**Maria T. Bourlon, MD, MSc**  
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán  
*International Women Who Conquer Cancer Mentorship Award Recipient*

**Jane Perlmutter, PhD, MBA, FASCO**  
Gemini Group  
*Patient Advocate Award Recipient*

*Panel Question and Answer*

---

**11:30 AM - 12:30 PM Case-Based Panel**

**Managing Cancer Risk in Transgender Patients With Inherited Cancer Predisposition**  
Location: S504

**Swati Patel, MD, MS - Chair**  
University of Colorado Cancer Center  
*Moderator*

**Oluwadamilola Motunrayo Fayanju, MD, FACS**  
University of Pennsylvania Health System  
*Surgical Oncology Perspective*

**Megha Ranganathan, MS**  
Memorial Sloan Kettering Cancer Center  
*Genetic Counselor Perspective*

**Judith Balmana Gelpi, MD, PhD**  
Vall d'Hebron University Hospital  
*Medical Oncology Perspective*

*Panel Question and Answer*

---

**11:30 AM - 12:45 PM Education Session**

**Building an Impactful Oncology Care Team With Aligning Incentives**  
Location: S102

**Todd Alan Pickard, MMSc, FASCO - Chair**  
The University of Texas MD Anderson Cancer Center  
*APP Insights: Onboarding, Scope of Practice, and Maximizing Practice*

**Stephanie Williams, MD, FACP**  
Spectrum Health Medical Group  
*Top of Licensure Practice: Empowering the Team and Serving the Patient*

**Eric Daniel Tetzlaff, MHS**  
Fox Chase Cancer Center  
*Aligning Incentives to Recognize and Reward Team Care Delivery*  
*Panel Question and Answer*

---

**11:30 AM - 12:45 PM Education Session**

**Establishing Equitable Partnerships in Global Cancer Control: Best Practices**  
Location: S103

**Fidel Rubagumya, MD - Chair**  
Rwanda Military Hospital  
*Principles of Equitable Partnerships in Global Health*

Sunday, June 4, 2023

**Michelle L. Hermiston, MD, PhD**  
University of California, San Francisco  
*Partnering to Establish the First Pediatric Oncology Fellowship in Vietnam*

**Dao Thi Thanh An, PhD**  
University of Medicine and Pharmacy  
*Partnering to Establish the First Pediatric Oncology Fellowship in Vietnam*

**Aimee Kreimer, PhD**  
National Cancer Institute  
*Partnering to Eradicate Cervical Cancer*

**Carolina Porras, MSc**  
Agencia Costarricense de Investigaciones Biomédicas  
*Partnering to Eradicate Cervical Cancer*

*Panel Question and Answer*

---

**11:30 AM - 12:45 PM Education Session**

**Minimizing Toxicity in the Neoadjuvant Treatment for Rectal Cancer**  
Location: E451

**Kristen Keon Ciombor, MD, MS**  
Vanderbilt University  
*Neoadjuvant Immunotherapy in MSI-High Rectal Cancer*

**Nina Niu Sanford, MD**  
UT Southwestern Medical Center  
*Evolving Role of Radiation in Rectal Cancer: Optimizing a Crucial Tool*

**Jose G. Guillem, MD, MPH - Chair**  
University of North Carolina at Chapel Hill  
*Watching or Waiting After Complete Response to Total Neoadjuvant Therapy: No Doubt About It*

*Panel Question and Answer*

---

**11:30 AM - 12:45 PM Education Session**

**Patient-Centric Clinical Trial Design in Genitourinary Cancers: Meaningful Endpoints, Assessments, and Outcome Measures**  
Location: S100bc

**To be determined**  
*How Can Real-World Data Strengthen Trial Design?*

**Dena Battle, BS**  
KCCure  
*Do Clinical Trials Address the Questions Important to Patients?*

**Elizabeth Marie Wulff-Burchfield, MD**  
University of Kansas Medical Center  
*How PROMs Can Reveal More About Patient Buy-in to Therapy*

*Panel Question and Answer*

---

**11:30 AM - 12:45 PM Education Session**

**Patient-Reported Outcomes, Digital Health, and the Quest to Improve Health Equity**  
Location: E350

**Claire Frances Snyder, PhD - Chair**  
Johns Hopkins University School of Medicine  
*How Do We Use Digital Health to Implement PROs in Cancer Care?*

**Gita Thanarajasingam, MD**  
Mayo Clinic  
*Harnessing Digital Health Tools to Expand Access and Generalizability of Oncology Care: Opportunities and Challenges*

**Debra A. Patt, MD, PhD, MBA, FASCO**  
Texas Oncology  
*Implementation, Tenets, and Solutions for Broader Use of Digital Medicine*

*Panel Question and Answer*

---

**11:30 AM - 12:45 PM Education Session**

**The Times, They Are a Changing: Updates to Pathologic and Prognostic Classifications in Myeloid Malignancies**  
Location: S406

**Sandeep Gurbuxani, MD, PhD - Chair**  
University of Chicago  
*Understanding the 2022 WHO and ICC Classifications of Myeloid Neoplasms*

**Amy Elizabeth Dezern, MD**  
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins  
*Updating MDS Prognosis in the Molecular Era*

**Akiko Shimamura, MD, PhD**  
Boston Children's Hospital  
*Inherited Predisposition to Hematologic Malignancy Syndromes: Recognition and Implications for the Practicing Clinician*

*Panel Question and Answer*

---

**11:30 AM - 12:45 PM Education Session**

**What the NET? Advances and Challenges in Neuroendocrine Cancers**  
Location: E450

**Andrew Bellizzi, MD**  
University of Iowa  
*Background, Classification, and Genomic Updates in Gastroenteropancreatic Neuroendocrine Neoplasms*

**Rachel Pimenta Riechelmann, MD**  
A.C. Camargo Cancer Center  
*Choices in Treatment and Sequencing for Patients With Advanced Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors*

**Nikolaos Trikalinos, MD, MS - Chair**  
Siteman Cancer Center, Washington University School of Medicine  
*The Emerging Treatment Landscape for Patients With Advanced Extrapulmonary Neuroendocrine Carcinoma*

*Panel Question and Answer*

---

**11:30 AM - 12:45 PM Ticketed Session**

**Extending the Patient Legacy: Rapid Tissue Donation Programs and Their Impact on Cancer Discovery**  
Location: E253d

**Marty Chakoian, MA**  
Us TOO International Prostate Cancer Education and Support Network  
*Leaving a Research Legacy: Why Patients Are Interested in Rapid Tissue Donation*

**Elisabeth I. Heath, MD**

Barbara Ann Karmanos Cancer Institute  
Starting a Rapid Tissue Donation Program

Panel Question and Answer

**11:30 AM - 1:00 PM Poster Discussion Session**

**Breast Cancer—Metastatic**

Location: Hall D2

**Gaorav P. Gupta, MD, PhD - Chair**

The University of North Carolina at Chapel Hill

**Margaret Elena Gatti-Mays, MD, MPH, FACP - Chair**

Ohio State University Comprehensive Cancer Center

- 11:30 AM Anne F. Schott, MD (Discussion of Abstract(s) 1014-1016)**  
University of Michigan Rogel Cancer Center  
*Who and When: Optimizing HER2+ Therapy to Achieve Exceptional Response*
- 11:42 AM** Panel Question and Answer
- 11:52 AM Maryam B. Lustberg, MD (Discussion of Abstract(s) 1017-1019)**  
Yale School of Medicine  
*CDK4/6 Inhibitors: New Populations, Different Settings*
- 12:04 PM** Panel Question and Answer
- 12:14 PM Rita Nanda, MD (Discussion of Abstract(s) 1020-1022)**  
University of Chicago  
*HER2-Low: Learning As We Go*
- 12:26 PM** Panel Question and Answer
- 12:36 PM Hannah Linden, MD (Discussion of Abstract(s) 1023-1025)**  
University of Washington  
*Biomarker Big Picture: From Cells to Imaging*
- 12:48 PM** Panel Question and Answer

Posters discussed in this session are on display in the Breast Cancer—Metastatic Poster Session. To view abstract titles and presentations, see the online program guide (meetings.asco.org).

**11:30 AM - 1:00 PM Poster Discussion Session**

**Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers**

Location: Hall D1

**Chandra Prakash Belani, MD - Chair**

Penn State Cancer Institute

**Karen L. Reckamp, MD - Chair**

Cedars-Sinai Medical Center

- 11:30 AM Alexander V. Louie, MD, PhD, MSc, FRCPC (Discussion of Abstract(s) 8512-8514)**  
Sunnybrook Health Sciences Centre  
*Beam Me Up: Reshaping Lung Cancer Radiation*
- 11:45 AM** Panel Question and Answer
- 12:00 PM Afshin Dowlati, MD (Discussion of Abstract(s) 8516-8519)**  
Case Western Reserve University  
*Think Small, Live Large: Balancing Innovation and Quality of Life in Small Cell Lung Cancer*

- 12:15 PM** Panel Question and Answer

- 12:30 PM Suresh S. Ramalingam, MD, FACP, FASCO (Discussion of Abstract(s) 8520-8523)**  
Emory University School of Medicine  
*Dissecting Subtleties: Navigating Nuances in Perioperative Immunotherapy Trials for Lung Cancer*

- 12:45 PM** Panel Question and Answer

Posters discussed in this session are on display in the Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Poster Session. To view abstract titles and presentations, see the online program guide (meetings.asco.org).

**11:30 AM - 1:00 PM Poster Discussion Session**

**Professional Development and Educational Advances**

Location: S404

**Gregory Peter Kalemkerian, MD, FASCO - Chair**

University of Michigan

**Niki Patel, MD - Chair**

Cedars-Sinai Medical Center

- 11:30 AM Christina Hunter Chapman, MD, MS (Discussion of Abstract(s) 11003-11005)**  
Baylor College of Medicine  
*Fostering Diversity and Safety in the Oncology Workplace*
- 11:42 AM** Panel Question and Answer
- 11:52 AM Taylor Turner, MD, MS (Discussion of Abstract(s) 11006-11007)**  
St. Luke's Cancer Institute  
*Caring for Ourselves to Better Care for Our Patients*
- 12:04 PM** Panel Question and Answer
- 12:14 PM Jennifer Tseng, MD (Discussion of Abstract(s) 11008-11010)**  
City of Hope  
*#OncMedEd: Are We Harnessing the Educational Power of Social Media?*
- 12:26 PM** Panel Question and Answer
- 12:36 PM Julia Lee Close, MD (Discussion of Abstract(s) 11011-11014)**  
UF Health Cancer Center, University of Florida  
*Crafting Current Curricula: Bringing Oncology Education Into the Twenty-First Century*
- 12:48 PM** Panel Question and Answer

Posters discussed in this session are on display in the Professional Development and Education Advances Poster Session. To view abstract titles and presentations, see the online program guide (meetings.asco.org).

**1:00 PM - 4:00 PM Plenary Session**

Location: Hall B1

**Eric P. Winer, MD, FASCO - Chair**

Yale Cancer Center

**Kimmie Ng, MD, MPH - Chair**

Dana-Farber Cancer Institute

- 1:00 PM Eric P. Winer, MD, FASCO, and Kimmie Ng, MD, MPH**  
*Welcome and Opening Remarks*

Sunday, June 4, 2023

- 1:05 PM Abstract LBA1:** INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.  
First Author: Ingo K. Mellingerhoff, MD, FACP
- 1:17 PM Rimas Vincas Lukas, MD**  
Northwestern University  
*Discussion of LBA1*
- 1:29 PM** Panel Question and Answer
- 1:41 PM Abstract LBA2:** PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOL-FOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).  
First Author: Deborah Schrag, MD, MPH, FASCO
- 1:53 PM Corrie Marijnen, MD, PhD**  
Netherlands Cancer Institute  
*Discussion of LBA2*
- 2:05 PM** Panel Question and Answer
- 2:17 PM Abstract LBA3:** Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).  
First Author: Roy S. Herbst, MD, PhD
- 2:29 PM Benjamin J. Solomon, MBBS, PhD**  
Peter MacCallum Cancer Centre  
*Discussion of LBA3*
- 2:41 PM** Panel Question and Answer
- 2:53 PM Abstract LBA4:** SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).  
First Author: Alex Francisco Herrera, MD
- 3:05 PM Ann S. LaCasce, MD**  
Dana-Farber Cancer Institute  
*Discussion of LBA4*
- 3:17 PM** Panel Question and Answer
- 3:30 PM** Closing Remarks

---

**4:30 PM - 5:30 PM Case-Based Panel**

**The Role of Bladder Preservation in the Management of Muscle Invasive Bladder Cancer**

Location: E450

**Simon Hughes, MD, MBBS, FRCR - Chair**

Guy's Cancer, Guy's and St Thomas' NHS Foundation Trust  
*Moderator*

**Melanie Costin**

Fight Bladder Cancer  
*The Patient's Perspective*

**Sarah P. Psutka, MD, MS**

University of Washington, Fred Hutchinson Cancer Center  
*The Urology Perspective*

**Omar Y. Mian, MD, PhD**

Cleveland Clinic  
*The Radiation Oncology Perspective*

*Panel Question and Answer*

**4:30 PM - 5:45 PM Education Session**

**Addressing Financial Toxicity in Cancer Survivors**

Location: E350

**Silvia Riva, PhD**

St. Mary's University  
*Financial Toxicity: Not the Same for All Patients*

**Shelley Fuld Nasso, MPP**

National Coalition Cancer Survivorship  
*Partnering With Patients and Lawmakers to Lessen the Burden of Financial Toxicity*

**Veena Shankaran, MD - Chair**

University of Washington, Fred Hutchinson Cancer Center  
*Beyond Screening: Mitigating Financial Toxicity in the Clinic*

*Panel Question and Answer*

---

**4:30 PM - 5:45 PM Education Session**

**Current Treatment Strategies and Risk Stratification for Oral Carcinoma**

Location: E451

**Vanita Noronha, MD**

Tata Memorial Centre  
*Alternative Strategies to Cisplatin Combined With Radiotherapy as Adjuvant Treatment and the Contribution of Induction Chemotherapy to Mandibular Sparing*

**Stephen Yenzen Lai, MD, PhD**

The University of Texas MD Anderson Cancer Center  
*Sentinel Lymph Node Biopsy and Conservative Surgical Approaches*

**Ali Hosni, PhD, MBBCh, MSc - Chair**

Princess Margaret Cancer Centre  
*The Indications and Techniques of Radiotherapy and Its Role in Managing Early Relapse Prior to Adjuvant Treatment and in Organ Preservation*

*Panel Question and Answer*

---

**4:30 PM - 5:45 PM Education Session**

**Developing Sustainable Cancer and Aging Programs**

Location: S404

**Tina Hsu, MD - Chair**

Ottawa Hospital  
*Developing Sustainable Clinical Geriatric Oncology Services Outside the United States*

**Andrew E. Chapman, DO**

Thomas Jefferson University Hospital  
*Developing and Sustainably Funding Clinical Geriatric Oncology Programs: Perspectives From a U.S. Cancer Center Director*

**Rawad Elias, MD**

Hartford HealthCare  
*Creating Community Oncology-Based Clinical Geriatric Oncology Programs*

*Panel Question and Answer*

**4:30 PM - 5:45 PM Education Session**

**Next-Generation Antibody-Drug Conjugates: Past, Present, and Future**

Location: Hall D2

**Sarat Chandralapaty, MD, PhD**

Memorial Sloan Kettering Cancer Center  
*The Evolution of ADC Development*

**Thomas Powles, MD**

Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital  
*Managing Antibody Drug Conjugate Toxicities*

**Erika P. Hamilton, MD - Chair**

Sarah Cannon Research Institute, Tennessee Oncology  
*The Next Frontier: Resistance to ADCs and Combination Strategies*

*Panel Question and Answer*

---

**4:30 PM - 5:45 PM Education Session**

**Novel Immunotherapeutics: Perspectives on Checkpoints, Bispecifics, and Vaccines in Development**

Location: S100a

**Hossein Borghaei, DO, MS**

Fox Chase Cancer Center  
*Bispecifics and T-Cell Engagers: The Current State of Development*

**Hussein A. Tawbi, MD, PhD - Chair**

The University of Texas MD Anderson Cancer Center  
*Novel Approaches to Checkpoint Inhibition*

**Lana E. Kandalaft, PhD, PharmD**

Ludwig Institute  
*Vaccine Approaches to Immune Modulation*

*Panel Question and Answer*

---

**4:30 PM - 5:45 PM Education Session**

**Older Adults With Newly Diagnosed AML: Hot Topics for the Practicing Clinician**

Location: S103

**Catherine Lai, MD, MPH - Chair**

University of Pennsylvania Health System  
*Mix and Match: Integrating BCL2, FLT3, and IDH Inhibitors Into Frontline Acute Myeloid Leukemia Therapy*

**Gabriel N. Mannis, MD**

Stanford University  
*Managing the Toxicities and Supportive Care Associated With Novel Acute Myeloid Leukemia Agents*

**Richard Jirui Lin, MD, PhD**

Memorial Sloan Kettering Cancer Center  
*What Is the Role of Allogeneic Stem Cell Transplant for Older Patients With Acute Myeloid Leukemia in 2023?*

*Panel Question and Answer*

**4:30 PM - 5:45 PM Education Session**

**Pediatric Immunotherapy: CARs of the Future**

Location: S504

**Katy Rezvani, MD, PhD - Chair**

The University of Texas MD Anderson Cancer Center  
*Beyond Original CAR T Therapy: Natural Killer CARs as an Alternate Platform*

**Yvonne Y Chen, PhD**

University of California, Los Angeles  
*Engineering The Next Generation CARs*

**Edward Robert Scheffer Cliff, MBBS, MPH**

Program on Regulation, Therapeutics and Law  
*The Costs of CAR T: How to Assess the Value of Expensive Therapies in Pediatric Oncology*

*Panel Question and Answer*

---

**4:30 PM - 5:45 PM Ticketed Session**

**Meet the Professors: All About Bispecifics in Myeloma**

Location: E253d

**Philippe Moreau, MD**

Hematology Department, CHU Nantes  
*Clinical Efficacy of Bispecifics in Myeloma*

**Alfred L. Garfall, MD, MS**

University of Pennsylvania  
*Patient Selection and Toxicity Considerations*

*Panel Question and Answer*

---

**4:30 PM - 6:00 PM Clinical Science Symposium**

**Interplay Between Germline and Somatic Tumor Genomes**

Location: S100bc

**Eduardo Vilar Sanchez, MD, PhD - Chair**

The University of Texas MD Anderson Cancer Center

**Pauline Funchain, MD - Chair**

Cleveland Clinic

**4:30 PM Abstract 10509:** Effect of germline mutations on somatic alteration landscapes in BRCA-associated cancers.  
First Author: Ali Arafa, MD

**4:42 PM Abstract 10510:** Redefining early-onset cancer and risk of hereditary cancer predisposition.  
First Author: Zsofia Kinga Stadler, MD

**4:54 PM Stacy W. Gray, MD (Discussion of Abstract(s) 10509-10510)**  
City of Hope Comprehensive Cancer Center  
*Clinical Germline and Somatic Sequencing: Causation Versus Association*

**5:06 PM Abstract 10511:** POT1 germline pathogenic variants and evolving understanding of tumor spectrum: Evidence for lung cancer predisposition.  
First Author: Michael Francis Walsh, MD

**5:18 PM Abstract 10512:** Germline alterations in patients with lung cancer.  
First Author: Ramaswamy Govindan, MD



Sunday, June 4, 2023

5:30 PM **Kara Noelle Maxwell, PhD (Discussion of Abstract(s) 10511-10512)**  
University of Pennsylvania  
*Germline Testing for Patients With Lung Cancer: Ready for Prime Time?*

5:42 PM Panel Question and Answer

---

#### 4:30 PM - 6:00 PM Clinical Science Symposium

##### Target or TIGIT in Hepatobiliary Cancer

Location: Arie Crown Theater

##### Harshabad Singh, MBBS - Chair

Dana-Farber Cancer Institute

##### Sheela Rao, MD, MBBS, MRCP - Chair

The Royal Marsden NHS Foundation Trust

4:30 PM **Abstract 4009:** Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors.  
First Author: Mitesh J. Borad, MD

4:42 PM **Arndt Vogel, MD (Discussion of Abstract(s) 4009)**  
Hannover Medical School  
*FGFR 2.0: Is There a Best in Class?*

4:54 PM **Abstract 4010:** Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC).  
First Author: Richard S. Finn, MD

5:06 PM **Ghassan K. Abou-Alfa, MD, MBA (Discussion of Abstract(s) 4010)**  
Memorial Sloan Kettering Cancer Center  
*Is Anti-TIGIT Another Addition to the Hepatocellular Carcinoma Matrix?*

5:18 PM **Abstract 4011:** Subgroup analysis of double-blind, placebo-controlled Ph. 2 study of nanvuranlat in treatment of pre-treated, advanced, refractory biliary tract cancer (BTC): Patients with high LAT1 expression and response to nanvuranlat.  
First Author: Masafumi Ikeda, MD, PhD

5:30 PM **Angela Lamarca, MD (Discussion of Abstract(s) 4011)**  
Fundacion Jimenez Diaz University Hospital  
*Targeting Biliary Cancer: A LATeral Move?*

5:42 PM Panel Question and Answer

---

#### 4:30 PM - 6:00 PM Poster Discussion Session

##### Breast Cancer—Local/Regional/Adjuvant

Location: Hall B1

##### Alastair Mark Thompson, MD, FRCS, FACS - Chair

Baylor College of Medicine

##### Rachel Lynn Yung, MD - Chair

University of Washington

4:30 PM **David Rimm, MD, PhD (Discussion of Abstract(s) 514-516)**  
Yale School of Medicine  
*Are We Splitting HERs? The Highs and Lows*

4:42 PM Panel Question and Answer

4:52 PM **Carey K. Anders, MD, FASCO (Discussion of Abstract(s) 517-519)**  
Duke Cancer Institute  
*Refining HER2 Treatment*

5:04 PM Panel Question and Answer

5:14 PM **Priyanka Sharma, MD (Discussion of Abstract(s) LBA520-522)**  
University of Kansas Medical Center  
*Learning From Neoadjuvant Therapy*

5:26 PM Panel Question and Answer

5:36 PM **Seema Ahsan Khan, MD (Discussion of Abstract(s) 523-525)**  
Prentice Women's Center Lynn Sage Comprehensive Breast Center  
*Breast Cancer Surgery: Too Much, Too Little, Just Right*

5:48 PM Panel Question and Answer

Posters discussed in this session are on display in the Breast Cancer—Local/Regional/Adjuvant Poster Session. To view abstract titles and presentations, see the online program guide (meetings.asco.org).

---

#### 4:30 PM - 6:00 PM Poster Discussion Session

##### Lung Cancer—Non-Small Cell Metastatic

Location: Hall D1

##### Nick Pavlakakis, MBBS, PhD, FRACP - Chair

Genesis Care, North Shore Health Hub

##### Angel Qin, MD - Chair

University of Michigan

4:30 PM **Xiuning Le, MD, PhD (Discussion of Abstract(s) 9014-9015, 9025)**  
The University of Texas MD Anderson Cancer Center  
*Extending Options for EGFR- and ALK-Altered Tumors*

4:42 PM Panel Question and Answer

4:52 PM **Myung-Ju Ahn, PhD (Discussion of Abstract(s) LBA9016-9018)**  
Samsung Medical Hospital  
*Fine-Tuning Therapies for Oncogene-Driven Lung Cancer*

5:04 PM Panel Question and Answer

5:14 PM **Joel W. Neal, MD, PhD (Discussion of Abstract(s) 9019-9021)**  
Stanford University Medical Center  
*Setting the Stage: New Diagnostics*

5:26 PM Panel Question and Answer

5:36 PM **Apar Kishor Ganti, MD, FASCO (Discussion of Abstract(s) 9022-9024)**  
University of Nebraska Medical Center  
*Delving Deeper Into Immunotherapy*

5:48 PM Panel Question and Answer

Posters discussed in this session are on display in the Lung Cancer—Non-Small Cell Metastatic Poster Session. To view abstract titles and presentations, see the online program guide (meetings.asco.org).

**7:30 AM - 8:00 AM Oral Abstract Session**

**Late-Breaking Abstract Session: Presentation and Discussion of LBA4619**

Location: Hall D1

**Srikala Sridhar, MD, MSc, FRCPC - Chair**  
Princess Margaret Cancer Centre, University Health Network

**7:30 AM Abstract LBA4619:** Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).  
First Author: Yohann Loriot, MD, PhD

**7:42 AM Daniel P. Petrylak, MD**  
Yale School of Medicine  
*Discussion of LBA4619*

**7:54 AM** Panel Question and Answer

---

**7:30 AM - 9:30 AM Education Session**

**Oncology Division Chiefs and Department Chairs' Breakfast**

Location: N229

**7:00 AM** Breakfast and Networking

**7:30 AM Sonali M. Smith, MD, FASCO - Chair**  
University of Chicago  
*Welcome*

**7:35 AM Ishwaria M. Subbiah, MD, MS**  
The University of Texas MD Anderson Cancer Center  
*Retention in a Competitive Market*

**7:50 AM** Panel: Retention in Academia

**Julie Vose, MD, MBA, FASCO**  
University of Nebraska Medical Center  
*Panelist*

**Nathan A. Pennell, MD, PhD, FASCO**  
Cleveland Clinic  
*Panelist*

**Suzanne Conzen, MD**  
UT Southwestern Medical Center  
*Panelist*

**8:20 AM** Panel: Environment and Culture

**Pavani Chalasani, MD, MPH**  
George Washington University  
*Panelist*

**S. Gail Eckhardt, MD, FASCO**  
University of Texas at Austin Dell Medical School  
*Panelist*

**Ishwaria M. Subbiah, MD, MS**  
The University of Texas MD Anderson Cancer Center  
*Panelist*

**8:50 AM** Small Group Discussion

**9:10 AM** Large Group Discussion

**9:27 AM Sonali Smith, MD, FASCO**  
University of Chicago  
*Wrap-up and Closing Remarks*

**8:00 AM - 9:00 AM Case-Based Panel**

**Multidisciplinary Management Challenges in Merkel Cell Carcinoma**

Location: S100bc

**Zeynep Eroglu, MD - Chair**  
H. Lee Moffitt Cancer Center and Research Institute  
*Moderator*

**Shailender Bhatia, MD**  
Division of Medical Oncology, University of Washington and Fred Hutchinson Cancer Center  
*Medical Oncologist's Perspective*

**Danielle Nina Margalit, MD, MPH**  
Dana-Farber/Brigham and Women's Cancer Center  
*Radiation Oncologist's Perspective*

**Kelly Olino, MD**  
Yale School of Medicine  
*Surgical Oncologist's Perspective*

*Panel Question and Answer*

---

**8:00 AM - 9:15 AM Education Session**

**A Juggling Act: Managing the Toxicity of Estrogen Deprivation for Patients With Breast Cancer**

Location: E451

**Kristin E. Rojas, MD - Chair**  
Sylvester Comprehensive Cancer Center, University of Miami  
*Better Sexual Health for All: Strategies Across the Age Spectrum*

**Terri Lynn Woodard, MD**  
The University of Texas MD Anderson Cancer Center  
*Innovations in Fertility: Are We Where We Want to Be?*

**Matteo Lambertini, MD**  
IRCCS Ospedale Policlinico San Martino, Università degli Studi di Genova  
*Essential Building Blocks for Bone Health*

*Panel Question and Answer*

---

**8:00 AM - 9:15 AM Education Session**

**Accelerated Approvals in Oncology: Balancing Access With Evidence**

Location: S102

**Romeo Angelo M. De Claro, MD**  
U.S. Food and Drug Administration  
*An FDA Perspective on Accelerated Approvals*

**Andrew James Schorr**  
PatientPower.info  
*Weighing the Tradeoffs: A Patient Perspective on Regulation of New Cancer Medicines*

**Walid Gellad, MD, MPH - Chair**  
University of Pittsburgh  
*Updating the Accelerated Approval Pathway*

*Panel Question and Answer*

Monday, June 5, 2023

**8:00 AM - 9:15 AM Education Session**

**Aligning Germline Cancer Predisposition With Tumor-Based Next-Generation Sequencing**

Location: Arie Crown Theater

**Zsofia Kinga Stadler, MD**

Memorial Sloan Kettering Cancer Center  
*When Should Tumor Sequencing Prompt a Referral to Cancer Genetics?*

**Timothy A. Yap, MD, PhD**

The University of Texas MD Anderson Cancer Center  
*BRCA Alterations: Beyond Breast and Ovarian Cancer*

**Bryan P. Schneider, MD - Chair**

Indiana University  
*Is Tumor Sequencing Enough to Rule Out Inherited Cancer Predisposition?*

*Panel Question and Answer*

---

**8:00 AM - 9:15 AM Education Session**

**Are We Ready for Universal Screening for Colorectal Cancer?**

Location: S406

**Martin Lajous, PhD, MSc, MD - Chair**

Instituto Nacional de Salud Publica  
*Making a Case for Colorectal Cancer Screening in Low- and Middle-Income Countries*

**Akwi Asombang, MD, MPH**

Massachusetts General Hospital  
*Colorectal Cancer Screening in Africa: Is It Time?*

**Ali Shamseddine, MD, FRCP**

American University of Beirut Medical Center  
*Colorectal Cancer Screening in the Middle East: The Who, What, Where, When, and How*

*Panel Question and Answer*

---

**8:00 AM - 9:15 AM Education Session**

**Structural Sexism and Cancer Care: The Effects on the Patient and Oncologist**

Location: S404

**Bridget P. Keenan, MD, PhD - Chair**

University of California, San Francisco  
*Defining Structural Sexism in Oncology*

**Sarah M. Temkin, MD**

Office of Research on Women's Health  
*Sex, Gender, and the Cancer Continuum*

**Caprice Christian Greenberg, MD, MPH**

University of North Carolina  
*Breaking the Glass Ceiling: Gender Equity in the Workplace*

*Panel Question and Answer*

**8:00 AM - 9:15 AM Education Session**

**Treatment Decisions for Resectable Non-Small Cell Lung Cancer: Balancing Less With More**

Location: E450

**Jessica Donington, MD - Chair**

University of Chicago  
*Resection of Localized Lung Cancer*

**Cecile Le Pechoux, MD**

Gustave Roussy  
*The Role of Radiation in Resectable Lung Cancer*

**Jarushka Naidoo, MHS, MBBCh**

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins  
*Adjuvant and Neoadjuvant Immunotherapy in Resectable Lung Cancer*

*Panel Question and Answer*

---

**8:00 AM - 9:15 AM Ticketed Session**

**Meet the Professors: Shared Decision-Making and Patient-Reported Outcomes—Definitions, Concepts, and Strategies to Optimally Engage With Patients With Gastrointestinal Malignancies**

Location: E253d

**Mary C. Politi, PhD - Chair**

Washington University in St. Louis  
*Opportunities for Shared Decision-Making and Direct Patient Engagement in Oncology*

*Question and Answer*

---

**8:00 AM - 11:00 AM Oral Abstract Session**

**Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology**

Location: Hall D2

**Manish Sharma, MD - Chair**

START Midwest

**Emil Lou, MD, PhD - Chair**

University of Minnesota

**8:00 AM Abstract LBA3000:** Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.  
First Author: Funda Meric-Bernstam, MD

**8:12 AM Abstract 3001:** BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study.  
First Author: Li Zhang, MD

**8:24 AM Abstract 3002:** First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)-targeting antibody-drug conjugate, in patients with small cell lung cancer.  
First Author: Daniel Morgensztern, MD

**8:36 AM Kohei Shitara, MD (Discussion of Abstract(s) LBA3000-3002)**  
National Cancer Center Hospital East  
*Manifest DESTINY: Expanding the Effectiveness of ADCs Across Multiple Solid Tumors*

- 8:48 AM** Panel Question and Answer
- 9:00 AM** **Abstract 3003:** Detection of peritoneal metastases during cytoreductive surgery using pegsitacianine, a pH sensitive imaging agent: Final results from a phase 2 study.  
First Author: Patrick Wagner, MD
- 9:12 AM** **Abstract 3004:** Methylated DNA biomarkers and incident cancer in the American Cancer Society (ACS) Cancer Prevention Study-3 (CPS-3) cohort.  
First Author: Alpa Patel, PhD
- 9:24 AM** **Abstract 3005:** Tumor fraction to improve patient selection for oncology early phase clinical trials: Analysis of two precision medicine studies.  
First Author: Sophie Cousin, MD
- 9:36 AM** **Kiran Turaga, MD, MPH (Discussion of Abstract(s) 3003-3005)**  
Yale Cancer Center  
*Not-So-Private DETECTives: Novel Diagnostics and Their Applications*
- 9:48 AM** Panel Question and Answer
- 10:00 AM** **Abstract 3006:** Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study.  
First Author: Macarena Ines De La Fuente, MD
- 10:12 AM** **Abstract 3007:** A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors.  
First Author: Qing Zhou, MD, PhD
- 10:24 AM** **Abstract 3008:** A phase 1 study of the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients (pts) with recurrent high-grade glioma or uveal melanoma (UM).  
First Author: Varun Monga, MBBS
- 10:36 AM** **Ardaman Shergill, MD (Discussion of Abstract(s) 3006-3008)**  
University of Chicago  
*Breaking Bad Barriers: Brain-Penetrant Small Molecule Inhibitors*
- 10:48 AM** Panel Question and Answer

---

**8:00 AM - 11:00 AM Oral Abstract Session**

**Head and Neck Cancer**

Location: Hall B1

**Cesar Augusto Perez, MD - Chair**

Sarah Cannon Research Institute at Florida Cancer Specialists - Lake Nona

**Jessica Lyn Geiger, MD - Chair**

Cleveland Clinic

- 8:00 AM** **Abstract 6000:** Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial.  
First Author: Lin-Quan Tang, PhD
- 8:12 AM** **Abstract 6001:** Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial.  
First Author: Mingyuan Chen, PhD

- 8:24 AM** **Abstract LBA6002:** PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): a multicenter, phase 3, randomized controlled trial (CONTINUUM).  
First Author: Jun Ma
- 8:36 AM** **Anthony T. C. Chan, MD (Discussion of Abstract(s) 6000-LBA6002)**  
Chinese University of Hong Kong  
*What's the Right Treatment? Nobody Nose*
- 8:48 AM** Panel Question and Answer
- 9:00 AM** **Abstract 6003:** Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies.  
First Author: Jerome Fayette, MD, PhD
- 9:12 AM** **Abstract LBA6004:** Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second-line therapy in head and neck cancer (CRSF 2021-HN-001).  
First Author: Rushabh Kiran Kothari, MD
- 9:24 AM** **Abstract 6005:** Dose expansion results of the bifunctional EGFR/TGF $\beta$  inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma.  
First Author: Glenn J. Hanna, MD
- 9:36 AM** **Ezra E.W. Cohen, MD, FASCO (Discussion of Abstract(s) 6003-6005)**  
Moores Cancer Center, University of California San Diego  
*Something Old, New, and Borrowed*
- 9:48 AM** Panel Question and Answer
- 10:00 AM** **Abstract 6006:** Randomised phase III trial of the hypoxia modifier nimorazole added to radiotherapy with benefit assessed in hypoxic head and neck cancers determined using a gene signature (NIMRAD).  
First Author: David Thomson, MD, FRCR
- 10:12 AM** **Abstract 6007:** Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial.  
First Author: Ari Rosenberg, MD
- 10:24 AM** **Abstract 6008:** Immuno-chemotherapy as single treatment modality for larynx preservation (ICoLP): Co-primary endpoints and safety results.  
First Author: Renata Ferrarotto, MD
- 10:36 AM** **Sean Matthew McBride, MD, MPH (Discussion of Abstract(s) 6006-6008)**  
Memorial Sloan Kettering Cancer Center  
*To Protect and Preserve*
- 10:48 AM** Panel Question and Answer

---

**8:00 AM - 11:00 AM Oral Abstract Session**

**Pediatric Oncology II**

Location: S504

**Mark A. Applebaum, MD - Chair**

University of Chicago

**Maria Gramatges, MD, PhD - Chair**

Baylor College of Medicine

## Monday, June 5, 2023

- 8:00 AM Abstract 10009:** Feasibility of the Poverty-Targeted Pediatric Cancer Resource Equity (PediCARE) intervention.  
First Author: Haley Newman, MD
- 8:12 AM Abstract 10010:** Feasibility and acceptability of social determinants of health data collection in the context of a Children's Oncology Group trial.  
First Author: Emily Jones, BS
- 8:24 AM Abstract 10011:** Medicaid enrollment changes among U.S. adult survivors of childhood cancer following Medicaid expansion: A report from the Childhood Cancer Survivor Study (CCSS).  
First Author: Xu Ji, PhD
- 8:36 AM Paula Aristizabal, MD, MS (Discussion of Abstract(s) 10009-10011)**  
University of California San Diego  
*Incorporating Social Determinants of Health Into Pediatric Oncology Care*
- 8:48 AM** Panel Question and Answer
- 9:00 AM Abstract 10012:** Enhancing prediction of cancer therapy-related cardiomyopathy from surveillance echocardiograms: A Children's Oncology Group (COG) report.  
First Author: Eric Jessen Chow, MD, MPH
- 9:12 AM Abstract 10013:** Carvedilol for prevention of heart failure in anthracycline-exposed survivors of childhood cancer: Results from COG ALTE1621.  
First Author: Saro Armenian, DO, MPH
- 9:24 AM Abstract 10014:** Clonal hematopoiesis in survivors of childhood cancer.  
First Author: Danielle Novetsky Friedman, MD
- 9:36 AM Bonnie Ky, MD, MSCE (Discussion of Abstract(s) 10012-10014)**  
Hospital of the University of Pennsylvania  
*Predicting, Preventing, and Addressing Treatment-Related Morbidity in Pediatric Cancer*
- 9:48 AM** Panel Question and Answer
- 10:00 AM Abstract 10015:** Genomic determinants of outcome in acute lymphoblastic leukemia: A Children's Oncology Group study.  
First Author: Ti-Cheng Chang, PhD
- 10:12 AM Abstract 10016:** A phase 3 trial of inotuzumab ozogamicin for high-risk B-ALL: Second safety phase results from Children's Oncology Group AALL1732.  
First Author: Maureen Megan O'Brien, MD, MS
- 10:24 AM Abstract 10017:** Preliminary results from the first-in-child phase II trial (ITCC-054/COG-AAML1921) of bosutinib in pediatric patients with newly diagnosed (ND) chronic myeloid leukemia (CML).  
First Author: Edoardo Pennesi
- 10:36 AM Sarah K. Tasian, MD (Discussion of Abstract(s) 10015-10017)**  
Children's Hospital of Philadelphia  
*Looking to the Future in Pediatric Leukemia*
- 10:48 AM** Panel Question and Answer

---

### 8:00 AM - 11:00 AM Oral Abstract Session

#### Symptoms and Survivorship

Location: S100a

#### Mazie Tsang, MD, MS - Chair

Mayo Clinic

#### June M. McKoy, MD, MPH, JD, MBA - Chair

Northwestern University Feinberg School of Medicine

- 8:00 AM Abstract 12000:** A multicenter randomized controlled trial (RCT) for the effectiveness of Comprehensive Geriatric Assessment (CGA) with extensive patient coaching on quality of life (QoL) in older patients with solid tumors receiving systemic therapy: G-oncoCOACH study.  
First Author: Cindy Kenis, PhD
- 8:12 AM Abstract 12001:** Effect of a telephone-based weight loss intervention (WLI) on weight at 12-months in women with early breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.  
First Author: Jennifer A. Ligibel, MD, FASCO
- 8:24 AM Abstract 12002:** Results of a tailored multimodal lifestyle follow-up care program focusing on physical activity, nutritional behavior and psychological processes in adolescent and young adult cancer survivors: The CARE for CAYA multicenter, randomized clinical trial.  
First Author: Simon Elmers
- 8:36 AM Kathryn Elizabeth Hudson, MD (Discussion of Abstract(s) 12000-12002)**  
Texas Oncology PA  
*Lifestyle Across Ages*
- 8:48 AM** Panel Question and Answer
- 9:00 AM Abstract 12003:** Chemotherapy induced peripheral neuropathy (CIPN) due to paclitaxel versus docetaxel in patients with early-stage breast cancer receiving taxane therapy: SWOG S1714.  
First Author: Meghna S. Trivedi, MD, MS
- 9:12 AM Abstract 12004:** Phase 3 randomized placebo-controlled trial of donepezil for late cancer-related cognitive impairment in breast cancer survivors exposed to chemotherapy from the Wake Forest NCORP Research Base REMEMBER trial (WF97116).  
First Author: Steve R. Rapp, PhD
- 9:24 AM Abstract 12005:** Randomized double-blind, placebo-controlled study of topical diclofenac in prevention of hand-foot syndrome in patients receiving capecitabine.  
First Author: Akhil Santhosh, MD
- 9:36 AM Pallavi Kumar, MD, MPH (Discussion of Abstract(s) 12003-12005)**  
Hospital of the University of Pennsylvania  
*A New Age of Symptom Control*
- 9:48 AM** Panel Question and Answer
- 10:00 AM Abstract 12006:** Reduced symptom burden after implementation of an electronic symptom management program.  
First Author: Jessica J. Bian, MD
- 10:12 AM Abstract LBA12007:** Effectiveness of a cardiovascular health EHR application for cancer survivors in community oncology practice: Results from WF-1804CD.  
First Author: Kathryn E. Weaver, PhD, MPH
- 10:24 AM Abstract 12008:** Telehealth-based psychological intervention for caregivers of patients with primary malignant brain tumors: A randomized controlled trial.  
First Author: Deborah Anne Forst, MD
- 10:36 AM Sarah Schellhorn, MD (Discussion of Abstract(s) 12006-12008)**  
Yale Cancer Center  
*Ushering in the Digital Age*
- 10:48 AM** Panel Question and Answer

**8:00 AM - 11:00 AM Poster Session****Gastrointestinal Cancer—Colorectal and Anal**

Location: Hall A

Abstracts on Boards 212-223 will be discussed during the Gastrointestinal Cancer—Colorectal and Anal Poster Discussion Session. See the online program guide (meetings.asco.org) for session details.

**Posters by Topic****Anal Cancer:** Boards 224-225, 324a**Biologic Correlates:** Boards 226-227**Biomarkers/Epidemiology/Outcomes:** Boards 228-245, 324b-325a  
**Colorectal Cancer—Advanced/Metastatic Disease:** Boards 212-218, 247, 249-271, 273-307, 325b-328a**Colorectal Cancer—Local-Regional Disease:** Boards 219-223, 308-320, 328b-332b**Other Colorectal and Anal Cancer:** Boards 321-323

- Board 212 **ABSTRACT 3512:** Overall survival results for trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab: Results from the phase 3 SOLSTICE study.  
First Author: Thierry Andre, MD
- Board 213 **ABSTRACT 3513:** Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 101 phase 1b safety and efficacy.  
First Author: David S. Hong, MD
- Board 214 **ABSTRACT 3514:** Phase 1 study of WNT pathway Porcupine inhibitor CGX1321 and phase 1b study of CGX1321 + pembrolizumab (pembro) in patients (pts) with advanced gastrointestinal (GI) tumors.  
First Author: Marios Giannakis, MD, PhD
- Board 215 **ABSTRACT 3515:** Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: A multicenter randomized phase II trial (PRODIGE 43 - PACHA-01).  
First Author: Maximiliano Gelli, MD, PhD
- Board 216 **ABSTRACT 3516:** Adjuvant systemic chemotherapy with or without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastases resection (HARVEST): A prospective, randomized controlled trial.  
First Author: Yu-hong Li
- Board 217 **ABSTRACT 3517:** Upfront palliative resection of primary tumor versus no resection in patients with synchronous metastatic colorectal cancer: The randomized phase 3 CAIRO4 study of the Dutch Colorectal Cancer Group (DCCG).  
First Author: Miriam Koopman, MD, PhD
- Board 218 **ABSTRACT 3518:** 15-month safety and efficacy data after intraperitoneal treatment with <sup>224</sup>Radium-labelled microparticles after CRS-HIPEC for peritoneal metastasis from colorectal cancer.  
First Author: Stein G. Larsen
- Board 219 **ABSTRACT 3519:** Neoadjuvant chemotherapy (NAC) followed by total mesorectal excision (TME) and adjuvant chemotherapy versus TME followed by adjuvant chemotherapy in very low-lying clinical (c) T3 rectal cancer (NAIR): A multicenter, randomized, open-label, phase 2/3 trial.  
First Author: Yuichiro Tsukada, MD, PhD
- Board 220 **ABSTRACT 3520:** Sustained organ preservation in rectal cancer patients treated with total neoadjuvant therapy: Long-term results of the OPRA trial.  
First Author: Floris S. Verheij, BSc
- Board 221 **ABSTRACT 3521:** Circulating tumor DNA dynamics as an early predictor of recurrence in patients with radically resected colorectal cancer: Updated results from GALAXY study in the CIRCULATE-Japan.  
First Author: Eiji Oki, MD, PhD, FACS
- Board 222 **ABSTRACT 3522:** Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program.  
First Author: Arvind Dasari, MD, MS
- Board 223 **ABSTRACT 3523:** Predictive models of recurrence from transcriptomic signatures of the tumor microenvironment and cell cycle in stage III colon cancer from PETACC-8 and IDEA France trials.  
First Author: Claire Gallois, MD
- Board 224 **ABSTRACT 3524:** Circulating tumor DNA (ctDNA) to assess response in patients with anal cancer treated with definitive chemoradiation.  
First Author: Janet Alvarez, MD
- Board 225 **ABSTRACT 3525:** HPV integration as a prognostic biomarker for metastatic anal cancer: A next-generation sequencing ctDNA-based approach.  
First Author: Benny Johnson, DO
- Board 226 **ABSTRACT 3526:** Variation in FOLFOX, FOLFIRI, and FOLFOXIRI effects on CD8+ T cell and PDL1 levels in MSS CRC patients.  
First Author: Lindsey Carlsen, BS
- Board 227 **ABSTRACT 3527:** Pathological analysis of tumor microenvironmental features using deep learning to predict survival of colon carcinomas.  
First Author: Frank A. Sinicrope, MD
- Board 228 **ABSTRACT 3528:** HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS.  
First Author: John H. Strickler, MD
- Board 229 **ABSTRACT 3529:** A prospective, cross-sectional, multicentre study to evaluate the clinical performance of the ColoSTAT in vitro diagnostic for the detection of biomarkers associated with colorectal cancer.  
First Author: Emily He, MBBS, MPH, FRACP, PhD
- Board 230 **ABSTRACT 3530:** Comprehensive study of the intra-tumoral microbiome in early- vs. late-onset colorectal cancer: Final analysis of COSMO CRC.  
First Author: Benjamin Adam Weinberg, MD
- Board 231 **ABSTRACT 3531:** Chemotherapeutic sensitivity in colorectal cancer expressing low RNA of wild type homologous recombination genes.  
First Author: Daniel Walden, MD
- Board 232 **ABSTRACT 3532:** Circulating tumor DNA in plasma as an early predictor for pathological lymph node involvement and (neo-)adjuvant chemotherapy in patients with colon cancer.  
First Author: Louise Raunkilde, MD
- Board 233 **ABSTRACT 3533:** Correlation of single-cell cytokine secretion with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with capecitabine (C), bevacizumab (B), ± atezolizumab (A).  
First Author: Niharika B. Mettu, MD, PhD
- Board 234 **ABSTRACT 3534:** Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the AtezoTRIBE study.  
First Author: Federica Marmorino, MD

## Monday, June 5, 2023

- Board 235 **ABSTRACT 3535:** Consensus molecular subtyping of colorectal cancer to demonstrate cetuximab benefit in right-sided CMS2 tumors, and pembrolizumab benefit in MSS CMS1 tumors.  
First Author: John Paul Y.C. Shen, MD
- Board 236 **ABSTRACT 3536:** Genomic landscapes of early-onset versus average-onset colorectal cancer populations.  
First Author: Michael H. Storandt, MD
- Board 237 **ABSTRACT 3537:** Deep learning tumor heterogeneity metric from histopathology images vs next generation sequencing-derived scores for colon cancer prognostication.  
First Author: Hatim Amiji
- Board 238 **ABSTRACT 3538:** Evaluation of microsatellite instability status, a definitive predictive biomarker for immune checkpoint inhibitors (ICI), in underrepresented minorities (URM) with gastrointestinal (GI) cancers.  
First Author: Fiyinfolu Balogun, MD, PhD
- Board 239 **ABSTRACT 3539:** Prognostic & predictive significance of pre- and post-operative plasma tumor markers in patients with appendiceal adenocarcinoma undergoing cytoreductive surgery: Insights from a single-center study.  
First Author: Abdelrahman M.G. Yousef, MD
- Board 240 **ABSTRACT 3540:** Does serial circulating tumor DNA (ctDNA) monitoring identify additional acquired actionable alterations in metastatic colorectal cancer (mCRC)?  
First Author: Jonathan M. Loree, MD, MS
- Board 241 **ABSTRACT 3541:** Racial and genetic ancestry associations with gene expression patterns in a real-world cohort of colorectal cancer patients.  
First Author: David Hein
- Board 242 **ABSTRACT 3542:** Artificial intelligence-derived immune phenotypes for prediction of prognosis in patients with stage III colon cancer (NCCTG N0147; Alliance).  
First Author: Bahar Saberzadeh Ardestani, MD, MPH
- Board 243 **ABSTRACT 3543:** A deep learning model for the prediction of microsatellite instability and pathogenic POLE mutations in colorectal cancer using histopathologic images.  
First Author: Ting Xu, MD
- Board 244 **ABSTRACT 3544:** Prognostic role of TP53 variants in the phase III study of FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (ERMES study).  
First Author: Nicola Normanno, MD
- Board 245 **ABSTRACT 3545:** Plasma arginine as a candidate predictive biomarker for response to immune checkpoint inhibition (ICI) in metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial.  
First Author: Lucy Xiaolu Ma, MD
- Board 247 **ABSTRACT 3547:** A phase 1 dose escalation study of GCC19CART: A novel coupled CAR therapy for patients with metastatic colorectal cancer.  
First Author: Lei Xiao, PhD
- Board 249 **ABSTRACT 3549:** A prospective study of FOLFIRI plus aflibercept as second-line treatment after failure of FOLFOXIRI plus bevacizumab in patients with unresectable/metastatic colorectal cancer (CRC): EFFORT study.  
First Author: Hironaga Satake, MD
- Board 250 **ABSTRACT 3550:** First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142.  
First Author: Heinz-Josef Lenz, MD
- Board 251 **ABSTRACT 3551:** Impact of number and size of colorectal metastases (CRM) on survival in patients with RAS wild-type metastatic colorectal cancer treated within the PanaMa trial (AIO KRK 0212).  
First Author: Greta Sommerhäuser, MD
- Board 252 **ABSTRACT 3552:** Alternating short-course oxaliplatin-based chemotherapy and nivolumab as first-line treatment of patients with abdominal metastases from microsatellite-stable (MSS) colorectal cancer (CRC): A randomized phase 2 trial.  
First Author: Anne Hansen Ree, MD, PhD
- Board 253 **ABSTRACT 3553:** Size-related heterogeneity of colorectal liver metastases (CRLM) in patients with advanced RAS wild-type metastatic colorectal cancer (mCRC) treated in the PanaMa trial: Implication for treatment decisions.  
First Author: Greta Sommerhäuser, MD
- Board 254 **ABSTRACT 3554:** Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.  
First Author: Romain Cohen, MD, PhD
- Board 255 **ABSTRACT 3555:** A phase Ib/II study to evaluate surufatinib combined with camrelizumab and chemotherapy in the second-line treatment of advanced colorectal cancer: Phase Ib results.  
First Author: Sheng Li
- Board 256 **ABSTRACT 3556:** Trifluridine/tipiracil (FTD/TPI) in extensively pre-treated metastatic colorectal cancer (mCRC) patients: Evaluation of prognostic subgroups of the TALLISUR study.  
First Author: Meinolf Karthaus, MD
- Board 257 **ABSTRACT 3557:** Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers).  
First Author: Michael Sangmin Lee, MD
- Board 258 **ABSTRACT 3558:** Preliminary results from ERAS-007 plus palbociclib (palbo) in patients (pts) with KRAS/ NRAS mutant (m) colorectal cancer (CRC) or KRASm pancreatic ductal adenocarcinoma (PDAC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers).  
First Author: Susanna Varkey Ulahannan, MD
- Board 259 **ABSTRACT 3559:** Novel GUCY2C targeting CAR-T therapy: Efficacy in advanced colorectal cancer.  
First Author: Qianyu Zhang, MD
- Board 260 **ABSTRACT 3560:** Matching-adjusted indirect treatment comparisons (MAIC) of sotorasib vs trifluridine/tipiracil (T/T) and regorafenib as monotherapy in chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC).  
First Author: Timothy Jay Price, D.H.Sc, MBBS, FRACP
- Board 261 **ABSTRACT 3561:** Determinants of permanent liver limited disease (pLLD) in metastatic colorectal cancer (mCRC).  
First Author: Francesc Salva

- Board 262 **ABSTRACT 3562:** A phase II study of regorafenib plus sintilimab as salvage-line treatments in non-MSI-H metastatic colorectal cancer (mCRC).  
First Author: Rui Liu
- Board 263 **ABSTRACT 3563:** Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study.  
First Author: Dan-yun Ruan, MD, PhD
- Board 264 **ABSTRACT 3564:** Impact of sex on the efficacy of first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus Y90-radioembolization in patients with metastatic colorectal cancer: An exploratory, retrospective analysis of the phase III SIRFLOX trial.  
First Author: Kathrin Heinrich, MD
- Board 265 **ABSTRACT 3565:** A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.  
First Author: Hideaki Bando, MD, PhD
- Board 266 **ABSTRACT 3566:** Associations between early tumor shrinkage (ETS)/depth of response (DpR) and overall and post-progression survivals (OS/PPS) from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.  
First Author: Hideaki Bando, MD, PhD
- Board 267 **ABSTRACT 3567:** Reversion of RAS mutations in metastatic colorectal cancer in the CCTG CO.26 clinical trial.  
First Author: Florence T.H. Wu, MD, PhD
- Board 268 **ABSTRACT 3568:** Prognostic impact of depth of response (DpR) and early tumour shrinkage (ETS) in patients (pts) with BRAF V600E mutated (mut) metastatic colorectal cancer (mCRC) receiving targeted therapy (TT) as second-line treatment.  
First Author: Guglielmo Vetere, MD
- Board 269 **ABSTRACT 3569:** Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAF V600E mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT).  
First Author: Marco Maria Germani, MD
- Board 270 **ABSTRACT 3570:** Transcriptomic signatures of MSI-high metastatic colorectal cancer to predict efficacy of immune checkpoint inhibitors.  
First Author: Claire Gallois, MD
- Board 271 **ABSTRACT 3571:** Intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): An update of survival/toxicity and preliminary results of genomic alterations from IMPROVE study.  
First Author: Antonio Avallone, MD
- Board 273 **ABSTRACT 3573:** Impact of WNT/B-catenin alterations and metastasis location among patients with metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI) combinations.  
First Author: Javier Ros Montaña, MD, PhD
- Board 274 **ABSTRACT 3574:** Real-world comparison of triplet-versus doublet-chemotherapy with bevacizumab in patients with newly diagnosed metastatic colorectal cancer (mCRC).  
First Author: William Joseph Chapin, MD, MSCE
- Board 275 **ABSTRACT 3575:** Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO.  
First Author: Veronica Conca, MD
- Board 276 **ABSTRACT 3576:** Exploring the prognostic and predictive impact of genomic loss of heterozygosity (LOH) in patients with metastatic colorectal cancer (mCRC).  
First Author: Martina Carullo, MD
- Board 277 **ABSTRACT 3577:** Analysis of primary and acquired resistance to cetuximab from multiomic data in the New EPOC trial.  
First Author: Sian Alexandra Pugh, MBBS
- Board 278 **ABSTRACT 3578:** Single nucleotide polymorphisms (SNPs) in MHC class I and II genes to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3, MAVERICC, and TRIBE trials.  
First Author: Pooja Mittal, MS
- Board 279 **ABSTRACT 3579:** Nipavect: Phase II study of niraparib and panitumumab in advanced RAS WT colorectal cancer.  
First Author: Olatunji B. Alese, MD, FWACS
- Board 280 **ABSTRACT 3580:** OniLon: Phase II trial of trifluridine/tipiracil (TAS-102) and nanoliposomal irinotecan (nal-IRI) in advanced colorectal cancer.  
First Author: Olatunji B. Alese, MD, FWACS
- Board 281 **ABSTRACT 3581:** Deep learning-derived spatial organization features on histopathology images to predict prognosis in patients with colorectal liver metastasis, after hepatectomy.  
First Author: Xin Wang
- Board 282 **ABSTRACT 3582:** Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: A multicenter, single-arm phase 2 trial.  
First Author: Wensi Zhao, MD
- Board 283 **ABSTRACT 3583:** The impact of sodium-glucose cotransporter-2 inhibitors on the outcome of patients with colorectal adenocarcinoma.  
First Author: Cho Han Chiang, MD, MSCI
- Board 284 **ABSTRACT 3584:** A phase II study of nivolumab and ipilimumab with radiation therapy in patients with metastatic, microsatellite stable colorectal cancer.  
First Author: Julie L. Koenig, MD
- Board 285 **ABSTRACT 3585:** Efficacy and safety of irinotecan-eluting HepaSphere transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for unresectable colorectal liver metastases.  
First Author: Aiwei Feng, MD
- Board 286 **ABSTRACT 3586:** Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRAS<sup>G12C</sup> mutation: Preliminary results from a pooled analysis of two phase I studies.  
First Author: Ying Yuan
- Board 287 **ABSTRACT 3587:** Understanding resistance in V600E BRAF advanced colon cancer treated with BRAF inhibitors plus anti-EGFR antibodies +/- MEK inhibitors: The URBAN study.  
First Author: Francesca Bergamo, MD
- Board 288 **ABSTRACT 3588:** Optimal molecular-targeted therapies as first-line treatment for RAS wild-type, right-sided metastatic colorectal cancer from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.  
First Author: Kentaro Yamazaki, MD, PhD



- Board 289 **ABSTRACT 3589:** Overall survival of patients with BRAF-mutant metastatic colorectal cancer treated with encorafenib-cetuximab in a real-world nationwide study in the Netherlands.  
First Author: Sietske C.M.W. van Nassau, MD
- Board 290 **ABSTRACT 3590:** Phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (TABASCO).  
First Author: Patrick M. Boland, MD
- Board 291 **ABSTRACT 3591:** Real-world treatment trends and outcomes in elderly patients with metastatic colorectal cancer in the United States.  
First Author: Andrew Trunk
- Board 292 **ABSTRACT 3592:** MicroOrganoSpheres as a clinically applicable precision oncology platform for the discovery of novel therapies in colorectal cancer.  
First Author: Divya Lakshmi Dayanidhi, BS
- Board 293 **ABSTRACT 3593:** Management of Early-onset Metastatic Colorectal Cancer (ERMIONE): A single institution analysis.  
First Author: Giustina Valente, MD
- Board 294 **ABSTRACT 3594:** Effect of trifluridine/tipiracil in combination with bevacizumab on ECOG-PS in refractory metastatic colorectal cancer: An analysis of the phase 3 SUNLIGHT trial.  
First Author: Julien Taieb, MD, PhD
- Board 295 **ABSTRACT 3595:** PolyPEP11018 vaccine in combination with TAS-102 in participants with late-stage microsatellite-stable metastatic colorectal cancer (MSS mCRC): A phase Ib study to evaluate safety, tolerability, immunogenicity and efficacy (OBERTO-201).  
First Author: Joleen M. Hubbard, MD
- Board 296 **ABSTRACT 3596:** VIC regimen (vemurafenib/irinotecan/cetuximab) versus bevacizumab plus chemotherapy as first-line treatment for BRAF V600E-mutated advanced colorectal cancer.  
First Author: Yijiao Chen
- Board 297 **ABSTRACT 3597:** Upfront vs deferred monoclonal antibodies in metastatic colorectal cancer: A target trial emulation using the GEMCAD 14-01 prospective cohort.  
First Author: Joan Maurel
- Board 298 **ABSTRACT 3598:** Preoperative assessment in lung-limited metastatic patients with colorectal cancer: The Meta-Lung Score.  
First Author: Pina Ziranu, MD
- Board 299 **ABSTRACT 3599:** Targeting EZH2 to overcome the resistance to immunotherapy in microsatellite stable colorectal cancer: Results from the CAIRE study.  
First Author: Lola Jade Palmieri, MD, MSc
- Board 300 **ABSTRACT 3600:** Molecular landscape and survival outcomes on early phase clinical trials in sporadic young onset colorectal cancer.  
First Author: Benny Johnson, DO
- Board 301 **ABSTRACT 3601:** Analysis of fruquintinib adverse events of special interest from phase 3 of the FRESCO-2 study.  
First Author: Cathy Eng, MD, FACP, FASCO
- Board 302 **ABSTRACT 3602:** Real-world rates of FDA-approved targeted therapy and immunotherapy prescriptions for metastatic colorectal cancer patients in the VA's National Precision Oncology Program (NPOP).  
First Author: Alice Blanche Sylvie Nono Djotsa, PhD
- Board 303 **ABSTRACT 3603:** Early tumor shrinkage (ETS) as clinical factor to select maintenance with cetuximab (cet) monotherapy in *RAS/BRAF* wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): A secondary endpoint analysis of the ERMES study.  
First Author: Armando Orlandi, MD, PhD
- Board 304 **ABSTRACT 3604:** Subgroup analyses of safety and efficacy by number and types of prior lines of treatment in FRESCO-2, a global phase III study of fruquintinib in patients with refractory metastatic colorectal cancer.  
First Author: Arvind Dasari, MD, MS
- Board 305 **ABSTRACT 3605:** Cost-effectiveness analysis of later-line therapies for metastatic colorectal cancer (mCRC) based on a novel methodology of network meta-analysis (NMA) of survival curves.  
First Author: Mavis Obeng-Kusi, BPharm, MPharm
- Board 306 **ABSTRACT 3606:** Cancer of unknown primary with gastrointestinal profiles: A distinct CUP subset.  
First Author: Aakash Tushar Shah, MD
- Board 307 **ABSTRACT 3607:** Impact of vitamin d on the colon tumor immune microenvironment: Results of a randomized clinical trial of preoperative vitamin D supplementation in patients with stage I-III colon cancer.  
First Author: Andressa Dias-Costa, MD
- Board 308 **ABSTRACT 3608:** Predictive value of tumor-infiltrating lymphocyte (TIL) dynamics in the tumor microenvironment (TME) during preoperative chemoradiotherapy (CRT) on pathologic complete response (pCR) in microsatellite-stable (MSS) locally advanced rectal cancer (LARC).  
First Author: Mitsuho Imai, MD, PhD
- Board 309 **ABSTRACT 3609:** Combined associations of a healthy lifestyle and body mass index on colorectal cancer recurrence and survival: A cohort study.  
First Author: Shabane Barot, MD
- Board 310 **ABSTRACT 3610:** Immunotherapy for localized MSI-H colorectal cancer: Characterizing endoscopic and imaging response.  
First Author: Dan A. Fox, MD
- Board 311 **ABSTRACT 3611:** The role of image-guided volume-adapted high-dose-rate endorectal brachytherapy boost in total neoadjuvant treatment of distal locally advanced rectal cancer.  
First Author: Huangang Jiang, MD
- Board 312 **ABSTRACT 3612:** The number of lymph nodes examined as a poor prognosis factor in stage II and stage III colon cancer patients undergoing curative surgery.  
First Author: Jeon Jeongseok, BA
- Board 313 **ABSTRACT 3613:** Efficacy and safety of mFOLFOX6 with apatinib as postoperative adjuvant chemotherapy in stage IIIB or IIIC colorectal cancer.  
First Author: Xiaodong Gu
- Board 314 **ABSTRACT 3614:** The significance of mucin on rectal MRI in patients with locally advanced rectal cancer being considered for watch-and-wait after neoadjuvant therapy.  
First Author: Sean Judge, MD, MS
- Board 315 **ABSTRACT 3615:** Mismatch Repair system protein deficiency as a factor of resistance to chemo-radiotherapy treatment in patients with locally advanced rectal adenocarcinoma and its influence on disease-free survival.  
First Author: Andrea Pretta, MD

- Board 316 **ABSTRACT 3616:** The Ave-Rec trial: Phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer—Toxicity and interim efficacy data.  
First Author: Michael Michael, FRACP, DM, MBBS, BSc
- Board 317 **ABSTRACT 3617:** Organ preservation and total neoadjuvant therapy for rectal cancer: Investigating long course chemoradiation versus short course radiation therapy.  
First Author: Paul Bernard Romesser, MD
- Board 318 **ABSTRACT 3618:** A prospective evaluation of pelvic radiation vs. no radiation among patients with young-onset rectal cancer: Impact on patient-reported outcomes.  
First Author: Kelsey L. Corrigan, MD, MPH
- Board 319 **ABSTRACT 3619:** Prophylactic hyperthermic intraperitoneal chemotherapy in T4 colorectal cancer: Can it improve the oncologic prognosis?  
First Author: Lifeng Sun
- Board 320 **ABSTRACT 3620:** Treatments and clinical outcomes in stage II colon cancer (CC) patients (pts) with 12-gene Oncotype DX Colon Recurrence Score assay-guided therapy: Real-world data.  
First Author: Baruch Brenner, MD
- Board 321 **ABSTRACT 3621:** Efficacy and safety of KN026 in combination with KN046 in patients with locally advanced unresectable or metastatic HER2-positive other solid tumors.  
First Author: Jifang Gong, MD
- Board 322 **ABSTRACT 3622:** Molecular profiling and characterization of the tumor immune microenvironment (TME) in appendiceal carcinoma (AC).  
First Author: Muneeb Rehman, MD
- Board 323 **ABSTRACT 3623:** Comparison of synchronous neoplasms at colonoscopic diagnosis of early-onset versus average-onset colorectal cancer.  
First Author: Oluwadunni Eunice Emiloju, MD, MSc
- Board 324a **ABSTRACT TPS3624:** Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.  
First Author: Jaume Capdevila, MD, PhD
- Board 324b **ABSTRACT TPS3625:** Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).  
First Author: Van K. Morris II, MD
- Board 325a **ABSTRACT TPS3626:** The Ohio State University Guardant Shield Colorectal Cancer Screening Project.  
First Author: Peter Stanich, MD
- Board 325b **ABSTRACT TPS3627:** BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC).  
First Author: Scott Kopetz, MD, PhD
- Board 326a **ABSTRACT TPS3628:** An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma.  
First Author: Dale Randall Shepard, MD, PhD
- Board 326b **ABSTRACT TPS3629:** Alliance A022101: A pragmatic, randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: Evaluating Radiation, Ablation, and Surgery (ERASur).  
First Author: Kathryn Hitchcock, MD, PhD
- Board 327a **ABSTRACT TPS3630:** STELLAR-303: A phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer.  
First Author: J. Randolph Hecht, MD
- Board 327b **ABSTRACT TPS3631:** MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer.  
First Author: Tarios S. Bekaii-Saab, MD
- Board 328a **ABSTRACT TPS3632:** A phase 1/2a, multicenter, open-label study of CNA3103 (LGR5-targeted, autologous CAR-T cells) in patients with metastatic colorectal cancer (mCRC).  
First Author: Jayesh Desai, FRACP
- Board 328b **ABSTRACT TPS3633:** Total neoadjuvant treatment without surgery for locally advanced rectal cancer: Prospective study to assess tumor response, circulating genetic, and epigenetic biomarkers, and stromal transcriptome to interpret clinical outcome (NO-CUT trial).  
First Author: Salvatore Siena, MD
- Board 329a **ABSTRACT TPS3634:** Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.  
First Author: Arvind Dasari, MD, MS
- Board 329b **ABSTRACT TPS3635:** The CIRCULATE Spain study: Circulating tumor DNA based decision for adjuvant treatment in localized colon cancer.  
First Author: Noelia Tarazona, MD
- Board 330a **ABSTRACT TPS3636:** The FOxTROT platform: Clinical trials and exploratory research for personalization of neoadjuvant (NA) therapy in locally advanced colon cancer (LACC)—ISRCTN83842641.  
First Author: Christopher Williams, MBChB, MRCP
- Board 330b **ABSTRACT TPS3637:** PACE: A phase III trial of CAPOX versus anti-PD-1 inhibitor as adjuvant therapy for patients with dMMR/MSI-H stage III colon cancer.  
First Author: Zhenlin Hou
- Board 331a **ABSTRACT TPS3638:** Neoadjuvant short-course radiotherapy followed by chemotherapy plus camrelizumab versus long-course chemoradiotherapy followed by chemotherapy for patients with locally advanced rectal cancer: A randomized, multicenter, open-label phase 3 trial (Union).  
First Author: Zhenyu Lin
- Board 331b **ABSTRACT TPS3639:** Phase II, single-arm, open-label study of dostarlimab monotherapy in previously untreated patients with stage II/III dMMR/MSI-H locally advanced rectal cancer.  
First Author: Andrea Cercek, MD
- Board 332a **ABSTRACT TPS3640:** Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer—The Janus Rectal Cancer trial.  
First Author: Jesse Joshua Smith, MD, PhD
- Board 332b **ABSTRACT TPS3641:** A randomized trial of consolidation-targeted adjuvant therapy with encorafenib and cetuximab versus usual care for patients with stage II/III BRAF V600E colon cancer: Alliance for Clinical Trials in Oncology A022004.  
First Author: Rona Yaeger, MD

8:00 AM - 11:00 AM Poster Session

**Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary**

Location: Hall A

Abstracts on Boards 334-344 will be discussed during the Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary Poster Discussion Session. See the online program guide (meetings.asco.org) for session details.

**Posters by Topic**

**Biologic Correlates:** Board 346

**Esophageal or Gastric Cancer—Advanced/Metastatic Disease:**

Boards 334-335, 347-353, 355-374, 492a-494b

**Esophageal or Gastric Cancer—Local-Regional Disease:** Boards 375-379, 381-391, 495a

**Hepatobiliary Cancer—Advanced/Metastatic Disease:** Boards 336, 392-422, 424-439, 495b-499a

**Hepatobiliary Cancer—Local-Regional Disease:** Boards 337-338, 340, 344, 440-452, 499b-501b

**Neuroendocrine/Carcinoid:** Boards 343, 453-454, 456, 502a-502b

**Pancreatic Cancer—Advanced/Metastatic Disease:** Boards 339, 341-342, 457-477, 503a-507a

**Pancreatic Cancer—Local-Regional Disease:** Boards 479-488, 507b-509a

**Other GI Cancer:** Boards 489-491, 509b

Board 334 **ABSTRACT 4014:** KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations.  
First Author: Sun Young Rha, MD

Board 335 **ABSTRACT 4027:** A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab + chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA).  
First Author: Samuel J. Klempner, MD

Board 336 **ABSTRACT 4015:** A phase 2 randomized, open-label, multicentre study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC.  
First Author: Li Jingjing

Board 337 **ABSTRACT 4016:** A randomized study of consolidation chemoradiation (CTRT) vs observation after first-line chemotherapy (CT) in advanced gall bladder cancers (GBC): RACE-GB Study.  
First Author: Sushma Agrawal, MD

Board 338 **ABSTRACT 4017:** A multicenter, open-label, randomized phase II study evaluating adjuvant gemcitabine plus cisplatin (GC) and capecitabine with concurrent capecitabine radiotherapy (CAPE-RT) in patients with operated gallbladder adenocarcinoma (GBC): The GECCOR-GB trial.  
First Author: Anant Ramaswamy, DM

Board 339 **ABSTRACT 4018:** Clinical and genomic characterization of early-onset pancreatic cancer.  
First Author: Florian Castet, MD

Board 340 **ABSTRACT 4019:** Investigating alterations in cancer driver genes and other potentially targetable mutations in patients with intrahepatic cholangiocarcinoma (iCCA) treated on the randomised phase III multicentre BILCAP clinical trial.  
First Author: Valerie Elizabeth Crolley, MBBS, MRCP

Board 341 **ABSTRACT 4020:** Not all treated KRAS-mutant pancreatic adenocarcinomas are equal: KRAS G12D and survival outcome.  
First Author: Bach Ardalan, MD

Board 342 **ABSTRACT 4021:** FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naive metastatic pancreatic cancer (mPDAC).  
First Author: Benedikt Westphalen, MD

Board 343 **ABSTRACT 4022:** Prospective evaluation of the utility of concurrent 18F-FDG PET/CT and 68Ga-DOTA-TOC imaging in gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): The PETNET study.  
First Author: Joao Paulo Solar Vasconcelos, MD

Board 344 **ABSTRACT 4023:** Neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: A multi-center, phase 3, randomized, controlled clinical trial.  
First Author: Wei Wei, MD, PhD

Board 346 **ABSTRACT 4024:** Preliminary translational immune and stromal correlates in a randomized phase II trial of pembrolizumab with or without defactinib for resectable pancreatic ductal adenocarcinoma (PDAC).  
First Author: Anser Ali Abbas, BS

Board 347 **ABSTRACT 4025:** Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.  
First Author: Yelena Y. Janjigian, MD

Board 348 **ABSTRACT 4026:** Final survival results of ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive esophageal adenocarcinoma: The randomized AIO INTEGA trial.  
First Author: Joseph Tintelnot, MD

Board 349 **ABSTRACT 4028:** AdvanTIG-105: A phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC).  
First Author: Se Hyun Kim, MD, PhD

Board 350 **ABSTRACT 4029:** A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma.  
First Author: Jing Huang, MD

Board 351 **ABSTRACT 4030:** Expression molecular subtype as a predictor of outcomes of chemoradiotherapy for esophageal cancer.  
First Author: Manabu Muto, MD

Board 352 **ABSTRACT 4031:** A phase Ib/II, multicenter, open-label study of AK104, a PD-1/CTLA-4 bispecific antibody, combined with chemotherapy (chemo) as first-line therapy for advanced gastric (G) or gastroesophageal junction (GEJ) cancer: 2-Year update data.  
First Author: Jiafu Ji, MD, PhD

Board 353 **ABSTRACT 4032:** Ramucirumab, avelumab and paclitaxel (RAP) as second line treatment in esophagogastric adenocarcinoma: Final results of the phase 2 RAP trial (AIO-STO-0218).  
First Author: Peter C. Thuss-Patience, MD

Board 355 **ABSTRACT 4034:** EpCAM CAR T (IMC001) for the treatment of advanced GI cancers.  
First Author: Tianhang Luo

- Board 356 **ABSTRACT 4035:** Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW).  
First Author: Kohei Shitara, MD
- Board 357 **ABSTRACT 4036:** Cell free DNA (cfDNA) assessment of esophagogastric (EG) cancer using MSK-ACCESS.  
First Author: Samuel Louis Cytryn, MD
- Board 358 **ABSTRACT 4037:** Effect of autologous lymphocytes combined with chemotherapy as the first-line treatment of advanced gastric cancer.  
First Author: Xiaoting Ma
- Board 359 **ABSTRACT 4038:** Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): 36-month results of nivolumab plus chemotherapy (N+C) versus (C) from CheckMate 649.  
First Author: Elena Elimova, MD
- Board 360 **ABSTRACT 4039:** Survival analysis by tumor response of nivolumab treatment in previously treated advanced gastric cancer from the DELIVER trial (JACCRO GC-08).  
First Author: Yu Sunakawa, MD, PhD
- Board 361 **ABSTRACT 4040:** Ultra-sensitive, tumor-informed ctDNA profiling in patients with gastroesophageal cancer and treated with pembrolizumab and longitudinal ctDNA kinetics.  
First Author: Andrew B. Nixon, PhD
- Board 362 **ABSTRACT 4041:** Updated results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial.  
First Author: Zhiye Zhang, MD
- Board 363 **ABSTRACT 4042:** Phase II study of lenvatinib plus pembrolizumab for patients with immunotherapy-naive advanced gastric cancer following first line therapy.  
First Author: Deirdre Jill Cohen, MD
- Board 364 **ABSTRACT 4043:** Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy within the prospective phase II IKF-S628/AIO-STO-0417 (MOONLIGHT) trial.  
First Author: Michael Masetti, MD
- Board 365 **ABSTRACT 4044:** A phase 2 single-arm study of berzosertib in combination with irinotecan in patients with progressive TP53 mutant gastric and gastroesophageal junction cancer.  
First Author: Shannon Stockton, MD
- Board 366 **ABSTRACT 4045:** FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase 2 IKF-S628/AIO-STO-0417 (Moonlight) trial of the AIO.  
First Author: Sylvie Lorenzen, MD
- Board 367 **ABSTRACT 4046:** Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer: Updated data of cohort C from a phase I/IIa, multi-center study (TransTar102/TST001-1002).  
First Author: Lin Shen, MD, PhD
- Board 368 **ABSTRACT 4047:** Heterogeneous baseline immune cell infiltration landscape as a predictor of pathological complete response in locally advanced esophageal squamous cell carcinoma (ESCC) following neoadjuvant chemotherapy and immunotherapy: Results from a single-arm, phase II clinical trial (SEEK-01).  
First Author: Guangyu Yao
- Board 369 **ABSTRACT 4048:** Camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II trial.  
First Author: Lei Gong
- Board 370 **ABSTRACT 4049:** Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).  
First Author: Zhihao Lu, MD
- Board 371 **ABSTRACT 4050:** Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: The randomized phase 2 IKF-S628 Moonlight trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).  
First Author: Sylvie Lorenzen, MD
- Board 372 **ABSTRACT 4051:** Advancing individualized care in advanced gastroesophageal cancers (GEC): A quality improvement initiative.  
First Author: Matthew Strickland, MD
- Board 373 **ABSTRACT 4052:** Phase II study of telomelysin (OBP-301) in combination with pembrolizumab in gastroesophageal (GEA) adenocarcinoma.  
First Author: Manish A. Shah, MD
- Board 374 **ABSTRACT 4053:** Circulating tumor DNA and association with CAR-T cell therapy response in gastric and pancreatic cancer patients.  
First Author: Sindhu Kubendran, MD, MPH
- Board 375 **ABSTRACT 4054:** Adjuvant nab-paclitaxel plus S-1 versus capecitabine plus oxaliplatin for patients with stage III gastric adenocarcinoma after D2 dissection: A multicenter, open-label, randomized phase 3 study.  
First Author: Yu Pengfei, MD
- Board 376 **ABSTRACT 4055:** Perioperative immunochemotherapy (mDCF + avelumab) in locally advanced gastroesophageal adenocarcinoma: A phase II trial.  
First Author: Thierry Alcindor, MD, MSc
- Board 377 **ABSTRACT 4056:** Predicting role of circulating tumor DNA and blood-based tumor mutational burden in esophageal squamous cell carcinoma receiving chemoradiotherapy combined with toripalimab: Exploratory analyses from a phase II trial (EC-CRT-001).  
First Author: BaoQing Chen, MD
- Board 378 **ABSTRACT 4057:** Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive gastric (GC) and esophagogastric junction cancer (EGJC): First results of the EORTC 1203 INNOVATION study, in collaboration with the Korean Cancer Study Group, and the Dutch Upper GI Cancer group.  
First Author: Anna Dorothea Wagner, MD
- Board 379 **ABSTRACT 4058:** Concordance among the three commercially available PD-L1 assays for esophageal squamous cell carcinoma.  
First Author: Lizhen Wang, PhD

Monday, June 5, 2023

- Board 381 **ABSTRACT 4060:** Multi-dimensional cell-free DNA-based liquid biopsy and early detection of gastric cancer.  
First Author: Yu Pengfei, MD
- Board 382 **ABSTRACT 4061:** Induction chemotherapy plus definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: Long-term results and exploratory analyses of a randomized controlled trial.  
First Author: Mian Xi, MD
- Board 383 **ABSTRACT 4062:** Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): Assessment of pathologic response and toxicity in a prospective, phase II single-arm trial.  
First Author: Pooja Karukonda, MD
- Board 384 **ABSTRACT 4063:** Development of an artificial intelligence algorithm for adjuvant chemotherapy based on a nationwide registry of patients with gastric cancer by the Japanese Gastric Cancer Association (JGCA).  
First Author: Yasuhide Yamada, MD, DMSc, FACP
- Board 385 **ABSTRACT 4064:** Efficacy and safety of camrelizumab combined with chemotherapy versus chemotherapy alone as preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma: Preliminary results from a multicenter, prospective, randomized controlled study.  
First Author: Renquan Zhang
- Board 386 **ABSTRACT 4065:** Five-year overall survival with S-1 plus docetaxel as adjuvant treatment in curatively resected pStage III gastric cancer in JACCRO GC-07.  
First Author: Wataru Ichikawa, MD, DMSc
- Board 387 **ABSTRACT 4066:** Circulating tumor DNA as a marker of recurrence risk in locoregional esophagogastric cancers with pathologic complete response.  
First Author: Eric Michael Lander, MD
- Board 388 **ABSTRACT 4067:** Neoadjuvant docetaxel, oxaliplatin, and s-1 plus surgery and adjuvant s-1 for resectable advanced gastric cancer: Final survival outcomes of the randomized phase 3 PRODIGY trial.  
First Author: Yoon-Koo Kang, MD, PhD
- Board 389 **ABSTRACT 4068:** Neoadjuvant tislelizumab combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Single arm phase II study.  
First Author: Peng Jin
- Board 390 **ABSTRACT 4069:** GaEsSeer: Early detection of gastric and esophageal cancer by integrating methylation and fragmentomics signatures in cfDNA.  
First Author: Yun-Shi Zhong
- Board 391 **ABSTRACT 4070:** Long-term quality of life and nutritional results of stomach-preserving surgery after sentinel node evaluation in patients with early gastric cancer: A multicenter, randomized phase 3 trial (SENORITA).  
First Author: Bang Wool Eom, MD, PhD
- Board 392 **ABSTRACT 4071:** Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated biliary tract cancer.  
First Author: Wen-Zhuo He
- Board 393 **ABSTRACT 4072:** Transarterial chemoembolization combined with lenvatinib and camrelizumab for unresectable hepatocellular carcinoma: A prospective, single-arm, multicenter study.  
First Author: Zhibo Zhang
- Board 394 **ABSTRACT 4073:** Temporal patterns of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).  
First Author: George Lau, MD
- Board 395 **ABSTRACT 4074:** Landmark analysis of OS by response status in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post hoc analysis of the KEYNOTE-394 study.  
First Author: Zhenggang Ren, MD
- Board 396 **ABSTRACT 4075:** A phase 1b study of E7386, a CREB-binding protein (CBP)/ $\beta$ -catenin interaction inhibitor, in combination with lenvatinib in patients with advanced hepatocellular carcinoma.  
First Author: Masafumi Ikeda, MD, PhD
- Board 397 **ABSTRACT 4076:** Early experience with nivolumab, gemcitabine, and lenvatinib for fibrolamellar hepatocellular carcinoma.  
First Author: Paul Kent, MD
- Board 398 **ABSTRACT 4077:** An open-label, multicenter, adaptive, phase Ib/II study of QL1706 or QL1604 plus bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma.  
First Author: Feng Bi, MD, PhD
- Board 399 **ABSTRACT 4078:** Efficacy of lenvatinib (LEN) vs sorafenib (SOR) in the first-line (1L) treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC): A post hoc analysis of patients with nonviral etiology from REFLECT.  
First Author: Ari David Baron, MD
- Board 400 **ABSTRACT 4079:** Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma.  
First Author: Jinpeng Li
- Board 401 **ABSTRACT 4080:** Safety and efficacy of allogeneic natural killer cells in combination with pembrolizumab in patients with chemotherapy-refractory biliary tract cancer: A multicenter open-label phase 1/2a trial.  
First Author: Galam Leem, MD, PhD
- Board 402 **ABSTRACT 4081:** Economic evaluation for the US of durvalumab plus gemcitabine and cisplatin (DGC) in advanced biliary tract cancer (BTC).  
First Author: Osama Aqel, BPharm
- Board 403 **ABSTRACT 4082:** Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): The RATIONALE-301 European/North American (EU/NA) subgroup.  
First Author: Arndt Vogel, MD
- Board 404 **ABSTRACT 4083:** Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS).  
First Author: Masatoshi Kudo, MD, PhD
- Board 405 **ABSTRACT 4084:** A novel patient-centric longitudinal data registry platform to generate insights into real-world cholangiocarcinoma (CCA) clinical practice.  
First Author: Amanda Nottke, PhD
- Board 406 **ABSTRACT 4085:** Liquid-biopsy detection of FGFR2 and other actionable rearrangements in GI malignancies.  
First Author: Pashtoon Murtaza Kasi, MD, MSc

- Board 407 **ABSTRACT 4086:** Sintilimab plus gemcitabine and cisplatin as a first-line treatment for patients with advanced biliary tract cancer: A biomolecular exploratory, phase II clinical trial.  
First Author: Zhen-gang Yuan
- Board 408 **ABSTRACT 4087:** Phase II clinical trial of olaparib plus pembrolizumab in the treatment of patients with advanced biliary tract cancer.  
First Author: James O'Bryan, MD
- Board 409 **ABSTRACT 4088:** Characterizing KRAS allele variants within biliary tract cancers.  
First Author: Gordon Taylor Moffat, MD, FRCPC
- Board 410 **ABSTRACT 4089:** Trastuzumab (T) plus gemcitabine-cisplatin (GC) for treatment naive HER2 positive biliary tract adenocarcinomas (BTC): A multicentre open-label, phase II study (TAB).  
First Author: Vikas S. Ostwal, MD
- Board 411 **ABSTRACT 4090:** Individual patient-level data validation of surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma: Post-hoc analysis of IMbrave150 and real-world observations.  
First Author: Mir Lim, MD
- Board 412 **ABSTRACT 4091:** Salvage ipilimumab plus nivolumab in advanced hepatocellular carcinoma after prior anti-PD-(L)1 blockade.  
First Author: Stephanie L. Alden, MD
- Board 413 **ABSTRACT 4092:** The metabolic activity assessed by <sup>18</sup>F-FDG PET and its correlation with tumor immune status and prognosis in advanced biliary tract cancer patients treated with 1L GemCis plus durvalumab +/-tremelimumab.  
First Author: Jeusun Yoon, MD
- Board 414 **ABSTRACT 4093:** Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program.  
First Author: Subotheni Thavaneswaran, PhD, FRACP, MMed
- Board 415 **ABSTRACT 4094:** Efficacy and safety of first-line treatments for patients with advanced hepatocellular carcinoma: A systematic review and network meta-analysis.  
First Author: Danni Li
- Board 416 **ABSTRACT 4095:** Phase I trial of chimeric anti-GPC3 scFv-CD3 $\epsilon$  engineered T cells (CT0180) in patients with advanced hepatocellular carcinoma.  
First Author: Yi Zheng
- Board 417 **ABSTRACT 4096:** A prospective, open-label, randomized, controlled trial of radiofrequency ablation versus stereotactic body radiation therapy for recurrent small hepatocellular carcinoma.  
First Author: Yaojun Zhang, MD
- Board 418 **ABSTRACT 4097:** Circulating tumor DNA (ctDNA) analyses in patients with HER2-positive biliary tract cancer (BTC) treated with trastuzumab deruxtecan (T-DXd): Exploratory results from the HERB trial.  
First Author: Akihiro Ohba, MD
- Board 419 **ABSTRACT 4098:** BOLD-100-001 (TRIO039): A phase 1b/2a study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pre-treated advanced gastric and biliary tract cancer: Efficacy and safety analysis.  
First Author: Grainne M. O'Kane, MD, MRCP, BCh, MB
- Board 420 **ABSTRACT 4099:** A phase II study of olaparib and durvalumab in patients with IDH-mutated cholangiocarcinoma.  
First Author: Erica S Tsang, MD, MPH
- Board 421 **ABSTRACT 4100:** Racial and socioeconomic disparities in time to chemotherapy and survival in patients with pancreatic cancer.  
First Author: Shivani Shah, MD
- Board 422 **ABSTRACT 4101:** Progression-free survival as a surrogate endpoint of overall survival in advanced biliary tract cancer: A meta-analysis of randomized trials and individual-patient level correlation.  
First Author: Carles Fabregat Franco, MD
- Board 424 **ABSTRACT 4103:** Ex-vivo analysis of programmed cell death on fibrolamellar carcinoma.  
First Author: Olutani-Grace Ajay, BS
- Board 425 **ABSTRACT 4104:** Alteration of gut microbiota composition in patients with cholangiocarcinoma with non-responsiveness to first-line chemotherapy: A pilot study.  
First Author: Thanika Ketpueak, MD
- Board 426 **ABSTRACT 4105:** Real-world multicentre analysis of patients with hepatocellular carcinoma (HCC) treated with atezolizumab and bevacizumab (A+B): Efficacy, esophagogastroduodenoscopy (EGD) uptake and bleeding complications.  
First Author: Cha Len Lee, MD
- Board 427 **ABSTRACT 4106:** Association of a high E2F targets score with survival in hepatocellular carcinoma patients.  
First Author: Kohei Chida, MD
- Board 428 **ABSTRACT 4107:** Application of the albumin-bilirubin (ALBI) grade as predictive marker of atezolizumab plus bevacizumab (A+B) treatment outcomes for patients with advanced hepatocellular carcinoma (HCC): Real-world retrospective analysis at Veterans Health Administration (VHA).  
First Author: Munaf Alkadimi, MD
- Board 429 **ABSTRACT 4108:** Comprehensive profiling of clock genes expression in hepatocellular carcinoma (HCC).  
First Author: Francesca Battaglin, MD
- Board 430 **ABSTRACT 4109:** Evaluating racial disparities for patients with advanced hepatocellular carcinoma (HCC) receiving first line immunotherapy within an equal access system.  
First Author: Lauren Diaz Boyle, DO, MS
- Board 431 **ABSTRACT 4110:** The clinical feasibility of circulating tumor DNA alterations in patients with advanced hepatocellular carcinoma.  
First Author: Gwangil Kim, MD, PhD
- Board 432 **ABSTRACT 4111:** Lenvatinib (LEN) combined with tislelizumab (TIS) plus transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II clinical trial.  
First Author: Xiang Nong
- Board 433 **ABSTRACT 4112:** Molecular subtypes from comprehensive clustering from multi-omics dataset to predict the therapeutic efficacy of immunotherapeutic agent-based treatments in advanced hepatocellular carcinoma.  
First Author: Hong Jae Chon, MD, PhD
- Board 434 **ABSTRACT 4113:** Phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy following first-line platinum-based chemotherapy in patients with advanced biliary tract cancer (BTC): BiT-02.  
First Author: Vaibhav Sahai, MBBS, MS

- Board 435 **ABSTRACT 4114:** Tracking the evolving ecosystem of recurrent hepatocellular carcinoma after liver transplantation.  
First Author: Zijie Zhang, MD, PhD
- Board 436 **ABSTRACT 4115:** Geographical and baseline clinical characteristics of participants enrolled in hepatocellular carcinoma (HCC) trials: Analysis of US FDA approvals.  
First Author: M. Naomi Horiba, MD, MPH
- Board 437 **ABSTRACT 4116:** Effect of MYC-targeting programmable epigenetic mRNA therapeutics on TME and immunotherapy responses.  
First Author: Yan Moore, MD, MBA
- Board 438 **ABSTRACT 4117:** FDA analysis of treatment efficacy based on etiology of hepatocellular carcinoma.  
First Author: May Tun Saung, MD
- Board 439 **ABSTRACT 4118:** Characteristics and outcomes of patients with young-onset versus average-onset cholangiocarcinoma in the United States.  
First Author: Udhayvir Singh Grewal, MD
- Board 440 **ABSTRACT 4119:** Adjuvant immune checkpoint inhibitors and association with recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): A prospective cohort study.  
First Author: Le Li
- Board 441 **ABSTRACT 4120:** Camrelizumab in combination with apatinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: A prospective, single-arm, phase 2 study.  
First Author: Yunlong Cui
- Board 442 **ABSTRACT 4121:** Machine learning-based multimodal prediction of prognosis in patients with resected intrahepatic cholangiocarcinoma.  
First Author: Benoit Schmauch, PhD
- Board 443 **ABSTRACT 4122:** Efficacy and safety of HepaSphere drug-eluting bead transarterial chemoembolization combined with hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma.  
First Author: Baojiang Liu, MD
- Board 444 **ABSTRACT 4123:** Utility of circulating tumor DNA (ctDNA) as a predictive biomarker for disease monitoring in patients (pts) with cholangiocarcinoma (CCA) before and during adjuvant chemotherapy (ACT): Sub-analysis of the randomized phase 2 STAMP trial.  
First Author: Changhoon Yoo, MD, PhD
- Board 445 **ABSTRACT 4124:** Preliminary results of sequential transarterial chemoembolization and stereotactic body radiotherapy followed by immunotherapy using single tremelimumab regular interval durvalumab in locally advanced, unresectable hepatocellular carcinoma (START-FIT using STRIDE): A single-arm, phase II study.  
First Author: Chi Leung Chiang
- Board 446 **ABSTRACT 4125:** Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study.  
First Author: Kazuomi Ueshima, MD, PhD
- Board 447 **ABSTRACT 4126:** A phase II/III study of camrelizumab plus apatinib as perioperative treatment of resectable hepatocellular carcinoma at intermediate-high risk of recurrence: Primary results of major pathologic response from phase II stage.  
First Author: Jian Zhou, MD, PhD
- Board 448 **ABSTRACT 4127:** Robotic and laparoscopic surgery versus open surgery for perihilar cholangiocarcinoma: A meta-analysis.  
First Author: Laynara Vitória Da Silva Vieira
- Board 449 **ABSTRACT 4128:** Development and validation of a non-invasive cfDNA targeted sequencing assay for early-stage hepatocellular carcinoma detection using cfDNA methylation and fragmentomics.  
First Author: Rui Liu
- Board 450 **ABSTRACT 4129:** Neoadjuvant immunotherapy with ipilimumab plus nivolumab and radiologically and pathologically quantifiable responses through modulation of the tumour microenvironment in resectable hepatocellular carcinoma.  
First Author: Antonio D'Alessio
- Board 451 **ABSTRACT 4130:** The efficacy of radical hepatectomy versus stereotactic body radiotherapy for primary hepatocellular carcinoma: A propensity score matching analysis.  
First Author: Yulin Hu, master
- Board 452 **ABSTRACT 4131:** Racial disparities in the outcomes of liver transplantation in the treatment of hepatocellular carcinoma.  
First Author: Syeda Ashna Fatima Kamal, MD
- Board 453 **ABSTRACT 4132:** ACTION-1 phase Ib/3 trial of RYZ101 in somatostatin receptor subtype 2-expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after <sup>177</sup>Lu somatostatin analogue (SSA) therapy: Initial safety analysis.  
First Author: Michael Morris, MD, MS
- Board 454 **ABSTRACT 4133:** Novel use of alternate (Alt) response (Rp) criteria (Cr) for early prediction of outcomes in pancreatic (P) neuroendocrine tumors (NETs): Utilizing banked imaging data from the ECOG-ACRIN E2211 study.  
First Author: Namrata Vijayvergia, MD
- Board 456 **ABSTRACT 4135:** Prevalence of germline variants in patients with pancreatic neuroendocrine tumors.  
First Author: Chirayu Mohindroo, MD
- Board 457 **ABSTRACT 4136:** Safety and clinical activity of oleclumab (O) ± durvalumab (D) + chemotherapy (CT) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A phase 1b/2 randomized study.  
First Author: Andrew L. Coveler, MD
- Board 458 **ABSTRACT 4137:** Retrospective evaluation of the value of DNA damage repair gene signature in response to platinum-based chemotherapy in advanced pancreatic ductal adenocarcinoma.  
First Author: Tian Tian, MD, PhD
- Board 459 **ABSTRACT 4138:** Genomic characterization of somatic mutations by race and ethnicity in pancreatic cancer defined through AACR project GENIE.  
First Author: J. Alberto Maldonado, BA
- Board 460 **ABSTRACT 4139:** Efficacy and safety of mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): An interim analysis of the optimize-1 phase 1b/2 study.  
First Author: Hans Prenen, MD, PhD
- Board 461 **ABSTRACT 4140:** Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy.  
First Author: Wungki Park, MD, MS

- Board 462 **ABSTRACT 4141:** Development and evaluation of 5FUCore, OxaliCore, and IrinoCore transcriptomic signatures for predicting response to individual drugs in the FOLFIRINOX regimen: Towards toxicity reduction and personalized chemotherapy in PDAC.  
First Author: Nicolas Fraunhofer, PhD
- Board 463 **ABSTRACT 4142:** A phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel, and S-1 (NASCAs) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC).  
First Author: Guang-Hai Dai, MD
- Board 464 **ABSTRACT 4143:** A phase II study of nivolumab and ipilimumab with radiation therapy in patients with metastatic, microsatellite stable pancreatic adenocarcinoma.  
First Author: Julie L. Koenig, MD
- Board 465 **ABSTRACT 4144:** Correlation of comprehensive molecular mapping of pancreatic ductal adenocarcinoma with XPO1 mRNA expression levels to potential clinical targets.  
First Author: Andreas Seeber, MD, PhD
- Board 466 **ABSTRACT 4145:** Clinical genomic implications of transcriptional subtypes in pancreatic cancer.  
First Author: Harshabad Singh, MBBS
- Board 467 **ABSTRACT 4146:** Tumor mutational burden (TMB) in real-world patients with pancreatic ductal adenocarcinoma (PDAC): Differences in genomic alterations (GA) and predictive value for immune checkpoint inhibitor (ICI) effectiveness.  
First Author: Amit Mahipal, MPH, MBBS
- Board 468 **ABSTRACT 4147:** Randomized phase 2 study of nab-paclitaxel and gemcitabine with or without tocilizumab as first-line treatment in patients with advanced pancreatic cancer (PACTO).  
First Author: Inna Markovna Chen, MD
- Board 469 **ABSTRACT 4148:** Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.  
First Author: Lorenzo Pilla, MD
- Board 470 **ABSTRACT 4149:** Validation of the PDACai signature in predicting relative benefit from frontline FOLFIRINOX (FFX) and gemcitabine/nab-paclitaxel (GA) for patients (pts) with metastatic pancreatic cancer (mPDAC).  
First Author: Michael J. Pishvaian, MD, PhD
- Board 471 **ABSTRACT 4150:** KRAS G12C-mutated pancreatic cancer: Clinical outcomes based on chemotherapeutic regimen.  
First Author: Aaron Ciner, MD
- Board 472 **ABSTRACT 4151:** Molecular and clinical correlates of DSCR1 expression in pancreatic cancer (PDAC).  
First Author: Francesca Battaglin, MD
- Board 473 **ABSTRACT 4152:** Nationwide implementation of best practices in pancreatic cancer care (PACAP-1): Stepped-wedge cluster randomized trial.  
First Author: Tara Mackay, MD, PhD
- Board 474 **ABSTRACT 4153:** First in class TLR7/8 agonist BDB001 combined with atezolizumab and stereotactic body radiation therapy in patients with advanced pancreatic adenocarcinoma: Results from the AGADIR study.  
First Author: Simon Pernot, MD, MhD
- Board 475 **ABSTRACT 4154:** Clinical utility of next generation sequencing (NGS) on circulating tumor DNA (ctDNA) in patients (pts) with pancreatic cancer (PC).  
First Author: Fergus Keane, MBChB, MA
- Board 476 **ABSTRACT 4155:** Impact of novel pan-RAS inhibitors on efficacy and resistance to AMG-510 and MRTX-1133 in pancreatic cancer cell lines.  
First Author: Tariq Arshad, MD, MBA
- Board 477 **ABSTRACT 4156:** Targeting germline or somatic DNA repair defects (beyond BRCA) in pancreatic cancer with niraparib: A phase II study (NIRA-PANC).  
First Author: Anup Kasi, MD, MPH
- Board 479 **ABSTRACT 4158:** Chemotherapy dose density and effect on prognosis for patients with resectable pancreas cancer: A secondary analysis of SWOG S1505.  
First Author: Sameer H. Patel, MD
- Board 480 **ABSTRACT 4159:** PD-1 blockade plus chemotherapy followed by concurrent SBRT with SIB as preoperative therapy for patients with borderline resectable and locally advanced pancreatic cancer: A biomolecular exploratory, single-arm phase II clinical trial.  
First Author: Juan Du, MD
- Board 481 **ABSTRACT 4160:** Impact of positive resection margins on recurrence and survival following resection and adjuvant chemotherapy in pancreatic cancer: Results of the PRODIGE 24-CCTG PA-6 trial.  
First Author: Aurélien Lambert, MD, PhD
- Board 482 **ABSTRACT 4161:** Tandem duplicator phenotype: A novel targetable subgroup in pancreatic cancer?  
First Author: Abdul Rehman Farooq, MBBS
- Board 483 **ABSTRACT 4162:** Artificial intelligence (AI)-powered spatial analysis of tumor-infiltrating lymphocytes (TILs) for prediction of prognosis in resectable pancreatic adenocarcinoma (PDAC).  
First Author: Yoojoo Lim, MD
- Board 484 **ABSTRACT 4163:** Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): An international randomised trial.  
First Author: Mohammed Abu Hilal, MD, PhD
- Board 485 **ABSTRACT 4164:** A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer.  
First Author: Richard Tuli, MD, PhD
- Board 486 **ABSTRACT 4165:** Meta-analyses of factors associated with long-term survival after resection of pancreatic ductal adenocarcinoma.  
First Author: Asad Saulat Fatimi, MBBS
- Board 487 **ABSTRACT 4166:** Mutation-site localized non-B DNA burden and survival heterogeneity in early-stage pancreatic cancer.  
First Author: Qi Xu
- Board 488 **ABSTRACT 4167:** The five periampullary cancers: Not just different siblings but different families—An international multicenter cohort study.  
First Author: Bas Uijterwijk, MD
- Board 489 **ABSTRACT 4168:** Incidence, epidemiological characteristics, and cause-specific survival analysis of ampullary carcinoma using the SEER database.  
First Author: Rajvi Gor, MD
- Board 490 **ABSTRACT 4169:** Detection and localization of gastrointestinal cancers based on multi-dimensional signatures from a single cfDNA targeted sequencing assay.  
First Author: Xin-Rong Yang, MD, PhD
- Board 491 **ABSTRACT 4170:** Multi-institutional study evaluating the role of circulating tumor DNA (ctDNA) in management of appendiceal cancers (AC).  
First Author: Erika Belmont, MD



**Monday, June 5, 2023**

- Board 492a **ABSTRACT TPS4171:** A phase 2 trial of chemotherapy, pembrolizumab, and propranolol in patients with advanced esophageal/gastroesophageal junction adenocarcinoma (EGAC).  
First Author: Sarbajit Mukherjee, MD, MS
- Board 492b **ABSTRACT TPS4172:** Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic esophageal and gastroesophageal carcinoma with dysphagia: A single arm phase 2 clinical trial, PALEO.  
First Author: Fiona Day, PhD, MBBS, FRACP
- Board 493a **ABSTRACT TPS4173:** Phase 2 trial of zolbetuximab in combination with mFOLFOX6 and nivolumab in patients with advanced or metastatic claudin 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas.  
First Author: Kohei Shitara, MD
- Board 493b **ABSTRACT TPS4174:** A phase 2 basket trial of ulixertinib (BVD-523) in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies harboring MAPK pathway mutations (BVD-523-HCQ).  
First Author: Andrew H. Ko, MD, FASCO
- Board 494a **ABSTRACT TPS4175:** Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA).  
First Author: Haeseong Park, MD, MPH
- Board 494b **ABSTRACT TPS4176:** A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101.  
First Author: Yelena Y. Janjigian, MD
- Board 495a **ABSTRACT TPS4177:** A randomized, open-label, phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF-S633/DANTE trial, a trial of AIO in collaboration with SAKK.  
First Author: Salah-Eddin Al-Batran, MD
- Board 495b **ABSTRACT TPS4178:** An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab and bevacizumab therapy in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.  
First Author: Tanios S. Bekaii-Saab, MD
- Board 496a **ABSTRACT TPS4179:** A phase IIa/IIb, open-label trial of BI 907828, an MDM2-p53 antagonist, in patients with locally advanced/metastatic biliary tract carcinoma or pancreatic ductal adenocarcinoma: Brightline-2.  
First Author: Lipika Goyal, MD
- Board 496b **ABSTRACT TPS4180:** Randomized phase 2 study of maintenance olaparib vs olaparib plus durvalumab for DNA damage repair (DDR) gene mutated unresectable or metastatic biliary tract cancer (BTC) with durable response to first-line platinum-based chemotherapy: OPTIMUM trial.  
First Author: YunJung Kim, BSN
- Board 497a **ABSTRACT TPS4181:** Autologous cytotoxic T-cell receptor T cell therapy (SCG101) against hepatitis B surface antigen phase I/II trial for patients with advanced hepatitis B-related hepatocellular carcinoma.  
First Author: Ghassan K. Abou-Alfa, MD, MBA
- Board 498a **ABSTRACT TPS4183:** ABC-12: Exploring the microbiome in patients (pts) with advanced biliary tract cancer (BTC) in a first-line study of durvalumab in combination with cisplatin/gemcitabine (cis/gem).  
First Author: Mairead Geraldine McNamara, PhD, MBCh
- Board 498b **ABSTRACT TPS4184:** Phase II trial of XmAb20717 (vudalimab) in patients with advanced biliary tract cancers.  
First Author: William Joseph Chapin, MD, MSCE
- Board 499a **ABSTRACT TPS4185:** Phase II study on safety and efficacy of NMS-01940153E, an MPS1 inhibitor with first-in-class potential, in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy.  
First Author: Lorenza Rimassa, MD
- Board 499b **ABSTRACT TPS4186:** NeoTACE: A multicenter, randomized study evaluating the efficacy and safety of neoadjuvant HAIC for TACE plus donafenib in BCLC B stage hepatocellular carcinoma outside of up-to-seven.  
First Author: Xiaodong Wang, MD
- Board 500a **ABSTRACT TPS4187:** ADJUBIL: A phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer.  
First Author: Thorsten Oliver Goetze, MD
- Board 500b **ABSTRACT TPS4188:** Durvalumab and tremelimumab for hepatocellular carcinoma in patients listed for a liver transplant.  
First Author: Davendra Sohal, MD, MPH
- Board 501a **ABSTRACT TPS4189:** An open-label window of opportunity trial to evaluate the activity of durvalumab and tremelimumab with platinum-based chemotherapy (gemcitabine and cisplatin) in intrahepatic cholangiocarcinoma.  
First Author: Olumide B. Gbolahan, MBBS
- Board 501b **ABSTRACT TPS4190:** A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.  
First Author: Sherise C. Rogers, MD, MPH
- Board 502a **ABSTRACT TPS4191:** Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma.  
First Author: Jaydira Del Rivero, MD
- Board 502b **ABSTRACT TPS4192:** LANTana trial protocol: An open label, single arm, phase Ib study to evaluate the effect of pre-treatment with ASTX727 (a demethylating agent) followed by lutetium Lu 177 dotatate in patients with progressive, metastatic neuroendocrine neoplasias (NENs).  
First Author: Rohini Sharma, PhD, FRACP, MBBS
- Board 503a **ABSTRACT TPS4193:** Open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with oxaliplatin and 5-fluorouracil/folinic acid followed by curative surgical resection in patients with hepatic oligometastatic adenocarcinoma of the pancreas (HOLIPANC).  
First Author: Florian Gebauer, MD
- Board 503b **ABSTRACT TPS4194:** Phase II trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC).  
First Author: Benjamin Adam Weinberg, MD

- Board 504a **ABSTRACT TPS4195:** Phase 1b/2 trial of pepinemab plus avelumab as second line combination immunotherapy for patients with metastatic pancreatic adenocarcinoma.  
First Author: Luis I. Ruffolo, MD
- Board 504b **ABSTRACT TPS4196:** A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of LB4330, a peptide fused to CLDN18.2 antibody targeting the tumor antigen associated CD8+t CELLS in patients with advanced solid tumors.  
First Author: Jiajian Liu, PhD
- Board 505a **ABSTRACT TPS4197:** ASCEND: A randomised, double-blinded, phase II study of gemcitabine and nab-paclitaxel with CEND-1/LSTA1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma.  
First Author: Andrew Peter Dean, MD
- Board 505b **ABSTRACT TPS4198:** Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.  
First Author: Vincent Chung, MD
- Board 506a **ABSTRACT TPS4199:** Phase 3 PANOVA-3 study: Tumor treating fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic cancer.  
First Author: Hani M. Babiker, MD
- Board 506b **ABSTRACT TPS4200:** CheMo4METPANC: A phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) Motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in metastatic treatment-naive pancreatic adenocarcinoma.  
First Author: Gulam Abbas Manji, MD
- Board 507a **ABSTRACT TPS4201:** A phase 1b, open-label, two-part safety, tolerability, and efficacy study of a soluble beta-glucan (odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma whose disease did not progress during first-line (1L) chemotherapy.  
First Author: Mark H. O'Hara, MD
- Board 507b **ABSTRACT TPS4202:** Apollo: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2, or PALB2 mutation—ECOG-ACRIN EA2192.  
First Author: Kim Anna Reiss, MD
- Board 508a **ABSTRACT TPS4203:** ExoLuminate: An observational registry study for detection of pancreatic adenocarcinoma (PDAC) in high-risk or clinically suspicious patients.  
First Author: Harmeet Dhani, MD, MSC
- Board 508b **ABSTRACT TPS4204:** Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer.  
First Author: Akhil Chawla, MD
- Board 509a **ABSTRACT TPS4205:** Targeting minimal residual disease (MRD) in resected RAS mutated pancreatic cancer with vaccine TG01/QS-21 +/- PD-1 inhibitor, balstilimab: A randomized phase II study (TESLA).  
First Author: Anup Kasi, MD, MPH

- Board 509b **ABSTRACT TPS4206:** STAR-221: A randomized, open-label, multicenter, phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in previously untreated, locally advanced, unresectable or metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma.  
First Author: Samuel J Klemper, MD

---

**8:00 AM - 11:00 AM Poster Session**

**Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allogeneic Transplant**

Location: Hall A

Abstracts on Boards 139-150 will be discussed during the Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allogeneic Transplant Poster Discussion Session. See the online program guide ([meetings.asco.org](https://meetings.asco.org)) for session details.

**Posters by Topic**

Acute Leukemia: Boards 142-144, 151-178, 203a-206a

Allogeneic Stem Cell Transplantation: Boards 139, 179-182, 206b

Chronic Leukemia—CML and Hairy Cell: Boards 183-185, 207a-207b

Myelodysplastic Syndromes (MDS): Boards 148, 186-190, 208a-209a

Myeloproliferative Syndromes (MPD): Boards 141, 145-147, 149,

191-200, 209b-210b

Other Leukemia, Myelodysplastic Syndromes, and Allogeneic Transplant:

Boards 140, 150, 201-202, 211a

- Board 139 **ABSTRACT 7009:** Adherence and satisfaction with remote cognitive training in blood or marrow transplant (BMT) survivors: The Cognitive Training and Attitudes Towards Genetics (cTAG) study.  
First Author: Noha Sharafeldin, MD, PhD
- Board 140 **ABSTRACT 7010:** Identification and management of clonal hematopoiesis of indeterminate potential (CHIP) in cancer survivors: The Cleveland Clinic experience.  
First Author: Teodora Kuzmanovic, BA
- Board 141 **ABSTRACT 7011:** Association of Agent Orange and myeloproliferative neoplasms, thrombosis, and bleeding among veterans.  
First Author: Andrew Chua Tiu, MD
- Board 142 **ABSTRACT 7012:** Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine.  
First Author: Stephane De Botton, MD, PhD
- Board 143 **ABSTRACT 7013:** Addition of venetoclax to FLAI induction chemotherapy (VFLAI) improves survival in patients with intermediate and high-risk AML vs FLAI and 3 + 7: A GIMEMA Italian Cooperative analysis.  
First Author: Giovanni Martinelli, MD
- Board 144 **ABSTRACT 7014:** Outcomes of 3- versus 5-day administration schedule of consolidation cytarabine in adults with acute myeloid leukemia (AML).  
First Author: Kendall Diebold, APRN-BC
- Board 145 **ABSTRACT 7015:** A randomized, double-blind, phase 3 study of jaktinib versus hydroxyurea (HU) in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF).  
First Author: Yi Zhang
- Board 146 **ABSTRACT 7016:** Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis: Results from the ACE-536-MF-001 study.  
First Author: Aaron Thomas Gerds, MD, MS

Monday, June 5, 2023

- Board 147 **ABSTRACT 7017:** Phase 1/2 study of the activin receptor-like kinase (ALK)-2 inhibitor zilversertib (INCB000928, LIMBER-104) as monotherapy or with ruxolitinib (RUX) in patients (pts) with anemia due to myelofibrosis (MF).  
First Author: Prithviraj Bose, MD
- Board 148 **ABSTRACT 7018:** Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis.  
First Author: Helen Ajufo, MD
- Board 149 **ABSTRACT 7019:** Pelabresib (CPI-0610) monotherapy in high-risk essential thrombocythemia refractory or intolerant to hydroxyurea: Preliminary results from MANIFEST study.  
First Author: Francesco Passamonti
- Board 150 **ABSTRACT 7020:** Refining risk stratification in CMML: A comprehensive assessment of the IPSS-M and other molecularly informed models.  
First Author: Luis E. Aguirre, MD
- Board 151 **ABSTRACT 7021:** Implications for acute myeloid leukemia (AML) treatment and care during the COVID-19 pandemic: A Connect Myeloid Registry study.  
First Author: Bart L. Scott, MD
- Board 152 **ABSTRACT 7022:** Outcomes of 10-day decitabine with venetoclax for AML.  
First Author: Alexander Coltoff, MD
- Board 153 **ABSTRACT 7023:** Impact of age, prior therapies, and subsequent transplant on long-term outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucl (brexu-cel) in ZUMA-3.  
First Author: Bijal D. Shah, MD, MS
- Board 154 **ABSTRACT 7024:** UCHMC 1812: A phase 1b trial of CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myeloid leukemia.  
First Author: Daria Louise Gaut, MD
- Board 155 **ABSTRACT 7025:** Efficacy and safety of venetoclax in combination with cytarabine and azacitidine (VAA) in relapsed/refractory acute myeloid leukemia: An open-label, single-arm, phase II study.  
First Author: Liangshun You, MD
- Board 156 **ABSTRACT 7026:** Examining safety and durable disease remission in R/R B-ALL after autologous CD19-directed CAR T cells produced by novel PRIMCAR manufacture platform.  
First Author: Zhi Yang, PhD
- Board 157 **ABSTRACT 7027:** Survival outcomes with CPX-351 vs 7 + 3 by baseline bone marrow blast percentage in older adults with newly diagnosed high-risk or secondary acute myeloid leukemia: A 5-year follow-up study.  
First Author: Ellen K. Ritchie, MD
- Board 158 **ABSTRACT 7028:** First-in-human trial of tocilizumab in combination with a standard induction chemotherapy in newly diagnosed acute myeloid leukemia patients: The phase 1 TOCILAM study.  
First Author: Pierre Peterlin, MD
- Board 159 **ABSTRACT 7029:** Cardiotoxicity of CPX-351 vs 7 + 3 in patients with untreated high-risk acute myeloid leukemia.  
First Author: Joshua Mitchell, MD, MSc
- Board 160 **ABSTRACT 7030:** BOS-371, a monoclonal antibody against IL1RAP: Characterization in preclinical models of AML.  
First Author: Kip A West, PhD
- Board 161 **ABSTRACT 7031:** Identification of factors to predict low risk febrile neutropenia admissions in patients with acute myeloid leukemia (AML) following intensive chemotherapy.  
First Author: Khushboo Pal, MD
- Board 162 **ABSTRACT 7032:** Shattering myths regarding Hispanic ethnicity and survival in acute myeloid leukemia: Insights from the National Cancer Database.  
First Author: Naveen Premnath, MD
- Board 163 **ABSTRACT 7033:** Comparison of next-generation sequencing and flow cytometry in detecting minimal residual disease in adult acute lymphoid leukemia: Evaluating clinical outcomes in a single-center study.  
First Author: Vinay Nittur, MD
- Board 164 **ABSTRACT 7034:** Results from a phase (Ph) 1 clinical study of the all-oral regimen of CC-486 and venetoclax for acute myeloid leukemia (AML).  
First Author: Maria Amaya, MD, PhD
- Board 165 **ABSTRACT 7035:** Clinical outcomes of patients with newly diagnosed acute myeloid leukemia receiving treatment in a safety-net hospital system.  
First Author: Jason Lu, MD
- Board 166 **ABSTRACT 7036:** Clinical and molecular characteristics of patients with AML with an exceptional response to ivosidenib.  
First Author: Justin M. Watts, MD
- Board 167 **ABSTRACT 7037:** A step toward genomic equity: Mutational profiling of patients with myeloid neoplasm in the largest minority-serving hospital in metropolitan Chicago.  
First Author: Maha AT Elsebaie
- Board 168 **ABSTRACT 7038:** Evaluation of cardiac failure and recovery in acute myelogenous leukemia.  
First Author: Matthew Wu, MD, MBA
- Board 169 **ABSTRACT 7039:** Analysis of short-term efficacy and safety of mitoxantrone hydrochloride liposome regimen therapy in adult acute myeloid leukemia.  
First Author: Jun Ma, MD
- Board 170 **ABSTRACT 7040:** Association of intensive chemotherapy with the rate of pathogenic driver mutation clearance in acute myeloid leukemia.  
First Author: Ruby Maini, MD
- Board 171 **ABSTRACT 7041:** Predictors of early port infection in adult patients with acute myeloid leukemia.  
First Author: Hyndavi Kandala, MD
- Board 172 **ABSTRACT 7042:** Comparison of characteristics and prognostic impact of FUS-ERG and AML1-MTG16 fusion genes in adult AML patients: A retrospective study from 1988 to 2022 with a medical database.  
First Author: Ziyue Zhou
- Board 173 **ABSTRACT 7043:** An analysis of a first-in-human study of NEXI-001 donor-derived antigen-specific CD8+ T-cell treatment of relapsed AML after allogeneic hematopoietic cell transplantation (HCT).  
First Author: Monzr M. Al Malki, MD
- Board 174 **ABSTRACT 7044:** Real-world (RW) use of venetoclax (VEN) in patients (pts) with acute myeloid leukemia (AML) in a US RWE database (COTA).  
First Author: Amer Methqal Zeidan, MBBS
- Board 175 **ABSTRACT 7045:** Preliminary results of a phase 1, first-in-human study of INA03, an anti-CD71 antibody-drug conjugate, in patients with relapsed or refractory (R/R) acute leukemias.  
First Author: Sylvain Garciaz, MD, PhD

- Board 176 **ABSTRACT 7046:** Capped F10, a novel DNA directed fluoropyrimidine, in TP53 mutated acute myeloid leukemia (AML).  
First Author: Timothy S. Pardee, MD, PhD
- Board 177 **ABSTRACT 7047:** Superior outcomes after allogeneic stem cell transplantation (SCT) among patients (Pts)  $\geq$  60 years (yrs) treated with cladribine (CLAD), low dose cytarabine (LDAC) plus venetoclax (Ven) for newly diagnosed acute myeloid leukemia (AML).  
First Author: Jayastu Senapati, MD, DM
- Board 178 **ABSTRACT 7048:** Treatment outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: A comparison between pediatric-inspired regimens and HyperCVAD at a Hispanic-serving cancer center.  
First Author: Shawn Patrick Griffin, PharmD
- Board 179 **ABSTRACT 7049:** Effect of disease status prior to T-cell depleted allogeneic stem cell transplantation on relapse-free and overall survival in patients with adverse-risk acute myeloid leukemia (AML).  
First Author: Alexandra Ewa Rojek, MD
- Board 180 **ABSTRACT 7050:** Early in vivo generation of V $\gamma$ 9V $\delta$ 2 T-cells after haploidentical stem cell transplant with post-transplant cyclophosphamide: Updated results of a monocentric phase 1 study.  
First Author: Maxime Jullien, MD
- Board 181 **ABSTRACT 7051:** Myeloablative fractionated busulfan-based conditioning regimen in patients with AML and MDS: Results of a randomized clinical trial comparing 2 fractionation schedules.  
First Author: Uday R. Popat, MD
- Board 182 **ABSTRACT 7052:** Financial toxicity and quality of life in patients undergoing bone marrow transplant evaluation: A single center analysis.  
First Author: S. M. Qasim Hussaini, MD, MS
- Board 183 **ABSTRACT 7053:** Longitudinal, prospective cardiovascular and metabolic risk in treatment-naive patients with chronic myeloid leukemia in chronic phase (CML-CP) starting tyrosine kinase inhibitor (TKI) therapy in a real-world setting.  
First Author: Javid J. Moslehi, MD
- Board 184 **ABSTRACT 7054:** Report of a chronic myeloid leukemia registry in a low-and middle-income setting.  
First Author: Nicolas Anthony Othieno-Abinya, MD
- Board 185 **ABSTRACT 7055:** Mortality rate and social disparity trends with tyrosine kinase inhibitory availability in chronic myelogenous leukemia: An analysis in the US from 1999 to 2020.  
First Author: Tony Varughese, MD
- Board 186 **ABSTRACT 7056:** External validation of the Molecular International Prognostic Scoring System (IPSS-M) for myelodysplastic syndromes.  
First Author: Brian Chernak, MD
- Board 187 **ABSTRACT 7057:** Hematologic and transfusion outcomes in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) receiving luspatercept: Real-world assessment in the community practice setting.  
First Author: Sudipto Mukherjee, MD, PhD, MPH
- Board 188 **ABSTRACT 7058:** Methylation-based prediction of myelodysplastic syndrome survival outcomes.  
First Author: Alvin Shi, PhD
- Board 189 **ABSTRACT 7059:** Outcome of TP53-mutated CCUS and the risk of progression to myeloid neoplasms.  
First Author: Syed Naseem Shah, MBBS
- Board 190 **ABSTRACT 7060:** Defining the immune microenvironment in myelodysplastic syndrome and acute myeloid leukemia using machine learning.  
First Author: Maher Albitar, MD
- Board 191 **ABSTRACT 7061:** Jaktinib in patients (pts) with myelofibrosis (MF) who were intolerant to ruxolitinib (RUX): An open-label, single-arm phase 2b study.  
First Author: Yi Zhang
- Board 192 **ABSTRACT 7062:** Jaktinib in patients (pts) with myelofibrosis (MF) who were refractory to or relapsed after ruxolitinib: A single-arm, open-label, multicenter, phase 2 study.  
First Author: Jie Jin, PhD
- Board 193 **ABSTRACT 7063:** Selinexor (SEL) plus ruxolitinib (RUX) in JAK inhibitor (JAKi) treatment-naive patients with myelofibrosis: Updated results from XPORT-MF-034.  
First Author: Haris Ali, MD
- Board 194 **ABSTRACT 7064:** Effects of ruxolitinib and magrolimab on calreticulin in myelofibrosis CD34+ cells in vitro: Proof of concept for combination therapy.  
First Author: Ciro Roberto Rinaldi, MD, PhD
- Board 195 **ABSTRACT 7065:** Indirect treatment comparison (ITC) of momelotinib (MMB) vs fedratinib (FED) safety in patients (pts) with myelofibrosis (MF).  
First Author: Lucia Masarova, MD
- Board 196 **ABSTRACT 7066:** Impact of transfusion burden on health-related quality of life (HRQOL) and functioning in patients (pts) with myelofibrosis (MF): Post hoc analysis of SIMPLIFY-1 (S1) and -2 (S2).  
First Author: Ruben A. Mesa, MD
- Board 197 **ABSTRACT 7067:** Longitudinal assessment of cardiac involvement in Erdheim-Chester disease using cardiac magnetic resonance imaging.  
First Author: Levi-Dan Azoulay, MD
- Board 198 **ABSTRACT 7068:** Consistency of pacritinib for spleen and symptom reduction in patients with myelofibrosis regardless of cytopenias.  
First Author: Prithviraj Bose, MD
- Board 199 **ABSTRACT 7069:** Bromodomain and extra-terminal (BET) inhibitor INCB057643 (LIMBER-103) in patients (pts) with relapsed or refractory myelofibrosis (R/R MF) and other advanced myeloid neoplasms: A phase 1 study.  
First Author: Justin M. Watts, MD
- Board 200 **ABSTRACT 7070:** Outcomes of patients with a myeloproliferative neoplasm and atrial fibrillation.  
First Author: Orly Leiva, MD
- Board 201 **ABSTRACT 7071:** Clinical outcomes by SF3B1 mutation status in patients (pts) with lower-risk myelodysplastic syndrome (LR-MDS) retreated with erythropoiesis-stimulating agents (ESAs).  
First Author: Adeola Y. Makinde, PhD
- Board 202 **ABSTRACT 7072:** Outcomes of individuals with clonal hematopoiesis evaluated at a cancer center.  
First Author: Kelly Sharon Chien, MD
- Board 203a **ABSTRACT TPS7073:** A phase 1b/2 study of pivekimab sunirine (PVEK, IMG632) in combination with venetoclax/azacitidine or magrolimab for patients with CD123-positive acute myeloid leukemia (AML).  
First Author: Naval Guastad Daver, MD

- Board 203b **ABSTRACT TPS7074:** A randomized, open-label study of the efficacy and safety of galinpepimut-S (GPS) maintenance monotherapy compared to investigator's choice of best available therapy (BAT) in patients with acute myeloid leukemia (AML) who have achieved complete remission (CR) after second-line salvage therapy.  
First Author: Omer Hassan Jamy, MD
- Board 204a **ABSTRACT TPS7075:** Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myeloid leukemia.  
First Author: Amir Tahmasb Fathi, MD
- Board 204b **ABSTRACT TPS7076:** A phase II study of vibecotamab, a CD3-CD123 bispecific T-cell engaging antibody, for MRD-positive AML and MDS after hypomethylating agent failure.  
First Author: Nicholas James Short, MD
- Board 205a **ABSTRACT TPS7077:** A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML).  
First Author: Catherine Choy Smith, MD
- Board 205b **ABSTRACT TPS7078:** Phase 1B/2A safety, pharmacokinetics and pharmacodynamics study of fosciclopirox alone and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia.  
First Author: Tara L. Lin, MD, MS
- Board 206a **ABSTRACT TPS7079:** Phase 1 study of ziftomenib (KO-539) in combination with venetoclax or venetoclax/azacitidine or standard induction cytarabine/daunorubicin (7 + 3) chemotherapy for the treatment of patients with acute myeloid leukemia.  
First Author: Amer Methqal Zeidan, MBBS
- Board 206b **ABSTRACT TPS7080:** A phase 1b study to evaluate the efficacy, safety, and pharmacokinetics of an investigational microbiome therapeutic, SER-155, in adults undergoing hematopoietic stem cell transplantation.  
First Author: Doris M. Ponce, MD
- Board 207a **ABSTRACT TPS7081:** A phase 1, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10382 (TERN-701) in patients (pts) with chronic myeloid leukemia (CML).  
First Author: Weiming Li
- Board 207b **ABSTRACT TPS7082:** ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI).  
First Author: Ehab L. Atallah, MD
- Board 208a **ABSTRACT TPS7083:** A phase 2/3 trial of oral azacitidine (Oral-AZA) in patients (pts) with low- or intermediate-risk myelodysplastic syndromes (MDS).  
First Author: Guillermo Garcia-Manero, MD
- Board 208b **ABSTRACT TPS7084:** A phase I study of MEK inhibitor selumetinib in combination with azacitidine in patients with higher-risk chronic myeloid neoplasia.  
First Author: Gregory Roloff, MD
- Board 209a **ABSTRACT TPS7085:** Phase 1b clinical study of IRAK1/4 inhibition for low-risk myelodysplastic syndromes refractory/resistant to prior therapies.  
First Author: Guillermo Garcia-Manero, MD
- Board 209b **ABSTRACT TPS7086:** A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.  
First Author: Jan Philipp Bewersdorf, MD

- Board 210a **ABSTRACT TPS7087:** Phase Ib, open-label study of add on therapy with CK0804 in participants with myelofibrosis, with suboptimal response to ruxolitinib.  
First Author: Lucia Masarova, MD
- Board 210b **ABSTRACT TPS7088:** EXCEED-ET: A single-arm multicenter study to assess the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft (P1101) in North American adults with essential thrombocythemia.  
First Author: Lucia Masarova, MD
- Board 211a **ABSTRACT TPS7089:** Phase 1 study to determine the safety and efficacy of onvansertib, a novel, oral, PLK1 inhibitor in patients with proliferative chronic myelomonocytic leukemia relapsed/refractory or intolerant to available therapies.  
First Author: Kristen McCullough, PharmD

---

**8:00 AM - 11:00 AM Poster Session**

**Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia**

Location: Hall A

Abstracts on Boards 60-71 will be discussed during the Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Poster Discussion Session. See the online program guide ([meetings.asco.org](https://meetings.asco.org)) for session details.

**Posters by Topic**

**Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL:** Boards 70, 72-82, 129a-130a  
**Chronic Lymphocytic Leukemia (CLL):** Boards 62-63, 83-89, 91-92, 130b-132a

**Hodgkin Lymphoma:** Boards 66-68, 93, 132b

**Non-Hodgkin Lymphoma:** Boards 60, 69, 71, 94-109, 112-123, 133a-136b

**Other Lymphoma and Chronic Lymphocytic Leukemia:** Boards 64-65, 124-128, 137a-138a

- Board 60 **ABSTRACT 7509:** Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R/R) follicular lymphoma (FL).  
First Author: Caron Alyce Jacobson, MD
- Board 62 **ABSTRACT 7511:** Five-year follow-up update of defined-composition CD19 CAR T-cell therapy for relapsed/refractory CLL.  
First Author: Emily C. Liang, MD
- Board 63 **ABSTRACT 7512:** SAVE (Safe Accelerated Venetoclax Escalation): Initial results of a prospective, phase Ib study of venetoclax with an accelerated dose ramp-up in patients with CLL.  
First Author: Jennifer L. Crombie, MD
- Board 64 **ABSTRACT 7513:** Long-term safety with  $\geq 12$  months of pirtobrutinib in relapsed/refractory (R/R) B-cell malignancies.  
First Author: Catherine Callaghan Coombs, MD
- Board 65 **ABSTRACT 7514:** Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with 3 years follow-up from start of enrollment.  
First Author: Nirav Niranjana Shah, MD
- Board 66 **ABSTRACT 7515:** Response-adapted therapy (tx) with nivolumab plus brentuximab vedotin (nivo + BV) without autologous hematopoietic cell transplantation (auto-HCT) in children, adolescents, and young adults (CAYA) with low-risk relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL): CheckMate 744.  
First Author: Paul David Harker-Murray, MD, PhD

- Board 67 **ABSTRACT 7516:** Circulating tumor DNA of classical Hodgkin lymphoma.  
First Author: Maria Cristina Piroso
- Board 68 **ABSTRACT 7517:** Efficacy and safety of pembrolizumab every six weeks in relapsed/refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma: The phase 2 KEYNOTE-B68 trial.  
First Author: Andrew McDonald, MD
- Board 69 **ABSTRACT 7518:** Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study.  
First Author: Bei Hu, MD
- Board 70 **ABSTRACT 7519:** Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data.  
First Author: Lorenzo Falchi, MD
- Board 71 **ABSTRACT 7520:** Impact of imaging frequency on progression free survival in Alliance clinical trials enrolling patients with untreated follicular lymphoma.  
First Author: Sarah C. Rutherford, MD
- Board 72 **ABSTRACT 7521:** Effectiveness and safety outcomes in patients with EBV<sup>+</sup> PTLD treated with allogeneic EBV-specific T-cell immunotherapy (tabelecleucel) under an expanded access program (EAP) in Europe.  
First Author: Sylvain Choquet, MD
- Board 73 **ABSTRACT 7522:** A phase 1 study of AT101, a novel anti-CD19 CAR-T cell therapy targeting a membrane-proximal epitope of CD19, in patients with relapsed or refractory B cell non-Hodgkin lymphoma.  
First Author: Dok Hyun Yoon, MD, PhD
- Board 74 **ABSTRACT 7523:** Circulating tumor DNA (ctDNA) status and clinical outcomes in patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL) in the POLARIX study.  
First Author: Alex Francisco Herrera, MD
- Board 75 **ABSTRACT 7524:** High complete response rate with TNB-486 in relapsed/refractory follicular lymphoma: Interim results from an ongoing phase 1 study.  
First Author: Ranjit Nair, MD, MBBS
- Board 76 **ABSTRACT 7525:** Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial.  
First Author: Yasmin Karimi, MD
- Board 77 **ABSTRACT 7526:** Subgroup analyses of primary refractory (refr) vs early relapsed (rel) large B-cell lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line (2L) therapy.  
First Author: Loretta J. Nastoupil, MD
- Board 78 **ABSTRACT 7527:** Preliminary results from a phase I/II study of IMM0306, a CD47 and CD20 bispecific monoclonal antibody-trap, in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.  
First Author: Jianliang Yang, MD
- Board 79 **ABSTRACT 7528:** Rates of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) from Center for International Blood and Marrow Transplant Research (CIBMTR) data on US subjects (SUBJ) with lymphoma following chimeric antigen receptor T cell therapy (CAR-T).  
First Author: Matthew J. Frigault, MD
- Board 81 **ABSTRACT 7530:** Systemic VSV-IFN $\beta$ -NIS oncolytic virotherapy in patients with relapsed refractory T-cell lymphoma.  
First Author: Nabila Nora Bennani, MD
- Board 82 **ABSTRACT 7531:** Zilovetamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.  
First Author: Muhit Ozcan, MD
- Board 83 **ABSTRACT 7532:** Efficacy of COVID vaccinations in patients with chronic lymphocytic leukemia.  
First Author: Kaitlin Annunzio, DO
- Board 84 **ABSTRACT 7533:** Analysis of racial disparities accounting for treatment received in chronic lymphocytic leukemia: A real-world cohort analysis.  
First Author: Adam Kittai, MD
- Board 85 **ABSTRACT 7534:** Patient perspectives on CLL treatment side effects: A sub-analysis of the VOICE survey.  
First Author: Constantine Si Lun Tam, MD, FRCPA
- Board 86 **ABSTRACT 7535:** Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study.  
First Author: Paul M. Barr, MD
- Board 87 **ABSTRACT 7536:** Real-world outcomes by race in patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Final analysis results from the informCLL registry.  
First Author: Jacqueline Claudia Barrientos, MD, MS
- Board 88 **ABSTRACT 7537:** Real-world (RW) dosing patterns and outcomes among chronic lymphocytic leukemia (CLL) patients (pts) with or without an ibrutinib (IBR) dose adjustment (DA) in first-line (1L).  
First Author: Kerry Anne Rogers, MD
- Board 89 **ABSTRACT 7538:** Ibrutinib dose modifications for management of cardiac adverse events in patients with B-cell malignancies: Pooled analysis of 10 clinical trials.  
First Author: Deborah Marie Stephens, DO
- Board 91 **ABSTRACT 7540:** A matching-adjusted indirect comparison (MAIC) of the efficacy and safety of acalabrutinib (acala) versus zanubrutinib (zanu) in relapsed or refractory chronic lymphocytic leukemia (RR CLL).  
First Author: Adam Kittai, MD
- Board 92 **ABSTRACT 7541:** Utility of pharmacogenomic testing in predicting intolerance to BTK inhibitors.  
First Author: Fahmin Basher, MD, PhD
- Board 93 **ABSTRACT 7542:** Brentuximab vedotin + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): Incidence and management of peripheral neuropathy in a multi-institution cohort.  
First Author: Jackson Bowers, MD
- Board 94 **ABSTRACT 7543:** Depth of metabolic response at interim PET and survival outcomes among patients with primary refractory and early relapsing diffuse large B-cell lymphoma (DLBCL).  
First Author: Allison Marie Bock, MD
- Board 95 **ABSTRACT 7544:** Identifying racial and ethnic disparities in patients diagnosed with mycosis fungoides/Sezary syndrome in the United States: A contemporary SEER analysis.  
First Author: Maria Elena Fierro, MD

Monday, June 5, 2023

- Board 96 **ABSTRACT 7545:** Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study.  
First Author: Christopher Flowers, MD, MS, FASCO
- Board 97 **ABSTRACT 7546:** Safety and efficacy of ABR in pts with TN or R/R MCL: Ph Ib trial.  
First Author: Tycel Jovelle Phillips, MD
- Board 98 **ABSTRACT 7547:** Circulating tumor DNA (ctDNA) by clonoSEQ to monitor residual disease after axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL).  
First Author: Brodie Miles, PhD
- Board 99 **ABSTRACT 7548:** Final three-year follow-up analysis of phase I/II study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma.  
First Author: Katsunori Asai
- Board 100 **ABSTRACT 7549:** Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study.  
First Author: Michael Dickinson, MBBS
- Board 101 **ABSTRACT 7550:** Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study.  
First Author: Lorenzo Falchi, MD
- Board 102 **ABSTRACT 7551:** A phase 1a/b study of BR101801, a PI3K $\gamma$  $\delta$  and DNA PK triple inhibitor, in adult patients with advanced hematologic malignancies.  
First Author: Bong-Seog Kim, MD, PhD
- Board 103 **ABSTRACT 7552:** Real-world outcomes with novel therapies in R/R DLBCL.  
First Author: Jennifer L. Crombie, MD
- Board 104 **ABSTRACT 7553:** Safety and efficacy profile of a very low dose of MC-1-50 for treatment of r/r NHL.  
First Author: Shiqi Li, MD, PhD
- Board 105 **ABSTRACT 7554:** Phase II trial of split-dose R-CHOP for older patients with diffuse large B-cell lymphoma (DLBCL).  
First Author: Nirav Niranjan Shah, MD
- Board 106 **ABSTRACT 7555:** Six-year safety and efficacy results from the CHRONOS-1 study of the PI3K inhibitor copanlisib in patients with relapsed or refractory follicular lymphoma.  
First Author: Martin H. Dreyling, MD, PhD
- Board 107 **ABSTRACT 7556:** Evaluation of outcomes between rituximab-abbs and reference product rituximab in adult patients with newly diagnosed diffuse large B-cell lymphoma in a non-inferiority study.  
First Author: Vivian Nguyen, PharmD, BCPS
- Board 108 **ABSTRACT 7557:** First interim analysis of a phase 1 study of zanubrutinib (zanu) plus lenalidomide (len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).  
First Author: Huilai Zhang, MD, PhD
- Board 109 **ABSTRACT 7558:** A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies.  
First Author: Caixia Li, MD, PhD
- Board 112 **ABSTRACT 7561:** Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.  
First Author: Carrie Ho, MD
- Board 113 **ABSTRACT 7562:** Updated clinical results of first-in-human study of CD19/BCMA dual-targeting fast CAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma.  
First Author: Xinfeng Chen
- Board 114 **ABSTRACT 7563:** A multi-institutional prospective cohort study of minimal residual disease in peripheral T-cell lymphoma: Impact of autologous stem cell transplant.  
First Author: Nicole C. Foley, MD
- Board 115 **ABSTRACT 7564:** Impact of neighborhood deprivation on disability free survival in patients with aggressive B cell non-Hodgkin lymphoma.  
First Author: Madelyn Burkart
- Board 116 **ABSTRACT 7565:** Treatments and outcomes of patients with localized extranodal NK/T-cell lymphoma (ENKL) diagnosed between 2014 and 2021: A cooperative study in Japan.  
First Author: Kana Miyazaki, MD, PhD
- Board 117 **ABSTRACT 7566:** Final analysis of the phase IB part of the LOC-R01 trial, a non-comparative randomized phase IB/II study of escalating doses of lenalidomide and ibrutinib in association with R-MPV for patients with a newly diagnosed primary central nervous system lymphoma (PCNSL).  
First Author: Marion Alcantara, MD, PhD
- Board 118 **ABSTRACT 7567:** Racial and ethnic disparities in risk of second primary malignancies among diffuse large B-cell lymphoma survivors.  
First Author: Pragati Gole Advani, MD, DrPH, MPH
- Board 119 **ABSTRACT 7568:** Uncertainty and coping in patients with newly diagnosed indolent non-Hodgkin's lymphoma (iNHL).  
First Author: Richard Newcomb, MD
- Board 120 **ABSTRACT 7569:** Preliminary data of a phase 1b/2 study of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).  
First Author: Sikander Ailawadhi, MD
- Board 121 **ABSTRACT 7570:** Epidemiologic characteristics, treatment patterns, and survival analysis of plasmablastic lymphoma in the US.  
First Author: Alec Hansen, MD
- Board 122 **ABSTRACT 7571:** Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma.  
First Author: Laura S. Samples, MD
- Board 123 **ABSTRACT 7572:** Unveiling the prognostic significance of BCL6+/CD10+ mantle cell lymphoma: A systematic analysis.  
First Author: Dan Ran Castillo
- Board 124 **ABSTRACT 7573:** Investigating the impact of demographic disparities on clinical outcomes in cutaneous T-cell lymphoma (CTCL): A multicenter retrospective cohort analysis.  
First Author: Tim Niyogusaba
- Board 125 **ABSTRACT 7574:** A phase 2 study of HLX208, a BRAF<sup>V600E</sup> inhibitor, in adult patients with Langerhans cell histiocytosis and/or Erdheim-Chester disease harboring BRAF<sup>V600E</sup> mutation.  
First Author: Xin-xin Cao
- Board 126 **ABSTRACT 7575:** Clinical characteristics, survival outcomes, and prognostic factors in extranodal natural killer/T-cell lymphoma, nasal type: The National Cancer Database study (2004-2019).  
First Author: Firas Baidoun, MD, FACP

- Board 127 **ABSTRACT 7576:** Association of pharmacist interventions with adherence upon targeted anticancer oral therapy initiation.  
First Author: Richard Mcshinsky
- Board 128 **ABSTRACT 7577:** Risk of incident melanoma among individuals with low-count monoclonal B-cell lymphocytosis (MBL).  
First Author: Bryan A. Vallejo, MD
- Board 129a **ABSTRACT TPS7578:** ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma.  
First Author: Jason Westin, MD, FACP, MS
- Board 129b **ABSTRACT TPS7579:** ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axicel) versus standard-of-care therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL).  
First Author: Ian W. Flinn, MD, PhD
- Board 130a **ABSTRACT TPS7580:** The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.  
First Author: Krish Patel, MD
- Board 130b **ABSTRACT TPS7581:** Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (LOTIS-7).  
First Author: Brian T. Hess
- Board 131a **ABSTRACT TPS7582:** BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator's choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma.  
First Author: George Follows, MA, BM, BCh, PhD, FRCP, FRCPath
- Board 131b **ABSTRACT TPS7583:** BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma.  
First Author: Toby A. Eyre, MBChB, MRCP
- Board 132a **ABSTRACT TPS7584:** BRUIN CLL-314: A phase 3, open-label, randomized study of pirtobrutinib versus ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.  
First Author: Jennifer Ann Woyach, MD
- Board 132b **ABSTRACT TPS7585:** KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.  
First Author: David Lavie, MD
- Board 133a **ABSTRACT TPS7586:** SUNMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.  
First Author: Jason Westin, MD, FACP, MS
- Board 133b **ABSTRACT TPS7587:** BRUIN MCL-321: A phase 3, open-label, randomized study of pirtobrutinib versus investigator choice of BTK inhibitor in patients with previously treated, BTK inhibitor naive mantle cell lymphoma.  
First Author: Michael Wang, MD
- Board 134a **ABSTRACT TPS7588:** A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL).  
First Author: Adam J Olszewski, MD
- Board 134b **ABSTRACT TPS7589:** waveLINE-007: Phase 2 study of zilovetamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).  
First Author: David Lavie, MD
- Board 135a **ABSTRACT TPS7590:** MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma.  
First Author: Loretta J. Nastoupil, MD
- Board 135b **ABSTRACT TPS7591:** A phase 1/2 study of STP938, a first-in-class inhibitor of CTP synthase 1, in patients with relapsed/refractory B or T cell lymphoma.  
First Author: Manish R. Patel, MD
- Board 136b **ABSTRACT TPS7592:** Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2.  
First Author: Laurie Helen Sehn, MD, MPH
- Board 137a **ABSTRACT TPS7593:** BELLWAVE-003: A phase 2 dose escalation, confirmation, and cohort expansion study of nemtabrutinib in hematologic malignancies.  
First Author: Guilherme Fleury Perini
- Board 137b **ABSTRACT TPS7594:** BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations.  
First Author: Ömür Gökmen Sevindik
- Board 138a **ABSTRACT TPS7595:** waveLINE-006: A phase 2 study of the safety and efficacy of zilovetamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies.  
First Author: Pier Luigi Zinzani, MD

---

**8:00 AM - 11:00 AM Poster Session**

**Hematologic Malignancies—Plasma Cell Dyscrasia**

Location: Hall A

Abstracts on Boards 1-12 will be discussed during the Hematologic Malignancies—Plasma Cell Dyscrasia Poster Discussion Session. See the online program guide ([meetings.asco.org](https://meetings.asco.org)) for session details.

**Posters by Topic**

**Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell**

**Transplantation for Plasma Cell Disorders:** Boards 1-2, 4-5, 11, 13-18, 55a

**Multiple Myeloma:** Boards 3, 7-10, 12, 19-53, 55b-58b

**Plasma Cell Disorders:** Boards 6, 54, 59a

Board 1 **ABSTRACT 8009:** CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.  
First Author: Yi Lin, MD, PhD

Board 2 **ABSTRACT 8010:** Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment of LCAR-B38M CAR-T: At least 5-year follow-up in LEGEND-2.  
First Author: Jian-Qing Mi



- Board 3 **ABSTRACT 8011:** Long-term follow-up from Majes-TEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).  
First Author: Niels W.C.J. van de Donk, MD, PhD
- Board 4 **ABSTRACT 8012:** Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucl (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM).  
First Author: Doris K. Hansen, MD
- Board 5 **ABSTRACT 8013:** Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world experience from the US myeloma CAR T consortium.  
First Author: Aimaz Afrough, MD
- Board 6 **ABSTRACT 8014:** Plasma cell leukemia: A multicenter retrospective study of 150 patients.  
First Author: Iloabueke Gabriel Chineke, MD
- Board 7 **ABSTRACT 8015:** Disparities in multiple myeloma: A global perspective on drug toxicity trends.  
First Author: Majid Jaber-Douraki, PhD
- Board 8 **ABSTRACT 8016:** Investigation into aberrant B cell repertoire in myeloma on humoral immunity and patient survival.  
First Author: Lakshmi Bhavani Potluri, MD
- Board 9 **ABSTRACT 8017:** Final results of pilot trial to evaluate anti-PD1 and 8 Gy in 1 fx for relapsed refractory multiple myeloma.  
First Author: Mohammad Khurram Khan, MD, PhD, MS
- Board 10 **ABSTRACT 8018:** A phase 1 study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: An interim analysis of DREAMM-9.  
First Author: Saad Zafar Usmani, MD, FACP, MBA
- Board 11 **ABSTRACT 8019:** Changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody therapy in patients with relapsed refractory multiple myeloma (RRMM).  
First Author: Abhishek Janardan, BA
- Board 12 **ABSTRACT 8020:** Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumentAL-1.  
First Author: Paula Rodríguez-Otero, MD, PhD
- Board 13 **ABSTRACT 8021:** Busulfan, melphalan, and carfilzomib (BuMelCar) conditioning for autologous stem cell transplant (ASCT) in multiple myeloma: Phase I/II data.  
First Author: Joseph Allan Norton, DO
- Board 14 **ABSTRACT 8022:** Treatment patterns for extramedullary multiple myeloma and outcomes with CAR-T therapy and bispecific antibodies.  
First Author: Saurabh Zanwar, MD
- Board 15 **ABSTRACT 8023:** Plinabulin to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant.  
First Author: Gunjan L. Shah, MD
- Board 16 **ABSTRACT 8024:** Prognostic value of month 1 bone marrow and PET MRD status in CAR-T therapy for myeloma.  
First Author: Radhika Bansal, MBBS
- Board 17 **ABSTRACT 8025:** CT103A, a novel fully human BCMA-targeting CAR-T cells, in patients with relapsed/refractory multiple myeloma: Updated results of phase 1b/2 study (FUMANBA-1).  
First Author: Chunrui Li
- Board 18 **ABSTRACT 8026:** Updated OS of patients with AL amyloidosis after CAEL-101.  
First Author: Michael Sang Hughes, MD, BA
- Board 19 **ABSTRACT 8027:** Population pharmacokinetic-pharmacodynamic model of nirogacestat effects on B-cell maturation antigen in healthy subjects.  
First Author: Todd Shearer, PhD, MS, BS
- Board 20 **ABSTRACT 8028:** Measurable residual disease (MRD) and clonal diversity for multiple myeloma treatment monitoring.  
First Author: Joaquin Martinez-Lopez, MD, PhD
- Board 21 **ABSTRACT 8029:** Long-term outcomes with isatuximab-carfilzomib-dexamethasone (Isa-Kd) in relapsed multiple myeloma patients with 1q21+ status: Updated results from the phase 3 IKEMA study.  
First Author: Thierry Facon, MD
- Board 22 **ABSTRACT 8030:** Phase 2 study of abatacept, ixazomib, and dexamethasone in patients with relapsed/refractory multiple myeloma.  
First Author: Khalid Shalaby, MBCh
- Board 23 **ABSTRACT 8031:** Baseline and early post-infusion biomarkers associated with optimal response to idecabtagene vicleucl (ide-cel) in the KarMMa-3 study of triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM).  
First Author: Julia Piasecki, BA
- Board 24 **ABSTRACT 8032:** Health related quality of life (HRQoL) in patients with triple-class-exposed relapsed/refractory multiple myeloma (TCE RRMM) treated with idecabtagene vicleucl (ide-cel) versus standard regimens: Patient-reported outcomes (PROs) from KarMMa-3 phase 3 randomized controlled trial (RCT).  
First Author: Michel Delforge
- Board 25 **ABSTRACT 8033:** Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1.  
First Author: Niels W.C.J. van de Donk, MD, PhD
- Board 26 **ABSTRACT 8034:** Durability of responses with bi-weekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study.  
First Author: Saad Zafar Usmani, MD, FACP, MBA
- Board 27 **ABSTRACT 8035:** Tumor-intrinsic features associated with progression-free survival (PFS) in patients (pts) with relapsed and refractory multiple myeloma (RRMM) treated with idecabtagene vicleucl (ide-cel).  
First Author: Nicholas Stong, PhD
- Board 28 **ABSTRACT 8036:** Pivotal phase 2 MonumentAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).  
First Author: Carolina D. Schinke, MD
- Board 29 **ABSTRACT 8037:** Adjusted indirect treatment comparison of progression-free survival (PFS) associated with DRd and VRd based on MAIA and SWOG S0777 individual patient-level data.  
First Author: Brian G. Durie, MD
- Board 30 **ABSTRACT 8038:** Results from a first-in-human phase I study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma.  
First Author: Mingyuan Sun, MD

- Board 31 **ABSTRACT 8039:** Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.  
First Author: Mohamad Mohty, MD, PhD
- Board 32 **ABSTRACT 8040:** Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple (RRMM): A subgroup analysis from MagnetisMM-3.  
First Author: Noopur S. Raje, MD
- Board 33 **ABSTRACT 8041:** Efficacy, safety, pharmacokinetic (PK), and pharmacodynamic (PD) support for talquetamab (tal) QW and Q2W dosing in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Analyses from MonumentAL-1.  
First Author: Xuewen Ma
- Board 34 **ABSTRACT 8042:** Phase 1 study of tasquinimod, an S100A9 inhibitor, alone and in combination with IRd for relapsed and refractory multiple myeloma (RRMM).  
First Author: Dan T. Vogl, MD, MSCE
- Board 35 **ABSTRACT 8043:** Clinical characteristics, markers of adverse prognosis, and predictors of development of extramedullary multiple myeloma.  
First Author: Saurabh Zanwar, MD
- Board 36 **ABSTRACT 8044:** Identification of cytokines associated with response and cytokine release syndrome: Analysis of MagnetisMM-3 cohort A.  
First Author: HANG QUACH, MD
- Board 37 **ABSTRACT 8045:** Genomic analysis to identify determinants of inherent response and resistance to elranatamab in MagnetisMM-3 cohort A.  
First Author: Nizar J. Bahlis, MD
- Board 38 **ABSTRACT 8046:** ISAMAR: Multicenter phase II single arm trial of isatuximab (ISA) with/without lenalidomide (LEN) in pts with high risk smoldering multiple myeloma (HRSMM).  
First Author: Elisabet Esteve Manasanch, MD
- Board 39 **ABSTRACT 8047:** Patient-derived MicroOrganospheres (MOS) and precision clinical decision-making for patients with multiple myeloma.  
First Author: Rui Xi, PhD
- Board 40 **ABSTRACT 8048:** Retrospective analysis of the relationship between time to anti-resorptive therapy and incidence of skeletal related events in patients with multiple myeloma.  
First Author: Adam F Binder, MD
- Board 41 **ABSTRACT 8049:** Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies.  
First Author: Ross Firestone, MD, PhD
- Board 42 **ABSTRACT 8050:** Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: The phase 1/2, prospective, open-label, BelaRd study.  
First Author: Evangelos Terpos, MD, PhD
- Board 43 **ABSTRACT 8051:** Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy.  
First Author: Charalampos Charalampous
- Board 44 **ABSTRACT 8052:** Determinants of overall survival of young adults with multiple myeloma: A National Cancer Database (NCDB) analysis of years 2004-2017.  
First Author: Chakra Pani Chaulagain, MD, FACP
- Board 46 **ABSTRACT 8054:** Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: Results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).  
First Author: Cyrille Touzeau, MD, PhD
- Board 47 **ABSTRACT 8055:** Lenalidomide-based monotherapy versus augmented therapy for maintenance in standard risk multiple myeloma patients with no complete response post autologous hematopoietic cell transplantation.  
First Author: Hussein Awada
- Board 48 **ABSTRACT 8056:** Three-dimensional telomere profiling to predict risk of progression in smoldering multiple myeloma.  
First Author: Shaji Kumar, MD
- Board 49 **ABSTRACT 8057:** A phase 2 evaluation of daratumumab-based induction therapy in patients with multiple myeloma with severe renal insufficiency.  
First Author: R. Donald Harvey, PharmD, FCCP, FASCO
- Board 50 **ABSTRACT 8058:** Genomic landscape of multiple myeloma with extramedullary disease: Results from a large patient database.  
First Author: Mateo Mejia Saldarriaga, MD
- Board 51 **ABSTRACT 8059:** Curability of multiple myeloma (MM) based on relative survival rate (RSR) in patients (pts) treated on earlier total therapy (TT) protocols.  
First Author: Samer Al Hadidi, FACP, MS
- Board 52 **ABSTRACT 8060:** T cell exhaustion markers in multiple myeloma patients before and after physical activity intervention.  
First Author: Janine M. Joseph, MS, MBA
- Board 53 **ABSTRACT 8061:** Utilizing a two-step frailty assessment strategy in older adults with multiple myeloma (MM): A decision curve analysis.  
First Author: Andrew Gahagan, MD
- Board 54 **ABSTRACT 8062:** Presence of hyperdiploidy and history of tobacco use in African American patients with SMM.  
First Author: Rujul H Parikh, MD
- Board 55a **ABSTRACT TPS8063:** A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CAMMOU-FLAGE trial).  
First Author: Jesus G. Berdeja, MD
- Board 55b **ABSTRACT TPS8064:** CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent.  
First Author: Shaji Kumar, MD
- Board 56a **ABSTRACT TPS8065:** MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM).  
First Author: Sebastian Grosicki, MD
- Board 56b **ABSTRACT TPS8066:** MagnetisMM-7: An open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma.  
First Author: Maria Victoria Mateos Manteca

## Monday, June 5, 2023

- Board 57a **ABSTRACT TPS8067:** MajesTEC-9: A randomized phase 3 study of teclistamab versus pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.  
First Author: Cyrille Touzeau, MD, PhD
- Board 57b **ABSTRACT TPS8068:** OMNIA-2: Phase I/II study of ANV419, an IL-2R- $\beta\gamma$  targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma.  
First Author: Dagmar Hess, MD
- Board 58a **ABSTRACT TPS8069:** EXCALIBER-RRMM: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DvD) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).  
First Author: Sagar Lonial, MD, FACP
- Board 58b **ABSTRACT TPS8070:** A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.  
First Author: Paul G. Richardson, MD
- Board 59a **ABSTRACT TPS8071:** Enrolling patients in Cardiac Amyloid Reaching for Extended Survival (CARES) trials: Two placebo-controlled, double-blind, randomized, international phase 3 trials assessing CAEL-101 in patients with Mayo stage IIIa or stage IIIb AL amyloidosis.  
First Author: Michaela Liedtke, MD

---

### 8:15 AM - 9:30 AM Highlights of the Day Session

#### Highlights of the Day Session #2

Location: Hall D1

#### Shom Goel, MBBS, PhD, FRACP - Chair

The Sir Peter MacCallum Department of Oncology, University of Melbourne

- 8:15 AM Nazanin Majd, MD, PhD**  
The University of Texas MD Anderson Cancer Center  
*Highlights of Central Nervous System Tumors*
- 8:30 AM Daniel H. Ahn, DO**  
Mayo Clinic in Arizona  
*Highlights of Gastrointestinal Cancer—Colorectal and Anal*
- 8:45 AM Mehmet Asim Bilen, MD**  
Winship Cancer Institute of Emory University  
*Highlights of Genitourinary Cancer—Prostate, Penile, and Testicular*
- 9:00 AM Mark Yarchoan, MD**  
Johns Hopkins University  
*Highlights of Developmental Therapeutics—Immunotherapy*
- 9:15 AM Raid Aljumaily, MD**  
University of Oklahoma Health Sciences Center  
*Highlights of Lung Cancer—Non-Small Cell Local Regional and Small Cell*

---

### 9:45 AM - 10:30 AM Award Lecture

#### Science of Oncology Award and Lecture

Location: E451

#### Lori J. Pierce, MD, FASTRO, FASCO

University of Michigan

#### Alan Ashworth, PhD, FRS

UCSF Helen Diller Family Comprehensive Cancer Center  
*Science of Oncology Award Lecture*

---

### 9:45 AM - 10:45 AM Case-Based Panel

#### Germline Testing Around the Globe: Challenges in Different Practice Settings

Location: S102

#### Sana A. Al Sukhun, MD, MSc, FASCO - Chair

The University of Jordan  
*Moderator*

#### Timothy Rebbeck, PhD

Dana-Farber Cancer Institute, Harvard T. H. Chan School of Public Health  
*Molecular Perspective*

#### Shailesh V. Shrikhande, MD, FRCS, MS

Tata Memorial Centre  
*Surgeon's Perspective*

#### Talia Wegman-Ostrosky, MD, PhD

Instituto Nacional de Cancerologia  
*Geneticist's Perspective*

*Panel Question and Answer*

---

### 9:45 AM - 11:00 AM Education Session

#### Innovative Solutions to the Challenges of Cancer Clinical Trials: FDA and NCI Perspectives

Location: E450

#### Julie Gralow, MD, FACP, FASCO - Chair

American Society of Clinical Oncology

#### Monica Bertagnolli, MD

National Cancer Institute

#### James Doroshow, MD

National Cancer Institute

#### Sheila Prindiville, MD, MPH

National Cancer Institute

#### Michael Morris, MD

Memorial Sloan Kettering Cancer Center and National Cancer Institute

#### Richard Pazdur, MD

FDA Oncology Center of Excellence

#### Paul Kluetz, MD

FDA Oncology Center of Excellence

---

### 9:45 AM - 11:00 AM Education Session

#### Prioritizing and Sequencing Therapy for Advanced Prostate Cancer

Location: Arie Crown Theater

#### Neeraj Agarwal, MD, FASCO - Chair

Huntsman Cancer Institute (NCI-CCC), University of Utah  
*When More Is More: Treatment Intensification for Hormone-Sensitive Prostate Cancer*

**Anis Hamid, MBBS**

University of Melbourne  
*When Less Is More: Decreasing Exposure to Systemic Therapy for Hormone-Sensitive Prostate Cancer*

**Julie N. Graff, MD**

OHSU Knight Cancer Institute  
*Timing of PARP Inhibition for Prostate Cancer With Defects in Homologous Recombination Repair*

*Panel Question and Answer*

---

**9:45 AM - 11:00 AM Education Session**

**Screening Patients at High Risk of Developing Pancreatic Cancer**

Location: S406

**Diane M. Simeone, MD - Chair**

NYU Langone Health-Perlmutter Cancer Center  
*Defining the Patients at Risk for Developing Pancreatic Cancer*

**Randall E. Brand, MD**

University of Pittsburgh  
*Which Patients Merit Screening for Pancreatic Cancer and How Should They Be Screened?*

**Michael Goggins, MD**

Johns Hopkins University School of Medicine  
*Development and Implementation of Noninvasive Pancreatic Cancer Screening Tools*

*Panel Question and Answer*

---

**9:45 AM - 11:00 AM Education Session**

**Town Hall: Prioritizing a Sustainable Oncology Workforce Through Organizational and System-Level Strategies for Professional Wellness**

Location: E450

**Ishwaria M. Subbiah, MD, MS - Chair**

The University of Texas MD Anderson Cancer Center  
*Moderator*

**Jill Jin, MD, MPH**

American Medical Association  
*System-Level Strategies to Promote Professional Wellness*

**Amanda Noble, BSN, RN, OCN**

Oncology Hematology Care, Inc  
*Organizational Strategies to Promote Professional Wellness: A Community Practice Administrator's Perspective*

**Fumiko Chino, MD**

Memorial Sloan Kettering Cancer Center  
*Organizational Strategies to Promote Professional Wellness*

*Discussion With Dr. Ishwaria Subbiah, Dr. Jill Jin, Dr. Fumiko Chino, and Ms. Amanda Noble*

---

**9:45 AM - 11:00 AM Education Session**

**When the World Becomes a Waiting Room: Setting Boundaries With Our Patients and Ourselves**

Location: S404

**Monica Sheila Chatwal, MD - Chair**

H. Lee Moffitt Cancer Center and Research Institute  
*Fencing in Our Lawns: Where Do We Stand on Boundaries in Medicine?*

**Arif Kamal, MD, MBA, FAAHPM, MHS, FASCO**

Duke University  
*Setting Boundaries While Maintaining Trust: The Good, the Bad, and the Ugly*

**Jonathan M. Marron, MD, FAAP, MPH**

Dana-Farber/Boston Children's Cancer and Blood Disorders Center  
*Is There a Limit to My Ethical Obligations for Patient Care?*

*Panel Question and Answer*

---

**9:45 AM - 11:00 AM Ticketed Session**

**Meet the Professors: Overcoming Geographical Obstacles in Cervical Cancer Care**

Location: E253d

**Ricardo Dos Reis, PhD**

Barretos  
*Obstacles to Gynecologic Cancer Care in South America*

**Patti Gravitt, PhD**

National Cancer Institute Sri Lanka  
*The WHO Cervical Cancer Elimination Initiative: Lessons Learned on Access to Care*

*Panel Question and Answer*

---

**9:45 AM - 11:15 AM Special Clinical Science Symposium**

**Moving Cellular Therapy Into Earlier Lines of Treatment in Hematologic Malignancies: Latest Efficacy Data and The Need to Improve Access**

Location: Hall D1

**Kunle Odunsi, MD, PhD - Chair**

University of Chicago

**9:45 AM Caron Jacobson, MD**

Dana-Farber Cancer Institute  
*CAR-T: Where We Have Been and Where We Are Headed*

**9:57 AM**

**Abstract LBA106:** First phase 3 results from CART1-TUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma.  
First Author: Binod Dhakal, MD

**10:09 AM**

**Abstract LBA107:** Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory large B-cell lymphoma.  
First Author: Jason R. Westin, MD, FACP, MS

**10:21 AM**

**Asher Alban Akmal Chanan-Khan, MD (Discussion of Abstract(s) LBA106-LBA107)**  
Mayo Clinic  
*CAR T in 2023: Have We Reached the Promised Land?*

**10:33 AM**

**Leyla Shune, MD**  
University of Kansas Cancer Center  
*Putting the CAR-T Before the Horse: Improving Access to Better Outcomes*

**10:45 AM**

**To be determined**  
*Mind the Gap: How Do Technologic Advances Widen Disparities in Care?*

**10:57 AM**

Panel Question and Answer

Monday, June 5, 2023

**11:30 AM - 12:30 PM Rapid Abstract Session**

**Lung Cancer**

Location: S406

**Dwight Hall Owen, MD - Chair**

Ohio State University Comprehensive Cancer Center

**Martin Reck, MD, PhD - Chair**

Lungen Clinic

**11:30 AM Abstract 8509:** Pembrolizumab and ramucirumab neoadjuvant therapy for PD-L1-positive stage IB-IIIa lung cancer (EAST ENERGY).  
First Author: Keiju Aokage, MD, PhD

**11:36 AM Abstract 8510:** Preliminary results from the Female Asian Nonsmoker Screening Study (FANSS).  
First Author: Elaine Shum, MD

**11:42 AM Abstract 9011:** BLU-945 monotherapy and in combination with osimertinib (OSI) in previously treated patients with advanced EGFR-mutant (EGFRm) NSCLC in the phase 1/2 SYMPHONY study.  
First Author: Yasir Y Elamin, MD

**11:48 AM Abstract 9012:** First-line immune checkpoint inhibitors alone or in combination with chemotherapy in real-life elderly patients with advanced non-small cell lung cancer (NEJ057).  
First Author: Mao Uematsu

**11:54 AM Abstract 8511:** Bemcentinib and pembrolizumab in patients with relapsed mesothelioma: MIST3, a phase IIa trial with cellular and molecular correlates of efficacy.  
First Author: Matthew G Krebs, PhD, FRCP

**12:00 PM** Panel Question and Answer

---

**11:30 AM - 12:30 PM Case-Based Panel**

**Addressing Grief, Burnout, and Well-Being in the Practice of Oncology**

Location: S102

**Fay J. Hlubocky, MA - Chair**

University of Chicago Medicine  
*Moderator*

**Laurie Jean Lyckholm, MD**

West Virginia University School of Medicine  
*Physician Perspective*

**Christopher Ryan Friese, PhD, RN, AOCN**

University of Michigan  
*Nursing Perspective*

**Vicki A. Jackson, MD, MPH**

Massachusetts General Hospital  
*Palliative Care Perspective*

*Panel Question and Answer*

---

**11:30 AM - 12:30 PM Case-Based Panel**

**Cardiac Toxicity in Oncology: Prevention and Surveillance Strategies for Early and Late Effects of Treatment**

Location: S100bc

**Bogda Koczwara, MD - Chair**

Flinders Medical Centre  
*Moderator*

**Susan Faye Dent, MD**

Duke Cancer Institute  
*The Oncologist Perspective*

**Anant Mandawat, MD**

Winship Cancer Institute of Emory University  
*The Cardiologist Perspective*

**Jessica Scott, PhD**

Memorial Sloan Kettering Cancer Center  
*The Exercise Physiologist Perspective*

*Panel Question and Answer*

---

**11:30 AM - 12:45 PM Education Session**

**Leptomeningeal Disease: Toward Patient-Centered Care and Research for a Pressing Clinical Problem**

Location: Arie Crown Theater

**Adrienne Ann Boire, MD, PhD - Chair**

Memorial Sloan Kettering Cancer Center  
*Advances in Diagnostics and Response Assessment for Leptomeningeal Disease*

**Emilie Le Rhun, MD, PhD**

University Hospital Zurich  
*State of the Art: Use of Systemic and Intrathecal Therapies for Patients With Leptomeningeal Disease*

**Michelle Alonso-Basanta, MD, PhD**

University of Pennsylvania  
*Use of Radiotherapy for Leptomeningeal Disease: Applying Trial Data to the Real World*

*Panel Question and Answer*

---

**11:30 AM - 12:45 PM Education Session**

**Partnering With Patients and Caregivers to Increase the Efficacy and Quality of Oncology Care**

Location: S504

**Elena Martinez, PhD, MPH**

University of California, San Diego School of Medicine  
*Considering Language and Cultural Differences to Improve Quality Cancer Care*

**Naomi Katz, MBBS, FRACP - Chair**

Royal Children's Hospital  
*Balancing the Needs of Children and Caregivers in Pediatric Cancer Care*

**Ash B. Alpert, MD, MFA**

Wilmot Cancer Institute, University of Rochester Medical Center  
*Addressing Barriers to Care Experienced by Transgender Patients*

*Panel Question and Answer*

---

**11:30 AM - 12:45 PM Ticketed Session**

**Meet the Professors: The Influence of Smoking on HPV-Positive Oropharyngeal Cancer—Evidence and Implications**

Location: E253d

**Amanda Psyrrri, MD, PhD**

University of Athens  
*Smoking and Smoking Cessation During Radiotherapy for Head and Neck Cancer*

**Dylan Roden, MD**  
Rutgers University  
*The Influence of Smoking on the Pathology and Management of HPV-Related Oropharynx Cancer*

Panel Question and Answer

---

**11:30 AM - 1:00 PM Poster Discussion Session**

**Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary**

Location: Hall D2

**Katrina Sophia Pedersen, MD, MS - Chair**  
Washington University in St. Louis

**Jingquan Jia, MD, PhD - Chair**  
University of North Carolina at Chapel Hill

**11:30 AM Anna Dorothea Wagner, MD (Discussion of Abstract(s) 4012-4027)**  
Lausanne University Hospital and University of Lausanne  
*Treating Gastroesophageal Cancer: New Lights on the Horizon*

11:42 AM Panel Question and Answer

**11:52 AM Eric David Miller, MD, PhD (Discussion of Abstract(s) 4015-4017)**  
Ohio State University Comprehensive Cancer Center  
*A Tightrope: Balancing Local and Systemic Risk in Biliary Cancer*

12:04 PM Panel Question and Answer

**12:14 PM Anirban Maitra, MD (Discussion of Abstract(s) 4018-4020)**  
The University of Texas MD Anderson Cancer Center  
*Bringing Home the Genome in Pancreaticobiliary Cancer*

12:26 PM Panel Question and Answer

**12:36 PM Suneel Deepak Kamath, MD (Discussion of Abstract(s) 4021-4023)**  
Cleveland Clinic  
*Charting New Paths in Gastrointestinal Cancer*

12:48 PM Panel Question and Answer

Posters discussed in this session are on display in the Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary Poster Session. To view abstract titles and presentations, see the online program guide ([meetings.asco.org](https://meetings.asco.org)).

---

**11:30 AM - 1:00 PM Poster Discussion Session**

**Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft**

Location: E450

**Patrick William Burke, MD - Chair**  
University of Michigan

**Michael William Drazer, MD, PhD - Chair**  
University of Chicago Medical Center

**11:30 AM Minoo Battiwalla, MD, MS (Discussion of Abstract(s) 7009-7011)**  
Sarah Cannon Blood Cancer Network  
*Survivor's Tale: Late Effects and Secondary Hematologic Malignancies*

11:42 AM Panel Question and Answer

**11:52 AM Ann-Kathrin Eisfeld, MD (Discussion of Abstract(s) 7012-7014)**  
Ohio State University James Cancer Hospital  
*Taming of the Old and New in Acute Myeloid Leukemia*

12:04 PM Panel Question and Answer

**12:14 PM Idoroenyi Usua Amanam, MD (Discussion of Abstract(s) 7015-7017)**  
City of Hope National Comprehensive Cancer Center  
*Of the Exaltation of Myeloproliferative Neoplasms*

12:26 PM Panel Question and Answer

**12:36 PM William Shomali, MD (Discussion of Abstract(s) 7018-7020)**  
Stanford Cancer Center  
*TeMPNest: A Potpourri of MPNs*

12:48 PM Panel Question and Answer

Posters discussed in this session are on display in the Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft Poster Session. To view abstract titles and presentations, see the online program guide ([meetings.asco.org](https://meetings.asco.org)).

---

**11:30 AM - 2:30 PM Oral Abstract Session**

**Breast Cancer—Metastatic**

Location: Hall B1

**Michael A. Danso, MD, FASCO - Chair**  
US Oncology Network/Virginia Oncology Associates

**Ayca Guzalp, MD - Chair**  
Memorial Sloan Kettering Cancer Center

**11:30 AM Abstract LBA1000:** Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).  
First Author: Gabe S. Sonke, MD, PhD

**11:42 AM Abstract 1001:** Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR+)]/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial.  
First Author: Antonio Llombart-Cussac, MD

**11:54 AM Abstract 1002:** Dynamics and type of ESR1 mutations under aromatase inhibitor or fulvestrant combined with palbociclib after randomization in the PADA-1 trial.  
First Author: Luc Cabel, MD

**12:06 PM Daniel G. Stover, MD (Discussion of Abstract(s) LBA1000-1002)**  
Ohio State University Comprehensive Cancer Center  
*Seeking Sensitivity and Resisting Resistance: Learning From the CDK4/6 Experience*

12:18 PM Panel Question and Answer

**12:30 PM Abstract 1003:** Final overall survival (OS) analysis from the phase 3 TROPICS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC).  
First Author: Sara M. Tolaney, MD, MPH

**12:42 PM Abstract 1004:** A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC).  
First Author: Erika P. Hamilton, MD

## Monday, June 5, 2023

- 12:54 PM Abstract 1005:** Dynamic HER2-low status among patients with triple negative breast cancer (TNBC): The impact of repeat biopsies.  
First Author: Yael Bar, MD, PhD
- 1:06 PM Barbara Pistilli, MD (Discussion of Abstract(s) 1003-1005)**  
Institit Macerata  
*"Moving Targets" in Antibody-Drug Conjugate Therapy*
- 1:18 PM** Panel Question and Answer
- 1:30 PM Abstract 1006:** An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03.  
First Author: Ian E. Krop, MD, PhD
- 1:42 PM Abstract 1007:** Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-777 trial.  
First Author: Qamar J. Khan, MD
- 1:54 PM Abstract 1008:** CANKADO PRO-React eHealth support in patients with HR+ HER2- metastatic breast cancer receiving palbociclib and endocrine therapy and the affect on time to deterioration of quality of life: Primary outcome analysis of the multicenter randomized PreCycle trial.  
First Author: Nadia Harbeck, MD, PhD
- 2:06 PM Dawn L. Hershman, MD, MS, FASCO (Discussion of Abstract(s) 1006-1008)**  
Columbia University  
*Hitting the Mark: Patient-Centered Outcomes in Metastatic Breast Cancer*
- 2:18 PM** Panel Question and Answer

---

### 11:30 AM - 2:30 PM Oral Abstract Session

#### Genitourinary Cancer—Kidney and Bladder

Location: Hall D1

**Neha Vapiwala, MD, FACR, FASTRO, FASCO - Chair**  
Abramson Cancer Center

**Manojkumar Bupathi, MD - Chair**  
Rocky Mountain Cancer Centers

- 11:30 AM Abstract LBA4500:** Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.  
First Author: Toni K. Choueiri, MD
- 11:42 AM Abstract LBA4501:** Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.  
First Author: Brian I. Rini, MD, FASCO
- 11:54 AM Abstract 4502:** Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).  
First Author: Robert J. Motzer, MD
- 12:06 PM David A. Braun, MD, PhD (Discussion of Abstract(s) LBA4500-4502)**  
School of Medicine, Yale University  
*Combination Therapies Come of Age in Kidney Cancer*
- 12:18 PM** Panel Question and Answer

- 12:30 PM Abstract 4503:** Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with metastatic urothelial carcinoma (mUC): Updated data from the IMvigor130 OS final analysis.  
First Author: Enrique Grande, MD
- 12:42 PM Abstract 4504:** Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study.  
First Author: Arlene O. Siefker-Radtke, MD
- 12:54 PM Abstract 4505:** Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up.  
First Author: Shilpa Gupta, MD
- 1:06 PM Maria Teresa Bournalon, MD, MSc (Discussion of Abstract(s) 4503-4505)**  
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán  
*Potpourri of Options in First-Line Urothelial Cancer: Are We Ready to Select?*
- 1:18 PM** Panel Question and Answer
- 1:30 PM Abstract 4506:** Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial.  
First Author: Robert J. Motzer, MD
- 1:42 PM Abstract LBA4507:** Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial.  
First Author: Christian Pfister, MD, PhD
- 1:54 PM Abstract 4508:** SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.  
First Author: Seth P. Lerner, MD
- 2:06 PM To be determined (Discussion of Abstract(s) 4506-4508)**  
*Hitting Harder in Locoregional Disease: The Urologist's Perspective*
- 2:18 PM** Panel Question and Answer

---

### 11:30 AM - 2:30 PM Oral Abstract Session

#### Sarcoma

Location: S100a

**Herbert H. F. Loong, MBBS, FRCP - Chair**  
The Chinese University of Hong Kong

**Aimee Marie Crago, MD, PhD, FACS - Chair**  
Memorial Sloan Kettering Cancer Center

- 11:30 AM Abstract 11500:** Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc).  
First Author: Peter Reichardt, MD, PhD

- 11:42 AM Abstract 11501:** A single-arm, open-label phase 2 trial of doxorubicin plus zalifrelimab, a CTLA-4 inhibitor, with balstilimab, a PD-1 inhibitor, in patients with advanced/metastatic soft tissue sarcomas.  
First Author: Breeelyn A. Wilky, MD
- 11:54 AM Abstract 11502:** ImmunoSarc2: A Spanish Sarcoma Group (GEIS) phase Ib trial of doxorubicin and dacarbazine plus nivolumab in first line treatment of advanced leiomyosarcoma.  
First Author: Javier Martin Broto, MD, PhD
- 12:06 PM Nam Bui, MD (Discussion of Abstract(s) 11500-11502)**  
Stanford University Medical Center  
*ImmuneHOT or NOT: Does Chemotherapy Boost Responses to Immunotherapy?*
- 12:18 PM** Panel Question and Answer
- 12:30 PM Abstract 11503:** A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902).  
First Author: Juneko E. Grilley-Olson, MD
- 12:42 PM Abstract LBA11504:** Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma.  
First Author: Brian Andrew Van Tine, MD
- 12:54 PM Abstract 11505:** A phase II study of cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas.  
First Author: Mark Agulnik, MD
- 1:06 PM Neeta Somaiah, MD (Discussion of Abstract(s) 11503-11505)**  
The University of Texas MD Anderson Cancer Center  
*Optimal Pairings With Broad Spectrum TKIs*
- 1:18 PM** Panel Question and Answer
- 1:30 PM Abstract 11506:** A phase III randomized trial of neoadjuvant chemotherapy in high-risk soft tissue sarcoma (ISG-STs 1001): Feasibility and activity of concurrent chemotherapy and radiation therapy.  
First Author: Elena Palassini, MD
- 1:42 PM Abstract 11507:** Efficacy of combination lurbinectedin (LURBI) + doxorubicin (DOX) from the phase 1B soft-tissue sarcoma (STS) lead-in to a randomized phase 2 trial in leiomyosarcoma (LMS).  
First Author: Gregory Michael Cote, MD
- 1:54 PM Abstract 11508:** Safety and clinical activity of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma: Results from the low-dose expansion cohort.  
First Author: Sujana Movva, MD
- 2:06 PM Arun S. Singh, MD (Discussion of Abstract(s) 11506-11508)**  
University of California Los Angeles Translational Oncology Research  
*New Lessons From the Old School: Building on Anthracyclines Foundations*
- 2:18 PM** Panel Question and Answer

---

**12:00 PM - 1:00 PM Annual Business Meeting**

**ASCO Annual Business Meeting (ASCO Members Only)**  
Location: S103

**1:00 PM - 2:15 PM Education Session**

**Down the Yellow Brick Road: Balancing Benefit and Toxicity of Immunotherapy in Melanoma**  
Location: S100bc

**Jaivid J. Moslehi, MD**  
University of California San Francisco  
*A Heart: Cardiac Toxicity of Immunotherapy*

**Peter A. J. Forsyth, MD**  
H. Lee Moffitt Cancer Center and Research Institute  
*A Brain: Neurotoxicity of Immunotherapy*

**Leslie Anne Fecher, MD - Chair**  
University of Michigan  
*The Courage: Managing Steroid Refractory and Long-Term Effects of Immunotherapy*

*Panel Question and Answer*

---

**1:00 PM - 2:15 PM Education Session**

**Family Matters: Germline Testing in Thoracic Cancers**  
Location: E451

**Feighanne Hathaway, MSc**  
University of Chicago  
*Basics of Germline Testing and Approaches to Genetic Counseling*

**Renato G. Martins, MD, MPH**  
Virginia Commonwealth University  
*Pathogenic Germline Alterations in Lung Cancer*

**Dean Anthony Fennell, PhD, FRCP - Chair**  
University of Leicester and Leicester University Hospitals  
*Germline Alterations and Inherited Predisposition to Mesothelioma*

*Panel Question and Answer*

---

**1:15 PM - 2:15 PM Case-Based Panel**

**CAR T-Related Toxicities: Everything Clinicians Need to Know**  
Location: Arie Crown Theater

**Saar Gill, MD, PhD - Chair**  
University of Pennsylvania  
*Moderator*

**Bianca Santomasso, MD, PhD**  
Memorial Sloan Kettering Cancer Center  
*Perspective on Incidence and Management of Neurotoxicity*

**John B. A. G. Haanen, MD, PhD**  
Netherlands Cancer Institute  
*Perspective on Cytokine Release Syndrome in Patients With Solid Tumors Receiving T-Cell Therapies*

**Nirali N. Shah, MD**  
National Cancer Institute  
*Perspective on Cytopenias and Hemophagocytic Lymphohistiocytosis: Management in Hematologic Malignancies*

*Panel Question and Answer*



Monday, June 5, 2023

**1:15 PM - 2:30 PM Ticketed Session**

**Meet the Professors: Challenges for Drug Development in Cancer Prevention**

Location: E253d

**Eduardo Vilar Sanchez, MD, PhD**

The University of Texas MD Anderson Cancer Center  
*From Bench to Bedside: Developing Novel Cancer Prevention Strategies in Patients at High Risk of Colorectal Cancer*

**John Burn, MD, FRCP, FMedSci**

Newcastle University  
*Repurposing Existing Therapeutics for Cancer Prevention*

*Panel Question and Answer*

---

**1:15 PM - 2:45 PM Poster Discussion Session**

**Gastrointestinal Cancer—Colorectal and Anal**

Location: Hall D2

**Cathy Eng, MD, FACP, FASCO - Chair**

Vanderbilt-Ingram Cancer Center

**Sunnie S. Kim, MD - Chair**

University of Colorado Cancer Center

**1:15 PM Bassel F. El-Rayes, MD (Discussion of Abstract(s) 3512-3514)**  
Emory University  
*Systemic Therapies for Advanced Colorectal Cancer: The Past, Present and Future*

**1:27 PM** Panel Question and Answer

**1:37 PM Alex Kim, MD, PhD (Discussion of Abstract(s) 3515-3518)**  
The Ohio State University James Cancer Center  
*The Evolving Role of Surgery in Advanced Colorectal Cancer*

**1:49 PM** Panel Question and Answer

**1:59 PM Jeremy Jones, MD (Discussion of Abstract(s) 3519-3520)**  
Mayo Clinic  
*Is Total Neoadjuvant Therapy the Preferred Approach for Every Patient With Rectal Cancer?*

**2:11 PM** Panel Question and Answer

**2:21 PM Clara O. Montagut, MD (Discussion of Abstract(s) 3521-3523)**  
Hospital del Mar-Institut Hospital del Mar d'Investigacions Mèdiques  
*Early Predictors of Recurrence in the Curative Setting in Colorectal Cancer: Are We Getting Closer?*

**2:33 PM** Panel Question and Answer

Posters discussed in this session are on display in the Gastrointestinal Cancer—Colorectal and Anal Poster Session. To view abstract titles and presentations, see the online program guide ([meetings.asco.org](https://meetings.asco.org)).

---

**1:15 PM - 2:45 PM Poster Discussion Session**

**Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia**

Location: E450

**Alexey Valeryevich Danilov, MD, PhD - Chair**

City of Hope

**Deborah Marie Stephens, DO - Chair**

Hunstan Cancer Institute at the University of Utah

**1:15 PM Elise A. Chong, MD (Discussion of Abstract(s) 7509-7511)**  
Hospital of the University of Pennsylvania  
*Expanding and Extending CAR T-Cell Therapy*

**1:27 PM** Panel Question and Answer

**1:37 PM Michael Y. Choi, MD (Discussion of Abstract(s) 7512-7514)**  
University of California San Diego School of Medicine  
*Safety First in CLL and MCL*

**1:49 PM** Panel Question and Answer

**1:59 PM Allison Claire Rosenthal, DO (Discussion of Abstract(s) 7515-7517)**  
Mayo Hospital  
*Personalized and Patient-Centric Therapy in Hodgkin and Primary Mediastinal Large B-Cell Lymphoma*

**2:11 PM** Panel Question and Answer

**2:21 PM Julio C. Chavez, MD (Discussion of Abstract(s) 7518-7520)**  
H. Lee Moffitt Cancer Center and Research Institute  
*Moving Beyond R-CHOP and Excessive Imaging in Non-Hodgkin Lymphoma*

**2:33 PM** Panel Question and Answer

Posters discussed in this session are on display in the Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Poster Session. To view abstract titles and presentations, see the online program guide ([meetings.asco.org](https://meetings.asco.org)).

---

**1:15 PM - 4:15 PM Poster Session**

**Care Delivery and Regulatory Policy**

Location: Hall A

Abstracts on Boards 103-114 will be discussed during the Care Delivery and Regulatory Policy Poster Discussion Session. See the online program guide ([meetings.asco.org](https://meetings.asco.org)) for session details.

**Posters by Topic**

Care Delivery/Models of Care: Boards 106-108, 113, 115-141, 202a, 202b

Clinical Informatics/Advanced Algorithms/Machine Learning: Boards 109-111, 142-158

Clinical Research Design: Boards 159-170, 203a-204b

Digital Technology/Therapeutics: Boards 112, 171-173, 175-181, 205a-205b

Health Policy: Boards 103-105, 182-193

Practice Management: Boards 194-195, 206a

Telemedicine: Boards 114, 196-201, 206b

Board 103 **ABSTRACT 1509:** Association of Medicaid expansion with treatment receipt, delays in treatment initiation, and survival among young adult women with breast cancer.  
First Author: Xuesong Han, PhD

Board 104 **ABSTRACT 1510:** Association between state Medicaid policies and accrual of Black and Hispanic patients to cancer clinical trials.  
First Author: Samuel U Takvorian, MD, MS

Board 105 **ABSTRACT 1511:** State mandatory paid medical leave policies and survival among adults with cancer in the US.  
First Author: Justin Michael Barnes, MD, MS

- Board 106 **ABSTRACT 1512:** Impact of the oncology care model (OCM) on Medicare payments, utilization, and care delivery: Update through year 5.  
First Author: Gabriel A. Brooks, MD, MPH
- Board 107 **ABSTRACT 1513:** Engagement of Patients with Advanced Cancer (EPAC) randomized clinical trial: Long-term effects on survival and healthcare use.  
First Author: Manali I. Patel, MD, MPH, MS
- Board 108 **ABSTRACT 1514:** Patient- and clinician-directed implementation strategies to improve serious illness communication for high-risk patients with cancer: A cluster-randomized pragmatic trial.  
First Author: Samuel U Takvorian, MD, MS
- Board 109 **ABSTRACT 1515:** Identifying clinical trial candidates using AI predictions of treatment change: A pilot implementation study.  
First Author: Kenneth L. Kehl, MPH
- Board 110 **ABSTRACT 1516:** Developing machine learning algorithms incorporating patient reported outcome measures to predict acute care events among patients with cancer.  
First Author: Thomas J Roberts, MD, MBA
- Board 111 **ABSTRACT 1517:** AI-based radiomic biomarkers to predict PD-(L)1 immune checkpoint inhibitor response within PD-L1 high/low/negative expression categories in stage IV NSCLC.  
First Author: George R. Simon, MD, FCCP, FACP
- Board 112 **ABSTRACT 1518:** Towards improvement of oncology care through digital technology: A snapshot of Resilience remote patient monitoring (RPM) system implementation across 19 hospitals in Europe.  
First Author: Arlindo R. Ferreira, MD, PhD, MSc
- Board 113 **ABSTRACT 1519:** Expanding veteran treatment access points through Close To Me (CTM) infusion service.  
First Author: Jenna L Shields, PharmD BCOP
- Board 114 **ABSTRACT 1520:** Improving cancer care in underserved regions through technology-enabled patient-reported outcomes.  
First Author: Kingsley Ndoh
- Board 115 **ABSTRACT 1521:** Multidisciplinary prostate cancer consultation at home: Does the virtual visit platform adversely affect care for elderly patients or impact treatment recommendations?  
First Author: Ryan P. Dorin, MD, FACS
- Board 116 **ABSTRACT 1522:** Smoking cessation support and knowledge among newly diagnosed individuals at community cancer centers (ECOG-ACRIN trial EAQ171CD).  
First Author: Elyse R. Park, PhD, MPH
- Board 117 **ABSTRACT 1523:** The impact of the 4R Oncology model of team-based care delivery on timing and sequence of guideline recommended interdependent care in breast and lung cancers.  
First Author: Raymond Liu, MD
- Board 118 **ABSTRACT 1524:** English- and Spanish-preferring patient perspectives on managing acute care needs at two disparate health systems.  
First Author: Beverly Kyalwazi, MD
- Board 119 **ABSTRACT 1525:** Assessing mail-in cryopreservation for fertility preservation.  
First Author: Andre R Belarmino, MD
- Board 120 **ABSTRACT 1526:** Implementation of a multi-cancer early detection (MCED) test using a centralized model within (w/i) a multi-state health system.  
First Author: Gautum Agarwal, MD
- Board 121 **ABSTRACT 1527:** Differential responses to systemic therapy among patients who are financially fragile and receiving Medicaid: Results from ePRO and biometric monitoring study.  
First Author: Scott David Ramsey, PhD
- Board 122 **ABSTRACT 1528:** Team-based versus technology-based supportive cancer care (SCC): Assessment of implementation across 24 different clinical settings.  
First Author: Sacha T. Moufarrej, MA
- Board 123 **ABSTRACT 1529:** Dose rounding bevacizumab and its biosimilars to reduce drug waste in the oncology care model in a community oncology network.  
First Author: Puneeth Indurlal, MD, MS, MBBS
- Board 124 **ABSTRACT 1530:** Impact of geography on receipt of medical oncology consultation and neoadjuvant chemotherapy for triple negative and HER2 positive breast cancer.  
First Author: Elliott Kenneth Yee, MD
- Board 125 **ABSTRACT 1531:** Implementation of a streamlined prior authorization process to improve cancer care delivery.  
First Author: Aarti Sonia Bhardwaj, MD
- Board 126 **ABSTRACT 1532:** Best practices study to enhance the quality of multi-disciplinary teams in lung cancer care.  
First Author: Marcos Gallego Llorente, PhD
- Board 127 **ABSTRACT 1533:** Outpatient practice utilization for CAR-T and T cell engager in patients with lymphoma and multiple myeloma.  
First Author: Radhika Bansal, MBBS
- Board 128 **ABSTRACT 1534:** Real-world experience of an in-house dihydropyrimidine dehydrogenase (DPYD) genotype test to guide fluoropyrimidine (FP) dosing at a multisite cancer hospital.  
First Author: Jai Narendra Patel, PharmD, BCOP
- Board 129 **ABSTRACT 1535:** Decreasing the burden of febrile neutropenia through dynamic remote patient monitoring: The DEFENDER program.  
First Author: Joshua Pritchett, MD
- Board 130 **ABSTRACT 1536:** Outcomes on the hematology malignancy hospitalist service: A model for inpatient care.  
First Author: Alaina J. Kessler, MD, MPH
- Board 131 **ABSTRACT 1537:** Are we ready to mitigate time toxicity of cancer care? Oncologists' perceptions on digital interventions to fast-track cancer care.  
First Author: Erin Mary Bange, MD
- Board 132 **ABSTRACT 1538:** Overcoming barriers and improving genetic testing completion rate for hereditary cancer in an underserved population at a large safety net hospital.  
First Author: Autumn Vara, MS
- Board 133 **ABSTRACT 1539:** Antineoplastic and immunomodulating agent effects on immunization outcomes.  
First Author: Jacob New, MD, PhD
- Board 134 **ABSTRACT 1540:** Genomic therapy matching in rare and refractory cancers: Updated results from a retrospective cohort study in the Molecular Screening and Therapeutic (MoST) program.  
First Author: Frank Po-Yen Lin, PhD, FRACP, MBChB

Monday, June 5, 2023

- Board 135 **ABSTRACT 1541:** Surgical care and outcomes in older patients with cancer through implementation of a pre-surgical toolkit (OPTI-Surg): Interim results of a phase III cluster randomized trial (Alliance A231601CD).  
First Author: George J. Chang, MD, MS
- Board 136 **ABSTRACT 1542:** Distribution of alternate site infusion providers in the US.  
First Author: Cindy Revol, MPH, MBA
- Board 137 **ABSTRACT 1543:** National lung cancer screening rates among women veterans within the Veterans' Health Administration.  
First Author: Jennifer Bail, PhD, RN
- Board 138 **ABSTRACT 1544:** Association between inpatient clinical nursing acuity and 30-day rehospitalization among hospitalized patients with advanced cancer.  
First Author: Daniel E Lage, MD
- Board 139 **ABSTRACT LBA1545:** A randomized trial of patient navigation with symptom-monitoring in advanced lung cancer.  
First Author: Vanita Noronha, MD
- Board 140 **ABSTRACT 1546:** Evolving adjuvant estrogen therapy prescribing among breast oncology workforce.  
First Author: Kayla Polcari, MD, MPH
- Board 141 **ABSTRACT 1547:** Effect of an oncology care management program on unplanned hospital admissions in a commercially insured population.  
First Author: Wendy L. French, DO
- Board 142 **ABSTRACT 1548:** An AI tool for chest X-ray interpretation and lung cancer pre-screening in developing countries.  
First Author: Iván Romarico González Espinoza, MD
- Board 143 **ABSTRACT 1549:** Deep learning-based approach to predict multiple genetic mutations in colorectal and lung cancer tissues using hematoxylin and eosin-stained whole-slide images.  
First Author: Teppei Konishi
- Board 144 **ABSTRACT 1550:** Gene expression-based machine learning approach to predict immunotherapy response and survival in patients with advanced cancer.  
First Author: Zheng Zhang
- Board 145 **ABSTRACT 1551:** Prediction of cancer treatment response from histopathology images through imputed transcriptomics.  
First Author: Danh-Tai Hoang
- Board 146 **ABSTRACT 1552:** Utilizing predictive modeling to identify patients at high-risk of death from immune checkpoint inhibitor therapy-related pneumonitis.  
First Author: Antonious Ziad Hazim, MD
- Board 147 **ABSTRACT 1553:** Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome.  
First Author: Ranit Aharonov, PhD
- Board 148 **ABSTRACT 1554:** Can synthetic data accurately mimic oncology clinical trials?  
First Author: Samer El Kababji, PhD
- Board 149 **ABSTRACT 1555:** Relevance and accuracy of ChatGPT-generated NGS reports with treatment recommendations for oncogene-driven NSCLC.  
First Author: Zac Hamilton
- Board 150 **ABSTRACT 1556:** Identification of genes encoding targets associated with adverse events in multiple myeloma.  
First Author: Xuan Xu, PhD
- Board 151 **ABSTRACT 1557:** An intelligent machine learning model for real-time early detection of undesirable cancer events: AIM2REDUCE.  
First Author: Robert C. Grant, MD, PhD
- Board 152 **ABSTRACT 1558:** Lost in translation? Information exchange during breast cancer care and implications for technology design.  
First Author: Megan Salwei, PhD
- Board 153 **ABSTRACT 1559:** Association of smoking history extracted from electronic health records (EHR) using machine-learning methods and tumor characteristics in patients with lung cancer.  
First Author: Semanti Mukherjee, PhD
- Board 154 **ABSTRACT 1560:** Early assessment of sotorasib for treatment of patients with advanced non-small cell lung cancer using real-world data in the United States.  
First Author: Dvir Aran, PhD
- Board 155 **ABSTRACT 1561:** Natural language processing identification of documented mental health symptoms associated with risk of mental health disorders in patients with cancer.  
First Author: Isabel Friesner, BA
- Board 156 **ABSTRACT 1562:** Accuracy of a clinical decision support system in identifying patients at risk of cancer in primary care.  
First Author: Bea Bakshi, MBBS, BSc
- Board 157 **ABSTRACT 1563:** ALAN as an omic tool to build gene signatures and to stratify patients.  
First Author: Hannah E. Bergom
- Board 158 **ABSTRACT 1564:** Deep learning to estimate RECIST in cancer patients treated in real-world settings.  
First Author: Irbaz Bin Riaz, MBBS, MS
- Board 159 **ABSTRACT 1565:** Impact of COVID-19 pandemic mitigation strategies on industry and NCI cancer treatment trials.  
First Author: Joseph M. Unger, PhD
- Board 160 **ABSTRACT 1566:** Trial eligibility criteria (EC) and diversity among patients with advanced non small cell lung cancer (advNSCLC).  
First Author: Maneet Kaur
- Board 161 **ABSTRACT 1567:** Toxicity reporting consistency and subjective minimizing language use in colorectal cancer (CRC) and pancreatic cancer (PaC) clinical trials: A systematic review of phase III randomized controlled trials (RCTs) presented at ASCO between 2012-2022.  
First Author: James Yu, MD
- Board 162 **ABSTRACT 1568:** Technology-enabled clinical trials: Intentional capture of source data (IDC) in the electronic-health record (EHR) and direct transfer to trial database (electronic data capture [EDC]) in a phase II multicenter trial.  
First Author: Trevor Joseph Royce, MD, MPH
- Board 163 **ABSTRACT 1569:** The inclusion of health-related quality of life and other patient-reported outcomes in landmark trials for Food and Drug Administration oncology drug approvals: An analysis of cancer drug approvals between 2006 and 2022.  
First Author: Ademola Samuel Ojo, MD
- Board 164 **ABSTRACT 1570:** Endpoints reported in phase 3 randomized clinical trials at ASCO 2022.  
First Author: Laure-Anne Marie Nicole Teuwen, PhD
- Board 165 **ABSTRACT 1571:** Utilizing Drug Combo to improve the design of phase 1 trials for anticancer drugs.  
First Author: Lei Wang, PhD

- Board 166 **ABSTRACT 1572:** Streamlining regulatory review in a multicenter platform trial: Opportunity to enhance patient centered care and drive innovation and efficiency.  
First Author: Alexis Colley
- Board 167 **ABSTRACT 1573:** Survival-inferred fragility index of FDA-approved cancer drugs using surrogate endpoints.  
First Author: Jonathan Ofer, MD
- Board 168 **ABSTRACT 1574:** Use of gender-neutral language in clinical trial protocols in select cancers.  
First Author: Garima Gupta, MD
- Board 170 **ABSTRACT 1576:** Trends in U.S and global patient enrollment from 2014 to 2022 in lung cancer clinical trials supporting marketing applications: An FDA analysis.  
First Author: Oladimeji Akinboro, MD, MPH
- Board 171 **ABSTRACT 1577:** Quantifying the growth of clinical actionability in precision oncology using OncoKB.  
First Author: Sarah P. Suehnholz, PhD, BS, MS
- Board 172 **ABSTRACT 1578:** Clinical pathways innovation: A lesson on the value of clinician based feedback and collaboration with Flatiron Health.  
First Author: Christopher Davella, MD
- Board 173 **ABSTRACT 1579:** Completion rates and trends of the patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) across 14 oncology clinical trials.  
First Author: Jessica A Emerson, PhD, MS
- Board 175 **ABSTRACT 1581:** Association of remote, longitudinal patient-reported outcomes (PROs) and step counts with hospitalization or death among patients with advanced cancer undergoing chemotherapy: Secondary analysis of the PROStep randomized trial.  
First Author: Ravi Bharat Parikh, MD
- Board 176 **ABSTRACT 1582:** Differences in perceptions and use of remote patient monitoring technology in rural cancer programs.  
First Author: David Penberthy, MD, MBA
- Board 177 **ABSTRACT 1583:** The Tempus TIME trial portal and clinical trial enrollment.  
First Author: Amol Rao, MD
- Board 178 **ABSTRACT 1584:** Global adoption of remote technologies to enable patient-centric oncology clinical trials: Analysis by the Bloomberg New Economy International Cancer Coalition.  
First Author: Robert Michael Daly, MD, MBA
- Board 179 **ABSTRACT 1585:** Longitudinal changes in patient reported outcome measures in patients with cancer six months prior to death: A case-control study.  
First Author: Samantha Tam, MD, MPH
- Board 180 **ABSTRACT 1586:** Patient-reported usefulness of an intervention to promote job retention among women undergoing (neo)adjuvant breast cancer chemotherapy.  
First Author: Victoria Susana Blinder, MD, MSc, FASCO
- Board 181 **ABSTRACT 1587:** Acceptability and effectiveness of digital prehabilitation and personalised support for cancer patients in the UK National Health Service.  
First Author: Venetia Wynter-Blyth
- Board 182 **ABSTRACT 1588:** Comparison of publications between cancer sites in high impact factor journals.  
First Author: Nikita Sinha, MD
- Board 183 **ABSTRACT 1589:** Association of state policies regulating short-term limited-duration insurance plans and cancer stage at diagnosis.  
First Author: Justin Michael Barnes, MD, MS
- Board 184 **ABSTRACT 1590:** Clinical practice guideline descriptions of oncologic drugs granted FDA accelerated approval: A cross-sectional study.  
First Author: Maryam Mooghali, MD, MSc
- Board 185 **ABSTRACT 1591:** "It was so many hoops to jump through": Patient-reported administrative burden from disability, Family and Medical Leave Act (FMLA), and insurance appeals.  
First Author: Fumiko Chino, MD
- Board 186 **ABSTRACT 1592:** Trends in new and persistent opioid use in older adults with cancer.  
First Author: Laura Van Metre Baum, MD, MPH
- Board 187 **ABSTRACT 1593:** Cost-effectiveness of trastuzumab deruxtecan in HER2 low metastatic breast cancer.  
First Author: James Dickerson
- Board 188 **ABSTRACT 1594:** Data transparency and demographic representation in approval packages of FDA-approved oncology drugs from 2012-2021.  
First Author: Jingyi Liu, MD, MBA
- Board 189 **ABSTRACT 1595:** Race and ethnicity reporting by US federal standards in high-impact phase 2/3 oncology clinical trial publications.  
First Author: Kekoa A. Taparra, MD, PhD
- Board 190 **ABSTRACT 1596:** Association of participation in Medicare's Oncology Care Model with spending, utilization, and quality outcomes among commercially insured and Medicare Advantage members: A national difference-in-differences analysis.  
First Author: Samyukta Mullangi, MD, MBA
- Board 191 **ABSTRACT 1597:** Is Medicare Advantage associated with more favorable health care access, acute care utilization, and affordability among beneficiaries with cancer?  
First Author: Vishal R. Patel, BS
- Board 192 **ABSTRACT 1598:** Dosage optimization in drug development: An FDA Project Optimus analysis of postmarketing requirements issued to repair the cracks.  
First Author: Brian Heiss, MD
- Board 193 **ABSTRACT 1599:** Association of accelerated approval (AA) status with National Comprehensive Cancer Network (NCCN) guideline recommendation for cancer drug indications: A cross-sectional study.  
First Author: Edward Robert Scheffer Cliff, MPH, MBBS
- Board 194 **ABSTRACT 1600:** System-wide approach on biosimilars adoption in oncology: Strategic plan on switching and cost savings.  
First Author: Suwicha Limvorasak, PharmD, BCOP
- Board 195 **ABSTRACT 1601:** Correlation between Oncotype DX, Predict, and Nottingham Prognostic Index on HR+, HER2- early breast cancer treatment: The current value of molecular testing.  
First Author: Leticia Campoverde, MD.
- Board 196 **ABSTRACT 1602:** Telemedicine-supervised cancer therapy for patients with an aggressive lymphoma and metastatic lung cancer in the U.S. Veterans Affairs National TeleOncology Service.  
First Author: Chenyu Lin, MD
- Board 197 **ABSTRACT 1603:** Use and value of self-management (SM) recommendations in a real-world evidence study evaluating digital patient monitoring (DPM) of patients (pts) receiving cancer care.  
First Author: Manuela Eicher, MD

## Monday, June 5, 2023

- Board 198 **ABSTRACT 1604:** SpotCheck: A skin cancer diagnostic clinical trial comparing dermoscopy-enhanced telemedicine to in-person evaluation.  
First Author: Jenne P. Ingrassia
- Board 199 **ABSTRACT 1605:** A study to assess the diagnostic performance of a digital remote monitoring tool for patients with cancer: The POSITEA-VA study.  
First Author: Charles Georges Parnot, PhD.
- Board 200 **ABSTRACT 1606:** Trends and disparities in oncology telehealth after the initial pandemic era.  
First Author: Michael Jisoo Lee, MD
- Board 201 **ABSTRACT 1607:** Impact of state policies on telehealth use among the privately insured with newly diagnosed cancer.  
First Author: Ya-Chen Tina Shih, PhD
- Board 202a **ABSTRACT TPS1608:** Korean Precision Medicine Networking Group study of molecular profiling guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) II (KCSG AL 22-09).  
First Author: Sun Young Kim, MD
- Board 202b **ABSTRACT TPS1609:** Open label single arm study to assess the implementation of home based daratumumab administration in patients being treated for multiple myeloma.  
First Author: Adam F Binder, MD
- Board 203a **ABSTRACT TPS1610:** Screening for high frequency malignant disease (SHIELD).  
First Author: HA NGUYEN
- Board 203b **ABSTRACT TPS1611:** Progress report of a cross-organ and biomarker-based platform study: BELIEVE trial NCCH1901.  
First Author: Yayoi Ando, MD
- Board 204a **ABSTRACT TPS1612:** Infrastructure for rare cancer in the Netherlands: Towards a comprehensive platform for early detection and diagnosis of rare cancers (FORCE).  
First Author: Carolina R.C. Pieterman, MD, PhD
- Board 204b **ABSTRACT TPS1613:** The PLATON Network: An interactive platform for precision oncology.  
First Author: Salah-Eddin Al-Batran, Prof. Dr. med.
- Board 205a **ABSTRACT TPS1614:** Electronic collection of cancer patient-reported outcomes using a novel digital oncology platform: A multi-site randomized controlled trial.  
First Author: Chris Fidyk, MBA, BSc
- Board 205b **ABSTRACT TPS1615:** Mixed-methods clinical trial to evaluate the feasibility of the CURATE.AI optimised digital cognitive rehabilitation therapeutic (COR-Tx) in patients post brain radiotherapy.  
First Author: Marlena N. Raczowska, PhD
- Board 206a **ABSTRACT TPS1616:** Liquid biopsy-informed precision oncology study to evaluate utility of plasma genomic profiling for therapy selection.  
First Author: Jessica Tao, MD
- Board 206b **ABSTRACT TPS1617:** An interventional study of the impact of digital patient monitoring (DPM) on health outcomes, healthcare resource utilization, and feasibility of a combination with at-home treatment (tx) for delivery of systemic anticancer tx in clinical practice.  
First Author: Sanna Iivanainen, MD, PhD

---

### 1:15 PM - 4:15 PM Poster Session

#### Gynecologic Cancer

Location: Hall A

Abstracts on Boards 207-218 will be discussed during the Gynecologic Cancer Poster Discussion Session. See the online program guide ([meetings.asco.org](https://meetings.asco.org)) for session details.

#### Posters by Topic

**Biologic Correlates:** Boards 219-222

**Cervical Cancer:** Boards 213-215, 224-238

**Ovarian Cancer:** Boards 207-210, 216-217, 239-288, 307a-313b

**Uterine Cancer:** Boards 289-302, 314a-318a

**Other Gynecologic Cancer:** Boards 211, 218, 303-306, 318b

- Board 207 **ABSTRACT 5512:** Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses.  
First Author: Panagiotis A. Konstantinopoulos, MD
- Board 208 **ABSTRACT 5513:** Correlation of cyclin E1 expression and clinical outcomes in a phase 1b dose-escalation study of azenosertib (ZN-c3), a WEE1 inhibitor, in combination with chemotherapy (CT) in patients (pts) with platinum-resistant or refractory (R/R) epithelial ovarian, peritoneal, or fallopian tube cancer (EOC).  
First Author: Joyce F. Liu, MD
- Board 209 **ABSTRACT 5514:** A phase II trial of palbociclib combined to letrozole after progression on second-line chemotherapy for women with ER/PR-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer: LACOG 1018.  
First Author: Fernanda Bronzon Damian, MD
- Board 210 **ABSTRACT 5515:** Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).  
First Author: Susana N. Banerjee, PhD, FRCP, MA, MBBS
- Board 211 **ABSTRACT 5517:** A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: The vulvar cancers.  
First Author: Young Kwang Chae, MD, MBA
- Board 213 **ABSTRACT 5519:** Efficacy and final safety analysis of pre- and co-administration of nivolumab (Nivo) with concurrent chemoradiation (CCRT) followed by Nivo maintenance therapy in patients (pts) with locally advanced cervical carcinoma (LACvCa): Results from the phase I trial, GOTIC-018.  
First Author: Kazuto Nakamura, MD, PhD
- Board 214 **ABSTRACT 5520:** Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI study): A prospective, single-arm, phase II trial.  
First Author: Jing Chen
- Board 215 **ABSTRACT 5528:** Advanced cervical cancer therapy: Comparison of contemporary expert and healthcare professional recommendations from an online treatment decision tool.  
First Author: Lauren S. Prescott, MD, MPH
- Board 216 **ABSTRACT 5521:** Toxicity profile and discordance between patients/physicians regarding niraparib maintenance in recurrent ovarian cancer (ROC) patients: Lessons from the NIQOLE real-life study—GINECO study.  
First Author: Florence Joly, MD, PhD
- Board 217 **ABSTRACT 5522:** The Normal Risk Ovarian Screening Study (NROSS): Twenty-one year update.  
First Author: Chae Young Han, PhD

- Board 218 **ABSTRACT 5523:** The effects of the Covid-19 pandemic on practice patterns and outcomes in patients diagnosed with gynecological malignancies in the United States.  
First Author: Adrian Kohut, MD
- Board 219 **ABSTRACT 5524:** Active bone marrow-sparing to reduce the incidence of grade 3+ acute hematologic toxicity in patients with locally advanced cervical cancer who receive chemoradiotherapy: A single-center prospective randomized controlled trial.  
First Author: ShanBing Wang
- Board 220 **ABSTRACT 5525:** Neoplastic and blood-based biomarkers of response in patients with advanced endometrial cancer: Results from NRG GY012.  
First Author: Helen Mackay, MD, MRCP
- Board 221 **ABSTRACT 5526:** Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program.  
First Author: Damien Kee, MBBS
- Board 222 **ABSTRACT 5527:** Association of HRD ovarian cancer by RAD51 with hot immune microenvironment: Translational analyses of MITO 16A/MaNGO-OV2 trial.  
First Author: Benedetta Pellegrino
- Board 224 **ABSTRACT 5529:** SHR-1701 in combination with platinum-based chemotherapy and BP102 (a bevacizumab biosimilar) for persistent, recurrent, or metastatic cervical cancer: Data from a phase 1b/3 study.  
First Author: Jihong Liu
- Board 225 **ABSTRACT 5530:** Efficacy and safety of combining PD-1 blockade and human papillomavirus vaccine for patients with relapsed/refractory advanced cervical cancer.  
First Author: Buhai Wang, MD, PhD
- Board 226 **ABSTRACT 5531:** The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.  
First Author: Jianqing Zhu, MD
- Board 227 **ABSTRACT 5532:** A confirmatory trial of modified radical hysterectomy for patients with FIGO stage IB1 cervical cancer with tumor diameter preoperatively estimated at 2 cm or less: Japan Clinical Oncology Group study, JCOG1101.  
First Author: Takahide Arimoto, MD, PhD
- Board 228 **ABSTRACT 5533:** Patient-reported outcomes during pelvic radiation therapy: A secondary analysis on sexual function from NRG-RT0G 1203.  
First Author: Kelsey L Corrigan, MD, MPH
- Board 229 **ABSTRACT 5534:** The value of progression-free survival at three years as a primary endpoint for studies on radiotherapy in patients with locally advanced cervical cancer: Individual patient data from Chinese National Cancer Center and validation from 27 global randomized trials.  
First Author: Xi Yang, MD
- Board 230 **ABSTRACT 5535:** A multicenter, open-label, single-arm, phase II trial to evaluate the efficacy and safety of geptanolimab (GB226) in the treatment of patients (pts) with programmed cell death ligand 1 (PD-L1)-positive recurrent or metastatic cervical cancer, for whom prior platinum-containing chemotherapy has failed.  
First Author: Jusheng An, MD, PHD
- Board 231 **ABSTRACT 5536:** Final results of a phase II trial of proglumab with platinum-based therapy and bevacizumab in patients with advanced cervical cancer.  
First Author: Sergey Focht, MD, PhD
- Board 232 **ABSTRACT 5537:** Development of cervical cancer patient reported clinical outcome assessment scale (CC-PRO137): A dedicated tool for multidimensional evaluation of treatment outcomes.  
First Author: Xin Wu, MD
- Board 233 **ABSTRACT 5538:** A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).  
First Author: Mayumi Nakagawa, MD, PhD
- Board 234 **ABSTRACT 5539:** Surgical resection based on ontogenetic cancer field theory for cervical cancer: 10-year updated results of the MMR study.  
First Author: Laura Weydandt, MD
- Board 236 **ABSTRACT 5541:** Association between serum folate and vitamin B12 and cervical high-risk human papillomavirus (HPV) infection.  
First Author: Josephine Peitz
- Board 237 **ABSTRACT 5542:** Efficacy and safety of camrelizumab in combination with radiation and chemotherapy for recurrent or metastatic cervical cancer.  
First Author: Zhongjie Chen
- Board 238 **ABSTRACT 5543:** The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?  
First Author: Muhammad Danyal Ahsan
- Board 239 **ABSTRACT 5544:** Phase 1 dose escalation study of SL-172154 (SIRP $\alpha$ -Fc-CD40L) in platinum-resistant ovarian cancer.  
First Author: Nehal J. Lakhani, MD, PhD
- Board 240 **ABSTRACT 5545:** Correlating expression of NaPi2b and FRa in high grade serous ovarian cancer (HGSOC).  
First Author: Debra L. Richardson, MD
- Board 241 **ABSTRACT 5546:** Systematic high-throughput combination drug screen to enhance poly (ADP-ribose) polymerase (PARP) inhibitor efficacy in ovarian cancer.  
First Author: Katherine Foster, MD
- Board 242 **ABSTRACT 5547:** The impact of adjuvant platinum-based chemotherapy in early adult granulosa cell tumor of the ovaries: A meta-analysis of comparative studies.  
First Author: Dinesh Keerty, MD, FACP
- Board 243 **ABSTRACT 5548:** Nivolumab plus ipilimumab (N+I) in patients (pts) with ovarian cancer (OC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.  
First Author: Charles Drescher, MD
- Board 244 **ABSTRACT 5549:** Utility of surgically documented minimal residual disease as a therapeutic target and early surrogate of frontline treatment outcomes in ovarian cancer.  
First Author: Anne Knisely
- Board 245 **ABSTRACT 5550:** Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance.  
First Author: Philipp Harter, MD, PhD
- Board 246 **ABSTRACT 5551:** Real-world data from a multi-center study: Insights to the efficacy and safety in patients with ovarian cancer (OC) received niraparib as first-line (1st-L) maintenance therapy (MT).  
First Author: Minmin Zhao

## Monday, June 5, 2023

- Board 247 **ABSTRACT 5552:** Venous thromboembolism prophylaxis during neoadjuvant chemotherapy for patients with ovarian cancer.  
First Author: Hannah Dysinger McLaughlin
- Board 248 **ABSTRACT 5553:** Circulating tumor DNA (ctDNA) as a marker of residual disease and recurrence in resected stage I-IV epithelial ovarian cancer (EOC).  
First Author: Sumitra Ananda, MBBS, FRACP
- Board 249 **ABSTRACT 5554:** Safety and efficacy of PIPAC in ovarian cancer patients with peritoneal metastases: A first-in-US phase I study.  
First Author: Rosemary Senguttuvan, MD
- Board 250 **ABSTRACT 5555:** Analyses of tumor microenvironment affecting the survival in patients with ovarian cancer receiving intraperitoneal chemotherapy: Translational research from the phase 3 trial of intraperitoneal therapy for ovarian cancer with carboplatin (TRiPocc).  
First Author: Aiko Ogasawara, MD
- Board 251 **ABSTRACT 5556:** Pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin as first-line treatment for Chinese patients with ovarian cancer: A multi-center, randomized, open-label trial.  
First Author: Yuanming Shen, MD
- Board 252 **ABSTRACT 5557:** The role of innate immune system in modulating CHK1 inhibitor (CHK1i) response in BRCA wild-type (BRCAwt), platinum-resistant high-grade serous ovarian cancer (PR-HGSOC): Exploratory analysis from a phase II study of CHK1i prexasertib.  
First Author: Elena Giudice, MD
- Board 253 **ABSTRACT 5558:** DNA methylation patterns between tissue and blood samples in ovarian cancer.  
First Author: Hao Wen
- Board 254 **ABSTRACT 5559:** BRCA1 and RAD51 methylation impact on outcome in patients with advanced ovarian cancer: A PAOLA-1 ancillary study.  
First Author: Helene Blons
- Board 255 **ABSTRACT 5560:** Randomized phase 2 trial of personal dendritic cell (DC)-autologous tumor antigen (ATA) vaccines in newly diagnosed advanced ovary cancer.  
First Author: Bradley Corr, MD
- Board 256 **ABSTRACT 5561:** Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response: A translational sub-study of the REZOLVE (ANZGOG-1101) clinical trial.  
First Author: Bonnita Werner
- Board 257 **ABSTRACT 5562:** Efficacy and safety of niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer who had measurable residual disease: A post-hoc subgroup analysis of the PRIME study.  
First Author: Beihua Kong, MD
- Board 258 **ABSTRACT 5563:** Ex vivo tumor testing platform for predicting clinical response to platinum-based therapy in patients with high grade serous ovarian cancer.  
First Author: P. B. Ottevanger, MD, PhD
- Board 259 **ABSTRACT 5564:** Phase 2 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with granulosa cell ovarian cancer.  
First Author: Sarah Shin, MD, MPH
- Board 260 **ABSTRACT 5565:** Germline variants in non-BRCA1/2 homologous recombination-related genes and ovarian cancer: Analysis of tumor phenotype and survival.  
First Author: Ryan M Kahn, MD
- Board 261 **ABSTRACT 5566:** Anastomotic leakage following bowel resection in radical cytoreductive surgery for ovarian cancer: A subgroup analysis of the prospective AGO-OVAR.OP3/LION.  
First Author: Bastian Czogalla, MD
- Board 262 **ABSTRACT 5567:** Proactive assessment of patient reported outcomes in patients with ovarian cancer.  
First Author: Ainhoa Madariaga, MD
- Board 263 **ABSTRACT 5568:** The effect of maintenance hormone therapy on overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective study.  
First Author: Syem Barakzai, MD
- Board 264 **ABSTRACT 5569:** CD47 expression in ovarian cancer: Dynamic correlation with lymphocyte and macrophage features as well as thrombospondin-1 (TSP-1) under neoadjuvant chemotherapy.  
First Author: Alexandra Leary, MD, PhD
- Board 265 **ABSTRACT 5570:** Trends in ovarian cancer incidence and incidence-based mortality: A 15-year population-based analysis.  
First Author: Sahana Somasegar, MD
- Board 266 **ABSTRACT 5571:** Mechanisms of resistance to bispecific T-cell engager therapy for ovarian cancer.  
First Author: Syem Barakzai, MD
- Board 267 **ABSTRACT 5572:** Patterns of ovarian cancer care in an elderly population in Australia: A prospective cohort study from the National Gynaecology Oncology Registry (NGOR).  
First Author: Mahendra Naidoo, FRACP, MBChB
- Board 268 **ABSTRACT 5573:** Impact of cytoreductive surgery on survival outcomes for recurrent adult-type granulosa cell tumors of the ovary.  
First Author: Jeffrey How, MD, MS, MPH
- Board 269 **ABSTRACT 5574:** A phase 1 study of the SYK inhibitor fostamatinib and weekly paclitaxel for recurrent platinum-resistant ovarian cancer.  
First Author: Stephanie Gaillard, MD, PhD
- Board 270 **ABSTRACT 5575:** Anlotinib combined with carboplatin/paclitaxel and maintenance anlotinib as front-line treatment for newly diagnosed advanced ovarian cancer: A phase II, single-arm, multicenter study (ALTER-GO-010).  
First Author: Yi Jiang
- Board 271 **ABSTRACT 5576:** Understanding differences in the rates of BRCA/HRD testing and treatment in 1<sup>st</sup> line maintenance in patients with ovarian cancer treated by gynecologic oncologists compared to other providers: A quality initiative by Integra Connect (IC) PrecisionQ.  
First Author: Fred J. Kudrik, MD
- Board 272 **ABSTRACT 5577:** First-in-human, phase I study of CBP-1008, a bi-specific ligand drug conjugate, in patients with advanced solid tumors.  
First Author: Jifang Gong, MD
- Board 273 **ABSTRACT 5578:** Response to subsequent platinum-based chemotherapy post PARP inhibitor in recurrent epithelial ovarian cancer.  
First Author: Genevieve MacAulay Vacheresse, MD
- Board 274 **ABSTRACT 5579:** Molecular and immune profiling of TP53-mutated ovarian cancers with non-BRCA1/2 homologous recombination gene alterations.  
First Author: Kyle C Strickland, MD, PhD

- Board 275 **ABSTRACT 5580:** Exploring the significance of PARP inhibitor therapy after first-line chemotherapy in patients with homologous recombination proficient ovarian cancer: An extracted individual patient data and trial-level meta-analysis.  
First Author: Mateus Trinconi Cunha, MD
- Board 276 **ABSTRACT 5581:** Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States.  
First Author: Jason Silberman, MD
- Board 277 **ABSTRACT 5582:** Distinguishing primary mucinous ovarian tumors from metastases of non-gynecologic mucinous cancers: Can we leverage next-generation sequencing?  
First Author: Muhammad Danyal Ahsan
- Board 278 **ABSTRACT 5583:** Effectiveness of PARP inhibitor maintenance therapy (mPARPi) in advanced ovarian cancer (OC) by BRCA1/2 and HRD signature in real-world practice.  
First Author: Debra L. Richardson, MD
- Board 279 **ABSTRACT 5584:** Triplet maintenance (olaparib, pembrolizumab, and bevacizumab) in *BRCA* non-mutated patients with platinum-sensitive recurrent ovarian cancer: A multi-center, single-arm phase II study (OPEB-01).  
First Author: Yoo Na Kim, MD
- Board 280 **ABSTRACT 5585:** The diagnostic landscape of HRD testing based on cross-sectional survey of physicians and molecular biologists conducting testing (INDICATOR ONE).  
First Author: Robert L. Coleman, MD, FCOG, FACS, FASCO
- Board 281 **ABSTRACT 5586:** Immune features of ovarian tumors with a good response to neo-adjuvant chemotherapy in combination with an anti-PD-L1 alone or with an anti-CTLA4: Data from the randomized IneOV trial (a GINECO study).  
First Author: Alexandra Leary, MD, PhD
- Board 282 **ABSTRACT 5587:** Ovarian cancer and bevacizumab: Real-world use across western countries and effect on survival in high-risk subgroups.  
First Author: Kristina Lindemann, MD, PhD
- Board 283 **ABSTRACT 5588:** Blinded-assessment of a solution to evaluate olaparib maintenance treatment efficacy in patients with ovarian cancer from the GINECO/ENGOT PAOLA-1 trial.  
First Author: Adrien Buisson, PharmD
- Board 284 **ABSTRACT 5589:** Predictors of long-term progression-free survival (PFS) in niraparib-treated patients (pts) from the PRIMA/ENGOT-OV26/GOG-3012 study.  
First Author: Whitney Graybill
- Board 285 **ABSTRACT 5590:** Phase 1/1b study of PRGN-3005 autologous UltraCAR-T cells manufactured overnight for infusion next day to advanced stage platinum resistant ovarian cancer patients.  
First Author: John B. Liao, MD, PhD
- Board 286 **ABSTRACT 5591:** The role of Chemotherapy Response Score (CRS) in the decision making process for advanced high grade serous ovarian cancer patients undergoing neoadjuvant chemotherapy.  
First Author: Claudia Marchetti, BA
- Board 287 **ABSTRACT 5592:** Real-world overall survival in second-line maintenance niraparib monotherapy vs active surveillance in BRCA wild-type patients with recurrent ovarian cancer.  
First Author: Robert L. Coleman
- Board 288 **ABSTRACT 5593:** Gynecologic-cancer analysis of ARID1A alterations detected in tissue and liquid biopsies.  
First Author: Natalie Danziger, BS
- Board 289 **ABSTRACT 5594:** Healthcare access dimensions and uterine cancer survival: A National Cancer Database study.  
First Author: Mary Katherine Anastasio, MD
- Board 290 **ABSTRACT 5595:** Preliminary antitumor activity of the combination of COM701 + BMS-986207 + nivolumab in patients with recurrent, metastatic MSS endometrial cancer.  
First Author: Drew W. Rasco, MD
- Board 291 **ABSTRACT 5596:** Pathogenic germline variants in patients with endometrial cancer across diverse ancestries.  
First Author: Ying L Liu, MD, MPH
- Board 292 **ABSTRACT 5597:** The effect of megestrol acetate +/- pterostilbene in endometrial cancer: A prospective, randomized, window-of-opportunity clinical trial.  
First Author: Rosemary Senguttuvan, MD
- Board 293 **ABSTRACT 5598:** Overall survival and subsequent therapy from a phase II study of sintilimab and anlotinib in patients with advanced or recurrent endometrial cancer.  
First Author: Zhen Zeng
- Board 294 **ABSTRACT 5599:** Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2.  
First Author: Alessandro Santin, MD
- Board 295 **ABSTRACT 5600:** Racial and ethnic disparities in quality of diagnostic evaluation for uterine cancer among Medicare patients.  
First Author: Xiao Xu, PhD
- Board 296 **ABSTRACT 5601:** OATH trial: A phase II clinical trial evaluating the combination of onapristone with anastrozole for women with hormone receptor positive endometrial cancer—Preliminary results.  
First Author: Russell J. Schilder, MD
- Board 297 **ABSTRACT 5602:** Correlation of cardiovascular disease with racial disparities in endometrial cancer outcomes.  
First Author: Mitchell Depke, MD
- Board 298 **ABSTRACT 5603:** Association of the Duffy-null allele and endometrial cancer characteristics: An effort to explore racial disparity in Black women with endometrial cancer.  
First Author: Emily Webster, MD
- Board 299 **ABSTRACT 5604:** The impact of cause of mismatch repair deficiency and other molecular markers on clinical outcomes with the use of durvalumab in advanced endometrial cancer in the phase 2 PHAEDRA trial (ANZGOG1601).  
First Author: Daniel D. Buchanan, PhD
- Board 300 **ABSTRACT 5605:** Laparoscopic versus open-surgery in FIGO stage II endometrioid endometrium cancers: Is there a prognostic effect?  
First Author: Daniel Uwe Reimer, MD, PhD
- Board 301 **ABSTRACT 5606:** Impact of best practice advisory on genetic counseling referral patterns for patients with endometrial cancer.  
First Author: Julia M Nagle, MD



## Monday, June 5, 2023

- Board 302 **ABSTRACT 5607:** Impact of surgical weight loss treatments on care burden among obese endometrial cancer survivors.  
First Author: Katia Noyes, PhD, MPH
- Board 303 **ABSTRACT 5608:** Efficacy and safety of anlotinib in overall and disease-specific advanced gynecological cancer: A real-world study.  
First Author: Xinyi Hong
- Board 304 **ABSTRACT 5609:** A multicenter, single-arm, phase 2 study of surufatinib plus toripalimab for patients with advanced endometrial cancer.  
First Author: Guangwen Yuan
- Board 305 **ABSTRACT 5610:** TROPiCS-03: A phase 2 basket study of sacituzumab govitecan (SG) in patients (pts) with metastatic solid tumors—Early analysis in pts with advanced/metastatic endometrial cancer (EC).  
First Author: Alessandro Santin, MD
- Board 306 **ABSTRACT 5611:** Clinical and genomic landscape of RAS pathway mutations in gynecologic cancers.  
First Author: Ji Son, MD, MS
- Board 307a **ABSTRACT TPS5612:** ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68).  
First Author: Thomas J. Herzog, MD
- Board 307b **ABSTRACT TPS5613:** UPGRADE-A: Phase 1 expansion trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi) in combination with carboplatin in patients with high-grade serous ovarian cancer (HGSOC).  
First Author: John L. Hays, MD, PhD
- Board 308a **ABSTRACT TPS5614:** UP-NEXT (GOG-3049/ENGOT-Ov71-NSGO-CTU): A study of upitifamab rilsodotin (UpRi), a NaPi2b-directed antibody drug conjugate (ADC), in platinum-sensitive recurrent ovarian cancer.  
First Author: Debra L. Richardson, MD
- Board 308b **ABSTRACT TPS5615:** A randomized trial of olaparib, durvalumab, and cancer vaccine, UV1, as maintenance therapy in patients with BRCAwt with recurrent ovarian cancer: ENGOT-OV56/NSGO-CTU-DOVACC trial.  
First Author: Mansoor Raza Mirza, MD
- Board 309a **ABSTRACT TPS5616:** A phase 1/2 open-label, multicenter, dose escalation and expansion study of AVB-001, an intraperitoneally administered, cell-generated, human IL-2 immunotherapy in patients with platinum-resistant, high-grade, serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube.  
First Author: Shannon Neville Westin, MD
- Board 309b **ABSTRACT TPS5617:** CRI-CCTG-0003/IND.240: An immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC).  
First Author: Helen Mackay, MD, MRCP
- Board 310a **ABSTRACT TPS5618:** TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab vs best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum.  
First Author: Alexandra Leary, MD, PhD
- Board 310b **ABSTRACT TPS5619:** Uncovering mechanisms of response of pembrolizumab and lenvatinib for the treatment of platinum-resistant high grade serous ovarian cancer.  
First Author: Jeffrey How, MD, MS, MPH
- Board 311a **ABSTRACT TPS5620:** First trial of chemotherapy de-escalation in ovarian cancer (OC): A phase III randomized, open label study of niraparib maintenance after carboplatin and paclitaxel in patients with optimally debulked advanced (homologous recombination deficient) HRD high-grade ovarian cancer in first line therapy (N-PLUS/NOGGO-ov53/ENGOT-ov62).  
First Author: Elena Ioana Braicu, MD, PhD
- Board 311b **ABSTRACT TPS5621:** Oregovomab and non-platinum chemotherapy in PARP inhibitor-resistant ovarian, fallopian tube, or primary peritoneal cancer patients not candidates for platinum retreatment: A multicenter, two-cohort, single-arm phase 2 trial (OPERA/KGOG 3065/ APGOT-OV6).  
First Author: Jung-Yun Lee, MD, PhD
- Board 312a **ABSTRACT TPS5622:** GLORIOSA: A randomized, open-label, phase 3 study of mirvetuximab soravtansine with bevacizumab vs. bevacizumab as maintenance in platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.  
First Author: David M. O'Malley, MD
- Board 312b **ABSTRACT TPS5623:** Exactis-03: A phase I trial of the combination of olaparib and navitoclax in women with high grade serous ovarian cancer and triple negative breast cancer.  
First Author: Helen Mackay, MD, MRCP
- Board 313a **ABSTRACT TPS5624:** First-in-human phase 1/2 study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer.  
First Author: Kathleen N. Moore, MD, MS
- Board 313b **ABSTRACT TPS5625:** FLORA-5/GOG3035: Chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] vs chemotherapy (paclitaxel-carboplatin-placebo [PCP]) as front-line treatment in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double blind, placebo controlled, global, multinational study.  
First Author: Lisa Marie Barroilhet, MD, MS
- Board 314a **ABSTRACT TPS5626:** A phase II, randomized, double-blind study of the use of rucaparib vs placebo maintenance therapy in metastatic and recurrent endometrial cancer.  
First Author: Bradley Corr, MD
- Board 314b **ABSTRACT TPS5627:** ENGOT-EN20/GOG-3083/xport-EC-042: A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma.  
First Author: Ignace Vergote, MD, PhD
- Board 315a **ABSTRACT TPS5628:** A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair-proficient (MMR-P) recurrent or persistent endometrial cancer (EC).  
First Author: Elizabeth Katherine Lee, MD
- Board 315b **ABSTRACT TPS5629:** A randomized phase II study comparing single-agent olaparib, single-agent cediranib, and the combinations of cediranib/olaparib, olaparib/durvalumab (MEDI4736), cediranib/durvalumab (MEDI4736), and olaparib/AZD5363 (capivasertib) in women with recurrent, persistent, or metastatic endometrial cancer.  
First Author: Bj Rimel, MD

- Board 316a **ABSTRACT TPS5630:** Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study).  
First Author: Florence Joly, MD, PhD
- Board 316b **ABSTRACT TPS5631:** RT-PACE: Phase I/II study of adjuvant whole pelvic hypofractionated radiotherapy for non-metastatic cervical and endometrial cancer.  
First Author: Christina H. Son, MD
- Board 317a **ABSTRACT TPS5632:** CCTG EN10: A phase II study of tailored adjuvant therapy in POLE-mutated and p53-wildtype/NSMP early-stage endometrial cancer (EC)—RAINBO BLUE and TAPER.  
First Author: Jessica N. McAlpine, MD
- Board 317b **ABSTRACT TPS5633:** The RAINBO MMRd-GREEN trial (GCIG/DGOG/ENGOT-EN14<sup>2</sup>): A phase III trial on the addition of adjuvant durvalumab to radiotherapy in patients with high-risk MMRd endometrial cancer.  
First Author: Merve Kaya, MD
- Board 318a **ABSTRACT TPS5634:** AFT-50 EndoMAP: A phase IB/II multi-cohort study of targeted agents for patients with recurrent or persistent endometrial cancer.  
First Author: Evelyn Cantillo, MD, MPH
- Board 318b **ABSTRACT TPS5635:** GCIG SB-001/NSGO-CTU-PEACE/ANZGOG 1923/2020: Palliation in gynaecology—Patients' expectations and assessment of care.  
First Author: Kristina Lindemann, MD, PhD

**1:15 PM - 4:15 PM Poster Session**

**Head and Neck Cancer**

Location: Hall A

Abstracts on Boards 1-12 will be discussed during the Head and Neck Cancer Poster Discussion Session. See the online program guide (meetings.asco.org) for session details.

**Posters by Topic**

**Advanced/Metastatic Disease:** Boards 1, 4-6, 8- 10, 13-43, 93a-96b

**Biologic Correlates:** Boards 44-55

**Local-Regional Disease:** Boards 2, 7, 11-12, 56-79, 97a-100a

**Other Head and Neck Cancer (Salivary, Thyroid):** Boards 3, 80-92, 100b-101a

- Board 1 **ABSTRACT 6009:** Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).  
First Author: Hai-Qiang Mai, MD, PhD
- Board 2 **ABSTRACT 6010:** NEOSPACE trial: Neoadjuvant pembrolizumab-gemcitabine-cisplatin followed by concurrent pembrolizumab-chemoradiation and maintenance pembrolizumab for stage IVA nasopharyngeal cancer (NPC).  
First Author: Edwin P Hui, MD
- Board 3 **ABSTRACT 6011:** Dual PD1 and CTLA4 immune checkpoint blockade and hypofractionated radiation in patients with salivary gland cancers.  
First Author: Cristina P. Rodriguez, MD
- Board 4 **ABSTRACT 6012:** Safety and efficacy of immune checkpoint inhibitor (ICI) naive cohort from study of PDS0101 and pembrolizumab in HPV16-positive head and neck squamous cell carcinoma (HNSCC).  
First Author: Katharine Andress Rowe Price, MD

- Board 5 **ABSTRACT 6013:** A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.  
First Author: Christine H. Chung, MD
- Board 6 **ABSTRACT 6014:** Phase II trial of adjuvant de-escalated radiation + adjuvant nivolumab for intermediate-high risk P16+ oropharynx cancer.  
First Author: Heath Devin Skinner, MD, PhD
- Board 7 **ABSTRACT 6015:** Correlation of CDKN2A genomic alterations with tumor response to palbociclib given before chemoradiation therapy (CRT) to patients with human papillomavirus (HPV)-negative, locally advanced head and neck squamous-cell carcinoma (LA-HNSCC): A single-arm, phase 2 trial.  
First Author: Peter John Oppelt, MD
- Board 8 **ABSTRACT 6016:** Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with pembrolizumab and carboplatin as first-line treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC): A single-arm, phase 2 trial.  
First Author: Jared Cohen, MD
- Board 9 **ABSTRACT 6017:** Enfortumab vedotin in the previously treated advanced head and neck cancer (HNC) cohort of EV-202.  
First Author: Paul Swiecicki, MD
- Board 10 **ABSTRACT 6018:** Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC).  
First Author: Robert L. Ferris, MD, PhD
- Board 11 **ABSTRACT 6019:** Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC).  
First Author: Winston Wong, MD
- Board 12 **ABSTRACT 6020:** The Quarterback trials: A phase 2 series of sequential studies of induction chemotherapy followed by reduced dose chemoradiation for human papillomavirus positive oropharynx cancer.  
First Author: Marshall R. Posner, MD
- Board 13 **ABSTRACT 6021:** Association of neutrophil-lymphocyte ratio (NLR) with clinical outcomes in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with combination of cetuximab and nivolumab (C+N).  
First Author: Robin Park
- Board 14 **ABSTRACT 6022:** Tazemetostat, a selective EZH2 inhibitor, with pembrolizumab as treatment of anti-PD-1 resistant head and neck squamous-cell carcinoma (HNSCC): A phase 1-2 trial.  
First Author: Sidharth Puram, MD, PhD
- Board 15 **ABSTRACT 6023:** Nanoparticle albumin-bound (nab) paclitaxel in combination with nivolumab as treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC) that progressed on a PD-1 inhibitor: A single-arm, phase 2 trial.  
First Author: Jared Cohen, MD
- Board 16 **ABSTRACT 6024:** Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: A recursive partitioning risk stratification analysis.  
First Author: Fang-Fang Kong

## Monday, June 5, 2023

- Board 17 **ABSTRACT 6025:** A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer.  
First Author: Antoine Desilets, MD
- Board 18 **ABSTRACT 6026:** A phase Ib/II study of GFH018 in combination with toripalimab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).  
First Author: Hai-Qiang Mai, MD, PhD
- Board 19 **ABSTRACT 6027:** Effect of extended treatment with IAP inhibitor xevinapant post radiotherapy (RT) on efficacy and the tumor microenvironment (TME) in preclinical models.  
First Author: Tsz Lun Yeung
- Board 20 **ABSTRACT 6028:** Phase 2 study of ISA101b (peltopemiput-S) and cemiplimab in patients with advanced HPV16+ oropharyngeal cancer who failed anti-PD1 therapy.  
First Author: Anthony H Kong, MD, PhD
- Board 21 **ABSTRACT 6029:** Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.  
First Author: Bernard Doger de Spéville, MD, PhD
- Board 22 **ABSTRACT 6030:** Influence of widely targeted quantitative lipidomics on plasma lipid predictors and pathway dysregulation for nasopharyngeal carcinoma.  
First Author: Xi Chen, MD
- Board 23 **ABSTRACT 6031:** Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: An open-label phase II study.  
First Author: Nian Lu
- Board 24 **ABSTRACT 6032:** A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody.  
First Author: Taiji Koyama, MD
- Board 25 **ABSTRACT 6033:** To test, or not to test, that is the question: A real-world analysis of PD-L1 expression testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).  
First Author: Chris M. Black, PhD, MPH
- Board 26 **ABSTRACT 6034:** Afatinib in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) harboring alterations in the HER pathway: Results of the B1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).  
First Author: Rachel Galot, MD, PhD
- Board 27 **ABSTRACT 6035:** Phase I/IIa clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein Barr virus positive nasopharyngeal cancer with pharmacokinetic and pharmacodynamic correlative studies.  
First Author: A. Dimitrios Colevas, MD, BA
- Board 28 **ABSTRACT 6036:** Outcomes by time to adjuvant therapy in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.  
First Author: Robert L. Ferris, MD, PhD
- Board 29 **ABSTRACT 6037:** Results from two phase II studies of SI-B001, an EGFR×HER3 bispecific antibody, with/without chemotherapy in patients (pts) with recurrent and metastatic head and neck squamous cell carcinoma (HNSCC).  
First Author: Liqiong Xue, MD
- Board 30 **ABSTRACT 6038:** Efficacy from the ongoing phase I trial Study 1100 with NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with locoregionally recurrent or metastatic HNSCC.  
First Author: Colette Shen, MD, PhD
- Board 31 **ABSTRACT 6039:** Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in patients with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC).  
First Author: Lova Sun, MD
- Board 32 **ABSTRACT 6040:** Updated results from a phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor rivoceranib for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).  
First Author: Hyunseok Kang, MD, MPH
- Board 33 **ABSTRACT 6041:** Evaluation of ICI sensitivity for pembrolizumab in combination with anti-platelet therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC).  
First Author: Karthik Chakravarthy, BS
- Board 34 **ABSTRACT 6042:** Evaluation of small extracellular vesicles as biomarkers of efficacy with anti-PD-1 mAb therapy in patients with recurrent/metastatic HNSCC.  
First Author: Dan Paul Zandberg, MD
- Board 35 **ABSTRACT 6043:** A phase 1 clinical trial of DB-020 intratympanic injections administered prior to high dose cisplatin chemotherapy to reduce ototoxicity.  
First Author: Danny Rischin, MD
- Board 36 **ABSTRACT 6044:** Abemaciclib in recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC) harboring CDKN2A loss, and/or CCND1 and/or CDK6 amplification: A phase II multicenter trial.  
First Author: Jerome Fayette, MD, PhD
- Board 37 **ABSTRACT 6045:** Personalized therapy for head and neck squamous carcinoma (HNSCC) utilizing tissue proteomics profiling.  
First Author: Sheeno P. Thyparambil, PhD
- Board 38 **ABSTRACT 6046:** Phase II study evaluating the efficacy of niraparib and dostarlimab (TSR-042) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) patients.  
First Author: Olga Zamulko, MD
- Board 39 **ABSTRACT 6047:** TCR-T cells armored with immune checkpoint blockade in EBV-positive nasopharyngeal carcinoma: The first-in-human phase 1/2 trial.  
First Author: Qingzhu Jia, MD
- Board 40 **ABSTRACT 6048:** A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.  
First Author: Maliheh Mohamadpour, MD
- Board 41 **ABSTRACT 6049:** Low-dose fractionated radiotherapy combined with neoadjuvant chemotherapy for T3-4 nasopharyngeal carcinoma patients: Preliminary results of a phase II randomized controlled trial.  
First Author: Mei Feng
- Board 42 **ABSTRACT 6050:** Phase I/II trial of durvalumab plus tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma: Final results.  
First Author: Houda Bahig, MD, PhD

- Board 43 **ABSTRACT 6051:** Safety and efficacy of time restricted eating (TRE) in improving response to immunotherapy in head and neck cancer (HNSCC) patients.  
First Author: Humaira Sarfraz, MD
- Board 44 **ABSTRACT 6052:** Association of pretreatment lymphocyte-monocyte ratio with survival outcome in patients with head and neck cancer treated with chemoradiation.  
First Author: Brian Yu, BSc
- Board 45 **ABSTRACT 6053:** Evaluation of tumor mutation burden (TMB) in tumor (tDNA) and plasma cell free DNA (cfDNA) in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with a combination of cetuximab and nivolumab (C+N).  
First Author: Christine H. Chung, MD
- Board 46 **ABSTRACT 6054:** Association between locoregional failure and NFE2L2/KEAP1/CUL3 pathway mutations in NRG/RTOG 9512: A randomized trial of hyperfractionation vs. conventional fractionation in T2N0 glottic squamous cell carcinoma (SCC).  
First Author: Li Guan, PhD
- Board 47 **ABSTRACT 6055:** A proteomic signature associated with prognosis in HPV-related locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC).  
First Author: Jia (Jenny) Liu, MD, PhD
- Board 48 **ABSTRACT 6056:** Single-cell RNA and T cell receptor (TCR) sequencing in patients with HPV-positive head and neck squamous cell carcinoma (HNSCC) after induction CTLA4 and PD-1 immune checkpoint blockade (ICB).  
First Author: Xianli Jiang
- Board 49 **ABSTRACT 6057:** Introduction of E-Score: A gene expression score to characterize immunogenic versus oncogenic HPV expression in HNSCC.  
First Author: Bailey Fabiny Garb
- Board 50 **ABSTRACT 6058:** Association of HPV genotype and phylogenetic clade with oropharyngeal cancer outcomes.  
First Author: Michael Wotman, MD
- Board 51 **ABSTRACT 6059:** Spatial genomics to reveal an immunosuppressive tumor microenvironment after chemoradiation in head and neck cancer patients.  
First Author: Jennifer Hsing Choe, MD, PhD
- Board 52 **ABSTRACT 6060:** Clinical validity of TTMV-HPV DNA liquid biopsies for the diagnosis and surveillance of HPV-associated oropharyngeal carcinoma.  
First Author: Scott A Roof, MD
- Board 53 **ABSTRACT 6061:** Spatial relationships and immune subsets in the tumor immune microenvironment of head and neck cancers.  
First Author: Leanne E. Henry
- Board 54 **ABSTRACT 6062:** Peripheral blood epigenetic immune-profiling and survival outcomes with anti-programmed death (PD)-1 based therapy in recurrent/metastatic (R/M) squamous cell carcinoma of head and neck (SCCHN).  
First Author: Kartik Sehgal, MD
- Board 55 **ABSTRACT 6063:** The impact of genetic predisposition to depression on quality of life in patients with head and neck cancer immediately post-treatment: A longitudinal study.  
First Author: Melissa Henry, PhD
- Board 56 **ABSTRACT 6064:** Radiotherapy alone versus concurrent or adjuvant chemoradiotherapy for nasopharyngeal carcinoma patients with negative Epstein-Barr virus DNA post-induction chemotherapy.  
First Author: Fang-Fang Kong
- Board 57 **ABSTRACT 6065:** Multimodal detection in plasma of molecular residual disease (MRD) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).  
First Author: Enrique Sanz Garcia, MD
- Board 58 **ABSTRACT 6066:** One-year reductions in cisplatin-related chronic kidney disease (CKD) in patients with head and neck (HNC) cancer treated with avasopasem manganese: A prespecified analysis from the phase 3 ROMAN trial.  
First Author: Bryan G. Allen, MD
- Board 59 **ABSTRACT 6067:** Induction chemotherapy with nedaplatin, docetaxel and 5-fluorouracil followed by concurrent nedaplatin and radiotherapy in locoregionally advanced nasopharyngeal carcinoma: A single arm, open label, phase II clinical trial.  
First Author: Chen Fangzheng
- Board 60 **ABSTRACT 6068:** Induction chemotherapy and toripalimab for larynx preservation in resectable locally advanced laryngeal/hypopharyngeal carcinoma: Preliminary results of INSIGHT study.  
First Author: Xiaomin Ou, MD
- Board 61 **ABSTRACT 6069:** A pilot phase II trial of neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin (NeoCPC) for locoregionally advanced, resectable squamous cell carcinoma of the head and neck.  
First Author: Di Wu, MD
- Board 62 **ABSTRACT 6070:** Induction therapy of toripalimab combined with docetaxel and cisplatin in locally advanced hypopharyngeal squamous cell carcinoma (HPSCC): A single-arm, phase II clinical trial.  
First Author: Chunmei Bai, MD, PhD
- Board 63 **ABSTRACT 6071:** Nab-paclitaxel plus cisplatin versus docetaxel plus cisplatin and 5-FU induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: A multicenter parallel controlled phase III trial.  
First Author: Xing Lv, MD, PhD
- Board 64 **ABSTRACT 6072:** Prospective study of integrating post-radiotherapy [18F] fluorodeoxyglucose-positron emission tomography/computed tomography scan and plasma Epstein-Barr virus DNA in surveillance of locoregionally advanced nasopharyngeal carcinoma.  
First Author: Lin-Quan Tang, PhD
- Board 65 **ABSTRACT 6073:** CT radiomic signature to predict overall survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma.  
First Author: Bolin Song
- Board 66 **ABSTRACT 6074:** Induction chemotherapy with nanosomal docetaxel lipid suspension (NDLS), cisplatin, and fluorouracil in patients with locally advanced head and neck squamous cell carcinoma.  
First Author: Ghanashyam Biswas
- Board 67 **ABSTRACT 6075:** Neoadjuvant pembrolizumab, GX-188E, and GX-17 in patients with human papillomavirus-16- and/or 18-positive head and neck squamous cell carcinoma: Single-arm, phase 2 trial with single cell transcriptomic analysis and artificial intelligence-powered spatial analysis.  
First Author: Hye Ryun Kim, MD, PhD

- Board 68 **ABSTRACT 6076:** Development of CT-based radiomic model to predict 5-year progression-free survival (PFS) in locally advanced head and neck squamous cell carcinoma (LAHNSCC) treated with definitive chemoradiation.  
First Author: Gema Bruixola, MD
- Board 69 **ABSTRACT 6077:** Neoadjuvant chemoimmunotherapy for the treatment of locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: A single-arm phase 2 clinical trial.  
First Author: Yanfeng Chen, Professor
- Board 70 **ABSTRACT 6078:** Neoadjuvant low-dose radiotherapy, tislelizumab, combined with albumin-bound paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoRTPC02): The first-stage result from an open label, single-arm, two stage, phase II clinical trial.  
First Author: Zhigang Liu, MD
- Board 71 **ABSTRACT 6079:** Impact of acute kidney injury on overall survival in postoperative patients with head and neck cancer who received chemoradiotherapy with cisplatin: A supplementary analysis of a phase II/III trial of JCOG1008.  
First Author: Yoshinori Imamura, MD, PhD
- Board 72 **ABSTRACT 6080:** Neoadjuvant tislelizumab combined with APF for patients with locally advanced head and neck squamous cell carcinoma: A prospective single-arm clinical trial.  
First Author: Jing Yan
- Board 73 **ABSTRACT 6081:** Neoadjuvant durvalumab and tremelimumab in resectable locally advanced SCC of the oral cavity: DUTRELASCO study.  
First Author: Michel Bila, MD, DDS
- Board 74 **ABSTRACT 6082:** Safety and immunogenicity of TG4050: A personalized cancer vaccine in head and neck carcinoma.  
First Author: Christian H.H Ottensmeier, MD, PhD, FRCP
- Board 75 **ABSTRACT 6083:** Combined pulsed radiotherapy (QUAD shot regimen) with immune checkpoint inhibition (ICI) to enhance immune response for LAHNSCC in patients considered ineligible for curative intent therapy.  
First Author: Jennifer F. De Los Santos, MD
- Board 76 **ABSTRACT 6084:** Are we ready for biomarker driven, radiation dose-adaptable de-escalation studies for HPV+ oropharyngeal cancer?  
First Author: Krzysztof Misiukiewicz, MD
- Board 77 **ABSTRACT 6085:** 10-year outcomes of technically unresectable oral cancers with neoadjuvant chemotherapy: Real-world data and implications for clinical practice.  
First Author: Aditya Dhanawat
- Board 78 **ABSTRACT 6086:** Use of machine learning derived features from CT and H&E whole-slide images to predict overall survival in head and neck squamous cell carcinoma.  
First Author: Bolin Song
- Board 79 **ABSTRACT 6087:** Tislelizumab plus chemotherapy as induction treatment followed by chemoradiotherapy or surgery in locally advanced hypopharyngeal squamous cell carcinoma: A single-arm, phase II trial.  
First Author: Lin Gui, MD
- Board 81 **ABSTRACT 6089:** A multicenter, single-arm phase 2 study of surufatinib plus toripalimab for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.  
First Author: Dongmei Ji, MD
- Board 82 **ABSTRACT 6090:** Phase II prospective trial of induction chemotherapy for advanced sinonasal squamous cell or poorly differentiated carcinoma.  
First Author: Kevin J. Contrera, MD, MPH
- Board 83 **ABSTRACT 6091:** Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC).  
First Author: Maria E. Cabanillas, MD
- Board 84 **ABSTRACT 6092:** A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer.  
First Author: Yoshiaki Nagatani, MD, PhD
- Board 85 **ABSTRACT 6093:** Darolutamide for patients with androgen receptor positive salivary gland cancers (DISCOVERY): The results of phase 2 study of darolutamide monotherapy.  
First Author: Susumu Okano, MD, PhD
- Board 86 **ABSTRACT 6094:** Clinical and genomic characterisation of adenoid cystic carcinoma of the head and neck, lung, and breast.  
First Author: Emily Heathcote
- Board 87 **ABSTRACT 6095:** Safety and early efficacy results of phase 1 study of affinity tuned and trackable AIC100 CAR T cells in ICAM-1 positive relapsed and/or refractory advanced poorly differentiated and anaplastic thyroid cancers.  
First Author: Samer Ali Srour, MBChB, MS
- Board 88 **ABSTRACT 6096:** Predictive biomarkers of benefit to axitinib plus avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC).  
First Author: Camilla Oliveira Hoff, BA
- Board 89 **ABSTRACT 6097:** Monitoring epithelial, epithelial-mesenchymal, and mesenchymal circulating tumor cells on papillary thyroid cancer following thyroidectomy: A prospective cohort study.  
First Author: Eunju Park, PhD
- Board 90 **ABSTRACT 6098:** Retrospective analysis of genetically matched therapies in salivary gland cancer entities using a real-world database in a tertiary salivary gland cancer expertise center.  
First Author: Jetty A.M. Weijers
- Board 91 **ABSTRACT 6099:** <sup>177</sup>Lu-PSMA radioligand therapy for recurrent/metastatic (R/M) salivary gland cancer (SGC) patients: A phase II pilot study.  
First Author: Carla M.L.- Van Herpen, MD, PhD
- Board 92 **ABSTRACT 6100:** Artificial intelligence (AI) analysis of tumor-infiltrating lymphocytes (TILs) in hematoxylin and eosin (H&E) slides to explore immune phenotypes in papillary thyroid cancer.  
First Author: Myungwoo Nam, MD
- Board 93a **ABSTRACT TPS6101:** XRay Vision: A phase 3 study of xevinapant plus radiotherapy (RT) for high-risk, cisplatin-ineligible patients with resected, locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).  
First Author: Robert L. Ferris, MD, PhD
- Board 93b **ABSTRACT TPS6102:** A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC.  
First Author: A. Dimitrios Colevas, MD, BA
- Board 94a **ABSTRACT TPS6103:** Palbociclib + cetuximab versus cetuximab in patients with CDKN2A-altered, anti-PD-1 resistant, HPV-negative head and neck squamous cell carcinoma (HNSCC): A phase 3 trial.  
First Author: Jessica C. Ley, CCRP

- Board 94b **ABSTRACT TPS6104:** Phase 2 trial of retifanlimab (anti-PD-1) in combination with INCAGN02385 (anti-LAG-3) and INCAGN02390 (anti-TIM-3) as first-line treatment in patients with PD-L1-positive recurrent/metastatic squamous cell carcinoma of the head and neck.  
First Author: Ezra E.W. Cohen, MD, FASCO
- Board 95a **ABSTRACT TPS6105:** A phase 2 study of neoadjuvant lenvatinib in locally advanced invasive thyroid cancer.  
First Author: Amr Hesham Abdelhamid Ahmed, MBCh, MMedSc
- Board 95b **ABSTRACT TPS6106:** A phase 2, open-label, multi-center study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck.  
First Author: Kevin Joseph Harrington, PhD, MBBS
- Board 96a **ABSTRACT TPS6107:** A phase 2 open-label study of conditionally active biologic ozuriftamab vedotin (BA3021) in failed PD-1/L1 treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck.  
First Author: Alan Loh Ho, MD, PhD
- Board 96b **ABSTRACT TPS6108:** Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.  
First Author: Douglas Adkins, MD
- Board 97a **ABSTRACT TPS6109:** Phase 2 trial of three schedules of CUE-101 administered before surgery or chemoradiotherapy in HLA-A\*0201 positive patients with HPV16+ OPSCC.  
First Author: Jesse Meir Zaretsky, MD, PhD
- Board 97b **ABSTRACT TPS6110:** A phase II trial of neoadjuvant nivolumab, docetaxel, and cisplatin therapy followed by surgery and radiation therapy for resectable high-grade salivary gland carcinoma.  
First Author: Sehhoon Park, MD
- Board 98a **ABSTRACT TPS6111:** A single-arm, multi-institutional, phase 2 study of a pembrolizumab-based organ preservation strategy for locally advanced larynx cancers: SMART-KEY (LACOG 0720) trial.  
First Author: Thiago Bueno Oliveira Sr., PhD
- Board 98b **ABSTRACT TPS6112:** Response-adapted therapy for locally advanced nasopharyngeal carcinoma based on clinical response and circulating Epstein-Barr virus DNA level post induction chemotherapy.  
First Author: Chaosu Hu, MD
- Board 99a **ABSTRACT TPS6113:** KEVLAR: A phase 2b, multi-institutional, randomized, blinded, controlled trial to assess the safety and efficacy of two schedules of RRx-001 vs. standard of care in attenuating severe oral mucositis (SOM) in patients receiving concomitant chemoradiation (CRT) for the treatment of locally advanced squamous cell carcinomas (SCC) of the oral cavity (OC) or oropharynx (OPC).  
First Author: Tony R. Reid, MD, PhD
- Board 99b **ABSTRACT TPS6114:** CCTG HN11: SPECT-CT guided elective contralateral neck treatment (SELECT) for patients with lateralized oropharyngeal cancer—A phase III randomized controlled trial.  
First Author: John R de Almeida, MD

- Board 100a **ABSTRACT TPS6115:** Randomized phase I/II trial of TheraT vectors expressing HPV16 specific antigens with neoadjuvant chemotherapy followed by transoral robotic surgery (TORS) or risk/response stratified chemoradiotherapy (CRT) for locoregional HPV16+ oropharyngeal cancer (OPC).  
First Author: Ari Rosenberg, MD
- Board 100b **ABSTRACT TPS6116:** Phase 2 study of bintrafusp alfa in recurrent/metastatic olfactory neuroblastoma.  
First Author: Dara Mark Bracken-Clarke, MBCh
- Board 101a **ABSTRACT TPS6117:** IMRT followed by pembrolizumab in the adjuvant setting in anaplastic cancer of the thyroid (IMPAACT): Phase II trial adjuvant pembrolizumab after IMRT in ATC.  
First Author: Maria E. Cabanillas, MD

---

**1:15 PM - 4:15 PM Poster Session**

**Pediatric Oncology**

Location: Hall A

Abstracts on Boards 324-335 will be discussed during the Pediatric Oncology Poster Discussion Session. See the online program guide ([meetings.asco.org](http://meetings.asco.org)) for session details.

**Posters by Topic**

**Leukemia/Lymphoma:** Boards 331-333, 336-339

**Pediatric Solid Tumors:** Boards 324-326, 328-330, 340-352, 372b-375b

**Survivorship:** Boards 334-335, 353-358, 360-364, 366-368

**Symptom Management/Supportive Care/Palliative Care:** Boards 327, 369-371

- Board 324 **ABSTRACT 10018:** Frequency and spectrum of clinically significant molecular alterations detected by tumor gene panel testing for pediatric cancer patients in the Texas KidsCanSeq study.  
First Author: Frank Y. Lin, MD
- Board 325 **ABSTRACT 10019:** Comprehensive nationwide study on the prescription of experimental anticancer therapies for compassionate use in children and adolescents in France.  
First Author: Pablo Berlanga, MD PhD
- Board 326 **ABSTRACT 10020:** Prognostic factors of early mortality in children and adolescents enrolled in oncology trials with a dose-finding part in the era of targeted and immune therapies: An Innovative Therapies for Children with Cancer (ITCC) study.  
First Author: Fernando Carceller
- Board 327 **ABSTRACT 10021:** Intensity at the end of life in pediatric neuro-oncology patients: The case for pediatric palliative care.  
First Author: Chinwe Udemgba
- Board 328 **ABSTRACT 10022:** Identifying osteosarcoma signatures in cell free DNA using 5-hydroxymethylcytosine profiling.  
First Author: Evan W Neczypor, BS
- Board 329 **ABSTRACT 10023:** A multicenter, open-label, single-arm phase 1/2 study to evaluate the safety and efficacy of FCN-159 in pediatric participants with neurofibromatosis type 1.  
First Author: Xiaojie Hu, MD
- Board 330 **ABSTRACT 10024:** A phase 2 study of sirolimus in combination with metronomic chemotherapy (CHOA-nome) in children with recurrent and/or refractory solid and CNS tumors.  
First Author: Thomas Cash, MD, MSc

- Board 331 **ABSTRACT 10025:** Physical and emotional quality of life in children with B-acute lymphoblastic leukemia randomized to every 4- vs. 12-week vincristine/dexamethasone during maintenance: Children's Oncology Group AALL0932.  
First Author: Lyn M. Balsamo, PhD
- Board 332 **ABSTRACT 10026:** Pediatric oncologist referral practices for CAR T-cell therapy: A mixed methods study.  
First Author: Anurekha Gollapudi Hall, MD, MS
- Board 333 **ABSTRACT 10027:** Efficacy and safety of pembrolizumab (pembro) in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo) in the phase 2, open-label, KEYNOTE-667 study.  
First Author: Luciana Vinti, MD, PhD
- Board 334 **ABSTRACT 10028:** Accelerated brain age and associated neurocognitive impairments in adult survivors of childhood cancer.  
First Author: Nicholas Steve Phillips, MD, PhD
- Board 335 **ABSTRACT 10029:** Genetic study of type 2 diabetes risk in diverse populations of survivors of childhood cancer: A report from the St. Jude Lifetime Cohort (SJLIFE) and the Childhood Cancer Survivor Study (CCSS).  
First Author: Cindy Im, PhD
- Board 336 **ABSTRACT 10030:** Adherence to mercaptopurine (6-MP) and habit strength in pediatric acute lymphoblastic leukemia (ALL).  
First Author: Mira Muxi Yang, BA
- Board 337 **ABSTRACT 10031:** Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas.  
First Author: Jonathan Bender, MD
- Board 338 **ABSTRACT 10032:** Outcomes in pediatric relapsed/refractory anaplastic large cell lymphoma: A multi-institutional retrospective analysis.  
First Author: Lianna Jean Marks, MD
- Board 339 **ABSTRACT 10033:** Impact of fludarabine exposure on the depth and duration of lymphopenia and CAR T-cell outcomes.  
First Author: Keagan Lipak, BA
- Board 340 **ABSTRACT 10034:** Single-agent activity of the anti-GD2 antibody dinutuximab beta given as a long-term infusion in relapsed and refractory neuroblastoma (APN311-304).  
First Author: Holger N. Lode, MD, PhD
- Board 341 **ABSTRACT 10035:** Comprehensive genomic profiling and individual therapeutic planning in high-risk/refractory pediatric solid tumors: A single-center real-world study.  
First Author: Ondrej Slaby
- Board 342 **ABSTRACT 10036:** A phase 1b study of crizotinib in combination with temsirolimus in pediatric ALK- or MET-aberrated relapsed or refractory neuroblastoma (ITCC-053): Results of the phase 1 part.  
First Author: Kim P.J. Schellekens, MD
- Board 343 **ABSTRACT 10037:** Stage 4N neuroblastoma before and during the era of anti-GD2 immunotherapy.  
First Author: Brian H. Kushner, MD
- Board 344 **ABSTRACT 10038:** Healthcare resource use for pediatric low-grade glioma care: A cohort of linked electronic health records and claims data.  
First Author: Tab Cooney, MD
- Board 345 **ABSTRACT 10039:** Recommended phase 2 dose (RP2D) for abemaciclib in combination with irinotecan (IRN) and temozolomide (TMZ) in pediatric patients with relapsed/refractory solid tumors (JPCS Part A).  
First Author: Alvaro Lassaletta, MD PhD
- Board 346 **ABSTRACT 10040:** Safety and PK (pharmacokinetic) profile of niraparib (nir) + dostarlimab (dost) in pediatric patients (pts) with recurrent or refractory (RR) solid tumors: SCOOP study.  
First Author: Francois Doz, MD
- Board 347 **ABSTRACT 10041:** Clinical application of ctDNA detection in Chinese pediatric patients with soft tissue sarcoma (STS).  
First Author: Jia Zhu, PhD
- Board 348 **ABSTRACT 10042:** Reduction in Curie score in neuroblastoma patients treated with naxitamab.  
First Author: Jaume Mora, MD, PhD
- Board 349 **ABSTRACT 10043:** Effect of bispecific B7H3 x CD19 CAR T cells on host CD19 expression and CAR T cell engraftment.  
First Author: Navin R. Pinto, MD
- Board 350 **ABSTRACT 10044:** Neurosurgical morbidity in pediatric supratentorial midline low-grade glioma: Results from the German LGG studies.  
First Author: Michèle Simon, MD
- Board 351 **ABSTRACT 10045:** Quality of cancer family history taking in pediatric solid tumor patients.  
First Author: Benjamin Hu
- Board 352 **ABSTRACT 10046:** <sup>18</sup>F-MFBG PET imaging in patients with neuroblastoma: Lesion targeting and comparison with MIBG.  
First Author: Shakeel Modak, MD
- Board 353 **ABSTRACT 10047:** Adherence to surveillance guidelines in survivors of Hodgkin lymphoma: A report from the Childhood Cancer Survivor Study (CCSS).  
First Author: Jamie Michelle Shoag, MD
- Board 354 **ABSTRACT 10048:** Financial hardship among siblings of long-term survivors of childhood cancer: A Childhood Cancer Survivor Study (CCSS) report.  
First Author: Timothy James Daeun Ohlsen, MD
- Board 355 **ABSTRACT 10049:** Associations between psychosocial and lifestyle factors and biological age acceleration among long-term survivors of childhood cancer: A prospective study from the St. Jude Lifetime Cohort.  
First Author: Brennan Streck, PhD, MPH
- Board 356 **ABSTRACT 10050:** Demographic predictors of successful transition to adult survivorship care for survivors of pediatric cancer.  
First Author: Renee Gilbert, MA
- Board 357 **ABSTRACT 10051:** Treatment and treatment-related toxicity following subsequent breast cancer: A report from the Childhood Cancer Survivor Study (CCSS).  
First Author: Cindy Im, PhD
- Board 358 **ABSTRACT 10052:** Mortality and the burden of subsequent malignant neoplasms in survivors of childhood cancer beyond age 50: A report from the Childhood Cancer Survivor Study (CCSS).  
First Author: Rusha Bhandari, MD, MS
- Board 360 **ABSTRACT 10054:** Longitudinal associations between peripheral neuropathy and neurocognitive decline in long-term survivors of pediatric cancer treated without central nervous system (CNS) directed therapy.  
First Author: AnnaLynn Williams, PhD

- Board 361 **ABSTRACT 10055:** Predictors of cancer center-based follow-up among pediatric and adolescent/young adult cancer survivors.  
First Author: Emily M Pang, MS
- Board 362 **ABSTRACT 10056:** Outcomes of childhood, adolescent, and young adult cancer survivors (CAYACS) with solid organ transplants: A population-based study.  
First Author: Sumit Gupta, MD, PhD
- Board 363 **ABSTRACT 10057:** Outcomes among survivors of childhood cancer in low- and middle-income countries: A systematic review.  
First Author: Avram Denburg, MD, PhD, MSc, FRCPC
- Board 364 **ABSTRACT 10058:** Subsequent meningiomas in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).  
First Author: Tab Cooney, MD
- Board 366 **ABSTRACT 10060:** Leveraging a community-academic partnership to evaluate the needs of Latinx AYA cancer survivors.  
First Author: Stephanie M Smith, MD, MPH
- Board 367 **ABSTRACT 10061:** Influence of genetic predisposition and lifestyle on modifiable cardiovascular risk factors among survivors of childhood cancer.  
First Author: Carmen L Wilson, PhD
- Board 368 **ABSTRACT 10062:** Racial disparities in treatment and outcomes of pediatric hepatoblastoma.  
First Author: Taylor Billion, BA
- Board 369 **ABSTRACT 10063:** Clinical course and native antibody development after COVID-19 infection in 50 pediatric oncology patients.  
First Author: Maeve Smart
- Board 370 **ABSTRACT 10064:** Expansion of the fertility preservation program to all newly diagnosed prepubertal oncology patients at a pediatric hospital.  
First Author: Antonia Pryor Leavitt, MSN, APRN-BC
- Board 371 **ABSTRACT 10065:** Self-reported sleep difficulties and association with cognitive function in pediatric cancer survivors.  
First Author: Pete Stavinoha
- Board 372b **ABSTRACT TPS10067:** LOGGIC/FIREFLY-2: A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.  
First Author: Cornelis Martinus van Tilburg, MD
- Board 372s **ABSTRACT TPS10066:** Phase 1/2 study of tiragolumab and atezolizumab in patients with relapsed or refractory SMARCB1 or SMARCA4 deficient tumors.  
First Author: Mary Frances Wedekind, MD
- Board 373a **ABSTRACT TPS10068:** Phase 1b/2 study of abemaciclib combined with chemoimmunotherapy in pediatric and young adult patients with relapsed/refractory neuroblastoma (JPCS Part C).  
First Author: Emily Gustava Greengard, MD
- Board 373b **ABSTRACT TPS10069:** Evaluation of palbociclib in combination with topotecan and cyclophosphamide in pediatric patients with recurrent or refractory neuroblastoma.  
First Author: Theodore Willis Laetsch, MD
- Board 374a **ABSTRACT TPS10070:** Phase 1/2, first-in-child study of sonodynamic therapy (SDT) using low intensity focused ultrasound and 5-aminolevulinic acid (ALA) for patients with diffuse intrinsic pontine glioma.  
First Author: Hasan R Syed, MD

- Board 374b **ABSTRACT TPS10071:** Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers.  
First Author: Donald Williams Parsons, MD, PhD
- Board 375a **ABSTRACT TPS10072:** A multicenter, phase II trial of maintenance sirolimus in combination with metronomic chemotherapy in children and adolescents with high-risk solid tumors.  
First Author: Kathryn S. Sutton, MD
- Board 375b **ABSTRACT TPS10073:** A pilot clinical study of oral irinotecan HCl (VAL-413) in patients with recurrent pediatric solid tumors.  
First Author: Jeffrey A. Bacha

---

**1:15 PM - 4:15 PM Poster Session**

**Symptoms and Survivorship**

Location: Hall A

Abstracts on Boards 381-392 will be discussed during the Symptoms and Survivorship Poster Discussion Session. See the online program guide ([meetings.asco.org](https://meetings.asco.org)) for session details.

**Posters by Topic**

**Caregivers:** Boards 393-394

**End-of-Life Care:** Boards 395-402

**Geriatric Oncology:** Boards 391, 403-433, 505a-506a

**Health Promotion:** Boards 383, 435-443, 506b-507a

**Late and Long-Term Adverse Effects:** Boards 381-382, 384-386, 390, 392, 444-453, 455-465, 507b-508b

**Palliative Care and Symptom Management:** Boards 387-389, 466-497, 509a-512a

**Psychosocial and Communication Research:** Boards 498-504, 512b

- Board 381 **ABSTRACT 12013:** Impact of immune checkpoint inhibition on ovarian reserve in patients with melanoma enrolled in the ECOG-ACRIN E1609 adjuvant trial.  
First Author: Elizabeth Iannotti Buchbinder, MD
- Board 382 **ABSTRACT 12014:** Fertility post immune checkpoint blockade.  
First Author: Martinique Ogle, BA
- Board 383 **ABSTRACT 12015:** Effect of flibanserin on libido in women with breast cancer on adjuvant endocrine therapy.  
First Author: Shari Beth Goldfarb, MD
- Board 384 **ABSTRACT 12016:** Long-term outcomes of adolescents and young adults with testicular germ cell tumors: A population-based retrospective matched cohort study.  
First Author: Rand Ajaj, BS
- Board 385 **ABSTRACT 12017:** Social determinants of health burden among adolescent and young adult cancer patients and impact on overall survival.  
First Author: Elizabeth Rodriguez, BS
- Board 386 **ABSTRACT 12018:** Predicting therapy-induced cardiomyopathy in long-term survivors of childhood cancer: A report from the St. Jude Lifetime Cohort (SJLIFE) and the Childhood Cancer Survivor Study (CCSS).  
First Author: Kateryna Petrykey, PhD
- Board 387 **ABSTRACT 12019:** Cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: Results of a phase II/III, placebo-controlled, randomised trial.  
First Author: Antony Mersiades, MBBS, FRACP, BSc
- Board 388 **ABSTRACT 12020:** Safety and efficacy of cannabidiol in the management of chemotherapy-induced peripheral neuropathy.  
First Author: Marisa C. Weiss, MD



Monday, June 5, 2023

- Board 389 **ABSTRACT 12021:** Long term efficacy of psilocybin in cancer patients with major depressive disorder (MDD).  
First Author: Manish Agrawal, MD
- Board 390 **ABSTRACT 12022:** Neurocognitive function outcomes in NRG/RTOG 0534, the SPPORT trial.  
First Author: Jeffrey Scott Wefel, PhD
- Board 391 **ABSTRACT 12023:** Yoga vs. behavioral placebo for fatigue and quality of life among older cancer survivors.  
First Author: Evelyn Arana, DrPH
- Board 392 **ABSTRACT 12024:** The menopause after cancer study: A multimodal technology assisted intervention for the management of menopausal symptoms after cancer.  
First Author: Fionán Donohoe
- Board 393 **ABSTRACT 12025:** A meta-analysis studying the utility of cryotherapy in the prevention of peripheral neuropathy in breast cancer patients receiving paclitaxel and nab-paclitaxel.  
First Author: Prashanth Ashok Kumar, MBBS
- Board 394 **ABSTRACT 12026:** Interventions to improve outcomes for caregivers of patients with advanced cancer: A systematic review and meta-analysis.  
First Author: Ronald Chow, MS
- Board 395 **ABSTRACT 12027:** Use of clinical pathways to identify patients with cancer who may benefit from serious illness conversations.  
First Author: Cody E Cotner, MD
- Board 396 **ABSTRACT 12028:** Quality for all: Clinical trial enrollment and end-of-life care in solid and hematologic malignancies.  
First Author: Melissa R Rosen, BA
- Board 397 **ABSTRACT 12029:** Trends in place of death in adolescents and young adults dying from cancer in the US, 2003-2019.  
First Author: S. M. Qasim Hussaini, MD, MS
- Board 398 **ABSTRACT 12030:** End-of-life outcomes of patients with advanced cancer enrolled in palliative care.  
First Author: Andrew Lynch, MD
- Board 399 **ABSTRACT 12031:** Patient characteristics associated with psychosocial distress about end-of-life.  
First Author: Ana Isabel Tergas, MD, MPH
- Board 400 **ABSTRACT 12032:** Psychosocial health of patients engaging in medical aid in dying and their family members: A prospective descriptive analysis.  
First Author: Chloe Turner
- Board 401 **ABSTRACT 12033:** Risk of malnutrition and predisposing factors among Mexican patients with advanced cancer.  
First Author: Sergio Contreras, MD
- Board 402 **ABSTRACT 12034:** The impact of patient age on palliative care utilization and end-of-life outcomes among metastatic breast cancer patients.  
First Author: Carley Mitchell, MD
- Board 403 **ABSTRACT 12035:** Falls and hospitalization during chemotherapy in older women with early breast cancer.  
First Author: Jingran Ji, MD
- Board 404 **ABSTRACT 12036:** The association of the comorbidity polypharmacy score (CPS) with functional limitations, frailty, and mortality in older adults with gastrointestinal malignancies.  
First Author: Brian Westbrook, MD
- Board 405 **ABSTRACT 12037:** Biologic profile to predict overall survival in non-metastatic breast cancer: A latent class analysis on aging biomarkers.  
First Author: Claire Falandry, MD, PhD
- Board 406 **ABSTRACT 12038:** Association of sarcopenia and treatment tolerability in older adults with advanced cancer: Secondary analysis of a nationwide NCI Community Oncology Research Program (NCORP) randomized clinical trial.  
First Author: Richard Francis Dunne, MD, MS
- Board 407 **ABSTRACT 12039:** Defining an abnormal geriatric assessment for older adults with cancer: Which deficits matter most?  
First Author: Anthony Carrozzi, HBSc
- Board 408 **ABSTRACT 12040:** Associations of frailty with overall survival (OS) and functional decline among older adults with non-small-cell lung cancer (NSCLC) receiving chemotherapy, immunotherapy, and/or targeted therapy.  
First Author: Howard Jinsoo Lee Jr., MD
- Board 409 **ABSTRACT 12041:** Satisfaction in older patients by geriatric assessment using a novel tablet-based questionnaire system: A cluster-randomized, phase III trial of patients with non-small-cell lung cancer (ENSURE-GA study; NEJ041/CS-Lung001).  
First Author: Sayo Soda, MD, PhD
- Board 410 **ABSTRACT 12042:** Exploring decisional control preferences in older patients with cancer and their caregivers.  
First Author: Sofiiia Hryniv
- Board 411 **ABSTRACT 12043:** Association of nutrition with psychological health and quality of life among older adults with advanced cancer.  
First Author: Surbhi Singhal, MD
- Board 412 **ABSTRACT 12044:** Racial differences in muscle measures and survival among older adults with GI malignancies.  
First Author: Gabriel Aleixo, MD
- Board 413 **ABSTRACT 12045:** Peaceful acceptance of illness among older adults with cancer.  
First Author: Elizabeth Gilbride
- Board 414 **ABSTRACT 12046:** Association between food insecurity and frailty among older adults with gastrointestinal malignancies: The CARE Registry.  
First Author: Mackenzie Elisha Fowler, PhD
- Board 415 **ABSTRACT 12047:** Regorafenib in older adults with metastatic colorectal cancer: A multi-center, single arm phase II trial.  
First Author: Nabeel Badri
- Board 416 **ABSTRACT 12048:** An evaluation of the financial toxicity amongst older patients with cancer in India.  
First Author: Anant Ramaswamy, DM
- Board 417 **ABSTRACT 12049:** Overall survival outcomes in older patients with metastatic breast cancer: A National Cancer Database analysis.  
First Author: Rima Patel, MD
- Board 418 **ABSTRACT 12050:** Association of emotional support with quality of life, mental health, and survival among older adults with gastrointestinal (GI) malignancies.  
First Author: Daniel Clausing, MD
- Board 419 **ABSTRACT 12051:** Toxicity and outcomes of ipilimumab plus nivolumab in patients 80 years and older.  
First Author: Haley M Meyer, MD

- Board 420 **ABSTRACT 12052:** Association of frailty and high-risk immuno-nutritional score with outcomes in patients with relapsed and refractory multiple myeloma treated with chimeric antigen receptor T-cells.  
First Author: Karnav Modi, MBBS
- Board 421 **ABSTRACT 12053:** The influence of sex on the impact of age and frailty on acute care use among older adults receiving immune checkpoint inhibitor (ICI) treatment: A population-based study.  
First Author: Elizabeth Faour
- Board 422 **ABSTRACT 12054:** Understanding treatment toxicity patterns through remote symptom monitoring and examining the effect of frailty in older men with metastatic prostate cancer.  
First Author: Milothy Parthipan, BSc
- Board 423 **ABSTRACT 12055:** Feasibility of daily physical activity monitoring and associations with treatment toxicity in older adults with metastatic prostate cancer.  
First Author: Gregory Feng, BSc
- Board 424 **ABSTRACT 12056:** Associations between sarcopenia and clinical outcomes in men with metastatic castrate-resistant prostate cancer.  
First Author: Efthymios Papadopoulos, PhD
- Board 425 **ABSTRACT 12057:** A study of frontline therapy in adults 80 years with chronic lymphocytic leukemia (CLL).  
First Author: Mazie Tsang, MD, MS
- Board 426 **ABSTRACT 12058:** Sedentary lifestyle as a predictor of early death in older adults with cancer: A prospective cohort study with 2692 patients.  
First Author: Jurema Telles O Lima, MD, PhD
- Board 427 **ABSTRACT 12059:** Safety of checkpoint inhibitors in older patients with genitourinary cancers.  
First Author: Brian Hemendra Ramnaraigh, MD
- Board 428 **ABSTRACT 12060:** Demographic stratification, evaluation of symptoms burden on basis of gender, and implications of G8 questionnaires in elderly patients with cancer in Bangladesh.  
First Author: Muhammad Rafiqul Islam, MD, MBBS
- Board 429 **ABSTRACT 12061:** Impact of comorbidity burden on immune-related adverse events and survival among older adults with cancer on immunotherapy.  
First Author: Andrew T. Fauchaux, MD
- Board 430 **ABSTRACT 12062:** Frailty IO: Frailty parameters and incidence of immune related adverse events in older patients treated with immune checkpoint blockers (ICB).  
First Author: Capucine Baldini, MD
- Board 431 **ABSTRACT 12063:** Older patients with early-stage triple-negative breast cancer: The Memorial Sloan Kettering Cancer Center experience.  
First Author: Wanqing Iris Zhi, MD, PhD
- Board 432 **ABSTRACT 12064:** Frailty and pre-frailty associated with physical functional performance and quality of life in breast cancer and bone marrow transplant survivors.  
First Author: Shuo Wang, PhD, MPH
- Board 433 **ABSTRACT 12065:** Geriatric-assessment-guided interventions for older adults with multiple myeloma: A feasibility study.  
First Author: Christopher Edward Jensen, MD, MS
- Board 435 **ABSTRACT 12067:** Dissecting the prognostic role of baseline body mass index (BMI) in early breast cancer (BC): Individual patient-level analysis from five Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) randomized clinical trials (RCTs).  
First Author: Davide Soldato, MD
- Board 436 **ABSTRACT 12068:** A pilot study of intraneural facilitation versus standard physical therapy for prevention of chemotherapy-induced peripheral neuropathy.  
First Author: Dan Ran Castillo
- Board 437 **ABSTRACT 12069:** The effect of exercise on physical function and medication adherence in women receiving endocrine therapy for breast cancer: The Breast Cancer Endocrine Therapy Fitness (BE-FIT) randomized controlled trial.  
First Author: Samantha Myers, MSc, PhD (c)
- Board 438 **ABSTRACT 12070:** Evaluation of a mobile behavior change program for weight loss in breast cancer survivors: A prospective single-arm pilot study.  
First Author: Sherry Shen, MD
- Board 439 **ABSTRACT 12071:** Preliminary outcomes of a financial navigation program among lower socioeconomic cancer patients.  
First Author: Chiu Yi Joey Tan, MSW
- Board 440 **ABSTRACT 12072:** Nutritional program among patients with prostate cancer receiving androgen deprivation therapy (ADT).  
First Author: Dr. Paulo Sergio Lages, MD
- Board 441 **ABSTRACT 12073:** Dietary and lifestyle profiles between patients with and without cancer in the National Health Interview Survey.  
First Author: Emma Gong, B.S.
- Board 442 **ABSTRACT 12074:** Associations between body mass index with cancer recurrence and all-cause mortality among survivors of breast cancer.  
First Author: Po-Hua Chen, MD
- Board 443 **ABSTRACT 12075:** Survivorship care and breast and cervical cancer screening.  
First Author: Marco Santos Teles, BS
- Board 444 **ABSTRACT 12076:** Phase 3 randomized placebo-controlled trial of donepezil for cancer-related cognitive impairment among breast cancer survivors: Results on patient-reported cognitive function from the Wake Forest NCI Community Oncology Research Program (NCORP) Research Base REMEMBER trial (WF97116).  
First Author: Alayna E Ernster, PhD
- Board 445 **ABSTRACT 12077:** Impact of exercise on chemotherapy-induced peripheral neuropathy (CIPN) in survivors with post-treatment primary breast cancer.  
First Author: Kirin Saint
- Board 446 **ABSTRACT 12078:** Cardiac dysfunction (CD) among breast cancer survivors (BCS): Role of cardiotoxic therapy and cardiovascular risk factors.  
First Author: Geoffrey S. Bostany, BA
- Board 447 **ABSTRACT 12079:** Pharmacological cardioprotective strategy for non-metastatic patients affected by breast cancer receiving an anthracycline-based chemotherapy: Final results of the phase 3 SAFE trial.  
First Author: Lorenzo Livi, MD
- Board 448 **ABSTRACT 12080:** Serum cytokines and autoantibodies to GM-CSF and immune-related colitis in ipilimumab-treated patients with cancer.  
First Author: Edgar Gonzalez-Kozlova
- Board 449 **ABSTRACT 12081:** Long-term longitudinal patterns of patient-reported quality of life (QOL) after breast cancer (BC) to inform the implementation of personalized pathways of care.  
First Author: Maria Alice B Franzoi, MD

- Board 450 **ABSTRACT 12082:** Estimating burden of cardiovascular disease among survivors of breast, colorectal, lung, and prostate cancer in the Detroit Research on Cancer Survivors (ROCS) cohort.  
First Author: Vidhya Nair, DO
- Board 451 **ABSTRACT 12083:** Cardiac safety of reduced surveillance for cancer therapy related cardiac dysfunction in patients with breast cancer treated with HER2-targeted therapy.  
First Author: Anthony Francis Yu, MD
- Board 452 **ABSTRACT 12084:** Social determinants of health and neurocognitive and psychosocial outcomes in adult childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS).  
First Author: Jinbing Bai, PhD, FAAN, RN, MSN
- Board 453 **ABSTRACT 12085:** A prospective study evaluating the association of patient-reported outcomes with activity level and sleep patterns in sarcoma survivors.  
First Author: Elizabeth J. Davis, MD
- Board 455 **ABSTRACT 12087:** Training and validation of a model predicting clusters of long-term cancer-related behavioral symptoms (CRBS) after breast cancer (BC).  
First Author: Martina Pagliuca, MD
- Board 456 **ABSTRACT 12088:** A genome-wide association study for doxorubicin-induced cardiomyopathy in childhood cancer survivors from the St. Jude Lifetime Cohort (SJLIFE) and the Childhood Cancer Survivor (CCSS) Studies.  
First Author: Kateryna Petrykey, PhD
- Board 457 **ABSTRACT 12089:** Burden of chronic health conditions (CHCs) among people with HIV (PWH) and non-AIDS defining cancers (NADC): A report from the Center for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS).  
First Author: Gaurav Goyal, MD
- Board 458 **ABSTRACT 12090:** Polygenic risk of anthracycline-related cardiomyopathy in childhood cancer survivors: Report from Children's Oncology Group and Childhood Cancer Survivor Study.  
First Author: Noha Sharafeldin, MD, PhD
- Board 459 **ABSTRACT 12091:** Long-term prospective data on correlation between overall mortality and HADS (Hospital Anxiety and Depression Scale) assessed psychological distress in prostate cancer patients (11 year follow-up data).  
First Author: Santhanam Sundar, MD
- Board 460 **ABSTRACT 12092:** The impact of population pharmacogenomics and risk allele frequencies on cisplatin-induced peripheral sensory neuropathy (PSN).  
First Author: Swetha Nakshatri, BS
- Board 461 **ABSTRACT 12093:** Racial and ethnic disparities in survival among persons with subsequent primary cancer.  
First Author: Hyuna Sung, PhD
- Board 462 **ABSTRACT 12094:** Sexual dysfunction in patients with cancer: Results from the CLARIFY project.  
First Author: Aylene Vanessa Ospina Serrano, MD
- Board 463 **ABSTRACT 12095:** Associations among anesthesia-induced brain biomarkers during surgery, preoperative exposure to cancer therapeutics, and clinical outcomes.  
First Author: Tom A.D. Stone, ScM
- Board 464 **ABSTRACT 12096:** Propensity score matched analysis of major adverse cardiac events in patients with localized prostate cancer receiving short term vs long term ADT.  
First Author: Ye Yuan, MD, PhD
- Board 465 **ABSTRACT 12097:** Associations of employment disruptions and financial hardship among individuals diagnosed with cancer in the US.  
First Author: Michael T. Halpern, MD, PhD, MPH
- Board 466 **ABSTRACT LBA12098:** Dexamethasone and exercise for cancer related fatigue: A phase III randomized controlled trial.  
First Author: Vanita Noronha, MD
- Board 467 **ABSTRACT 12099:** Patient-reported symptom monitoring linked to an alert algorithm: Effects on progression-free and overall survival in the SYMPRO-Lung trial.  
First Author: Nicole Erica Billingsy, MSc
- Board 468 **ABSTRACT 12100:** Patient- versus clinician-reported symptoms in the POLARIX study.  
First Author: Carrie A. Thompson, MD
- Board 469 **ABSTRACT 12101:** Acupuncture versus massage for pain in patients living with advanced cancer: The IMPACT randomized clinical trial.  
First Author: Jun J. Mao, MD, MSCE
- Board 470 **ABSTRACT 12102:** Early palliative care for patients with metastatic upper gastrointestinal cancers: A survival analysis of the EPIC randomized trial.  
First Author: Antoine Adenis, MD, PhD
- Board 471 **ABSTRACT 12103:** Prospective evaluation of factors associated with acceptance of feeding tube (FT) placement and clinical outcomes during radiation therapy (RT) or radiochemotherapy (RTCT) for head and neck squamous cell carcinoma (HNSCC).  
First Author: Florian Clatot
- Board 472 **ABSTRACT 12104:** A risk prediction model for cisplatin-induced acute kidney injury in head and neck cancer patients who receive chemoradiotherapy: A supplement analysis of a phase II/III trial of JCOG1008.  
First Author: Yoshinori Imamura, MD, PhD
- Board 473 **ABSTRACT 12105:** Out-of-pocket costs burden for cancer treatment toxicities and symptoms management in Italy: A prospective, multicenter pilot study.  
First Author: Giusti Raffaele, MD
- Board 474 **ABSTRACT 12106:** Quality of pain management in patients with cancer in the outpatient setting.  
First Author: Biplov Adhikari
- Board 475 **ABSTRACT 12107:** The efficacy of hydrocolloid dressing as a prophylactic use for hand-foot skin reaction induced by multitargeted kinase inhibitors: A phase 3 randomized self-controlled study, J-SUPPORT 1701 APRON trial.  
First Author: Atsuo Takashima, MD
- Board 476 **ABSTRACT 12108:** Efficacy of paxman scalp cooling system at lower temperatures for prevention of anthracycline associated chemotherapy induced alopecia.  
First Author: Shari Beth Goldfarb, MD
- Board 477 **ABSTRACT 12109:** Patient-reported hope, prognostic understanding, quality of life, symptom burden, coping mechanisms, and financial wellbeing in early phase clinical trial participants.  
First Author: Debra Lundquist, PhD, RN
- Board 478 **ABSTRACT 12110:** Self-reported overall wellbeing and physical function among chemotherapy and surgery patients completing symptom questionnaires across six health systems.  
First Author: Michael J. Hassett, MD, MPH, FASCO
- Board 479 **ABSTRACT 12111:** Effects of yoga vs placebo on inflammation among cancer survivors: A nationwide multicenter phase III randomized controlled trial (RCT).  
First Author: Po-Ju Lin, PhD, RD, MPH

- Board 480 **ABSTRACT 12112:** Phase 3 RCT of dexamethasone versus placebo for chemotherapy induced fatigue in patients with advanced solid malignancies.  
First Author: Venkatraman Radhakrishnan, MD, MBBS, MSc, DM
- Board 481 **ABSTRACT 12113:** Apixaban versus rivaroxaban for treatment of acute deep venous thrombosis in patients with cancer.  
First Author: Brittany Miles, MSc
- Board 482 **ABSTRACT 12114:** Rose geranium in sesame oil nasal spray to improve symptoms of nasal vestibulitis: A phase III double blinded randomized controlled trial.  
First Author: Elizabeth Jane Cathcart-Rake, MD
- Board 483 **ABSTRACT 12115:** Feasibility and acceptability of implementing electronic patient reported outcomes (ePRO) collection in Zambia: Findings from a patient needs assessment.  
First Author: Susan K. Peterson, PhD
- Board 484 **ABSTRACT 12116:** Nationwide phase II randomized controlled trial of low-dose ibuprofen vs placebo for cancer-related cognitive impairment (CRCI).  
First Author: Michelle Christine Janelsins, PhD, MPH
- Board 485 **ABSTRACT 12117:** Baseline symptom, health status, and health utilities in patients in early-phase clinical trials combining immune checkpoint blockade with other anticancer therapies.  
First Author: Goldy C George, PhD
- Board 486 **ABSTRACT 12118:** Experiences with pain management for survivors of complex cancers: Focus on opioids and cannabis.  
First Author: Talya Salz, PhD
- Board 487 **ABSTRACT 12119:** Opioid use, gabapentinoid use, and pain-related emergency department visits for patients living with advanced cancer.  
First Author: Vikram Jairam, MD
- Board 488 **ABSTRACT 12120:** Unveiling inequities in palliative care and clinical trial participation among patients with metastatic breast cancer in the state of Florida.  
First Author: Oluwadamilola Temilade Oladeru, MD, MA
- Board 489 **ABSTRACT 12121:** End-of-life outcomes after implementation of an embedded, criteria-based palliative care consultation service in inpatient oncology.  
First Author: Kathryn Norman, MD
- Board 490 **ABSTRACT 12122:** A supervised remote exercising program for patients receiving immunotherapy alone or in combination with chemotherapy in Brazil: ExIO.  
First Author: Paulo Gustavo Bergerot, MD
- Board 491 **ABSTRACT 12123:** Risk of severe toxicity from topical fluoropyrimidine treatment in patients carrying DPYD variant alleles.  
First Author: Javier Granados
- Board 492 **ABSTRACT 12124:** Patient-controlled subcutaneous analgesia with hydromorphone versus oral oxycodone for opioid titration of cancer pain: A prospective multicenter randomized trial.  
First Author: Xiaoguang Xiao, MD, PhD
- Board 493 **ABSTRACT 12125:** Concurrent hospice healthcare utilization in the hematology/oncology patient population at Veterans Affairs.  
First Author: Anshu Hemrajani
- Board 494 **ABSTRACT 12126:** Denosumab biosimilar (LY01011) in the treatment of bone metastases in patients with solid tumors: A multicenter, randomized, double-blind, active comparator-controlled phase 3 study.  
First Author: Mingchuan Zhao
- Board 495 **ABSTRACT 12127:** A phase III, double-blind, non-inferiority, randomized controlled trial of antiemetic prophylaxis for highly emetogenic chemotherapy without dexamethasone: CINV POD study.  
First Author: Venkatraman Radhakrishnan, MD, MBBS, MSc, DM
- Board 496 **ABSTRACT 12128:** Utilization of early integrated palliative medicine among patients with metastatic solid tumor cancers: Findings from a safety net medical center treating a majority African American population.  
First Author: Aneesha Ananthula, MD
- Board 497 **ABSTRACT 12129:** Palliative care in hematopoietic stem cell transplant recipients and impact on survival: A nationwide analysis.  
First Author: Naveen Premnath, MD
- Board 498 **ABSTRACT 12130:** Key components of goals of care conversations on determining end-of-life care for advanced cancer patients.  
First Author: Amy An
- Board 499 **ABSTRACT 12131:** Adjuvant endocrine therapy adherence changes among patients after a virtual behavioral intervention.  
First Author: Jamie M. Jacobs, PhD
- Board 500 **ABSTRACT 12132:** Facilitating the transition to post-treatment survivorship for adolescent and young adults: A randomized waitlist control trial of a virtual mind-body intervention.  
First Author: Giselle K. Perez, PhD
- Board 501 **ABSTRACT 12133:** Will we have a match? Observations from decision making conversations between hematologists and White and Black patients considering allogeneic stem cell transplant.  
First Author: Thorunn Halldora Thordardottir, MD
- Board 502 **ABSTRACT 12134:** Associations between psychosocial risk factors and immune checkpoint inhibitor outcomes.  
First Author: Heather Derry-Vick, PhD
- Board 503 **ABSTRACT 12135:** Comparing the time toxicity of cancer treatments in the CCTG LY.12 trial.  
First Author: Arjun Gupta, MD
- Board 504 **ABSTRACT 12136:** Analysis of delivery of cancer survivorship education to community healthcare professionals.  
First Author: Ashley Pariser, MD
- Board 505a **ABSTRACT TPS12137:** The FARGO study: Frailty assessment for risk prediction in gynecologic oncology.  
First Author: Julie My Van Nguyen, MD, MSc, FRCSC
- Board 505b **ABSTRACT TPS12138:** Comprehensive geriatric assessment based multidisciplinary team intervention for hospitalized frail patients in oncology: COMPASS-ONCO/KCSG AL21-13.  
First Author: Yun-Gyoo Lee, MD, PhD
- Board 506a **ABSTRACT TPS12139:** Digital voice analysis as a measure of frailty and distress: A feasibility study (DIVAN).  
First Author: Marcus Vetter, MD
- Board 506b **ABSTRACT TPS12140:** Evaluating the impact of exercise in women living with indolent metastatic breast cancer: The EMBody trial.  
First Author: Martha Cancilla, MD
- Board 507a **ABSTRACT TPS12141:** Comprehensive Outcomes for After Cancer Health: COACH.  
First Author: Robin Mary Lally, PhD, FAAN, MS, RN, AOCN

Monday, June 5, 2023

- Board 507b **ABSTRACT TPS12142:** The CROWN study (CaRdiac Outcomes With Near complete estrogen deprivation): A multicenter, prospective cohort study of cardiovascular outcomes in premenopausal women with hormone receptor positive breast cancer treated with ovarian suppression and an aromatase inhibitor.  
First Author: Emily H. Douglas, MD
- Board 508a **ABSTRACT TPS12143:** A randomized phase III clinical trial of yoga for chemotherapy-induced peripheral neuropathy treatment.  
First Author: Kirin Saint
- Board 508b **ABSTRACT TPS12144:** A randomized phase III clinical trial of acupuncture for chemotherapy-induced peripheral neuropathy in survivors of cancer.  
First Author: Ivana Lopez-Nieves
- Board 509a **ABSTRACT TPS12145:** Objective assessment of fatigue, sleep and insomnia in breast cancer survivors on estrogen deprivation therapy.  
First Author: Lauren A. Fowler, PhD
- Board 509b **ABSTRACT TPS12146:** Phase III, international, multi-centre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain.  
First Author: Hiromichi Matsuo, MD, PhD
- Board 510a **ABSTRACT TPS12147:** Phase 2 study to assess the efficacy, safety, and tolerability of the GDF-15 inhibitor ponesimomab in patients with cancer cachexia.  
First Author: Jeffrey Crawford, MD, FASCO
- Board 510b **ABSTRACT TPS12148:** Prospective observational study to evaluate lemborexant utility in insomnia among women with breast cancer (WJOG14921B, LUNAR study).  
First Author: Yukinori Ozaki, MD
- Board 511a **ABSTRACT TPS12149:** Study for the prevention of oral mucositis.  
First Author: Artem Oganessian, MD
- Board 511b **ABSTRACT TPS12150:** Effects of virtual reality on pain and anxiety in patients with cancer undergoing bone marrow biopsy.  
First Author: Jacek K. Pinski, MD
- Board 512a **ABSTRACT TPS12151:** Exploratory study investigating the efficacy and safety of olanzapine prophylaxis for opioid-induced nausea and vomiting (JORTC-PAL20).  
First Author: Eriko Satomi, MD
- Board 512b **ABSTRACT TPS12152:** Empathic communication skills training: Randomized controlled trial to reduce lung cancer stigma in lung cancer care.  
First Author: Jamie S. Ostroff, PhD

---

**3:00 PM - 4:00 PM Case-Based Panel**

**ctDNA in the Management of Early Colorectal Cancer: The Time Has Come!**

Location: Hall D2

**Richard D. Kim, MD - Chair**

H. Lee Moffitt Cancer Center and Research Institute  
*Moderator*

**Kellie Leanne Mathis, MD**

Mayo Clinic  
*Surgical Oncologist Perspective*

**Aparna Raj Parikh, MD**

Massachusetts General Hospital, Harvard Medical School  
*Medical Oncologist Perspective*

**Jeanne Tie, MD, MBChB, FRACP**

Peter MacCallum Cancer Centre  
*Medical Oncologist Perspective*

*Panel Question and Answer*

---

**3:00 PM - 4:15 PM Education Session**

**ASCO/ESMO Joint Session: Optimizing Screening for Lung and Colorectal Cancer: Overcoming Barriers and Eliminating Disparities**

Location: Arie Crown Theater

**Eric P. Winer, MD, FASCO - Chair**

Yale Cancer Center

**Andres Cervantes, MD, PhD - Chair**

INCLIVA, Biomedical Research Institute, Hospital Clínico, University of Valencia

**Kimmie Ng, MD, MPH - Chair**

Dana-Farber Cancer Institute

**Folasade May, MD, PhD, MPhil**

University of California, Los Angeles  
*Updated Guidelines and Emerging Evidence for Colorectal Cancer Screening*

**Christophe Von Garnier, MD**

Centre Hospitalier Universitaire Vaudois  
*Updated Guidelines and Emerging Evidence for Lung Cancer Screening*

**Cary Philip Gross, MD**

Yale School of Medicine  
*Novel Strategies to Mitigate Disparities in Cancer Screening*

**Charles Swanton, MD, PhD, FCRP**

The Francis Crick Institute  
*The Future of Screening for Lung and Colorectal Cancer: Novel Technologies and Precision Prevention*

*Panel Question and Answer*

---

**3:00 PM - 4:15 PM Education Session**

**Bad to the Bone: Emerging Approaches to Aggressive Bone Sarcoma**

Location: S404

**Sandra J. Strauss, MBBS, MRCP - Chair**

University College Hospital  
*Systemic Approaches Across the Spectrum of Chondrosarcoma*

**Richard F. Riedel, MD**

Duke Cancer Institute  
*Controversies in Managing High-Risk and Relapsed Ewing Sarcoma and Other Small Blue Round Cell Sarcoma*

**Damon R. Reed, MD**

H. Lee Moffitt Cancer Center and Research Institute  
*Emerging Strategies in Osteosarcoma and Ewing Sarcoma*

*Panel Question and Answer*

**3:00 PM - 4:15 PM Education Session**

**Genetic and Genomic Testing for Prostate Cancer: Beyond DNA Repair Deficiencies**

Location: Hall B1

**Heather H. Cheng, MD, PhD - Chair**

University of Washington Medical Center  
*Clinical and Therapeutic Implications of Genetic/Genomic Testing in Prostate Cancer*

**Paul L. Nguyen, MD**

Brigham and Women's Hospital  
*What Providers Need to Know about Prostate Cancer RNA Expression and How It Influences Management Decisions*

**Alexander William Wyatt, PhD**

University of British Columbia  
*How Can Technology Help Us?*

*Panel Question and Answer*

**3:00 PM - 4:15 PM Education Session**

**Not Too Little, Not Too Much: Optimizing More Versus Less for the Older Patient With Breast Cancer**

Location: S102

**Jennifer Tseng, MD - Chair**

City of Hope  
*De-Escalating Locoregional Therapy: When and How*

**Mara A. Schonberg, MD, MPH**

Beth Israel Deaconess Medical Center  
*Shared Decision Making: What Does the Patient Want?*

**Etienne Brain, MD, PhD**

Institut Curie  
*Systemic Therapy in the Older Patient With High-Risk Disease*

*Panel Question and Answer*

**3:00 PM - 4:15 PM Education Session**

**Spotlight on the Spectrum of Neuroendocrine Tumors**

Location: E451

**Lynnette Fernandez-Cuesta, PhD**

University of Lyon  
*Unraveling the Biology of Carcinoid and Large Cell Neuroendocrine Tumors*

**Ticiana Leal, MD - Chair**

Winship Cancer Institute of Emory University  
*Transcriptional Subsets of SCLC and Potential for Personalized Approaches*

**Sally C. M. Lau, MD, MPH**

Perlmutter Cancer Center at NYU Langone  
*Where Do We Stand with Immunotherapy for Small-Cell Lung Cancer?*

*Panel Question and Answer*

**3:00 PM - 4:15 PM Ticketed Session**

**Meet the Professors: Expert Approach to Genomic Sequencing in Patients With Sarcoma**

Location: E253d

**Benjamin Alexander Nacev, MD, PhD**

Memorial Sloan Kettering Cancer Center  
*Integrating Genomic Profiling in the Care of Patients With Sarcoma: From Diagnosis to Therapy*

**Elizabeth Demicco, MD**

Mount Sinai Hospital  
*Interpreting Next-Generation Sequencing in Sarcoma: Understanding the Molecular Landscape*

*Panel Question and Answer*

**3:00 PM - 4:30 PM Clinical Science Symposium**

**Traversing Toxicities of Immuno-Oncology Agents: Molecular Predictors and Rational Outcomes**

Location: S406

**Alexander M. Menzies, MBBS, FRACP, PhD - Chair**

Melanoma Institute Australia

**Edward B. Garon, MD, MS - Chair**

University of California Los Angeles

**3:00 PM Abstract 2509:** Clinical and immune phenotypes associated with immune checkpoint inhibitor-induced autoimmune diabetes.

First Author: Karina Nicole Ruiz-Esteves, MD

**3:12 PM Jennifer Mammen, MD, PhD (Discussion of Abstract(s) 2509)**

Johns Hopkins Medical Institutes  
*Understanding the Mechanism of a Rare and Irreversible Toxicity*

**3:24 PM Abstract 2510:** First-line treatment of fecal microbiota transplantation for immune-mediated colitis.

First Author: Yinghong Wang, MD, PhD, MS

**3:36 PM Diwakar Davar, MBBS (Discussion of Abstract(s) 2510)**

UPMC Hillman Cancer Center  
*So, Our Recommendation for Your Immune-Mediated Colitis Is...*

**3:48 PM Abstract 2511:** Identifying molecular targets for rational immunosuppressive strategies in patients with immune checkpoint therapy-induced myocarditis and myositis.

First Author: Bilal Ahmed Siddiqui, MD

**4:00 PM Jarushka Naidoo, MHS, MBBCh (Discussion of Abstract(s) 2511)**

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins  
*Getting to the Heart of the Matter, Beyond Steroids*

**4:12 PM** Panel Question and Answer

**3:00 PM - 4:30 PM Poster Discussion Session**

**Hematologic Malignancies—Plasma Cell Dyscrasia**

Location: E450

**Noa Biran, MD - Chair**

Hackensack University Medical Center

## Monday, June 5, 2023

**Natalie S. Callander, MD - Chair**

University of Wisconsin, Carbone Cancer Center

- 3:00 PM Krina K. Patel, MD, MSc (Discussion of Abstract(s) 8009-8011)**  
MD Anderson Cancer Center  
*Minimizing Uncertainty in Myeloma*
- 3:12 PM** Panel Question and Answer
- 3:22 PM Nisha S. Joseph, MD (Discussion of Abstract(s) 8012-8015)**  
Winship Cancer Institute of Emory University  
*How Real Is the "Real World"?*
- 3:34 PM** Panel Question and Answer
- 3:44 PM Jacalyn Rosenblatt, MD (Discussion of Abstract(s) 8016-8017)**  
Harvard Medical School  
*More Than Immunity*
- 3:56 PM** Panel Question and Answer
- 4:06 PM Ajai Chari, MD (Discussion of Abstract(s) 8018-8020)**  
Mt. Sinai  
*Infections and Toxicities: Dotting the "i"s and Crossing the "t"s"*
- 4:18 PM** Panel Question and Answer

Posters discussed in this session are on display in the Hematologic Malignancies—Plasma Cell Dyscrasia Poster Session. To view abstract titles and presentations, see the online program guide ([meetings.asco.org](https://meetings.asco.org)).

---

### 3:00 PM - 6:00 PM Oral Abstract Session

#### Melanoma/Skin Cancers

Location: Hall D1

**Allison Betof Warner, MD, PhD - Chair**

Stanford Cancer Institute

**Anna C. Pavlick, MD, MBA - Chair**

Weill Cornell Medical Center

- 3:00 PM Abstract 9501:** Significant durable response with fiantimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis.  
First Author: Omid Hamid, MD
- 3:12 PM Abstract 9502:** Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.  
First Author: Hussein A. Tawbi, MD, PhD
- 3:24 PM Abstract 9511:** Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466).  
First Author: Zeynep Eroglu, MD
- 3:36 PM James Larkin, PhD (Discussion of Abstract(s) 9501-9511)**  
Royal Marsden Hospital NHS Foundation Trust  
*Jumping Ahead, Falling Behind, or Standing Still in the Frontline Setting for Advanced Melanoma?*
- 3:48 PM** Panel Question and Answer
- 4:00 PM Abstract LBA9503:** Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.  
First Author: Adnan Khattak

- 4:12 PM Abstract 9504:** Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K).  
First Author: Georgina V. Long, MD, PhD, FRACP
- 4:24 PM Abstract LBA9505:** Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.  
First Author: Jason J. Luke, MD, FACP
- 4:36 PM Olivier Michielin, MD, PhD (Discussion of Abstract(s) LBA9503-LBA9505)**  
Ludwig Institute for Cancer Research Lausanne  
*Shifting the Goal Posts for Adjuvant Therapy in Melanoma*
- 4:48 PM** Panel Question and Answer
- 5:00 PM Abstract 9506:** Non-comparative, open-label, international, multicenter phase I/II study of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic Merkel cell carcinoma (MCC) (CheckMate 358).  
First Author: Shailender Bhatia, MD
- 5:12 PM Abstract 9507:** Towards organ preservation and cure via 2 infusions of immunotherapy only, in patients normally undergoing extensive and mutilating curative surgery for cutaneous squamous cell carcinoma: An investigator-initiated randomized phase II trial—The MATISSE trial.  
First Author: Charlotte L. Zuur, MD, PhD
- 5:24 PM Abstract 9508:** Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma.  
First Author: Bin Lian, MD
- 5:36 PM Ines Esteves Domingues Pires Da Silva, MD, PhD (Discussion of Abstract(s) 9506-9508)**  
Melanoma Institute Australia, The University of Sydney  
*Tough Nuts to Crack in Cutaneous Oncology*
- 5:48 PM** Panel Question and Answer

---

### 3:00 PM - 6:00 PM Oral Abstract Session

#### Prevention, Risk Reduction, and Hereditary Cancer

Location: S100a

**James M. Ford, MD, FASCO - Chair**

Stanford University Medical Center

**Meghna S. Trivedi, MD, MS - Chair**

Columbia University

- 3:00 PM Abstract 10500:** Germline genetic testing use and results after a cancer diagnosis.  
First Author: Allison W. Kurian, MD, MSc
- 3:12 PM Abstract 10501:** Breast cancer risk associated with missense variants in BRCA2.  
First Author: Siddhartha Yadav, MD
- 3:24 PM Abstract 10502:** Incidence round screening performance among women with dense breasts undergoing abbreviated breast MRI and digital breast tomosynthesis (ECOG-ACRIN EA1141).  
First Author: Christiane K. Kuhl, MD
- 3:36 PM Abstract 10503:** Second primary breast cancer in young breast cancer survivors.  
First Author: Kristen D. Brantley, PhD

- 3:48 PM Erin Frances Cobain, MD (Discussion of Abstract(s) 10500-10503)**  
Michigan Medicine  
*Germline Genetic Testing and Screening in Breast Cancer: Getting It Right*
- 4:00 PM** Panel Question and Answer
- 4:12 PM Abstract 10504:** Ancestry-adjusted genomic analysis to identify known and novel associations with single and multiple cancer phenotypes.  
First Author: Vijai Joseph, PhD
- 4:24 PM Abstract 10505:** Polygenic risk score calibration and association with breast cancer in diverse ancestries.  
First Author: Matthew Kucera, MS
- 4:36 PM Abstract 10506:** Integrating polygenic risk scores into clinical breast cancer models: Influence on prediction in diverse cohorts.  
First Author: George B.J. Busby, BSc (Hons), MRes, DPH
- 4:48 PM Payal Deepak Shah, MD (Discussion of Abstract(s) 10504-10506)**  
University of Pennsylvania  
*Integration of Polygenic Scores Into Clinical Breast Cancer Risk Assessment*
- 5:00 PM** Panel Question and Answer
- 5:12 PM Abstract 10507:** Whole exome sequencing and machine learning germline analysis of individuals presenting with phenotypes of extreme high and low risk of developing tobacco-induced lung adenocarcinoma.  
First Author: Jose Luis Perez-Gracia, MD, PhD
- 5:24 PM Abstract 10508:** Lung cancer metabolomics: A pooled analysis in the Cancer Prevention Studies.  
First Author: Ziyin Tang
- 5:36 PM Christine M. Lovly, MD, PhD (Discussion of Abstract(s) 10507-10508)**  
Vanderbilt University Medical Center  
*Innovations for Lung Cancer Risk and Early Detection*
- 5:48 PM** Panel Question and Answer

---

**4:30 PM - 5:30 PM Case-Based Panel**

**State-of-the-Art Management of Biliary Tract Cancers**

Location: Hall D2

**Mairead Geraldine McNamara, PhD, MBBCh - Chair**  
University of Manchester/The Christie NHS Foundation Trust  
*Moderator*

**Naureen Starling, MD, FRCP, MBBS**  
The Royal Marsden NHS Foundation Trust  
*The Medical Oncologist's Perspective*

**Michael Lidsky, MD**  
Duke University Medical Center  
*The Surgeon's Perspective*

**Ryan Hickey, MD**  
NYU Medical Center  
*The Interventional Radiologist's Perspective*

*Panel Question and Answer*

**4:30 PM - 6:00 PM Poster Discussion Session**

**Care Delivery and Regulatory Policy**

Location: S102

**Sibel Blau, MD - Chair**  
Northwest Medical Specialties

**Vonetta Michelle Williams, MD, PhD - Chair**  
Memorial Sloan Kettering Cancer Center

**4:30 PM Matthew F. Hudson, PhD, MPH (Discussion of Abstract(s) 1509-1511)**  
Prisma Health  
*Improving Care and Saving Lives: The Potential of State Policy*

**4:42 PM** Panel Question and Answer

**4:52 PM Kerin B. Adelson, MD, FASCO (Discussion of Abstract(s) 1512-1514)**  
The University of Texas MD Anderson Cancer Center  
*Moving Toward Coordinated, High-Value Care*

**5:04 PM** Panel Question and Answer

**5:14 PM Adam P. Dicker, MD, PhD, FASTRO, FASCO (Discussion of Abstract(s) 1515-1517)**  
Thomas Jefferson University Methodist Hospital  
*The Machine Will See You Now: Using AI to Enhance Cancer Care*

**5:26 PM** Panel Question and Answer

**5:36 PM Gita Suneja, MD (Discussion of Abstract(s) 1518-1520)**  
University of Utah  
*Going the Distance: Remote Cancer Care Delivery*

**5:48 PM** Panel Question and Answer

Posters discussed in this session are on display in the Care Delivery and Regulatory Policy Poster Session. To view abstract titles and presentations, see the online program guide ([meetings.asco.org](https://meetings.asco.org)).

---

**4:30 PM - 6:00 PM Poster Discussion Session**

**Gynecologic Cancer**

Location: S100bc

**Cornelia Kolberg-Liedtke, MD, PhD - Chair**  
University Hospital Essen

**Anuja Jhingran, MD - Chair**  
The University of Texas MD Anderson Cancer Center

**4:30 PM Jalid Sehouli, MD (Discussion of Abstract(s) 5512-5515)**  
Charité University of Medicine Virchow Campus Clinic  
*Meeting at the TKI Bar*

**4:42 PM** Panel Question and Answer

**4:52 PM Oliver Dorigo, MD, PhD (Discussion of Abstract(s) 5517-5518)**  
Stanford Medicine  
*Expanding Options in Immunotherapy for Gynecologic Cancers*

**5:04 PM** Panel Question and Answer

**5:14 PM Jennifer Michelle Scalici, MD (Discussion of Abstract(s) 5519-5528)**  
University of South Alabama Mitchell Cancer Institute  
*Optimizing Treatment for Cervical Cancer*

**5:26 PM** Panel Question and Answer



## Monday, June 5, 2023

**5:36 PM Kathryn Pennington, MD (Discussion of Abstract(s) 5521-5523)**  
University of Washington School of Medicine  
*Everything, Everywhere, All at Once: Treatment Options in Gynecologic Cancer*

**5:48 PM** Panel Question and Answer

Posters discussed in this session are on display in the Gynecologic Cancer Poster Session. To view abstract titles and presentations, see the online program guide ([meetings.asco.org](https://meetings.asco.org)).

---

### 4:30 PM - 6:00 PM Poster Discussion Session

#### Head and Neck Cancer

Location: E451

**Michelle Lynn Mierzwa, MD - Chair**

University of Michigan

**Vatche Tchekmedyan, MD - Chair**

Maine Medical Partners, MaineHealth Cardiology

**4:30 PM Nabil F. Saba, MD, FACP (Discussion of Abstract(s) 6009-6011)**  
Emory University Winship Cancer Institute  
*Immunotherapy for a Rarity*

**4:42 PM** Panel Question and Answer

**4:52 PM Erminia Massarelli, MD, PhD (Discussion of Abstract(s) 6012-6014)**  
City of Hope Comprehensive Cancer Center  
*Going Viral*

**5:04 PM** Panel Question and Answer

**5:14 PM Trisha Michel Wise-Draper, MD (Discussion of Abstract(s) 6015-6017)**  
University of Cincinnati  
*Trendy Targets*

**5:26 PM** Panel Question and Answer

**5:36 PM Richard Bryan Bell, MD (Discussion of Abstract(s) 6018-6020)**  
Providence Cancer Institute  
*Primed To Kill*

**5:48 PM** Panel Question and Answer

Posters discussed in this session are on display in the Head and Neck Cancer Poster Session. To view abstract titles and presentations, see the online program guide ([meetings.asco.org](https://meetings.asco.org)).

---

### 4:30 PM - 6:00 PM Poster Discussion Session

#### Pediatric Oncology

Location: S504

**Damon R. Reed, MD - Chair**

H. Lee Moffitt Cancer Center and Research Institute

**Mallory Taylor, MD, MS - Chair**

Seattle Children's Research Institute

**4:30 PM Kieuhoa Tran Vo, MD, MS (Discussion of Abstract(s) 10018-10021)**  
University of California, San Francisco  
*Aligning Care Goals in Hard-to-Treat Pediatric Cancers*

**4:42 PM** Panel Question and Answer

**4:52 PM Rishi Ramesh Lulla, MD (Discussion of Abstract(s) 10022-10024)**  
Hasbro Children's Hospital  
*Emerging Strategies in Pediatric Tumors*

**5:04 PM** Panel Question and Answer

**5:14 PM Jennifer Lynn McNeer, MD (Discussion of Abstract(s) 10025-10027)**  
University of Utah  
*Intervention and Beyond in Pediatric Hematologic Malignancies*

**5:26 PM** Panel Question and Answer

**5:36 PM Peter D. Cole, MD (Discussion of Abstract(s) 10028-10029)**  
Rutgers Cancer Institute of New Jersey  
*Aging in Survivors of Pediatric Cancer*

**5:48 PM** Panel Question and Answer

Posters discussed in this session are on display in the Pediatric Oncology Poster Session. To view abstract titles and presentations, see the online program guide ([meetings.asco.org](https://meetings.asco.org)).

---

### 4:30 PM - 6:00 PM Poster Discussion Session

#### Symptoms and Survivorship

Location: S404

**Tara B. Sanft, MD - Chair**

Yale University

**Lindsay Leuthen Peterson, MD, MS - Chair**

Washington University

**4:30 PM Halle C. F. Moore, MD (Discussion of Abstract(s) 12013-12015)**  
Cleveland Clinic  
*"Checking" In on Sexual and Reproductive Health*

**4:42 PM** Panel Question and Answer

**4:52 PM Luciana Garcia Landeiro, MD (Discussion of Abstract(s) 12016-12018)**  
Núcleo de Oncologia da Bahia - Grupo Oncoclínicas  
*Predicting the Future for AYA Survivors*

**5:04 PM** Panel Question and Answer

**5:14 PM Deepti Behl, MD (Discussion of Abstract(s) 12019-12021)**  
Sutter Medical Group  
*New "Highs" in Symptoms Management*

**5:26 PM** Panel Question and Answer

**5:36 PM Ryan David Nipp, MD (Discussion of Abstract(s) 12022-12024)**  
University of Oklahoma  
*Managing the Lows of Cancer Treatment*

**5:48 PM** Panel Question and Answer

Posters discussed in this session are on display in the Symptoms and Survivorship Poster Session. To view abstract titles and presentations, see the online program guide ([meetings.asco.org](https://meetings.asco.org)).

---

### 4:45 PM - 5:45 PM Case-Based Panel

#### Integrating Liquid Biopsies Into Patient Care and Clinical Trial Design

Location: Arie Crown Theater

**Tyler Paul Johnson, MD - Chair**  
Stanford University Hospital  
*Moderator*

**Luis A. Diaz Jr., MD**  
Memorial Sloan Kettering Cancer Center  
*Medical Oncologist Perspective*

**Lillian L. Siu, MD, FASCO**  
Princess Margaret Cancer Centre, University Health Network, University  
of Toronto  
*Early-Stage Drug Development/Clinical Trial Design Expert*

**Peter Gibbs, MD, FRACP, MBBS**  
Royal Melbourne Hospital  
*Science of Liquid Biopsies Expert*  
  
*Panel Question and Answer*

---

**4:45 PM - 6:00 PM Education Session**

**Improving Quality of Life on Chemotherapy for Patients  
With Breast Cancer: Realistic or Wishful Thinking?**  
Location: E450

**Melissa Kate Accordino, MD, MS - Chair**  
Columbia University Irving Medical Center  
*Mitigating Neuropathy: Cooling Down and Other Options*

**Richard T. Lee, MD**  
City of Hope  
*Cannabinoids and Integrative Approaches to Symptom Management*

**Elahe Salehi, NP**  
Dana-Farber Cancer Institute  
*Preventing Hair Loss: Scalp Cooling for All?*  
  
*Panel Question and Answer*

---

**4:45 PM - 6:00 PM Education Session**

**Management of Prostate Cancer in Older Adults**  
Location: S406

**Elizabeth R. Kessler, MD**  
University of Colorado Cancer Center Anschutz Medical Campus  
*Assessment and Decision Tools for Balancing Survival and Quality of Life*

**Ravi Bharat Parikh, MD**  
Perelman School of Medicine, University of Pennsylvania  
*Helping Older Patients Survive and Thrive With Prostate Cancer: Known  
and Novel Intervention Strategies*

**Alicia K. Morgans, MD, MPH - Chair**  
Dana-Farber Cancer Institute  
*Applying Risk/Benefit Considerations for Older Patients to Current  
Treatment Advances in Prostate Cancer*  
  
*Panel Question and Answer*

















**8:00 AM - 9:15 AM Highlights of the Day Session**

**Highlights of the Day Session #3**

Location: Hall D1

**Cardinale B. Smith, MD, PhD - Chair**

Icahn School of Medicine at Mount Sinai

- 8:00 AM Primo N. Lara Jr., MD**  
University of California Davis Comprehensive Cancer Center  
*Highlights of Genitourinary Cancer: Kidney and Bladder*
- 8:15 AM Katy K. Tsai, MD**  
University of California, San Francisco  
*Highlights of Melanoma/Skin Cancers*
- 8:30 AM Alexander E. Drilon, MD**  
Memorial Sloan Kettering Cancer Center  
*Highlights of Developmental Therapeutics: Molecularly Targeted Agents and Tumor Biology*
- 8:45 AM Barbara Burtness, MD**  
Yale School of Medicine  
*Highlights of Head and Neck Cancer*
- 9:00 AM Harold J. Burstein, MD, PhD, FACP**  
Dana-Farber Cancer Institute  
*Highlights of Breast Cancer: Metastatic*

**8:00 AM - 9:15 AM Education Session**

**Expanding the Reach and Grasp of Lung Cancer Screening**

Location: E451

**Raymond U. Osarogiagbon, MBBS, FACP - Chair**

Baptist Cancer Center

*Building a Stronger Net: Improving Uptake of Lung Cancer Screening*

**Pan-Chyr Yang, MD, PhD**

National Taiwan University College of Medicine

*Casting a Wider Net: Expanding Eligibility Criteria for Lung Cancer Screening*

**Lecia V. Sequist, MD, MPH**

Massachusetts General Hospital

*Sharpening Our Tools: The Next Wave of Early Detection Technologies*

Panel Question and Answer

**8:00 AM - 9:15 AM Education Session**

**Incorporating Minimal Residual Disease to Optimize Treatment of Leukemia**

Location: S100a

**Michael Heuser, MD - Chair**

Hannover Medical School

*Measurable Residual Disease in the Acute Myeloid Leukemia Clinic: Ready for Prime Time?*

**Jessica Taft Leonard, MD**

Oregon Health and Science University

*How I Incorporate Measurable Residual Disease in the Management of Acute Lymphoblastic Leukemia*

**Delphine Rea, MD, PhD**

Hôpital Saint-Louis

*Chronic Myeloid Leukemia: Molecular Measurable Residual Disease in Practice*

Panel Question and Answer

**8:00 AM - 11:00 AM Oral Abstract Session**

**Health Services Research and Quality Improvement**

Location: S100bc

**Lova Sun, MD - Chair**

University of Pennsylvania

**Stephanie B. Wheeler, PhD, MPH - Chair**

The University of North Carolina at Chapel Hill

- 8:00 AM Abstract 6500:** Biologic indicators of donor socioeconomic disadvantage and recipient mortality following allogeneic hematopoietic cell transplantation.  
First Author: Jennifer M. Knight, MD, MS
- 8:12 AM Abstract 6501:** Evaluation of potential socioeconomic and racial/ethnic disparities in all-cause mortality in adolescent and young adult patients with cancer.  
First Author: Scott Henderson
- 8:24 AM Abstract 6502:** Disparities in outcomes among hospitalized unhoused patients with cancer in the US.  
First Author: Kanan Shah, MD
- 8:36 AM Sharon H. Giordano, MD, MPH, FASCO (Discussion of Abstract(s) 6500-6502)**  
The University of Texas MD Anderson Cancer Center  
*Determinants of Health in the Marginalized: Mechanisms and Mediators*
- 8:48 AM** Panel Question and Answer
- 9:00 AM Abstract 6503:** Risk of early mortality in patients with cancer experiencing adverse financial events.  
First Author: Hiba Khan, MD, MPH
- 9:12 AM Abstract 6504:** Health insurance continuity and survival among children, adolescents, and young adults with blood cancer: An analysis based on SEER-Medicaid data.  
First Author: Xu Ji, PhD
- 9:24 AM Abstract 6505:** Association of medical debt and cancer mortality in the US.  
First Author: Xin Hu
- 9:36 AM Helen M. Parsons, PhD, MPH (Discussion of Abstract(s) 6503-6505)**  
University of Minnesota  
*Grade 5 Financial Toxicity: Death by Debt*
- 9:48 AM** Panel Question and Answer
- 10:00 AM Abstract 6506:** The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC): Results from a prospective observational reference laboratory testing program.  
First Author: Mary K. Nesline, MS
- 10:12 AM Abstract 6507:** Clinical value of timely targeted therapy (TT) for patients with advanced non-small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADO).  
First Author: Thomas Stricker
- 10:24 AM Abstract 6508:** Practice- and provider-level inequities in next-generation sequencing (NGS) testing by race/ethnicity for patients (pts) with advanced non-small cell lung cancer (aNSCLC) treated in the community setting.  
First Author: Gregory A. Vidal, MD, PhD
- 10:36 AM Charu Aggarwal, MD (Discussion of Abstract(s) 6506-6508)**  
University of Pennsylvania  
*No Time to Lose: Early Access to Precision Oncology*
- 10:48 AM** Panel Question and Answer

Tuesday, June 6, 2023

**9:45 AM - 11:00 AM Education Session**

**Oligometastatic Renal Cell Carcinoma: Observe, Excise, Ablate?**

Location: E451

**Karie Runcie, MD - Chair**

Columbia University Irving Medical Center  
*When to Play the Systemic Therapy Card*

**Shawn Dason, MD**

The Ohio State University Comprehensive Cancer Center  
*The Role of Cytoreductive Nephrectomy and Surgical Metastectomy*

**Raquibul Hannan, MD, PhD**

UT Southwestern  
*When Is Stereotactic Ablative Body Radiotherapy an Option?*

*Panel Question and Answer*

---

**9:45 AM - 11:00 AM Education Session**

**Who's on First? The Expanding Role of Neoadjuvant Therapy in Melanoma**

Location: S102

**Rodabe Navroze Amaria, MD - Chair**

The University of Texas MD Anderson Cancer Center  
*Defining and Monitoring Response in Neoadjuvant Immunotherapy*

**Tina J. Hieken, MD**

Mayo Clinic  
*Changes in Surgical Management Following Neoadjuvant Therapy*

**Grant A. McArthur, MBBS, PhD, FRACP**

Peter MacCallum Cancer Centre  
*Beyond PD-1: Immunotherapy Alternatives in the Neoadjuvant Setting*

*Panel Question and Answer*

---

**9:45 AM - 12:45 PM Oral Abstract Session**

**Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia**

Location: S100a

**Boyu Hu, MD - Chair**

Hunstman Cancer Institute at the University of Utah

**Jakub Svoboda, MD - Chair**

University of Pennsylvania

**9:45 AM Abstract 7500:** Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance).  
First Author: Jennifer Ann Woyach, MD

**9:57 AM Abstract 7501:** Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of TRANSCEND CLL 004.  
First Author: Tanya Siddiqi, MD

**10:09 AM Abstract 7502:** Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome.  
First Author: Anna Maria Frustaci, MD

**10:21 AM Carolyn Owen, MD (Discussion of Abstract(s) 7500-7502)**  
Tom Baker Cancer Center  
*Targeting Unmet Needs in Chronic Lymphocytic Leukemia*

**10:33 AM** Panel Question and Answer

**10:45 AM Abstract 7503:** Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8).  
First Author: Qingqing Cai, MD

**10:57 AM Abstract 7504:** A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for elderly patients with CCR4-positive adult T-cell leukemia/lymphoma.  
First Author: Ilseung Choi

**11:09 AM Abstract LBA7505:** Observation vs. radiotherapy in primary mediastinal B-cell lymphoma patients with complete response to standard immunochemotherapy: The IELSG37 randomized trial.  
First Author: Emanuele Zucca, MD

**11:21 AM Neha Mehta-Shah, MD (Discussion of Abstract(s) 7503-LBA7505)**  
Washington University School of Medicine  
*Did We Hit the Jackpot in Rare Lymphomas?*

**11:33 AM** Panel Question and Answer

**11:45 AM Abstract 7506:** Epcoritamab + R<sup>2</sup> regimen and responses in high-risk follicular lymphoma, regardless of POD24 status.  
First Author: Reid Merryman, MD

**11:57 AM Abstract 7507:** Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) mantle cell lymphoma (MCL): A CIBMTR subgroup analysis by prior treatment.  
First Author: Swetha Kambhampati, MD

**12:09 PM Abstract 7508:** Very long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma included in the LYMA trial, a LYSA study.  
First Author: Clémentine Sarkozy, MD

**12:21 PM Reem Karmali, MD (Discussion of Abstract(s) 7506-7508)**  
Northwestern Memorial Hospital  
*Striking a Balance With Immunotherapy in Non-Hodgkin Lymphoma*

**12:33 PM** Panel Question and Answer

---

**9:45 AM - 12:45 PM Oral Abstract Session**

**Lung Cancer—Non-Small Cell Metastatic**

Location: Hall D1

**Clarissa Mathias, MD, PhD - Chair**  
Oncoclínicas Bahia and Hospital Santa Izabel

**Heather A. Wakelee, MD, FASCO - Chair**  
Stanford Hospital and Clinics

**9:45 AM Abstract LBA9000:** Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.  
First Author: James Chih-Hsin Yang, MD, PhD

**9:57 AM Abstract 9001:** Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm<sup>+</sup>) non-small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.  
First Author: Yi-Long Wu, FACS

- 10:09 AM Abstract 9002:** Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results.  
First Author: Mengzhao Wang, MD, PhD
- 10:21 AM Jonathan W. Riess, MD, MS (Discussion of Abstract(s) LBA9000-9002)**  
UC Davis Comprehensive Cancer Center  
EGFR-Mutated Non-Small Cell Lung Cancer: What's Next?
- 10:33 AM** Panel Question and Answer
- 10:45 AM Abstract 9003:** Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations.  
First Author: Jie Wang, MD
- 10:57 AM Abstract 9004:** TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).  
First Author: Yasushi Goto, MD
- 11:09 AM Abstract LBA9005:** Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study.  
First Author: Ticiana Leal, MD
- 11:21 AM Rebecca Suk Heist, MD (Discussion of Abstract(s) 9003-LBA9005)**  
Massachusetts General Hospital  
*Confirming and Reinventing the Standard for Non-Small Cell Lung Cancer*
- 11:33 AM** Panel Question and Answer
- 11:45 AM Abstract 9006:** The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer with KRAS G12C mutation (WJOG14821L).  
First Author: Shinya Sakata, MD, PhD
- 11:57 AM Abstract 9007:** KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC).  
First Author: Philippe Alexandre Cassier, MD, PhD
- 12:09 PM Abstract 9008:** Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC).  
First Author: Ferdinandos Skoulidis, PhD

- 12:21 PM Joshua K. Sabari, MD (Discussion of Abstract(s) 9006-9008)**  
New York University  
*Have We Reached the Ceiling in KRAS-Mutated Non-Small Cell Lung Cancer?*

**12:33 PM** Panel Question and Answer

---

**11:30 AM - 12:45 PM Education Session**

**Doublet and Triplet Therapy for Metastatic Renal Cell Carcinoma: The More the Merrier or Is Three a Crowd?**  
Location: E451

**Laurence Albiges, MD, PhD**  
Gustave Roussy, Université Paris Saclay  
*The Case for Doublet Therapy*

**Katy Beckermann, MD, PhD**  
Vanderbilt  
*The Case for Triplet Therapy: Factors That Influence Decision-Making*

**Naomi Haas, MD - Chair**  
University of Pennsylvania-Abramson Cancer Center  
*Factors That Influence Decision-Making*  
  
*Panel Question and Answer*

---

**11:30 AM - 12:45 PM Education Session**

**The Evolving Management of Stage IV Melanoma**  
Location: S100bc

**Elizabeth Iannotti Buchbinder, MD**  
Dana-Farber Cancer Institute  
*Optimizing Current Treatment Paradigms for Stage IV Melanoma*

**Igor Puzanov, MD, FACP - Chair**  
Roswell Park Cancer Institute  
*Challenging Scenarios in Stage IV Melanoma*

**Sophie Piperno-Neumann, MD**  
Institut Curie Paris  
*The Changing Landscape of Uveal Melanoma*  
  
*Panel Question and Answer*











